Therapeutic,Format,CH1 Isotype,VD LC,Highest_Clin_Trial (Oct '21),Est. Status,Heavy Sequence,Light Sequence,Heavy Sequence (if bispec),Light Sequence (if bispec),100% SI Structure,99% SI Structure,95-98% SI Structure,Year Proposed,Year Recommended,Target,Companies,Conditions Approved,Conditions Active,Conditions Discontinued,Development Tech,Notes,Heavy Sequence second,Light Sequence second
Abagovomab,Whole mAb,G1,Kappa,Phase-III,Discontinued,QVKLQESGAELARPGASVKLSCKASGYTFTNYWMQWVKQRPGQGLDWIGAIYPGDGNTRYTHKFKGKATLTADKSSSTAYMQLSSLASEDSGVYYCARGEGNYAWFAYWGQGTTVTVSS,DIELTQSPASLSASVGETVTITCQASENIYSYLAWHQQKQGKSPQLLVYNAKTLAGGVSSRFSGSGSGTHFSLKIKSLQPEDFGIYYCQHHYGILPTFGGGTKLEIK,na,na,None,None,None,2006,2007,CA125,Menarini,na,na,Ovarian cancer;Pancreatic cancer ,na,,Q VKLQ ESGA ELA RPGA SVKLSCK ASGY TFTNYWMQWVK QRPGQGLD WIGAI YPGDGNT RYTHKF KG KATLTA DKSSST AYMQLSS LASEDSG VYYCA RGEGN YAWFAYW GQGT TVTVS S,DI ELT QSPA SLSA SVGE TVTITCQ ASEN IYSYLAWHQ QKQGKSP QLLVYN AK T LAGG VSSRF SGSGSGT HFSLKIKS LQPEDF GIYYCQ HHYG IL PTFGGGT KLEI K
Abciximab,Fab,G1,Kappa,Approved,NFD,EVQLQQSGTVLARPGASVKMSCEASGYTFTNYWMHWVKQRPGQGLEWIGAIYPGNSDTSYIQKFKGKAKLTAVTSTTSVYMELSSLTNEDSAVYYCTLYDGYYVFAYWGQGTLVTVSA,EIVLTQSPVTLSVTPGDSVSLSCRASRDISNNLHWFQQTSHESPRLLIKYASQSMSGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQTNSWPYTFGGGTKLEIK,na,na,6v4p:CD,None,None,1993,1994,CD41_CD61,Janssen Biologics BV;Eli Lilly,Coronary artery restenosis;Unstable angina pectoris,na,Arterial occlusive disorders;Myocardial infarction;Stroke,na,Sequence sourced through DrugBank.,EV QLQ QSG TVLA RPGA SVKMSCE ASGY TFTNYWMHWVK QRPGQGL EWIGAI YPGNSDTS YIQKF KGK AKLTAVT STT SVYMELS SLTNEDS AVYYCTL YDG YYVFAYW GQG TLVTVS A,E IVLT QSP VTLSV TPGD SVSLSCRA SRDISNNL HWFQQ TSHESP RLLIKYA SQSMSGIPS R FSGSGSGT DFTLSINSV ETEDF GMYFCQ QTNSWP YT FGGG TKLEI K
Abelacimab,Whole mAb,G1,Lambda,Phase-III,Active,QVQLLESGGGLVQPGGSLRLSCAASGFTFSTAAMSWVRQAPGKGLEWVSGISGSGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARELSYLYSGYYFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNDVSWYQQLPGTAPKLLIYKNYNRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCSAWDQRQFDVVFGGGTKLTVL,na,na,None,None,6r8x:CB,2018,2019,F11,Novartis;Anthos Therapeutics;Labcorp Drug Development;TIMI Study Group,na,Venous Thromboembolism; Stroke;Thrombosis,na,na,(Feb '22) Added in missing residues 97 and 98. (Jun '22) Added missing residues at start of VL CDR3.,Q VQLLES GGG LV QPGG SLRLSC AASGF TFST A A MSWVR QAPGKGL EWVS GISGSGSS TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYC ARELSY LY SG YYFD YWGQG TLVTV SS,QSVLTQPPSASGTPGQ RVTISC SGSSSNIGSNDV SWYQ QLPGTAP KLLIYK NYNRPSGVPDRFSGSKSGTS A SLAI SGLQSEDEAD YYCS AWDQRQF DVVF GGGT KLTV L
Abituzumab,Whole mAb,G2,Kappa,Phase-II,Active,QVQLQQSGGELAKPGASVKVSCKASGYTFSSFWMHWVRQAPGQGLEWIGYINPRSGYTEYNEIFRDKATMTTDTSTSTAYMELSSLRSEDTAVYYCASFLGRGAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLAWYQQKPGKAPKLLIYYTSKIHSGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQGNTFPYTFGQGTKVEIK,na,na,None,None,None,2013,2014,ITGAV,Merck,na,Colorectal cancer;Systemic scleroderma ,Ovarian cancer;Prostate cancer;Solid tumours ,na,"4o02 claims to be abituzumab (17E6), but is not",Q VQLQQ SGGE L AKPGA SVKVSCK ASGY TFSSFWMHWVR QAPGQG LEWIGYI NPRSGYTEYN EIF RDKA TMTT DTSTS TAYMELS SLRSEDT AVYYCASFL GRGAMDYWGQG TTVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQD ISNYLAWYQ QKPGKAP KLLIYYT SKIHSGVPSRFSGSGSGTD YTFTIS SLQ PEDIA TYYC QQGNTFP YT FGQGT KVEI K
Abrezekimab,Fab,G1,Kappa,Phase-I,Discontinued,QVTLKESGPVLVKPTETLTLTCTVSGFSLTNYHVQWIRQPPGKALEWLGVMWSDGDTSFNSVLKSRLTISRDTSKSQVVLTMTNMDPVDTATYYCARDGTIAAMDYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCLASEDISNYLAWYQQKPGKAPKLLIYHTSRLQDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYRFPLTFGGGTKVEIK,na,na,None,None,None,2017,2018,IL13,UCB,na,na,Asthma,na,(Jun '22) Added missing FWH3 and CDRL3 residues,QV TLK ESGP VLV KPTE TLTLTCTV SGF S LT NYHVQWIR QPPGKA LEWLGVMW SDGDTSFN SVLKSRLTIS RDTSKS QVVLTMT NMDPVDT ATYYCA RDGT IAAMDY FDYWGQG TLVTVS S,DIQMTQSPSS LSA SVGD RVTITCL AS E D ISNYLAWYQ QKPGKAP KLLIYHT SRLQDGVPS R FSGSGSGTD FTLTIS SLQ PEDFATYYCQ QGY RFPLTF GGGT KVEI K
Abrilumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKVSGYTLSDLSIHWVRQAPGKGLEWMGGFDPQDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLKSEDTAVYYCATGSSSSWFDPWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFANYYCQQANSFPWTFGQGTKVEIK,na,na,None,None,None,2014,2015,α4β7,Amgen;AstraZeneca,na,na,Crohn's disease;Ulcerative colitis ,na,,Q VQLVQ SGA EVK KPGA SVKVSCKV SGY T LSD LSIHWVR QAPGKG LEWMG G F DPQDGE TIYAQKF QG RVTMT EDTSTDT AYMELS SLKSEDT AVYYCA TGSSSSW F DPWGQG TLVTVS S,DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISSWLAWYQ QKPGKAP KLLIYG ASNLESGVPSRFSGSGSGTD FTLTIS SLQ PEDFANYYCQ QANSFPW T FGQGT KVEI K
Acapatamab,Bispecific scFv,na;na,Kappa;Lambda,Phase-I/II,Active,QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKCLEWVAIISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSASYVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGCGTKLEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2020,2021,FOLH1;CD3E,Amgen,na,Cancers;Prostrate cancer;Metastatic cancer,na,BiTE Technology,,Q VQLVES GGG LV KPGE SLRLSCA ASGF TF SD YYMYWVR QAPGKC LEWVAIIS DGG YYTYYS DI I KG RFTISR DNAKNS LYLQMN SLKAEDT AVYYC ARGFP LLR HGAMDYWGQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITCK ASQNVDTN VAWYQ QKPGQAPK SLIYSASYVYWD VPSRFSGSASGT DFTLTISS VQSEDF ATYYCQQ YDQ QLITF GCGT KLEI K
Acasunlimab,Bispecific mAb,G1;G1,Lambda;Kappa,Phase-I/II,Active,EVQLLEPGGGLVQPGGSLRLSCEASGSTFSTYAMSWVRQAPGKGLEWVSGFSGSGGFTFYADSVRGRFTISRDSSKNTLFLQMSSLRAEDTAVYYCAIPARGYNYGSFQHWGQGTLVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDNDRPSGLPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL,EVQLVESGGGLVQPGRSLRLSCTASGFSLNDYWMSWVRQAPGKGLEWVGYIDVGGSLYYAASVKGRFTISRDDSKSIAYLQMNSLKTEDTAVYYCARGGLTYGFDLWGQGTLVTVSS,DIVMTQSPSSLSASVGDRVTITCQASEDISSYLAWYQQKPGKAPKRLIYGASDLASGVPSRFSASGSGTDYTFTISSLQPEDIATYYCHYYATISGLGVAFGGGTKVEIK,None;None,None;None,None;None,2020,2021,CD274;TNFRSF9,Genmab;BioNTech,na,Solid tumours,na,na,,E VQLL EPGGG LV QPGG SLRLSCE ASGST FSTYAMSWVR QAPGKG LEWVS GFSGSGG FTFYA DSVRG RFTISR DSSKN TLFLQMS SLRAEDT AVYYCAI PARGYNYGS FQH WGQG TLVTVS S,SY VL TQPPS VSV APGQ TARITC GGNNIGSK SVHWYQ QKPGQAP VLVVY DDNDRPSGLPERFSGSNSGN TATLTISRVE AGDE ADYYCQVWD SSSD HVVFG GGT KLTV L
Acrixolimab,Whole mAb,G4,Kappa,Phase-I,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFLRYAMHWVRQAPGKGLEWVAVISYDGRYKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTTTTFDSWGQGTLVTVSS,DIVMTQTPLSLPVTPGEAASISCRSSQSLLDSEDGNTYLDWYLQKPGQSPQLLIYTLSHRASGVPDRFSGSGSGTDFTLEISRVEAEDVGVYYCMQRRDFPFTFGQGTKVDIK,na,na,None,None,None,2022,na,PDCD1,Y-Biologics,na,Solid tumours,na,na,,Q VQLVES GGG VV QPGR SLRLSC AASGF TFLRYAMHWVR QAPGKGL EWVAVIS YDGR YKYYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCTT T T FDSWGQ GTLVTVS S,DI VMT QTPLSLPVTPGEA ASISC RSSQ SLLD SEDGN TYLDWYL QKPGQSP QLLIYTLSH RASGVPDRFSGSGSGTD FTLEISRVE AEDV GVYYCMQ RRDFPF T FGQGT KVDI K
Actoxumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFSFSNYGMHWVRQAPGKGLEWVALIWYDGSNEDYTDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARWGMVRGVIDVFDIWGQGTVVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQHKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPWTFGQGTKVEIK,na,na,None,None,None,2012,2013,Toxin A,Bristol-Myers Squibb;Merck;University of Massachussets Medical School,na,na,Clostridium difficile,Medarex HuMAb Mouse,,Q VQLVES GGG VV QPGR SLRLSC AASGF SF SNY GMHWVRQ APGKGL EWVALIWY DGSNEDYTDS VKGRFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RWGM VRGVIDVFDI WGQG TVVTVS S,DIQ MT QSPSS VSAS VGD RVTITCR ASQGIS SWLAWY QHKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQP EDFA TYYC QQANSFPW T FGQGT KVEI K
Adalimumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIK,na,na,6cr1:HL/4nyl:AB:CD:EF:HL,3wd5:HL,None,1999,2000,TNFA,Abbvie;MedImmune;180 Life Sciences,Ankylosing spondylitis;Behcet's syndrome;Crohn's disease;Hidradenitis suppurativa;Juvenile rheumatoid arthritis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis;Rheumatoid arthritis;Spondylarthritis;Ulcerative colitis;Uveitis;Pyoderma,Dupuytren's contracture;Cognition disorders;Frozen shoulder;Non-alcoholic steatohepatitis,Interstitial cystitis ,CAT Phage Display,,E VQLVES GGG LV QPGR SLRLSC AASGFT F DDY AMHWVRQ APGKGL EWVSAITW NSGH ID YADSVE GRFTISR DNAKN SLYLQMNS LRAEDT AVYYCAKVSYL STASSLD Y WGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQG IRNYLAWYQ QKPGKAP KLLIYAA STLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDVATYYCQR YNRAPY T FGQGT KVEI K
Adebrelimab,Whole mAb,G4,Kappa,Preregistration,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWMGRIGPNSGFTSYNEKFKNRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGGSSYDYFDYWGQGTTVTVSS,DIVLTQSPASLAVSPGQRATITCRASESVSIHGTHLMHWYQQKPGQPPKLLIYAASNLESGVPARFSGSGSGTDFTLTINPVEAEDTANYYCQQSFEDPLTFGQGTKLEIK,na,na,None,None,None,2019,2020,PDL1,Jiangsu Hengrui Medicine;Atridia,na,Small cell lung cancer;Non-small cell lung cancer;Oesophageal cancer;Cancer;Solid tumours,Haematological malignancies,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYWMHWVR QAPGQG LEWMGRI GPNSGFTSYNEKFKN RVTMTR DTSTS TVYMELS SLRSEDT AVYYCA RGGSSYD YFD YWGQG TTVTVS S,D IVLTQ SPA SLAV SPGQ RATITCR ASE SVSIH G THLMHWYQ QKPGQPP KLLIYAA SNLESGVP ARFS GSGSGT DFTLTIN PVEAEDTA NYYCQQ SFEDPL T FGQGT KLEI K
Adecatumumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLLESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDMGWGSGWRPYYYYGMDVWGQGTTVTVSS,ELQMTQSPSSLSASVGDRVTITCRTSQSISSYLNWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQPEDSATYYCQQSYDIPYTFGQGTKLEIK,na,na,None,None,None,2004,2004,EPCAM,Micromet Inc;Merck Sorono;Amgen,na,na,Breast cancer;Colorectal cancer;Prostate cancer,na,Sequence sourced through https://www.tandfonline.com/doi/full/10.1080/19420862.2022.2123299,E VQLLES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKG LEWVAVISY DGSNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA KDMGWGSGWRP YYYYGMDV WGQG TTVTVS S,ELQ MT QSPSS LSA SVGD RVTITCR TSQS ISSYLNWY QQKPGQPP KLLIYWAS TRESGVPDRFSGSGSGTD FTLTISS LQPEDSA TYYCQQS YDIPY T FGQGT KLEI K
Adintrevimab,Whole mAb,G1,Lambda,Phase-II/III,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSSISEDGYSTYYPDSLKGRFTISRDSAKNSLYLQMNSLRADDTAVYYCARDFSGHTAWAGTGFEYWGQGTLVTVSS,QSVLTQPPSVSGAPGQRITISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGSSSRNSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSVLYTFGTGTKVTVL,na,na,None,None,None,2021,2022,SARS-CoV-2 Spike,Adagio Therapeutics,na,COVID-19,na,na,,E VQLVES GGG LV KPGG SLRLSC AASGF TFSSYYMNWVR QAPGKGL EWVSSI SEDGY STY YPDSLKG RFTISR DSAKN SLYLQMNSL RADDT AVYYCAR DFSGHT AW AGTG FEYW GQG TLVTVS S,QSVLTQPPSVSGAPGQ RITISCT GSSSNIGAG YDVHWYQ QLPGTAP KLLIYG SSSRNSGVPDRFSGSKSGTS AS LAI TGLQAEDEAD YYCQS YDSSL SVLYTF GTGT KVTV L
Aducanumab,Whole mAb,G1,Kappa,Approved,NFD,QVQLVESGGGVVQPGRSLRLSCAASGFAFSSYGMHWVRQAPGKGLEWVAVIWFDGTKKYYTDSVKGRFTISRDNSKNTLYLQMNTLRAEDTAVYYCARDRGIGARRGPYYMDVWGKGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIK,na,na,6cnr:HL/6co3:HL,None,None,2013,2014,APP,Biogen;Neurimmune,Alzheimer's disease ,na,na,na,,Q VQLVES GGG VV QPGR SLRLSC AASGF AFS SY GMHWVRQ APGKGL EWVAVIWF DGT KKYYTD SVKG RFTISR DNSKN TLYLQMNTL RAEDT AVYYCAR DRGIGARRGP YYMDVW GKG TTVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQS ISSYLNWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQP EDFA TYYCQ QSYSTP LTF GGG TKVEI K
Afasevikumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGINWSSGGIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDIGGFGEFYWNFGLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPATFGGGTKVEIK,na,na,6ppg:HL:BA,None,None,2015,2016,IL17A,NovImmune;Genentech,na,na,Autoimmune disorders;Inflammation,na,,E VQLVES GGG LV QPGR SLRLSC AASGFT F DDY AMHWVR QAPGKGL EWVS G IN WSSGGI GY ADSVKG RFTISR DNAKNS LYLQMN SLRAEDT ALYYCAR DIGGFG EFYWNF G L WGRG TLVTVS S,E IVLTQ SPA TLSL SPGE RATLSCR ASQS VRSY LA W Y QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPED FAVYYCQ QRSNWPPATFGGG TKVEI K
Alacizumab,di-Fab,na,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVATITSGGSYTYYVDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCVRIGEDALDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIAGSLNWLQQKPGKAIKRLIYATSSLDSGVPKRFSGSRSGSDYTLTISSLQPEDFATYYCLQYGSFPPTFGQGTKVEIK,na,na,None,None,None,2007,2008,KDR,UCB,na,na,Non-small cell lung cancer ,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFSS YG MSWVRQ APGKG LEWVATIT SGGS YTYYVD SVKG RFTISR DNAKN TLYLQMN SLRAEDT AVYYCVRI GEDAL DYW GQ GTLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQD IAGSLNWLQ QKPGKA IKRLIYAT SSLDSGVPK R FSGSRSGSD YTLTISS LQPED F ATYYCLQ YGSFPPTFGQGT KVEI K
Alemtuzumab,Whole mAb,G1,Kappa,Approved,Active,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIK,na,na,1bey:HL/1ce1:HL,None,None,2000,2001,CD52,Bayer HealthCare Pharmaceuticals Inc.;Dana-Farber Cancer Institute;German CLL Study Group;Ohio State University Comprehensive Cancer Center;Sanofi;Sanofi Oncology;University of Cologne;University of Cambridge,Chronic lymphocytic leukaemia;Multiple sclerosis ,Lymphoma;T-cell prolymphocytic leukaemia ,Rheumatoid arthritis;Diffuse large B cell lymphoma;Graft-versus-host disease;Sezary syndrome;T-cell lymphoma ,na,,Q VQLQE SGPGL V RPSQ TLSLTCTV SG FTFTDFYMNWVR QPPGRGL EWIGFIR DKAKGY TTEY NPSVKG RVTMLVD TSKN QFSLRLSS VTAAD TAVYYCA REGHTAAPFDYWGQG SLVTVS S,DIQ M TQSPSS LSA SVGD RVTITCK ASQN IDKYLNWYQ QKPGKAP KLLIYN TNNLQTGVPSRFSGSGSGTD FTFTIS SLQ PEDIATYYCLQH ISRPRTFGQGT KVEI K
Alirocumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFNNYAMNWVRQAPGKGLDWVSTISGSGGTTNYADSVKGRFIISRDSSKHTLYLQMNSLRAEDTAVYYCAKDSNWGNFDLWGRGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYRSNNRNFLGWYQQKPGQPPNLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYTTPYTFGQGTKLEIK,na,na,None,None,None,2012,2013,PCSK9,Regeneron Pharmaceuticals;Sanofi;University Hospital Inselspital,Hypercholesterolaemia;Hyperlipoproteinaemia type IIa;Atherosclerosis;Dyslipidaemias,Coronary artery disease,na,VelocImmune Mouse,,E VQLVES GGG LV QPGG SLRLSC AASGF TF NNY AMNWVR QAPGKGLD WVSTIS GSGGTTNYADSVKG RFIISR DSSKH TLYLQMN SLRAED TAVYYCA KDSNWGN FDL WGRG TLVTV SS,D IVMT QSPDS LAVS LGE RATINC KSSQ SVLYR SNNRN FLGWYQ QKPGQPPN LLIYWAS TRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQQ YYTTPY T FGQGT KLEI K
Alomfilimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGVVRPGGSLRLSCVASGVTFDDYGMSWVRQAPGKGLEWVSGINWNGGDTDYSDSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDFYGSGSYYHVPFDYWGQGILVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSRSYLAWYQQKRGQAPRLLIYGASSRATGIPDRFSGDGSGTDFTLSISRLEPEDFAVYYCHQYDMSPFTFGPGTKVDIK,na,na,7joo:HL,None,None,2020,2021,ICOS,Kymab,na,Gastic cancers;Non-small cell lung cancer;Melanoma;Hepatocellular carcinoma;Esophageal cancer;Head and neck squamous cell carcinoma,na,na,,E VQLVES GG GVV RPGG SLRLSCVA SGV TF DDYGM SWVRQ APGKGL EWVSGIN WNGGDTDYSDSVK GRFTISR DNAKN SLYLQMN SLRAEDT ALYYCAR DFYGSGS YYHV PFDYWGQ GILVTV SS,E IVLTQ SPG TLSL SPGE RATLSCR ASQS VSRSYLAWYQQK RGQAP RLLIYG ASSRATGIPDRFSGDGSGT DFTLSIS RLE PEDF AVYYC H QYDMSPFTFGPGT KVD IK
Alnuctamab,Bispecific mAb with Domain Crossover,G1;G1,Kappa;Lambda,Phase-I,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSDNAMGWVRQAPGKGLEWVSAISGPGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVLGWFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSDEYLSWYQQKPGQAPRLLIHSASTRATGIPDRFSGSGSGTDFTLAISRLEPEDFAVYYCQQYGYPPDFTFGQGTKVEIK,EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVSRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2020,2021,TNFRSF17;CD3E,Celgene Corporation,na,Multiple myeloma,na,na,,E VQLLES GGG LV QPGG SLRLSC AASGF TF SDNAM GWVRQ APGKGL EWVSAI SGPGSS TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAKVL G WF DYWGQG TLVTV SS,E IVLTQ SPG TLSL SPGE RATLSCR ASQSVS DEYLSWYQ QKPGQAP RLLIHS ASTRATGIPDRFSGSGSGTD FTLAIS RLE PEDFAVYYCQQY GYPPDF T FGQGT KVEI K
Alsevalimab,Whole mAb,G1,Kappa,Phase-I,Active,QLQLQESGPGLVKPSETLSLTCTVSGGSIKSGSYYWGWIRQPPGKGLEWIGNIYYSGSTYYNPSLRSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGSYPNQFDPWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYHSFPFTFGGGTKVEIK,na,na,None,None,None,2019,2020,VTCN1,Five Prime Therapeutics,na,Solid tumours,na,na,,QL QLQE SGPGL V KPSE TLSLTCTV SGGSIKSGS YYWGWIR QPPGKGL EWIGNIYYS GS TY YNPSLR SRVTISVD TSKN QFSLKLSS VTAADT AVYYCA REGSYPNQFDPWGQG TLVTVS S,E IVMT QSPA TLSV SPGE RATLSCR ASQSVSSN LAWYQ QKPGQAP RLLIYG ASTRATGIP ARFS GSGSGT EFTLTISS LQSED FAVYYC QQYHSFP FTF GGGT KVEI K
Amatuximab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLQQSGPELEKPGASVKISCKASGYSFTGYTMNWVKQSHGKSLEWIGLITPYNGASSYNQKFRGKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARGGYDGRGFDYWGSGTPVTVSS,DIELTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKRWIYDTSKLASGVPGRFSGSGSGNSYSLTISSVEAEDDATYYCQQWSKHPLTFGSGTKVEIK,na,na,None,4f33:BA:DC:FE:HG/4f3f:BA,None,2010,2011,MSLN,Eisai Co Ltd;Morphotek;National Cancer Institute (USA),na,Mesothelioma,Pancreatic cancer;Solid tumours ,na,,QV QLQ QSGPELEKPGA SVKISCK ASGY SFTGYTMNWVK QSHGKS LEWIGLIT PYNGASSYNQKFRG KATLTVD KSSST AYMDLLS LTSEDS AVYFCA RGGYDGRGF DY WGSGTP VTV SS,DI ELT QSP AIMS ASPGE KVTMTCS ASSS VSYMHWYQ QKSGTSPK RWIYD TSKLASGVPG RFS GSGSGN SYSLTISSVE AEDDA TYYCQQW SKHPL TF GSGT KVEI K
Amivantamab,Bispecific mAb,G1;G1,Kappa;Kappa,Approved,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSESGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,QVQLVQSGAEVKKPGASVKVSCETSGYTFTSYGISWVRQAPGHGLEWMGWISAYNGYTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDLRGTNYFDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISNWLAWFQHKPGKAPKLLIYAASSLLSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPITFGQGTRLEIK,None;6wvz:HL,None;None,None;None,2019,2020,EGFR;MET,Genmab;Janssen Research & Development,Non-small cell lung cancer,Gastic cancer;Oesophageal cancer;Solid tumours,na,na,,Q VQLVES GGG VV QPGR SLRLSC AASGF TFSTYGMHWVRQ APGKG LEWVAVIW DDGS YKYY GDS VKGRFTISR DNSKN TLYLQMN SLRAED TAVYYCA RDG ITMVRGVM KDYFDYWGQG TLVTVS S,AI QLT QSPSS LSAS VGD RVTITCR ASQDIS SALVWYQ QKPGKAP KLLIYD ASSLESGVPSRFSGSESGTD FTLTIS SLQ PEDFATYYCQQ FNSYP LTF GGG TKVEI K
Amlitelimab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYAMNWVRQAPGKGLEWVSTISGSGGATRYADSVKGRFTISRDNSRNTVYLQMNSLRVEDTAVFYCTKDRLIMATVRGPYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPNLLIYAASSLQSGVPSRFSGSGSETDFTLTISSLQPEDFATYYCQQSHSVSFTFGPGTKVDIK,na,na,None,None,None,2020,2021,TNFSF4,Kymab,na,Atopic dermatitis,na,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFS NY AMNWVR QAPGKG LEWVSTIS GSGGA TRY ADSVKG RFTISR DNSRN TVYLQMN S LRV ED TAVFYC TKDR LIMATVR GPY YYGMDV WGQG TTVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQS ISSYLNWYQ QKPGKAPN LLIYAA SSLQSGVPSRFSGSGSET DFTLTIS SLQPE DFA TYYC QQSH SVSFTF GPGT KVDI K
Amubarvimab,Whole mAb,G1,Kappa,Phase-II/III,Active,EVQLVESGGGLVQPGGSLRLSCAASGITVSSNYMNWVRQAPGKGLEWVSLIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYHCARDLVVYGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPTFGQGTKLEIK,na,na,7cdi:HL,7e8m:HL,None,2021,2022,SARS-CoV-2 Spike RBD,Brii Biosciences,na,COVID-19,na,na,,E VQLVES GGG LV QPGG SLRLSC AASG ITVS SNY MNWVR QAPGKGL EWVSLIY SGGS TYYA DSVKG RFTISR DNSKN TLYLQMNS LRAEDT AVYHC ARD LVVYGMDV WGQG TTVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSS S YLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYCQ QYGSSPTFGQGT KLEI K
Anbenitamab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-II/III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,None;1fvc:DC:BA/1n8z:BA/4hkz:BA/4ub0:HL/5xhg:BA:DC/5xhf:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/6mh2:AB:CD/6oge:ED/7mn8:DC,None;1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC,None;5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,2020,2021,ERBB2 (Domain II);ERBB2 (Domain IV),Alphamab,na,Breast cancer;Gastric cancer,na,na,4llu is 94.7% identical to ERBB2 (domain II) Fv,E VQLVES GGG LV QPGG SLRLSC AASGF TFT DY TMDWVR QAPGKG LEWVADV NPNSGGS IY NQRFKG RFTLSVD RSKN TLYLQMNS LRAEDT AVYYCA RNLGPS FYFDY WGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQD VNTA VAWYQ QKPGKAP KLLIYSASFLY SGVPSRFSGSRSGTD FTLTIS SLQP EDFAT YYCQ QHYTTPPTFGQGT KVEI K
Andecaliximab,Whole mAb,G4,Kappa,Phase-III,Discontinued,QVQLQESGPGLVKPSETLSLTCTVSGFSLLSYGVHWVRQPPGKGLEWLGVIWTGGTTNYNSALMSRFTISKDDSKNTVYLKMNSLKTEDTAIYYCARYYYGMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVRNTVAWYQQKPGKAPKLLIYSSSYRNTGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYITPYTFGGGTKVEIK,na,na,5th9:HL:IM:JN,None,None,2016,2017,MMP9,Gilead Sciences,na,na,Chronic obstructive pulmonary disease;Crohn's disease;Cystic fibrosis;Rheumatoid arthritis;Ulcerative colitis;Gastric cancer;Solid tumours;Glioblastoma,na,,QV QLQE SGPGL V KPSE TLSLTCTV SGF SLLSYGVHWVR QPPGKGL EWLGVIWT GGTTNYNSA LMSRFTIS KDDSKN TVYLKM NSLKTEDT AIYYCARYY YGMDYWGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCK ASQD VRNT VAWYQ QKPGKAP KLLIYS SSYRNTGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC Q QHYITP YT FGGGT KVEI K
Anetumab,Whole mAb ADC,G1,Lambda,Phase-II,Active,QVELVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQAPGKGLEWMGIIDPGDSRTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGQLYGGTYMDGWGQGTLVTVSS,DIALTQPASVSGSPGQSITISCTGTSSDIGGYNSVSWYQQHPGKAPKLMIYGVNNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYDIESATPVFGGGTKLTVL,na,na,None,None,None,2013,2014,MSLN,Bayer HealthCare;ImmunoGen;MorphoSys;National Cancer Institute (USA) ,na,Lung cancer;Mesothelioma;Ovarian cancer;Pancreatic cancer;Solid tumours;Non-small cell lung cancer;Malignant thymoma,Fallopian tube cancer;Peritoneal cancer,MorphoSys HuCAL Phage Display,,Q VELVQ SGA EVK KPGE SLKISC KGSGY SFTSYWIGWVR QAPGKG LEWMGII DPGDSRT RY SPSFQG QVTIS ADKS ISTAYLQWS SLKASDT AMYYC ARGQ LY GG TY MDGWGQG TLVTVS S,DI ALT QPA SV SGSPGQ SITISCT GTSSDIGGY NSVSWYQ QHPGKAP KLMIYGV NNRPSGVSNRFSGSKSGN TASLTIS GLQAEDEAD YYCSSY DIESATP V FGGGT KLTV L
Anifrolumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVQSGAEVKKPGESLKISCKGSGYIFTNYWIAWVRQMPGKGLESMGIIYPGDSDIRYSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHDIEGFDYWGRGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFFAWYQQKPGQAPRLLIYGASSRATGIPDRLSGSGSGTDFTLTITRLEPEDFAVYYCQQYDSSAITFGQGTRLEIK,na,na,4qxg:HL,None,None,2013,2014,IFNAR1,Medarex;Medical University of Vienna;MedImmune,Systemic lupus erythematosus,Lupus nephritis,Rheumatoid arthritis;Scleroderma,Medarex UltiMAb Mouse,,E VQLVQ SGA EVK KPGE SLKISC KGSG YIFT N YWIAWVR QMPGKGLE SMGII YPGDSD IRY SPSFQG QVTIS ADKS ITTAYLQWS SLKASDT AMYYCAR HDIEGFDYWGRG TLVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSSS FFAWYQ QKPGQAP RLLIYG ASSRATGIPDRLSGSGSGT DFTLTITR LEPED FAVYYCQ QYDSSA ITF GQGT RLEI K
Anivovetmab,Canine Whole mAb,G2,Kappa,Unknown,Active,QVQLKESGPGLVAPSQTLSLTCTVSGFSLSSYHVHWVRQPPGKGLEWLGVMWNDGDTSYNLALNSRLSISRDTSKSQVFFKMSSLQTEDTATYYCARPELPGLTYGVWFPYWGQGTLVTVSA,DIVMTQTPASMSISVGDRVTMNCKASQNVDSNVDWYQQKTGQSPNLLIYKASNRNTGVPDRFTGSGSGTDFTFTISNMQAEDLAVYYCMQSTSYPLTFGSGTKLEIK,na,na,None,None,3iy6:BA/3jcx:HL,2022,na,VP2 (Canine),TBC,TBC,TBC,TBC,TBC,,Q VQLKE SGPGL V APSQ TLSLTCTV SGF S LS SYHVHWVR QPPGKGL EWLGVMW NDGDTS YNLAL NS RLSIS RDTSKS QVFFKM SSLQTEDT ATYYCA RPELPGL TYGVWF PYWGQG TLVTVS A,D IVMT QTPA SMSIS VGD RVTMNCK ASQNVDSNV DWYQQ KTGQSPN LLIYKA SNRNTGVPDRFTGSGSGT DFTFTIS NMQAED LAVYYCM QSTSYP LTF GSGT KLEI K
Anrukinzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFISYAMSWVRQAPGKGLEWVASISSGGNTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLDGYYFGFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASESVDNYGKSLMHWYQQKPGKAPKLLIYRASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPWTFGGGTKVEIK,na,na,None,None,None,2007,2008,IL13,Pfizer;Wyeth,na,na,Asthma;Ulcerative colitis,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFISYAMSWVR QAPGKG LEWVASIS SGGNT Y YPDSVK GRFTIS RDNAKN SLYLQMNS LRAEDT AVYYCARL DG YYFGFAYW GQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCK ASESVD NYGKSLMHWYQ QKPGKAP KLLIYRA SNLESGVPSRFSGSGSGTD FTLTIS SLQP EDFA TYYCQ QSNEDPWTFGGG TKVEI K
Anselamimab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLKESGPGLVAPSQSLSITCTVSGFSLSSYGVSWVRQPPGKGLEWLGVIWGDGSTNYHPNLMSRLSISKDISKSQVLFKLNSLQTDDTATYYCVTLDYWGQGTSVTVSS,DVVMTQTPLSLPVSLGDQASISCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGLYFCFQTTYVPNTFGGGTKLEIK,na,na,None,None,None,2021,2022,Light Chain Amyloid Fibrils,Caelum Biosciences,na,AA amyloidosis,na,na,Oct '22: Amended target. Targets a conserved epitope across light chain amyloid fibrils: Am J Pathol. 2000;157(4):1239–46;Clin Cancer Res. 2003;9(10):3831S-3838S;Biochemistry. 2007;46(5):1240–7.,Q VQLKE SGPGL V APSQ SLSITCTV SG FSL S SYGVSWVR QPPGKGL EWLGVIW GDGSTNYHPNLMS RLSI SKDISKS QVLFKLNS LQTDDTA TYYCVTLD YWGQG TSVTVS S,DV VMT QTPLSLPVSLGDQ ASISC RSSQ SLVHR NGN TYLHWYLQ KPGQSP KLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDL GLYFCFQTTY VPNTFGGG TKLEI K
Ansuvimab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLIQPGGSLRLSCAASGFALRMYDMHWVRQTIDKRLEWVSAVGPSGDTTYADSVKGRFAVSRENAKNSLSLQMNSLTAGDTAIYYCVRSDRGVAGLFDSWGQGILVTVSS,DIQMTQSPSSLSASVGDRITITCRASQAFDNYVAWYQQRPGKVPKLLISAASALHAGVPSRFSGSGSGTHFTLTISSLQPEDVATYYCQNYNSAPLTFGGGTKVEIK,na,na,None,5fha:HL/5fhc:HL,None,2020,2021,Zaire Ebolavirus GP1,Ridgeback Biotherapeutics,Zaire ebolavirus infection,na,na,na,,E VQLVES GGG LI QPGG SLRLSC AASGF ALRMY DM HW V R QT IDKR LEWVSAV GPSGDTT YA DSVKG RFAVS R ENAKNS LSLQM N S LTAGDT AIYYCVR SDRGV AGLF DSWGQ GILVTVS S,DIQ MT QSPSS LSA SVGD RITITCR AS Q A FDNYVAWYQ QRPGKVP KLLISA A SA LHAGVPS R FSGSGSGT HFTLTIS SLQP EDVAT YYC QNYNSAP LTF GGG TKVEI K
Anumigilimab,Whole mAb,G4,Kappa,Phase-I,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSLYWMGWVRQAPGKGLEWVSSISSSGGVTPYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKLGELGWFDPWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSYLNWYQQKPGKAPKLLIYYASNLQNGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIK,na,na,None,None,None,2021,2022,CSF3R,CSL Behring,na,Inflammatory diseases;Hidradenitis suppurativa;Localised pustular psoriasis,na,na,,E VQLLES GGG LV QPGG SLRLSCA ASGF TFSLYWMGWVR QAPGKG LEWVSSIS SSGGVTPYADSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAK LGELGW F DPWGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQGI SSYLNWY QQKPGKAP KLLIYYA SNLQNGVPS RF SGSGSGTD FTLTIS SLQPE DFA TYYCQ QSYSTP LTF GGG TKVEI K
Anvatabart,Whole mAb ADC,G1,Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,na,na,1fvc:DC:BA/4hkz:BA/1n8z:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD/6oge:ED/7mn8:DC,1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC,5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,2022,na,ERBB2,TBC,TBC,TBC,TBC,Humanised,"Anvatabart has an identical V domain to Coprelotamab, Cinrebafusp, Timigutuzumab, and Trastuzumab",E VQLVES GGG LV QPGG SLRLSCA ASGFNIKD TYIHWVRQ APGKG LEWVARIY PTNGY TRYA DSVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYCS RWGGDG FYAMD YWGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQD VNTA VAWYQ QKPGKAP KLLIYSASFLY SGVPSRFSGSRSGTD FTLTIS SLQP EDFAT YYCQ QHYTTPPTFGQGT KVEI K
Anzurstobart,Whole mAb,G1,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFRGYGISWVRQAPGQGLEWMGWISAYGGETNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAREAGSSWYDFDLWGRGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGASFPITFGGGTKVEIK,na,na,None,None,None,2022,na,SIRPα,Celgene Corporation,na,Acute myeloid leukaemia;Myelodysplastic syndromes,Non-Hodgkin's lymphoma;Solid tumours,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFRGYGISWVRQ APGQGL EWMGWISA YGGETNY AQKL QG RVTMTT DTSTS TAYMELRSL RSDDT AVYYCAR EAGSS WYDFDL WGRG TLVTV SS,DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISSWLAWY QQKPGKAP KLLIYAA SNLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYC QQGASF PITF GGG TKVEI K
Apamistamab,Whole mAb Radiolabelled,G1,Kappa,Phase-III,Active,EVKLLESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPTSSTINFTPSLKDKVFISRDNAKNTLYLQMSKVRSEDTALYYCARGNYYRYGDAMDYWGQGTSVTVSS,DIALTQSPASLAVSLGQRATISCRASKSVSTSGYSYLHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRELPFTFGSGTKLEIK,na,na,None,None,None,2018,2019,PTPRC,Actinium Pharmaceuticals;Fred Hutchinson Cancer Research Center,na,Acute myeloid leukaemia;Myelodysplastic syndromes;Precursor cell lymphoblastic leukaemia-lymphoma,Hodgkin's disease;Non-Hodgkin's lymphoma,na,,E VKLLES GGG LV QPGG SLKLSCA ASGFDFSR YWMSWVR QAPGKGL EWIGEI NPTSS TINF TPSLKD KVFISR DNAKN TLYLQMSKV RSEDT ALYYC ARGN YYRY GDAMDYWGQG TSVTVS S,DI ALT QSPA SLAVS LGQ RATISCRA SKSVSTSGY SYLHWYQ QKPGQPP KLLIYLA SNLESGVP ARFS GSGSGTD FTLNIHP VEEEDA A TYYC QHSRELP FT FGSGT KLEI K
Apitegromab,Whole mAb,G4,Lambda,Phase-III,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLLVRFLEWSHYYGMDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVHWYQQLPGTAPKLLIYSDNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGVFGGGTKLTVL,na,na,None,None,6umx:HL:hl,2020,2021,pro-GDF-8,Scholar Rock,na,Spinal muscular atrophy;Muscular atrophy;Spinal cord injuries,na,na,,Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKG LEWVAVISY DGSNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYC ARDLLVRFLEWSHY YGMD V WGQG TTVTVS S,QSVLTQPPSASGTPGQ RVTISC SGSSSNIGSN TVHWYQQ LPGTAP KLLIY SDNQRPSGVPDRFSGSKSGTS ASL A I SGLQSEDEAD YYCAAW DDSLNGVFGGGT KLTV L
Aprutumab,Whole mAb ADC,G1,Lambda,Phase-I,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGTSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVRYNWNHGDWFDPWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYENYNRPAGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSSWDDSLNYWVFGGGTKLTVL,na,na,None,None,None,2016,2017,FGFR2,Bayer,na,na,Solid tumours,na,,E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKGL EWVSAI SGSGT STYYA DSVKG RFTISR DNSKN TLYLQMNS LRAEDT AVYYCARVRYN WNHGDWFDPWGQ GTLVTVS S,QSVLTQPPSASGTPGQ RVTISC SGSSSNIGNN YVSWYQQ LPGTAP KLLIYE NYNRPAGVPDRFSGSKSGT SASLAI SGLRSEDEAD YYC SSWDDSLN YWVF GGGT KLTV L
Arcitumomab,Whole mAb,G1,Kappa,Approved (w),NFD,EVKLVESGGGLVQPGGSLRLSCATSGFTFTDYYMNWVRQPPGKALEWLGFIGNKANGYTTEYSASVKGRFTISRDKSQSILYLQMNTLRAEDSATYYCTRDRGLRFYFDYWGQGTTLTVSS,QTVLSQSPAILSASPGEKVTMTCRASSSVTYIHWYQQKPGSSPKSWIYATSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQHWSSKPPTFGGGTKLEIK,na,na,1clo:HL,None,None,1995,1996,CEA,Immunomedics;Giliad Sciences,Colorectal cancer,na,na,na,,E VKLVES GGG LV QPGG SLRLSC ATSGF TFTDYYMNWVR QPPGKA LEWLGFIG NKANGY TTEYSASVKGRFTIS RDKSQ SILYLQMNTL RAEDS ATYYCT RDRG LRFYFDY WGQG TTLTVS S,QT VL SQSP AILS ASPGE KVTMTCR ASSS VTYIHWYQ QKPGSSPK SWIYAT SNLASGVP ARFS GSGSGT SYSLTISRVE AEDA ATYYCQH WSSKPPTFGGGT KLEI K
Ascrinvacumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGEYYWNWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARESVAGFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGTSSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPITFGQGTRLEIK,na,na,None,None,None,2015,2016,ACVRL1,Duke University Medical Center;Fondazione IRCCS Istituto Nazionale dei Tumori;Pfizer;Suzhou Kintor Pharmaceuticals,na,na,Colorectal cancer;Liver cancer;Solid tumours;Urogenital cancer;Age-related macular degeneration;Cancer;Liver Cancer,na,,QV QLQE SGPGLVKPSQ TLSLTCTV SGGSISSG EYY WNWIR QHPGKGL EWIGYIYYS GST Y YNPSLK SRVTISVD TSKN QFSLKLSS VTAADT AVYYCA RESVAG FDY WGQG TLVTV SS,E IVLTQ SPG TLSL SPGE RATLSCR ASQSVS SSY LAWYQ QKPGQAP RLLIYG TSSRATGIPDRFSGSGSGT DFTLTISR LE PEDFA VYY CQQ YGSSP ITF GQGT RLEI K
Aselizumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMSWVRQAPGKGLEWVASISTGGSTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARDYDGYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASNLESGIPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPWTFGQGTKVEIK,na,na,None,None,None,2003,2003,L-Selectin,PDL Biopharma,na,na,Adult respiratory distress syndrome;Crohn's disease;Psoriasis;Reperfusion injury;Shock,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFSTYAMSWVR QAPGKG LEWVASIS TGGST Y YPDSVK GRFTISR DNAKN TLYLQMNS LRAEDT AVYYCAR DYDGY FDY WGQG TLVTV SS,DI QMT QSPSS LSA SVGD RVTITCK ASQS V DYDGD SYMNWYQ QKPGKAP KLLIYAA SNLESGIPSRFSGSGSGTD FTLTISS LQPED F ATYYCQ QSNEDPWTFGQGT KVEI K
Astegolimab,Whole mAb,G2,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWIGWVRQMPGKGLEWMGIIYPGNSDTRFSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHGTSSDYYGLDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQDDNFPLTFGGGTKVEIK,na,na,None,None,None,2019,2020,IL1RL1,Amgen;Genentech;University of Leicester,na,Allergic asthma;Atopic dermatitis;Chronic obstructive pulmonary disease,Asthma;Rhinosinusitis,na,,E VQLVQ SGA EVK KPGE SLKISC KGSGYS F T NYWIGWVRQ MPGKGL EWMGIIY PGNSDTRFSPSFQG QVTIS ADKS ITTAYLQWS SLKASDT AMYYCA RHGTSSDY YGLDVW GQG TTVTVS S,DIQMTQSPSS LSA SVGD RVTITCQ ASQD ISNYLNWYQ QKPGKAP KLLIYD ASNLETGVPSRFSGSGSGTD FTFTIS SLQ PEDIATY YC QQDDNFP LTF GGG TKVEI K
Atezolizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIK,na,na,5x8l:FK:HM:GL:JO:SN,5xxy:HL,None,2014,2015,CD274,Amgen;ARCAGY/GINECO Group;BioLineRx;Chugai Pharmaceutical;Clovis Oncology;Dana-Farber Cancer Institute;Duke University;European Organisation for Research and Treatment of Cancer;Exelixis;Fondazione Michelangelo;GEICO (Spanish Ovarian Cancer Research Group);Genentech;GERCOR;Gradalis;H. Lee Moffitt Cancer Center and Research Institute;Immune Design;Incyte Corporation;Johns Hopkins University;Kaiser Permanente;M. D. Anderson Cancer Center;Memorial Sloan-Kettering Cancer Center;National Cancer Center (Korea);National Cancer Institute (USA);Netherlands Cancer Institute;Roche;Sanofi;Seattle Genetics;University Hospital Southampton NHS Foundation Trust;University Medical Center Groningen;University of California;University of California at San Francisco;University of Oklahoma;Yale University,Non-small cell lung cancer;Urogenital cancer;Breast cancer;Small cell lung cancer,Bladder cancer;Cervical cancer;Colorectal cancer;Fallopian tube cancer;Head and neck cancer;Liver cancer;Malignant melanoma;Ovarian cancer;Peritoneal cancer;Prostate cancer;Renal cell carcinoma;Anal cancer;Brain metastases;Chronic lymphocytic leukaemia;Cutaneous T-cell lymphoma;Diffuse large B cell lymphoma;Endometrial cancer;Gastric cancer;Gynaecological cancer;Mantle-cell lymphoma;Marginal zone B-cell lymphoma;Oesophageal cancer;Soft tissue sarcoma;Solid tumours;Thyroid cancer;Waldenstrom's macroglobulinaemia;Acute myeloid leukaemia;Follicular lymphoma;Glioblastoma;Pancreatic cancer;Haematological malignancies;Multiple myeloma;Non-Hodgkin's lymphoma,Hodgkin's disease;Myelodysplastic syndromes,Human Phage Display,,E VQLVES GGG LV QPGG SLRLSC AASGF TF SDS WIHWVRQ APGKG LEWVAWI SPYGGS TYYAD SVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYCAR RHWPGGFD Y WGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQD VSTA VAWY Q QKPGKAP KLLIYSASFLY SGVPSRFSGSGSGTD FTLTIS SLQ PEDFAT YYCQQYLY HPATFGQGT KVEI K
Atibuclimab,Whole mAb,G4,Kappa,Phase-II,Active,DVQLQQSGPGLVKPSQSLSLTCTVTGYSITSDSAWNWIRQFPGNRLEWMGYISYSGSTSYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCVRGLRFAYWGQGTLVTVSS,DIVLTQSPASLAVSLGQRATISCRASESVDSYVNSFLHWYQQKPGQPPKLLIYRASNLQSGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQSNEDPYTFGGGTKLEIK,na,na,None,None,None,2020,2021,CD14,ICOS Corporation;Implicit Bioscience,na,Acute lung injury;COVID-19,Adult respiratory distress syndrome;Motor neuron disease;Septic shock,na,,DV QLQQ SGPGLVKPSQ SLSLTCTVT G YSI TSDS AWNWIR QFPGNR LEWMGYISY SGSTSYNPSLK SRISITR DTSKN QFFLQLN S V TTEDTA TYYCVR G LRFAYW GQG TLVTVS S,D IVLT QSPA SLAVS LGQ RATISCR ASES VDSYVNSFLHWYQ QKPGQPP KLLIYRA SNLQSGIPA RF SGSGSRT DFTLTI NPVEADD V ATYYCQ QSNEDPYTFGGGT KLEI K
Atidortoxumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLQESGPGLVRPSETLSLTCAVSGYSISSGMGWGWIRQPPGKGLEWIGSIDQRGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDAGHAVDMDVWGKGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYVFPLTFGGGTKVEIK,na,na,None,None,None,2017,2018,Toxin A,Adimab;Arsanis;X4 Pharmaceuticals,na,na,Staphylococcal infections,na,,E VQLQ ESGPG LV RPSE TLSLTCAV SGY SI SSGMG WGWIR QPPGKGL EWIGSI DQRGS TYY NPSLKS RVTISVD TSKN QFSLKLSS VTAADT AVYYCA RDAGH AVDMDV WGKG TTVTVS S,DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISRWLAWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQ PEDFATY YC QQGY VFPLTF GGG TKVEI K
Atinumab,Whole mAb,G4,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMSWVRQAPGKGLEWVATIKQDGSQKNYVDSVKGRFTISRDNAKNSLYLRLNSLRAEDTAVYYCATELFDLWGRGSLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTKLEIK,na,na,None,None,None,2010,2011,RTN4,Novartis,na,na,Spinal cord injuries,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TF SN YWMSWVR QAPGKG LEWVATIK QDGSQK NYVD SVKG RFTISR DNAKN SLYLRLN SLRAEDT AVYYCA TEL F DLWGRGS LVTV SS,E IVLTQ SPA TLSL SPGE RATLSCR ASQS VSSY LAWY QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPE D FAVYYCQ QRSNWP ITF GQGT KLEI K
Atisnolerbart,Whole mAb,G4,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFISYNIFWVRQATGQGLDWMGWMNPFRNNAGYAQKFQGRVTVTWDTSISTAYMELSSLSSEDTAIYYCAREHGSSWGFFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,7mxl:JK/7n0v:HL,None,None,2022,na,Bet v 1,Regeneron,TBC,TBC,TBC,na,Antigen: Bet v 1 (Betula alleghaniensis (yellow birch) pollen allergen 1. Also known as REGN5715. Identical V region sequence to Bremzalerbart.,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFISYNIFWVR QATGQGLD WMGW MNPFRNNAGY AQKF QG RVTVTW DTSI STAYMELS SLSSEDT AIYYCAR EHGSSW GFFD YWGQG TLVTV SS,E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSS S YLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYC Q QYGSSPWTFGQGT KVEI K
Atoltivimab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFNNYGMHWVRQAPGMGLEWVAVIWHDGSDKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARNWNLFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRITITCRASQSISTYLHWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFSTPPINFGQGTKLEIK,na,na,None,None,None,2018,2019,Zaire Ebolavirus GP,Regeneron Pharmaceuticals,na,na,Ebola virus infections,na,,Q VQLVES GGG VV QPGR SLRLSC AASGF TF NNY GMHWVRQ APGMG LEWVAVIWH DGSDK YYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RNWN LF DYWGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RITITCR ASQS ISTYLHWY QQKPGKAP KLLIYAA STLQSGVPS R FSGSGSGTD FTLTIS SLQP EDFA TYYCQ QSFSTPPINFGQGT KLEI K
Avdoralimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMHWVRQATGKGLEWVSAIDTGGGTYYADSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARDYYYYASGSYYKAFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSPLTFGQGTKLEIK,na,na,None,None,None,2019,2020,C5AR1,Novo Nordisk;Innate Pharma,na,Bullous pemphigoid;COVID-19;Urticaria;Liver cancer;Non-small cell lung cancer;Solid tumours,Rheumatoid arthritis,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFSSYVMHWVR Q ATGKGL EWVSAID TGGG TYYA DSVKG RFTIS RE NAKNS LYLQMNS LRAGD TAVYYCA RD YYYY ASGS YYKAFDI WGQG TMVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQSVS SR YLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LE PEDFA VYY CQQ YGSPL T FGQGT KLEI K
Avelumab,Whole mAb,G1,Lambda,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL,na,na,4nki:HL/5grj:HL,None,None,2015,2016,CD274,AIO Studien gGmbH;Array BioPharma;Chong Kun Dang;Dana-Farber Cancer Institute;Debiopharm;eFFECTOR Therapeutics;EMD Serono;Forty Seven;Fred Hutchinson Cancer Research Center;Gachon University Gil Medical Center;Hellenic Cooperative Oncology Group;Hospices Civils de Lyon;Johannes Gutenberg-University Mainz;M. D. Anderson Cancer Center;Merck KGaA;National Cancer Institute (USA);National Cancer Institute Slovakia;Netherlands Cancer Institute;Pfizer;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Syndax Pharmaceuticals;Transgene;University College London;University of Birmingham;University of California San Diego;University of Iowa;Vaccinex;Vanderbilt-Ingram Cancer Center;VAXIMM;Verastem Oncology;Washington University School of Medicine,Merkel cell carcinoma;Urogenital cancer;Renal cell carcinoma,Breast cancer;Diffuse large B cell lymphoma;Gastric cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer;Bladder cancer;Endometrial cancer;Fallopian tube cancer;Germ cell and embryonal neoplasms;Gestational trophoblastic disease;Glioblastoma;Haemangiosarcoma;Intestinal cancer;Leiomyosarcoma;Nasopharyngeal cancer;Neuroendocrine tumours;Osteosarcoma;Peripheral T-cell lymphoma;Peritoneal cancer;Prostate cancer;Recurrent respiratory papillomatosis;Small cell lung cancer;Solid tumours;Squamous cell cancer;Thymoma;Liposarcoma;Lymphoma;Oropharyngeal cancer;Pancreatic cancer;Acute myeloid leukaemia;Follicular lymphoma;Hodgkin's disease;Liver cancer;Meningioma;Bone metastases;Anal cancer;Cervical cancer;Vulvovaginal cancer;Meningioma,na,Human Phage Display,Avelumab and Bintrafusp have identical V domains,E VQLLES GGG LV QPGG SLRLSCA ASGF TFSSYIMMWVRQ APGKG LEWVSSI YPSGG ITFYAD TVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCARIK LGT VTTVDY WGQG TLVTVS S,QSALTQPA SV SGSPGQ SITISCT GTSSDVGG YNYVSWYQ QHPGKAP KLMIYD VSNRPSGVSNRFSGSKSGN TASLTIS GLQAEDEAD YYCSS YTSSST RVF GTGT KVTV L
Avizakimab,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYWMHWVRQAPGQGLEWMGTIDPSDQYTIYSQNFKGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYGFAMDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQDISNFLNWYQQKPGKAVKLLIYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGHTLPRTFGGGTKVEIK,na,na,None,None,None,2019,2020,IL21,MedImmune;Boston Pharmaceuticals,na,Systemic lupus erythematosus,Autoimmune disorders,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTDYWMHWVR QAPGQG LEWMGTI DPSDQ YTIYSQ NFKG RVTMTR DTSTS TVYMELS SLRSEDT AVYYCA RYGF AMD YWGQG TLVTVS S,DI QLT QSPSS LSA SVGD RVTITCR ASQD ISNFLNWYQ QKPGK AVKLLIYYT SRLHSGVPS R FSGSGSGTD YTLTIS SLQ PEDFATY Y C QQGHTLPRTFGGGT KVEI K
Axatilimab,Whole mAb,G4,Kappa,Phase-II,Active,EVTLKESGPALVKPTQTLTLTCTFSGFSLTTYGMGVGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIGPIKYPTAPYRYFDFWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCLASEDIYDNLAWYQQKPGKAPKLLIYYASSLQDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCLQDSEYPWTFGGGTKVEIK,na,na,None,None,None,2019,2020,CSF1R,Syndax Pharmaceuticals;AstraZeneca;UCB,na,Cholangiocarcinoma;Graft-versus-host disease;COVID-19,Solid tumours,na,,E VTLKE SGPA LV KPTQ TLTLTCTF SGF SLTTYGMGVGWIR QPPGKA LEW LANIW WDDDKYYNPSLKN RLTIS KDTSKN QVVLTMT NMDPVDTA TYYCARI GPIKYPTAPY RYFDF WGQG TMVTVS S,DIQMTQSPSS LSA SVGD RVTITCL ASED IYDNLAWYQ QKPGKAP KLLIYYA SSLQDGVPS RF SGSGSGTD YTLTIS SLQPEDF ATYYCL QDSEYPW T FGGG TKVEI K
Azintuxizumab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMAWVRQAPGKGLEWVASINYDGSSTYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDRGYYFDYWGQGTTVTVSS,DVVMTQTPLSLSVTPGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPPFTFGGGTKVEIK,na,na,None,None,None,2016,2017,SLAMF7,AbbVie,na,na,Multiple myeloma,na,,E VQLVES GGG LV QPGG SLRLSCA ASGF TF SD YYMAWVRQ APGKG LEWVASIN YDGS STYYVD SVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCA RDRG YYFDY WGQG TTVTVS S,DV VMT QTP LSLSV TPGQP ASISCR SSQ SLVH SNGN TYLHWYLQ KPGQSP QLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AED VGVYFCS QSTHVPPF T FGGG TKVEI K
Bafisontamab,Bispecific Mixed mAb and Fab,G1;na,Kappa;Kappa,Phase-I/II,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIK,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGFSWVRQAPGQGLEWMGWISASNGNTYYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARVYADYADYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGINTWLAWYQQKPGKAPKLLIYAASSLKSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPLTFGGGTKVEIK,5sx4:HL:JI/5sx5:JK:HL;None,None;None,None;None,2021,2022,EGFR;MET,EpimAb Biotherapeutics,na,Non-small cell lung cancer;Solid tumours,na,na,Fv1 is Panitumumab,Q VQLQE SGPGL V KPSE TLSLTCTVS GGSVSSGD YYWTWIRQ SPGKGL EWIGHIYYS GNTNYNPSLK SRLTISID TSKT QFSLKLSS VTAADT AIYYCVR DRVTG AFDIW GQG TMVTVS S,DIQMTQSPSS LSA SVGD RVTITCQ AS QDISNYLNWYQ QKPGKAP KLLIYD ASNLETGVPSRFSGSGSGTD FTFTIS SLQ PEDIATYFCQH FDHLP LAF GGGT KVEI K
Balstilimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASNGDHWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPRTFGQGTKVEIK,na,na,None,None,None,2018,2019,PDCD1,Agenus;Ludwig Institute for Cancer Research,na,Cervial cancer;Solid tumours;Colorectal cancer;Haemangiosarcoma;Soft tissue sarcoma,na,na,,Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKGL EWVAVIWY DGSNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAED TAVYYCA SNGDHWGQ GTLVTVS S,E IVMT QSPA TLSV SPGE RATLSCR ASQSVSSN LAWYQ QKPGQAP RLLIYG ASTRATGIP ARFS GSGSGT EFTLTISS LQSED FAVYYCQQ YNNWPRTFGQGT KVEI K
Bamlanivimab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYAISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGYYEARHYYYYYAMDVWGQGTAVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLSWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTITSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK,na,na,7l3n:DE/7kmg:AB:DE,None,None,2020,2021,SARS-CoV-2 Spike,Abcellera;Eli Lilly and Company;National Institute of Allergy and Infectious Diseases,COVID-19,na,na,Baiting from convalescent human B-cells,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT F S NYAISWVR QAPGQGL EWMGRIIPILG IANYAQK FQG RVTITA DKSTS TAYMELS SLRSEDT AVYYCA RG YY EAR HYYYYYAMD VWGQG TAVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQS ISSYLSWY QQKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTITS LQP EDFA TYYCQ QSYSTPRTFGQGT KVEI K
Bapineuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAPGKGLEWVASIRSGGGRTYYSDNVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRYDHYSGSSDYWGQGTLVTVSS,DVVMTQSPLSLPVTPGEPASISCKSSQSLLDSDGKTYLNWLLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPRTFGQGTKVEIK,na,na,None,None,4ojf:HL/4hix:HL,2005,2006,APP,JANSSEN Alzheimer Immunotherapy;Pfizer;Wyeth;Elan Corporation,na,na,Alzheimer's disease,na,"Jain paper: ""Conflicting literature sequences in FR3 of VH - AKNTLYLQMNSLRAEDTAV vs. AKNSLYLQMNSLRAEDTAL""",E VQLLES GGG LV QPGG SLRLSC AASGF TFS NYG MSWVRQ APGKG LEWVASIR SGGGR TYYS DNVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCVRYD HYSGSSDYWGQ GTLVTVS S,DV VMT QSPLSLPVTPGEPA SISC KSSQ SLL DSDGK TYLNWLL QKPGQSPQ RLIYLVSK LDSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCW QGTHFPRTFGQGT KVEI K
Bapotulimab,Whole mAb,G2,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGRLPYGDFWDSWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGGGTKLEIR,na,na,None,None,None,2020,2021,ILDR2,Bayer,na,Solid tumours,na,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSSYAISWVR QAPGQGL EWM GG IIPILGI A N YAQ KFQG RVTITA DKSTS TAYMELS SLRSEDT AVYYCA RGRLPYGDFWDSWGQG TLVTV SS,DI VMT QSPLSLPVTPGEPA SISC RSSQ SLLY SNGYN YLDWYL QKPGQSP QLLIYL GSNRASGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCMQA LQTPL TF GGGT KLEI R
Barecetamab,Whole mAb,G1,Lambda,Phase-I,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYDMSWVRQAPGKGLEWVSTIDLDSGSIYYADSVQGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDLHMGPEGPFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNSVSWYQQLPGTAPKLLIYSDNHRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCQGWDTSLSGHVFGGGTKLTVL,na,na,7d85:BC:EF,None,None,2020,2021,ERBB3,ISU Abxis,na,Head and neck cancer,Solid tumours,Antibody Phage Display,,E VQLLES GGG LV QPGG SLRLSC AASGF TF SDYDM SWVR QAPGKGL EWVSTID LDSG SIYYAD SVQG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA KDLHMGPEGPFDYWGQG TLVTVS S,QSVLTQPPSASGTPGQ RVTISC SGSSSNIGSNS VS WYQ QLPGTAP KLLIY SDNHRPSGVPDRFSGSKSGT SASLAI SGLRSED E A DY YC QGWDTSLSG HVF GGGT KLTV L
Barzolvolimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKLSCKASGYTFTDYYINWVRQAPGKGLEWIARIYPGSGNTYYNEKFKGRATLTADKSTSTAYMQLSSLRSEDTAVYFCARGVYYFDYWGQGTTVTVSS,DIVMTQSPSSLSASVGDRVTITCKASQNVRTNVAWYQQKPGKAPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISSLQPEDFADYFCQQYNSYPRTFGGGTKVEIK,na,na,None,None,None,2021,2022,KIT,Celldex Therapeutics,na,Chronic idiopathic urticaria,na,na,,Q VQLVQ SGA EVK KPGA SVKLSCK ASGY TFTDYYINWVR QAPGKG LEWIARI YPGSGNT YY NEKFKG RATLTA DKSTS TAYMQLS SLRSEDT AVYFC ARG VYYFD YWGQG TTVTVS S,D IVMT QSPSS LSA SVGD RVTITCK ASQNV RTNVAWYQ QKPGKAPK ALIYSASYRY SGVPDRFTGSGSGTD FTLTIS SLQ PEDFADYFCQQY NSYPRTFGGGT KVEI K
Basiliximab,Whole mAb,G1,Kappa,Approved,NFD,QVQLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIYPGNSDTSYNQKFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCSRDYGYYFDFWGQGTTLTVSS,QIVSTQSPAIMSASPGEKVTMTCSASSSRSYMQWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQRSSYTFGGGTKLEIK,na,na,1mim:HL/3iu3:AB:CD:HL,None,None,1996,1997,IL2RA,Cerimon Pharmaceuticals;Novartis,Renal transplant rejection;Transplant rejection,na,Ulcerative colitis;Uveitis,na,,QV QLQ QSG TVLA RPGA SVKMSCK ASGYS FTRYWMHWIK QRPGQGL EWIGAI YPGNSDTSYNQK F EGK AKLTAVT SAST AYMEL SSLTHEDS AVYYC SRDYG YYFDF WGQG TTLTVS S,QI VS TQSP AIMS ASPGE KVTMTCS ASSSRS YMQWYQ QKPGTSPK RWIYD TSKLASGVP ARFS GSGSGT SYSLTISS MEAEDA ATYYCHQ RSS YTF GGGT KLEI K
Batoclimab,Whole mAb,G1,Lambda,Phase-III,Active,QLLLQESGPGLVKPSETLSLTCTVSGGSLSSSFSYWVWIRQPPGKGLEWIGTIYYSGNTYYNPSLKSRLTISVDTSKNHFSLKLSSVTAADTAVYYCARRAGILTGYLDSWGQGTLVTVSS,SYVLTQSPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSASNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL,na,na,None,None,None,2019,2020,FCGRT,Immunovant Sciences,na,Graves' Ophtalmopathy;Myasthenia gravis;Autoimmune disorders;Neuromyelitis optica;Idiopathic thrombocytopenic purpura,na,na,,Q LLLQE SGPGL V KPSE TLSLTCTV SGGSLSSS FSYWVWIR QPPGKGL EWIGTIYYS GNT Y YNPSLK SRLTISVD TSKN HFSLKLSS VTAADT AVYYCAR RAG ILTGYL DSWGQG TLVTVS S,S YVLT QSPS VSV APGQ TARITC GGNNIGSK SVHWYQ QKPGQAP VLVVY DDSDRPSGIPE RFSA SNSGN TATLTISRVE AGDE ADYYCQVWD SSSD HVVFG GGT KLTV L
Bavituximab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLQQSGPELEKPGASVKLSCKASGYSFTGYNMNWVKQSHGKSLEWIGHIDPYYGDTSYNQKFRGKATLTVDKSSSTAYMQLKSLTSEDSAVYYCVKGGYYGHWYFDVWGAGTTVTVSS,DIQMTQSPSSLSASLGERVSLTCRASQDIGSSLNWLQQGPDGTIKRLIYATSSLDSGVPKRFSGSRSGSDYSLTISSLESEDFVDYYCLQYVSSPPTFGAGTKLELK,na,na,None,None,None,2006,2007,Phosphatidylserine,Avid Bioservices;IMV;Massachusetts General Hospital;Merck Sharp & Dohme;Peregrine Pharmaceuticals;University of Arizona;University of Texas Southwestern Medical Center;University of Texas M. D. Anderson Cancer Center,na,Non-small cell lung cancer;Glioblastoma;Liver cancer;Solid tumours,Breast cancer;Malignant melanoma;Pancreatic cancer;Brain cancer;Hepatitis C;HIV infections;Rectal cancer;Viral haemorrhagic fevers;Influenza virus infections;Prostate cancer,na,,EV QLQ QSGPELEKPGA SVKLSCK ASGY SFTGYNMNWVK QSHGK SLEWIGHI DPYYGDTSYNQK F RG KATLTVD KSSST AYMQLKS LTSEDS AVYYCV KGGYYG HWYFDVW GAGT TVTVS S,DI QMT QSPSS LS ASLGE RVSLTCR ASQDIGSS LNWLQQ GPDGT IKRLIYAT SSLDSGVPK R FSGSRSGSD YSLTISS LESEDF VDYYCLQYV SSPPTFGAGT KLEL K
Bavunalimab,Bispecific Mixed mAb and scFv,G1;na,Kappa;Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFDDAWMSWVRQAPGKGLEWVAEISTKANNHATYYAESVKGRFTISRDDSKSSVYLQMNSLRAEDTAVYYCTRLATWDWYFDVWGQGTTVTVSS,DIVLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKPPKLLIYAASELESGIPARFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPFTFGSGTKLEIK,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVSFISYDGNYKYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGGHLGPFDLWGQGTMVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,None;None,None;None,None;None,2020,2021,LAG3;CTLA4,Xencor,na,na,Solid tumours,na,Bavunalimab is the new name for Pavunalimab (PL125). (Jun '22) Corrected IMGT H25 S->A.,E VQLVES GGG LV QPGG SLRLSC AASGFTFDDA WMSWVR QAPGKGL EWVAEIST KANNH ATYYAES VKG RFTISR DDSKS SVYLQMN SLRAEDT AVYYCTR LATWD WYFDV WGQG TTVTVS S,D IVLT QSPSS LSA SVGD RVTITCRA SQS V DYDGD SYMNWYQ QKPGKPP KLLIYAA SELESGIP ARFS GSGSGTD FTLTISS LQPEDF ATYYCQ QSNEDPF T FGSGT KLEI K
Bebtelovimab,Whole mAb,G1,Lambda,Approved,Active,QITLKESGPTLVKPTQTLTLTCTFSGFSLSISGVGVGWLRQPPGKALEWLALIYWDDDKRYSPSLKSRLTISKDTSKNQVVLKMTNIDPVDTATYYCAHHSISTIFDHWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTATSSDVGDYNYVSWYQQHPGKAPKLMIFEVSDRPSGISNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTTSSAVFGGGTKLTVL,na,na,7mmo:AB:DE,None,None,2022,na,SARS-CoV-2 Spike RBD,Eli Lilly;AbCellera,COVID-19,na,na,na,,Q ITLK ESGP TLV KPTQ TLTLTCTF SG FSLSIS G VGVGWLR QPPGKA LEWLALIYW DDDKRYSPSLK SRLTIS KDTSKN QVVLKMTN IDPVDTA TYYC AHHS ISTIF DHWGQG TLVTVS S,QSALTQPA SV SGSPGQ SITISCTA TSSDVGD YNYVSWYQ QHPGKAP KLMIFEV SDRPSGISNRFSGSKSGN TASLTIS GLQAEDEAD YYCSS YTTSS AVF GGGT KLTV L
Becotatug,Whole mAb,G1,Kappa,TBC,Active,QVQLQESGPGLVKPSETLSLTCTVSGFSLSNYDVHWVRQAPGKGLEWLGVIWSGGNTDYNTPFTSRLTISVDTSKNQFSLKLSSVTAADTAVYYCARALDYYDYEFAYWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCRASQSIGTNIHWYQQKPDQSPKLLIKYASESISGIPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQNNEWPTSFGQGTKLEIK,na,na,None,None,None,2022,na,EGFR,TBC,TBC,TBC,TBC,TBC,,QV QLQE SGPGL V KPSE TLSLTCTV SGF S LSNY DVHWVRQ APGKGL EWLGVIWS GGNTDYNTPF TSRLTISVD TSKN QFSLKLSS VTAADT AVYYCA RALDYYD YEFAYW GQG TLVTVS S,E IVLTQ SPDFQSVTPKE KVTITCR ASQSIGT NIHWYQ QKPDQSP KLLIKYA SESISGIPSRFSGSGSGT DFTLTINS LEAED AA TYYCQ QNNEWPTSFGQGT KLEI K
Bedinvetmab,Canine Whole mAb,G2,Lambda,Approved,Active,EVQLVESGGDLVKPGGSLRLSCVASGFTFSSHGMHWVRQSPGKGLQWVAVINSGGSSTYYTDAVKGRFTISRDNAKNTVYLQMNSLRAEDTAMYYCAKESVGGWEQLVGPHFDYWGQGTLVIVSS,QSVLTQPTSVSGSLGQRVTISCSGSTNNIGILGASWYQLFPGKAPKLLVYGNGNRPSGVPDRFSGADSGDSVTLTITGLQAEDEADYYCQSFDTTLGAHVFGGGTHLTVL,na,na,None,None,None,2018,2019,Canine NGFB,na,na,Canine lupus familiaris,na,na,(June '22: Corrected FWL1 sequence),E VQLVE SGGD LV KPGG SLRLSCV ASG FTFS SHG MHWVRQ SPGKG LQWVAVIN SGGSS TYYTD AVKG RFTISR DNAKN TVYLQMN SLRAEDT AMYYCAK ESVGGW EQLV GPHFD Y WGQG TLVIVS S,QSVLTQPT SVS GSLGQ RVTISC SGSTNN IGILGASWYQL FPGKAP KLLVY GNGNRPSGVPDRFSGADSGD SVTLTITG LQAEDEAD YYCQS FDTTLGA HVF GGGT HLTV L
Befovacimab,Whole mAb,G2,Lambda,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMDWVRQAPGKGLEWVSSIRGSRGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLYRYWFDYWGQGTLVTVSS,SYELTQPPSVSVSPGQTARITCSGDNLPKYYAHWYQQKPGQAPVVVIFYDVNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWWSSTPVFGGGTKLTVL,na,na,None,None,None,2019,2020,TFPI,na,na,Haemophilia,na,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFSS YGM DWVR QAPGKG LEWVSSIR GSRGS TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAED TAVYYCARLYRYWFDY WGQG TLVTVS S,SYELTQPPS VSV SPGQ TARITC SGDNLP KY YAHWYQ QKPGQAP VVVIFYD VNRPSGIPERFSGSNSGN TATLTIS GTQAMDEAD YYCQAWW SSTPVFGGGT KLTV L
Begelomab,Whole mAb,G2b,Kappa,Phase-II/III,Active,QVQLQQSGAELVKPGASVKLSCKASGYTFRSYDINWVRQRPEQGLEWIGWIFPGDGSTKYNEKFKGKATLTTDKSSSTAYMQLSRLTSEDSAVYFCARWTVVGPGYFDVWGAGTTVTVSS,QIVLTQSPAIMSASPGEKVTITCSASSSVSYMNWFQQKPGTSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISRMEAEDAATYYCQQRSSYPNTFGGGTKLEIK,na,na,None,None,None,2014,2015,DPP4,ADIENNE,na,Graft-versus-host disease,na,na,,Q VQLQQ SGA ELV KPGA SVKLSCK ASGY TFRSYDINWVR QRPEQGL EWIGWIF PGDGSTKYNEKFKG KATLTT DKSSS TAYMQLSR LTSEDS AVYFCARWTVV GPGY FDVW GAG TTVTVS S,Q IVLT QSP AIMS ASPGE KVTITCS ASSS VSYMNWF QQKPGTSP KLWIYS TSNLASGVP ARFS GSGSGT SYSLTISR MEAEDA ATYYCQQ RSSYPNTFGGG TKLEI K
Belantamab,Whole mAb ADC,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGAIYDGYDVLDNWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKLLIYYTSNLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYRKLPWTFGQGTKLEIK,na,na,None,None,None,2017,2018,TNFRSF17,GlaxoSmithKline,Multiple myeloma,na,na,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT F S NYWMHWVR QAPGQG LEWMGATYR GHSDTYYNQKFK GRVTITA DKSTS TAYMELS SLRSEDT AVYYCA RGA IY DG YDVL DNWGQG TLVTVS S,DIQMTQSPSS LSA SVGD RVTITCS ASQD ISNYLNWYQ QKPGKAP KLLIYYT SNLHSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ YRKLPWTFGQGT KLEI K
Belimumab,Whole mAb,G1,Lambda,Approved,Active,QVQLQQSGAEVKKPGSSVRVSCKASGGTFNNNAINWVRQAPGQGLEWMGGIIPMFGTAKYSQNFQGRVAITADESTGTASMELSSLRSEDTAVYYCARSRDLLLFPHHALSPWGRGTMVTVSS,SSELTQDPAVSVALGQTVRVTCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCSSRDSSGNHWVFGGGTELTVL,na,na,5y9k:HL/5y9j:HL/6fxn:OP:QR:MN:FG:HI:DE,None,6erx:HI:DE:QR:MN:FG:OP,2003,2004,TNFSF13B,Assistance Publique Hopitaux de Paris;Cancer Trials Australia;GlaxoSmithKline;Hospital for Special Surgery;Human Genome Sciences;North Shore-Long Island Jewish Health System;University of Alabama at Birmingham;University of Pennsylvania;University of Wisconsin-Madison;Washington University School of Medicine;Cambridge Antibody Technology,Systemic lupus erythematosus;Lupus nephritis,Anti-neutrophil cytoplasmic antibody-associated vasculitis;Myositis;Emphysema;Membranous glomerulonephritis;Myasthenia gravis;Renal transplant rejection;Systemic scleroderma;Graft-versus-host disease,Waldenstrom's macroglobulinaemia;Rheumatoid arthritis;Sjogren's syndrome,CAT Phage Display,,Q VQLQQ SGA EVK KPGS SVRVSCK ASGGTFNNN AINWVR QAPGQGL EWM GG IIP MFGTA KY SQNFQG RVAITA DESTG TASMELSS LRSEDT AVYYCA RSRD LLLF PHHALSPWGRG TMVTVS S,SSELTQDPA VSVA LGQ TVRVTC QGDS LR S Y YA SW Y QQKPGQAP VLVIY GKNNRPSGIPDRFSGSSSGN TASLTIT GAQAEDEA DYYCSSR DSSGN HWVF GGGT ELTV L
Belrestotug,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGVIGPSGASTSYAQKFQGRVTLTRDTSTSTVYMELSSLRSEDTAVYYCARDHSDYWSGIMEVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVRSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYFSPPWTFGGGTKVEIK,na,na,None,None,None,2022,na,TIGIT,GlaxoSmithKline;iTeos Therapeutics,na,Multiple myeloma;Haematological malignancies;Solid tumours;Non-small cell lung cancer,na,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYYMHWVR QAPGQG LEWMGVI GPSGASTSYA QK FQG RVTLTR DTSTS TVYMELS SLRSEDT AVYYCA RDHSDYW SGIMEVW GQGT TVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQSV RSS YLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYCQ QYFSPPWTFGGGT KVEI K
Beludavimab,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYPFTSYGISWVRQAPGQGLEWMGWISTYQGNTNYAQKFQGRVTMTTDTSTTTGYMELRRLRSDDTAVYYCARDYTRGAWFGESLIGGFDNWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQTVSSTSLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHDTSLTFGGGTKVEIK,na,na,None,7jx3:AB:CD:HL/6ws6:AB:CD:EF/6wps:CD:FG:HL/6wpt:DE:HL/7bep:HL:GI/7l0n:CD:AB/7r6x:AB/7r6w:AB/7sob:GI:HJ:NO/7soc:HL/7tly:AB;7tm0:JK:LM:NO/7tn0:BA:CD,None,2021,2022,SARS-CoV-2 Spike RBD,GlaxoSmithKline,na,COVID-19,na,Beludavimab and Sotrovimab have identical Fvs,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGYPFT SYGISWVRQ APGQGL EWMGWISTY QGNTNY AQKF QG RVTMTT DTSTTT GYMELRRL RSDDT AVYYCAR DYTRGA WF GE SLI GG F DNWGQG TLVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQ TV SST SLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQ QHDT SLTF GGG TKVEI K
Bemarituzumab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYIFTTYNVHWVRQAPGQGLEWIGSIYPDNGDTSYNQNFKGRATITADKSTSTAYMELSSLRSEDTAVYYCARGDFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQGVSNDVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQHSTTPYTFGQGTKLEIK,na,na,None,None,7sob:GI:HJ:NO/7soc:HL,2017,2018,FGFR2,Five Prime Therapeutics;ZAI Lab,na,Gastric cancer,Oesophageal cancer;Solid tumours,POTELLIGENT Technology,,Q VQLVQ SGA EVK KPGS SVKVSCK ASG YIFTTYNVHWVRQ APGQG LEWIGSI YPDNGDTSYNQNFKG RATITA DKSTS TAYMELS SLRSEDT AVYYCA RGD FAYW GQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITCK ASQGVSND VAWYQ QKPGKAP KLLIYSASYRY TGVPSRFSGSGSGT DFTFTIS SLQ PEDIAT YYC QQHSTTPY T FGQGT KLEI K
Bempikibart,Whole mAb,G1,Kappa,TBC,Active,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDHAMHWVRQAPGKGLEWVSGISWNSRGIGYADSVKGRFTIFRDNAKNSLYLQMNSLRAEDTALYYCAKDEYSRGYYVLDVWGQGTTVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLWITFGQGTRLEIK,na,na,None,None,None,2022,na,IL7R,TBC,TBC,TBC,TBC,TBC,,E VQLVES GGG LV QPGR SLRLSC AASGF TF DDHA MHWVRQ APGKGL EWVSGISW NSRGI G YADSVKG RFTIFR DNAKN SLYLQMN SLRAEDT ALYYCA KDEYSRG YYVLDV WGQG TTVTVS S,AI QLT QSPSS LSA SVGD RVTITCR ASQG ISSALAWYQ QKPGKAP KLLIYD ASSLESGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ FNSYP LWITF GQGT RLEI K
Benralizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVIHWVRQRPGQGLAWMGYINPYNDGTKYNERFKGKVTITSDRSTSTVYMELSSLRSEDTAVYLCGREGIRYYGLLGDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCGTSEDIINYLNWYQQKPGKAPKLLIYHTSRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYTLPYTFGQGTKVEIK,na,na,None,None,None,2009,2010,IL5RA,AstraZeneca;Cincinnati Children's Hospital Medical Center;Kyowa Hakko;Kyowa Hakko Kirin;McMaster University;MedImmune;National Jewish Medical and Research Center;BioWa,Asthma,Chronic obstructive pulmonary disease;Nasal polyps;Atopic dermatitis;Churg-Strauss syndrome;Hypereosinophilic syndrome;Rhinosinusitis;Eosinophilic gastroenteritis,Skin disorders,POTELLIGENT Technology,,E VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYVIHWVR QRPGQG LAWMGYI NPYNDGTKYNE RF KG KVTITS DRSTS TVYMELS SLRSED TAVYLC GREGI RYYGLL GDYWGQG TLVTVS S,DIQMTQSPSSL SA SVGD RVTITC GT SEDIINYLNWYQ QKPGKAP KLLIYH TSRLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQ QGY T LP YT FGQGT KVEI K
Bentracimab,Whole mAb,G1,Lambda,Phase-III,Active,QVQLQESGAEVKKPGSSVRVSCKASGGTFDSYSIHWVRQAPGQGLEWMGGIIPAFGTLSSAQDFQARVTISADKSTSTAYMELSGLRSEDTAVYYCARGSFDYYFWSASHPPNDALAIWGQGTLVTVSS,QSVVTQPPSVSAAPGQKVTISCSGSNSDIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLAITGLQAGDEADYYCGTWLYDRAVGLFGGGTKVTVL,na,na,5alb:HL,None,5alc:HL,2020,2021,AR-C124910XX,MedImmune;AstraZeneca;PhaseBio,na,Haemorrhage (reversal of effects of ticagrelor),na,na,,Q VQLQE SGA EVK KPGS SVRVSCK ASGGTFD SYSIHWVRQ APGQG LEWMGGIIP AFGTLSSAQD FQARVTISA DKSTS TAYMEL SGLRSEDT AVYYC ARGS FDYYFWS ASHPPND ALAIW GQG TLVTVS S,QSV V TQPPSVSAAPGQ KVTISC SGSNSDIGN NYVSWYQQ LPGTAP KLLIY DNNKRPSGIPDRFSGSKSGTS ATLAIT GLQAGDEAD YY CG TWL YDRAVGL FGGGT KVTV L
Benufutamab,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLQQSGAEVVKPGASVKLSCKASGFNIKDTFIHWVKQAPGQGLEWIGRIDPANTNTKYDPKFQGKATITTDTSSNTAYMELSSLRSEDTAVYYCVRGLYTYYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSISNNLHWYQQKPGQAPRLLIKFASQSITGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQGNSWPYTFGQGTKLEIK,na,na,6t3j:AB:FG,None,None,2019,2020,TNFRSF10B,Genmab;VU University Medical Center;iDD Biotech,na,Solid tumours;Multiple myeloma,na,na,,E VQLQQ SGA EVV KPGA SVKLSCK ASGFNIKD TFIHWVK QAPGQG LEWIGRI DPANTNTKYDPKFQG KATITT DTSSN TAYMELS SLRSEDT AVYYCV RG LYTYYFD YWGQG TLVTVS S,E IVMT QSPA TLSV SPGE RATLSCRA SQSISNN LHWYQ QKPGQAP RLLIKF ASQS ITGI P ARF SGSGSGT EFTLTISS LQSED FAVYYC QQGNSWP YTF GQGT KLEI K
Bepranemab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLQESGPGLVKPSETLSLTCTVSGFSLTSNDIAWIRQPPGKGLEWMGTIWTDGSTNYNTAVQSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHRLYYGAFDYWGQGTMVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSQSLEYSDGYTYLEWYLQKPGQSPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQATHNPYTFGQGTKLEIK,na,na,None,None,None,2019,2020,MAPT,UCB BioPharma,na,Progressive supranuclear palsy (PSP);Alzheimer's Disease,na,na,(June '22: Removed duplicate residue from FWL3),E VQLQE SGPGL V KPSE TLSLTCTV SG FS LTSND IAWIR QPPGKGL EWMGTIWT DGSTNYNTA VQSRVTISVD TSKN QFSLKLSS VTAADT AVYYC ARHR LYYGAFD YWGQG TMVTVS S,DI VMT QTP LSLSV TPGQP ASISCR SSQ SLEY SDGY TYLEWYL QKPGQSP QLLIYEVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCFQA THNPYTFGQG TKLEI K
Berlimatoxumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,ELQLQESGPGLVKPSETLSLTCTVSGGSISSGSYYWDWIRQPPGKGLEWIGNIYKSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARERGMHYMDVWGKGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSINSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQFDPPFTFGGGTKVEIK,na,na,5k59:HL:EF,None,None,2017,2018,Toxin A,Adimab;Arsanis;X4 Pharmaceuticals,na,na,Staphylococcal infections,na,,EL QLQE SGPGL V KPSE TLSLTCTV SGGSISSGS YYWDWIR QPPGKGL EWIGNIYK SGS TYY NPSLKS RVTISVD TSKN QFSLKLSS VTAAD T AVYYCA R ERGM HYMDV WGKG TTVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQS INSYLNWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQ PEDFATYYCQ QQFDPPF T FGGGT KVEI K
Bermekimab,Whole mAb,G1,Kappa,Preregistration,Active,QVQLVESGGGVVQPGRSLRLSCTASGFTFSMFGVHWVRQAPGKGLEWVAAVSYDGSNKYYAESVKGRFTISRDNSKNILFLQMDSLRLEDTAVYYCARGRPKVVIPAPLAHWGQGTLVTFSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYEASNLETGVPSRFSGSGSGSDFTLTISSLQPEDFATYYCQQTSSFLLSFGGGTKVEHK,na,na,None,None,None,2018,2019,IL1A,XBiotech Inc.,na,Colorectal cancer;Cachexia;Atopic dermatitis;Acne vulgaris;Hidradenitis suppurativa;Non-small cell lung cancer;Plaque psoriasis;Systemic scleroderma;Type 2 diabetes mellitus;Vascular restenosis;Pancreatic cancer,Haematological malignancies,na,,Q VQLVES GGG VV QPGR SLRLSCT ASGF TFSMFGVHWVRQ APGKG LEWVAAVSY DGSNK YYAESV KG RFTISR DNSKN ILFLQM DSLRLEDT AVYYC ARGRP KVVIP APLAHWGQG TLVTF SS,DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISSWLAWY QQKPGKAP KLLIYE ASNLETGVPSRFSGSGSGSD FTLTIS SLQP EDFA TYYC QQTSS FLLSF GGGT KVE HK
Bersanlimab,Whole mAb,G1,Lambda,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVAFIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYSGWYFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYDNNNRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCQSYDSSLSAWLFGGGTKLTVL,na,na,None,None,None,2017,2018,ICAM1,BioInvent International,na,na,Multiple myeloma,n-CoDeR,,E VQLLES GGG LV QPGG SLRLSC AASGF TF SNA WMSWVR QAPGKGL EWVAFIWY DGSNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAR YSG WYFD YWGQG TLVTVS S,QSVLTQPPSASGTPGQ RVTISCT GSSSNIGAG YDVHWYQ QLPGTAP KLLIY DNNNRPSGVPDRFSGSKSGTS A SLAI SGLRSEDEA D YYCQ SYDSS LSA WLF GGGT KLTV L
Betifisolimab,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKLSCKASGYIFTTYWMHWVKQRPGQGLEWIGMIQPNSGGTKYNEKFKKKATLTVDKSISTAYMELSRLTSDDTAVYYCARGAGTVDYFDYWGQGSTLTVSS,DIVLTQSPASLAVSVGQRATITCRASESVDIYGNSFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSRTDFTLTINPVEAQDTATYYCQQSTEDPYTFGGGTKLEIK,na,na,None,None,None,2022,na,CD274,MabSpace Biosciences;Transcenta Holding,na,Solid tumours,Haematological malignancies,na,,Q VQLVQ SGA EVK KPGA SVKLSC KASG YIFTTYWMHWVK QRPGQGL EWIGMI QPNSGGTKYNEKFKK KATLTV DKSI STAYME L S RLTSDDT AVYYCA RGAGT VDYFD YWGQGS TLTVS S,D IVLT QSPA SLAVS VGQ RATITCR ASE SVDIY GNS FMHWYQ QKPGQPP KLLIYRA SNLESGIP ARF SGSGSRT DFTLTIN PVEAQDT ATYYCQQ STEDPYTFGGG TKLEI K
Bevacizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,na,na,1bj1:HL:KJ,None,6bft:AB:HL/1cz8:HL:YX,2000,2001,VEGFA,All Ireland Cooperative Oncology Research Group;ARCAGY/GINECO Group;Austrian Breast & Colorectal Cancer Study Group;Bayer;Beth Israel Deaconess Medical Center;Breast Cancer Research Foundation;Brigham and Women's Hospital;Bristol-Myers Squibb;Cancer and Leukemia Group B;Cancer Research UK;Chugai Pharmaceutical;Cincinnati Children's Hospital Medical Center;Dana-Farber Cancer Institute;Duke University;European Organisation for Research and Treatment of Cancer;European Thoracic Oncology Platform;Genentech;Hackensack University Medical Center;Hoosier Cancer Research Network;Indiana University School of Medicine;Japan Breast Cancer Research Group;M. D. Anderson Cancer Center;Massachusetts General Hospital;Medical University of South Carolina;Melanoma Research Foundation Breakthrough Consortium;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);National Comprehensive Cancer Network;NCIC Clinical Trials Group;North Central Cancer Treatment Group;NSABP Foundation;Ohio State University Medical Center;Peter MacCallum Cancer Centre;Roche;Royal Marsden NHS Foundation Trust;Sanofi;Sarcoma Alliance for Research through Collaboration;SCRI Development Innovations;South Eastern European Research Oncology Group;Spanish Cooperative Group for Digestive Tumour Therapy;Spanish Lung Cancer Group;Stanford University School of Medicine;SWOG;The Catalan Institute of Oncology;UNICANCER;University College London;University of Alabama at Birmingham;University of Arkansas System;University of California Davis;University of Iowa;University of Oklahoma;University of Tennessee;University of Texas M. D. Anderson Cancer Center;US Oncology Research;West German Study Group;Xijing Hospital,Breast cancer;Cervical cancer;Colorectal cancer;Glioblastoma;Glioma;Non-small cell lung cancer;Ovarian cancer;Renal cell carcinoma;Fallopian tube cancer;Peritoneal cancer,Head and neck cancer;Biliary cancer;Brain metastases;Endometrial cancer;Ewing's sarcoma;Gynaecological cancer;Hodgkin's disease;Intestinal cancer;Liver cancer;Liver metastases;Malignant melanoma;Meningioma;Multiple myeloma;Neuroblastoma;Neurofibromatoses;Rectal cancer;Soft tissue sarcoma;Solid tumours;Urogenital cancer;Neoplastic meningitis;Sarcoma,Carcinoid tumour;Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Eye disorders;Gastric cancer;Gastrointestinal stromal tumours;Mesothelioma;Oesophageal cancer;Pancreatic cancer;Prostate cancer;Small cell lung cancer,na,,E VQLVES GGG LV QPGG SLRLSC AASGY TFTN YGM NWVRQ APGKGL EWVGWIN TYTGEPT YA ADFKR RFTFSL DTSKS TAYLQMN SLRAEDT AVYYCA KYPHYYGSS HWYFDV WGQG TLVTVS S,DIQMTQSPSS LSA SVGD RVTITCS ASQD ISNYLNWYQ QKPGKAP KVLIYFT SSLHSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ YSTVPW T FGQGT KVEI K
Bexmarilimab,Whole mAb,G4,Kappa,Phase-I/II,Active,QVTLKESGPTLVKPTQTLTLTCSFSGFSLSTSGMGIGWIRQPPGKALEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCARHYGYDPYYAMDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCTASSSVSSSYLHWYQQKPGKAPKLLIYRTSNLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCHQYHRSPPTFGQGTKLEIK,na,na,None,None,None,2019,2020,STAB1,Faron Pharmaceuticals,na,Solid tumours;Cancer;Immunocompromised infections;Pertussis;Tuberculosis,na,na,,QV TLK ESGP TLV KPTQ TLTLTCSF SG FSLS TSGM GIGWIR QPPGKA LEWLAHIWW DDDKRYNPALK SRLTIS KDTSKN QVVLTMT NMDPV DTATYYCARH YGYDPY YAMD YWGQG TLVTV SS,E IVLTQ SPG TLSL SPGE RATLSCTA SSSVSSS YLHWYQ QKPGKAP KLLIYRT SNLASGVPS R FSGSGSGTD YTLTISS LQPE DF ATYYCHQ YHRSPPTFGQGT KLEI K
Bezlotoxumab,Whole mAb,G1,Kappa,Approved,NFD,EVQLVQSGAEVKKSGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIFYPGDSSTRYSPSFQGQVTISADKSVNTAYLQWSSLKASDTAMYYCARRRNWGNAFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSTWTFGQGTKVEIK,na,na,4np4:HL:IM,None,None,2012,2013,Toxin A,Medarex;University of Massachusetts Medical School;Merck & Co;Merck Sharp & Dohme,Clostridium difficile,na,na,Medarex HuMAb Mouse,,E VQLVQ SGA EVK KSGE SLKISC KGSGY SFTSYWIGWVRQ MPGKGL EWMGIF YPGDSSTR Y SPSFQG QVTIS ADKSVN TAYLQWSS LKASDT AMYYCAR RRNWGNA FDIW GQG TMVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSS S YLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYC Q QYGSS TWTF GQGT KVEI K
Bifikafusp,Whole mAb Fusion,E,Kappa,Phase-III,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK,na,na,None,None,None,2010,2011,FN extra domain B,Philogen,na,Non-small cell lung cancer;Diffuse large B-cell lymphoma;[With onfekafusp] Malignant melanoma;[With onfekafusp] Basal cell cancer;[With onfekafusp] Squamous cell cancer;[With onfekafusp] Solid tumours,Malignant melanoma;Renal cell carcinoma;Solid tumours;Atherosclerosis;Head and neck cancer;Pancreatic cancer,na,Radretumab+Bifikafusp+Onfekafusp have identical V domains,E VQLLES GGG LV QPGG SLRLSC AASGF TFSSFSMSWVR QAPGKG LEWVSSIS GSSGT TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA KPFPYFDYWGQG TLVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQSVS SSFLAWY Q QKPGQAP RLLIYYA SSRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYCQ QTGRIPPTFGQGT KVEI K
Bimagrumab,Whole mAb,G1,Lambda,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSSYINWVRQAPGQGLEWMGTINPVSGSTSYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGWFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNYVNWYQQHPGKAPKLMIYGVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCGTFAGGSYYGVFGGGTKLTVL,na,na,5nhr:HL:AB,5nhw:HL/5nh3:HL:IM/5ngv:HL,None,2012,2013,ACVR2B,MorphoSys;Novartis,na,Cachexia;Muscular atrophy;Type 2 diabetes mellitus,Inclusion body myositis,MorphoSys HuCAL Phage Display,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSSYINWVR QAPGQG LEWMGTI NPVSGSTSY AQKF QG RVTMT RDTS ISTAYMELSR LRSDDT AVYYC ARGG WFDY WGQG TLVTVS S,QSALTQPA SV SGSPGQ SITISCT GTSSDVGS YNYVN WYQ QHPGKAP KLMIYGVS KRPSGVSNRFSGSKSGNT ASLTIS GLQAEDEAD YYC G T FAGGS YYGVF GGGT KLTV L
Bimekizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYNMAWVRQAPGKGLEWVATITYEGRNTYYRDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASPPQYYEGSIYRLWFAHWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCRADESVRTLMHWYQQKPGKAPKLLIYLVSNSEIGVPDRFSGSGSGTDFRLTISSLQPEDFATYYCQQTWSDPWTFGQGTKVEIK,na,na,None,None,None,2013,2014,IL17A,UCB,Plaque psoriasis,Ankylosing spondylitis;Psoriatic arthritis;Hidradenitis suppurativa;Ulcerative colitis;Axial spondylarthritis,Psoriasis;Rheumatoid arthritis,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TF SDY NMAWVRQ APGKG LEWVATITY EGRN TYYRD SVKG RFTISR DNAKNS LYLQMNS LRAEDT AVYYCA SPPQYYEGS IYRLWFAH WGQG TLVTVS S,AI QLT QSPSS LSA SVGD RVTITCR ADE SVRTLMHWYQ QKPGKAP KLLIYLVS NSEIGVPDRFSGSGSGTD FRLTIS SLQPE DFA TYYCQ QTWSDPWTFGQGT KVEI K
Bintrafusp,Whole mAb Fusion,G1,Lambda,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL,na,na,4nki:HL/5grj:HL,None,None,2015,2016,CD274,AIO Studien gGmbH;Array BioPharma;Chong Kun Dang;Dana-Farber Cancer Institute;Debiopharm;eFFECTOR Therapeutics;EMD Serono;Forty Seven;Fred Hutchinson Cancer Research Center;Gachon University Gil Medical Center;Hellenic Cooperative Oncology Group;Hospices Civils de Lyon;Johannes Gutenberg-University Mainz;M. D. Anderson Cancer Center;Merck KGaA;National Cancer Institute (USA);National Cancer Institute Slovakia;Netherlands Cancer Institute;Pfizer;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Syndax Pharmaceuticals;Transgene;University College London;University of Birmingham;University of California San Diego;University of Iowa;Vaccinex;Vanderbilt-Ingram Cancer Center;VAXIMM;Verastem Oncology;Washington University School of Medicine,Merkel cell carcinoma;Urogenital cancer,Renal cell carcinoma;Breast cancer;Diffuse large B cell lymphoma;Gastric cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer;Bladder cancer;Endometrial cancer;Fallopian tube cancer;Germ cell and embryonal neoplasms;Gestational trophoblastic disease;Glioblastoma;Haemangiosarcoma;Intestinal cancer;Leiomyosarcoma;Nasopharyngeal cancer;Neuroendocrine tumours;Osteosarcoma;Peripheral T-cell lymphoma;Peritoneal cancer;Prostate cancer;Recurrent respiratory papillomatosis;Small cell lung cancer;Solid tumours;Squamous cell cancer;Thymoma;Liposarcoma;Lymphoma;Oropharyngeal cancer;Pancreatic cancer;Acute myeloid leukaemia;Follicular lymphoma;Hodgkin's disease;Liver cancer;Meningioma,na,Human Phage Display,Avelumab and Bintrafusp have identical V domains,E VQLLES GGG LV QPGG SLRLSCA ASGF TFSSYIMMWVRQ APGKG LEWVSSI YPSGG ITFYAD TVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCARIK LGT VTTVDY WGQG TLVTVS S,QSALTQPA SV SGSPGQ SITISCT GTSSDVGG YNYVSWYQ QHPGKAP KLMIYD VSNRPSGVSNRFSGSKSGN TASLTIS GLQAEDEAD YYCSS YTSSST RVF GTGT KVTV L
Birtamimab,Whole mAb,G1,Kappa,Phase-III,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMYWIRQAPGKGLEWVARIRSKSNNYAIYYADSVKDRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARPYSDSFAYWGQGTLVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSLVHSTGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPFTFGGGTKVEIK,na,na,None,None,None,2018,2019,SAA1,Neotope Biosciences;Onclave Therapeutics;Prothena,na,na,Amyloid light-chain amyloidosis,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFNTYAMYWIRQ APGKG LEWVARIR SKSNN YAIYYA DSVKD RFTISR DDSKNS LYLQMN SLKTEDT AVYYCA RPYSDS FAYW GQG TLVTVS S,DV VMT QSPLSLPVTPGEPA SISC RSSQ SLVH STGNT YLHWYLQ KPGQSP QLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYC SQSTHVP FTF GGG TKVEI K
Bleselumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,QLQLQESGPGLLKPSETLSLTCTVSGGSISSPGYYGGWIRQPPGKGLEWIGSIYKSGSTYHNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCTRPVVRYFGWFDPWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPTFGQGTKVEIK,na,na,None,None,None,2015,2016,CD40,Kirin Brewery;Astellas Pharma;Kyowa Hakko Kirin,na,na,Transplant rejection;Plaque psoriasis;Focal segmental glomerulosclerosis;Renal transplant rejection,na,,QL QLQE SGPGLLKPSE TLSLTCTV SGGSISSPGY YGGWIR QPPGKGL EWIGSIYK SGSTYHNPSLK SRVTISVD TSKN QFSLKLSS VTAADT AVYYC TRP VVRYFGWF DPWGQG TLVTVS S,AI QLT QSPSS LSA SVGD RVTITCR ASQG ISSALAWYQ QKPGKAP KLLIYD ASNLESGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ FNSYPTFGQGT KVEI K
Blinatumomab,Bispecific T-Cell Engager,na;na,Kappa;Kappa,Approved,Active,QVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATLTADESSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAMDYWGQGTTVTVSS,DIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLNWYQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTEDPWTFGGGTKLEIK,DIKLQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSS,DIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELK,None;None,None;None,None;None,2008,2009,CD19;CD3E,Amgen;Astellas Pharma;M. D. Anderson Cancer Center;Merck & Co;Micromet Inc;National Cancer Institute (USA);University of California Davis,Precursor B-cell lymphoblastic leukaemia-lymphoma,Non-Hodgkin's lymphoma;Diffuse large B cell lymphoma;Richter's syndrome;Burkitt's lymphoma,Chronic lymphocytic leukaemia,BiTE Technology,,Q VQLQQ SGA ELV RPGS SVKISCK ASGY AFSS Y WMNWVK QRPGQGL EWIGQI WPGDGDTNYNG KFKGKATLTA DESSS TAYMQLS SLASEDS AVYFCAR RETT T VG RYYYAMD YWGQG TTVTVS S,DI QLT QSPA SLAVS LGQ RATISCK ASQ SV DYDGD SYLNWYQ QIPGQPP KLLIYD ASNL V SGIPPRFSGSGSGTD FTLNIH PVE K VDAA TYHCQ QSTEDPWTFGGG TKLEI K
Blontuvetmab,Canine Whole mAb,G2,Kappa,Unknown,Active,QVQLQQSRAELVRPGASVTLSCKPSGYTFTDYEVHWVKQTPVHGLEWIGAIDPETGGTADNQKFKGKAILTADKSSSTAYMELRSLTSEDSAVYYCTNFVDVWGTGTTVTVSS,DVVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSGNQKNYLAWYQQKPGQSPRLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVFYCQQYYNYPLTFGGGTHL,na,na,None,None,None,2015,2016,MS4A1,Aratana Pharmaceuticals,na,Canine B-cell lymphoma,na,na,,QV QLQQ S RAELV RPGA SVTLSC KPSGY TF TD YEVHWVK QTPVHG LEWIGAI DPETGGTADNQ KF KG KAILTA DKSSS TAYMELRS LTSEDS AVYYCTNFVDV WGTG TTVTVS S,DV VMS QSPS SLAVS VGE KVTMSC KSSQ SLLY SGNQKN YLAWYQ QKPGQSP RLLIYWA STRESGVPDR F TGSGSGTD FTLTISS VK A E D LAVFYCQQ YYNYPL T FGGGTHL
Blosozumab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKVSGFPIKDTFQHWVRQAPGKGLEWMGWSDPEIGDTEYASKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGDTTYKFDFWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVHTAVAWYQQKPGKAPKLLIYWASTRWTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSDYPWTFGGGTKVEIK,na,na,None,None,None,2011,2012,SOST,Eli Lilly,na,Postmenopausal osteoporosis,na,na,,Q VQLVQ SGA EVK KPGA SVKVSCKV SGFPIKDT FQHWVR QAPGKGL EW MGWSDPEIGDTE YAS KFQG RVTMT EDTSTDT AYMELS SLRSEDT AVYYC ATGDT TYKFDF WGQG TTVTVS S,DIQ MT QSPSS LSA SVGD RVTITCK ASQDV H TAVAWYQ QKPGKAP KLLIYWA STRWTGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQ QYSDYPW T FGGG TKVEI K
Bococizumab,Whole mAb,G2,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGEISPFGGRTNYNEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARERPLYASDLWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQRYSLWRTFGQGTKLEIK,na,na,3sqo:HL,None,None,2013,2014,PCSK9,Halozyme Therapeutics;Pfizer,na,na,Cardiovascular disorders;Hypercholesterolaemia;Hyperlipidaemia,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYYMHWVR QAPGQGL EWMGEI SPFGGRTNYNEKF KSRVTMTR DTSTS TVYMELS SLRSEDT AVYYCA RERPL YA SDLWGQG TTVTVS S,DIQ M TQSPSS LSA SVGD RVTITCR ASQG ISSALAWYQ QKPGKAP KLLIYSASYRY TGVPSRFSGSGSGTD FTFTIS SLQ PEDIATYYCQ QRY SLWRT FGQGT KLEI K
Boserolimab,Whole mAb,G1,Kappa,Phase-II,Active,EIQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVKQAPGQGLKWMGWINTNTGEPTYAEEFKGRFTFTLDTSISTAYMELSSLRSEDTAVYYCAREGDAMDYWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQAPKRWIYDTSKLASGVPARFSGSGSGTDYSLTISSLEPEDFAVYYCQQWNSYPFTFGQGTKLEIK,na,na,None,None,None,2022,na,CD27,Bionovion;Merck Sharp & Dohme,na,Non-small cell lung cancer;Small cell lung cancer,Solid tumours,na,,E IQLVQ SGA EVK KPGA SVKVSCK ASGY TFTN YG MNWVK QAPGQG LKWMGWIN TNTGEPT YAEEF KG RFTFTL DTSI STAYMELS SLRSEDT AVYYCA REGDAMDYWGQG TTVTVS S,E IVLTQ SPA TLSL SPGE RATLSCS ASSS VSYMHWYQ QKPGQAPK RWIYD TSKLASGVP ARFS GSGSGTD YSLTIS SLEPED FAVYYCQ QWNSYPF TF GQGT KLEI K
Botensilimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYAESVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVGLFGPFDIWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSRYLGWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTITRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,None,None,None,2020,2021,CTLA4,Agenus,na,Solid tumours,na,na,,E VQLVES GGG LV KPGG SLRLSC AASGF TFSS Y SMNWVR QAPGKG LEWVSS ISSSSS YIYYAE SVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCARV G LF GPF DI WGQG TLVTV SS,E IVLTQ SPG TLSL SPGE RATLSCR ASQS VSRY LGWY QQKPGQAP RLLIYG ASTRATGIPDRFSGSGSGTD FTLTITR LEP ED FAVYYCQ QYGSSPW T FGQGT KVEI K
Brazikumab,Whole mAb,G2,Lambda,Phase-III,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNEYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGYTSSWYPDAFDIWGQGTMVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNTGAGYDVHWYQQVPGTAPKLLIYGSGNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTRLTVL,na,na,None,None,None,2016,2017,IL23A,Allergan;Amgen;AstraZeneca,na,Crohn's disease;Ulcerative colitis,Psoriasis,na,,Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKGL EWVAVIWY DGSNE YYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RDRGYTSSWYPDA FDIW GQG TMVTVS S,QSVLTQPPSVSGAPGQ RVTISCT GSSSNTGAG YDVHWYQQ VPGTAP KLLIYG SGNRPSGVPDRFSGSKSGTS ASLAIT GLQAEDEAD YYCQS YDSSLSG WVF GGGT RLTV L
Bremzalerbart,Whole mAb,G4,Kappa,TBC,Active,QVQLQESGPGLVKPSETLSLTCSVSGGSITNYFWTWIRQSPGKGLEWIGYIYYSGGTNYNPSLKSRVTISIDTSKNQFSLNMNSVTAADTAVYYCAGSYYYGVDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSIKSFLAWYRQKPGQAPRLLIYDASNRPTGIPARFSGSGSGTDFTLTINSLESEDFAVYFCQQRNNWPFTFGPGTKVDIK,na,na,7mxl:JK/7n0v:HL,None,None,2022,na,Bet Pollen Antigen 1,TBC,TBC,TBC,TBC,TBC,Identical V region sequence to Atisnolerbart,QV QLQE SGPGL V KPSE TLSLTCSV SGGS ITNYFWTWIR QSPGKGL EWIGYIYYS GGTNYNPSLK SRVTISID TSKN QFSLNM NSVTAADT AVYYC AGS YYYGVDVW GQG TTVTVS S,E IVLT QSPA TLSL SPGE RATLSCR AS QSIKSFLAWYR QKPGQAP RLLIYD ASNRPTGIP ARF SGSGSGT DFTLTIN SLESED FAVYFCQ QRNNWPF T FGPGT KVDI K
Brentuximab,Whole mAb ADC,G1,Kappa,Approved,Active,QIQLQQSGPEVVKPGASVKISCKASGYTFTDYYITWVKQKPGQGLEWIGWIYPGSGNTKYNEKFKGKATLTVDTSSSTAFMQLSSLTSEDTAVYFCANYGNYWFAYWGQGTQVTVSA,DIVLTQSPASLAVSLGQRATISCKASQSVDFDGDSYMNWYQQKPGQPPKVLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPWTFGGGTKLEIK,na,na,None,None,None,2010,2011,TNFRSF8,Bristol-Myers Squibb;Celgene Corporation;Dana-Farber Cancer Institute;Fondazione Italiana Linfomi;Fox Chase Cancer Center;Immune Tolerance Network;Lymphoma Academic Research Organisation;Massachusetts General Hospital;National Cancer Institute (USA);National Institute of Allergy and Infectious Diseases;Seattle Genetics;Stanford University;Takeda;Takeda Oncology;UNC Lineberger Comprehensive Cancer Center;Washington University School of Medicine,Anaplastic large cell lymphoma;Cutaneous T-cell lymphoma;Hodgkin's disease;Mycosis fungoides;T-cell lymphoma,Adult T-cell leukaemia-lymphoma;Diffuse large B cell lymphoma;Germ cell and embryonal neoplasms;Mastocytosis;Mesothelioma;Non-Hodgkin's lymphoma;Peripheral T-cell lymphoma;Sezary syndrome;Diffuse scleroderma,Graft-versus-host disease;Leukaemia;Multiple myeloma;Solid tumours;Systemic lupus erythematosus,na,,Q IQLQ QSGPE VV KPGA SVKISCK ASGY TFTDYYITWVK QKPGQG LEWIGWIY PGSGNTKYNEKFKG KATLTVD TSSST AFMQLS SLTSEDT AVYFCA NYGN YWFAYW GQGT QVTVS A,D IVLT QSPA SLAVS LGQ RATISCK ASQ SV DFDGD SYMNWYQ QKPGQPP KVLIYAA SNLESGIP ARFS GSGSGTD FTLNIHP VEEEDA A TYYCQ QSNEDPWTFGGGT KLEI K
Briakinumab,Whole mAb,G1,Lambda,Preregistration (w),Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWGQGTMVTVSS,QSVLTQPPSVSGAPGQRVTISCSGSRSNIGSNTVKWYQQLPGTAPKLLIYYNDQRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRYTHPALLFGTGTKVTVL,na,na,5n2k:LK:BA:PO:DC:NM:FE/5njd:RQ:TS:XW:VU:PO:NM,None,None,2009,2010,IL12B,Cambridge Antibody Technology;Abbott GmbH & Co. KG,na,na,Plaque psoriasis;Crohn's disease;Multiple sclerosis;Rheumatoid arthritis,na,,Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKG LEWVAFIRY DGSNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAED TAVYYCKT HGSHDNWGQG TMVTVS S,QSVLTQPPSVSGAPGQ RVTISC SGSRSNIGSN TVKWYQQ LPGTAP KLLIYY NDQRPSGVPDRFSGSKSGTS A SLAI TGLQAEDEAD YYCQS YDRYTHP ALLF GTGT KVTV L
Briquilimab,Whole mAb,G1,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGVIYSGNGDTSYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARERDTRFGNWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCRASESVDIYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPYTFGGGTKVEIK,na,na,None,None,None,2022,na,KIT,TBC,TBC,TBC,TBC,TBC,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYNMHWVRQ APGQG LEWMGVIYS GNGDTSYNQ KFKGRVTITA DKSTS TAYMELSS LRSEDT AVYYCARE RDTRFGNWGQ GTLVTVS S,D IVMT QSPDS LAVS LGER ATINCR ASE SVDIY GNS FMHWYQ QKPGQPP KLLIYLA SNLESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQ QNNEDPY T FGGG TKVEI K
Brodalumab,Whole mAb,G2,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTRYGISWVRQAPGQGLEWMGWISTYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARRQLYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWFQQKPGQAPRPLIYDASTRATGVPARFSGSGSGTDFTLTISSLQSEDFAVYYCQQYDNWPLTFGGGTKVEIK,na,na,None,None,None,2011,2012,IL17RA,Amgen;AstraZeneca;Bausch Health Companies;Kyowa Hakko Kirin;LEO Pharma,Erythrodermic psoriasis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis;Psoriasis,Axial Spondylarthritis;Systemic scleroderma;Palmoplantar pustulosis,Asthma;Crohn's disease;Rheumatoid arthritis,Abgenix XenoMouse,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTRYGISWVRQ APGQGL EWMGWISTY SGNTNY AQKL QG RVTMTT DTSTS TAYMELRSL RSDDT AVYYCA RR QLYFDY WGQG TLVTVS S,E IVMT QSPA TLSV SPGE RATLSCR ASQSVSSNL AWFQ QKPGQAPRP LIYD ASTRATGVP ARFS GSGSGTD FTLTISS LQSED FAVYYCQQ YDNWP LTF GGG TKVEI K
Brolucizumab,scFv,na,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCTASGFSLTDYYYMTWVRQAPGKGLEWVGFIDPDDDPYYATWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGGDHNSGWGLDIWGQGTLVTVSS,EIVMTQSPSTLSASVGDRVIITCQASEIIHSWLAWYQQKPGKAPKLLIYLASTLASGVPSRFSGSGSGAEFTLTISSLQPDDFATYYCQNVYLASTNGANFGQGTKLTVL,na,na,None,None,None,2014,2015,VEGFA,ESBATech;Alcon,Wet age-related macular degeneration,Diabetic macular oedema;Retinal vein occlusion;Diabetic retinopathy,na,na,,E VQLVES GGG LV QPGG SLRLSCT ASGFSLTD YYYMTWVRQ APGKG LEWVGFI DPDDDPY YATW AKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYC AGGDHNSGW GLDIW GQG TLVTVS S,E IVMT QSPS TLSAS VGD RVIITC Q ASEIIHSWLAWYQ QKPGKAP KLLIYLA ST LASGVPS RF SGSGSGA EFTLTISS LQPDDF ATYYCQNVYLAS TNGANFGQGT KLTV L
Brontictuzumab,Whole mAb,G2,Lambda,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKISCKVSGYTLRGYWIEWVRQAPGKGLEWIGQILPGTGRTNYNEKFKGRVTMTADTSTDTAYMELSSLRSEDTAVYYCARFDGNYGYYAMDYWGQGTTVTVSS,QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWFQQKPGQAPRTLIGGTNNRAPGVPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNHWVFGGGTKLTVL,na,na,None,None,None,2014,2015,NOTCH1,OncoMed Pharmaceuticals;University of Texas M. D. Anderson Cancer Center,na,na,Adenoid cystic carcinoma;Solid tumours;Haematological malignancies;Colorectal cancer,na,,Q VQLVQ SGA EVK KPGA SVKISCKV SG YTLRGYWIEWVR QAPGKG LEWIGQI LPGTGRTNYNEKFKG RVTMTA DTSTDT AYMELSS LRSEDT AVYYCARF DGNY GYYAMDY WGQG TTVTVS S,QA VVT QEP SLTV SPGG TVTLTCR SSTGA VTT SN YANWF QQKPGQAPR TLI GGTNNRAPGVPA RFS G SL LGGK AALTL SGAQPEDEA EYYCALWY SNH WVF GGGT KLTV L
Budigalimab,Whole mAb,G1,Kappa,Phase-II,Active,EIQLVQSGAEVKKPGSSVKVSCKASGYTFTHYGMNWVRQAPGQGLEWVGWVNTYTGEPTYADDFKGRLTFTLDTSTSTAYMELSSLRSEDTAVYYCTREGEGLGFGDWGQGTTVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSIVHSHGDTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHIPVTFGQGTKLEIK,na,na,None,None,None,2018,2019,PDCD1,AbbVie,na,Colorectal cancer;Ovarian cancer;Small cell lung cancer;Solid tumours;Endometrial cancer;Fallopian tube cancer;HIV-1 infections;Peritoneal cancer;Squamous cell cancer,na,na,,E IQLVQ SGA EVK KPGS SVKVSCK ASGY TFTHY G MNWVR QAPGQGL EWVGWVN TYTGEPT Y ADDFKG RLTFTLD TSTS TAYMELS SLRSEDT AVYYCTR EGEGLGFGDWGQG TTVTVS S,DV VMT QSPLSLPVTPGEPA SISC RSSQ SIVHS HGD TYLEWYL QKPGQSP QLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCF QGSH IPVTF GQGT KLEI K
Burfiralimab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTGYNMNWVRQAPGKGLEWMGNIDPYYGSDTYAQKFQGRVTMTVDKSISTAYMELSRLRSDDTAVYYCARETGTRAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASENIYSNLAWYQQKPGKAPKLLIYVADNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHFYGSPRTFGGGTKVEIK,na,na,None,None,None,2022,na,VIM,ImmuneMed,na,COVID-19 Pneumonia;Pneumonia;Hepatitis B;Alcholic hepatitis;Non-alcoholic steatohepatitis;Psoriasis;Scleroderma,na,na,,E VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTGYNMNWVR QAPGKGL EWM GNIDPYYGSDTY AQ KF QG RVTMTV DKSI STAYMELSR LRSDDT AVYYCAR ETGTRA M DYWGQG TLVTV SS,DIQ MT QSPSS LSA SVGD RVTITCR ASENIYSN LAWY QQKPGKAP KLLIYVA DNLADGVPS RF SGSGSGTD FTLTIS SLQ PEDFATY Y CQH FYGSPRTFGGGT KVEI K
Burosumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHYMHWVRQAPGQGLEWMGIINPISGSTSNAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDIVDAFDFWGQGTMVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNDYFTFGPGTKVDIK,na,na,None,None,None,2016,2017,FGF23,Kyowa Hakko Kirin;Ultragenyx Pharmaceutical ,X-linked dominant hypophosphataemic rickets;Osteomalacia,Nevus,na,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFT NH YMHWVRQ APGQGL EWMGII NPISGSTSNAQ KFQGRVTMTR DTSTS TVYMELS SLRSEDT AVYYCA RD IVDAF DFWGQG TMVTVS S,AI QLT QSPSS LSAS VGD RVTITCR ASQGIS SALVWYQ QKPGKAP KLLIYD ASSLESGVPS R FSGSGSGTD FTLTIS SLQ PEDFATYYCQQ FNDY FTF GPGT KVD IK
Cabiralizumab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDNYMIWVRQAPGQGLEWMGDINPYNGGTTFNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARESPYFSNLYVMDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCKASQSVDYDGDNYMNWYQQKPGQAPRLLIYAASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHLSNEDLSTFGGGTKVEIK,na,na,None,None,None,2015,2016,CSF1R,Apexigen;Bristol-Myers Squibb;Five Prime Therapeutics;University of Chicago;Yale University,na,Pancreatic cancer;Pigmented villonodular synovitis;Cancer;Malignant melanoma;Non-small cell lung cancer;Renal cell carcinoma;Solid tumours ,Rheumatoid arthritis,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TF TDN YMIWVRQ APGQG LEWMGD INPYNGGTT F NQK F KG RVTITA DKSTS TAYMELS SLRSEDT AVYYCA RESPYFS NLYVMD YWGQG TLVTVS S,E IVLTQ SPA TLSL SPGE RATLSCK ASQ SV DYDGDNY MNWYQ QKPGQAP RLLIYAA SNLESGIP ARFS GSGSGTD FTLTIS SLEPED FAVYYCHL SNEDLSTFGGG TKVEI K
Cadonilimab,Bispecific Mixed mAb and scFv,G1;na,Kappa;Lambda,Approved,Active,QVQLVESGAEVKKPGASVKVSCKASGYSFTGYTMNWVRQAPGQCLEWIGLINPYNNITNYAQKFQGRVTFTVDTSISTAYMELSRLRSDDTGVYFCARLDYRSYWGQGTLVTVSA,DIQMTQSPSSMSASVGDRVTFTCRASQDINTYLSWFQQKPGKSPKTLIYRANRLVSGVPSRFSGSGSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELK,QVVLVESGAEVKKPGASVKVSCKASGYSFTGYTMNWVRQAPGQCLEWIGLINPYNNITNYAQKFQGRVTFTVDTSISTAYMELSRLRSDDTGVYFCARLDYRSYWGQGTLVTVSA,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNFPNWVQQKPGQAPRSLIGGTNNKASWTPARFSGSLLGGKAALTISGAQPEDEAEYYCALWYSNHWVFGCGTKLTVL,None;None,None;None,None;None,2020,2021,PDCD1;CTLA4,Akeso Biopharma,Cervical cancer,Non-small cell lung cancer;Solid tumours;Peripheral T/NK cell lymphoma;Hepatocellular carcinoma;Gastic adenocarcinoma;Nasopharyngeal carcinoma,na,na,(June '22: Corrected FWH1 and FWL2 sequences),Q VQLVE SGA EVK KPGA SVKVSCK ASGY SFTGYTMNWVR QAPGQ CLEWIGLI NPYNNITN YAQ KFQG RVTFTV DTSIS TAYMELSRL RSDDTG VYFCARLD YRSYWGQG TLVTVS A,DIQ MT QSPSSM SA SVGD RVTFTCR ASQD INTYLSWFQ QKPGKSPK TLIYRA N RLV SGVPS R FSGSGSGQD YTLTISS LQPEDM A TYYCLQ YDEFP LTF GAGT KLEL K
Calpurbatug,Whole mAb,G1,Kappa,TBC,Active,QSQVQLVESGPGLVKPSETLSLTCRVSGDSNRPSYWSWIRQAPGKAMEWIGYVYDSGVTIYNPSLKGRVTISLDTSKTRFSLKLTSVIAADTAVYYCARERFDRTSYKSWWGQGTQVTVSS,DIVLTQAPGTLSLSPGDRATLSCRASQRLGGTSLAWYQHRSGQAPRLILYGTSNRATDTPDRFSGSGSGTDFVLTISSLEPEDFAVYYCQQYGSPPYTFGQGTTLDIK,na,na,None,None,None,2022,na,Bacteria Proteins HU and IHF,TBc,TBC,TBC,TBC,TBC,Conserved epitopes on HU (histone-like protein) and IHF (integrin host factor),QS QVQLVES GPGL V KPSE TLSLTCRVS GDSNRPS YWSWIR QAPGKA MEWIGYVY DSG VTIY NPSLKG RVTISL DTSKT RFSLKLTSVIA ADT AVYYCARE RFDRTSYKSWWGQG TQVTVS S,D IVLTQ APG TLSL SPGDR ATLSCRA SQRLGGT SLAWYQH RSGQAP RLILYG TSNRATDTPDRFSGSGSGT DFVLTIS SLE PEDFA VYY CQQ YGSPPYTFGQGT TLD IK
Camidanlumab,Whole mAb ADC,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRYIINWVRQAPGQGLEWMGRIIPILGVENYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARKDWFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK,na,na,None,None,None,2017,2018,IL2RA,ADC Therapeutics;Genmab,na,Hodgkin's disease;Non-Hodgkin's lymphoma;Solid tumours,Acute myeloid leukaemia;Precursor cell lymphoblastic leukaemia-lymphoma,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSRYIINWVR QAPGQGL EWMGRIIPIL GVEN YAQ KFQG RVTITA DKSTS TAYMELS SLRSEDT AVYYCA RKDWFDYWGQG TLVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQS VSSYLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGTD FTLTIS RLE PEDFA VYY CQQ YGSSPL TF GGGT KVEI K
Camoteskimab,Whole mAb,G1,Kappa,Phase-I,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSISADGYYWSWIRQPPGKGLEWIGSLYYSGSTYYNPSLKGRVTISGDTSKNQFSLKLSSVTAADTAVYYCARTPAYFGQDRTDFFDVWGRGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKVLIYKASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQSHHPPWTFGQGTKLEIK,na,na,None,None,None,2022,na,IL18,Avalo Therapeutics;MedImmune,na,Adult-onset Still's disease;Juvenile rheumatoid arthritis,Chronic obstructive pulmonary disease;Multiple myeloma,na,,Q VQLQE SGPGL V KPSE TLSLTCTV SGG SI SADG YYWSWIR QPPGKGL EWIGSLYY SGS TYY NPSLK GRVTIS GDTSKN QFSLKLSS VTAADT AVYYCA RTPAYFGQDRTD FFDVW GRG TLVTVS S,DIQ MT QSPS TLSAS VGD RVTITCR ASQGI SSW LAWY QQKPGKAP KVLIYK ASTLESGVPS R FSGSGSGT EFTLTISS LQPDDF ATYYCQ QSHHPPWTFGQGT KLEI K
Camrelizumab,Whole mAb,G4,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYMMSWVRQAPGKGLEWVATISGGGANTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQLYYFDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCLASQTIGTWLTWYQQKPGKAPKLLIYTATSLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQVYSIPWTFGGGTKVEIK,na,na,None,None,None,2016,2017,PDCD1,Chinese PLA General Hospital;Hangzhou Cancer Hospital;Incyte Corporation;Jiangsu Hengrui Medicine Co.;Nanjing Medical University;Peking University People's Hospital;Sun Yat-Sen University,Hodgkin's disease,Nasopharyngeal cancer;Non-small cell lung cancer;Oesophageal cancer;Liver cancer;Biliary cancer;Cervical cancer;Cholangiocarcinoma;Colorectal cancer;Endometrial cancer;Fallopian tube cancer;Gastric cancer;Osteosarcoma;Ovarian cancer;Pancreatic cancer;Peritoneal cancer;Renal cell carcinoma;Solid tumours;Urogenital cancer;Diffuse large B cell lymphoma;Breast cancer;Malignant melanoma,na,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFSSYMMSWVR QAPGKG LEWVATIS GGGANT Y YPDSVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCA R QLYYFD YWGQG TTVTVS S,DIQ M TQSPSS LSA SVGD RVTITCL ASQTIG TWLTWYQ QKPGKAP KLLIYTAT SLADGVPS R FSGSGSGTD FTLTIS SLQP EDFA TYYCQQVYSI PW T FGGG TKVEI K
Canakinumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPFTFGPGTKVDIK,na,na,None,4g5z:HL/5bvj:HG:FE:BA:DC/4g6j:HL/5bvp:HL,None,2007,2008,IL1B,Charite - Universitatsmedizin Berlin;Novartis;Triemli hospital;University Hospital Tubingen;University Hospital Zurich,Adult-onset Still's disease;Cryopyrin-associated periodic syndromes;Familial autosomal dominant periodic fever;Familial Mediterranean fever;Gouty arthritis;Juvenile rheumatoid arthritis;Peroxisomal disorders,Cardiovascular disorders;Behcet's syndrome;Non-small cell lung cancer;Abdominal aortic aneurysm;Atherosclerosis;Malignant melanoma;Osteoarthritis;Peripheral arterial occlusive disorders;Pulmonary sarcoidosis;Schnitzler syndrome;Sickle cell anaemia;Breast cancer;Pancreatic cancer;Renal cell carcinoma,Chronic obstructive pulmonary disease;Asthma;Diabetic retinopathy;Polymyalgia rheumatica;Rheumatoid arthritis;Type 1 diabetes mellitus;Type 2 diabetes mellitus,Medarex UltiMAb Mouse,,Q VQLVES GGG VV QPGR SLRLSC AASGF TFSVYGMNWVR QAPGKGL EWVAIIWY DGDNQ YYAD SVKG RFTISR DNSKN TLYLQM NGLRAEDT AVYYCAR DLRTGPFDYWGQG TLVTV SS,E IVLTQ SPDFQSVTPKE KVTITCR ASQSIGS SLHWYQ QKPDQSP KLLIKYA SQSFSGVPSRFSGSGSGT DFTLTIN SLEAED AAA YYC HQSSSLP FTF GPGT KVDI K
Cantuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGETVKISCKASDYTFTYYGMNWVKQAPGQGLKWMGWIDTTTGEPTYAQKFQGRIAFSLETSASTAYLQIKSLKSEDTATYFCARRGPYNWYFDVWGQGTTVTVSS,DIVMTQSPLSVPVTPGEPVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLVSGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCLQHLEYPFTFGPGTKLELK,na,na,None,None,None,2003,2004,MUC1,ImmunoGen;GlaxoSmithKline,na,na,Gastric cancer;Solid tumours,na,,Q VQLVQ SGA EVK KPGE TVKISCK ASDY TFTYYGMNWVK QAPGQG LKWMGWID TTTGEPT YAQKF QG RIAFSLE TSAST AYLQIKSL KSEDT ATYFCAR RGPYN WYFDV WGQG TTVTVS S,D IVMT QSPLSVPVTPGEP VSISCR SSK SLLH SNGN TYLYWFLQ RPGQSP QLLIYRM SNLVSGVPDRFSGSGSGT AFTLRISRVE AEDV GVYYCLQH LEYPF TF GPGT KLEL K
Caplacizumab,Nanobody,na,na,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGRTFSYNPMGWFRQAPGKGRELVAAISRTGGSTYYPDSVEGRFTISRDNAKRMVYLQMNSLRAEDTAVYYCAAAGVRAEDGRVRTLPSEYTFWGQGTQVTVSS,na,na,na,7a6o:B/7eow:B,None,None,2011,2012,VWF,Ablynx,Thrombotic thrombocytopenic purpura,na,Thrombosis,Nanobody Technology,,E VQLVES GGG LV QPGG SLRLSC AASGR TFSY NPMGW FR QAPGKGR ELVAAIS RTGGSTYYPDSV EGRFTIS RDNAK RMVYLQM NSLRAEDT AVYYCAA AG VR AEDGR VRT LPSE YTFW GQG TQVTVS S,NA
Carlumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDGIYGELDFWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSDAYLAWYQQKPGQAPRLLIYDASSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYIQLHSFTFGQGTKVEIK,na,na,None,4dn3:HL/4dn4:HL,None,2010,2011,CCL2,MorphoSys;Janssen Biotech,na,na,Idiopathic pulmonary fibrosis;Ovarian cancer;Prostate cancer;Solid tumours,Human Phage Display,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSSYGISWVRQ APGQGL EWMGGIIPIF GTANYAQKFQG RVTITA DESTS TAYMELS SLRSEDT AVYYCAR YDGI Y G ELDFW GQG TLVTVS S,E IVLT QSPA TLSL SPGE RATLSCR ASQSVS DAYLAWYQ QKPGQAP RLLIYD ASSRATGVP ARFS GSGSGT DFTLTIS SLEPE D FAVYYC HQ YIQLHSFTF GQGT KVEI K
Carotuximab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVKLEESGGGLVQPGGSMKLSCAASGFTFSDAWMDWVRQSPEKGLEWVAEIRSKASNHATYYAESVKGRFTISRDDSKSSVYLQMNSLRAEDTGIYYCTRWRRFFDSWGQGTTLTVSS,QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWSSNPLTFGAGTKLELK,na,na,None,None,None,2015,2016,ENG,National Cancer Institute (USA);Santen Pharmaceutical;TRACON Pharmaceuticals;University of Alabama at Birmingham;University of Minnesota;Roswell Park Cancer Institute,na,na,Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Prostate cancer;Haemangiosarcoma;Choriocarcinoma;Glioblastoma;Liver cancer;Renal cell carcinoma;Soft tissue sarcoma;Breast cancer;Non-small cell lung cancer;Acute myeloid leukaemia;Colorectal cancer;Precursor B-cell lymphoblastic leukaemia-lymphoma;Wet age-related macular degeneration,na,,E VKLEE SGGG LV QPGGS MKLSC AASGFTFS DAWMDWVRQ SPEKGL EWVAEIRS KASNHA TYYAES VKG RFTISR DDSKS SVYLQMN SLRAEDTG IYYCTRWRRFF DSWGQG TTLTVS S,Q IVLS QSP AILS ASPGE KVTMTCR ASSS VSYMHWYQ QKPGSSPKP WIYAT SNLASGV PVRFS GSGSGT SYSLTISRVE AEDA ATYYCQQ WSSNPL TF GAGT KLEL K
Casdozokitug,Whole mAb,G1,Kappa,TBC,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFRSYGMNWVRQAPGKGLEWVSGISSSGSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDGGRTSYTATAHNWFDPWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLFSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHASAPPTFGGGTKVEIK,na,na,None,None,None,2022,na,IL27,TBC,TBC,TBC,TBC,TBC,,E VQLVES GGG LV KPGG SLRLSC AASGF TFRSY GM NWVR QAPGKG LEWVSGI SSSGS YIYYA DSVKG RFTISR DNAKNS LYLQMN SLRAED TAVYYCA RDGGR TSYTATA HN WF DPWGQ GTLVTVS S,D IVMT QSPDS LAVS LGE RATINC KSSQ SVLFS SNNKN YLAWYQ QKPGQPP KLLIYWAS TRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQ QHASAPPTFGGG TKVEI K
Cemiplimab,Whole mAb,G4,Kappa,Approved,Active,EVQLLESGGVLVQPGGSLRLSCAASGFTFSNFGMTWVRQAPGKGLEWVSGISGGGRDTYFADSVKGRFTISRDNSKNTLYLQMNSLKGEDTAVYYCVKWGNIYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDSITITCRASLSINTFLNWYQQKPGKAPNLLIYAASSLHGGVPSRFSGSGSGTDFTLTIRTLQPEDFATYYCQQSSNTPFTFGPGTVVDFR,na,na,None,None,None,2018,2019,PDCD1,Inovio Pharmaceuticals;ISA Pharmaceuticals;Regeneron Pharmaceuticals;Sanofi;Sidney Kimmel Cancer Center;SillaJen Biotherapeutics;University of Texas M. D. Anderson Cancer Center,Squamous cell cancer;Basal cell cancer;Non-small cell lung cancer,Cervical cancer;Oropharyngeal cancer;Prostate cancer;Fallopian tube cancer;Glioblastoma;Multiple myeloma;Ovarian cancer;Peritoneal cancer;Solid tumours;Head and neck cancer;Malignant melanoma;Renal cell carcinoma,B-cell lymphoma,na,,E VQLLE SGG VLV QPGG SLRLSC AASGF TF SNFG MTWVRQ APGKG LEWVSG ISGGGRD TYFA DSVKG RFTISR DNSKN TLYLQMN SLKGEDT AVYYCVK WGN IYFDY WGQG TLVTVS S,DIQ MT QSPSS LSA SVGD SITITCRAS LS INTFLNWYQ QKPGKAPN LLIYAA SSLHGGVPSRFSGSGSGTD FTLTIRT LQ PEDFA TYYCQ QSSNTPF TF GPGT VVDF R
Cendakimab,Whole mAb,G1,Kappa,Phase-III,Active,EVTLRESGPGLVKPTQTLTLTCTLYGFSLSTSDMGVDWIRQPPGKGLEWLAHIWWDDVKRYNPALKSRLTISKDTSKNQVVLKLTSVDPVDTATYYCARTVSSGYIYYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTISCRASQDIRNYLNWYQQKPGKAPKLLIFYTSKLHSGVPSRFSGSGSGTDYTLTISSLQPEDIATYYCQQGNTLPLTFGGGTKVEIK,na,na,None,None,None,2018,2019,IL13,Abbott Laboratories;AbbVie;Receptos,na,Eosinophilic oesophagitis,Allergic asthma,na,,E VTLRE SGPGLVKPTQ TLTLTCTLYGFSL STSDMG VDWIR QPPGKGL EWLAHIW WDDVKR YNPALK SRLTISK DTSKN QVVLKLTS VDPVDT ATYYCARTV SSG YIYYAMD YWGQG TLVTVS S,DIQMTQSPSS LSA SVGD RVTISCR AS QDIRNYLNWYQ QKPGKAP KLLIFYT SKLHSGVPSRFSGSGSGTD YTLTIS SLQ PEDIATY Y C QQGN TLPLTF GGGT KVEI K
Cergutuzumab,Whole mAb Fusion,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTEFGMNWVRQAPGQGLEWMGWINTKTGEATYVEEFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARWDFAYYVEAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASAAVGTYVAWYQQKPGKAPKLLIYSASYRKRGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQYYTYPLFTFGQGTKLEIK,na,na,None,None,None,2015,2016,CEACAM5,Roche,na,na,Solid tumours,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTEFGMNWVR QAPGQG LEWMGWIN TKTGE ATYVEEF KG RVTFTT DTSTS TAYMELRSL RSDDT AVYYCAR WDF AYYVEAM DYWGQG TTVTVS S,DI QMT QSPSS LSA SVGD RVTITCK ASAAVG TYVAWYQ QKPGKAP KLLIYSASY RKRGVPS RF SGSGSGTD FTLTIS SLQPE DFA TYYC HQ Y Y T YP LFTF GQGT KLEI K
Certolizumab,Fab,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGYVFTDYGMNWVRQAPGKGLEWMGWINTYIGEPIYADSVKGRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCARGYRSYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVGTNVAWYQQKPGKAPKALIYSASFLYSGVPYRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPLTFGQGTKVEIK,na,na,5wuv:HL/5wux:HL:AB:CD,None,None,2004,2004,TNFA,UCB,Ankylosing spondylitis;Crohn's disease;Plaque psoriasis;Psoriatic arthritis;Rheumatoid arthritis;Spondylitis;Non-radiographic axial spondyloarthritis,Interstitial cystitis;Juvenile rheumatoid arthritis,Cognition disorders,na,,E VQLVES GGG LV QPGG SLRLSC AASG YVFT DYGM NWVR QAPGKGL EWMGWINTY IGEP IY ADSVKG RFTFSL DTSKS TAYLQMN SLRAEDT AVYYC ARGY RSYAMD YWGQG TLVTV SS,DI QMT QSPSS LSA SVGD RVTITCK ASQNVGT NVAWYQ QKPGKAPK ALIYSASFLY SGV PYRFS GSGSGTD FTLTIS SLQ PEDFATYYCQQ YNI YPLTF GQGT KVEI K
Cetrelimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFDTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARPGLAAAYDTGSLDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRNYWPLTFGQGTKVEIK,na,na,None,None,None,2017,2018,PDCD1,Janssen Research & Development ,na,Multiple myeloma;Prostate cancer;Solid tumours;Urogenital cancer;Bladder cancer,na,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSSYAISWVR QAPGQGL EWMGGIIPIF DTANYAQKFQG RVTITA DESTS TAYMELS SLRSEDT AVYYCA RPGL AAAY DTGSLDYWGQG TLVTVS S,E IVLT QSPA TLSL SPGE RATLSCR ASQS VRSYLAWYQ QKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLE PEDF AVYYC Q QRNYWP LT FGQGT KVEI K
Cetuximab,Whole mAb,G1,Kappa,Approved,Active,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSA,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK,na,na,6au5:DC:BA/6axp:BA:DC/6ayn:BA:DC/6azk:DC:BA/6azl:BA:DC,5i76:DC:BA/1yy8:DC:BA/5th2:DC:BA/5f88:DC:BA/5hyq:DC:BA/5ir1:DC:BA/5ivz:DC:BA/5iv2:DC:BA/5t1k:DC:BA/5t1l:DC:BA/5id0:DC:BA/5id1:DC:BA/5euk:DC:BA/5ff6:DC:BA/5iop:DC:BA/5icy:DC:BA/5itf:DC:BA/5etu:DC:BA/5t1m:DC:BA/5esq:DC:BA/5icz:DC:BA/5i2i:DC:BA/5icx:DC:BA/5hpm:DC:BA/4gw5:DC:BA/4gw1:DC:BA/1yy9:DC/4krp:DC/4kro:DC,5gz0:BA:DC/6arp:BA:DC/6aru:CB,1999,2000,EGFR,Array BioPharma;Bristol-Myers Squibb;Celldex Therapeutics Inc;Centre Jean Perrin;Eli Lilly;Merck KGaA;New York University School of Medicine;Novartis;Pierre Fabre;Roche;University Hospital Ghent;University of California;University of Heidelberg;University of Michigan Comprehensive Cancer Center,Colorectal cancer;Head and neck cancer,Non-small cell lung cancer;Bladder cancer;Breast cancer;Gastric cancer;Mesothelioma;Rectal cancer;Squamous cell cancer;Adenoid cystic carcinoma;Oesophageal cancer,Pancreatic cancer;Prostate cancer,na,,QV QLKQ SGPGLVQPSQ SLSITCTV SGF SL T N Y GVHWVRQ SPGKGL EWLGVIWS GGNTDYNTPF TSRLSI NKDNSKS QVFFKM NSLQSNDT AIYYCA RAL TYY D YEFAYW GQG TLVTVS A,DI LLT QSP VILSV SPGE RVSFSCR ASQSIGT NIHWYQQ RTNGSP RLLIKYA SESISGIPSRFSGSGSGT DFTLSIN SVES EDIADYYCQ QNNNWPTTFGAGT KLEL K
Cevostamab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-I,Active,EVQLVESGPGLVKPSETLSLTCTVSGFSLTRFGVHWVRQPPGKGLEWLGVIWRGGSTDYNAAFVSRLTISKDNSKNQVSLKLSSVTAADTAVYYCSNHYYGSSDYALDNWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVRNLVVWFQQKPGKAPKLLIYSGSYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSPPYTFGQGTKVEIK,EVQLVQSGAEVKKPGASVKVSCKASGFTFTSYYIHWVRQAPGQGLEWIGWIYPENDNTKYNEKFKDRVTITADTSTSTAYLELSSLRSEDTAVYYCARDGYSRYYFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRTRKNYLAWYQQKPGQSPKLLIYWTSTRKSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSFILRTFGQGTKVEIK,None;None,None;None,None;None,2019,2020,FCRL5;CD3,Genentech,na,Multiple myeloma,na,na,,E VQLVE SGPGL V KPSE TLSLTCTV SGF SLTRFGVHWVR QPPGKGL EWLGVIWR GGSTDYN AAFVSRLTIS KDNSKN QVSLKLSS VTAADT AVYYC SNHYYGSSDY AL DNWGQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITCK ASQDVR NLVVWFQ QKPGKAP KLLIYS GS YRY SGVPSRFSGSGSGTD FTLTISS LQP EDFAT YYC QQHYSPPY T FGQGT KVEI K
Cibisatamab,Bispecific mAb with Domain Crossover,G1;G1,Kappa;Lambda,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTEFGMNWVRQAPGQGLEWMGWINTKTGEATYVEEFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARWDFAYYVEAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASAAVGTYVAWYQQKPGKAPKLLIYSASYRKRGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQYYTYPLFTFGQGTKLEIK,QVQLVQSGAEVKKPGASVKVSCKASGYTFTEFGMNWVRQAPGQGLEWMGWINTKTGEATYVEEFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARWDFAYYVEAMDYWGQGTTVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2017,2018,CEACAM5&CD3E;CD3E,Roche,na,Non-small cell lung cancer;Colorectal cancer,Solid tumours,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTEFGMNWVR QAPGQG LEWMGWIN TKTGE ATYVEEF KG RVTFTT DTSTS TAYMELRSL RSDDT AVYYCAR WDF AYYVEAM DYWGQG TTVTVS S,DI QMT QSPSS LSA SVGD RVTITCK ASAAVG TYVAWYQ QKPGKAP KLLIYSASY RKRGVPS RF SGSGSGTD FTLTIS SLQPE DFA TYYC HQ Y Y T YP LFTF GQGT KLEI K
Ciduvectamig,Bispecific mAb,G4;G4,Kappa;Lambda,TBC,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYSMSWVRQAPGKGLEWVSVISGSGGFTDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARMPLNSPHDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQDYNYPLTFGGGTKVEIK,QVQLQQSGPRLVRPSQTLSLTCAISGDSVFNNNAAWSWIRQSPSRGLEWLGRTYYRSKWLYDYAVSVKSRITVNPDTSRNQFTLQLNSVTPEDTALYYCARGYSSSFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSNIGTYKFVSWYQQHPDKAPKVLLYEVSKRPSGVSSRFSGSKSGNTASLTISGLQAEDQADYHCVSYAGSGTLLFGGGTKLTVL,None;None,None;None,None;None,2022,na,TMEFF2;CD3E,TBC,TBC,TBC,TBC,TBC,,E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYSMSWVR QAPGKG LEWVSVIS GSGGFTDYADSVKG RFTISR DNSKN TLYLQMNS LRAEDT AVYYCAR MPLNSPHDYWGQ GTLVTVS S,DI QMT QSPSS LSA SVGD RVTITCR ASQGIRNDLG WYQ QKPGKAP KLLIYAA SSLQSGVPS RF SGSGSGTD FTLTISS LQPEDF ATYYCL QDYNYP LTF GGG TKVEI K
Cifurtilimab,Whole mAb,G1,Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQAPGKGLEWVARVIPNAGGTSYNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYYCAREGIYWWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKLLIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVEIK,na,na,None,None,None,2022,na,CD40,TBC,TBC,TBC,TBC,TBC,,E VQLVES GGG LV QPGG SLRLSCA ASGY SFTGYYIHWVRQ APGKG LEWVARVI PNAGGTSYNQK F K GRFTLSVD NSKN TAYLQMN SLRAEDT AVYYCA REG IYWW GQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITCR SSQ SLVH SNGN TFLHWYQ QKPGKAP KLLIYTVS NRFSGVPS R FSGSGSGT DFTLTISS LQPED F ATYFC SQTTHVPW T FGQGT KVEI K
Cilgavimab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFRDVWMSWVRQAPGKGLEWVGRIKSKIDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTAGSYYYDTVGPGLPEGKFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLMYWASTRESGVPDRFSGSGSGAEFTLTISSLQAEDVAIYYCQQYYSTLTFGGGTKVEIK,na,na,7l7e:CD:EF:MN:OP,None,None,2020,2021,SARS-CoV-2 Spike RBD,AstraZeneca,COVID-19,na,na,na,,E VQLVES GGG LV KPGG SLRLSC AASGF TFRDVWMSWVR QAPGKGL EWVGRIKSK IDGGTTDYAAP VKGRFTISR DDSKN TLYLQMN SLKTEDT AVYYCT TAGS YYYD TVGPGLPEGK FDY WGQG TLVTVS S,D IVMT QSPDS LAVS LGE RATINC KSSQ SVLYS SNNKN YLAWYQ QKPGQPP KLLMYWAS TRESGVPDRFSGSGSGA EFTLTISS LQAED VAIYYCQ QYYS TLTF GGG TKVEI K
Cinpanemab,Whole mAb,G1,Lambda,Phase-II,Discontinued,EVQLVESGGGLVEPGGSLRLSCAVSGFDFEKAWMSWVRQAPGQGLQWVARIKSTADGGTTSYAAPVEGRFIISRDDSRNMLYLQMNSLKTEDTAVYYCTSAHWGQGTLVTVSS,SYELTQPPSVSVSPGQTARITCSGEALPMQFAHWYQQRPGKAPVIVVYKDSERPSGVPERFSGSSSGTTATLTITGVQAEDEADYYCQSPDSTNTYEVFGGGTKLTVL,na,na,6ct7:HL:AB,None,None,2018,2019,SNCA,Neurimmune Therapeutics;Biogen,na,na,Parkinson's disease,na,,E VQLVES GGG LV EPGG SLRLSCAV SGFDFE KA WMSWVR QAPGQG LQWVARIKS TADGGT TSYA AP V EG RFIISR DDSRN MLYLQM NSLKTEDT AVYYCT SAHWGQG TLVTVS S,SYELTQPPS VSV SPGQ TARITC SGEALP MQFAHWYQ QRPGKAP VIVVYK DSERPSGVPE R FSGSSSGT TATLTITGVQ AEDEAD YYCQ SPDSTN TYEVF GGGT KLTV L
Cinrebafusp,Fusion Protein,G4,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,na,na,1fvc:DC:BA/4hkz:BA/1n8z:BA/4ub0:HL/5xhf:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD/6oge:ED/7mn8:DC,1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC,5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,2019,2020,ERBB2,Eli Lilly and Company;Pieris Pharmaceuticals;Seagen,na,Gastic cancer;Solid tumours,na,na,"Identical Fv sequence to Anvatabart, Coprelotamab, Trastuzumab, Timigutuzumab",E VQLVES GGG LV QPGG SLRLSCA ASGFNIKD TYIHWVRQ APGKG LEWVARIY PTNGY TRYA DSVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYCS RWGGDG FYAMD YWGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQD VNTA VAWYQ QKPGKAP KLLIYSASFLY SGVPSRFSGSRSGTD FTLTIS SLQP EDFAT YYCQ QHYTTPPTFGQGT KVEI K
Cirevetmab,Canine Whole mAb,G2,Kappa,Unknown,Active,EVQLVQSGAEVKKPGASVKVSCKTSGYTFISSWMNWVRQAPGAGLDWMGQIYPGDGDTNYNGKFKGRVTLTADTSTSTAYMELSSLRAGDIAVYYCARHYDGSTDYWGQGTLVTVSS,EIVMTQSPASLSLSQGEKVTITCRASENIYSNLAWYQQRPGQAPKLLIYAATNLADGVPSRFSGSGSGTDFSLTISSLEPEDVAVYYCQHFWGTPYTFGQGTKLEIK,na,na,None,None,None,2022,na,TGFB1 (Canine),TBC,TBC,TBC,TBC,TBC,,E VQLVQ SGA EVK KPGA SVKVSC KTSG YTFIS SWMNWVR QAPGAGLD WMGQI YPGDGDTNYNG KFKGRVTLTA DTSTS TAYMELS SLRAGD IAVYYCARH YDGSTDY W GQ GTLVTVS S,E IVMT QSPA SLSL SQGE KVTITCR ASENIYSN LAWYQ QRPGQAP KLLIYAAT NLADGVPS RF SGSGSGTD FSLTIS SLEPED VAVYYCQH FWGTPY T FGQGT KLEI K
Citatuzumab,Fab Fusion,G1,Kappa,Phase-I,Discontinued,EVQLVQSGPGLVQPGGSVRISCAASGYTFTNYGMNWVKQAPGKGLEWMGWINTYTGESTYADSFKGRFTFSLDTSASAAYLQINSLRAEDTAVYYCARFAIKGDYWGQGTLLTVSS,DIQMTQSPSSLSASVGDRVTITCRSTKSLLHSNGITYLYWYQQKPGKAPKLLIYQMSNLASGVPSRFSSSGSGTDFTLTISSLQPEDFATYYCAQNLEIPRTFGQGTKVELK,na,na,None,None,None,2008,2009,EPCAM,Viventia Biotech;Sesen Bio,na,na,Solid tumours,na,,E VQLVQ SGPG LV QPGG SVRISC AASGY TFTN YGM NWVK QAPGKGL EWMGWIN TYTGES TY ADSFKG RFTFSL DTSAS AAYLQINSL RAEDT AVYYCARFAIK GDYWGQ GTLLTVS S,DI QMT QSPSS LSA SVGD RVTITCR STK SLLH SNG ITYLYWYQ QKPGKAP KLLIYQM SNLASGVPS RF SSSGSGT DFTLTISS LQPE DF ATYYCA QNLEIPRTFGQGT KVEL K
Cixutumumab,Whole mAb,G1,Lambda,Phase-II,Discontinued,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARAPLRFLEWSTQDHYYYYYMDVWGKGTTVTVSS,SSELTQDPAVSVALGQTVRITCQGDSLRSYYATWYQQKPGQAPILVIYGENKRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCKSRDGSGQHLVFGGGTKLTVL,na,na,None,None,None,2008,2009,IGF1R,Eli Lilly;ImClone Systems;M. D. Anderson Cancer Center;National Cancer Institute (USA) ,na,na,Breast cancer;Colorectal cancer;Head and neck cancer;Liver cancer;Neuroendocrine tumours;Non-small cell lung cancer;Oesophageal cancer;Pancreatic cancer;Prostate cancer;Rhabdomyosarcoma;Sarcoma;Soft tissue sarcoma;Solid tumours;Thymoma,Dyax Human Phage Display,,E VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSSYAISWVR QAPGQGL EWMGGIIPIF GTANYAQKFQG RVTITA DKSTS TAYMELS SLRSEDT AVYYCA RAP LRFLEW STQDH YYYYYMDV WGKG TTVTVS S,SSELTQDPA VSVA LGQ TVRITC QGDS LR SYYATWYQ QKPGQAP ILVIY GENKRPSGIPDRFSGSSSGN TASLTIT GAQAEDEA DYYCK SRDGSGQ HLVFG GGT KLTV L
Clazakizumab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFSLSNYYVTWVRQAPGKGLEWVGIIYGSDETAYATSAIGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDSSDWDAKFNLWGQGTLVTVSS,AIQMTQSPSSLSASVGDRVTITCQASQSINNELSWYQQKPGKAPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQGYSLRNIDNAFGGGTKVEIK,na,na,None,None,None,2012,2013,IL6,Alder Biopharmaceuticals;Cedars-Sinai Medical Center;Medical University of Vienna;Vitaeris,na,Renal transplant rejection;COVID-19,Anaemia;Cachexia;Fatigue;Stomatitis;Crohn's disease;Graft-versus-host disease;Inflammation;Psoriatic arthritis;Rheumatoid Arthritis,na,,E VQLVES GGG LV QPGG SLRLSCA ASGFSLSN YYVTWVRQ APGKG LEWVGIIY GSDETA YAT S AIGRFTISR DNSKN TLYLQMNS LRAEDT AVYYCA RDDSSDWD AKFNLW GQG TLVTV SS,AI QMT QSPSS LSA SVGD RVTITCQ ASQSINNE LSWYQ QKPGKAP KLLIYRA STLASGVPS R FSGSGSGTD FTLTISS LQPDD F ATYYC QQGY SLRN IDNAFGGG TKVEI K
Clervonafusp,di-Fab Fusion,G1,Kappa,Phase-I/II,Active,EVQLQESGGGVVQPGGSLRLSCAASGFTFSNYGMHWIRQAPGKGLEWVSYISSGSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRSEDTAVYYCARRGLLLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTISCRASKSVSTSSYSYMHWYQQKPEKAPKLLIKYASYLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQHSREFPWTFGAGTKLELK,na,na,None,None,None,2018,2019,SLC29A2,Valerion Therapeutics,na,Glycogen storage disease type II,na,na,(June '22: Corrected FWL2 and CDRL3 sequences),E VQLQE SGG GVV QPGG SLRLSC AASGF TFS NYG MHWIRQ APGKGL EWVSYIS SGSS TIYYA DSVKG RFTISR DNSKN TLYLQMN SLRSEDT AVYYCA RRGL LLDY WGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTISCR ASKSVSTSSY SYMHWY QQKPEKAP K LLIK YASYL QSGVPS RF SGSGSGTD FTLTIS SLQ PEDVA TYYC QHSREFPW TF GAGT KLEL K
Clesrovimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVRPGRSLRLSCTVSGFSFDDSAMSWVRQAPGKGLEWISFIKSKTYGGTKEYAASVKGRFTISRDDSKNIAYLQMNSLKTEDTAVYYCTRGAPYGGNSDYYYGLDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSQDVRGALAWYQQKPGKAPKLLIFDASSLETGVPSRFSGSGSGTVFTLTISSLQPEDFAAYYCQQFLDFPFTFGQGTRLEIK,na,na,6ous:MN:OP:QR:ST:UV:WX,None,None,2022,na,RSV gpF,Merck Sharp & Dohme,na,Respiratory syncytial virus infections,na,na,,E VQLVES GGG LV RPGR SLRLSCTVS G FS FDDSA MSWVRQ APGKGL EWISFIK SKTYGGTK EYAASVKGRFTIS RDDSKN IAYLQM NSLKTEDT AVYYCT RGAPYGGNSDY YYGLDV WGQG TTVTVS S,DIQMTQSPSS LSA SVGD RVTITCR TS QDVRGALAWYQQ KPGKAP KLLIFD ASSLETGVPSRFSGSGSG TVFTLTIS SLQ PEDFAAYYCQQF LDFPF T FGQGT RLEI K
Clivatuzumab,Whole mAb Radiolabelled,G1,Kappa,Phase-III,Discontinued,QVQLQQSGAEVKKPGASVKVSCEASGYTFPSYVLHWVKQAPGQGLEWIGYINPYNDGTQYNEKFKGKATLTRDTSINTAYMELSRLRSDDTAVYYCARGFGGSYGFAYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTMTCSASSSVSSSYLYWYQQKPGKAPKLWIYSTSNLASGVPARFSGSGSGTDFTLTISSLQPEDSASYFCHQWNRYPYTFGGGTRLEIK,na,na,None,None,None,2009,2010,MUC1,Immunomedics,na,na,Pancreatic cancer,na,,Q VQLQQ SGA EVK KPGA SVKVSCE ASGYTFPS YVLHWVK QAPGQG LEWIGYI NPYNDGTQYNE KF KG KATLT RDTSIN TAYMELSR LRSDDT AVYYCA RGFGGS YGFAYW GQG TLVTVS S,DI QLT QSPSS LSAS VGD RVTMTCS ASSSVSS SYLYWYQ QKPGKAP KLWIYS TSNLASGVP ARFS GSGSGT DFTLTISS LQPEDSA SYFCH QWNRYPYTFGGG TRLEI K
Cobolimab,Whole mAb,G4,Kappa,Phase-II/III,Active,EVQLLESGGGLVQPGGSLRLSCAAASGFTFSSYDMSWVRQAPGKGLDWVSTISGGGTYTYYQDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSIRRYLNWYHQKPGKAPKLLIYGASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAVYYCQQSHSAPLTFGGGTKVEIK,na,na,None,None,None,2018,2019,HAVCR2,AnaptysBio;GlaxoSmithKline;TESARO,na,Non-small cell lung cancer;Liver cancer;Malignant Melanoma,Solid tumours,na,,E VQLLES GGG LV QPGG SLRLSCA AASGF TFSS YDM SWVR QAPGKGLD WVSTI SGGG TYTYYQ DSVK GRFTISR DNSKN TLYLQMNS LRAEDT AVYYCASM DYWGQG TTVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQ SIRRYLNWY HQKPGKAP KLLIYG ASTLQSGVPSRFSGSGSGTD FTLTIS SLQPED FAVYYC QQSHSAP LTF GGG TKVEI K
Codrituzumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYEMHWVRQAPGQGLEWMGALDPKTGDTAYSQKFKGRVTLTADKSTSTAYMELSSLTSEDTAVYYCTRFYSYTYWGQGTLVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSLVHSNRNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQNTHVPPTFGQGTKLEIK,na,na,None,None,None,2013,2014,GPC3,Perseus Proteomics;Chugai Pharmaceutical;Roche,na,Liver cancer,na,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TF TDY EMHWVRQ APGQG LEWMGAL DPKTGDTA Y SQKFKG RVTLTA DKSTS TAYMELS SLTSEDT AVYYCTRFYSYTY WGQG TLVTVS S,DV VMT QSPLSLPVTPGEPA SISC RSSQ SLVH SNRNT YLHWYLQ KPGQSP QLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AED VGVYYCS QNTHVPPTFGQGT KLEI K
Cofetuzumab,Whole mAb ADC,G1,Kappa,Phase-I,Active,QVQLVQSGPEVKKPGASVKVSCKASGYTFTDYAVHWVRQAPGKRLEWIGVISTYNDYTYNNQDFKGRVTMTRDTSASTAYMELSRLRSEDTAVYYCARGNSYFYALDYWGQGTSVTVSS,EIVLTQSPATLSLSPGERATLSCRASESVDSYGKSFMHWYQQKPGQAPRLLIYRASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSNEDPWTFGGGTKLEIK,na,na,None,None,None,2017,2018,PTK7,Stemcentrx;Indiana University;Pfizer;Stemcentrx,na,Non-small cell lung cancer;Solid tumours,Breast cancer,na,,Q VQLVQ SGPEVKKPGA SVKVSCK ASGY TFTDYAVHWVR QAPGK RLEWIGVISTY NDYTYNNQDFK GRVTMTR DTSAS TAYMELSR LRSEDT AVYYC ARGN SYFYALD YWGQG TSVTVS S,E IVLTQ SPA TLSL SPGE RATLSCRA SESVDSYGK SFMHWYQ QKPGQAP RLLIYRA SNLESGIP ARFS GSGSGTD FTLTIS SLEPED FAVYYCQ QSNEDPW T FGGG TKLEI K
Coltuximab,Whole mAb ADC,G1,Kappa,Phase-II,Active,QVQLVQPGAEVVKPGASVKLSCKTSGYTFTSNWMHWVKQAPGQGLEWIGEIDPSDSYTNYNQNFQGKAKLTVDKSTSTAYMEVSSLRSDDTAVYYCARGSNPYYYAMDYWGQGTSVTVSS,EIVLTQSPAIMSASPGERVTMTCSASSGVNYMHWYQQKPGTSPRRWIYDTSKLASGVPARFSGSGSGTDYSLTISSMEPEDAATYYCHQRGSYTFGGGTKLEIK,na,na,6ani:HL:IM,None,None,2013,2014,CD19,ImmunoGen,na,Diffuse large B cell lymphoma,Precursor cell lymphoblastic leukaemia-lymphoma,na,,Q VQLV QPGA EVV KPGA SVKLSC KTSG YTFT SN WMHWVK QAPGQGL EWIGEI DPSDSYTNYNQNFQG KAKLTVD KSTS TAYMEVSSL RSDDT AVYYCA RGSNP YYYAMD YWGQGT SVTVS S,E IVLT QSP AIMS ASPGE RVTMTCS ASSGV NYMHWYQ QKPGTSPR RWIYD TSKLASGVP ARFS GSGSGTD YSLTISS MEPEDAA TYYCH QRGS YTF GGG TKLEI K
Conatumumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYFWSWIRQLPGKGLEWIGHIHNSGTTYYNPSLKSRVTISVDTSKKQFSLRLSSVTAADTAVYYCARDRGGDYYYGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQGISRSYLAWYQQKPGQAPSLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFGSSPWTFGQGTKVEIK,na,na,4n90:DE:FG:HI,None,None,2008,2009,TNFRSF10B,Amgen;Takeda,na,na,Colorectal cancer;Lymphoma;Non-small cell lung cancer;Pancreatic cancer;Sarcoma;Solid tumours,Abgenix XenoMouse,,QV QLQE SGPGLVKPSQ TLSLTCTV SGGSISSGD YFWSWIR QLPGKGL EWIGHIH NSGT TYY NPSLKS RVTISVD TSKK QFSLRLSS VTAADT AVYYCAR DRGGD YYYGMDV WGQG TTVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQGIS RS YLAWYQ QKPGQAP SLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYCQ QFGSSPWTFGQGT KVEI K
Concizumab,Whole mAb,G4,Kappa,Phase-III,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSNYAMSWVRQTPEKRLEWVATISRSGSYSYFPDSVQGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLGGYDEGDAMDSWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCKSSQSLLESDGKTYLNWYLQKPGQSPQLLIYLVSILDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQATHFPQTFGGGTKVEIK,na,na,4dtg:HL,None,None,2012,2013,TFPI,Novo Nordisk,na,Haemophilia,na,na,,E VQLVES GGG LV KPGG SLRLSC AASGF TFS NY AMSWVR QTPEKR LEWVATIS RSGS YSY FPDSVQ GRFTISR DNAKNS LYLQMN SLRAEDT AVYYCAR LGGYDEGDAMDSWGQG TTVTVS S,DI VMT QTP LSLSV TPGQP ASISC KSSQ SLLE SDGK TYLNWYL QKPGQSPQ LLIYLVSI LDSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCLQAT HFPQTFGGG TKVEI K
Coprelotamab,Whole mAb,G1,Kappa,Preregistration,Active,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,na,na,1fvc:DC:BA/4hkz:BA/1n8z:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD/6oge:ED/7mn8:DC,1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC,5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,2020,2021,ERBB2,Genor Biopharma,na,Breast cancer,na,Coprelotamab is a biosimilar of Trastuzumab and Timigutuzumab with an identical Variable region. Cinrebafusp and Anvatabart have identical V domains.,,E VQLVES GGG LV QPGG SLRLSCA ASGFNIKD TYIHWVRQ APGKG LEWVARIY PTNGY TRYA DSVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYCS RWGGDG FYAMD YWGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQD VNTA VAWYQ QKPGKAP KLLIYSASFLY SGVPSRFSGSRSGTD FTLTIS SLQP EDFAT YYCQ QHYTTPPTFGQGT KVEI K
Cosfroviximab,Whole mAb,G1,Kappa,Phase-II,Active,DVKLLESGGGLVQPGGSLKLSCAASGFSLSTSGVGVGWFRQPSGKGLEWLALIWWDDDKYYNPSLKSQLSISKDFSRNQVFLKISNVDIADTATYYCARRDPFGYDNAMGYWGQGTSVTVSS,DIVMTQSPLSLSTSVGDRVSLTCKASQNVGTAVAWYQQKPGQSPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADYFCQQYSSYPLTFGAGTKLELR,na,na,None,5kel:CD:JN:MO/5kem:DE:IJ,None,2016,2017,Zaire Ebolavirus GP,Mapp Biopharmaceutical;Public Health Agency of Canada;National Institute of Allergy and Infectious Diseases,na,Ebola virus infections ,na,Zmapp Technology,,D VKLLES GGG LV QPGG SLKLSC AASG FSLS TSG VGVGWFR QPSGKGL EWLALIWW DDDKYYNPSLKS QLSIS KDFSRN QVFLKIS NV D IADT ATYYCAR RDPFGYDNAMG YW GQGT SVTVS S,D IVMT QSPL SLST SVGD RVSLTCK ASQNVG TAVAWYQ QKPGQSP KLLIYS ASNRYTGVPDRFTGSGSGTD FTLTIS NMQS EDLADYFCQQ YSSYP LTF GAGT KLEL R
Cosibelimab,Whole mAb,G1,Lambda,Phase-III,Active,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSRSAISWVRQAPGQGLEWMGVIIPAFGEANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGRQMFGAGIDFWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTRSSGSIDSNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSNNRHVIFGGGTKLTVL,na,na,None,None,None,2019,2020,PDL1,Dana-Farber Cancer Institute;Checkpoint Therapeutics;TG Therapeutics Inc,na,Cancer;Lymphoma,na,na,,E VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSRSAISWVR QAPGQGL EWMGVIIP AFGEANYAQ K FQG RVTITA DESTS TAYMELS SLRSEDT AVYYC ARGR QMFG A GIDFW GQG TLVTVS S,NF MLT QPH SVS ESPGK TVTISCT RSSGSIDSN YVQWYQ QRPGSAP TTVIYE DNQRPSGVPDR FSGSI DSSSNS ASLTIS GLKTEDEAD YYCQSY DSNNR HVIFG GGT KLTV L
Crefmirlimab,scFv Engineered Dimer,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHFVRQAPGKGLEWIGRIDPANDNTLYASKFQGKATISADTSKNTAYLQMNSLRAEDTAVYYCGRGYGYYVFDHWGQGTLVTVSS,DVQITQSPSSLSASVGDRVTITCRTSRSISQYLAWYQQKPGKVPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQQHNENPLTFGGGTKVEIK,na,na,None,None,None,2022,na,CD8A,ImaginAb,na,Solid tumours;Cervical cancer;Gastic cancer,Graft-versus-host disease,na,Uses G1 and CH3 region in the dimer,E VQLVES GGG LV QPGG SLRLSCA ASGFNIKD TYIHFVRQ APGKG LEWIGRI DPANDN TLYAS KFQG KATISA DTSKN TAYLQMN SLRAEDT AVYYC GRGY GYYVFD HWGQG TLVTVS S,DV QIT QSPSS LSA SVGD RVTITCR TS RSISQYLAWYQ QKPGKVP KLLIYS GSTLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDVATYYCQQ HNENPL T FGGGT KVEI K
Crenezumab,Whole mAb,G4,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLELVASINSNGGSTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASGDYWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLVYSNGDTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK,na,na,5vzx:HL:EI/5vzy:HL,5kmv:HL:EI,None,2011,2012,APP,AC Immune;Genentech;Universidad de Antioquia,na,Alzheimer's disease,na,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFSS YG MSWVRQ APGKG LELVASIN SNGGS TY YPDSVK GRFTISR DNAKNS LYLQMNS LRAEDT AVYYC ASGDYWGQG TTVTVS S,DI VMT QSPLSLPVTPGEPA SISC RSSQ SLVYS NGD TYLHWYLQ KPGQSP QLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCS QSTHVPW T FGQGT KVEI K
Crexavibart,Whole mAb,G1,Lambda,TBC,Active,EVQLVESGGGLIQPGGSLRLSCAASGFTVSNNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDKSKNTLYLQMNSLRAEDTAVYYCAREGEVEGYNDFWSGYSRDRYYFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL,na,na,7k90:HL:MN:OP,None,None,2022,na,SARS-CoV-2 Spike RBD,TBC,TBC,COVID-19,TBC,TBC,,E VQLVES GGG LI QPGG SLRLSC AASGF TVS NN YMSWVR QAPGKGL EWVSVIYS GGS TYYA DSVKG RFTISR DKSKN TLYLQMNS LRAEDT AVYYCA REGE VEGY NDFWSGYSRD RYYFDY WGQG TLVTVS S,QSALTQPA SV SGSPGQ SITISCT GTSSDVGG YNYVSWYQ QHPGKAP KLMIYD VSNRPSGVSNRFSGSKSGN TASLTIS GLQAEDEAD YYCSS YTSSST RVF GTGT KVTV L
Crizanlizumab,Whole mAb,G2,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKVSGYTFTSYDINWVRQAPGKGLEWMGWIYPGDGSIKYNEKFKGRVTMTVDKSTDTAYMELSSLRSEDTAVYYCARRGEYGNYEGAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQSVDYDGHSYMNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSDENPLTFGGGTKVEIK,na,na,None,None,None,2016,2017,SELP,Selexys Pharmaceuticals;Novartis,Vaso-occlusive crisis,Priapism;Myelofibrosis;COVID-19,na,na,,Q VQLVQ SGA EVK KPGA SVKVSCKV SG YTFTSYDINWVR QAPGKGL EWMGWIY PGDGS IKY NEKFKG RVTMTVD KSTD TAYMELSS LRSEDT AVYYCAR RGEYGNYEGA M DYWGQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITCK ASQS V DYDGH SYMNWYQ QKPGKAP KLLIYAA SNLESGVPS R FSGSGSGTD FTLTISS LQPEDF ATYYCQ QSDENPL TF GGG TKVEI K
Crotedumab,Whole mAb,G4,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYLMNWVRQAPGKGLEWLANIQEDGIEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREPSHYDILTGYDYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRFSGSGSGTEFILTVSSLQPEDFATYYCLQYNSNPFTFGPGTKVDIK,na,na,None,None,None,2015,2016,GCGR,Regeneron Pharmaceuticals;Sanofi,na,na,Type 2 diabetes mellitus,na,,E VQLVES GGG LV QPGG SLRLSC AASGFT FSNYLMNWVRQ APGKG LE WLAN IQEDGI EKYYVD SVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCA REPSHYD IL TGYDY YY G MDV WGQG TTVTVS S,DI QMT QSPSS LSA SVGD RVTITCR ASQGIRNDLG WYQ QKPGKAPK RLIYAA SSLQSGVPS RF SGSGSGT EFILTVS SLQPEDF ATYYCLQY NSNPF T FGPGT KVDI K
Crovalimab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVESGGGLVQPGRSLRLSCAASGFTVHSSYYMAWVRQAPGKGLEWVGAIFTGSGAEYKAEWAKGRVTISKDTSKNQVVLTMTNMDPVDTATYYCASDAGYDYPTHAMHYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSSLAWYQQKPGKAPKLLIYGASETESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNTKVGSSYGNTFGGGTKVEIK,na,na,5b71:DC:BA,None,None,2018,2019,C5,Chugai Pharmaceutical;Roche,na,Atypical Haemolytic Uraemic Syndrome;Paroxysmal nocturnal haemoglobinuria ,na,na,,Q VQLVES GGG LV QPGR SLRLSC AASGF TVH SS YYMAWVRQ APGKGL EWVGAIFT GSGA EYKAEW AKG RVTISK DTSKN QVVLTMT NMDPVDT ATYYCA SDAGYDYPTH AMHYW GQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQGISS SLAWYQ QKPGKAP KLLIYG ASETESGVPS R FSGSGSGTD FTLTIS SLQP EDFA TYYC QNTKVGSSYGNTFGGG TKVEI K
Cudarolimab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGRPWYSETGTSAFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQSDHYPTFGGGTKVEIK,na,na,None,None,None,2019,2020,TNFRSF4,Innovent Biologics,na,na,Solid tumours,na,,Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKG LEWVAVISY DGSNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RGRPW Y SETGTS AFDI WGQG TMVTVS S,DIQMTQSPSS LSA SVGD RVTITCQ ASQD ISNYLNWYQ QKPGKAP KLLIYD ASNLETGVPSRFSGSGSGTD FTFTIS SLQ PEDIATY YC QQSDHYPTFGGGT KVEI K
Cusatuzumab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSVYYMNWVRQAPGKGLEWVSDINNEGGTTYYADSVKGRFTISRDNSKNSLYLQMNSLRAEDTAVYYCARDAGYSNHVPIFDSWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGLKSGSVTSDNFPTWYQQTPGQAPRLLIYNTNTRHSGVPDRFSGSILGNKAALTITGAQADDEAEYFCALFISNPSVEFGGGTQLTVL,na,na,None,None,None,2017,2018,CD70,arGEN-X,na,Cutaneous T-cell lymphoma;Acute myeloid leukaemia;Haematological malignancies;Myelodysplastic syndromes;Solid tumours,Nasopharyngeal cancer;Autoimmune disorders,POTELLIGENT Technology;SIMPLE Antibody Technology,,E VQLVES GGG LV QPGG SLRLSC AASGF TFSVYYMNWVR QAPGKG LEWVSD INNEGGT TYYAD SVKG RFTISR DNSKN SLYLQMN SLRAEDT AVYYCA RDAGYSNH VPIF DSWGQG TLVTVS S,QA VVT QEP SLTV SPGG TVTLTCGL KSGS V TSDNFPT WYQ QTPGQAP RLLIYN TNTRHSGVPDRFSG SI LGNK AALTIT GAQADDEA EYFCALFIS NPS VEF GGGT QLTV L
Dacetuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQAPGKGLEWVARVIPNAGGTSYNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYYCAREGIYWWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKLLIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVEIK,na,na,None,None,None,2007,2008,CD40,Seattle Genetics,na,na,Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Multiple myeloma;Non-Hodgkin's lymphoma,na,,E VQLVES GGG LV QPGG SLRLSCA ASGY SFTGYYIHWVRQ APGKG LEWVARVI PNAGGTSYNQK F K GRFTLSVD NSKN TAYLQMN SLRAEDT AVYYCA REG IYWW GQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITCR SSQ SLVH SNGN TFLHWYQ QKPGKAP KLLIYTVS NRFSGVPS R FSGSGSGT DFTLTISS LQPED F ATYFC SQTTHVPW T FGQGT KVEI K
Daclizumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGQGTKVEVK,na,na,3nfs:HL/3nfp:HL:AB,None,None,1994,1998,IL2RA,AbbVie;Biogen;Dana-Farber Cancer Institute;National Cancer Institute (USA);PDL BioPharma,Renal transplant rejection,Multiple sclerosis,Asthma;Graft-versus-host disease;Haematological malignancies;Immune-mediated uveitis;Liver transplant rejection;Psoriasis;Tropical spastic paraparesis;Type 1 diabetes mellitus;Ulcerative colitis,GS Gene Expression System,Daclizumab is the new name for Dacliximab (PL78),Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TFTSYRMHWVRQ APGQG LEWIGYI NPSTGYTEYNQKFKDK ATITA DESTN TAYMELS SLRSEDT AVYYCA RGGG VFDY WGQG TLVTVS S,DIQ MT QSPS TLSAS VGD RVTITCS ASSS ISYMHWYQ QKPGKAP KLLIYTT SNLASGVP ARFS GSGSGT EFTLTISS LQPDDF ATYYCH QRSTYPL TF GQGT KVEV K
Dafsolimab,Whole mAb,G2b,Kappa,Phase-III,Active,QVQLQQSGAELARPGASVKMSCKASGYTFTSYTMHWVKQRPGQGLEWIGYINPSSGYTNYIQRFKDKATLTADKSSSTAYMQVSSLTSEDSAVYYCARGSRYDYYGMDYWGQGTSVTVSS,QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELK,na,na,None,None,None,2020,2021,CD3E,Xenikos,na,Steroid-refractory acute graft-versus-host disease;Graft-versus-host disease,na,na,,QV QLQ QSGA EL ARPGA SVKMSCK ASGY TFTSYTMHWVK QRPGQG LEWIGYI NPSSGYT NYIQR FKDK ATLTA DKSSST AYMQVSS LTSEDS AVYYC ARGS RYDY YGMDYWGQG TSVTVS S,Q IVLT QSP AIMS ASPGE KVTMTCS ASSS VSYMHWYQ QKSGTSPK RWIYD TSKLASGVP ARFS GSGSGT SYSLTISS MEAEDA A TYYCQQ WSSNPL TF GAGT KLEL K
Dalnicastobart,Whole mAb,G1,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPDSGGTNYAQKFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCARDQPLGYCTNGVCSYFDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGIYSWLAWYQQKPGKAPNLLIYTASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANIFPLTFGGGTKVEIK,na,na,None,None,None,2022,na,CD40,TBC,TBC,TBC,TBC,TBC,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTGYYMHWVR QAPGQG LEWMGWI NPDSGGTNY AQKF QG RVTMT RDTS ISTAYMEL NRLRSDDT AVYYCA RDQPLG Y CTNGV CSYFD YWGQG TLVTV SS,DIQ MT QSPSS VSAS VGD RVTITCR ASQG IY SWLAWY QQKPGKAPN LLIYT ASTLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ ANIF PLTF GGG TKVEI K
Dalotuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLQESGPGLVKPSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNYKPSLKDRVTISRDTSKNQFSLKLSSVTAADTAVYYCARYGRVFFDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSIVHSNGNTYLQWYLQKPGQSPQLLIYKVSNRLYGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPWTFGQGTKVEIK,na,na,None,None,None,2009,2010,IGF1R,Pierre Fabre;Merck & Co,na,na,Multiple myeloma;Neuroendocrine tumours;Non-small cell lung cancer;Solid tumours;Breast cancer;Colorectal cancer;Pancreatic cancer ,na,"Jain paper: ""Entries in WHO-INN documents (PL102 and RL64) have errors""",QV QLQE SGPGL V KPSE TLSLTCTV SG YSI TGG YLWNWIR QPPGKGL EWIGYISY DGTNNYKPSLKD RVTISR DTSKN QFSLKLS SVTAADT AVYYCA RYG RVFFDY WGQG TLVTVS S,DI VMT QSPLSLPVTPGEPA SISC RSSQ SIVH SNGN TYLQWYL QKPGQSP QLLIYKV SNR LY GVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCF QGSHVPW TF GQGT KVEI K
Dalutrafusp,Whole mAb Fusion,G1,Kappa,Phase-I,Discontinued,EVQLVQSGAEVKKPGESLKISCKASGYAFSSSWINWVRQMPGKGLEWMGRIYPRAGDTNYAGKFKDQVTISADKSISTAYLQWSSLKASDTAMYYCASLLDYSMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQGNTLPLTFGQGTKVEIK,na,na,None,None,None,2021,2022,TGFBR2,Gilead Sciences,na,na,Solid tumours,na,,E VQLVQ SGA EVK KPGE SLKISCK ASGY AF S SSWINWVRQ MPGKGL EWMGRI YPRAGDTNYAGKFKD QVTIS ADKS ISTAYLQWS SLKASDT A MYYC ASLL DYSMDYWGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQD ISNYLNWYQ QKPGKAP KLLIYYT SRLHSGVPSRFSGSGSGTD FTFTIS SLQ PEDIA TYYC QQGN TLPLTF GQGT KVEI K
Danburstotug,Whole mAb Fusion,G1,Lambda,Phase-II,Active,QMQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAYSWVRQAPGQGLEWMGGIIPSFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGPIVATITPLDYWGQGTLVTVSS,SYVLTQPPSVSVAPGKTATIACGGENIGRKTVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCLVWDSSSDHRIFGGGTKLTVL,na,na,None,None,None,2022,na,PDL1,Sorrento Therapeutics;Asan Medical Center;ImmuneOncia Therapeutics,na,Extranodal NK-T-cell lymphoma;Gastric cancer;Liver cancer;Oesophageal cancer;Solid tumours,na,na,,QM QLVQ SGA EVK KPGS SVKVSCK ASGGT FSSYAYSWVR QAPGQGL EWMGGII PSFGTANYAQKFQG RVTITA DESTS TAYMELS SLRSEDT AVYYC ARGP IVATIT PLDYWGQG TLVTVS S,SY VL TQPPS VSV APGK TATIAC GGENIGR KTVHWYQ QKPGQAP VLVIYY DSDRPSGIPERFSGSNSGN TATLTISRVE AGDEA DYYCLVWD SSSDH RIF GGGT KLTV L
Danvilostomig,Bispecific Mixed mAb and scFv,G1;na,Kappa;Kappa,TBC,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCTASGFSLSSYAMSWVRQAPGKGLEYIGYIGDTTGIAYASWANGRFTISKDNTKNTVDLQMNSLRAEDTAVYYCARGWSYLDIWGQGTLVTVSS,ALVMTQSPSSLSASVGDRVTITCQASQNIYSNLAWYQQKPGKVPKLLIYQASTLASGVPSRFSGSGYGTDFTLTISSLQPEDVATYYCQGGYYSAALNTFGGGTKVEIK,5tru:HL:hl/5xj3:AB:DE:JK:GH/6jc2:HL/6rp8:HL:hl/7elx:HL;None,None;None,7su0:HL:IM/7su1:HL;None,2022,na,CTLA4;PDCD1,TBC,TBC,TBC,TBC,TBC,Fv1 is Ipilimumab,Q VQLVES GGG VV QPGR SLRLSC AASGF TFSSYTMHWVRQ APGKGL EWVTFISY DGNNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AIYYCA RTGWLGPFDYWGQG TLVTV SS,E IVLTQ SPG TLSL SPGE RATLSCRA SQSVGS SYLAWYQ QKPGQAP RLLIYGAF SRATGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQ QYGSSPW TF GQGT KVEI K
Dapirolizumab,Fab,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAVSGFSSTNYHVHWVRQAPGKGLEWMGVIWGDGDTSYNSVLKSRFTISRDTSKNTVYLQMNSLRAEDTAVYYCARQLTHYYVLAAWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASEDLYYNLAWYQRKPGKAPKLLIYDTYRLADGVPSRFSGSGSGTDYTLTISSLQPEDFASYYCQQYYKFPFTFGQGTKVEIK,na,na,None,None,None,2013,2014,CD40LG,Biogen;Biogen Idec;UCB,na,Systemic lupus erythematosus;Multiple sclerosis,Amyotrophic lateral sclerosis;Rheumatoid Arthritis,na,,E VQLVES GGG LV QPGG SLRLSCAV SGFSSTN YHVHWVRQ APGKG LEWMGVIW GDGDTSYNS VLKSRFTISR DTSKN TVYLQMNS LRAEDT AVYYCA RQLT HYYVLAAW GQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITCR ASEDL YYNLAWYQ RKPGKAP KLLIYDTYR LADGVPS RF SGSGSGTD YTLTISS LQ PEDFASYYCQ QYYKFPF T FGQGT KVEI K
Daratumumab,Whole mAb,G1,Kappa,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIK,na,na,7dun:HL/7duo:HL/7dha:CB,None,None,2009,2010,CD38,Boston Medical Center;Bristol-Myers Squibb;Dana-Farber Cancer Institute;French Innovative Leukemia Organisation;Genentech;Genmab;Janssen Biotech;Janssen Research & Development;M. D. Anderson Cancer Center;Syros Pharmaceuticals,Multiple myeloma,Amyloid light-chain amyloidosis;Acute myeloid leukaemia;Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Follicular lymphoma;Mantle-cell lymphoma;Myelodysplastic syndromes;Precursor B-cell lymphoblastic leukaemia-lymphoma;Precursor T-cell lymphoblastic leukaemia-lymphoma;Prostate cancer;T-cell lymphoma;Waldenstrom's macroglobulinaemia;Solid tumours,Non-small cell lung cancer,Medarex HuMAb Mouse,,E VQLLES GGG LV QPGG SLRLSCAV SGF TF NS FAMSWVR QAPGKGL EWVSAIS GSGGG TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYFC AKDK ILWF GEP VF DYWGQG TLVTV SS,E IVLTQ SPA TLSL SPGE RATLSCR ASQS VSSY LAWY QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPED FAVYYCQ QRSNWPPTFGQGT KVEI K
Dargistotug,Whole mAb,G1,Kappa,TBC,Active,QVQLVQSGSELKKPGASVKVSCKASGYTFTSYPMNWVRQAPGQGLEWMGWINTNTGNPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARVGGYSVDEYAFDVWGQGTLVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLSSYPTFGGGTKVEIK,na,na,None,None,None,2022,na,TIGIT,TBC,TBC,TBC,TBC,TBC,,Q VQLVQ SGS E LKKPGA SVKVSCK ASGY TFTS YPMN WVR QAPGQGL EWMGWIN TNTGNPTYAQG FTGRFVFSL DTSVS TAYLQISS LKAEDT AVYYCARV GG YS VDE YAFDVW GQG TLVTVS S,DI QLT QSPS FLSA SVGD RVTITCR ASQG ISSYLAWYQ QKPGKAP KLLIYAA STLQSGVPS R FSGSGSGT EFTLTIS SLQ PEDFATYYCQQ LSSYPTFGGGT KVEI K
Datopotamab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTTAGMQWVRQAPGQGLEWMGWINTHSGVPKYAEDFKGRVTISADTSTSTAYLQLSSLKSEDTAVYYCARSGFGSSYWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHYITPLTFGQGTKLEIK,na,na,None,None,None,2019,2020,TACSTD2,Daiichi Sankyo,na,Breast cancer;Non-small cell lung cancer,na,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTT AG MQWVRQ APGQGL EWMGWIN THSGVPKYAEDFKG RVTISA DTSTS TAYLQLS SLKSEDT AVYYCA RSGFGSS YWYFDV WGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCK ASQD VST AVAWYQ QKPGKAP KLLIYSASYRY TGVPSRFSGSGSGTD FTLTIS SLQP ED FAVYYC QQHYITP LTF GQGT KLEI K
Daxdilimab,Whole mAb,G1,Lambda,Phase-II,Active,QVQLQQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTIDTSTSTAYMELRSLRSDDTAVYYCARNGLWGWDSDAFDIWGRGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTVVFGGGTKVTVL,na,na,None,None,None,2020,2021,LILRA4,Viela Bio,na,Cutaneous lupus erythematosus;Dermatomyositis;Polymyositis;Sjogren's syndrome;Systemic lupus erythematosus;Systemic scleroderma;Acute lung injury,na,na,,Q VQLQQ SGA EVK KPGA SVKVSCK ASGY TFTSYGISWVRQ APGQGL EWMGWISAY NGNTNY AQK LQG RVTMTID TSTST AYMELRSL RSDDT AVYYCA RNGLWGWDSDAF DIW GRG TLVTV SS,QSALTQPA SV SGSPGQ SITISCT GTSSDVGG YNYVSWYQ QHPGKAP KLMIYD VSNRPSGVSNRFSGSKSGN TASLTIS GLQAEDEAD YYCS SYTSSS TVVF GGGT KVTV L
Dectrekumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLWFGDLDAFDIWGQGTMVTVSS,EIVLTQSPATLSLSPGERAILSCRAGQSVSSYLVWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSSWPPVYTFGQGTKLEIK,na,na,None,None,None,2014,2015,IL13,Novartis,na,na,Asthma;Idiopathic pulmonary fibrosis;Keloids;Oesophagitis;Rectal fistula;Seasonal allergic rhinitis,na,,E VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKGL EWVAIIWY DGSNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCARLW FGDLDA FDI WGQG TMVTVS S,E IVLT QSPA TLSL SPGE RAILSCR AGQS VSSYLVWYQ QKPGQAP RLLIYD ASNRATG I P ARF SGSGSGT DFTLTIS SLEPED FAVYYCQ QRSSWPP VYTF GQGT KLEI K
Delpacibart,Whole mAb,G1,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPGQGLEWIGEINPINGRSNYAEKFQGRVTLTVDTSSSTAYMELSRLRSDDTAVYYCARGTRAMHYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSENIYNNLAWYQQKPGKSPKLLIYAATNLADGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQHFWGTPLTFGGGTKVEIK,na,na,None,None,None,2022,na,TFRC,TBC,TBC,TBC,TBC,TBC,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTNYWMHWVR QAPGQG LEWIGEI NPINGRSNYAEKFQG RVTLTVD TSSST AYMELSR LRSDDT AVYYC ARGT RAMHYW GQG TLVTV SS,DIQ MT QSPSS LSA SVGD RVTITCR TSEN IYNNLAW YQ QKPGKSP KLLIYAAT NLADGVPS RF SGSGSGTD YTLTIS SLQ PEDFATY Y CQH FWGTPL TF GGG TKVEI K
Demcizumab,Whole mAb,G2,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKISCKASGYSFTAYYIHWVKQAPGQGLEWIGYISSYNGATNYNQKFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARDYDYDVGMDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATISCRASESVDNYGISFMKWFQQKPGQPPKLLIYAASNQGSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEVPWTFGGGTKVEIK,na,na,None,None,None,2012,2013,DLL4,Celgene Corporation;OncoMed Pharmaceuticals,na,na,Colorectal cancer;Fallopian tube cancer;Non-small cell lung cancer;Ovarian cancer;Pancreatic cancer;Peritoneal cancer;Solid tumours,na,,Q VQLVQ SGA EVK KPGA SVKISCK ASGY SFTAYYIHWVK QAPGQG LEWIGYISS YNGATNYNQ KFKGRVTFTT DTSTS TAYMELRSL RSDDT AVYYCAR DYDYDVGMDYWGQG TLVTVS S,D IVMT QSPDS LAVS LGER ATISCR ASESVDNYG ISFMK W F QQKPGQPP KLLIYAA SNQGSGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC QQSKEVPW T FGGG TKVEI K
Demupitamab,Whole mAb,G1,Kappa,Phase-I,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSS,DIQMTQSPSTLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIK,na,na,None,5sx4:HL:JI/5sx5:HL:JK,None,2019,2020,EGFR,Sinocelltech,na,Cancers,na,na,Likely to be a Panitumumab biosimilar,Q VQLQE SGPGL V KPSE TLSLTCTVS GGSVSSGD YYWTWIRQ SPGKGL EWIGHIYYS GNTNYNPSLK SRLTISID TSKT QFSLKLSS VTAADT AIYYCVR DRVTG AFDIW GQG TMVTVS S,DIQMTQSPS TLSAS VGD RVTITCQ AS QDISNYLNWYQ QKPGKAP KLLIYD ASNLETGVPSRFSGSGSGTD FTFTIS SLQ PEDIATYFCQH FDHLP LAF GGGT KVEI K
Denicimig,Bispecific mAb,G4;G4,Kappa;Kappa,TBC,Active,EVQLVESGGGLVQPGRSLRLSCAASGFTFHDYAMHWVRQVPGKGLEWVSGISWRGDIGGYVKSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCVKSYGSGSFYNAFDSWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKFLIYKASKLERGTPSRFSGSGSGTEFSLTISSLQPDDFATYYCLEYSSYIRTFGQGTKVEIK,EVQLVQSGAEVKKPGESLRISCKGSGYSFSTSWIVWVRQMPGKGLEWMGMIDPSDSFTSYSPSFQGHVTISADKSISTAYLQWSSLKASDTAMYYCARLHYYNSEEFDVWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGQSSRTRGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFGDSQLFTFGQGTKLEIK,None,7ahv:AB,None,2022,na,F9;F10,TBC,TBC,TBC,TBC,TBC,,E VQLVES GGG LV QPGR SLRLSC AASGF TFH DY AMHWVRQ VPGKGL EWVSGISWR GDIGG YVKSV K GRFTISR DNAKN SLYLQMNS LRAEDT ALYYCVKS YGSGS FYN AFDSWGQG TLVTV SS,DIQ MT QSPS TLSAS VGD RVTITCR ASQS ISSWLAWYQ QKPGKAP KFLIYK ASKLERGTPS RF SGSGSGT EFSLTIS SLQPDDF ATYYCLE YSS YIRTF GQGT KVEI K
Denintuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,QVQLQESGPGLVKPSQTLSLTCTVSGGSISTSGMGVGWIRQHPGKGLEWIGHIWWDDDKRYNPALKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARMELWSYYFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQAPRLLIYDTSKLASGIPARFSGSGSGTDFTLTISSLEPEDVAVYYCFQGSVYPFTFGQGTKLEIK,na,na,None,None,None,2014,2015,CD19,Seattle Genetics,na,na,Diffuse large B cell lymphoma;Follicular lymphoma;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma,na,,Q VQLQE SGPGLVKPSQ TLSLTCTV SGGS IS TSGM GVGWIRQ HPGKGL EWIGHIWW DDDKRYNPALK SRVTISVD TSKN QFSLKLSS VTAADT AVYYCARMELWSYYFD YWGQG TLVTV SS,E IVLTQ SPA TLSL SPGE RATLSCS ASSS VSYMHWYQ QKPGQAP RLLIYD TSKLASGIP ARFS GSGSGT DFTLTISS LEPED VAVYYCF QGS VYPFT FGQGT KLEI K
Denosumab,Whole mAb,G2,Kappa,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGITGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGTTVIMSWFDPWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVRGRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVFYCQQYGSSPRTFGQGTKVEIK,na,na,None,None,None,2005,2006,TNFSF11,Amgen;Daiichi Sankyo Company;European Thoracic Oncology Platform;GlaxoSmithKline;Jules Bordet Institute;Melbourne Health;University Health Network,Bone cancer;Bone disorders;Bone metastases;Corticosteroid-induced osteoporosis;Male osteoporosis;Malignant hypercalcaemia;Osteoporosis;Postmenopausal osteoporosis;Rheumatoid arthritis,Breast cancer;Non-small cell lung cancer;Osteogenesis imperfecta;Malignant melanoma,Multiple myeloma ,Abgenix XenoMouse,,E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKG LEWVSGI TGSGGS TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAED TAVYYCA KDPGT TVIMSWF DPWGQ GTLVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQSVRG RYLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPED FAVFYCQ QYGSSPRTFGQGT KVEI K
Depatuxizumab,Whole mAb ADC,G1,Kappa,Phase-III,Discontinued,QVQLQESGPGLVKPSQTLSLTCTVSGYSISSDFAWNWIRQPPGKGLEWMGYISYSGNTRYQPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTAGRGFPYWGQGTLVTVSS,DIQMTQSPSSMSVSVGDRVTITCHSSQDINSNIGWLQQKPGKSFKGLIYHGTNLDDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCVQYAQFPWTFGGGTKLEIK,na,na,None,None,None,2016,2017,EGFR,Ludwig Institute for Cancer Research;AbbVie,na,na,Solid tumours,na,,Q VQLQE SGPGLVKPSQ TLSLTCTV SG YSI SSDF AWNWIR QPPGKGL EWMGYISY SGNTRYQPSLK SRITISR DTSKN QFFLKLN SVTAADTA TYYCVT AGRGFPYWGQ GTLVTVS S,DIQ MT QSPSS MSVS VGD RVTITCH SSQDINSN IGWLQ QKPGKS FKGLIYH GTNLDDGVPS RF SGSGSGTD YTLTISS LQPEDF ATYYCVQYA QFPWTFGGGT KLEI K
Depemokimab,Whole mAb,G1,Kappa,Phase-III,Active,QVTLRESGPALVKPTQTLTLTCTVSGFSLTGSSVHWVRQPPGKGLEWLGVIWASGGTDYNSALMSRLSISKDTSRNQVVLTMTNMDPVDTATYYCARDPPSGLLRLDYWGRGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLAWYQQKPGQPPKLLIYGASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNVHSFPFTFGGGTKLEIK,na,na,None,None,None,2020,2021,IL5,GlaxoSmithKline,na,Asthma,na,na,,Q VTLRE SGPA LV KPTQ TLTLTCTV SG FSL TGS SVHWVR QPPGKGL EWLGVIWA SGGTDYNS A LMSRLSIS KDTSRN QVVLTMT NMDPVDT ATYYCA RDPPSG LLRLDY WGRG TLVTVS S,D IVMT QSPDS LAVS LGER ATINC KSS QSLL NSGNQ KNYLAWYQ QKPGQPP KLLIYG ASTRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC QNVHSFP FTF GGGT KLEI K
Derlotuximab,Whole mAb Radiolabelled,G1,Kappa,Approved,Active,QVQLKESGPGLVAPSQSLSITCTVSGFSLTDYGVRWIRQPPGKGLEWLGVIWGGGSTYYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAKEKRRGYYYAMDYWGQGTSVTVSS,ENVLTQSPAIMSASPGEKVTMTCRASSSVSSSYLHWYQQKSGASPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSVEAEDAATYYCQQYSGYPLTFGGGTKLEIK,na,na,None,None,None,2015,2016,DNA/H1 Complex,Avid Bioservices;MediPharm Biotech,Lung cancer,Glioblastoma,na,na,,QV QLKE SGPGL V APSQ SLSITCTV SGF SL TDY GVRWIR QPPGKGL EWLGVIW GGGST YY NSALK SRLSI SKDNSKS QVFLKM NSLQTDDT AMYYCA KEKRRG YYYAMD YWGQGT SVTVS S,ENVLTQSP AIMS ASPGE KVTMTCR ASSSVSS SYL HWYQ QKSGASP KLWIYS TSNLASGVP ARFS GSGSGT SYSLTISS VE A E DAAT YYC QQ YSGYP LTF GGGT KLEI K
Devextinetug,Whole mAb,G2,Kappa,TBC,Active,EIQLQQSGPELGKPGASVKVSCRASGFSFADYYIYWVKQSHGKSLELIGYIDPFNGGDTYNQIFKGKATLTVDKSSSTAFMYLNSLTSEDSAVYYCAAFRNPSFDFWGQGTTLTVSS,QIVLIQSPPIMSASPGEKVTLTCSASSSVSSRYLYWYQQKPGSSPKLWIYGTSNLASGVPARFSGSGSGTSFSLTISSMEAEDAASYFCHQWSSFPFTFGSGTKLEIK,na,na,None,None,None,2022,na,Metamphetamine,TBC,TBC,TBC,TBC,TBC,,E IQLQQ SGPELGKPGA SVKVSCR ASGFSFA DYYIYWVK QSHGK SLELIGYI DPFNGGDTY NQIF KG KATLTV DKSSS TAFMYLN SLTSEDS AVYYCAAF RNPSFD F WGQG TTLTVS S,Q IVLIQ SPP IMS ASPGE KVTLTCS ASSSVSS RYLYWYQ QKPGSSP KLWIYG TSNLASGVP ARFS GSGSGT SFSLTISS MEAED AASY FC HQWSSFP FTF GSGT KLEI K
Dezamizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGFTFATYNMHWVRQAPGQGLEWMGYIYPGDGNANYNQQFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGDFDYDGGYYFDSWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASENIYSYLAWYQQKPGKAPKLLIHNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGAPLTFGQGTKLEIK,na,na,None,None,None,2016,2017,APCS,Pentraxin Therapeutics;GlaxoSmithKline,na,na,Amyloidosis,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGF TFATYNMHWVRQ APGQG LEWMGYIY PGDGNANYNQQ F K GRVTITA DKSTS TAYMELS SLRSEDT AVYYCA RGDFDYDGG YYF DSWGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASEN IYSYLAWY QQKPGKAP KLLIH NAK TL AEGVPSRFSGSGSGTD FTLTIS SLQ PEDFATY YCQ HHYGAP LTF GQGT KLEI K
Dilpacimab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFPMAWVRQAPGKGLEWVATISSSDGTTYYRDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGYYNSPFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASEDIYSNLAWYQQKPGKAPKLLIYDTNNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPPTFGQGTKLEIK,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,None;1bj1:HL:KJ,None;None,None;6bft:HL:AB/1cz8:HL:YX,2018,2019,DLL4;VEGFA,AbbVie,na,Colorectal cancer;Solid tumours,na,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TF SNFP MAWVRQ APGKG LEWVATIS SSDGT TYYRD SVKG RFTISR DNAKNS LYLQMNS LRAEDT AVYYCA RGYYNSPF AYW GQG TLVTV SS,DIQ MT QSPSS LSA SVGD RVTITCR ASED IYSNLAWYQ QKPGKAP KLLIYD TNNLADGVPS R FSGSGSGTD FTLTIS SLQ PEDFATYYCQQ YNNYPPTFGQGT KLEI K
Dinutuximab,Whole mAb,G1,Kappa,Approved,Active,EVQLLQSGPELEKPGASVMISCKASGSSFTGYNMNWVRQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKSSSTAYMHLKSLTSEDSAVYYCVSGMEYWGQGTSVTVSS,EIVMTQSPATLSVSPGERATLSCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELK,na,na,None,None,4tuj:CD:AB/4tul:HL/4trp:HL/4tuo:AB:CD/4tuk:HL,2013,2014,Ganglioside GD2,National Cancer Institute (USA);New Approaches to Neuroblastoma Therapy Consortium;St. John of God Foundation;United Therapeutics Corporation,Neuroblastoma,Small cell lung cancer,Malignant melanoma,na,,E VQLLQ SGPELEKPGA SVMISCK ASGSSFTGYN MNWVRQ NIGKS LEWIGAI DPYYGGTSYNQKFKG RATLTVD KSSS TAYMHLKS LTSEDS AVYYCV SGM EY WGQG TSVTVS S,E IVMT QSPA TLSV SPGE RATLSCR SSQ SLVHR NGN TYLHWYLQ KPGQSP KLLIHKV SNRFSGVPDRFSGSGSGT DFTLKISRVE AEDL GVYFCS QSTHVPPL TF GAGT KLEL K
Diridavumab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLVESGAEVKKPGSSVKVSCKASGGPFRSYAISWVRQAPGQGPEWMGGIIPIFGTTKYAPKFQGRVTITADDFAGTVYMELSSLRSEDTAMYYCAKHMGYQVRETMDVWGKGTTVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNDYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEANYYCATWDRRPTAYVVFGGGTKLTVL,na,na,3gbn:HL/3gbm:HL:IM/5c0s:HL/6uyn:HL,None,4evn:AB:CD:IJ:OP:KL:EF:GH:MN,2014,2015,Influenza A HA2,National Institute of Allergy and Infectious Diseases;Crucell,na,Influenza A virus (H1N1) infections,na,na,,E VQLVE SGA EVK KPGS SVKVSCK ASGGPF RSYAISWVR QAPGQGPEW MGGIIPIF GTTKYAPKFQG RVTITA DDFAG TVYMELS SLRSED TAMYYCAKH MGY QVRETMDV WGKG TTVTVS S,QSVLTQPPSVSAAPGQ KVTISC SGSSSNIGND YVSWYQ QLPGTAP KLLIY DNNKRPSGIPDRFSGSKSGTS ATLGITG LQTGDEA NYYCAT WDRRP TAYVVF GGGT KLTV L
Disitamab,Whole mAb ADC,G1,Kappa,Approved,Active,EVQLVQSGAEVKKPGATVKISCKVSGYTFTDYYIHWVQQAPGKGLEWMGRVNPDHGDSYYNQKFKDKATITADKSTDTAYMELSSLRSEDTAVYFCARNYLFDHWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASIRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQFATYTFGGGTKVEIK,na,na,None,None,None,2018,2019,ERBB2,Yantai Rongchang Biological Engineering,Gastric cancer,Breast cancer;Urogenital cancer;Non-small cell lung cancer;Cholangiocarcinoma;Lung cancer,Solid tumours,na,,E VQLVQ SGA EVK KPGA TVKISCKV SGY TFTDYYIHWVQQ APGKG LEWMGRV NPDHGDSYYNQKFKDK ATITA DKSTDT AYMELS SLRSEDT AVYFCA RN YLF DHWGQG TLVTVS S,DIQ MT QSPSS VSAS VGD RVTITCK ASQDVG TAVAWYQ QKPGKAP KLLIYWASIR HTGVPSRFSGSGSGTD FTLTISS LQPEDF ATYYCHQFATYTF GGG TKVEI K
Divozilimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVQPGAEVVKPGASVKVSCKASGYTFTSYNMHWVRQAPGRGLEWMGAIYPGNGDTSYNQKFKGRVTMTRDKSTSTVYMELSSLRSEDTAVYYCARSTYYGGDWYFNVWGQGTLVTVSS,QIVLSQSPAILSASPGERVTLTCRASSSVSYIHWFQQKPGKAPKPLIYATSNLASGVPSRFSGSGSGTDFSLTISRVEPEDFAVYYCQQWTSNPPTFGGGTKVEIK,na,na,None,None,None,2020,2021,MS4A1,Biocad,na,Relapsing-remitting multiple sclerosis,na,na,,E VQLV QPGA EVV KPGA SVKVSCK ASGY TFTSYNMHWVRQ APGRG LEWMGAI YPGNGDTSYNQK FKGRVTMTR DKSTS TVYMELS SLRSEDT AVYYCAR S T YYGGD WYFNVW GQG TLVTVS S,Q IVLS QSP AILS ASPGE RVTLTCR ASSS VSYIHWFQ QKPGKAPKP LIYAT SNLASGVPS R FSGSGSGT DFSLTISR VEPED FAVYYCQQW TSNPPTFGGG TKVEI K
Docaravimab,Whole mAb (Mouse),G2b,Kappa,Approved,Active,QVQLKESGPGLLAPSQSLSITCTVSGFSLTGHGVNWVRQPPGKGLEWLGIIWADGTTNYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTASYYCAREGDISGYYFDYWGQGTTLTVSS,DVQMTQTTSSLSASLGDRVTITCRPSQDINNYLSWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDFATYFCQQGNTLPPTFGGGTKLEIK,na,na,None,None,None,2019,2020,Rabies Virus Strain ERA GP Ectodomain Epitope G-III,Candila Healthcare,Rabies,na,na,na,Mouse antibody,Q VQLKE SGPGLLAPSQ SLSITCTV SG FSLTG H GVNWVR QPPGKGL EWLGIIWA DGTTNYNSAL KSRLSI SKDNSKS QVFLKM NSLQTDDTA SYYCA REGD I S GYYFDY WGQG TTLTVS S,DVQM TQ TTS SLSA SLGD RVTITC RPSQD INNYLSWYQ QKPDGT VKLLIYYT SRLHSGVPSRFSGSGSGTD YSLTIS NLEQE DFATY FC QQGNTLPPTFGGGT KLEI K
Domagrozumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSTISSGGSYTSYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKQDYAMNYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSTPWTFGGGTKVEIK,na,na,None,5f3h:EF:GH:AB:CD,None,2015,2016,MSTN,Kennedy Krieger Institute;Pfizer,na,na,Duchenne muscular dystrophy;Limb girdle muscular dystrophies,na,,E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKGL EWVSTI SSGGS Y TSYPDSVK GRFTISR DNSKN TLYLQMN SLRAEDT AVYYCA KQDYAMNYWGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCK ASQD VSTA VAWYQ QKPGKAP KLLIYSASYRY TGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQ QHYSTPW T FGGG TKVEI K
Domvanalimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAFISSGSSSIYYADTVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARMRLDYYAMDYWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRASKSISKYLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPWTFGGGTKVEIK,na,na,None,None,None,2020,2021,TIGIT,Arcus Biosciences,na,Solid tumours;Non-small cell lung cancer,na,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFS NF GMHWVRQ APGKG LEWVAFIS SGSS SIYYA DTVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCARMRLDYYAM DYWGQG TMVTVS S,DIQ M TQSPSS LSA SVGD RVTITCR ASKS ISKYLAWYQ QKPGKAP KLLIYS GSTLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQ QHNEYPW T FGGGT KVEI K
Donanemab,Whole mAb,G1,Kappa,Preregistration,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYDFTRYYINWVRQAPGQGLEWMGWINPGSGNTKYNEKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCAREGITVYWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCKSSQSLLYSRGKTYLNWLLQKPGQSPQLLIYAVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCVQGTHYPFTFGQGTKLEIK,na,na,None,None,None,2018,2019,APP,Eli Lilly,na,Alzheimer's disease,na,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGYDF TRYYINWVR QAPGQGL EWMGWI NPGSGNTKYNEKFKG RVTITA DESTS TAYMELS SLRSEDT AVYYCA REG ITVYW GQGT TVTVS S,DI VMT QTP LSLSV TPGQP ASISC KSSQ SLLYS RGK TYLNWLL QKPGQSP QLLIYAVSK LDSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCV QGTHYPF TF GQGT KLEI K
Dostarlimab,Whole mAb,G4,Kappa,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSTISGGGSYTYYQDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASPYYAMDYWGQGTTVTVSS,DIQLTQSPSFLSAYVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTLHTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQHYSSYPWTFGQGTKLEIK,na,na,None,None,None,2018,2019,PDCD1,AnaptysBio;European Network of Gynaecological Oncological Trial Groups;GlaxoSmithKline;TESARO,Endometrial cancer;Solid tumours,Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Non-small cell lung cancer;Breast cancer;Cervical cancer;Liver cancer;Malignant melanoma;Neuroendocrine tumours;Pancreatic cancer;Rectal cancer;Small cell lung cancer;Squamous cell cancer,na,na,,E VQLLES GGG LV QPGG SLRLSC AASGF TFSS YDM SWVR QAPGKG LEWVSTI SGGGS YTYYQ DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA SPYY AM DYWGQG TTVTVS S,DI QLT QSPS FLSAY VGD RVTITCK ASQDVG TAVAWYQ QKPGKAP KLLIYWA STLHTGVPSRFSGSGSGT EFTLTIS SLQP EDFA TYYCQ HYSSYPW T FGQGT KLEI K
Dovanvetmab,Feline Whole mAb,G1,Kappa,Unknown,Active,QVLLVQSGAEVRTPGASVKIFCKASGYSFTSYTIHWLRQAPAQGLEWMGNINPTSGYTENNQRFKDRLTLTADTSTNTAYMELSSLRSADTAMYYCARWGFKYDGEWSFDVWGAGTTVTVSS,EIQMTQSPSSLSASPGDRVTITCRASQGISIWLSWYQQKPGNIPKVLINKASNLHIGVPSRFSGSGSGTDFTLTISSLEPEDAATYYCLQSQTYPLTFGGGTKLEIK,na,na,None,None,None,2019,2020,IL31 (Feline),na,na,na,na,na,,Q VLLVQ SGA EVR TPGA SVKIFCK ASGYS FTSYTIHWLR QAPAQGL EWM GNINPTSGYTENNQRFKD RLTLTA DTSTN TAYMELS SLRS ADTAMYYCAR WGFKYDG EWSFDVW GAGT TVTVS S,EI QMT QSPSSL S ASPGD RVTITCR ASQG ISIWLSWY QQKPGNIP KVLIN KASN LHIGV PSRFSGSGSGT DFTLTISS LEPEDAA TYYCL QSQTYP LTF GGGT KLEI K
Dresbuxelimab,Whole  mAb,G1,Kappa,Phase-I,Active,QVQLVQSGAEVVKPGASVKVSCKASGYSFTGYTMNWVRQAPGQNLEWIGLINPYNAGTSYNQKFQGKVTLTVDKSTSTAYMELSSLRSEDTAVYYCARSEYRYGGDYFDYWGQGTTLTVSS,DIVMTQSPSSLAVSVGERVTISCKSSQSLLNSSNQKNYLAWYQQKPGQAPKLLIYFASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYDTPYTFGGGTKLEIK,na,na,None,None,None,2021,2022,NT5E,Akeso Biopharma,na,COVID-19,na,na,,Q VQLVQ SGA EVV KPGA SVKVSCK ASGY SFTGYTMNWVR QAPGQN LEWIGLI NPYNAGTSYNQK F QG KVTLTVD KSTS TAYMELSS LRSEDT AVYYCAR SE YR YGGD YF DYWGQG TTLTVS S,D IVMT QSPSS LAVS VGE RVTISC KSSQS L LNSSNQK N YLAWYQ QKPGQAP KLLIYFA STRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQ QHYDTPY T FGGGT KLEI K
Drozitumab,Whole mAb,G1,Lambda,Phase-II,Discontinued,EVQLVQSGGGVERPGGSLRLSCAASGFTFDDYAMSWVRQAPGKGLEWVSGINWQGGSTGYADSVKGRVTISRDNAKNSLYLQMNSLRAEDTAVYYCAKILGAGRGWYFDYWGKGTTVTVSS,SELTQDPAVSVALGQTVRITCSGDSLRSYYASWYQQKPGQAPVLVIYGANNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSADSSGNHVVFGGGTKLTVL,na,na,4od2:BA,None,None,2010,2011,TNFRSF10B,Genentech,na,na,Chondrosarcoma;Colorectal cancer;Non-Hodgkin's lymphoma;Non-small cell lung cancer,na,,E VQLVQS GGG VE RPGG SLRLSC AASGFTFDD YA MSWVR QAPGKGL EWVSGIN WQGGSTGYADSVKG RVTISR DNAKN SLYLQMN SLRAED TA VYY CAKI L GAGRG WYFDY WGKG TTVTVS S,SELTQDPA VSV A LGQ TVRITC SGD SLRSYYASWY QQKPGQAP VLVIY GANNRPSGIPDRFSGSSSGNT ASLTIT GAQAEDEAD YYC NSADSSGN HVVF GGGT KLTV L
Duligotuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTLSGDWIHWVRQAPGKGLEWVGEISAAGGYTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARESRVSFEAAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQNIATDVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSEPEPYTFGQGTKVEIK,na,na,None,None,3p0v:HL:IM/3p0y:HL/3p11:HL,2012,2014,ERBB3,Genentech;Roche,na,na,Solid tumours;Colorectal cancer;Head and neck cancer,na,Duligotuzumab is the new name for Duligotumab (PL110),E VQLVES GGG LV QPGG SLRLSC AASG FTL SGD WIHWVRQ APGKGL EWVGEIS AAGGYTDYADSVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYCA RESR VSFEAAM DYWGQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITCR ASQNIA TDVAWYQ QKPGKAP KLLIYSASFLY SGVPSRFSGSGSGTD FTLTIS SLQPE DF ATYYCQ QSEPEPY T FGQGT KVEI K
Dupilumab,Whole mAb,G4,Kappa,Approved,Active,EVQLVESGGGLEQPGGSLRLSCAGSGFTFRDYAMTWVRQAPGKGLEWVSSISGSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRLSITIRPRYYGLDVWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSIGYNYLDWYLQKSGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGFYYCMQALQTPYTFGQGTKLEIK,na,na,6wgb:AB:CD/6wgj:AB:CD:EF/6wgk:AB:CD:EF:GH/6wgl:AB/6wg8:AB,None,None,2012,2013,IL4R,Aimmune Therapeutics;Regeneron Pharmaceuticals;Sanofi,Asthma;Atopic dermatitis;Nasal polyps,Chronic obstructive pulmonary disease;Eosinophilic oesophagitis;Grass pollen hypersensitivity;Peanut hypersensitivity;Urticaria,Allergic asthma,VelocImmune Mouse,,E VQLVE SGGGLEQPGG SLRLSC AGSGF TFRDYAMTWVRQ APGKG LEWVSSIS GSGGN TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYC AKDR LSITIR PR Y YG LDVW GQG TTVTVS S,DI VMT QSPLSLPVTPGEPA SISC RSSQ SLLYSI G YNYLDWYLQK SGQSP QLLIYL GSNRASGVPDRFSGSGSGT DFTLKISRVE AEDV GFYYCMQA LQTPY T FGQGT KLEI K
Durvalumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIK,na,na,5xj4:HL/5x8m:BC,None,None,2014,2015,CD274,Advaxis;AIO Studien gGmbH;AstraZeneca;Big Ten Cancer Research Consortium;Canadian Cancer Trials Group;Case Comprehensive Cancer Center;Celgene International SARL;Centre hospitalier de l'Universite de Montreal;Centre Leon Berard;Charite - Universitatsmedizin Berlin;Childrens Hospital Los Angeles;Dana-Farber Cancer Institute;Eli Lilly;Fondazione IRCCS Istituto Nazionale dei Tumori;GlaxoSmithKline;Gradalis;Grand Hopital de Charleroi;Grupo Espanol de Tumores Neuroendocrinos;Gustave Roussy;Immunocore;Innate Pharma;Institut Claudius Regaud;Juno Therapeutics;Kyoto Breast Cancer Research Network;Ludwig Institute for Cancer Research;M. D. Anderson Cancer Center;MedImmune;Memorial Sloan-Kettering Cancer Center;Mirati Therapeutics;Myriad Genetic Laboratories;National Cancer Institute (USA);National Health and Medical Research Council;Northwestern University;Pharmacyclics;Plexxikon;Radboud University;Samsung Medical Center;Spanish Oncology Genito-Urinary Group;Swiss Group for Clinical Cancer Research;UNC Lineberger Comprehensive Cancer Center;UNICANCER;University College London;University of Colorado at Denver;University of Kansas Medical Center;University of Maryland Greenbaum Cancer Center;University of Southern California;University of Sydney;University of Texas M. D. Anderson Cancer Center;VentiRx Pharmaceuticals;Washington University School of Medicine;Yale University;Yonsei University College of Medicine,Non-small cell lung cancer;Urogenital cancer;Small cell lung cancer,Biliary cancer;Bladder cancer;Cervical cancer;Fallopian tube cancer;Head and neck cancer;Liver cancer;Ovarian cancer;Peritoneal cancer;Renal cell carcinoma;Solid tumours;Breast cancer;Gynaecological cancer;Pancreatic cancer;Acute myeloid leukaemia;Brain metastases;Cholangiocarcinoma;Colorectal cancer;Diffuse large B cell lymphoma;Endometrial cancer;Gallbladder cancer;Gastric cancer;Germ cell and embryonal neoplasms;Glioblastoma;Mesothelioma;Multiple myeloma;Myelodysplastic syndromes;Neuroendocrine tumours;Oesophageal cancer;Oropharyngeal cancer;Prostate cancer;Sarcoma;Soft tissue sarcoma;Chronic lymphocytic leukaemia;Cutaneous T-cell lymphoma;Haematological malignancies;Lung cancer;Lymphoma;Malignant melanoma;Non-Hodgkin's lymphoma;Peripheral T-cell lymphoma;Renal cancer;Gastrointestinal cancer;Myelofibrosis;Vulvovaginal cancer,CNS cancer;Lymphoproliferative disorders;Thyroid cancer,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFSRYWMSWVR QAPGKG LEWVANIK QDGS EKYYVD SVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCA REGG WFGELAFDY WGQG TLVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQRVSSS YLAWYQ QKPGQAP RLLIYD ASSRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYCQ QYGSLPW TF GQGT KVEI K
Dusigitumab,Whole mAb,G2,Lambda,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPNSGNTGYAQKFQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCARDPYYYYYGMDVWGQGTTVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIENNHVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCETWDTSLSAGRVFGGGTKLTVL,na,na,None,None,None,2012,2013,IGF1&IGF2,MedImmune,na,na,Breast cancer;Liver cancer;Solid tumours,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYDINWVRQ ATGQG LEWMGWM NPNSGNTGY AQKF QG RVTMT RNTS ISTAYMELS SLRSEDT AVYYCA RDPYY YYYGMDV WGQG TTVTVS S,QSVLTQPPS V SAAPGQ KVTISC SGSSSNIENN HVSWYQ QLPGTAP KLLIY DNNKRPSGIPDRFSGSKSGT SATLGITG LQTGDEA DYYCETW DTSLSAGR VF GGGT KLTV L
Duvortuxizumab,Bispecific scFv with Crossover,na;na,Kappa;Lambda,Phase-I,Discontinued,QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVGWIRQPPGKALEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVFLTMTNMDPVDTATYYCARMELWSYYFDYWGQGTTVTVSS,ENVLTQSPATLSVTPGEKATITCRASQSVSYMHWYQQKPGQAPRLLIYDASNRASGVPSRFSGSGSGTDHTLTISSLEAEDAATYYCFQGSVYPFTFGQGTKLEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPWTPARFSGSLLGGKAALTITGAQAEDEADYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2016,2017,CD19;CD3E,Janssen Biotech;MacroGenics,na,na,Diffuse large B cell lymphoma;Follicular lymphoma;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma,Dual-Affinity Re-Targeting Technology,,Q VTLRE SGPA LV KPTQ TLTLTCTF SG FSLS TSGM GVGWIR QPPGKA LEWLAHIWW DDDKRYNPALK SRLTIS KDTSKN QVFLTMT NMDPVDT ATYYCARMELWSY YFD YWGQGT TVTV SS,ENVL T QSPA TLSV TPGE KATITCR ASQS VSYMHWYQ QKPGQAP RLLIYD ASNRASGVPS R FSGSGSGTDH TLTISS LEAEDAA TYYCF QGS VY P FT FGQGT KLEI K
Ebdarokimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVQSGAEVKKPGESLKISCQSSGYTFTSYWIGWVRQMPGQGLEWIGIMSPVDSDIRYNPMFRGQVTMSVDKSSSTAYLQWSSLKASDTAMYYCARRRPGQGYFDFWGQGTMVTVSS,EIVLTQSPATLSASPGERATISCRASQSVGTWVAWYQQKPGQAPRSLIYAASNLQSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYNIYPYTFGQGTRLEIK,na,na,None,None,None,2020,2021,IL12B,Akeso Biopharma,na,Plaque Psoriasis;Ulcerative colitis;Systemic lupus erythematosus,Crohn's disease;Psoriatic arthritis,na,,E VQLVQ SGA EVK KPGE SLKISCQ SSGY TFTSYWIGWVRQ MPGQGL EWIGIM SPVDSDI RY NPMFRG QVTMSV DKSSS TAYLQWSS LKASDT AMYYCAR RRPGQG YFDFW GQG TMVTVS S,E IVLTQ SPA TLS ASPGE RATISCR ASQSVG TWVAWYQ QKPGQAPR SLIYAA SNLQSGIP ARFS GSGSGTD FTLTIS SLEP ED FAVYYC Q QYNIY P Y T FGQGT RLEI K
Eblasakimab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGVIYPGDSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARMPNWGSLDHWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSISSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYASFGQGTKVEIK,na,na,None,None,4hwe:HL/4hwb:HL,2021,2022,IL13RA1,ASLAN Pharmaceuticals,na,Atopic dermatitis,na,na,,E VQLVQ SGA EVK KPGE SLKISC KGSGY SFTSYWIGWVRQ MPGKGL EWMGVI YPGDSY TRY SPSFQG QVTIS ADKS ISTAYLQWS SLKASDT AMYYCAR MPNWGSLDHWGQG TLVTV SS,E IVLTQ SPG TLSL SPGE RATLSCR ASQSIS SSY LAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQQY ASFGQGT KVEI K
Ebronucimab,Whole mAb,G1,Lambda,Phase-III,Active,EVQLVESGGGLVQPGRSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSGISSSSSYISYADSVQGRFTISRDNGKNSLYLQMNSLRAEDTALYFCAREYDFWSAYYDAFDVWGQGTMVTVSS,QSELTQPRSVSGSPGQSVTISCTGTSRNIGGGNDVHWYQQHPGKAPKLLISGVIERSSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCQSFDGSLSGSVFGTGTDVTVL,na,na,None,None,None,2020,2021,PCSK9,Akeso Biopharma,na,Heterozygous familial hypercholesterolemia,na,na,,E VQLVES GGG LV QPGR SLRLSC AASGF TFSS Y SMNWVR QAPGKGL EWVS GISSSSS YISY ADSVQG RFTISR DNGKN SLYLQMN SLRAEDT ALYFCAR EYDF WSAYY DA FDV WGQG TMVTVS S,QSELTQPR SV SGSPGQ SVTISCT GTSRNIGGGND VHWYQ QHPGKAP KLLISGVIE RSSGVPDRFSGSKSGN TASLTIS GLQAEDEA DYYCQS FDGS L SG SVF GTGT DVTV L
Eciskafusp,Fusion Protein,G1,Kappa,TBC,Active,EVQLLESGGGLVQPGGSLRLSCAASGFSFSSYTMSWVRQAPGKGLEWVATISGGGRDIYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVLLTGRVYFALDSWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKASESVDTSDNSFIHWYQQKPGQSPKLLIYRSSTLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNYDVPWTFGQGTKVEIK,na,na,None,None,None,2022,na,PDCD1,TBC,TBC,TBC,TBC,TBC,,E VQLLES GGG LV QPGG SLRLSCA ASGF SF S SYTMSWVR QAPGKG LEWVATIS GGGRD IY YPDSVK GRFTISR DNSKN TLYLQMNS LRAEDT AVYYCVLL TGR VYFALD SWGQG TLVTVS S,D IVMT QSPDS LAVS LGER ATINCK ASESVDTSDNS FIHWYQ QKPGQSP KLLIYR SSTLESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQ QNYDVPW TF GQGT KVEI K
Ecleralimab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYWMHWVRQAPGKGLEWVGHIKSKTDAGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCAREIYYYAFDSWGQGTLVTVSS,SYELTQPLSVSVALGQTARITCSGDNIGSKYVHWYQQKPGQAPVLVIYGDNERPSGIPERFSGSNSGNTATLTISRAQAGDEADYYCQAADWVDFYVFGGGTKLTVL,na,na,None,None,None,2021,2022,TSLP,Novartis,na,Asthma,na,na,,E VQLVES GGG LV KPGG SLRLSC AASGF TF SD YWMHWVR QAPGKGL EWVGHIKS KTDAGTTDYAAP VKGRFTISR DDSKN TLYLQMN SLKTEDT AVYYCA R EIYYYAF DSWGQG TLVTVS S,SYELTQP LSVSVA LGQ TARITC SGDNIGS KYVHWYQ QKPGQAP VLVIY GDNERPSGIPERFSGSNSGN TATLTISR AQAGDEA DYYCQ AADW VDFYVF GGGT KLTV L
Ecromeximab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVTLVESGGDFVKPGGSLKVSCAASGFAFSHYAMSWVRQTPAKRLEWVAYISSGGSGTYYSDSVKGRFTISRDNAKNTLYLQMRSLRSEDSAMYFCTRVKLGTYYFDSWGQGTTLTVSS,DIQMTQTASSLPASLGDRVTISCSASQDISNYLNWYQQKPDGTVKLLIFYSSNLHSGVPSRFSGGGSGTDYSLTISNLEPEDIATYFCHQYSKLPWTFGGGTKLEIK,na,na,None,None,None,2002,2003,GD3 ganglioside,Kyowa Hakko;Kyowa Kirin;Life Science Pharmaceuticals;Ludwig Institute for Cancer Research,na,na,Malignant melanoma,na,,E VTLVE SGGD FV KPGG SLKVSC AASGFA FSHYAMSWVR QTPAKR LEWVAYIS SGGSG TYY SDSVKG RFTISR DNAKN TLYLQMRSL RSEDS AMYFCTRVK LG TYYF DSWGQG TTLTVS S,DIQ MT QTASSLPASLGD RVTISC SASQD ISNYLNWYQ QKPDGT VKLLIFY SSNLHSGVPSRFSGGGSGTD YSLTI SNLE PEDIATYFCHQY SKLPWTFGGGT KLEI K
Eculizumab,Whole mAb,G2,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYIFSNYWIQWVRQAPGQGLEWMGEILPGSGSTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK,na,na,5i5k:HL:XY,None,None,2002,2003,C5,Alexion Pharmaceuticals;Brigham and Womens Hospital;Chiba University;Handok Inc,Neuromyelitis optica;Haemolytic uraemic syndrome;Myasthenia gravis;Paroxysmal nocturnal haemoglobinuria,Delayed graft function;Guillain-Barre syndrome;Renal transplant rejection;COVID-19,Antiphospholipid syndrome;Heart transplant rejection;Adult respiratory distress syndrome;Age-related macular degeneration;Allergic asthma;Autoimmune haemolytic anaemia;Bullous pemphigoid;Dermatomyositis;Glomerulonephritis;Idiopathic thrombocytopenic purpura;Lupus nephritis;Membranous glomerulonephritis;Motor neuron disease;Psoriasis;Rheumatoid arthritis;Systemic lupus erythematosus,GS Gene Expression System,,Q VQLVQ SGA EVK KPGA SVKVSCK ASG YIF SN YWIQWVR QAPGQG LEWMGEI LPGSGST EYT ENFKD RVTMTR DTSTS TVYMELS SLRSEDT AVYYCARYF FGSSPN WYFDVW GQG TLVTVS S,DIQMTQSPSSL SA SVGD RVTITC GASEN IYGALNWYQ QKPGKAP KLLIYG ATNLADGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQN VLNTPL T FGQGT KVEI K
Edrecolomab,Whole mAb,G2a,Kappa,Approved (w),Discontinued,QVQLQQSGAELVRPGTSVKVSCKASGYAFTNYLIEWVKQRPGQGLEWIGVINPGSGGTNYNEKFKGKATLTADKSSSTAYMQLSSLTSDDSAVYFCARDGPWFAYWGQGTLVTVSA,NIVMTQSPKSMSMSVGERVTLTCKASENVVTYVSWYQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSATDFTLTISSVQAEDLADYHCGQGYSYPYTFGGGTKLEIK,na,na,None,None,None,1995,1996,EPCAM,Ajinomoto;Centocor Inc,Colorectal cancer ,na,Adenocarcinoma;Pancreatic cancer,na,,QV QLQ QSGA ELV RPGT SVKVSC KASG YAFTNYLIEWVK QRPGQGL EWIGVI NPGSGGTNYNEKFKG KATLTA DKSSST AYMQLS SLTSDDS AVYFCA RDGP WFAYW GQG TLVTVS A,N IVMT QSPKS MSM SVGE RVTLTCK ASEN VVTYVSWY QQKPEQSP KLLIYG ASNRYTGVPDRFTGSGSATD FTLTISSV QAEDLADYHCGQGYSYP YT FGGGT KLEI K
Efalizumab,Whole mAb,G1,Kappa,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGYSFTGHWMNWVRQAPGKGLEWVGMIHPSDSETRYNQKFKDRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARGIYFYGTTYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASKTISKYLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPLTFGQGTKVEIK,na,na,3eo9:HL/3eoa:HL:BA/3eob:HL:BA,None,None,2001,2002,ITGAL,Genentech;Merck Serono;XOMA,Psoriasis,na,Psoriatic arthritis;Type 1 diabetes mellitus,na,,E VQLVES GGG LV QPGG SLRLSC AASGY SFT G HWMNWVR QAPGKGL EWVGMI HPSDSETRYNQKFKD RFTISVD KSKN TLYLQMN SLRAEDT AVYYC ARG IYFY GT TYFD YWGQG TLVTVS S,DIQ M TQSPSS LSA SVGD RVTITCR ASK TISKYLAWYQ QKPGKAP KLLIYS GSTLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQ QHNEYPL T FGQGT KVEI K
Efungumab,scFv,na,Kappa,Phase-III,Discontinued,EVQLVESGAEVKKPGESLRISCKGSGCIISSYWISWVRQMPGKGLEWMGKIDPGDSYINYSPSFQGHVTISADKSINTAYLQWNSLKASDTAMYYCARGGRDFGDSFDYWGQGTLVTVSS,DVVMTQSPSFLSAFVGDRITITCRASSGISRYLAWYQQAPGKAPKLLIYAASTLQTGVPSRFSGSGSGTEFTLTINSLQPEDFATYYCQHLNSYPLTFGGGTKVDIK,na,na,None,None,None,2006,2007,Heat Shock Protein 90 Homolog,NeuTec Pharma,na,na,Breast cancer;Candidiasis,na,,E VQLVE SGA EVK KPGE SLRISC KGSG CIISSYWISWVR QMPGKGL EWMGK IDPGDS YINY SPSFQG HVTIS ADKSIN TAYLQWN SLKASDT AMYYCA RGGRDFGDS FDY WGQG TLVTV SS,DV VMT QSPS FLSAF VGD RITITCR ASSG ISRYLAWYQ QAPGKAP KLLIYA ASTLQTGVPSRFSGSGSGT EFTLTIN SLQ PEDFATYYCQH LNSYPL TF GGGT KVDI K
Eglatoprutug,Whole mAb,G1,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGVIYSGNGDTSYAQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARERDTRFGNWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRASESVDIYGQSFMHWYLQKPGQSPQLLIYLASNLESGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQNNEDPYTFGGGTKVEIK,na,na,None,None,None,2022,na,KIT,TBC,TBC,TBC,TBC,TBC,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYNMHWVRQ APGQG LEWMGVIYS GNGDTSY AQK FKG RVTITA DKSTS TAYMELS SLRSEDT AVYYCAR ERDTRFGNWGQ GTLVTVS S,DI VMT QSPLSLPVTPGEPA SISCR ASE SVDI YGQ SFMHWYL QKPGQSP QLLIYLA SNLESGVPDRFSGSGSGTD FTLKISRVE AED VGVYYCQ QNNEDPY T FGGG TKVEI K
Eldelumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QMQLVESGGGVVQPGRSLRLSCTASGFTFSNNGMHWVRQAPGKGLEWVAVIWFDGMNKFYVDSVKGRFTISRDNSKNTLYLEMNSLRAEDTAIYYCAREGDGSGIYYYYGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPIFTFGPGTKVDIK,na,na,None,None,None,2013,2014,CXCL10,Bristol-Myers Squibb;Medarex,na,na,Crohn's disease;Ulcerative colitis;Multiple sclerosis;Rheumatoid arthritis;Spinal cord injuries,Medarex UltiMAb Mouse,,QM QLVES GGG VV QPGR SLRLSCT ASG FTF SNNG MHWVRQ APGKGL EWVAVIWF DGMN KFYVD SVKG RFTISR DNSKN TLYLEMN SLRAED TAIYYCAR EGDGSG IYYYYGMD VWGQG TTVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQSVS SSY LAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LE PEDFAVYYCQQ YGSSP IFTF GPGT KVDI K
Elezanumab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTSHGISWVRQAPGQGLDWMGWISPYSGNTNYAQKLQGRVTMTTDTSTSTAYMELSSLRSEDTAVYYCARVGSGPYYYMDVWGQGTLVTVSS,QSALTQPRSVSGSPGQSVTISCTGTSSSVGDSIYVSWYQQHPGKAPKLMLYDVTKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCYSYAGTDTLFGGGTKVTVL,na,na,None,None,None,2016,2017,RGMA,AbbVie,na,Multiple sclerosis;Spinal cord injuries;Stroke,na,na,,E VQLVQ SGA EVK KPGA SVKVSCK ASG YTFTS HG ISWVR QAPGQGLD WMGWI SPYSGNTNY AQ K LQG RVTMTT DTSTS TAYMELS SLRSEDT AVYYCAR VGSGP YYYMDV WGQG TLVTVS S,QSALTQPR SV SGSPGQ SVTISCT GTSSSVGD SIYVSWYQ QHPGKAP KLMLYD VTKRPSGVPDRFSGSKSGN TASLTIS GLQAEDEAD YYCYSY AGTDT L FGGG TKVTV L
Elgemtumab,Whole mAb,G1,Kappa,Phase-I/II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINSQGKSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARWGDEGFDIWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSSFPTTFGQGTKVEIK,na,na,None,None,4p59:HL,2014,2015,ERBB3,MorphoSys;Novartis;Memorial Sloan-Kettering Cancer Center;Novartis Oncology,na,na,Breast cancer;Gastric cancer;Head and neck cancer;Oesophageal cancer;Solid tumours,Medarex HuMAb Mouse,,E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKG LEWVSAI NSQGK STYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAR WGDEGF DIW GQ GTLVTVS S,DIQ M TQSPSS LSA SVGD RVTITCR ASQG ISNWLAWYQ QKPGKAP KLLIYG ASSLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ YSSFPTTFGQGT KVEI K
Elipovimab,Whole mAb,G1,Lambda,Phase-I,Discontinued,QMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYNPSLKSRVHLSLDTSKNQVSLSLTGVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGTGTQVTVSS,SDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSRPGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVL,na,na,None,None,4fq1:HL/4jy4:BA/4fqc:HL,2018,2019,HIV-1 gp120,Gilead Sciences,na,na,HIV infections,na,,QM QLQE SGPGL V KPSE TLSLTCSV SGASISDS YWSWIR RSPGKGL EWIGYVHK SGDTNYNPSLK SRVHLSLD TSKN QVSLSLTGVT AADSGK YYCART LHGR RIYGIVAF NEWF TYFYMDV WGTGT QVTVS S,SDI SV APGE TARIS CGEKSLGS RAVQW YQ H RAGQAP SLIIY NNQDRPSGIPERFSGSPDSRPGT TATLTITSVE AGDE ADYYCHIW DSRVPT KWVF GGGT TLTV L
Elotuzumab,Whole mAb,G1,Kappa,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTINYAPSLKDKFIISRDNAKNSLYLQMNSLRAEDTAVYYCARPDGNYWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVGIAVAWYQQKPGKVPKLLIYWASTRHTGVPDRFSGSGSGTDFTLTISSLQPEDVATYYCQQYSSYPYTFGQGTKVEIK,na,na,None,None,None,2008,2009,SLAMF7,AbbVie;Australasian Leukaemia & Lymphoma Group;Bristol-Myers Squibb;PDL BioPharma,Multiple myeloma,na,na,na,,E VQLVES GGG LV QPGG SLRLSCA ASGFDFSR YWMSWVR QAPGKGL EWIGEI NPDSST IN YAPSLKD KFIISR DNAKNS LYLQMN SLRAEDT AVYYCA RPDGN YWYFDV WGQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITCK ASQD VGIAVAWYQ QKPGKVP KLLIYWA STRHTGVPDRFSGSGSGTD FTLTIS SLQ PEDVAT YYC QQYSSYPY T FGQGT KVEI K
Elranatamab,Bispecific mAb,G2;G2,Kappa;Kappa,Phase-III,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYPMSWVRQAPGKGLEWVSAIGGSGGSLPYADIVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYWPMDIWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLMYDASIRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYQSWPLTFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMTWVRQAPGKGLEWVAFIRNRARGYTSDHNPSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDRPSYYVLDYWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLFNVRSRKNYLAWYQQKPGQPPKLLISWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSYDLFTFGSGTKLEIK,None;None,None;None,None;None,2021,2022,TNFRSF17;CD3E,Pfizer,na,Multiple myeloma,na,na,,E VQLLES GGG LV QPGG SLRLSC AASGF TFS SYPM SWVR QAPGKGL EWVSAI GGSGGSLPYAD IVK G RFTISR DNSKN TLYLQMN SLRAEDT AVYYCARY WPMDIWGQG TLVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSSS YLAWYQ QKPGQAP RLLMYD A SIRA TGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQ QYQSWPL TF GQGT KVEI K
Eluvixtamab,Bispecific scFv,na;na,Kappa;Lambda,Phase-I,Discontinued,QVQLVQSGAEVKKPGESVKVSCKASGYTFTNYGMNWVKQAPGQGLEWMGWINTYTGEPTYADKFQGRVTMTTDTSTSTAYMEIRNLGGDDTAVYYCARWSWSDGYYVYFDYWGQGTSVTVSS,DIVMTQSPDSLTVSLGERTTINCKSSQSVLDSSTNKNSLAWYQQKPGQPPKLLLSWASTRESGIPDRFSGSGSGTDFTLTIDSPQPEDSATYYCQQSAHFPITFGQGTRLEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2020,2021,CD33;CD3E,Amgen,na,na,Acute myeloid leukaemia,BiTE Technology,,Q VQLVQ SGA EVK KPGE SVKVSCK ASGY TFTN YGM NWVK QAPGQGL EWMGWIN TYTGEPT Y ADKFQG RVTMTT DTSTS TAYMEIRN LGGDDT AVYYCARWS WSDG YYVYFD YWGQGT SVTVS S,D IVMT QSPDS LTVSL GER TTINC KSSQS VL DSSTNKNS LAWYQ QKPGQPP KLLLSWA STRESGIPDRFSGSGSGT DFTLTI DSPQPEDSA TYYCQ QSAHFP ITF GQGT RLEI K
Emactuzumab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDISWVRQAPGQGLEWMGVIWTDGGTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDQRLYFDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASEDVNTYVSWYQQKPGKAPKLLIYAASNRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFSYPTFGQGTKLEIK,na,na,4liq:HL,None,None,2014,2015,CSF1R,Roche;University of Texas M. D. Anderson Cancer Center,na,Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Solid tumours,Giant cell tumour of tendon sheath;Pigmented villonodular synovitis,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYDISWVR QAPGQG LEWMGVIWT DGGTNY AQKL QG RVTMTT DTSTS TAYMELRS LRSDDT AVYYCA RDQ RLYFDVW GQGT TVTVS S,DI QMT QSPSS LSA SVGD RVTITCR ASEDVN TYVSWYQ QKPGKAP KLLIYAA SNRYTGVPSRFSGSGSGTD FTLTISS LQPEDF ATYYCQ QSFSYPTFGQGT KLEI K
Emapalumab,Whole mAb,G1,Lambda,Approved,NFD,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDGSSGWYVPHWFDPWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDGSNRWMFGGGTKLTVL,na,na,None,None,None,2016,2017,IFNG,NovImmune SA;Swedish Orphan Biovitrum,Haemophagocytic lymphohistiocytosis,na,na,na,,E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKGL EWVSAIS GSGGS TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA KDGSSG WYV PHW F DPWGQG TLVTVS S,NF ML TQPH SV SESPGK TVTISCT RSSGS I ASN YVQWYQ QRPGSSP TTVIY EDNQRPSGVPDRFS GSI DSSSNS ASLTIS GLKTEDEAD YYCQS YDGSNR WMF GGGT KLTV L
Emerfetamab,Bispecific scFv,na;na,Kappa;Lambda,Phase-I,Active,QVQLVQSGAEVKKPGESVKVSCKASGYTFTNYGMNWVKQAPGQCLEWMGWINTYTGEPTYADKFQGRVTMTTDTSTSTAYMEIRNLGGDDTAVYYCARWSWSDGYYVYFDYWGQGTSVTVSS,DIVMTQSPDSLTVSLGERTTINCKSSQSVLDSSTNKNSLAWYQQKPGQPPKLLLSWASTRESGIPDRFSGSGSGTDFTLTIDSPQPEDSATYYCQQSAHFPITFGCGTRLEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2020,2021,CD33;CD3E,Amgen,na,Acute myeloid leukemia,na,BiTE Technology,,Q VQLVQ SGA EVK KPGE SVKVSCK ASGY TFTN YGM NWVK QAPGQ CLEWMGWIN TYTGEPT Y ADKFQG RVTMTT DTSTS TAYMEIRN LGGDDT AVYYCARWS WSDG YYVYFD YWGQGT SVTVS S,D IVMT QSPDS LTVSL GER TTINC KSSQS VL DSSTNKNS LAWYQ QKPGQPP KLLLSWA STRESGIPDRFSGSGSGT DFTLTI DSPQPEDSA TYYCQ QSAHFP ITF GCGT RLEI K
Emicizumab,Bispecific mAb,G4;G4,Kappa;Kappa,Approved,NFD,QVQLVQSGSELKKPGASVKVSCKASGYTFTDNNMDWVRQAPGQGLEWMGDINTRSGGSIYNEEFQDRVIMTVDKSTDTAYMELSSLRSEDTATYHCARRKSYGYYLDEWGEGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASRNIERQLAWYQQKPGQAPELLIYQASRKESGVPDRFSGSRYGTDFTLTISSLQPEDIATYYCQQYSDPPLTFGGGTKVEIK,QVQLVESGGGLVQPGGSLRLSCAASGFTFSYYDIQWVRQAPGKGLEWVSSISPSGQSTYYRREVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRTGREYGGGWYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASRNIERQLAWYQQKPGQAPELLIYQASRKESGVPDRFSGSRYGTDFTLTISSLQPEDIATYYCQQYSDPPLTFGGGTKVEIK,None;None,None;None,None;None,2015,2016,F9;F10,Chugai Pharmaceutical;Roche,Haemophilia A,na,na,na,,Q VQLVQ SGS E LKKPGA SVKVSCK ASGY TF TDNNMD WVR QAPGQGL EWMG DINTRSGG SIY NEEFQD RVIMTV DKSTD TAYMELSS LRSEDTA TYHCA RRKSY GYYL DEWGEG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCK ASRN IERQLAWYQ QKPGQAP ELLIYQA SRKESGVPDRFSGSRYGTD FTLTIS SLQ PEDIATYYCQQ YSDPPL TF GGG TKVEI K
Emibetuzumab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGRVNPNRRGTTYNQKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARANWLDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCSVSSSVSSIYLHWYQQKPGKAPKLLIYSTSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQVYSGYPLTFGGGTKVEIK,na,na,None,None,None,2014,2015,MET,Eli Lilly,na,Gastric cancer;Non-small cell lung cancer;Cancer,na,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTDYYMHWVRQ APGQG LEWMGRV NPNRRGTT Y NQ KFEGRVTMTT DTSTS TAYMELRSL RSDDT AVYYCAR ANW L DYWGQG TTVTVS S,DI QMT QSPSS LSAS VGD RVTITCSV SSSVS SIYLHWYQ QKPGKAP KLLIYS TSNLASGVPS R FSGSGSGT DFTLTISS LQPEDF ATYYCQVY SGYP LTF GGG TKVEI K
Emirodatamab,Bispecific scFv-scFv-scFc,na;na,Kappa;Lambda,Phase-I,Active,QVTLKESGPTLVKPTETLTLTCTLSGFSLNNARMGVSWIRQPPGKCLEWLAHIFSNDEKSYSTSLKNRLTISKDSSKTQVVLTMTNVDPVDTATYYCARIVGYGSGWYGFFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGCGTKVEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2022,na,FLT3;CD3E,Amgen;BeiGene,na,Acute myeloid leukaemia,na,na,,QV TLK ESGP TLV KPTE TLTLTCTL SGF S LNNA RMGVSWIR QPPGKC LEWLAHI F SNDEKSYSTSLK NRLTIS KDSSKT QVVLTMT NVDPVDTA TYYCARIVG YGSGW YGFFD YWGQG TLVTV SS,DI QMT QSPSS LSA SVGD RVTITCR ASQGIRNDLG WYQ QKPGKAPK RLIYAAS TLQSGVPS RF SGSGSGT EFTLTISS LQPEDF ATYYCL QHNSYP LTF GCGT KVEI K
Empasiprubart,Whole mAb,G1,Kappa,TBC,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQATGQGLEWIGDINPNYESTGYNQKFKGRATMTVDKSISTAYMELSSLRSEDTAVYYCAREDDHDAFAYWGQGTLVTVSS,DNVLTQSPDSLAVSLGERATISCRASKSVRTSGYNYMHWYQQKPGQPPKLLIYLASNLKSGVPDRFSGSGSGTDFTLTISSLQAEDAATYYCQHSRELPYTFGQGTKLEIK,na,na,None,None,None,2022,na,C2,TBC,TBC,TBC,TBC,TBC,,E VQLVQ SGA EVK KPGA SVKVSCK ASGY TFT DYN MDWVRQ ATGQGL EWIG DINPNYESTGYNQKFKG RATMTV DKSI STAYMELS SLRSEDT AVYYCA REDDHDA FAYW GQG TLVTV SS,DNV LT QSPDS LAVS LGER ATISCR ASKS V RTSGY NYMHWYQ QKPGQPP KLLIYLA SNLKSGVPDRFSGSGSGTD FTLTISS LQAEDAA TYYCQ HSRELPY T FGQGT KLEI K
Enapotamab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAPGKGLEWVSTTSGSGASTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKIWIAFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPYTFGQGTKLEIK,na,na,None,None,None,2017,2018,AXL,Genmab,na,na,Solid tumours,na,,E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMNWVR QAPGKG LEWVST TSGSGA STYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAKIWIAFDI WGQG TMVTV SS,E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSS S YLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEP EDF AVYYC QQ YGSSPYTFGQGT KLEI K
Enavatuzumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAEIRLKSDNYATHYAESVKGRFTISRDDSKNSLYLQMNSLRAEDTAVYYCTGYYADAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSTSSYSYMHWYQQKPGKAPKLLIKYASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSWEIPYTFGGGTKVEIK,na,na,None,None,None,2010,2011,TNFRSF12A,PDL BioPharma;Abbott Laboratories,na,na,Solid tumours,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFSSYWMSWVR QAPGKGL EWVAEIRLK SDNYA THYAES VKG RFTISR DDSKNS LYLQMNS LRAEDT AVYYCTGYY ADAMDYWGQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITCR ASQSVSTSSY SYMHWYQ QKPGKAP KLLIKYA SNLESGVPS RF SGSGSGTD FTLTISS LQPEDF ATYYC QHS WEI P YT FGGG TKVEI K
Encelimab,Whole mAb,G4,Kappa,Phase-I,Active,EVQLVQSGAEVKKPGATVKISCKASGFSIKDDYIHWVQQAPGKGLEWMGWIDAMNDDSQYSSKFQGRVTITVDTSTNTAYMKLSSLRSEDTAVYYCTYAFGGYWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSQSLVHSDSNTYLHWYLQKPGQSPQLLIYLVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCGQSTHVPYAFGGGTKVEIK,na,na,None,None,None,2019,2020,LAG3,Anaptys Bio;TESARO,na,Solid tumours,na,na,,E VQLVQ SGA EVK KPGA TVKISCK ASGF SI KDD YIHWVQQ APGKGL EWMGWID AMNDDSQYSSKFQG RVTITVD TSTN TAYMKLSS LRSEDT AVYYCTYAF GGYWGQG TTVTVS S,DI VMT QTP LSLSV TPGQP ASISC RSSQ SLVH SDSNT YLHWYLQ KPGQSP QLLIYLVS NRFSGVPDRFSGSGSGT DFTLKISRVE AED VGVYFC GQSTHVPYAFGGG TKVEI K
Enfortumab,Whole mAb ADC,G1,Kappa,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYNMNWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLSLQMNSLRDEDTAVYYCARAYYYGMDVWGQGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISGWLAWYQQKPGKAPKFLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPPTFGGGTKVEIK,na,na,None,None,None,2013,2014,PVRL4,Agensys;Seattle Genetics,Urogenital cancer,Bladder cancer;Prostate cancer;Solid tumours,na,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFSS YNM NWVR QAPGKGL EWVSYIS SSSS TIYYA DSVKG RFTISR DNAKNS LSLQMN SLRDEDT AVYYCARAYYY GM D VWGQG TTVTVS S,DIQ MT QSPSS VSAS VGD RVTITCR ASQGIS GWLAWYQ QKPGKAP KFLIYAA STLQSGVPS R FSGSGSGTD FTLTIS SLQP EDFA TYYCQ QANSFPPTFGGGT KVEI K
Englumafusp,Fusion Protein,G1,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMHWVRQAPGQGLEWMGYINPYNDGSKYTEKFQGRVTMTSDTSISTAYMELSRLRSDDTAVYYCARGTYYYGPQLFDYWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCKSSQSLETSTGTTYLNWYLQKPGQSPQLLIYRVSKRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQLLEDPYTFGQGTKLEIK,na,na,None,None,None,2021,2022,CD19,Roche,na,B cell Lymphoma,na,na,(June '22: Corrected CDRH2 sequence. Aug '22: WHO changed name from ensomafusp to englumafusp in PL127),Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTDYIMHWVR QAPGQGL EWMGYI NPYNDGSKY TEKF QG RVTM TSDTS ISTAYMELSR LRSDDT AVYYC ARGT YYY GPQ LF DYWGQG TTVTVS S,DI VMT QTP LSLSV TPGQP ASISC KSSQ SLE TSTGT TYLNWYL QKPGQSP QLLIYRVSK RFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCLQL LEDPYTFGQGT KLEI K
Enibarcimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFSRYWIEWVRQAPGQGLEWIGEILPGSGSTNYNQKFQGRVTITADTSTSTAYMELSSLRSEDTAVYYCTEGYEYDGFDYWGQGTTVTVSS,DVVLTQSPLSLPVTLGQPASISCRSSQSIVYSNGNTYLEWYLQRPGQSPRLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHIPYTFGGGTKLEIK,na,na,None,None,None,2020,2021,ADM,Adrenomed,na,Septic shock;Cardiogenic shock;COVID-19,na,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TFSRYWIEWVR QAPGQG LEWIGEI LPGSGSTNYNQK F QG RVTITA DTSTS TAYMELS SLRSEDT AVYYC TEGY E YDG FDY WGQG TTVTVS S,D VVLT QSPLSLP VT LGQP ASISC RSSQ SIVYS NGN TYLEWYLQ RPGQSP RLLIYRVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCF QGSHIP YTF GGG TKLEI K
Enoblituzumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSDSSAIYYADTVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCGRGRENIYYGSRLDYWGQGTTVTVSS,DIQLTQSPSFLSASVGDRVTITCKASQNVDTNVAWYQQKPGKAPKALIYSASYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPFTFGQGTKLEIK,na,na,None,None,None,2015,2017,CD276,MacroGenics;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,na,Prostate cancer;Solid tumours;Head and neck cancer,Malignant melanoma;Non-small cell lung cancer;Squamous cell cancer;Urogenital cancer,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFSS F GMHWVRQ APGKG LEWVAYIS SDSS AIYYAD TVKG RFTISR DNAKNS LYLQMN SLRDEDT AVYYC GRGREN IYY GS RLDY WGQG TTVTVS S,DI QLT QSPS FLSA SVGD RVTITCK ASQNVDTN VAWYQ QKPGKAPK ALIYSASYRY SGVPSRFSGSGSGTD FTLTISS LQP EDFAT YYCQ QYNNYPF T FGQGT KLEI K
Enokizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSYYWIEWVRQAPGQGLEWMGEILPGSGTTNPNEKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARADYYGSDYVKFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQHVITHVTWYQQKPGKAPKLLIYGTSYSYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFYEYPLTFGGGTKVEIK,na,na,None,None,None,2010,2011,IL9,Genaera Corporation;Ludwig Institute for Cancer Research;MedImmune,na,na,Asthma,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSYYWIEWVR QAPGQG LEWMGEI LPGSGTTNPNEKFK GRVTITA DESTS TAYMELSS LRSEDT AVYYCAR ADYYGSD YVKFDY WGQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITCK ASQH VITHVTWYQ QKPGKAP KLLIYG T SY SYSGVPSRFSGSGSGTD FTLTISS LQP EDFAT YYCQQF YEYPL T FGGG TKVEI K
Enoticumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVSFLWYDGTNKNYVESVKGRFTISRDNSKNMLYLEMNSLRAEDTAVYYCARDHDFRSGYEGWFDPWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHRSNWPPTFGGGTKVEIK,na,na,None,None,None,2012,2013,DLL4,Regeneron Pharmaceuticals;Sanofi,na,na,Solid tumours,VelocImmune Mouse,,Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS YG MHWVRQ APGKGL EWVSFLWY DGTNKN YVESV K GRFTISR DNSKN MLYLEMN SLRAEDT AVYYCA RDHDFRSGYEG WF DPWGQG TLVTVS S,E IVLTQ SPA TLSL SPGE RATLSCR ASQS VSSY LAWY QQKPGQAP RLLIYD ASNRATG I P ARF SGSGSGTD FTLTIS SLEPED FAVYYCQ HRSNWPPTFGGG TKVEI K
Ensituximab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLKESGPDLVAPSQSLSITCTVSGFSLSKFGVNWVRQPPGKGLEWLGVIWGDGSTSYNSGLISRLSISKENSKSQVFLKLNSLQADDTATYYCVKPGGDYWGHGTSVTVSS,QVVLTQSPVIMSASPGEKVTMTCSASSSISYMYWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISNMEAGDAATYYCHQRDSYPWTFGGGTNLEIK,na,na,None,None,None,2010,2011,MUC5AC,Neogenix Oncology;Duke University Medical Center;H. Lee Moffitt Cancer Center and Research Institute;Johns Hopkins Medical Institutions;Montefiore Medical Center;National Cancer Institute (USA);Precision Biologics;University of North Carolina;University of Texas Southwestern Medical Center;Yale University School of Medicine,na,Colorectal cancer;Pancreatic cancer,na,na,,QV QLK ESGPDLVAPSQ SLSITCTV SGF S LS KFGVNWVR QPPGKGL EWLGVIW GDGSTSYNSG LISRLSI SKENSKS QVFLKL NSLQADDT ATYYCV KPGGDYWGHG TSVTVS S,Q VVLT QSP VIMS ASPGE KVTMTCS ASSS ISYMYWYQ QKPGTSPK RWIYD TSKLASGVP ARFS GSGSGT SYSLTISN MEAGDA ATYYCH QRDSYPW TF GGGT NLEI K
Enuzovimab,Whole mAb,G4,Kappa,Phase-I,Active,EVQLVESGGGLIQPGGSLRLSCAASGFIVSSNYMSWVRQAPGKGLEWVSIIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRVEDTAVYYCARDLQELGSLDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQEANSFPYTFGQGTKLEIK,na,na,7cjf:AB,None,None,2021,2022,SARS-CoV-2 Spike RBD,ABL Bio;HiFiBiO Therapeutics,na,COVID-19,na,na,,E VQLVES GGG LI QPGG SLRLSC AASG FIVS SNY MSWVR QAPGKGL EWVSIIYS GGS TFYA DSVKG RFTISR DNSKN TLYLQMNSLRV EDT AVYYCA RD LQE LGSLD Y WGQG TLVTV SS,DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISSWLAWY QQKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQPE DFA TYYC QEANSFPY T FGQGT KLEI K
Envafolimab,Single Domain Variable Fragment;H,G1,na,Approved,Active,QVQLVESGGGLVQPGGSLRLSCAASGKMSSRRCMAWFRQAPGKERERVAKLLTTSGSTYLADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAADSFEDPTCTLVTSSGAFQYWGQGTLVTVSS,na,na,na,None,None,None,2018,2019,PDL1,Alphamab;3D Medicines;Sun Yat-Sen University,Solid tumours,Biliary cancer;Breast cancer;Gastric cancer;Gastrointestinal cancer;Hepatitis B;Malignant fibrous histiocytoma;Soft tissue sarcoma,na,na,(Oct '22) Sequence fixed to contain the full DJ/J regions.,Q VQLVES GGG LV QPGG SLRLSC AASGKMSS RRC M A W F R QAPGK ERERVAKL LT TSGS TYLA DSVKG RFTISR DNSKN TVYLQMN SLRAEDT AVYYCA ADSFEDPT CTLVT SSGA FQYW GQG TLVTV SS,NA
Epacmarstobart,Whole mAb,G1,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWITWVKQAPGQGLEWIGDIYPGSGSTNHIEKFKSKATLTVDTSISTAYMELSRLRSDDTAVYYCATGYGSSYGYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASENIYSYLAWYQQKPGKAPKLLIYTAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHQYGPPFTFGQGTKLEIK,na,na,None,None,None,2022,na,SIRPA,TBC,TBC,TBC,TBC,TBC,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYWITWVK QAPGQG LEWIGDI YPGSGSTNH IEKF KSK ATLTVD TSI STAYMELSR LRSDDT AVYYCA TGYGSSYG YFD YWGQG TLVTV SS,DIQ MT QSPSS LSA SVGD RVTITCR ASEN IYSYLAWY QQKPGKAP KLLIYTAKT LAEGVPSRFSGSGSGTD FTLTIS SLQP EDFAT YYCQ HQYGPPF T FGQGT KLEI K
Epcoritamab,Bispecific mAb,G1;G1,Lambda;Kappa,Phase-III,Active,EVKLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKSSLYLQMNNLKTEDTAMYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS,QAVVTQEPSFSVSPGGTVTLTCRSSTGAVTTSNYANWVQQTPGQAFRGLIGGTNKRAPGVPARFSGSLIGDKAALTITGAQADDESIYFCALWYSNLWVFGGGTKLTVL,EVQLVESGGGLVQPDRSLRLSCAASGFTFHDYAMHWVRQAPGKGLEWVSTISWNSGTIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIK,None;None,None;None,None;3giz:HL/6y92:CD:HL,2019,2020,CD3E;MS4A1,Genmab,na,Haematological malignancies;Diffuse large B-cell lymphoma;Chronic lymphocytic leukaemia;Follicular lymphoma;Non-Hodgkin's lymphoma,na,na,Second Fv closely related to Ofatumumab,E VKLVES GGG LV QPGG SLRLSC AASGF TFNTYAMNWVR QAPGKG LEWVARIR SKYNNY ATYYA DSVKD RFTIS RDDSKS SLYLQM NNLKTEDT AMYYCVRH GNFGNS YVSWFAYW GQG TLVTVS S,QA VVTQ EP SFSV SPGG TVTLTCR SSTGA VTT SNYAN WVQ QTPGQA FRGLI GGTNKRAPGVPA RFSGSL IGDK AALTIT GAQADDE SIYFCALWY SN LWVF GGGT KLTV L
Epratuzumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYWLHWVRQAPGQGLEWIGYINPRNDYTEYNQNFKDKATITADESTNTAYMELSSLRSEDTAFYFCARRDITTFYWGQGTTVTVSS,DIQLTQSPSSLSASVGDRVTMSCKSSQSVLYSANHKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCHQYLSSWTFGGGTKLEIK,na,na,None,5vkk:AB:HL/5vl3:EF:AB:HL:CD,None,1999,2000,CD22,Charite - Universitatsmedizin Berlin;Children's Oncology Group;Immunomedics;National Cancer Institute (USA);UCB,na,na,Precursor cell lymphoblastic leukaemia-lymphoma;Systemic lupus erythematosus;Non-Hodgkin's lymphoma;Cachexia,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TFTSYWLHWVR QAPGQG LEWIGYI NPRNDYTEYNQNFKDK ATITA DESTN TAYMELS SLRSEDT AFYFCA RRDI TTFYW GQGT TVTVS S,DI QLT QSPSS LSA SVGD RVTMSC KSSQ SVLYS ANHKN YLAWYQ QKPGKAP KLLIYWA STRESGVPS R FSGSGSGTD FTFTIS SLQ PEDIATY Y CHQYL SSW T FGGGT KLEI K
Eptinezumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAVSGIDLSGYYMNWVRQAPGKGLEWVGVIGINGATYYASWAKGRFTISRDNSKTTVYLQMNSLRAEDTAVYFCARGDIWGQGTLVTVSS,QVLTQSPSSLSASVGDRVTINCQASQSVYHNTYLAWYQQKPGKVPKQLIYDASTLASGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLGSYDCTNGDCFVFGGGTKVEIK,na,na,None,None,None,2016,2017,CALCA&CALCB,Alder Biopharmaceuticals,Migraine,Cluster headache,na,na,,E VQLVES GGG LV QPGG SLRLSCAV SG ID LSGY YMNWVR QAPGKGL EWVGVIGI NGA TYYASW AKG RFTISR DNSKT TVYLQM NSLRAEDT AVYFCA RGD I WGQG TLVTVS S,QVLTQSPSS LSA SVGD RVTINC QASQSVYHN TYLAWYQ QKPGKVPK QLIYD ASTLASGVPS RF SGSGSGT DFTLTISS LQPEDV ATYYCLGSYD CTNGD CFVF GGG TKVEI K
Eramkafusp,Whole mAb Fusion,G1,Kappa,Phase-I,Discontinued,QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSA,QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIK,na,na,None,2osl:AB:HL/4kaq:HL/6y90:HL:CD/6vja:HL:IM,None,2020,2021,CD20,Spectrum Pharmaceuticals;ImmunGene,na,na,Non-Hodgkin's lymphoma,na,Possibly a Rituximab biosimilar. (June '22): Corrected IMGT VH 128 S->A,QV QLQ QPGA ELV KPGA SVKMSCK ASGY TFTSYNMHWVK QTPGRG LEWIGAI YPGNGDTSYNQK F KG KATLTA DKSSST AYMQLS SLTSEDS AVYYCAR S T YYGGD WYFNVW GAGT TVTVS A,Q IVLS QSP AILS ASPGE KVTMTCR ASSS VSYIHWFQ QKPGSSPKP WIYAT SNLASGV PVRFS GSGSGT SYSLTISRVE AEDA ATYYCQQW TSNPPTFGGGT KLEI K
Erenumab,Whole mAb,G2,Lambda,Approved,NFD,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAVISFDGSIKYSVDSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCARDRLNYYDSSGYYHYKYYGMAVWGQGTTVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSTTLGITGLQTGDEADYYCGTWDSRLSAVVFGGGTKLTVL,na,na,6umg:HL:hl/6umh:HL:hl/6umi:HL/6umj:HL,None,None,2016,2017,CALCRL,Amgen;Novartis,Migraine,na,Hot flushes,Abgenix XenoMouse,,Q VQLVES GGG VV QPGR SLRLSC AASGF TFSSFGMHWVRQ APGKGL EWVAVIS FDGS IKYSVD SVKG RFTISR DNSKN TLFLQMN SLRAEDT AVYYCA RDRL NYY DSSGY YHYKYYGMAVW GQGT TVTVS S,QSVLTQPPS V SAAPGQ KVTISC SGSSSNIGNN YVSWY Q QLPGTAP KLLIY DNNKRPSGIPDRFSGSKSGTS TTLGITG LQTGDEAD YY CGTWDSR LSAVVF GGGT KLTV L
Erfonrilimab,Bispecific Single Domains (VH-VH'-CH),G1,na;na,Phase-III,Active,QVQLVESGGGLVQPGGSLRLSCAASGKMSSRRCMAWFRQAPGKERERVAKLLTTSGSTYLADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAADSFEDPTCTLVTSSGAFQYWGQGTLVTVSS,na,QVQLVESGGGLVQPGGSLRLSCAASGYIYSAYCMGWFRQAPGKGLEGVAAIYIGGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAADVIPTETCLGGSWSGPFGYWGQGTLVTVSS,na,None;6rqm:B,None;None,None;None,2020,2021,CD274;CTLA4,Alphamab,na,Non-small cell lung cancer;Triple-negative breast cancer;Esophageal carcinoma,na,na,(June '22: Corrected FWH1 sequence),Q VQLVES GGG LV QPGG SLRLSC AASGKMSS RRC M A W F R QAPGK ERERVAKL LT TSGS TYLA DSVKG RFTISR DNSKN TVYLQMN SLRAEDT AVYYCA ADSFEDPT CTLVT SSGA FQYW GQG TLVTV SS,NA
Erlizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCATSGYTFTEYTMHWMRQAPGKGLEWVAGINPKNGGTSHNQRFMDRFTISVDKSTSTAYMQMNSLRAEDTAVYYCARWRGLNYGFDVRYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDINNYLNWYQQKPGKAPKLLIYYTSTLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPPTFGQGTKVEIK,na,na,2fgw:HL,None,None,2000,2001,CD18,Genentech;PDL Biopharma; Roche,na,na,Myocardial infarction;Shock ,na,,E VQLVES GGG LV QPGG SLRLSC ATSGY TFTEYTMHWMR QAPGKG LEWVAGI NPKNGGTSHNQRF M D RFTISV DKSTS TAYMQMN SLRAEDT AVYYCARW RGLNYG FDVRYFDV WGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQD INNYLNWYQ QKPGKAP KLLIYYT STLHSGVPSRFSGSGSGTD YTLTIS SLQ PEDFAT YYC QQGNTLPPTFGQGT KVEI K
Etaracizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVAKVSSGGGSTYYLDTVQGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHLHGSFASWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCQASQSISNFLHWYQQRPGQAPRLLIRYRSQSISGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSGSWPLTFGGGTKVEIK,na,na,None,None,None,2008,2009,ITGAV_ITGB3,Applied Molecular Evolution;MedImmune,na,na,Colorectal cancer;Malignant melanoma;Prostate cancer;Psoriasis;Rheumatoid arthritis,na,,Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS YDM SWVR QAPGKG LEWVAKVS SGGGS TYYLD TVQG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAR HLHGS FAS WGQG TTVTVS S,E IVLT QSPA TLSL SPGE RATLSCQ ASQS ISNFLHWYQ QRPGQAP RLLIRYR SQSISGIP ARFS GSGSGTD FTLTIS SLEPED FAVYYC QQSGSWP LTF GGG TKVEI K
Etesevimab,Whole mAb,G1,Kappa,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSMNTLFLQMNSLRAEDTAVYYCARVLPMYGDYLDYWGQGTLVTVSS,DIVMTQSPSSLSASVGDRVTITCRASQSISRYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPEYTFGQGTKLEIK,na,na,7c01:CD:HL,None,None,2020,2021,SARS-CoV-2 Spike RBD,Eli Lilly and Company;Institute of Microbiology of the Chinese Academy of Sciences;Shanghai Junshi Biosciences,COVID-19,na,na,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TVS SN YMSWVR QAPGKGL EWVSVIY SGGS TFYA DSVKG RFTIS RDNSMN TLFLQM NSLRAEDT AVYYCARVL PMYGDY L D Y WGQG TLVTVS S,DI VMT QSPSS LSA SVGD RVTITCR ASQ SISRYLNWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQP EDFA TYYCQ QSYSTPPEY T FGQGT KLEI K
Etevritamab,Bispecific scFv,na;na,Kappa;Lambda,Phase-I,Discontinued,QVQLVESGGGVVQSGRSLRLSCAASGFTFRNYGMHWVRQAPGKCLEWVAVIWYDGSDKYYADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGYDILTGNPRDFDYWGQGTLVTVSS,DTVMTQTPLSSHVTLGQPASISCRSSQSLVHSDGNTYLSWLQQRPGQPPRLLIYRISRRFSGVPDRFSGSGAGTDFTLEISRVEAEDVGVYYCMQSTHVPRTFGCGTKVEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2020,2021,EGFR;CD3E,Amgen,na,na,Glioblastoma,na,,Q VQLVES GGG VVQ SGR SLRLSC AASGF TFRNYGMHWVRQ APGKC LEWVAVIWY DGSDK YYAD SVRG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RDGY DILT GNPRDFDYWGQG TLVTV SS,DT VMT QTPLSSH VT LGQPA SISC RSSQ SLV HSDGN TYLSWLQ QRPGQPP RLLIYRISR RFSGVPDRFSGSGAGT DFTLEISRVE AEDV GVYYCMQ STHVPRTFGCG TKVEI K
Etigilimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLQESGPGLVKPSETLSLTCAVSGYSITSDYAWNWIRQPPGKGLEWIGYISYSGSTSYNPSLRSRVTISRDTSKNQFFLKLSSVTAADTAVYYCARRQVGLGFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQHYSTPWTFGQGTKVEIK,na,na,None,None,None,2017,2018,TIGIT,OncoMed Pharmaceuticals,na,Solid tumours,na,na,,QV QLQ ESGPGL V KPSE TLSLTCAV SGY SI TSDY AWNWIR QPPGKGL EWIGYISY SGSTSYNPSL RSRVTISR DTSKN QFFLKLS SVTAADT AVYYCA RRQVG LGFAYW GQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCK ASQD VSTA VAWYQ QKPGKAP KLLIYSASYRY TGVPSRFSGSGSGTD FTFTIS SLQ PEDIATYYCQ QHYSTPW T FGQGT KVEI K
Etokimab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLMQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWMGTIYPRNSNTDYNQKFKARVTMTRDTSTSTVYMELSSLRSEDTAVYYCARPLYYYLTSPPTLFWGQGTLVTVSS,DIQLTQSPSFLSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTRHTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQAKTYPFTFGSGTKLEIK,na,na,None,None,None,2018,2019,IL13,AnaptysBio,na,na,Asthma;Atopic dermatitis;Peanut hypersensitivity;Rhinosinusitis,na,,Q VQLMQ SGA EVK KPGA SVKVSCK ASGY TFTSYWMHWVR QAPGQG LEWMGTIY PRNSNTDYNQ KFKARVTMTR DTSTS TVYMELS SLRSEDT AVYYCA RP LYYYL TSPP TLFW GQG TLVTV SS,DI QLT QSPS FLSA SVGD RVTITCK ASQDVG TAVAWYQ QKPGKAP KLLIYWA STRHTGVPSRFSGSGSGT EFTLTIS SLQP EDFAT YYC QQAKTYP FTF GSGT KLEI K
Etrolizumab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFFITNNYWGWVRQAPGKGLEWVGYISYSGSTSYNPSLKSRFTISRDTSKNTFYLQMNSLRAEDTAVYYCARTGSSGYFDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASESVDDLLHWYQQKPGKAPKLLIKYASQSISGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGNSLPNTFGQGTKVEIK,na,na,None,None,None,2010,2011,ITGA4_ITGB7&ITGAE_ITGB7,Genentech;Roche,na,Crohn's disease;Ulcerative colitis,na,na,,E VQLVES GGG LV QPGG SLRLSC AASG FFIT NNY WGWVRQ APGKGL EWVGYISY SGSTSYNPSLK SRFTISR DTSKN TFYLQMNS LRAEDT AVYYCA RTGSSG YFDFW GQG TLVTVS S,DIQ M TQSPSS LSA SVGD RVTITCR ASES VDDLLHWYQQ KPGKAP KLLIKYA SQSISGVPSRFSGSGSGTD FTLTIS SLQP EDFA TYYC QQGNSLPNTFGQGT KVEI K
Evinacumab,Whole mAb,G4,Kappa,Approved,Active,EVQLVESGGGVIQPGGSLRLSCAASGFTFDDYAMNWVRQGPGKGLEWVSAISGDGGSTYYADSVKGRFTISRDNSKNSLYLQMNSLRAEDTAFFYCAKDLRNTIFGVVIPDAFDIWGQGTMVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSIRSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSYTFGQGTKLEIK,na,na,None,None,None,2014,2015,ANGPTL3,Regeneron Pharmaceuticals;Sanofi,Hyperlipoproteinaemia type II,Hypertriglyceridaemia,na,na,,E VQLVES GG GVI QPGG SLRLSC AASGFT F DDY AMNWVR QGPGKGL EWVSAI SGDGGS TYYA DSVKG RFTISR DNSKN SLYLQMN SLRAED TAFFYCA KDLRN TIFGVVI PDAF DI WGQG TMVTVS S,DIQ M TQSPS TLSAS VGD RVTITCR ASQS IRSWLAWYQ QKPGKAP KLLIYKA SSLESGVPS R FSGSGSGT EFTLTIS SLQPDD FA TYYCQ QYNS YSYTF GQGT KLEI K
Evolocumab,Whole mAb,G2,Lambda,Approved,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTLTSYGISWVRQAPGQGLEWMGWVSFYNGNTNYAQKLQGRGTMTTDPSTSTAYMELRSLRSDDTAVYYCARGYGMDVWGQGTTVTVSS,ESALTQPASVSGSPGQSITISCTGTSSDVGGYNSVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCNSYTSTSMVFGGGTKLTVL,na,na,None,None,None,2012,2013,PCSK9,Amgen;Amgen Astellas BioPharma;University Hospital Inselspital,Coronary disorders;Hypercholesterolaemia;Hyperlipoproteinaemia type IIa;Myocardial infarction;Stroke,Hyperlipidaemia;Coronary artery disease;Dyslipidaemias,na,Abgenix XenoMouse,,E VQLVQ SGA EVK KPGA SVKVSCK ASGY TLTSYGISWVRQ APGQGL EWMGWVSFY NGNTN YAQKLQ GRG TMT TDPSTST AYMELRSL RSDDT AVYYCA RGYGM DV WGQG TTVTVS S,ESALTQPA SV SGSPGQ SITISCT GTSSDVGGY NSVSWYQ QHPGKAP KLMIYEV SNRPSGVSNRFSGSKSGN TASLTIS GLQAEDEAD YYC NSYTST SMVF GGGT KLTV L
Evunzekibart,Whole mAb,G4,Kappa,TBC,Active,EVQLLESGGGLVQPGGSLRLSCAASGFNFGYSYMSWVRQAPGKGLEWVSSIGSTSSHTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVYSSPGIDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSIGSTLNWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYTWVPFTFGQGTKLEIK,na,na,None,None,None,2022,na,TNFRSF9,TBC,TBC,TBC,TBC,TBC,,E VQLLES GGG LV QPGG SLRLSC AASGFN F G YSYMSWVR QAPGKG LEWVSS IGSTSSH TYYA DSVKG RFTISR DNSKN TLYLQMNS LRAEDT AVYYCARVY SSPGID Y WGQ GTLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQSIGS TLNWYQ QKPGKAP KLLIYG ASSLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYC QQY YTWVPFT FGQGT KLEI K
Exbivirumab,Whole mAb,G1,Lambda,Phase-II,Discontinued,QVQLVESGGGVVQPGGSLRLSCAPSGFVFRSYGMHWVRQTPGKGLEWVSLIWHDGSNRFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAMYFCARERLIAAPAAFDLWGQGTLVTVSS,SYVLTQPPSVSVAPGKTARISCGGNNIGTKNVHWYQQKPGQAPVLVVYADSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSVSYHVVFGGGTTLTVL,na,na,None,None,None,2004,2005,Hepatitis B Surface Antigen,XTL Biopharmaceuticals;Yeda,na,na,Hepatitis B infection,na,,Q VQLVES GGG VV QPGG SLRLSC APSG FVFRSY G MHWVRQ TPGKGL EWVSLIWH DGSNR FYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AMYFCA RE RLIA APAA FD LWGQG TLVTVS S,SY VL TQPPS VSV APGK TARISC GGNNIGTK NVHWYQ QKPGQAP VLVVYA DSDRPSGIPERFSGSNSGN TATLTISRVE AGDE ADYYCQVW DSV SYHVVF GGGT TLTV L
Exidavnemab,Whole mAb,G4,Kappa,Phase-I,Active,QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYGVHWIRQPPGKGLEWIGVIWRGGSTDYSAAFMSRLTISKDTSKNQVSLKLSSVTAADTAVYYCAKLLRSVGGFADWGQGTMVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQTIVHNNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPFTFGQGTKLEIK,na,na,None,None,None,2021,2022,SNCA,AbbVie,na,SNCA,na,na,,QV QLQE SGPGL V KPSE TLSLTCTV SG FSLTSYGVHWIR QPPGKGL EWIGVIWR GGSTDYS AAFMSRLTIS KDTSKN QVSLKLSS VT AADTAVYYCAKLLRS VGGFADWGQG TMVTV SS,DI VMT QSPLSLPVTPGEPA SISC RSSQ TIVH NNGN TYLEWYL QKPGQSP QLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCF QGSHVP FTF GQGT KLEI K
Exlinkibart,Whole mAb,G1,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFAGFEMHWVRQAPGQGLEWMGAIDPKTGGTDYNQKFKDRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDLGYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIRSNLNWYQQKPGGAVKLLIYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQQSEKLPRTFGGGTKVEIR,na,na,None,None,None,2022,na,TNFRSF9,TBC,TBC,TBC,TBC,TBC,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFAGFEMHWVRQ APGQG LEWMGAI DPKTGGTDYNQKFKD RVTM TRDTS ISTAYMELS RLRSDDT AVYYCA RDLGY FDV WGQG TLVTV SS,DI QMT QSPSS LSA SVGD RVTITCR ASQDI RS NLN W YQ QKPGGA VKLLIYYT SRLHSGVPS RF SGSGSGTD YTLTISS LQP EDFAT YFCQ QSEKLPRTFGGGT KVEI R
Ezabenlimab,Whole mAb,G4,Kappa,Phase-II,Active,EVMLVESGGGLVQPGGSLRLSCTASGFTFSKSAMSWVRQAPGKGLEWVAYISGGGGDTYYSSSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARHSNVNYYAMDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATMSCRASENIDVSGISFMNWYQQKPGQAPKLLIYVASNQGSGIPARFSGSGSGTDFTLTISRLEPEDFAVYYCQQSKEVPWTFGQGTKLEIK,na,na,None,None,None,2019,2020,PDCD1,Boehringer Ingelheim,na,Solid tumours;Squamous cell cancer;Colorectal caner;Head and neck cancer;Non-small cell lung cancer,na,na,(June '22: Corrected CDRH3/CDRL3 sequences),E VMLVES GGG LV QPGG SLRLSCT ASGF TFS KSA MSWVR QAPGKG LEWVAYIS GGGGDT YYS SSVK GRFTISR DNAKN SLYLQMNS LRAEDT AVYYCA RHSNV NYYAMD YWGQG TLVTVS S,E IVLTQ SPA TLSL SPGER ATMSCR ASENI DV SG ISFMNWY QQKPGQAP KLLIYVA SNQGSGIP ARFS GSGSGT DFTLTISR LEPED FAVYYCQ QSKEVPW T FGQGT KLEI K
Faricimab,Bispecific mAb,G1;G1,Kappa;Lambda,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSPNPYYYDSSGYYYPGAFDIWGQGTMVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHWVFGGGTKLTVL,1cz8:HL:YX;None,None;None,1bj1:HL:KJ/6bft:AB:HL;4iml:AB:HL/4imk:AD:BC,2017,2018,VEGFA;ANGPT2,Chugai Pharmaceutical;Roche,Diabetic macular oedema;Wet age-related macular degeneration,Diabetic retinopathy;Retinal oedema,na,Dual-Affinity Re-Targeting Technology,,E VQLVES GGG LV QPGG SLRLSCA ASGYDF THYGMNWVR QAPGKGL EWVGWIN TYTGEPT YA ADFKR RFTFSL DTSKS TAYLQMN SLRAEDT AVYYCA KYPYYYGTS HWYFDV WGQG TLVTVS S,DI QLT QSPSS LSA SVGD RVTITCS ASQD ISNYLNWYQ QKPGKAP KVLIYFT SSLHSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ YSTVPW T FGQGT KVEI K
Farletuzumab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGVVQPGRSLRLSCSASGFTFSGYGLSWVRQAPGKGLEWVAMISSGGSYTYYADSVKGRFAISRDNAKNTLFLQMDSLRPEDTGVYFCARHGDDPAWFAYWGQGTPVTVSS,DIQLTQSPSSLSASVGDRVTITCSVSSSISSNNLHWYQQKPGKAPKPWIYGTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSYPYMYTFGQGTKVEIK,na,na,None,None,None,2008,2009,FOLR1,Ludwig Institute for Cancer Research;Morphotek;Eisai Co Ltd,na,Ovarian cancer;Non-small cell lung cancer,Solid tumours,na,,E VQLVES GGG VV QPGR SLRLSCS ASGF TFS G YGLSWVRQ APGKG LEWVAMIS SGGS YTYYA DSVKG RFAISR DNAKN TLFLQM DSLRPEDT GVYFCAR HGDDPA WFAYW GQGT PVTVS S,DI QLT QSPSS LSAS VGD RVTITCSVS SSISSNNL HWYQ QKPGKAPKP WIY GTSNLASGVPS R FSGSGSGT DYTFTISS LQ PEDIA TYYC QQWSSYP YMYTF GQGT KVEI K
Fasinumab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKVSGFTLTELSIHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELTSLRSEDTAVYYCSTIFGVVTNFDNWGQGTLVTVSS,DIQMTQSPSSLSASAGDRVTITCRASQAIRNDLGWYQQKPGKAPKRLIYAAFNLQSGVPSRFSGSGSGTEFTLTISSLQPEDLASYYCQQYNRYPWTFGQGTKVEIK,na,na,None,None,None,2012,2013,NGFB,Mitsubishi Tanabe Pharma Corporation;Regeneron Pharmaceuticals;Teva Pharmaceutical Industries;Sanofi,na,Back pain;Pain,na,VelocImmune Mouse,,Q VQLVQ SGA EVK KPGA SVKVSCKV SG FTLTELSIHWVR QAPGKG LEWMG G F DPEDGE TIYAQKF QG RVTMT EDTSTDT AYMELTSL RSEDT AVYYCSTIFGVVTN FDNWGQG TLVTVS S,DI QMT QSPSS LS ASAGD RVTITCR AS QAIRN DLG W Y QQKPGKAPK RLIYAAFN LQSGVPS RF SGSGSGT EFTLTIS SLQ PEDLASYYCQQ YNRYPWTFGQGT KVEI K
Favezelimab,Whole mAb,G4,Kappa,Phase-II,Active,QMQLVQSGPEVKKPGTSVKVSCKASGYTFTDYNVDWVRQARGQRLEWIGDINPNDGGTIYAQKFQERVTITVDKSTSTAYMELSSLRSEDTAVYYCARNYRWFGAMDHWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCKASQSLDYEGDSDMNWYLQKPGQPPQLLIYGASNLESGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSTEDPRTFGGGTKVEIK,na,na,None,None,None,2019,2020,LAG3,Merck,na,Non-small cell lung cancer;Haematological malignancies;Solid tumours,na,na,Favezelimab is the new name for Mavezelimab (PL123),QM QLVQ SGPEVKKPGT SVKVSCK ASGY TFTD YN VDWVR QARGQ RLEWIGD INPNDGG TIYAQK FQE RVTITVD KSTS TAYMELS SLRSEDT AVYYCA RNY RWFG A M DHWGQG TTVTVS S,DI VMT QTP LSLSV TPGQP ASISCK ASQSLDYEGDSDM NWYL QKPGQPP QLLIYG ASNLESGVPDRFSGSGSGT DFTLKISRVE AED VGVYYCQQ STEDPRTFGGG TKVEI K
Fazpilodemab,Bispecific mAb,G1;G1,Kappa;Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASDFSLTTYGVHWVRQAPGKGLEWLGVIWSGGSTDYNAAFISRLTISKDNSKNTVYLQMNSLRAEDTAVYYCARDYGSTYVDAIDYWGQGTLVTVSS,DIVLTQSPDSLAVSLGERATINCRASESVESYGNRYMTWYQQKPGQPPKLLIYRAANLQSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPWTFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFTSNYISWVRQAPGKGLEWVGEIDPYDGDTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCATGTDVMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYTTPPTFGQGTKVEIK,None;None,None;None,None;None,2022,na,KLB;FGFR1,TBC,TBC,TBC,TBC,TBC,3sob is 94% similar to FGFR1 binding arm,E VQLVES GGG LV QPGG SLRLSCA ASDFS LTTYGVHWVRQ APGKGL EWLGVIWS GGSTDYN AAFISRLTIS KDNSKN TVYLQMNS LRAEDT AVYYCA RDYGST YVDAIDY WGQG TLVTVS S,D IVLT QSPDS LAVS LGER ATINCR ASES VES YGN RYMTWYQ QKPGQPP KLLIYRA ANLQSGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQ QSNEDPW T FGQG TKVEI K
Feladilimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYAMHWVRQAPGQGLEWMGLISIYSDHTNYNQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCGRNNYGNYGWYFDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQAPRLLIYDTSKLASGIPARFSGSGSGTDYTLTISSLEPEDFAVYYCFQGSGYPYTFGQGTKLEIK,na,na,None,None,None,2019,2020,ICOS,GlaxoSmithKline,na,Solid tumours;Multiple myeloma;Non-small cell lung cancer;Head and neck cancer,na,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TFT DY AMHWVRQ APGQGL EWMGLISIY SDHTNYNQ KFQGRVTITA DKSTS TAYMELS SLRSEDT AVYYC GRNNYGNY GWYFDV WGQG TTVTVS S,E IVLTQ SPA TLSL SPGE RATLSCS ASSS VSYMHWYQ QKPGQAP RLLIYD TSKLASGIP ARFS GSGSGTD YTLTISS LEPED FAVYYCF QGSGYPY TF GQGT KLEI K
Felzartamab,Whole mAb,G1,Lambda,Phase-III,Active,QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSGISGDPSNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLPLVYTGFAYWGQGTLVTVSS,DIELTQPPSVSVAPGQTARISCSGDNLRHYYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQTYTGGASLVFGGGTKLTVL,na,na,None,None,None,2019,2020,CD38,MorphoSys,na,Multiple myeloma;Membranous glomerulonephritis;Leukemia;Systemic lupus erythematosus,Non-small cell lung cancer,na,,Q VQLVES GGG LV QPGG SLRLSC AASGF TFSSYYMNWVR QAPGKG LEWVS GISGDPSNT YYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RDLP LVYTGFAYW GQG TLVTVS S,DIELTQPPS VSV APGQ TARISC SGDNLR HYYVYWYQ QKPGQAP VLVIY GDSKRPSGIPERFSGSNSGN TATLTIS GTQAEDEAD YYCQT YTGGA SLVF GGGT KLTV L
Fepixnebart,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDAYINWVRQAPGQGLEWMGWIWPGPVITYYNPKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARREVLSPFAYWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCRSSQSIVHSTGNTYLEWYQQKPGQPPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCFHGTHVPYTFGGGTKVEIK,na,na,5kn5:AB,None,None,2022,na,EREG,Eli Lilly and Company,na,Back pain;Neuropathic pain;Pain;Diabetic nephropathies,na,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TFTD A YINWVR QAPGQGL EWMGWI WPGP VITYY NPKFKG RVTITA DKSTS TAYMELS SLRSEDT AVYYCA RREVLSPF AYW GQGT TVTVS S,D IVMT QSPDS LAVS LGER ATINC RSSQ SIVH STGN TYLEWYQ QKPGQPP KLLIYKVS NRFSGVPDRFSGSGSGT DFTLTISS LQAED VAVYYCF HGTHVP YT FGGG TKVEI K
Fezakinumab,Whole mAb,G1,Lambda,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWVGWINPYTGSAFYAQKFRGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREPEKFDSDDSDVWGRGTLVTVSS,QAVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYGVHWYQQLPGTAPKLLIYGDSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDNSLSGYVFGGGTQLTVL,na,na,None,None,None,2009,2010,IL22,Pfizer;Wyeth,na,na,Psoriasis;Rheumatoid arthritis,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTNYYMHWVR QAPGQG LEWVGWI NPYTGS AFYAQK FRG RVTMT RDTS ISTAYMELSR LRSDDT AVYYCA REPEKFDSDDSDV W GR GTLVTVS S,QA VL TQPPSVSGAPGQ RVTISCT GSSSNIGAGY GVHWYQQ LPGTAP KLLIYG DSNRPSGVPDRFSGSKSGTS AS LAIT GLQAEDEAD YYCQS YDNSLS GYVF GGGT QLTV L
Fianlimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVESGGGVVQPGRSLRLSCVASGFTFSSYGMHWVRQAPGKGLEWVAIIWYDGSNKYYADSVKGRFTISRDNSKNTQYLQMNSLRAEDTAVYYCASVATSGDFDYYGMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERTTLSCRASQRISTYLAWYQQKPGQAPRLLIYDASKRATGIPARFSGSGSGTGFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK,na,na,None,None,None,2019,2020,LAG3,Regeneron Pharmaceuticals,na,Cancer,na,na,,Q VQLVES GGG VV QPGR SLRLSCV ASGF TFSS Y GMHWVRQ APGKGL EWVAIIWY DGSNK YYAD SVKG RFTISR DNSKNT QYLQMNSL RAEDT AVYYCASVA TSGDFD YYGMDV WGQG TTVTVS S,E IVLT QSPA TLSL SPGER TTLSCR ASQR I S TYLAWY QQKPGQAP RLLIYD ASKRATGIP ARFS GSGSGTG FTLTIS SLEPED FAVYYCQ QRSNWP LTF GGG TKVEI K
Ficlatuzumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQPGAEVKKPGTSVKLSCKASGYTFTTYWMHWVRQAPGQGLEWIGEINPTNGHTNYNQKFQGRATLTVDKSTSTAYMELSSLRSEDTAVYYCARNYVGSIFDYWGQGTLLTVSS,DIVMTQSPDSLAMSLGERVTLNCKASENVVSYVSWYQQKPGQSPKLLIYGASNRESGVPDRFSGSGSATDFTLTISSVQAEDVADYHCGQSYNYPYTFGQGTKLEIK,na,na,None,None,None,2011,2012,HGF,AVEO Oncology;AVEO Pharmaceuticals;Dana-Farber Cancer Institute;University of Arizona Cancer Center;University of California at San Francisco,na,Head and neck cancer;Non-small cell lung cancer;Acute myeloid leukaemia;Pancreatic cancer,Lymphoma;Multiple myeloma;Solid tumours;Glioblastoma,na,,QV QLV QPGA EVK KPGT SVKLSCK ASGY TFTTYWMHWVR QAPGQG LEWIGEI NPTNGHTNYNQK F QG RATLTVD KSTS TAYMELSS LRSEDT AVYYCA RNYVGS IFD YWGQG TLLTVS S,D IVMT QSPDS LAM SLGE RVTLNCK ASEN VVSYVSWYQ QKPGQSP KLLIYG ASNRESGVPDRFSGSGSATD FTLTISSV QAEDVADYHCGQSYNYPY T FGQGT KLEI K
Fidasimtamab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-I,Active,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLISAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANHLPFTFGGGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,None;1fvc:DC:BA/1n8z:BA/4hkz:BA/4ub0:HL/5xhg:BA:DC/5xhf:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/6mh2:AB:CD/6oge:ED/7mn8:DC,None;1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC,None;5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,2021,2022,PDCD1;ERBB2,Hanmi Pharmaceutical;Innovent Biologics,na,Solid tumours,na,na,(June '22: Corrected FWL4 sequence in LC1),E VQLVES GGG LV QPGG SLRLSCA ASGFNIKD TYIHWVRQ APGKG LEWVARIY PTNGY TRYA DSVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYCS RWGGDG FYAMD YWGQG TLVTVS S,DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISSWLAWYQ QKPGKAP KLLISA ASSLQSGVPS R FSGSGSGTD FTLTIS SLQ PEDFATYYCQ QANHLP FTF GGGT KVEI K
Figitumumab,Whole mAb,G2,Kappa,Phase-I,Discontinued,EVQLLESGGGLVQPGGSLRLSCTASGFTFSSYAMNWVRQAPGKGLEWVSAISGSGGTTFYADSVKGRFTISRDNSRTTLYLQMNSLRAEDTAVYYCAKDLGWSDSYYYYYGMDVWGQGTTVTVSS,DIQMTQFPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASRLHRGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPCSFGQGTKLEIK,na,na,None,None,None,2008,2009,IGF1R,Pfizer,na,na,Breast cancer;Colorectal cancer;Gastrointestinal cancer;Gynaecological cancer;Multiple myeloma;Non-small cell lung cancer;Prostate cancer;Rheumatoid arthritis;Sarcoma;Small cell lung cancer;Solid tumours,na,,E VQLLES GGG LV QPGG SLRLSCT ASGF TFSSYAMNWVR QAPGKGL EWVSAI SGSGG TTFYA DSVKG RFTISR DNSR TTLYLQMN SLRAEDT AVYYCA KDLGWSDS YYYYYGMDV WGQG TTVTVS S,DIQ MT QFPSS LSA SVGD RVTITCR ASQGIRNDLG WYQ QKPGKAPK RLIYAAS RLHRGVPS R FSGSGSGT EFTLTIS SLQPEDF ATYYCL QHNSYPCSFGQGT KLEI K
Finotonlimab,Whole mAb,G4,Kappa,Phase-III,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYGMSWVRQAPGKRLEWVATISGGGRDTYYSDSVKGRFTISRDNAKNNLYLQMNSLRAEDTAVYYCSRQYGTVWFFNWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASESVDSYGNSFMHWYQQKPGQPPRLLIYAASNQGSGVPARFSGSGSGTDFTLTISSLEPEDFAMYFCQQSKEVPWTFGQGTKVEIK,na,na,None,None,None,2020,2021,PDCD1,Sinocelltech,na,Hepatocellular carcinoma;Heavy and neck squamous cell carcinoma,na,na,,E VQLVES GGG LV KPGG SLRLSC AASGF TFSS YG MSWVR QAPGK RLEWVATIS GGGRDT YYS DSVKG RFTISR DNAKNN LYLQMNS LRAEDT AVYYCS RQYG TVWFFN WGQG TLVTVS S,E IVLTQ SPA TLSL SPGE RATLSCRA SESVDSYGN SFMHWYQ QKPGQPP RLLIYAA SNQGSGVP ARFS GSGSGTD FTLTIS SLE PEDFA MYFC QQSKEVPW T FGQGT KVEI K
Firivumab,Whole mAb,G1,Kappa,Preclinical,Discontinued,QVQLVQSGAEVKMPGSSVKVSCKTSGVFFSSHAISWVRQAPGQGLEWMGGISPMFGTTHYAQKFQGRVTITADQSTTTAYMELTSLTSEDTAVYYCARDGAGSYYPLNWFDPWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASENIWNNLAWYQQKPGQAPRLLISGASTGATGVPSRFRGSGSRTEFTLTISSLQSEDFAIYFCQQYNSWPRTFGPGTKVEIK,na,na,None,None,None,2014,2015,Influenza A HA,Celltrion,na,na,Influenza A virus H1N1 subtype;Influenza A virus H5N1 subtype;Influenza virus infections,na,,Q VQLVQ SGA EVK MPGS SVKVSC KTSG VFF SSH AISWVR QAPGQGL EWM GGISPMFGTT HYAQK FQG RVTITA DQSTT TAYMELTS LTSEDT AVYYCA RDGAGS YY PLN WF DPWGQG TLVTVS S,E IVLT QSPA TLSL SPGE RATLSCR ASEN IWNNLAWYQ QKPGQAP RLLIS GASTGATGVPSRFRGSGSR TEFTLTISS LQSED FAIYFCQ QYNSWPRTFGPGT KVEI K
Fiztasovimab,Whole mAb,G1,Lambda,TBC,Active,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWGWIRQPPGKGLEWIGEINHSGSANSNPSLKSRVTMSVDTSKNQFSLKVSSVTAADTAVYFCARVTRDLEWIPGDYYMDVWGKGTTVTVSS,QSVLTQPPSASGTPGQRVSISCSGSLSNIGTNYVYWYQQLPGTAPKLLIFKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLNGYVFGTGTKVTVL,na,na,None,None,None,2022,na,HHV gB AD-1,TBC,TBC,TBC,TBC,TBC,,QV QLQQW GAGLLKPSE TLSLTCAVY GGSFS GYYWGWIR QPPGKGL EWIGEIN HSGSANSNPSLK SRVTMSVD TSKN QFSLKVSSV TAADT AVYFCARVT RDLE W IPGD YYMDVW GKG TTVTVS S,QSVLTQPPSASGTPGQ RVSISC SGSLSNIGTN YVYWYQ QLPGTAP KLLIFK NNQRPSGVPDRFSGSKSGTS A SLAI SGLRSEDEAD YYCAAW DDSLNG YVF GTGT KVTV L
Flanvotumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVQSGSELKKPGASVKISCKASGYTFTSYAMNWVRQAPGQGLESMGWINTNTGNPTYAQGFTGRFVFSMDTSVSTAYLQISSLKAEDTAIYYCAPRYSSSWYLDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWLMYTFGQGTKLEIK,na,na,None,None,None,2011,2012,TYRP1,ImClone Systems;Eli Lilly,na,na,Malignant melanoma,na,,Q VQLVQ SGS E LKKPGA SVKISCK ASGY TFTSYAMNWVR QAPGQGL ESMGWIN TNTGNPTYAQGF TGRFVFSM DTSV STAYLQISS LKAEDT AIYYC APRYSSS WYLDY WGQG TLVTVS S,E IVLTQ SPA TLSL SPGE RATLSCR ASQS VSSY LAWY QQKPGQAP RLLIYD ASNRATG I P ARF SGSGSGTD FTLTIS SLEPED FAVYYCQ QRSN WLMYTF GQGT KLEI K
Fletikumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKRPGASVKVSCKASGYTFTNDIIHWVRQAPGQRLEWMGWINAGYGNTQYSQNFQDRVSITRDTSASTAYMELISLRSEDTAVYYCAREPLWFGESSPHDYYGMDVWGQGTTVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,na,na,None,None,None,2013,2014,IL20,ZymoGenetics;Novo Nordisk,na,na,Psoriasis;Rheumatoid arthritis,na,,Q VQLVQ SGA EVK RPGA SVKVSCK ASGY TF TND IIHWVR QAPGQ RLEWMGWIN AGYGNTQYSQNFQD RVSITR DTSAST AYMELISLR SEDT AVYYCA REPLWFGESSPHDYY GMDV WGQG TTVTVS S,AI QLT QSPSS LSA SVGD RVTITCR ASQG ISSALAWYQ QKPGKAP KLLIYD ASSLESGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ FNSYP LTF GGGT KVEI K
Flotetuzumab,Bispecific scFv with Crossover,na;na,Kappa;Lambda,Phase-I/II,Discontinued,EVQLVQSGAELKKPGASVKVSCKASGYTFTDYYMKWVRQAPGQGLEWIGDIIPSNGATFYNQKFKGRVTITVDKSTSTAYMELSSLRSEDTAVYYCARSHLLRASWFAYWGQGTLVTVSS,DFVMTQSPDSLAVSLGERVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPYTFGQGTKLEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKDRFTISRDDSKNSLYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPWTPARFSGSLLGGKAALTITGAQAEDEADYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2017,2018,IL3RA;CD3E,MacroGenics;Servier,na,na,Acute myeloid leukaemia;Myelodysplastic syndromes;Precursor cell lymphoblastic leukaemia-lymphoma,Dual-Affinity Re-Targeting Technology,,E VQLVQ SGA EL KKPGA SVKVSCK ASGY TFTDYYMKWVR QAPGQGL EWIGDII PSNGA TFY NQKFKG RVTITVD KSTS TAYMELS SLRSEDT AVYYC ARSHL LRASWFAYW GQG TLVTVS S,DF VMT QSPDS LAVS LGE RVTMSC KSSQS L LNSGNQKN YLTWYQ QKPGQPP KLLIYWAS TRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC QNDYSYPY T FGQGT KLEI K
Fontolizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAELKKPGSSVKVSCKASGYIFTSSWINWVKQAPGQGLEWIGRIDPSDGEVHYNQDFKDKATLTVDKSTNTAYMELSSLRSEDTAVYYCARGFLPWFADWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCKASENVDTYVSWYQQKPGKAPKLLIYGASNRYTGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCGQSYNYPFTFGQGTKVEVK,na,na,None,1t3f:BA/1t04:DC:BA,None,2002,2003,IFNG,PDL BioPharma,na,na,Autoimmune disorders;Crohn's disease;Psoriasis;Rheumatoid arthritis,na,,Q VQLVQ SGA EL KKPGS SVKVSCK ASG YIFT SSW INWVK QAPGQG LEWIGRI DPSDGE VHY NQDFKDK ATLTVD KSTN TAYMELS SLRSEDT AVYYCA RGFLPW F ADWGQG TLVTVS S,DIQ MT QSPS TLSAS VGD RVTITCK ASENVD TYVSWYQ QKPGKAP KLLIYG ASNRYTGVPSRFSGSGSGTD FTLTISS LQPDDF ATYY CGQSYNYPF T FGQGT KVEV K
Foralumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFKFSGYGMHWVRQAPGKGLEWVAVIWYDGSKKYYVDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQMGYWHFDLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPLTFGGGTKVEIK,na,na,None,None,None,2010,2011,CD3E,Medarex;NovImmune SA;Harvard Medical School;Tiziana Life Sciences,na,Crohn's disease;Neurodegenerative disorders;Primary biliary cirrhosis;Inflammatory bowel diseases;Non-alcoholic steatohepatitis;Type 2 diabetes mellitus,Transplant rejection;Type 1 diabetes mellitus,na,,Q VQLVES GGG VV QPGR SLRLSC AASGF KFS G YGMHWVRQ APGKGL EWVAVIWY DGSK KYYVD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAR QMGY WHFDL WGRG TLVTV SS,E IVLTQ SPA TLSL SPGE RATLSCR ASQS VSSYL A W Y QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPED FAVYYCQ QRSNWPPL TF GGG TKVEI K
Foravirumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVESGGGAVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVILYDGSDKFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVAVAGTHFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLNSYPPTFGGGTKVEIK,na,na,None,None,None,2008,2009,RV Antigenic Site III,Crucell;Sanofi Pasteur,na,na,Rabies,Human Phage Display,,Q VQLVES GGGAVQPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKGL EWVAVILY DGSDK FYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAKVAVA GT HFD YWGQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITCR ASQGIRNDLG WYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQ PEDFATYYCQQ LNSYPPTFGGGT KVEI K
Forimtamig,Bispecific mAb with Domain Crossover,G1;G1,Kappa;Lambda,TBC,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDAYINWVRQAPGQGLEWMGWIWPGPVITYYNPKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARREVLSPFAYWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSISGINLMNWYQQKPGQQPKLLIYHASILASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTRESPLTFGQGTRLEIK,EVQLLESGGGLVQPGGSLRLSCAASGFQFSSYAMNWVRQAPGKGLEWVSRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHTTFPSSYVSYYGYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2022,na,GPRC5D;CD3E,TBC,TBC,TBC,TBC,TBC,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TFTD A YINWVR QAPGQGL EWMGWI WPGP VITYY NPKFKG RVTITA DKSTS TAYMELS SLRSEDT AVYYCA RREVLSPF AYW GQGT TVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQ SVSIS G INLMN W Y QQKPGQQP KLLIYHASILA SGIPDRFSGSGSGTD FTLTISR LEPED FAVYYCQ QTRESPL T FGQG TRLEI K
Fremanezumab,Whole mAb,G2,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWISWVRQAPGKGLEWVAEIRSESDASATHYAEAVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLAYFDYGLAIQNYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCKASKRVTTYVSWYQQKPGQAPRLLIYGASNRYLGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCSQSYNYPYTFGQGTKLEIK,na,na,None,None,None,2016,2017,CALCA&CALCB,Rinat Neuroscience;Teva Pharmaceutical Industries,Migraine,Fibromyalgia;Headache;Interstitial cystitis,Cluster headache,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TF S NYWISWVR QAPGKG LEWVAEIR SESDASAT HYAE A V KG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCLAYF DY GL AIQ NYWGQG TLVTV SS,E IVLTQ SPA TLSL SPGE RATLSCK ASKR VTTYVSWYQ QKPGQAP RLLIYG ASNR YLGI P ARF SGSGSGT DFTLTIS SLEPED FAVYYCS QSYNYPY T FGQGT KLEI K
Freneslerbart,Whole mAb,G4,Kappa,TBC,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFRNYNINWVRQAPGKGLEWVSLISGSSSYIYYADSVKGRFTVSRDNAKNSLYLQMNSLRAEDTAVYYCARRTLSYYVMDVWGQGTTVTVSS,DIQVTQSPSPLSASVGDRVTITCRASQGISNYLAWYQQKPGRVPQLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQKYNSAPYTFGQGTKLEIK,na,na,None,None,None,2022,na,Fel d 1,TBC,TBC,TBC,TBC,TBC,Antigen: Felis silvestris catus (domestic cat) allergen 1,E VQLVES GGG LV KPGG SLRLSC AASGF TFRNYNINWVR QAPGKGL EWVSLI SGSSS YIYYA DSVKG RFTVSR DNAKN SLYLQMN SLRAEDT AVYYCA RRT LSYYVMDV WGQG TTVTVS S,DI QVT QSPSPLSASVGD RVTITCR ASQG ISNYLAWYQ QKPGRVP QLLIYA ASTLQSGVPS R FSGSGSGTD FTLTIS SLQ PEDVATYYCQK YNSAPY T FGQGT KLEI K
Fresolimumab,Whole mAb,G4,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVRQAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADESTSTTYMELSSLRSEDTAVYYCASTLGLVLDAMDYWGQGTLVTVSS,ETVLTQSPGTLSLSPGERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYADSPITFGQGTRLEIK,na,na,None,3eo0:DC:BA/4kxz:JI:HL:NM:QP/4kv5:EF:GK:HL:JI/3eo1:BA:ED:KJ:HG,None,2009,2010,TGFB,Cambridge Antibody Technology;Baylor College of Medicine;Genzyme Corporation;Sanofi Genzyme,na,na,Fibrosis;Malignant melanoma;Pulmonary fibrosis;Renal cancer;Focal segmental glomerulosclerosis;Osteogenesis imperfecta,CAT Phage Display,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TF SSN VISWVR QAPGQGL EWM GG VIPI VDIANYAQR FKG RVTITA DESTST TYMELS SLRSEDT AVYYC ASTL GL V LDAMD YWGQG TLVTV SS,ET VLT QSPG TLSL SPGE RATLSCRA SQSLGSS YLAWYQ QKPGQAP RLLIYG ASSRAPGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQ QYADSPI TF GQGT RLEI K
Frexalimab,Whole mAb,G1,Kappa,TBC,Active,EVQLQESGPGLVKPSETLSLTCTVSGDSITNGFWIWIRKPPGNKLEYMGYISYSGSTYYNPSLKSRISISRDTSKNQFSLKLSSVTAADTGVYYCAYRSYGRTPYYFDYWGQGTTLTVSS,DIVMTQSPSFLSASVGDRVTITCKASSNLGHAVAWYQQKPGKSPKLLIYSASNRYTGVPDRFSGSGSGTDFTLTISSLQPEDFADYFCQQYDDYPYTFGGGTKLEIK,na,na,None,None,None,2022,na,CD40LG,TBC,TBC,TBC,TBC,TBC,,E VQLQE SGPGL V KPSE TLSLTCTVS GDSITN GFWIWIR KPPGNK LEYMGYISY SGS TYY NPSLK SRISIS RDTSKN QFSLKLSSVT AADTG VYYCAYR SYGRTP YYFDY WGQG TTLTVS S,DI VMT QSPS FLSA SVGD RVTITCK ASSNLG H AVAWYQ QKPGKSP KLLIYS ASNRYTGVPDRFSGSGSGTD FTLTIS SLQ PEDFADYFCQQ YDDYPY T FGGGT KLEI K
Frovocimab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFPFSKLGMVWVRQAPGKGLEWVSTISSGGGYTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGISFQGGTYTYVMDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSKSLLHRNGITYSYWYLQKPGQSPQLLIYQLSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCYQNLELPLTFGQGTKVEIK,na,na,None,None,None,2018,2019,PCSK9,Eli Lilly,na,Hypercholesterolaemia,na,na,,E VQLVES GGG LV KPGG SLRLSCA ASGFPFSK LGMVWVRQ APGKG LEWVSTIS SGGG YTY YPDSVK GRFTISR DNAKNS LYLQMN SLRAEDT AVYYCA REGI SF QGG TYTYVMDY WGQG TLVTVS S,DI VMT QSPLSLPVTPGEPA SISCR SSKS LLH RNG ITYSYWYLQ KPGQSP QLLIYQL SNLASGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCYQ NLELPL TF GQGT KVEI K
Frunevetmab,Feline Whole mAb,G1,Kappa,Unknown,Active,QVQLVESGAELVQPGESLRLTCAASGFSLTNNNVNWVRQAPGKGLEWMGGVWAGGATDYNSALKSRLTITRDTSKNTVFLQMHSLQSEDTATYYCARDGGYSSSTLYAMDAWGQGTTVTVSA,DIEMTQSPLSLSVTPGESVSISCRASEDIYNALAWYLQKPGRSPRLLIYNTDTLHTGVPDRFSGSGSGTDFTLKISRVQTEDVGVYFCQHYFHYPRTFGQGTKLELK,na,na,None,None,None,2016,2017,NGFB,Nexvet,na,Feline osteoarthritis,na,PETization Technology,,Q VQLVE SGA ELV QPGE SLRLTCA ASGF S LTNNN VNWVRQ APGKG LEWM GG VWA GGATDYNSALK SRLTITR DTSKN TVFLQMHS LQSEDT ATYYCA RDGGYSSS TLYAMD AWGQG TTVTVS A,DIEMTQSPL SLSV TPGE SVSISCR AS EDIYNALAWYLQ KPGRSP RLLIYN TDTL H TGVPDRFSGSGSGTD FTLKISRVQ TEDV GVYFCQHYFH YPRTFGQGT KLEL K
Fulranumab,Whole mAb,G2,Kappa,Phase-III,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTLRSYSMNWVRQAPGKGLEWVSYISRSSHTIFYADSVKGRFTISRDNAKNSLYLQMDSLRDEDTAMYYCARVYSSGWHVSDYFDYWGQGILVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,na,na,None,4m6o:HL,None,2010,2011,NGFB,Janssen Pharmaceuticals;Janssen Research & Development;Takeda;Amgen,na,na,Pain;Back pain;Cancer pain;Musculoskeletal pain;Neuropathic pain,Abgenix XenoMouse,,E VQLVES GGG LV QPGG SLRLSC AASGF TLRSYSMNWVR QAPGKGL EWVSYIS RSSH TIFYA DSVKG RFTISR DNAKN SLYLQMD SLRDEDTA MYYCARVY SSGW HV SDY F DYWGQ GILVTVS S,AI QLT QSPSS LSA SVGD RVTITCR ASQG ISSALAWYQ QKPGKAP KLLIYD ASSLESGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ FNSYP LTF GGGT KVEI K
Futuximab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLQQPGSELVRPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGNIYPGSRSTNYDEKFKSKATLTVDTSSSTAYMQLSSLTSEDSAVYYCTRNGDYYVSSGDAMDYWGQGTSVTVSS,DIQMTQTTSSLSASLGDRVTISCRTSQDIGNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDFSLTINNVEQEDVATYFCQHYNTVPPTFGGGTKLEIK,na,na,None,None,None,2012,2013,EGFR,Symphogen;Merck,na,Colorectal cancer;Glioma;Non-small cell lung cancer,Head and neck cancer;Oesophageal cancer,na,,EV QLQ QPGS ELV RPGA SVKLSCK ASGY TFTSYWMHWVK QRPGQG LEWIGNI YPGSRSTNYDEKFKS KATLTVD TSSST AYMQLS SLTSEDS AVYYCT RNGD YYVSS GDAMDYWGQG TSVTVS S,DIQ MT QTTS SLS ASLGD RVTISCR TS QDIGNYLNWYQ QKPDGT VKLLIYYT SRLHSGVPSRFSGSGSGTD FSLTI NNVE QEDVATYFCQH YNTVPPTFGGGT KLEI K
Galcanezumab,Whole mAb,G4,Kappa,Approved,NFD,QVQLVQSGAEVKKPGSSVKVSCKASGYTFGNYWMQWVRQAPGQGLEWMGAIYEGTGKTVYIQKFADRVTITADKSTSTAYMELSSLRSEDTAVYYCARLSDYVSGFGYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASKDISKYLNWYQQKPGKAPKLLIYYTSGYHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDALPPTFGGGTKVEIK,na,na,None,None,None,2015,2016,CALCA&CALCB,Eli Lilly,Migraine;Cluster headache,na,Musculoskeletal pain,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TF GN YWMQWVR QAPGQG LEWMGAIYE GTGK TVYIQK FAD RVTITA DKSTS TAYMELS SLRSEDT AVYYCAR LSDYVSGFGYWGQG TTVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASKD ISKYLNWYQ QKPGKAP KLLIYYT SGYHSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATY YC QQGDALPPTFGGGT KVEI K
Galegenimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGASVKVSCKASGYKFTDSEMHWVRQAPGQGLEWIGGVDPETEGAAYNQKFKGRATITRDTSTSTAYLELSSLRSEDTAVYYCTRGYDYDYALDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASSSVEFIHWYQQKPGKAPKPLISATSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSSAPWTFGQGTKVEIK,na,na,None,None,None,2021,2022,HTRA1,Roche,na,Age-related macular degeneration,na,na,,E VQLVQ SGA EVK KPGA SVKVSCK ASGY KF TDSE MHWVRQ APGQG LEWI GGVDPETEGAAYNQKFKG RATITR DTSTS TAYLELS SLRSEDT AVYYCT RGYDYD YALDY WGQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITCR ASSS VEFIHWYQ QKPGKAPKP LISA TSNLASGVPS R FSGSGSGT DFTLTISS LQPE DF ATYYCQ QWSSAPW TF GQGT KVEI K
Galiximab,Whole mAb,G1,Lambda,Phase-II,Discontinued,QVQLQESGPGLVKPSETLSLTCAVSGGSISGGYGWGWIRQPPGKGLEWIGSFYSSSGNTYYNPSLKSQVTISTDTSKNQFSLKLNSMTAADTAVYYCVRDRLFSVVGMVYNNWFDVWGPGVLVTVSS,ESALTQPPSVSGAPGQKVTISCTGSTSNIGGYDLHWYQQLPGTAPKLLIYDINKRPSGISDRFSGSKSGTAASLAITGLQTEDEADYYCQSYDSSLNAQVFGGGTRLTVL,na,na,None,None,None,2003,2004,CD80,Biogen;Biogen Idec,na,na,Autoimmune disorders;Non-Hodgkin's lymphoma;Psoriasis,na,,QV QLQ ESGPGL V KPSE TLSLTCAV SGGSISGG YGWGWIR QPPGKGL EWIGSFY SSSGN TYY NPSLKS QVTIST DTSKN QFSLKL NSMTAADT AVYYCV RDRL FSVVGMVY NNW FDVW GPG VLVTVS S,ESALTQPPSVSGAPGQ KVTISC TGSTSNIGG YD LHWYQ QLPGTAP KLLIYD INKRPSGISDRFSGSKSGT AAS LAI TGLQTEDEAD YYCQ SYDSSLN AQVF GGGT RLTV L
Gancotamab,scFv,na,Lambda,Phase-II,Discontinued,QVQLVESGGGLVQPGGSLRLSCAASGFTFRSYAMSWVRQAPGKGLEWVSAISGRGDNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKMTSNAFAFDYWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYGVHWYQQLPGTAPKLLIYGNTNRPSGVPDRFSGFKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,na,na,None,None,None,2018,2019,ERBB2,Merrimack Pharmaceuticals;HERMES BioSciences,na,na,Breast cancer,na,,Q VQLVES GGG LV QPGG SLRLSC AASGF TFRSYAMSWVR QAPGKG LEWVSAI SGRGDN TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAK MTSNA FAFDY WGQG TLVTVS S,QSVLTQPPSVSGAPGQ RVTISCT GSSSNIGAGY GVHWYQQ LPGTAP KLLIYG NTNRPSGVPDRFSGFKSGTS A SLAIT GLQAEDEAD YYCQS YDSSLSG WVF GGGT KLTV L
Ganitumab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARWTGRTDAFDIWGQGTMVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGQGTKVEIK,na,na,None,None,None,2010,2011,IGF1R,Amgen;Millennium;NantWorks;National Cancer Institute (USA);Novartis;Takeda;Takeda Oncology;UCLAs Jonsson Comprehensive Cancer Center,na,Ewing's sarcoma;Solid tumours;Rhabdomyosarcoma,Breast cancer;Colorectal cancer;Sarcoma;Small cell lung cancer;Non-small cell lung cancer;Pancreatic cancer;Prostate cancer,na,,QV QLQE SGPG LV KPSG TLSLTCAV SGGSISSSN WWSWVR QPPGKGL EWIGEIYH SGSTNYNPSLK SRVTISVD KSKN QFSLKLSSV TAADT AVYYCARW TGRTDA FDIW GQG TMVTVS S,DV VMT QSPLSLPVTPGEPA SISC RSSQS LLH SNGYN YLDWYL QKPGQSP QLLIYL GSNRASGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCM QGTHWP LTF GQGT KVEI K
Gantenerumab,Whole mAb,G1,Kappa,Phase-III,Active,QVELVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINASGTRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGKGNTHKPYGYVRYFDVWGQGTLVTVSS,DIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGVPARFSGSGSGTDFTLTISSLEPEDFATYYCLQIYNMPITFGQGTKVEIK,na,na,5csz:HL:AB,None,None,2012,2008,APP,MorphoSys;Chugai Pharmaceutical;Roche,na,Alzheimer's disease,na,na,,Q VELVE SGGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKGL EWVSAI NASGT RTYYA DSVKG RFTISR DNSKN TLYLQMN SLRAED TAVYYCA RGKGNTHKPY GYVRYFDV WGQG TLVTVS S,D IVLTQ SPA TLSL SPGE RATLSCR ASQSVSS S YLAWYQ QKPGQAP RLLIYG ASSRATGVP ARFS GSGSGT DFTLTIS SLE PEDFAT YYCLQIY NMP ITF GQGT KVEI K
Garadacimab,Whole mAb,G4,Lambda,Phase-III,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSKYIMQWVRQAPGKGLEWVSGIDIPTKGTVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARALPRSGYLISPHYYYYALDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGRNYVYWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDASLRGVFGGGTKLTVL,na,na,None,None,None,2018,2019,F12,CSL Behring,na,Hereditary angioedema;COVID-19,na,na,,E VQLLES GGG LV QPGG SLRLSC AASGF TF SKY IMQWVR QAPGKGL EWV SGI D IPTKG TVYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAR ALPRSG YLI SPH YYYYALDV WGQG TTVTVS S,QSVLTQPPSASGTPGQ RVTISC SGSSSN IGRNYVYWYQQ LPGTAP KLLIYS NNQRPSGVPDRFSGSKSGT SASLAI SGLRS EDEADYYCAAWDASLRGV FGGGT KLTV L
Garetosmab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSFSSHFWSWIRQPPGKGLEWIGYILYTGGTSFNPSLKSRVSMSVGTSKNQFSLKLSSVTAADTAVYYCARARSGITFTGIIVPGSFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,None,None,None,2018,2019,INHBA,Regeneron Pharmaceuticals,na,Fibrodysplasia ossificans progressiva;Osteroporosis,Musculoskeletal disorders,na,,QV QLQE SGPGL V KPSE TLSLTCTV SGGSFS SHFWSWIR QPPGKGL EWIGYILYT GGTSFNPSLK SRVSMSV GTSKN QFSLKLSS VTAADT AVYYCAR ARSG ITFTGIIV PGS FDIW GQG TMVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSS S YLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYC Q QYGSSPWTFGQGT KVEI K
Garivulimab,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLRLSCAVSGFSLTSYGVHWVRQAPGKGLEWVAVIWAGGSTNYADSVKGRFTISKDTSKNTVYLQMNSLRAEDTAVYYCAKPYGTSAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVGIVVAWYQQKPGKAPKLLIYWASIRHTGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYSNYPLYTFGQGTKVEIK,na,na,None,None,None,2020,2021,CD274,BeiGene,na,Solid tumours,na,na,,E VQLVES GGG LV QPGG SLRLSCAV SGF SLTSYGVHWVRQ APGKGL EWVAVIWA GGSTNYADSVK GRFTISK DTSKN TVYLQMNS LRAEDT AVYYCA KPYGTSAMDYWGQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITCK ASQD VGIVVAWYQ QKPGKAP KLLIYWASIR HTGVPSRFSGSGSGT EFTLTISS LQPDDF ATYYCQ QYSNYP LYTF GQGT KVEI K
Gatipotuzumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSMRLSCVASGFPFSNYWMNWVRQAPGKGLEWVGEIRLKSNNYTTHYAESVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCTRHYYFDYWGQGTLVTVSS,DIVMTQSPLSNPVTPGEPASISCRSSKSLLHSNGITYFFWYLQKPGQSPQLLIYQMSNLASGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCAQNLELPPTFGQGTKVEIK,na,na,None,None,None,2016,2017,MUC1,NEMOD Biotherapeutics;Glycotope,na,Ovarian cancer;Solid tumours;Fallopian tube cancer,na,GlycoExpress Technology,Gatipotuzumab and PankoMab are the same mAb,E VQLVES GGG LV QPGGS MRLSCVA SGFPFSNY WMNWVR QAPGKGL EWVGEIRLK SNNY TTHYAES VKG RFTISR DDSKNS LYLQMN SLKTEDT AVYYCT R HYYFD YWGQG TLVTVS S,D IVMT QSPLSNPVTPGEPA SISCR SSK SLLH SNG ITYFFWYL QKPGQSP QLLIYQM SNLASGVPDRFSGSGSGT DFTLRISRVE AEDV GVYYCAQ NLELPPTFGQGT KVEI K
Gatralimab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFPFSNYWMNWVRQAPGKGLEWVGQIRLKSNNYATHYAESVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCTPIDYWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCKSSQSLLYSNGKTYLNWVLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCVQGSHFHTFGQGTKLEIK,na,na,6obd:HL:BA,None,None,2019,2020,CD52,Sanofi,na,na,Multiple sclerosis,na,,E VQLVES GGG LV QPGG SLRLSCA ASGFPFSN YWMNWVR QAPGKGL EWVGQIRLK SNNYA THYAES VKG RFTISR DDSKNS LYLQMN SLKTEDT AVYYCT PIDYWGQG TTVTVS S,DI VMT QTP LSLSV TPGQP ASISC KSSQ SLLYS NGK TYLNWVLQ KPGQSPQ RLIYLVSK LDSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCVQ GS HFHT FGQGT KLEI K
Gedivumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGVVQPGKSLRLSCAASGLTFSSYAVHWVRQAPGKGLEWVTLISYDGANQYYADSVKGRFTISRDNSKNTVYLQMNSLRPEDTAVYYCAVPGPVFGIFPPWSYFDNWGQGILVTVSS,EIVLTQSPATLSVSPGERATLSCRASQVISHNLAWYQQKPGQAPRLLIYGASTRASGIPARFSGSGSGTDYTLTITSLQSEDFAVYYCQHYSNWPPRLTFGGGTKVEIK,na,na,None,None,4kvn:HL,2016,2017,Influenza A HA,Genentech,na,na,Influenza A virus infections,na,,E VQLVES GGG VV QPGK SLRLSC AASGL TFSSYAVHWVRQ APGKGL EWVTLISY DGANQ YYA DSVKG RFTISR DNSKN TVYLQMN SLRPEDT AVYYCA VPGP VFGI FPPWSYFDNWGQ GILVTVS S,E IVLT QSPA TLSV SPGE RATLSCR ASQ VISH N LAW Y QQKPGQAP RLLIYG ASTRASGIP ARFS GSGSGTD YTLTITS LQSED FAVYYCQ HYSNWPPR LTF GGG TKVEI K
Gefurulimab,Bispecific Single Domains (VH-VH'),,na;na,Phase-I,Active,EVQLVESGGGLVKPGGSLRLSCAASGRPVSNYAAAWFRQAPGKEREFVSAINWQKTATYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAAVFRVVAPKTQYDYDYWGQGTLVTVSS,na,EVQLVESGGGLVQPGGSLRLSCAASGRAHSDYAMAWFRQAPGQEREFVAGIGWSGGDTLYADSVRGRFTNSRDNSKNTLYLQMNSLRAEDTAVYYCAARQGQYIYSSMRSDSYDYWGQGTLVTVSS,na,None;None,None;None,None;None,2022,na,C5;ALB,Alexion Pharmaceuticals,na,Myasthenia gravis;Proteinuria,na,na,,E VQLVES GGG LV KPGG SLRLSC AASGRPVS NYAAAWF R QAPGKER EFVSAIN WQKTA TY ADSVK GRFTISR DNAKN SLYLQMNS LRAEDT AVYYCAAVFRVV APKTQYDYD Y WGQG TLVTVS S,NA
Gemtuzumab,Whole mAb ADC,G4,Kappa,Approved,NFD,EVQLVQSGAEVKKPGSSVKVSCKASGYTITDSNIHWVRQAPGQSLEWIGYIYPYNGGTDYNQKFKNRATLTVDNPTNTAYMELSSLRSEDTAFYYCVNGNPWLAYWGQGTLVTVSS,DIQLTQSPSTLSASVGDRVTITCRASESLDNYGIRFLTWFQQKPGKAPKLLMYAASNQGSGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQTKEVPWSFGQGTKVEVK,na,na,None,None,None,2016,2017,CD33,UCB;Celgene Corporation;Pfizer;University of California San Diego,Acute myeloid leukaemia,na,na,na,,E VQLVQ SGA EVK KPGS SVKVSCK ASGY TIT DSN IHWVRQ APGQS LEWIGYIY PYNGGTDYNQKFKN RATLTV DNPTNT AYMELS SLRSEDT AFYYCV NGNP WLAYW GQG TLVTV SS,DI QLT QSPS TLSAS VGD RVTITCRA SESLDNY GIRFLTWFQ QKPGKAP KLLMYAA SNQGSGVPS RF SGSGSGT EFTLTISS LQPDDF ATYYCQ QTKEVPWSFGQGT KVEV K
Geptanolimab,Whole mAb,G4,Kappa,Preregistration,Active,QIQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLKWMGWISGYTREPTYAADFKGRFVISLDTSVSTAYLQISSLKAEDTAVYYCARDVFDYWGQGTLVTVSS,DIVLTQSPASLAVSPGQRATITCRASESVDNYGYSFMNWFQQKPGQPPKLLIYRASNLESGVPARFSGSGSRTDFTLTINPVEADDTANYYCQQSNADPTFGQGTKLEIK,na,na,None,None,None,2020,2021,PDCD1,Genor Biopharma;Appolomics,na,Peripheral T-cell lymphoma;Primary mediastinal B-cell lymphoma;Hepatocellular carcinoma,Lymphoma;Solid tumours,na,,Q IQLVQ SGS E LKKPGA SVKVSCK ASGY TFTNFGMNWVRQ APGQGL KWMGWIS GYTREPT YAA DFKG RFVISL DTSVS TAYLQISS LKAEDT AVYYCA RDVFDYWGQG TLVTV SS,D IVLTQ SPA SLAV SPGQ RATITCRA SESVDNYG YSFMNWF QQKPGQPP KLLIYRA SNLESGVP ARF SGSGSRT DFTLTIN PVEADDTA NYYCQQ SNADPTFGQGT KLEI K
Gevokizumab,Whole mAb,G2,Kappa,Phase-III,Active,QVQLQESGPGLVKPSQTLSLTCSFSGFSLSTSGMGVGWIRQPSGKGLEWLAHIWWDGDESYNPSLKSRLTISKDTSKNQVSLKITSVTAADTAVYFCARNRYDPPWFVDWGQGTLVTVSS,DIQMTQSTSSLSASVGDRVTITCRASQDISNYLSWYQQKPGKAVKLLIYYTSKLHSGVPSRFSGSGSGTDYTLTISSLQQEDFATYFCLQGKMLPWTFGQGTKLEIK,na,na,4g6k:HL/4g6m:HL,None,None,2010,2011,IL1B,IRIS;National Eye Institute;North Shore-Long Island Jewish Health System;Novartis;Servier;University of Zurich;XOMA,na,Uveitis;Acne vulgaris;Acute coronary syndromes;Diabetic nephropathies;Giant cell arteritis;Labyrinthitis;Myositis;Osteoarthritis;Schnitzler syndrome;Scleritis;Colorectal cancer;Renal cell carcinoma,Rheumatoid arthritis;Cancer;Gout;Juvenile rheumatoid arthritis;Type 1 diabetes mellitus;Type 2 diabetes mellitus;Pyoderma,na,,Q VQLQE SGPGLVKPSQ TLSLTCSF SG FSLS TSGM GVGWIR QPSGKGL EWLAHIWW DGDESYNPSLK SRLTIS KDTSKN QVSLKITSVT AADT AVYFCA RNRYDPPW FVD WGQG TLVTVS S,DI QMT QSTS SLSAS VGD RVTITCR ASQD ISNYLSWYQ QKPGK AVKLLIYYT SKLHSGVPS R FSGSGSGTD YTLTISS LQQEDF ATYFCL QGK M LPW T FGQGT KLEI K
Giloralimab,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLQESGPGLVKPSETLSLTCTVSGYSITSNYYWNWIRQPPGKGLEWMGYIRYDGSNNYNPSLKNRVTISRDTSKNQFSLKLSSVTAADTAVYYCARLDYWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSQSLENTNGNTFLNWYLQKPGQSPQLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQVTHVPFTFGQGTKLEIK,na,na,None,None,None,2019,2020,CD40,AbbVie,na,Solid tumours,na,na,,E VQLQE SGPGL V KPSE TLSLTCTV SG YSI TSN YYWNWIR QPPGKGL EWMGYIRY DGSNNYNPSLKN RVTISR DTSKN QFSLKLSS VTAADT AVYYCARLD YWGQG TTVTVS S,DI VMT QTP LSLSV TPGQP ASISCR SSQSL E NTNGN TFLNWYL QKPGQSP QLLIYRVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCLQVTHV PF T FGQG TKLEI K
Gilvetmab,Canine Whole mAb,G2,Kappa,Unknown,Active,EVQLVQSGGDLVKPGGSVRLSCVASGFNIKNTYMHWVRQAPGKGLQWIGRIAPANVDTKYAPKFQGKATISADTAKNTAYMQLNSLRAEDTAVYYCVLIYYDYDGDIDVWGQGTLVTVSS,DIVMTQTPLSLSVSLGEPASISCHASQNINVWLSWYRQKPGQIPQLLIYKASHLHTGVPDRFSGSGSGTDFTLRISRVEADDAGVYYCQQGQSWPLTFGQGTKVEIK,na,na,None,None,None,2016,2017,PDCD1 (Canine),Merck,na,Canine Cancers,na,na,,E VQLVQ SGGD LV KPGG SVRLSCVA SGFNIKNT YMHWVRQ APGKG LQWIGRI APANVDTKYAPKFQG KATISA DTAKN TAYMQLNSL RAEDTA VYYCVLIYY DYDGD IDVWGQGTLVTV SS,DI VMT QTPL SLSVS LGEP ASISCH ASQN INVWLSWY RQKPGQIP QLLIYK ASHLHTGVPDRFSGSGSGTD FTLRISRVE ADDAG VYYCQ QGQ S WP LTF GQGT KVEI K
Gimsilumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRHWMHWLRQVPGKGPVWVSRINGAGTSITYADSVRGRFTISRDNANNTLFLQMNSLRADDTALYFCARANSVWFRGLFDYWGQGTPVTVSS,EIVLTQSPVTLSVSPGERVTLSCRASQSVSTNLAWYQQKLGQGPRLLIYGASTRATDIPARFSGSGSETEFTLTISSLQSEDFAVYYCQQYDKWPDTFGQGTKLEIK,na,na,None,None,None,2017,2018,CSF2,Ludwig Institute for Cancer Research;Morphotek,na,na,Cancer;Rheumatoid arthritis,MORPHODOMA Technology,,E VQLVES GGG LV QPGG SLRLSC AASGF TFS RH W M HW LR QVPGKGP VWVSRI NGAGT SITYA DSVRG RFTISR DNANN TLFLQMN S L RADDT ALYFCAR ANS VWFR G LF DYWGQGTP VTV SS,E IVLT QSP VTLSV SPGE RVTLSCR ASQS VSTNLAWYQQK LGQGP RLLIYG ASTRATDIP ARF SGSGSE TEFTLTISS LQSED FAVYYCQQ YDKWPDTFGQGT KLEI K
Ginisortamab,Whole mAb,G4,Kappa,Phase-I/II,Active,QVQLVESGAEVKKPGATVKISCKVSGYTFTDYYMHWVQQAPGKGLEWMGLVDPEDGETIYAEKFQGRVTITADTSTDTAYMELSSLRSEDTAVYYCATDARGSGSYYPNHFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYFCQQYYDTPTFGQGTRLEIK,na,na,None,None,None,2021,2022,GREM1,UCB,na,Solid tumours,na,na,,Q VQLVE SGA EVK KPGA TVKISCKV SGY TFTDYYMHWVQ QAPGKG LEWMGLV DPEDGE TIYAEKF QG RVTITA DTSTDT AYMELSS LRSEDT AVYYCAT DARGSGSYYPNHFD Y WGQG TLVTV SS,D IVMT QSPDS LAVS LGE RATINC KSSQ SVLYS SNNK NYLAWYQ QKPGQPP KLLIYWAS TRESGVPDRFSGSGSGTD FTLTIN SLQAED VAVYFCQQY YDTPTFGQG TRLEI K
Girentuximab,Whole mAb Radiolabelled,G1,Kappa,Phase-III,Discontinued,DVKLVESGGGLVKLGGSLKLSCAASGFTFSNYYMSWVRQTPEKRLELVAAINSDGGITYYLDTVKGRFTISRDNAKNTLYLQMSSLKSEDTALFYCARHRSGYFSMDYWGQGTSVTVSS,DIVMTQSQRFMSTTVGDRVSITCKASQNVVSAVAWYQQKPGQSPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADFFCQQYSNYPWTFGGGTKLEIK,na,na,None,None,None,2009,2010,CA9,Centocor Inc;Heidelberg Pharma AG,na,na,Renal cancer,na,,D VKLVE SGGG LVKL GG SLKLSC AASGF TFSNYYMSWVR QTPEKR LELVAAI NSDGG ITYYLD TVKG RFTISR DNAKN TLYLQMS SLKSEDT ALFYCA RHRSG YFSMDY WGQG TSVTVS S,DI VMT QSQ RFMST TVGD RVSITCK ASQN VVSAVAWYQ QKPGQSP KLLIYS ASNRYTGVPDRFTGSGSGTD FTLTIS NMQS EDLADFFCQQ YSNYPWTFGGGT KLEI K
Glembatumumab,Whole mAb ADC,G2,Kappa,Phase-III,Discontinued,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSFNYYWSWIRHHPGKGLEWIGYIYYSGSTYSNPSLKSRVTISVDTSKNQFSLTLSSVTAADTAVYYCARGYNWNYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVDNNLVWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPWTFGQGTKVEIK,na,na,None,None,None,2015,2016,GPNMB,CuraGen Corporation;Celldex Therapeutics Inc;National Cancer Institute (USA),na,na,Brain cancer;Breast cancer;Malignant melanoma;Osteosarcoma;Squamous cell cancer;Uveal melanoma,na,,QV QLQE SGPGLVKPSQ TLSLTCTV SGGSIS SFNYYWSWIR HHPGKGL EWIGYIYYS GSTYSNPSLK SRVTISVD TSKN QFSLTLSS VTAADT AVYYCA RGYNWN YF DYWGQG TLVTVS S,E IVMT QSPA TLSV SPGER ATLSCRA SQSVDNN LVWYQ QKPGQAP RLLIYG ASTRATGIP ARFS GSGSGT EFTLTISS LQSED FAVYYCQQ YNNWPPWTFGQGT KVEI K
Glenzocimab,Fab,G1,Kappa,Phase-II/III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGGIYPGNGDTSYNQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGTVVGDWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQSLENSNGNTYLNWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQLTHVPWTFGQGTKVEIT,na,na,None,None,None,2018,2019,GP6,Acticor Biotech,na,Stroke;COVID-19,na,na,(June '22: Corrected FWL3 sequence),Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYNMHWVRQ APGQG LEWMGGI YPGNGDTSYNQK FQGRVTMTR DTSTS TVYMELS SLRSEDT AVYYC ARG TVV GD WYFDV WGQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITCR SSQSL E NSNGN TYLNWYQ QKPGKAP KLLIYRVS NRFSGVPS R FSGSGSGT DFTFTISS LQPEDI ATYYCLQLTH VPWTFGQGT KVEI T
Glofitamab,Bispecific mAb with Domain Crossover,G1;G1,Lambda;Kappa,Preregistration,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVSRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNLWVFGGGTKLTVL,QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS,DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIK,None;3pp3:HL/3pp4:HL,None;6y9a:HL,None;6y97:HL,2019,2020,CD3E;MS4A1,Roche,na,Diffuse large B cell lymphoma;Follicular lymphoma;Non-Hodgkin's lymphoma,na,na,,E VQLLES GGG LV QPGG SLRLSC AASGF TFSTYAMNWVR QAPGKGL EWVSRI R SKYNNY ATYYA DSVKG RFTISR DDSKN TLYLQMNS LRAEDT AVYYCVR HGNFGNS YVSWFAYW GQG TLVTVS S,QA VVT QEP SLTV SPGG TVTLTC GSSTGA VTT SN YANWV QEKPGQA FRGLI GGTNKRAPGTPA RFS G SL LGGK AALTL SGAQPEDEA E YYCALWY SN LWVF GGGT KLTV L
Golimumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVESGGGVVQPGRSLRLSCAASGFIFSSYAMHWVRQAPGNGLEWVAFMSYDGSNKKYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGIAAGGNYYYYGMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVYSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPFTFGPGTKVDIK,na,na,5yoy:RO:IF:QN:GD:HE:PM,None,None,2004,2005,TNFA,Centocor;Centocor Ortho Biotech;Janssen Biotech;Merck & Co;Mitsubishi Tanabe Pharma Corporation;Medarex,Ankylosing spondylitis;Juvenile rheumatoid arthritis;Non-radiographic axial spondyloarthritis;Psoriatic arthritis;Rheumatoid arthritis;Ulcerative colitis,Hearing disorders;Type 1 diabetes mellitus,Asthma;Cardiovascular disorders;Sarcoidosis;Uveitis,Medarex UltiMAb Mouse,,Q VQLVES GGG VV QPGR SLRLSC AASG FIFS SY AMHWVRQ APGNGL EWVAFMSY DGSNKKYADS V K GRFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RDRGIAAGGN YYYYGMDV WGQG TTVTVS S,E IVLT QSPA TLSL SPGE RATLSCR ASQS VY SYLAWY QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPED FAVYYCQ QRSNWPPFTFGPGT KVD IK
Golocdacimab,Whole mAb,G1,Lambda,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGFDPEDFKYHTHQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCALVWGTQGKGVRGWDYYYGMDVWGQGTTVTVSS,QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,na,na,None,None,None,2022,na,OLR1,TBC,TBC,TBC,TBC,TBC,,Q VQLVQ SGA EVK KPGA SVKVSCKV SGY TLTELSMHWVR QAPGKGL EW MGGFD PED FK Y HTHQK F QG RVTMT EDTSTD TAYMELSS LRSEDT AVYYCALVW GTQGKGVRG WDYYY G MDV WGQG TTVTVS S,QSV V TQPPSVSGAPGQ RVTISCT GSSSNIGAG YDVHWYQ QLPGTAP KLLIYG NSNRPSGVPDRFSGSKSGTS A SLAIT GLQAEDEAD YYCQS YDSSLSG WVF GGGT KLTV L
Gontivimab,Bispecific Single Domains (VH-VH'-VH'),na;na,na;na,Phase-II,Discontinued,DVQLVESGGGLVQAGGSLSISCAASGGSLSNYVLGWFRQAPGKEREFVAAINWRGDITIGPPNVEGRFTISRDNAKNTGYLQMNSLAPDDTAVYYCGAGTPLNPGAYIYDWSYDYWGRGTQVTVSS,na,EVQLVESGGGLVQAGGSLSISCAASGGSLSNYVLGWFRQAPGKEREFVAAINWRGDITIGPPNVEGRFTISRDNAKNTGYLQMNSLAPDDTAVYYCGAGTPLNPGAYIYDWSYDYWGRGTQVTVSS,na,None;None,None;None,None;None,2019,2020,RSV gpF;RSV gpF,Ablynx,na,na,Respiratory syncytial virus infections,na,,D VQLVE SGGG LVQ AGG SLSISCA ASGGSLS NYVLGWFR QAPGKER EFVAAIN WRGD ITI GPPNVEG RFTISR DNAKNT GYLQMN SLAPDDT AVYYC GAGTPLNPGA YIYD W S YDYWGRG TQVTVS S,NA
Gorivitug,Whole mAb,G1,Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCSASGFTFSRYAMYWVRQAPGKGLEYVSAISSDGGSTYDADSVKGRFTISRANSKNTLYLQMSSLRAEDTAVYYCVKGLRELLYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRAGQSISSFLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYITPFTFGPGTKVDIK,na,na,None,None,None,2022,na,SARS-CoV-2 Spike RBD,TBC,TBC,TBC,TBC,TBC,,E VQLVES GGG LV QPGG SLRLSCS ASGF TFSRYAMYWVRQ APGKG LEYVSAIS SDGGST Y DADSVK GRFTISR ANSKN TLYLQMSS LRAEDT AVYYCV KG LRELLYYYY GMDVWGQG TTVTVS S,DIQMTQSPSS LSA SVGD RVTITC RAGQS ISSFLNWYQ QKPGKAP KLLIYAA SSLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYY C QQSYITPF T FGPGT KVDI K
Gosuranemab,Whole mAb,G4,Kappa,Phase-II,Discontinued,EVHLVESGGALVKPGGSLRLSCAASGFSFSKYGMSWVRQAPGKGLEWVATISSSGSRTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAMYYCSISWDGAMDYWGQGTTVTVSS,DVVMTQSPLSLPVTLGQPASISCKSSQSIVHSNGNTYLEWYLQKPGQSPQLLVYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGTYYCFQGSLVPWAFGGGTKVEIK,na,na,None,None,None,2018,2019,MAPT,Biogen;Bristol-Myers Squibb;iPierian,na,na,Cardiovascular disorders;Metabolic disorders;Alzheimer's disease;Progressive supranuclear palsy;Neurodegenerative disorders,na,,E VHLVE SGG ALV KPGG SLRLSC AASGF SF SKYG MSWVRQ APGKG LEWVATIS SSGS RTY YPDSVK GRFTISR DNAKN TLYLQMN SLRAEDT AMYYCSISW DGAMDY W GQG TTVTVS S,DV VMT QSPLSLP VT LGQPA SISC KSSQ SIVH SNGN TYLEWYL QKPGQSP QLLVYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDVG TYYCF QGS L VPWAFGGG TKVEI K
Gremubamab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAPGKGLEWVSAITMSGITAYYTDDVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEEFLPGTHYYYGMDVWGQGTTVTVSS,AIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYSASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQDYNYPWTFGQGTKVEIK,QVQLQESGPGLVKPSETLSLTCTVSGGSISPYYWTWIRQPPGKCLELIGYIHSSGYTDYNPSLKSRVTISGDTSKKQFSLKLSSVTAADTAVYYCARADWDRLRALDIWGQGTMVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSIRSHLNWYQQKPGKAPKLLIYGASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSTGAWNWFGCGTKVEIK,None;None,None;None,None;None,2019,2020,PcrV type III secretion system;Polysaccharide synthesis locus (Pseudomonas),MedImmune,na,na,Nosocomial pneumonia,na,(May '22) Added missing Y102 in Fv1 LC.,E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMNWVR QAPGKGL EWVSAIT MSG ITAYYT DDVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAK EEFLPGT HYYYGMDV WGQG TTVTVS S,AI QMT QSPSS LSA SVGD RVTITCR ASQGIRNDLG WYQ QKPGKAP KLLIYS ASTLQSGVPS R FSGSGSGTD FTLTISS LQPEDF ATYYCL QDYNYPWTFGQGT KVEI K
Gresonitamab,Bispecific scFv-scFv-scFc,G1;G1,Kappa;Lambda,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQCLEWMGWINPNSGGTKYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDRITVAGTYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGVNNWLAWYQQKPGKAPKLLIYTASSLQSGVPSRFSGSGSGTDFTLTIRSLQPEDFATYYCQQANSFPITFGCGTRLEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2021,2022,CLDN18;CD3E,Amgen,na,GE Junction Cancer,na,BiTE Technology,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTGYYMHWVR QAPGQ CLEWMGWI NPNSGGT KYAQKF QG RVTMT RDTS ISTAYMELSR LRSDDT AVYYC ARDR ITVA G TYYYYGMDV WGQG TTVTVS S,DIQ MT QSPSS VSAS VGD RVTITCR ASQGVN NW LAWYQ QKPGKAP KLLIYT ASSLQSGVPS R FSGSGSGTD FTLTIRS LQ PEDFAT YYC QQANSFP ITF GCGT RLEI K
Grisnilimab,Whole mAb,G2a,Lambda,Phase-I/II,Active,QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWVKQAPGKGLMWLGWINTYTGEPTYADDFKGRFAFSLETSASTAYLQINNLKNEDTATYFCARWAYFYGSSPYFFDYWGQGTTLTVSS,QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWCSNHLVFGGGTKLTVL,na,na,None,None,None,2020,2021,CD7,Xenikos,na,Steroid-refractory acute graft-versus-host disease;Graft-versus-host disease,na,na,,Q IQLVQ SGPELKKPGE TVKISCK ASGY TFTN YG MNWVK QAPGKG LMWLGWIN TYTGEPTYADDFKG RFAFSLE TSAS TAYLQIN NLKNEDTA TYFCARWAYFY GSSPY FFD YWGQG TTLTVS S,QA VVTQ E SALT TSPGE TVTLTCR SSTGA VTT SN YANWV QEKPDH LFTGLI GGTNNRAPGVPA RFSGSL IGDK AALTIT GAQTEDE AIYFCALWC SNH LVF GGGT KLTV L
Gumokimab,Whole mAb,G1,Kappa,Phase-II,Active,DVQLQESGPGLVKPSQTLSLTCTVSSYSFTSDYAWSWIRQPPGKGLEWIGYITYSGVTSYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARADYDSYYTMDYWGQGTSVTVSS,DVVMTQTPLSLPVTLGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPRLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCSQSTHFWTFGGGTKLEIK,na,na,None,None,None,2021,2022,IL17A,Akeso Biopharma,na,Psoriasis,na,na,(June '22) Corrected CDRH2 sequence,DV QLQE SGPGLVKPSQ TLSLTCTVSS YSFTSDY AWSWIR QPPGKGL EWIGYITYS G VTS YNPSLKS RVTISVD TSKN QFSLKLSS VTAADT AVYYCAR ADYDS YYTMD YWGQG TSVTVS S,DV VMT QTPLSLP VT LGQPA SISC RSSQ SLVH SNGN TYLHWYLQ KPGQSP RLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDL GVYYCS QST HFWTF GGGT KLEI K
Guselkumab,Whole mAb,G1,Lambda,Approved,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIDPSNSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCASWTDGLSLVVFGGGTKLTVL,na,na,4m6m:HL/4m6n:HL,None,None,2013,2014,IL23A,Janssen Biotech;MorphoSys;Taiho Pharmaceutical,Erythrodermic psoriasis;Palmoplantar pustulosis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis ,Crohn's disease;Hidradenitis suppurativa;Ulcerative colitis;Familial adenomatous polyposis;Psoriasis;Giant cell arteritis;Lupus nephritis;Systemic scleroderma,Rheumatoid arthritis,MorphoSys HuCAL Phage Display,,E VQLVQ SGA EVK KPGE SLKISC KGSGYSFSN YWIGWVRQ MPGKGL EWMGII DPSNSY TRY SPSFQG QVTIS ADKS ISTAYLQWS SLKASDT AMYYCARWYY KPFD V WGQG TLVTVS S,QSVLTQPPSVSGAPGQ RVTISCT GSSSNIGSGY DVHWYQQ LPGTAP KLLIYG NSKRPSGVPDRFSGSKSGTS ASLAIT GLQSEDEAD YYCAS WTDGL SLVVF GGGT KLTV L
Ianalumab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWGWIRQSPGRGLEWLGRIYYRSKWYNSYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARYDWVPKIGVFDSWGQGTLVTVSS,DIVLTQSPATLSLSPGERATLSCRASQFISSSYLSWYQQKPGQAPRLLIYGSSSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQLYSSPMTFGQGTKVEIK,na,na,None,None,None,2017,2018,TNFRSF13C,H. Lee Moffitt Cancer Center and Research Institute;MorphoSys;Novartis,na,Autoimmune hepatitis;Idiopathic pulmonary fibrosis;Multiple sclerosis;Pemphigus vulgaris;Rheumatoid arthritis;Sjogren's syndrome;Systemic lupus erythematosus;Chronic lymphocytic leukaemia,na,POTELLIGENT Technology,(Feb '22) Residue 108 changed from Q to D according to amendment in RL83. (June '22) Corrected CDRL1/CDRL3 sequences.,QV QLQQ SGPGLVKPSQ TLSLTCAI SGDS V SSNSA AWGWIR QSPGRGL EWLGRIYYR SKWYNS YAVSVKSRITI NPDTSKN QFSLQL NSVTPEDT AVYYCA RYDWVP KIGVF DSWGQG TLVTVS S,D IVLT QSPA TLSL SPGE RATLSCR ASQFISS SYLSWY QQKPGQAP RLLIYG SSSRATGVP ARF SGSGSGT DFTLTIS SLE PEDF AVYY CQQL YSSPMTFGQGT KVEI K
Ibalizumab,Whole mAb,G4,Kappa,Approved,NFD,QVQLQQSGPEVVKPGASVKMSCKASGYTFTSYVIHWVRQKPGQGLDWIGYINPYNDGTDYDEKFKGKATLTSDTSTSTAYMELSSLRSEDTAVYYCAREKDNYATGAWFAYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERVTMNCKSSQSLLYSTNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQYYSYRTFGGGTKLEIK,na,na,3o2d:HL/7t0r:CB:HL,None,None,2007,2008,CD4,Biogen Idec;TaiMed Biologics;Theratechnologies,HIV-1 infections,na,na,na,,QV QLQ QSGPE VV KPGA SVKMSCK ASGY TFTSYVIHWVR QKPGQGL DWIGYI NPYNDGTDYDEKFKG KATLT SDTSTS TAYMELS SLRSEDT AVYYCAR EKDNYATG AWFAYW GQG TLVTVS S,D IVMT QSPDS LAVS LGE RVTMNC KSSQ SLLYS TNQKN YLAWYQ QKPGQSP KLLIYWAS TRESGVPDRFSGSGSGTD FTLTISSV QAED VAVYYCQQYYSYRT FGGGT KLEI K
Ibritumomab,Whole mAb,G1,Kappa,Approved,NFD,QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSA,QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELK,na,na,3bky:HL,None,None,1999,2000,MS4A1,Biogen;Schering;Spectrum Pharmaceuticals,Non-Hodgkin's lymphoma,na,Diffuse large B cell lymphoma;Mantle-cell lymphoma;Marginal zone B-cell lymphoma;Multiple myeloma,na,Sequence sourced through DrugBank.,QA YLQ QSGA ELV RPGA SVKMSCK ASGY TFTSYNMHWVK QTPRQGL EWIGAI YPGNGDTSYNQKFKG KATLTVD KSSST AYMQLS SLTSEDS AVYFCARVVYY SNS YWYFDVW GTGT TVTVS A,Q IVLS QSP AILS ASPGE KVTMTCR ASSS VSYMHWYQ QKPGSSPKP WIY APSNLASGVP ARFS GSGSGT SYSLTISRVE AEDA ATYYCQQWS FNPPTFGAGT KLEL K
Icrucumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QAQVVESGGGVVQSGRSLRLSCAASGFAFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVRGRFTISRDNSENTLYLQMNSLRAEDTAVYYCARDHYGSGVHHYFYYGLDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK,na,na,None,None,None,2010,2011,FLT1,ImClone Systems,na,na,Colorectal cancer;Urogenital cancer;Breast cancer,na,,QA QVVES GG GVVQ SGR SLRLSC AASGF AFS SY GMHWVRQ APGKGL EWVAVIWY DGSNK YYAD SVRG RFTISR DNSEN TLYLQMN SLRAEDT AVYYCAR DHYGSGV HHYFYYGLDV WGQG TTVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQSVS SSY LAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LE PEDF AVYYC QQ YGSSPL TF GGG TKVEI K
Idactamab,Whole mAb,G1,Kappa,Phase-I,Active,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEIHHSGGANYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGQGKNWHYDYFDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSIRSWLAWYQQKPGKAPKLLIYKASILKIGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYYSYSRTFGQGTKVEIK,na,na,None,None,None,2020,2021,SLC1A5,MedImmune,na,Acute myeloid leukemia;Multiple myeloma;Diffuse large B-cell lymphoma,na,na,,QV QLQQW GAGLLKPSE TLSLTCAVY GGSFS GYYWSWIR QPPGKGL EWIGEIHH SGGANYNPSLK SRVTISVD TSKN QFSLKLSS VTAADT AVYYCA RGQGKNW HYDYF DYWGQG TLVTVS S,DIQ MT QSPS TLSAS VGD RVTITCR ASQ SIRSWLAWYQ QKPGKAP KLLIYKASILKIG VPSRFSGSGSGT EFTLTISS LQPDD FA TYYCQQYYSYS R T FGQGT KVEI K
Idarucizumab,Fab,G1,Kappa,Approved,NFD,QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYIVDWIRQPPGKGLEWIGVIWAGGSTGYNSALRSRVSITKDTSKNQFSLKLSSVTAADTAVYYCASAAYYSYYNYDGFAYWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCKSSQSLLYTDGKTYLYWFLQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQSTHFPHTFGGGTKVEIK,na,na,4jn2:HL:BA/4jn1:HL,None,None,2013,2014,Dabigatran,Boehringer Ingelheim,Blood coagulation disorders,na,na,na,,QV QLQE SGPGL V KPSE TLSLTCTV SGF SLTSYIVDWIR QPPGKGL EWIGVIWA GGSTGYNSA LRSRVSITK DTSKN QFSLKLSS VTAADT AVYYCA SA AYYSYY NYDG FAYW GQG TLVTV SS,DV VMT QSPLSLPV T LGQPA SISC KSSQ SLLYT DGK TYLYWFLQ RPGQSPR RLIYLVSK LDSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCLQS THFPHTFGGG TKVEI K
Ieramilimab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGFTLTNYGMNWVRQARGQRLEWIGWINTDTGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARNPPYYYGTNNAEAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCSSSQDISNYLNWYLQKPGQSPQLLIYYTSTLHLGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYYNLPWTFGQGTKVEIK,na,na,None,None,None,2018,2019,CD223,Immutep Limited;Novartis,na,Breast cancer;Diffuse large B cell lymphoma;Malignant melanoma;Solid tumours,na,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASG FTLTNY G MNWVRQ ARGQ RLEWIGWIN TDTGEPT Y ADDFKG RFVFSL DTSVS TAYLQISS LKAEDT AVYYCA RNPPYYYGTNNAEA M DYWGQG TTVTVS S,DIQMTQSPSS LSA SVGD RVTITC SSSQ DISNYLNWYL QKPGQSP QLLIYYT S TLHL GVPSRFSGSGSGT EFTLTISS LQPDD FA TYYCQQ YYNLPWTFGQGT KVEI K
Ifabotuzumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYWMNWVRQAPGQGLEWMGDIYPGSGNTNYDEKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGYYEDFDSWGQGTTVTVSS,DIQMTQSPSFLSASVGDRVTITCRASQGIISYLAWYQQKPEKAPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCGQYANYPYTFGQGTKLEIK,na,na,None,None,None,2015,2017,EPHA3,Ludwig Institute for Cancer Research;Humanigen;Olivia Newton-John Cancer Research Institute,na,Acute myeloid leukaemia;Myelodysplastic syndromes;Myelofibrosis;Glioblastoma,na,POTELLIGENT Technology;Humaneering Technology,Ifabotuzumab is the new name for Fibatuzumab (PL115),Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTGYWMNWVR QAPGQGL EWMGDI YPGSGNTNYDEKFQG RVTMT RDTS ISTAYMELSR LRSDDT AVYYC ARGG YY EDFDSWGQG TTVTVS S,DIQ M TQSPS FLSA SVGD RVTITCR ASQG IISYLAWY QQKPEKAPK RLIYAA SSLQSGVPS RF SGSGSGT EFTLTISS LQPE DFA TYYC GQYANYPY T FGQGT KLEI K
Ifinatamab,Whole mAb,G1,Kappa,TBC,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTNYVMHWVRQAPGQGLEWMGYINPYNDDVKYNEKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARWGYYGSPLYYFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASSRLIYMHWYQQKPGQAPRPLIYATSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQWNSNPPTFGQGTKVEIK,na,na,None,None,None,2022,na,CD276,TBC,TBC,TBC,TBC,TBC,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TFTNYVMHWVR QAPGQG LEWMGYI NPYNDDVKYNEKFKG RVTITA DESTS TAYMELS SLRSEDT AVYYCAR WGYYGSP LYYFD YWGQG TLVTVS S,E IVLTQ SPA TLSL SPGE RATLSCR ASSR LIYMHWYQ QKPGQAPRP LIYAT SNLASGIP ARFS GSGSGT DFTLTISS LEPED FAVYYCQQ WNSNPPTFGQGT KVEI K
Iladatuzumab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKGLEWIGEILPGGGDTNYNEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTRRVPIRLDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCKASQSVDYEGDSFLNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPLTFGQGTKVEIK,na,na,None,None,None,2017,2019,CD79B,Roche,na,na,Non-Hodgkin's lymphoma,na,,E VQLVES GGG LV QPGG SLRLSC AASGY TFSSYWIEWVR QAPGKGL EWIGEI LPGGGDTNYN EIF KG RATFSA DTSKN TAYLQMN SLRAEDT AVYYCT RRVP IRLDY WGQG TLVTVS S,DI QLT QSPSS LSA SVGD RVTITCK ASQS V DYEGD SFLN W Y QQKPGKAP KLLIYAA SNLESGVPS R FSGSGSGTD FTLTIS SLQPED F ATYYCQ QSNEDPL T FGQGT KVEI K
Imalumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSIYSMNWVRQAPGKGLEWVSSIGSSGGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGSQWLYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQRIMTYLNWYQQKPGKAPKLLIFVASHSQSGVPSRFRGSGSETDFTLTISGLQPEDSATYYCQQSFWTPLTFGGGTKVEIK,na,na,6foe:HL:AB,None,None,2014,2015,MIF,Cytokine PharmaSciences;Baxalta;Shire;Takeda,na,na,Solid tumours;Lupus nephritis;Colorectal cancer;Malignant ascites,na,,E VQLLES GGG LV QPGG SLRLSC AASGF TFSIYSMNWVR QAPGKG LEWVSSI GSSGGT TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYC AGSQ WLYGMDV WGQG TTVTVS S,DIQ MT QSPSS LSA SVGD RVTITC RSSQR I M TYLN WY QQKPGKAP KLLIFVAS HSQSGVPSRFRGSGSETD FTLTIS GLQPEDSA TYYCQ QSFWTPL T FGGGT KVEI K
Imaprelimab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVTLKESGPVLVKPTETLTLTCTVSGFSLTSNAVSWVRQPPGKALEWIAAISSGGTTYYNSAFKSRLTISRDTSKSQVVLTMTNMDPVDTATYYCARRYGYGWYFDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTINCKASQNIYNSLAWYQQKPGKAPKVLIFNANSLQTGIPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFYSGYTFGQGTKLEIK,na,na,None,None,None,2017,2018,MCAM,Neotope Biosciences;Onclave Therapeutics;Prothena;Prothena Corporation,na,na,Cancer;Inflammation;Psoriasis,na,,QV TLK ESGP VLV KPTE TLTLTCTV SG FSL TSN AVSWVR QPPGKA LEWIAAIS SGGT TYY NSAFK SRLTIS RDTSKS QVVLTMT NMDPVDT AT YYCA R R YGYG WYFDF WGQG TLVTVS S,DIQMTQSPSSL SA SVGD RVTINC KAS QNIYNSLAWYQ QKPGKAP KVLIFN ANSLQTGIPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQF YSGY T FGQGT KLEI K
Imgatuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGFTFTDYKIHWVRQAPGQGLEWMGYFNPNSGYSTYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARLSPGGYYVMDAWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGINNYLNWYQQKPGKAPKRLIYNTNNLQTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSFPTFGQGTKLEIK,na,na,None,None,None,2012,2013,EGFR,GLYCART Biotechnology;Roche,na,na,Colorectal cancer;Head and neck cancer;Non-small cell lung cancer,GlycoMAb Technology,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGF TF TD YKIHWVRQ APGQG LEWMGYF NPNSGYS TYAQK FQG RVTITA DKSTS TAYMELS SLRSEDT AVYYCARL SPGG YYVMD AWGQG TTVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQGI NNYLNWY QQKPGKAPK RLIYN TNNLQTGVPS R FSGSGSGT EFTLTIS SLQPEDF ATYYCLQ HNSFPTFGQGT KLEI K
Imsidolimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMNWVRQAPRQGLEWMGMFHPTGDVTRLNQKFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARTTSMIIGGFAYWGQGTLVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSKSLLHRNAITYFYWYLHKPGQPPQLLIYQMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPLTFGGGTKVEIK,na,na,None,None,None,2020,2021,IL36R,AnaptysBio,na,Generalised pustular psoriasis;Localised pustular psoriasis,na,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTNYWMN W VR QAPRQGL EWMGMF HPTGD VT RL NQKFKD RVTMTR DTSTS TVYMELS SLRSEDT AVYYCA RTTS MIIGGFAYW GQG TLVTVS S,DI VMT QTP LSLSV TPGQP ASISCR SSKSLLHRNA ITYFYWYL HKPGQPP QLLIYQM SNLASGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCA QNLELP LTF GGG TKVEI K
Imvotamab,Pentameric IgM with Fused scFv,M,Kappa;Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFISYTMHWVRQAPGQGLEWMGYINPRSGYTHYNQKLKDKATLTADKSASTAYMELSSLRSEDTAVYYCARSAYYDYDGFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQKPGKAPKRLIYDTSKLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSSNPPTFGGGTKVEIK,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHPSYGSGSPNFDYWGQGTLVTVSS,DIVMTQTPLSSPVTLGQPASISCRSSQSLVYSDGNTYLSWLQQRPGQPPRLLIYKISNRFSGVPDRFSGSGAGTDFTLKISRVEAEDVGVYYCVQATQFPLTFGGGTKVEIK,None;None,None;None,None;None,2022,na,CD3E;MS4A1,TBC,TBC,TBC,TBC,TBC,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFISYTMHWVR QAPGQG LEWMGYI NPRSGY TH YNQKLKDK ATLTA DKSAS TAYMELS SLRSEDT AVYYCAR S AYY DYDGF AYW GQG TLVTV SS,DI QMT QSPSS LSAS VGD RVTITCS ASSS VSYMNWY QQKPGKAPK RLIYD TSKLASGVPS RF SGSGSGT DFTLTISS LQPE DF ATYYCQQ WSSNPPTFGGGT KVEI K
Inclacumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,EVQLVESGGGLVRPGGSLRLSCAASGFTFSNYDMHWVRQATGKGLEWVSAITAAGDIYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARGRYSGSGSYYNDWFDPWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK,na,na,None;None,None;None,None;None,2011,2012,SELP,Genmab;Roche;Global Blood Therapeutics,na,na,Acute coronary syndromes;Myocardial infarction;Peripheral vascular disorders,Medarex UltiMAb Mouse,,E VQLVES GGG LV RPGG SLRLSC AASGF TF SNYD MHWVRQ ATGKGL EWVSAIT AAGD IY YPGS VKGRFTIS RENAKN SLYLQMNS LRAGD TAVYYCA RGR Y SGSGSYYNDWFDPWGQG TLVTVS S,E IVLTQ SPA TLSL SPGE RATLSCR ASQS VSSY LAWY QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPE D FAVYYCQ QRSNWP LTF GGG TKVEI K
Indatuximab,Whole mAb ADC,G4,Kappa,Phase-II,Discontinued,QVQLQQSGSELMMPGASVKISCKATGYTFSNYWIEWVKQRPGHGLEWIGEILPGTGRTIYNEKFKGKATFTADISSNTVQMQLSSLTSEDSAVYYCARRDYYGNFYYAMDYWGQGTSVTVSS,DIQMTQSTSSLSASLGDRVTISCSASQGINNYLNWYQQKPDGTVELLIYYTSTLQSGVPSRFSGSGSGTDYSLTISNLEPEDIGTYYCQQYSKLPRTFGGGTKLEIK,na,na,None,None,None,2011,2012,SDC1,Biotest AG,na,na,Bladder cancer;Breast cancer;Multiple myeloma,na,,Q VQLQQ SGS ELM MPGA SVKISCKA TGY TF SN YWIEWVK QRPGHGL EWIGEI LPGTGR TIY NEKFKG KATFTAD ISSN TVQMQLS SLTSEDS AVYYCAR RDYYGN FYYAMD YWGQGT SVTVS S,DI QMT QSTS SLSA SLGD RVTISCS ASQG INNYLNW YQ QKPDGT VELLIYYT STLQSGVPS R FSGSGSGTD YSLTIS NLE PED IG TYYCQQ YSKLPRTFGGGT KLEI K
Indusatumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,QVQLQQWGAGLLKPSETLSLTCAVFGGSFSGYYWSWIRQPPGKGLEWIGEINHRGNTNDNPSLKSRVTISVDTSKNQFALKLSSVTAADTAVYYCARERGYTYGNFDHWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSRNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTIGSLQSEDFAVYYCQQYKTWPRTFGQGTNVEIK,na,na,None,None,None,2014,2015,GUCY2C,Millennium;Takeda Oncology,na,na,Colorectal cancer;Gastrointestinal cancer;Pancreatic cancer,na,,QV QLQQW GAGLLKPSE TLSLTCAVF GGSFSG YYWSWIR QPPGKGL EWIGEIN HRGNTNDNPSLK SRVTISVD TSKN QFALKLSS VTAA DTA VYYC ARE RGY TY GNFDHWGQG TLVTVS S,E IVMT QSPA TLSV SPGE RATLSCR ASQSVSRN LAW Y QQKPGQAP RLLIYG ASTRATGIP ARF SGSGSGT EFTLTIG SLQSED FAVYYCQ QYKTWPRTFGQGT NVEI K
Inebilizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSSWMNWVRQAPGKGLEWVGRIYPGDGDTNYNVKFKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARSGFITTVRDFDYWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCRASESVDTFGISFMNWFQQKPDQSPKLLIHEASNQGSGVPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQSKEVPFTFGGGTKVEIK,na,na,None,None,None,2015,2016,CD19,Cellective Therapeutics;MedImmune,Neuromyelitis optica,Autoimmune disorders;Myasthenia gravis;Renal transplant rejection,B-cell lymphoma;Chronic lymphocytic leukaemia;Diffuse large B-cell lymphoma;Follicular lymphoma;Multiple myeloma;Multiple sclerosis;Systemic scleroderma,POTELLIGENT Technology,,E VQLVES GGG LV QPGG SLRLSC AASGF TFS SSW MNWVR QAPGKG LEWVGRI YPGDGDTN YNVKFKGRFTISR DDSKN SLYLQMN SLKTEDT AVYYC ARSG FITTVRD FDYWGQG TLVTVS S,E IVLTQ SPDFQSVTPKE KVTITCR ASESVD TFGISFMN WF QQKPDQSP KLLIHE ASNQGSGVPS R FSGSGSGTD FTLTIN SLE AEDAATYYCQ QSKEVP FTF GGG TKVEI K
Inezetamab,Bispecific Mixed mAb and scFv,G1;na,Lambda;Kappa,TBC,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSRNAMSWVRQAPGKGLEWVSATGGSGISTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGYSNSWWYFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGNYNLVSWYQQHPGKAPKLMIFEVNQRPSGVSNRFSGSKSGTTASLTISGLQAADEADYFCSSYTTSSTYVIFGGGTKLTVL,QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKCLEWISYISSSESIIYYVDAVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDVGSHFDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQDISRWLAWYQQKPGKAPKLLISAASRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQAKSFPRTFGCGTKVEIK,None;None,None;None,None;None,2022,na,CD40;MSLN,TBC,TBC,TBC,TBC,TBC,,E VQLLES GGG LV QPGG SLRLSC AASGF TFS RNA MSWVR QAPGKG LEWVSA TGGSGI STYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RGYSNS WWYFD YWGQG TLVTVS S,QSALTQPA SV SGSPGQ SITISCT GTSSDVGN YNLVSWY Q QHPGKAP KLMIFEV NQRPSGVSNRFSGSKSGT TASLTIS GLQAADEAD YFCSS YTTSS TYVIF GGGT KLTV L
Infliximab,Whole mAb,G1,Kappa,Approved,NFD,EVKLEESGGGLVQPGGSMKLSCVASGFIFSNHWMNWVRQSPEKGLEWVAEIRSKSINSATHYAESVKGRFTISRDDSKSAVYLQMTDLRTEDTGVYYCSRNYYGSTYDYWGQGTTLTVSS,DILLTQSPAILSVSPGERVSFSCRASQFVGSSIHWYQQRTNGSPRLLIKYASESMSGIPSRFSGSGSGTDFTLSINTVESEDIADYYCQQSHSWPFTFGSGTNLEVK,na,na,5vh3:HL:AB/5vh4:HL:AB/4g3y:HL/6ugs:HL:AB/6ugv:HL:AB/6ugt:HL:AB/6ugu:HL:AB,None,None,1997,1998,TNFA,Centocor;Janssen Biotech;Merck & Co;Mitsubishi Tanabe Pharma Corporation;National Jewish Medical and Research Center;Xian-Janssen,Ankylosing spondylitis;Behcet's syndrome;Crohn's disease;Mucocutaneous lymph node syndrome;Plaque psoriasis;Psoriasis;Psoriatic arthritis;Rheumatoid arthritis;Ulcerative colitis,na,Berylliosis;Hepatitis C;Pyoderma,na,,E VKLEE SGGG LV QPGGS MKLSCVA SG FIF SNH WMNWVR QSPEKGL EWVAEIR SKSINSAT HYAES VKG RFTISR DDSKS AVYLQMT DLRTEDTG VYYCSR NYYGST Y DYWGQG TTLTVS S,D ILLT QSP AILSV SPGE RVSFSCR ASQFVGS SIHWYQQ RTNGSP RLLIKYA SESMSGIPSRFSGSGSGT DFTLSINTV ESE DIADYYC QQSHSWP FTF GSGT NLEV K
Inotuzumab,Whole mAb ADC,G4,Kappa,Approved,Active,EVQLVQSGAEVKKPGASVKVSCKASGYRFTNYWIHWVRQAPGQGLEWIGGINPGNNYATYRRKFQGRVTMTADTSTSTVYMELSSLRSEDTAVYYCTREGYGNYGAWFAYWGQGTLVTVSS,DVQVTQSPSSLSASVGDRVTITCRSSQSLANSYGNTFLSWYLHKPGKAPQLLIYGISNRFSGVPDRFSGSGSGTDFTLTISSLQPEDFATYYCLQGTHQPYTFGQGTKVEIK,na,na,None,None,None,2004,2005,CD22,Alliance for Clinical Trials in Oncology;Cancer Research UK;Case Comprehensive Cancer Center;Children's Oncology Group;Erasmus MC;M. D. Anderson Cancer Center;National Cancer Institute (USA);Pfizer;SWOG;University College London;University of Texas M. D. Anderson Cancer Center;Celltech Group,Precursor cell lymphoblastic leukaemia-lymphoma,Precursor B-cell lymphoblastic leukaemia-lymphoma;Chronic myeloid leukaemia,Acute biphenotypic leukaemia;Burkitt's lymphoma;Diffuse large B cell lymphoma;Non-Hodgkin's lymphoma,na,,E VQLVQ SGA EVK KPGA SVKVSCK ASGY RFTNYWIHWVR QAPGQG LEWIGGI NPGNNY ATYRRKF QG RVTMTA DTSTS TVYMELS SLRSEDT AVYYCT REGYGNYG AWFAYW GQG TLVTVS S,DV QVT QSPSS LSA SVGD RVTITCR SSQSLANSYGN TFLSWYL HKPGKAP QLLIYGI SNRFSGVPDRFSGSGSGT DFTLTISS LQPEDF ATYYCL QGTHQP YT FGQGT KVEI K
Intetumumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVESGGGVVQPGRSRRLSCAASGFTFSRYTMHWVRQAPGKGLEWVAVISFDGSNKYYVDSVKGRFTISRDNSENTLYLQVNILRAEDTAVYYCAREARGSYAFDIWGQGTMVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPFTFGPGTKVDIK,na,na,None,None,None,2009,2010,ITGAV_ITGB3,Centocor Inc;Janssen Biotech;Janssen-Cilag,na,na,Malignant melanoma;Prostate cancer,VelocImmune Mouse,,Q VQLVES GGG VV QPGRS RRLSC AASGF TFSRYTMHWVRQ APGKGL EWVAVISF DGSNK YYVD SVKG RFTISR DNSEN TLYLQVNILR AEDT AVYYCAR EARGS YAFDIW GQG TMVTVS S,E IVLTQ SPA TLSL SPGE RATLSCR ASQS VSSYL A W Y QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPED FAVYYCQ QRSNWPPFTFGPGT KVD IK
Iparomlimab,Whole mAb,G4,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWIHWVRQAPGQGLEWMGEIDPYDSYTNYNQKFKGRVTMTVDKSTSTVYMELSSLRSEDTAVYYCARPGFTYGGMDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKSSQSLFNSGNQKNYLAWYQQKPGKVPKLLIYGASTRDSGVPYRFSGSGSGTDFTLTISSLQPEDVATYYCQNDHYYPYTFGGGTKVEIK,na,na,None,None,None,2021,2022,PDCD1,Qilu Puget Sound Biotherapeutics,na,Neoplasms,na,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTNYWIHWVR QAPGQGL EWMGEI DPYDSYTNYNQKFKG RVTMTVD KSTS TVYMELS SLRSEDT AVYYCA RPGF TY GG MD FWGQG TLVTVS S,DIQMTQSPSS LSA SVGD RVTITC KSSQS L FNSGN QKNYLAWYQ QKPGKVP KLLIYG ASTRDSGVP YRF SGSGSGTD FTLTIS SLQ PEDVAT YYC QNDHYYPY T FGGGT KVEI K
Ipilimumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,5tru:HL:hl/5xj3:AB:DE:JK:GH/6jc2:HL/6rp8:HL:hl/7elx:HL,None,7su0:HL:IM/7su1:HL,2005,2006,CTLA4,Aduro BioTech;AIO Studien gGmbH;Australian and New Zealand Urogenital and Prostate Cancer Group;Bavarian Nordic;Big Ten Cancer Research Consortium;BioGene Pharmaceutical;Bristol-Myers Squibb;Canadian Cancer Trials Group;Dana-Farber Cancer Institute;European Thoracic Oncology Platform;Grupo Espanol Multidisciplinar de Melanoma;Icahn School of Medicine at Mount Sinai;Intergroupe Francophone de Cancerologie Thoracique;Ludwig Institute for Cancer Research;Massachusetts General Hospital;Medarex;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);National University Hospital (Singapore);Northwestern University;Olivia Newton-John Cancer Research Institute;OncoTherapy Science;Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;University College London;University of California at San Francisco;University of Texas M. D. Anderson Cancer Center,Malignant melanoma;Renal cell carcinoma,Colorectal cancer;Non-small cell lung cancer;Gastric cancer;Glioblastoma;Head and neck cancer;Mesothelioma;Oesophageal cancer;Prostate cancer;Small cell lung cancer;Urogenital cancer;Adrenocortical carcinoma;Breast cancer;CNS cancer;Gastrointestinal cancer;Genitourinary disorders;Gynaecological cancer;Liver metastases;Meningeal carcinomatosis;Myelodysplastic syndromes;Neuroendocrine tumours;Ovarian cancer;Pancreatic cancer;Penile cancer;Solid tumours;Thyroid cancer;Uveal melanoma;Diffuse large B cell lymphoma;Liver cancer;Lung cancer;Glioma,HIV infections;Lymphoma,Medarex UltiMAb Mouse,,Q VQLVES GGG VV QPGR SLRLSC AASGF TFSSYTMHWVRQ APGKGL EWVTFISY DGNNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AIYYCA RTGWLGPFDYWGQG TLVTV SS,E IVLTQ SPG TLSL SPGE RATLSCRA SQSVGS SYLAWYQ QKPGQAP RLLIYGAF SRATGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQ QYGSSPW TF GQGT KVEI K
Iratumumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSAYYWSWIRQPPGKGLEWIGDINHGGGTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTAVYYCASLTAYWGQGSLVTVSS,DIQMTQSPTSLSASVGDRVTITCRASQGISSWLTWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDSYPITFGQGTRLEIK,na,na,None,None,None,2005,2006,TNFRSF8,Medarex,na,na,Hodgkin's disease;Lymphoma;Non-Hodgkin's lymphoma,Medarex UltiMAb Mouse,,QV QLQQW GAGLLKPSE TLSLTCAVY GGS FSAYYWSWIR QPPGKGL EWIGDI NHGGGTNYNPSLKS RVTISVD TSKN QFSLKL N S VTAADT AVYYCASLTAYW GQGS LVTV SS,DIQ MT QSPT SLSAS VGD RVTITCR ASQGIS SW LTWY QQKPEKAPK SLIYAA SSLQSGVPS RF SGSGSGTD FTLTIS SLQP EDFAT YYC QQYDSYP ITF GQGT RLEI K
Isatuximab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVAKPGTSVKLSCKASGYTFTDYWMQWVKQRPGQGLEWIGTIYPGDGDTGYAQKFQGKATLTADKSSKTVYMHLSSLASEDSAVYYCARGDYYGSNSLDYWGQGTSVTVSS,DIVMTQSHLSMSTSLGDPVSITCKASQDVSTVVAWYQQKPGQSPRRLIYSASYRYIGVPDRFTGSGAGTDFTFTISSVQAEDLAVYYCQQHYSPPYTFGGGTKLEIK,na,na,4cmh:BC,None,None,2014,2015,CD38,ImmunoGen;Huntsman Cancer Institute;Roche;Sanofi,Multiple myeloma,Acute myeloid leukaemia;Precursor cell lymphoblastic leukaemia-lymphoma;Colorectal cancer;Diffuse large B cell lymphoma;Hodgkin's disease;Solid tumours;Urogenital cancer,Non-small cell lung cancer;Prostrate cancer;T-cell lymphoma,na,,Q VQLVQ SGA EVA KPGT SVKLSCK ASGY TFTDYWMQWVK QRPGQG LEWIGTI YPGDGDTGY AQKF QG KATLTA DKSSK TVYMHLS SLASEDS AVYYCA RGDYYGSNSLDYWGQGT SVTVS S,D IVMTQ S HLSMS TSLGDP VSITCK ASQDV STVVAWYQ QKPGQSPR RLIYSASYRYIG VPDRFTGSGAGT DFTFTISSV QAED LAVYYCQ QHYSPPY T FGGGT KLEI K
Iscalimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYEESNRYHADSVKGRFTISRDNSKITLYLQMNSLRTEDTAVYYCARDGGIAAPGPDYWGQGTLVTVSS,DIVMTQSPLSLTVTPGEPASISCRSSQSLLYSNGYNYLDWYLQKPGQSPQVLISLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQARQTPFTFGPGTKVDIR,na,na,None,None,None,2017,2018,CD40,Novartis;XOMA,na,Graves' disease;Lupus nephritis;Myasthenia gravis;Renal transplant rejection;Sjogren's syndrome;Systemic lupus erythematosus,Rheumatoid arthritis,na,,Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKG LEWVAVISY EESNR Y HADSV KGRFTIS RDNS KITLYLQM NSLRTEDT AVYYCA RDGG I AAPGPDYWGQG TLVTV SS,D IVMT QSPL SLTV TPGEP ASISCR SSQ SLLY SNGYN YLDWYL QKPGQSP QVLISL GSNRASGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCMQ ARQTPF TF GPGT KVD IR
Isecarosmab,Bispecific Single Domains (VH-VH'),na;na,na;na,Phase-I,Active,DVQLVESGGGVVQPGGSLRLSCAASGRTVSSYAMGWFRQAPGKEREFVAGISRSAERTYYVDSLKGRFTISRDNSKNTVYLQMNSLRPEDTALYYCAADLDPNRIFSREEYAYWGQGTLVTVSS,na,EVQLVESGGGVVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTALYYCTIGGSLSRSSQGTLVTVSS,na,None;None,None;None,None;None,2019,2020,ADAMTSL5;ALB,Merck,na,Solid tumours,na,na,,D VQLVES GGG VV QPGG SLRLSC AASGR TVSSYAMGWFR QAPGKE REFVAGIS RSAE RTYYVD SLKG RFTISR DNSKN TVYLQMN SLRPEDT ALYYCAA DLDPNRIFS REE YAYW GQG TLVTV SS,NA
Ispectamab,Whole mAb,G1,Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGFNISAPGIHWVRQAPGKGLEWVGFINPAGGYTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDYIRQYWTYVLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,na,na,None,None,None,2022,na,TNFRSF17,TBC,TBC,TBC,TBC,TBC,,E VQLVES GGG LV QPGG SLRLSC AASGF NI SAPG IHWVRQ APGKG LEWVGFI NPAGGYTDYADSVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYC ARD YIRQ YWTYVLDY WGQG TLVTV SS,DIQ MT QSPSS LSA SVGD RVTITCR ASQD VNTA VAWYQ QKPGKAP KLLIYSASFLY SGVPSRFSGSRSGTD FTLTIS SLQP EDFAT YYCQ QHYTTPPTFGQGT KVEI K
Istiratumab,Bispecific Mixed mAb and scFv,G1;na,Kappa;Lambda,Phase-II,Discontinued,EVQLLQSGGGLVQPGGSLRLSCAASGFMFSRYPMHWVRQAPGKGLEWVGSISGSGGATPYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDFYQILTGNAFDYWGQGTTVTVSS,DIQMTQSPSSLSASLGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAKSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDSATYYCQQYWTFPLTFGGGTKVEIK,QVQLVQSGGGLVQPGGSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVAGISWDSGSTGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDLGAYQWVEGFDYWGQGTLVTVSS,SYELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSTSGNSASLTITGAQAEDEADYYCNSRDSPGNQWVFGGGTKVTVL,None;None,None;None,None;None,2017,2018,IGF1R;ERBB3,Adimab;Merrimack Pharmaceuticals,na,na,Ovarian cancer;Pancreatic cancer;Solid tumours,na,,E VQLLQS GGG LV QPGG SLRLSC AASGF MF SRYPM HWVRQ APGKG LEWVGSIS GSGGATPYADSVK GRFTISR DNSKN TLYLQMN SLRAEDT AVYYC AKD F YQIL TGNAFDYWGQG TTVTVS S,DIQ MT QSPSS LSA SLGD RVTITCR ASQGIS SYLAWY QQKPGKAP KLLIYAK STLQSGVPS RF SGSGSGTD FTLTISS LQPEDSA TYYCQQYWTFPLTF GGG TKVEI K
Itepekimab,Whole mAb,G4,Kappa,Phase-III,Active,EVQLVESGGNLEQPGGSLRLSCTASGFTFSRSAMNWVRRAPGKGLEWVSGISGSGGRTYYADSVKGRFTISRDNSKNTLYLQMNSLSAEDTAAYYCAKDSYTTSWYGGMDVWGHGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGIFSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQANSVPITFGQGTRLEIK,na,na,None,None,None,2019,2020,IL33,Regeneron Pharmaceuticals;Sanofi,na,Chronic obstructive pulmonary disease,Allergic asthma;Inflammation;Asthma;Atopic dermatitis,na,,E VQLVE SGGNLEQPGG SLRLSCT ASG FTFS RSAM NWVRR APGKGL EWVSGI SGSGGR TYYA DSVKG RFTISR DNSKN TLYLQMN SLS AEDTAA YYC AKDSYTTSWYGG MDV WGHG TTVTVS S,DIQ MT QSPSS VSAS VGD RVTITCR ASQG IFSWLAWY QQKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQPED FAIYYC QQANSV PITF GQGT RLEI K
Itolizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVKPGGSLKLSCAASGFKFSRYAMSWVRQAPGKRLEWVATISSGGSYIYYPDSVKGRFTISRDNVKNTLYLQMSSLRSEDTAMYYCARRDYDLDYFDSWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASRDIRSYLTWYQQKPGKAPKTLIYYATSLADGVPSRFSGSGSGQDYSLTISSLESDDTATYYCLQHGESPFTLGSGTKLEIK,na,na,None,None,None,2010,2011,CD6,Center of Molecular Immunology;Biocon;Biotech Pharmaceutical;Equillium,Plaque psoriasis,Graft-versus-host disease;Cytokine release syndrome;COVID-19;Asthma;Lupus nephritis,Autoimmune disorders;Multiple sclerosis;Psoriasis;Rheumatoid arthritis,na,,E VQLVES GGG LV KPGG SLKLSC AASGF KFSRYAMSWVR QAPGK RLEWVATIS SGGS YIY YPDSVKG RFTIS RDNVKN TLYLQMS SLRSEDT AMYYCAR RDYDLDY F DSWGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCK ASRD IRSYL TWYQ QKPGKAPK TLIYYATS LADGVPS RF SGSGSGQD YSLTISS LESDDT ATYYCLQ HGESPF T LGSGT KLEI K
Ivicentamab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFSLSNYNMGWVRQAPGKGLEWVSVIDASGTTYYATWAKGRFTISRDNSKNTLYLQMNSLRAEDTATYYCARELLYFGSSYYDLWGQGTLVTVSS,DVVMTQSPSTLSASVGDRVTITCQASQNIDSNLAWYQQKPGKAPKFLIYYASNLPFGVPSRFKGSGSGTEFTLTISSLQPDDFATYYCQSADVGSTYVAAFGGGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFSLSYNAMNWVRQAPGKGLEWVSIIFASGRTDYASWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGSTWGDALDPWGQGTLVTVSS,AYDMTQSPSTLSASVGDRVTITCQASQNIIDYLAWYQQKPGKAPKLLIHKASTLASGVPSRFKGSGSGTEFTLTISSLQPDDFATYYCQQGYSNSNIDNTFGGGTKVEIK,None;None,None;None,None;None,2021,2022,CD37;CD37,Genmab,na,B cell Lymphoma,na,DuoBody,,E VQLVES GGG LV QPGG SLRLSC AASGF S LSNY NMGWVRQ APGKGL EWVSVID ASGT TYYATW AKG RFTISR DNSKN TLYLQMNS LRAEDT ATYYCA R ELLYF GSS YY DLWGQG TLVTV SS,D VVMT QSPS TLSAS VGD RVTITCQ ASQNIDSN LAWYQ QKPGKAP KFLIYYA SNLPFGVPSRFKGSGSGT EFTLTISS LQPDDF ATYYCQS ADVGS TYVAAF GGG TKVEI K
Ivonescimab,scFv-IGHC,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,na,na,1bj1:HL:KJ,None,6bft:AB:HL/1cz8:HL:YX,2021,2022,VEGFA,Akeso Biopharma,na,Non-small cell lung cancer;Solid tumours;Neoplasms;Gynecological Cancer,na,na,Bevacizumab and Ivonescimab have same Fv sequences,E VQLVES GGG LV QPGG SLRLSC AASGY TFTN YGM NWVRQ APGKGL EWVGWIN TYTGEPT YA ADFKR RFTFSL DTSKS TAYLQMN SLRAEDT AVYYCA KYPHYYGSS HWYFDV WGQG TLVTVS S,DIQMTQSPSS LSA SVGD RVTITCS ASQD ISNYLNWYQ QKPGKAP KVLIYFT SSLHSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ YSTVPW T FGQGT KVEI K
Ivuxolimab,Whole mAb,G2,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIDYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARESGWYLFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPPTFGGGTKVEIK,na,na,None,None,None,2019,2020,TNFRSF4,Pfizer;Dana-Farber Cancer Institute;M. D. Anderson Cancer Center;National Cancer Institute USA;University of Southern California,na,Breast cancer;Renal cell carcinoma;Solid tumours;Acute myeloid leukaemia;Squamous cell cancer;Follicular lymphoma,na,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFSS Y SMNWVR QAPGKGL EWVSYIS SSSST ID YADSVKG RFTISR DNAKNS LYLQMN SLRDEDT AVYYCA RESG WYLFDY WGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQG ISSWLAWYQ QKPEKAPK SLIYAA SSLQSGVPS RF SGSGSGTD FTLTIS SLQ PEDFATY Y CQQ YNSYPPTFGGGT KVEI K
Ixekizumab,Whole mAb,G4,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYSFTDYHIHWVRQAPGQGLEWMGVINPMYGTTDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGNTYLHWYLQKPGQSPQLLIYKVSNRFIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGQGTKLEIK,na,na,6nov:AB:CD,6nou:AA,None,2011,2012,IL17A,Eli Lilly;Oregon Health & Science University;Torii Pharmaceutical,Erythrodermic psoriasis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis,Ankylosing spondylitis;Spondylarthritis;Bullous pemphigoid;Pityriasis rubra pilaris;Pyoderma gangrenosum;Rheumatoid arthritis,na,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGYSFTD YHIHWVRQ APGQG LEWMGVI NPMYGTTDYNQR F K GRVTITA DESTS TAYMELSS LRSEDT AVYYCARYD YFTGT GVYW GQG TLVTVS S,DI VMT QTP LSLSV TPGQP ASISC RSSR SLVH SRGN TYLHWYLQ KPGQSP QLLIYKV SNR FIG VPDRFSGSGSGT DFTLKISRVE AEDV GVYYC SQSTHLPF TF GQGT KLEI K
Izalontamab,Bispecific Mixed mAb and scFv,G1;na,Kappa;Lambda,TBC,Active,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSS,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK,QVQLQESGGGLVKPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVANINRDGSASYYVDSVKGRFTISRDDAKNSLYLQMNSLRAEDTAVYYCARDRGVGYFDLWGRGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNFVSWYQQHPGKAPKLMIYDVSDRPSGVSDRFSGSKSGNTASLIISGLQADDEADYYCSSYGSSSTHVIFGGGTKVTVL,5etu:DC:BA/5ff6:DC:BA/5f88:DC:BA/5itf:DC:BA/5ivz:DC:BA/5ir1:DC:BA/5esq:DC:BA/5euk:DC:BA/5hpm:DC:BA/5id1:DC:BA/5icx:DC:BA/5hyq:DC:BA/5icz:DC:BA/5th2:DC:BA/5iop:DC:BA/5i2i:DC:BA/5t1l:DC:BA/5i76:DC:BA/5iv2:DC:BA/5t1k:DC:BA;None,6azk:DC:BA/6azl:BA:DC/6au5:DC:BA/6ayn:BA:DC/6axp:BA:DC/5id0:DC:BA/5t1m:DC:BA/5icy:DC:BA/1yy8:DC:BA/1yy9:DC/4gw5:DC:BA/4kro:DC/4gw1:DC:BA/4krp:DC;None,5gz0:BA:DC/6arp:BA:DC/6aru:CB;None,2022,na,EGFR;ERBB3,TBC,TBC,TBC,TBC,TBC,Arm 1 is highly identical to cetuximab,QV QLKQ SGPGLVQPSQ SLSITCTV SGF SL T N Y GVHWVRQ SPGKGL EWLGVIWS GGNTDYNTPF TSRLSI NKDNSKS QVFFKM NSLQSNDT AIYYCA RAL TY YD YEFAYW GQG TLVTVS S,DI LLT QSP VILSV SPGE RVSFSCR ASQSIGT NIHWYQQ RTNGSP RLLIKYA SESISGIPSRFSGSGSGT DFTLSIN SVES EDIADYYCQ QNNNWPTTFGAGT KLEL K
Izeltabart,Whole mAb,G1,Kappa,TBC,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYWMHWVRQAPGKGLEWVGEIIPIFGHTNYNEKFKSRFTISLDNSKNTLYLQMGSLRAEDTAVYYCARGGYYYYPRQGFLDYWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATISCKASQSVDYSGDSYMNWYQQKPGQPPKLLIYAASDLESGIPARFSGSGSGTDFTLTISSLEPEDFATYYCQQSHEDPFTFGQGTKLEIK,na,na,None,None,None,2022,na,ADAM9,TBC,TBC,TBC,TBC,Humanised,,E VQLVES GGG LV KPGG SLRLSC AASGF TFSSYWMHWVR QAPGKGL EWVGEIIPIF GHTNYNEKFK SRFTISL DNSKN TLYLQMG S L RAEDT AVYYC ARGG YYYY PRQGF LDY WGQG TTVTVS S,D IVMT QSPDS LAVS LGER ATISCK ASQS V DYSGDS YMNWYQ QKPGQPP KLLIYAA SDLESGIP ARFS GSGSGTD FTLTIS SLEPE DF ATYYCQ QSHEDPFTFGQGT KLEI K
Izenivetmab,Canine Whole mAb,G2,Kappa,Unknown,Active,EVQLVESGGDLVKPGGSLRLSCVASGFTFSNYWMHWVRQAPGKGLQWVARIDPYGGGTKHNEKFKRRFTISRDNAKNTLYLQMNSLRAEDTAMYYCVRSGYDYYFDVWGQGTLVTVSS,EIVMTQSPASLSLSQEEKVTITCRASENIYSFLAWYQQKPGQAPKLLIYNANTLAEGVPSRFSGSGSGTDFSFTISSLEPEDVAVYYCQHHFGTPFTFGQGTKLEIK,na,na,None,None,None,2022,na,NGFB (Canine),TBC,TBC,TBC,TBC,TBC,,E VQLVE SGGD LV KPGG SLRLSCVA SGF TF SN YWMHWVRQ APGKG LQWVARI DPYGGGTKHNEK FKRRFTISR DNAKN TLYLQMN SLRAEDT AMYYCVR SGYD YYFDVW GQG TLVTVS S,E IVMT QSPASL S LSQEE KVTITCR ASEN IYSFLAWY QQKPGQAP KLLIYN ANTLAEGVPSRFSGSGSGTD FSFTIS SLEPED VAVYYCQ HHFGTPF T FGQGT KLEI K
Izuralimab,Bispecific Mixed mAb and scFv,G1;na,Kappa;Kappa,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPHSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARTYYYDSSGYYHDAFDIWGQGTMVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISRLLAWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPWTFGQGTKVEIK,EVQLVESGGGLVKPGGSLRLSCVASGFTFSNYWMNWVRQAPGKGLEWVAEIRLYSNNYATHYAESVKGRFTISRDDSKSTLYLQMNNLKTEDTGVYYCTRYYGNYGGYFDVWGRGTLVTVSS,EIVLTQSPATLSASPGERVTLTCRASQSVGNDVAWYQQKPGQAPRLLINYASHRYTGVPDRFTGSGYGTEFTLTISSVQSEDFGVYYCQQDFSSPRTFGGGTKVEIK,None;None,None;None,None;None,2020,2021,ICOS;PDCD1,Xencor,na,Solid tumours,na,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTGYYMHWVR QAPGQG LEWMGWI NPHSGGTNY AQKF QG RVTMT RDTS ISTAYMELSR LRSDDT AVYYCARTYYY DSSGY YHDAFDI WGQG TMVTVS S,DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISRLLAWYQ QKPGKAP KLLIYVA SSLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATY YC QQANSFPW T FGQGT KVEI K
Labetuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGVVQPGRSLRLSCSASGFDFTTYWMSWVRQAPGKGLEWIGEIHPDSSTINYAPSLKDRFTISRDNAKNTLFLQMDSLRPEDTGVYFCASLYFGFPWFAYWGQGTPVTVSS,DIQLTQSPSSLSASVGDRVTITCKASQDVGTSVAWYQQKPGKAPKLLIYWTSTRHTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYSLYRSFGQGTKVEIK,na,na,None,None,None,2015,2016,CEACAM5,Immunomedics,na,na,Colorectal cancer;Ovarian cancer;Breast cancer,na,,E VQLVES GGG VV QPGR SLRLSCS ASGFD FTTYWMSWVR QAPGKGL EWIGEI HPDSST IN YAPSLKD RFTISR DNAKN TLFLQM DSLRPEDTG VYFCASLY FGFPW FAYW GQGT PVTV SS,DI QLT QSPSS LSA SVGD RVTITCK ASQDVGT SVAWYQ QKPGKAP KLLIYWT STRHTGVPSRFSGSGSGT DFTFTIS SLQ PEDIATYYCQQ YS LYRS FGQGT KVEI K
Lacnotuzumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLQESGPGLVKPSQTLSLTCTVSDYSITSDYAWNWIRQFPGKGLEWMGYISYSGSTSYNPSLKSRITISRDTSKNQFSLQLNSVTAADTAVYYCASFDYAHAMDYWGQGTTVTVSS,DIVLTQSPAFLSVTPGEKVTFTCQASQSIGTSIHWYQQKTDQAPKLLIKYASESISGIPSRFSGSGSGTDFTLTISSVEAEDAADYYCQQINSWPTTFGGGTKLEIK,na,na,None,None,None,2016,2017,CSF1,Dana-Farber Cancer Institute;Novartis;Novartis Oncology;Seoul National University Hospital,na,Breast cancer;Gastric cancer;Giant cell tumour of tendon sheath;Pigmented villonodular synovitis;Malignant melanoma;Solid tumours,Bone metastases;Prostate cancer,na,,QV QLQE SGPGLVKPSQ TLSLTCTV SDYS I TSD YAWNWIRQ FPGKGL EWMGYISY SGSTSYNPSLK SRITISR DTSKN QFSLQLN S V TAADT AVYYCAS FDYA H AMDYWGQG TTVTVS S,D IVLT QSPA FLSV TPGE KVTFTCQ ASQSIGT SIHWYQ QKTDQAP KLLIKYA SESISGIPSRFSGSGSGTD FTLTISSV EAEDA ADY YCQQ INSWPTTFGGGT KLEI K
Lacutamab,Whole mAb,G1,Kappa,Phase-II,Active,QIQLVQSGSELKKPGASVKVSCKASGYTFTTAGMQWVRQAPGQGLEWIGWINSHSGVPKYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYFCARGGDEGVMDYWGQGTTVTVSS,DIQMTQSPSFLSASVGDRVTITCKASQDVSTAVAWYQQKPGQPPKLLIYWTSTRHTGVPDRFSGSGSGTDYTLTISSLQAEDVAVYYCQQHYSTPWTFGGGTKVEIK,na,na,None,None,None,2018,2019,KIR3DL2,University of Genoa;Innate Pharma,na,Mycosis fungoides;Peripheral T-cell lymphoma;Sezary syndrome,na,na,,Q IQLVQ SGS E LKKPGA SVKVSCK ASGY TFTT AG MQWVRQ APGQGL EWIGWIN SHSGVPKYAEDFKG RFVFSL DTSVS TAYLQISS LKAED TAVYFCA RGGDEGV MDY WGQG TTVTVS S,DIQ M TQSPS FLSA SVGD RVTITCK ASQDV S TAVAWYQ QKPGQPP KLLIYWT STRHTGVPDRFSGSGSGTD YTLTISS LQAED VAVYYCQ QHYSTPW T FGGG TKVEI K
Ladiratuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGLTIEDYYMHWVRQAPGQGLEWMGWIDPENGDTEYGPKFQGRVTMTRDTSINTAYMELSRLRSDDTAVYYCAVHNAHYGTWFAYWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSLLHSSGNTYLEWYQQRPGQSPRPLIYKISTRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYTFGGGTKVEIK,na,na,None,None,None,2017,2018,SLC39A6,Merck & Co;Quantum Leap Healthcare Collaborative;Seattle Genetics,na,Breast cancer,na,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGLT IE D YYMHWVR QAPGQG LEWMGWI DPENGDTEYGPK FQGRVTMT RDTSI NTAYMELSR LRSDDT AVYYCAVH NAHYG TWFAYW GQG TLVTVS S,DV VMT QSPLSLP VT LGQPA SISC RSSQ SLLH SSGN TYLEWYQ QRPGQSPRP LIYKISTR FSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCF QGSHVP YTF GGG TKVEI K
Lampalizumab,Fab,G1,Kappa,Phase-III,Discontinued,EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSS,DIQVTQSPSSLSASVGDRVTITCITSTDIDDDMNWYQQKPGKVPKLLISGGNTLRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIK,na,na,4d9q:HL:ED/4d9r:HL:ED,None,None,2012,2013,CFD,Tanox;Genentech,na,na,Dry age-related macular degeneration,na,Erroneously dropped during Feb '22 update. Readded August '22.,E VQLVQ SGPELKKPGA SVKVSCK ASGY TFTN YG MNWVR QAPGQGL EWMGWIN TYTGE TTYA DDFKG RFVFSL DTSVS TAYLQISS LKAED TAVYYCER EGGVNNWGQG TLVTVS S,DI QVT QSPSS LSA SVGD RVTITCIT STDIDDDMN WY QQKPGKVP KLLIS GGNTLRPGVPSRFSGSGSGTD FTLTIS SLQPED V ATYYCL QSDSLPY T FGQGT KVEI K
Lanadelumab,Whole mAb,G1,Kappa,Approved,NFD,EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYIMMWVRQAPGKGLEWVSGIYSSGGITVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAYRRIGVPRRDEFDIWGQGTMVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNTYWTFGQGTKVEIK,na,na,4pub:HL/4ogy:HL:MN/4ogx:HL,None,None,2015,2016,KLKB1,Dyax;Shire;Takeda,Hereditary angioedema,na,Diabetic macular oedema,na,,E VQLLES GGG LV QPGG SLRLSCA ASGF TFSHYIMMWVRQ APGKG LEWVSGIY SSGG ITVYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAYRR IGVPRRDE FDIW GQG TMVTVS S,DIQ MT QSPS TLSAS VGD RVTITCR ASQS ISSWLAWYQ QKPGKAP KLLIYK ASTLESGVPS R FSGSGSGT EFTLTIS SLQPDD FA TYYCQ QYNT YWTF GQGT KVEI K
Landogrozumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGLTFSRYPMSWVRQAPGKGLVWVSAITSSGGSTYYSDTVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARLPDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASSSVSSSYLHWYQQKPGQAPRLLIYSTSNLVAGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHHSGYHFTFGGGTKVEIK,na,na,None,None,None,2015,2016,MSTN,Eli Lilly,na,na,Cancer;Cachexia;Muscular atrophy;Pancreatic cancer,na,,E VQLVES GGG LV QPGG SLRLSC AASGL TFS RYPM SWVR QAPGKG LVWVSAIT SSGGS TYYS DTVK GRFTISR DNAKN TLYLQMNS LRAEDT AVYYCAR LPDYWGQG TLVTVS S,E IVLTQ SPG TLSL SPGE RATLSCRA SSSVSSS YLHWYQ QKPGQAP RLLIYS TSNL VA GIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQ HHSG YHFTF GGG TKVEI K
Laprituximab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVAKPGASVKLSCKASGYTFTSYWMQWVKQRPGQGLECIGTIYPGDGDTTYTQKFQGKATLTADKSSSTAYMQLSSLRSEDSAVYYCARYDAPGYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDINNYLAWYQHKPGKGPKLLIHYTSTLHPGIPSRFSGSGSGRDYSFSISSLEPEDIATYYCLQYDNLLYTFGQGTKLEIK,na,na,None,None,None,2015,2016,EGFR,ImmunoGen,na,na,Solid tumours,na,,Q VQLVQ SGA EVA KPGA SVKLSCK ASGY TFTSYWMQWVK QRPGQG LECIGTIY PGDGDT TYTQKF QG KATLTA DKSSST AYMQLSS LRSEDS AVYYCAR YDAPGY AMDY WGQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITCR ASQD INNY LAWYQ HKPGKGP KLLIHYTS TLHPGIPSRFSGSGSGRD YSFSIS SLE PEDI ATYYCLQ YDN LLYTF GQGT KLEI K
Larcaviximab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLQESGPELEMPGASVKISCKASGSSFTGFSMNWVKQSNGKSLEWIGNIDTYYGGTTYNQKFKGKATLTVDKSSSTAYMQLKSLTSEDSAVYYCARSAYYGSTFAYWGQGTLVTVSA,DIQMTQSPASLSASVGETVTITCRASENIYSYLAWYQQKQGKSPQLLVYNAKTLIEGVPSRFSGSGSGTQFSLKINSLQPEDFGSYFCQHHFGTPFTFGSGTELEIK,na,na,None,5ken:CD:GH:NO,None,2016,2017,Zaire Ebolavirus GP,Mapp Biopharmaceutical;Public Health Agency of Canada;National Institute of Allergy and Infectious Diseases,na,Ebola virus infections ,na,Zmapp Technology,,EV QLQ ESGPEL E MPGA SVKISCK ASGSS FTGFSMNWVK QSNGK SLEWIGNID TYYGGTTYNQK F KG KATLTVD KSSST AYMQLKS LTSEDS AVYYCAR SAYYGS TFAYW GQG TLVTVS A,DIQ MT QSPA SLSA SVGE TVTITCR ASEN IYSYLAWYQQK QGKSP QLLVYN AK TLI EGVPSRFSGSGSGT QFSLKI NSLQP ED FGSY FCQ HHFGTPF T FGSGT ELEI K
Latikafusp,Whole mAb Fusion,G1,Lambda,TBC,Active,EVQLVESGGSVVRPGGSLRLSCAASGFTVDDYSMSWVRQVPGKGLEWVSGINWNAGRTRYADAVKGRFTISRDSAKNSLYLQMNSLRAEDTALYYCAREFNNFESNWFDPWGQGTLVTVSS,SYELTQPPSVSVSPGQTARITCSGDALPKKYAYWYQQKPGQAPVLVISEDAKRPSGIPERFSGSSSGTMATLTISGAQVEDEADYYCYSTDASGNHRVFGGGTKLTVL,na,na,None,None,None,2022,na,PDCD1,TBC,TBC,TBC,TBC,TBC,,E VQLVE SGG SVV RPGG SLRLSC AASGF TV DDY SMSWVRQ VPGKG LEWVSGIN WNAGRT RYA DAVKG RFTISR DSAKNS LYLQMN SLRAEDT ALYYCAR EFNNFESNW F DPWGQG TLVTVS S,SYELTQPPS VSV SPGQ TARITC SGDALPKK YAYWYQ QKPGQAP VLVIS EDAKRPSGIPERFSGSSSGT MATLTI SGA Q VEDEAD YYCYST DASGN HRVFG GGT KLTV L
Latozinemab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLQESGPGLVKPSETLSLTCAVSGYSISSGYYWGWIRQPPGKGLEWIGTIYHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARQGSIKQGYYGMDVWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLRSTGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRAEAEDVGVYYCMQQQEAPLTFGGGTKVEIK,na,na,None,None,None,2020,2021,SORT1,Alector,na,Frontotemporal dementia,na,na,,QV QLQ ESGPGL V KPSE TLSLTCAV SGY SI SSG YYWGWIR QPPGKGL EWIGTIYH SGS TYY NPSLKS RVTISVD TSKN QFSLKLSS VTAAD TAVYYCA RQGS IK QG YYGMDV WGQG TTVTVS S,DI VMT QSPLSLPVTPGEPA SISC RSSQ SLLRS TGYN YLDWYL QKPGQSP QLLIYL GSNRASGVPDRFSGSGSGT DFTLKIS RAEA EDV GVYYCM QQQEAP LTF GGG TKVEI K
Lebrikizumab,Whole mAb,G4,Kappa,Phase-III,Active,QVTLRESGPALVKPTQTLTLTCTVSGFSLSAYSVNWIRQPPGKALEWLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYYPYAMDNWGQGSLVTVSS,DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPRTFGGGTKVEIK,na,na,4i77:HL,None,None,2009,2010,IL13,Chugai Pharmaceutical;Comprehensive Clinical Research Network;Dermira;Genentech;Roche;Tanox,na,Atopic dermatitis,Asthma;Chronic obstructive pulmonary disease;Hodgkin's disease;Idiopathic pulmonary fibrosis,na,,Q VTLRE SGPA LV KPTQ TLTLTCTV SGF SLSAYSVNWIR QPPGKA LEWLAMIW GDG KIVYN SALKS RLTIS KDTSKN QVVLTMT NMDPVDT ATYYC AGDGYYPYAMDNWGQG SLVTV SS,D IVMT QSPDS LSVS LGER ATINCR ASKSVDSYGN SFMHWYQ QKPGQPP KLLIYLA SNLESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQ QNNEDPRTFGGG TKVEI K
Lecanemab,Whole mAb,G1,Kappa,Preregistration,Active,EVQLVESGGGLVQPGGSLRLSCSASGFTFSSFGMHWVRQAPGKGLEWVAYISSGSSTIYYGDTVKGRFTISRDNAKNSLFLQMSSLRAEDTAVYYCAREGGYYYGRSYYTMDYWGQGTTVTVSS,DVVMTQSPLSLPVTPGAPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLRISRVEAEDVGIYYCFQGSHVPPTFGPGTKLEIK,na,na,None,None,None,2019,2020,APP,Biogen;Eisai,na,Alzheimer's disease;Brain injuries;Down syndrome,na,na,(June '22: Corrected FWL3 sequence),E VQLVES GGG LV QPGG SLRLSCS ASGF TFSS F GMHWVRQ APGKG LEWVAYIS SGSS TIYY GD TVKGRFTISR DNAKNS LFLQMSS LRAEDT AVYYCA REGG YYY G RSYYTMD YWGQG TTVTVS S,DV VMT QSPLSLPVTPGAPA SISC RSSQ SIVH SNGN TYLEWYL QKPGQSP KLLIYKVS NRFSGVPDRFSGSGSGT DFTLRISRVE AEDV GIYYCF QGSHVPPTFGPGT KLEI K
Lemalesomab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLQESGPELKKPGETVKISCKASGYTFRNYGMNWVKQAPGKGLKWMGWINTYTGEPTYADDFKGRFAFSLETSASTAYLQINNVKNEDTATYFCARKGWMDFNGSSLDYWGQGTTVTVSS,DIQLTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPNLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPPTFGGGTKLEIK,na,na,None,None,None,2002,2002,NCA90,ND,na,na,Diagnosis of Lesions,na,,QV QLQ ESGPELKKPGE TVKISCK ASGY TFRN YGM NWVK QAPGKGL KWMGWIN TYTGEPTYADDFKG RFAFSLET SAS TAYLQIN NVKNEDTA TYFCAR KGW M DFNGS SLDY WGQG TTVTVS S,DI QLT QTPLSLPVSLGDQ ASISC RSSQ SIVH SNGN TYLEWYL QKPGQSPN LLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDL GVYYCF QGSHVPPTFGGGT KLEI K
Lemzoparlimab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGLTFERAWMNWVRQAPGKGLEWVGRIKRKTDGETTDYAAPVKGRFSISRDDSKNTLYLQMNSLKTEDTAVYYCAGSNRAFDIWGQGTMVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYAGNNRNYLAWYQQKPGQPPKLLINQASTRASGVPDRFSGSGSGTEFTLIISSLQAEDVAIYYCQQYYTPPLAFGGGTKLEIK,na,na,None,None,None,2020,2021,CD47,I-Mab Biopharma,na,Lymphoma;Solid tumours;Acute myeloid leukaemia;Myelodysplastic syndromes,na,na,,E VQLVES GGG LV KPGG SLRLSC AASGLT FER A WMNWVR QAPGKGL EWVGRIKR KTDGETTDYAAP V K GRFSISR DDSKN TLYLQMN SLKTEDT AVYYC AGSNR AFDIW GQG TMVTVS S,D IVMT QSPDS LAVS LGER ATINC KSSQ SVLYA GNNRN YLAWYQ QKPGQPP KLLIN QASTRASGVPDRFSGSGSGT EFTLIISS LQAED VAIYYCQQ YYTPPL A FGGGT KLEI K
Lenvervimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVKPGGSLRLSCSASGFSLTKYKMTWVRQAPGKGLEWVSSISSTSRDIDYADSVKGRFTISRDNAKNSLFLQMSSLRVDDTAVYYCTRDGWLWGWDVRSNYYYNALDVWGQGTTVTVSS,DIVVTQSPSSLSASVGDRVTITCRASQGIYNSIAWYQQKPGKAPKLLLYSTSTLLSGVPSRFSGSGSGTDYTLTITNLQPEDFATYYCQQYFVTPETFGQGTKLEIK,na,na,None,None,None,2017,2018,HBV,Green Cross;GC Pharma;AbbVie,na,Hepatitis B,na,na,,E VQLVES GGG LV KPGG SLRLSCS ASGFS L T KYKMTWVRQ APGKG LEWVSSIS STSRDIDYADSVKG RFTISR DNAKNS LFLQMSSLRV DDT AVYYC TRDG WLWGWD VRSN YYYNALDV WGQG TTVTVS S,D IVVTQ SPSS LSA SVGD RVTITCR ASQGI YNSIAWYQ QKPGKAP KLLLYS TSTL L SGVPSRFSGSGSGTD YTLTIT NLQ PEDFAT YYCQQYF VTPE T FGQGT KLEI K
Lenzilumab,Whole mAb,G1,Kappa,Preregistration,Active,QVQLVQSGAEVKKPGASVKVSCKASGYSFTNYYIHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCVRRQRFPYYFDYWGQGTLVTVSS,EIVLTQSPATLSVSPGERATLSCRASQSVGTNVAWYQQKPGQAPRVLIYSTSSRATGITDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFNKSPLTFGGGTKVEIK,na,na,None,None,None,2014,2015,CSF2,Humanigen;KaloBios Pharmaceuticals,na,COVID-19;Cytokine release syndrome;B-cell lymphoma;Drug hypersensitivity;Precursor cell lymphoblastic leukaemia-lymphoma;Graft-versus-host disease,Asthma;Rheumatoid arthritis;Chronic myelomonocytic leukaemia;Solid tumours,Humaneering Technology,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGYS FTNYYIHWVR QAPGQ RLEWMGWIN AGNGNTK YSQKF QG RVTITR DTSAS TAYMELS SLRSEDT AVYYCVR RQRFPY YFDY WGQG TLVTVS S,E IVLTQ SPA TLSV SPGE RATLSCR ASQSVGT NVAWYQ QKPGQAP RVLIYS TSSRATG ITD RFSGSGSGT DFTLTISR LEPED FAVYYCQ QFNKSPL TF GGG TKVEI K
Lepunafusp,Whole mAb Fusion,G1,Kappa,Phase-I/II,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFMNYWLGWVRQMPGKGLEWMGDIYPGGDYPTYSEKFKVQVTISADKSISTAYLQLSSLKASDTAMYYCARSGNYDEVAYWGQGTLVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK,na,na,None,None,None,2021,2022,TfR1,JCR Pharmaceuticals,na,Mucopolysaccharidosis I,na,na,,E VQLVQ SGA EVK KPGE SLKISC KGSGYS FMNYWL GWVR QMPGKGL EWMGDI YPGGDYPTYSEK FKVQVTIS ADKS ISTAYLQLS SLKASDT AMYYCA RSGNYD EVAYW GQG TLVTV SS,DI VMT QTP LSLSV TPGQP ASISCR SSQ SLVH SNGN TYLHWYLQ KPGQSP QLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCS QSTHVPW T FGQGT KVEI K
Lerdelimumab,Whole mAb,G4,Lambda,Phase-III,Discontinued,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMDSLRAEDTAVYYCGRTLESSLWGQGTLVTVSS,SSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSSTHRGVFGGGTKLTVL,na,na,None,None,None,2002,2002,TGFB1,Cambridge Antibody Technology,na,na,Cataracts;Proliferative vitreoretinopathy;Scars,na,,E VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKGL EWVAVIWY DGSNK YYAD SVKG RFTISR DNSKN TLYLQMD SLRAED TAVYYC GR TLES S L WGQG TLVTVS S,SSELTQDPA VSVA LGQ TVRITC QGDS LRSYYASWY QQKPGQAP VLVIY GKNNRPSGIPDRFSGSSSGN TASLTIT GAQAEDEAD YYC NSRDSSSTHRG VF GGGT KLTV L
Leronlimab,Whole mAb,G4,Kappa,Approved,Active,EVQLVESGGGLVKPGGSLRLSCAASGYTFSNYWIGWVRQAPGKGLEWIGDIYPGGNYIRNNEKFKDKTTLSADTSKNTAYLQMNSLKTEDTAVYYCGSSFGSNYVFAWFTYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQRLLSSYGHTYLHWYLQKPGQSPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPLTFGQGTKVEIK,na,na,None,None,None,2017,2018,CCR5,CytoDyn;Progenics Pharmaceuticals;The Scripps Research Institute,Breast cancer,HIV infections;HIV-1 infections;Graft-versus-host disease;Colorectal cancer;Non-alcoholic steatohepatitis;Prostate cancer;COVID-19;Autoimmune disorders;Stroke;Traumatic brain injuries,na,na,,E VQLVES GGG LV KPGG SLRLSCA ASGY TF SN YWIGWVRQ APGKGL EWIGDI YPGGN YIR NNEKFKDK TTLSA DTSKN TAYLQM NSLKTEDT AVYYC GSSFGSN YVFAWFTY WGQG TLVTVS S,DI VMT QSPLSLPVTPGEPA SISC RSSQ RLLS SYGH TYLHWYL QKPGQSP QLLIYEVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYC SQSTHVP LTF GQGT KVEI K
Lesabelimab,Whole mAb,G1,Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGYSISSGYYWGWIRQAPGKGLEWIGIIYPSGGGTNYAQKFQGRVTISRDNSKNTLYLQLNSLRAEDTAVYYCARGGGLGFDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSIPSFLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHYISWPRQFTFGQGTKVEIK,na,na,None,None,None,2022,na,CD274,TBC,TBC,TBC,TBC,TBC,,E VQLVES GGG LV QPGG SLRLSC AASGY SI SSG YYWGWIRQ APGKGL EWIGIIY PSGGGTNYA QKF Q GRVTISR DNSKN TLYLQLNS LRAEDT AVYYCA RGGGLG FDY WGQG TLVTV SS,DI QLT QSPSS LSA SVGD RVTITCR ASQSI PSFLNWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQ PEDFATYYCQH Y ISWPR QFTF GQGT KVEI K
Lesofavumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVQSGAEVKKPGESLKISCKVSGYSFTSQWIGWVRQMPGKGLEWIGMMYPGESETIYSPSFQGQVTISADNSISTAYLQWSSLKASDTAIYYCASGPGYSGYHYGWFDTWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLRSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTKLEIK,na,na,None,None,None,2016,2017,Influenza B Virus,Genentech,na,na,Influenza B virus infections,na,,E VQLVQ SGA EVK KPGE SLKISCKV SGY SF TS QWIGWVRQ MPGKGL EWIGMM YPGESE TIY SPSFQG QVTIS ADNS ISTAYLQWS SLKASDT AIYYC ASGPGYSG YHYGWF DTWGQG TLVTVS S,DI VMT QSPLSLPVTPGEPA SISC RSS QSLLR SNGYN YLDWYL QKPGQSP QLLIYL GSNRASGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCMQA LQTPY T FGQGT KLEI K
Letaplimab,Whole mAb,G4,Kappa,Phase-I/II,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGKTGSAAWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTVSFPITFGGGTKVEIK,na,na,None,None,None,2020,2021,CD47,Innovent Biologics,na,Acute myeloid leukaemia;Lymphoma;Myelodysplastic syndromes;Solid tumours,na,na,,Q VQLQE SGPGL V KPSE TLSLTCTV SGGS I S SYYWSWIR QPPGKGL EWIGYIYYS GSTNYNPSLK SRVTISVD TSKN QFSLKLSS VTAADT AVYYCA RGKTGSAAWGQG TLVTVS S,DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISRWLAWY QQKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQP EDFA TYYC QQ TVSFPITF GGG TKVEI K
Letolizumab,Single Domain Variable Fragment;H,G1,na,Phase-I/II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFNWELMGWARQAPGKGLEWVSGIEGPGDVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVKVGKDAKSDYRGQGTLVTVSS,na,na,na,None,None,None,2016,2017,CD40LG,Bristol-Myers Squibb;H. Lee Moffitt Cancer Center and Research Institute,na,Graft-versus-host disease;Idiopathic thrombocytopenic purpura,na,na,,E VQLLES GGG LV QPGG SLRLSC AASGF TFNWELMGWAR QAPGKG LEWVS GIEGPGD VTYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCVKV GKDAKSDYRGQ GTLVTVS S,NA
Levilimab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIYSDGTTHYGDSVKGRFTISRDNAKNTVYLQLNSLRAEDTAMYYCAKGAGPTWWYALDAWGQGTLVTVSS,DIQLTQSPSSVSVSVGERVTIDCKSSQSVLSASNTYLNWYQQKPGQAPQLLIYYASTRESGVPDRFSGSGSGTDFTLTISSLQAEDAAVYYCQQAYRAPVTFGQGTKLEIK,na,na,None,None,None,2018,2019,IL6R,Biocad,COVID-19;Cytokine release syndrome,Rheumatoid arthritis,na,na,,Q VQLVQS GGG LV QPGG SLRLSC AASGF TFSSYYMSWVR QAPGKG LEWVSGIY SDGT T HYGDS VKGRFTISR DNAKN TVYLQLNS LRAEDT AMYYCA KGAGPT WWYALD AWGQG TLVTVS S,DI QLT QSPS SVSVS VGE RVTID CKSSQS VLS ASNT YLNWY QQKPGQAP QLLIYYA STRESGVPDRFSGSGSGTD FTLTISS LQAEDA AVYYCQQ AYRAP VTF GQGT KLEI K
Lexatumumab,Whole mAb,G1,Lambda,Phase-I,Discontinued,EVQLVQSGGGVERPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSGINWNGGSTGYADSVKGRVTISRDNAKNSLYLQMNSLRAEDTAVYYCAKILGAGRGWYFDLWGKGTTVTVSS,SSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHVVFGGGTKLTVL,na,na,None,None,4od2:BA,2006,2007,TNFRSF10B,Cambridge Antibody Technology;Human Genome Sciences,na,na,Solid tumours,na,,E VQLVQS GGG VE RPGG SLRLSC AASGF TF DDYGM SWVRQ APGKGL EWVSGIN WNGGSTGYADSVKG RVTISR DNAKN SLYLQMN SLRAEDT AVYYCAKIL GAGRG WYFDL WGKG TTVTVS S,SSELTQDPA VSVA LGQ TVRITC QGDS LRSY Y ASWY QQKPGQAP VLVIY GKNNRPSGIPDRFSGSSSGN TASLTIT GAQAEDEA DYYCN SRDSSGN HVVF GGGT KLTV L
Libivirumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVESGGGVVRPGRSLRLSCAASGFAFSDYSINWVRQAPGKGLEWVAIISYDGRITYYRDSVKGRFTISRDDSKNTLYLQMNSLRTEDTAVYYCARQYYDFWSGSSVGRNYDGMDVWGLGTTVTVSS,DIVMTQSPLSLSVTPGEPASISCRSSQSLLHRSGNNYLDWYLQKPGHSPQLLIYVGSNRASGVPDRFSGSGSGTEYTLKISRVEAEDVGVYYCMQALQTPRTFGQGTKLEIK,na,na,None,None,None,2004,2005,Hepatitis B Surface Antigen,XTL Biopharmaceuticals;Yeda,na,na,Hepatitis B infection,na,,Q VQLVES GG GVV RPGR SLRLSC AASGF AF SDY SINWVRQ APGKGL EWVAIIS YDG RITYYR DSVKG RFTISR DDSKN TLYLQMN SLRTEDT AVYYCARQYY DFWSGSSVGRNYDGM DVW GLG TTVTVS S,D IVMT QSPL SLSV TPGEP ASISCR SSQS LLH RSGNN YLDWYL QKPGHSP QLLIYVG SNRASGVPDRFSGSGSGT EYTLKISRVE AEDV GVYYCMQA LQTPRTFGQGT KLEI K
Licaminlimab,scFv,na,Lambda,Phase-II,Active,EVQLVESGGGSVQPGGSLRLSCTASGFTISRSYWICWVRQAPGKGLEWVGCIYGDNDITPLYANWAKGRFTISRDTSKNTVYLQMNSLRAEDTATYYCARLGYADYAYDLWGQGTTVTVSS,EIVMTQSPSTLSASVGDRVIITCQSSQSVYGNIWMAWYQQKPGRAPKLLIYQASKLASGVPSRFSGSGSGAEFTLTISSLQPDDFATYYCQGNFNTGDRYAFGQGTKLTVL,na,na,None,None,None,2020,2021,TNFA,Oculis,na,Dry eye syndrome,na,na,(Jan '22) Added missing FWH1 residue. (Jun '22) Corrected CDRH3 sequence,E VQLVES GGG SV QPGG SLRLSCT ASGF TIS R SYWICWVRQ APGKGL EWVGCIY GDNDITP LYAN WAKG RFTISR DTSKN TVYLQMN SLRA EDTATYYCAR LGYAD YAYDL WGQG TTVTVS S,E IVMT QSPS TLSAS VGD RVIITC QSSQSVYGN IWMAWY QQKPGRAP KLLIYQA SKLASGVPS RF SGSGSGA EFTLTISS LQPDDF ATYYCQ GNFNTGDR YAF GQGT KLTV L
Lifastuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFSFSDFAMSWVRQAPGKGLEWVATIGRVAFHTYYPDSMKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHRGFDVGHFDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSETLVHSSGNTYLEWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFQGSFNPLTFGQGTKVEIK,na,na,None,None,None,2013,2014,SLC34A2,Genentech,na,na,Fallopian tube cancer;Non-small cell lung cancer;Ovarian cancer;Peritoneal cancer,na,,E VQLVES GGG LV QPGG SLRLSCA ASGFSFS DF AMSWVR QAPGKG LEWVATI G RVAFHTY YPDSMK GRFTISR DNSKN TLYLQMN SLRAEDT AVYYCA R HRGF DVGHFDFW GQG TLVTV SS,DI QMT QSPSS LSA SVGD RVTITCR SSE TLVH SSGN TYLEWYQ QKPGKAP KLLIYRVS NRFSGVPS R FSGSGSGT DFTLTISS LQPEDF ATYYCF QGSFNPL T FGQGT KVEI K
Ligelizumab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVMKPGSSVKVSCKASGYTFSWYWLEWVRQAPGHGLEWMGEIDPGTFTTNYNEKFKARVTFTADTSTSTAYMELSSLRSEDTAVYYCARFSHFSGSNYDYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSIGTNIHWYQQKPGQAPRLLIYYASESISGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQSWSWPTTFGGGTKVEIK,na,na,6uqr:AA:CC,None,None,2012,2013,IGHE,Novartis;Tanox,na,Urticaria;Allergic asthma;Atopic dermatitis;Bullous pemphigoid,Hypersensitivity,na,,Q VQLVQ SGA EVM KPGS SVKVSCK ASGY TFSWYWLEWVR QAPGHGL EWMGEI DPGT FTT NYNEK FKARVTFTA DTSTS TAYMELSS LRSEDT AVYYCARFS HFSGSNYD YFDY WGQG TLVTVS S,E IVMT QSPA TLSV SPGE RATLSCR ASQSIGT NIHWYQ QKPGQAP RLLIYYA SESISGIP ARFS GSGSGT EFTLTISS LQSED FAVYYCQ QSWSWPTTFGGG TKVEI K
Ligufalimab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVVKPGASVKLSCKASGYTFTSYWMNWVRQRPGQGLEWIGMIDPSDSETHNAQKFQGKATLTVDKSTSTAYMHLSSLRSEDTAVYYCARLYRWYFDVWGAGTTVTVSS,NIVMTQSPATMSMSPGERVTLSCRASEIVGTYVSWFQQKPGQAPRLLIYGASNRYTGVPARFSGSGSGTDFTLTISSVQPEDLADYHCGQSYNFPYTFGGGTKLEIK,na,na,None,None,None,2021,2022,CD47,Akeso Biopharma,na,Acute myeloid leukaemia;Neoplasms;Myelodysplastic syndromes,na,na,,Q VQLVQ SGA EVV KPGA SVKLSCK ASGY TFTSYWMNWVR QRPGQGL EWIGMI DPSDSETHNAQKFQG KATLTVD KSTS TAYMHLS SLRSED TAVYYCARLYRWYFDV WGAGT TVTVS S,N IVMTQ SPA TMS MSPGE RVTLSCR ASE IVGTYVSWF QQKPGQAP RLLIYG ASNRYTGVP ARF SGSGSGTD FTLTISS VQ PEDL ADYHCGQSYNFPYTFGGGT KLEI K
Lilotomab,Whole mAb ADC,G1,Kappa,Phase-II,Active,EIQLQQSGPELVKPGASVKVSCKASGYSFTDYNMYWVKQSHGKSLEWIGYIDPYNGDTTYNQKFKGKATLTVDKSSSTAFIHLNSLTSEDSAVYYCARSPYGHYAMDYWGQGTSVTVSS,DIVMTQSHKLLSTSVGDRVSITCKASQDVSTAVDWYQQKPGQSPKLLINWASTRHTGVPDRFTGSGSGTDYTLTISSMQAEDLALYYCRQHYSTPFTFGSGTKLEIK,na,na,None,None,None,2014,2015,CD37,Nordic Nanovector,na,Follicular lymphoma;Non-Hodgkin's lymphoma;Diffuse large B cell lymphoma,na,na,,EI QLQ QSGPE LV KPGA SVKVSCK ASGYSFTDY NMYWVK QSHGK SLEWIGYI DPYNGDTT Y NQ KF KG KATLTVD KSSS TAFIHLN SLTSEDS AVYYCAR SPYGH YAMD YWGQG TSVTVS S,DI VMT QSH KLLST SVGD RVSITCK ASQD VSTAVDWYQ QKPGQSP KLLINW ASTRHTGVPDRFTGSGSGTD YTLTISS MQ AEDLALYYCRQ HYSTPF TF GSGT KLEI K
Linavonkibart,Whole mAb,G4,Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCTASGFTFSSFSMDWVRQAPGKGLEWVSYISPSADTIYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARGVLDYGDMLMPWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQADNHPPWTFGGGTKVEIK,na,na,None,None,None,2022,na,TGFB1,TBC,TBC,TBC,TBC,TBC,,E VQLVES GGG LV QPGG SLRLSCT ASG FTFSSFSMDWVR QAPGKGL EWVSYI SPSAD TIYYA DSVKG RFTISR DNAKN TLYLQMN SLRAEDT AVYYCA RGV L DYGD ML MPWGQG TLVTVS S,DIQMTQSPSS LSA SVGD RVTITCQ AS QDITNYLNWYQ QKPGKAP KLLIYD ASNLETGVPSRFSGSGSGTD FTFTIS SLQ PEDIATYYCQ QADNHPPWTFGGGT KVEI K
Lintuzumab,Whole mAb Radiolabelled,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYNMHWVRQAPGQGLEWIGYIYPYNGGTGYNQKFKSKATITADESTNTAYMELSSLRSEDTAVYYCARGRPAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASESVDNYGISFMNWFQQKPGKAPKLLIYAASNQGSGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQSKEVPWTFGQGTKVEIK,na,na,None,None,None,1996,1997,CD33,PDL BioPharma;Seattle Genetics,na,na,Acute myeloid leukaemia;Myelodysplastic syndromes,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TFT DYN MHWVRQ APGQG LEWIGYIYP YNGGTGYNQK FKSKATITA DESTN TAYMELS SLRSEDT AVYYCA RGRPAMDYWGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCRA SESVDNY GISFMN W F QQKPGKAP KLLIYAA SNQGSGVPS R FSGSGSGTD FTLTISS LQPDD FA TYYC QQSKEVPW T FGQGT KVEI K
Linvoseltamab,Bispecific mAb,G4;G4,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFWMTWVRQAPGKGLEWVANMNQDGSEKYYVDSVKGRFTISRDNAKSSLYLQMNSLRAEDTAVYYCARDREYCISTSCYDDFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYSMHWVRQAPGKGLEWVSGISWNSGSKGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKYGSGYGKFYHYGLDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK,None;None,None;None,None;None,2022,na,TNFRSF17,Regeneron Pharmaceuticals,na,Multiple Myeloma,na,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TF SN FWMTWVR QAPGKG LEWVANM NQDGS EKYYVD SVKG RFTIS RDNAKS SLYLQMN SLRAEDT AVYYC ARDRE YCIST SCYDDFDYWGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQS ISSYLNWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQP EDFA TYYC QQSYSTPP ITF GQGT RLEI K
Lipustobart,Whole mAb,G4,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWMGGVNPSNGGTNFNEKFKSRVTITADKSTSTAYMELSSLRSEDTAVYYCARRDYRYDMGFDYWGQGTTVTVSS,EIVLTQSPATLSLSPGERATISCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFATYYCQHSRELPLTFGTGTKVEIK,na,na,None,None,None,2022,na,PDCD1,TBC,TBC,TBC,TBC,TBC,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYYMYWVRQ APGQG LEWMG G V NPSNGGTNFNEKFK SRVTITA DKSTS TAYMELSS LRSEDT AVYYCAR RDYR Y DMG FDY WGQG TTVTVS S,E IVLT QSPA TLSL SPGE RATISCR ASKGVSTSGY SYLHWY QQKPGQAP RLLIY LASYL ESGVP ARFS GSGSGTD FTLTIS SLE PEDFATY YC QHSRELPL TF GTGT KVEI K
Lirentelimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFSLTIYGAHWVRQAPGKGLEWVGVIWAGGSTNYNSALMSRFTISKDNSKNTVYLQMNSLRAEDTAVYYCARDGSSPYYYSMEYWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCSATSSVSYMHWFQQKPGQAPRLLIYSTSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSSYPFTFGPGTKLDIK,na,na,None,None,None,2020,2021,SIGLEC8,Allakos,na,Eosinophilic gastroenteritis;Eosinophilic oesophagitis;Urticari;Atopic dermatitis;Chronic obstructive pulmonary disease,Conjunctiviti;Fibrosis;Kertoconjunctivitis;Systemic mastocytosis,na,,E VQLVES GGG LV QPGG SLRLSC AASGF SLTIYGAHWVRQ APGKGL EWVGVIWA GGSTNYNSA LMSRFTIS KDNSKN TVYLQMNS LRAEDT AVYYCA RDGSSP YYYSMEYW GQGT TVTVS S,E IVLTQ SPA TLSL SPGE RATLSCS ATSS VSYMHWF QQKPGQAP RLLIYS TSNLASGIP ARFS GSGSGT DFTLTIS SLEPED FAVYYCQ QRSSYPF TF GPGT KLD IK
Lirilumab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSFYAISWVRQAPGQGLEWMGGFIPIFGAANYAQKFQGRVTITADESTSTAYMELSSLRSDDTAVYYCARIPSGSYYYDYDMDVWGQGTTVTVSS,EIVLTQSPVTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWMYTFGQGTKLEIK,na,na,None,None,None,2012,2013,KIRD2,Novo Nordisk;Bristol-Myers Squibb;Dana-Farber Cancer Institute;Innate Pharma;National Cancer Institute (USA);Ono Pharmaceutical;PrECOG;University of Texas M. D. Anderson Cancer Center,na,Chronic lymphocytic leukaemia;Head and neck cancer;Myelodysplastic syndromes;Solid tumours;Bladder cancer,Acute myeloid leukaemia;Hepatitis C;Haematological malignancies;Multiple myeloma;Lymphoma,Medarex UltiMAb Mouse,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSFYAISWVR QAPGQGL EWMGGFIPIF GAANYAQKFQG RVTITA DESTS TAYMELSS LRSDDT AVYYCAR IPSGS YYYD YDMD V WGQG TTVTVS S,E IVLT QSP VTLSL SPGE RATLSCR ASQS VSSY LAWY QQKPGQAP RLLIYD ASNRATG I P ARF SGSGSGTD FTLTIS SLEPED FAVYYCQ QRSN WMYTF GQGT KLEI K
Litifilimab,Whole mAb,G1,Kappa,Phase-III,Active,DVQLVESGGGLVKPGGSLRLSCAASGFTFSTYTMSWVRQAPGKGLEWVATISPGDSFGYYYPDSVQGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCTRDIYYNYGAWFAYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCKASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASTLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANEDPRTFGQGTKVEIK,na,na,None,None,None,2022,na,CLEC4C,Biogen Idec,na,Systemic lupus erythematosus;Cutaneous lupus erythematosus,na,na,,D VQLVES GGG LV KPGG SLRLSC AASGF TFSTYTMSWVR QAPGKG LEWVATI SPGDS FGYY YPDSVQ GRFTIS RDNAKN SLYLQMNS LRAEDT AVYYCT RDI YY NYG AWFAYW GQG TLVTVS S,DI QLT QSPSS LSA SVGD RVTITCK ASQS V DYDGD SYMNWYQ QKPGKAP KLLIYAA STLESGVPS R FSGSGSGTD FTLTIS SLQPE DFA TYYCQ QANEDPRTFGQGT KVEI K
Livmoniplimab,Whole mAb,G4,Kappa,Phase-I,Active,QVQLVQPGAEVRKPGASVKVSCKASGYRFTSYYIDWVRQAPGQGLEWMGRIDPEDAGTKYAQKFQGRVTMTADTSTSTVYVELSSLRSEDTAVYYCARYEWETVVVGDLMYEYEYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQSISSYLAWYQQKPGQAPKILIYGASRLKTGVPSRFSGSGSGTSFTLTISSLEPEDAATYYCQQYASVPVTFGQGTKVEIK,na,na,None,None,None,2021,2022,LRRC32,AbbVie,na,Solid tumours,na,na,,Q VQLV QPGA EVR KPGA SVKVSCK ASGY RFTSYYIDWVR QAPGQG LEWMGR IDP ED AGTK YAQK FQG RVTMTA DTSTS TVYVELS SLRSEDT AVYYCAR YE WETVVV GD LMYEYEYW GQG TLVTVS S,DIQMTQSPSS LSA SVGD RVTITCQ ASQS ISSYLAWYQ QKPGQAP KILIYG ASRLKTGVPSRFSGSGSGT SFTLTIS SLE PEDAATYYCQQ YASVP VTF GQGT KVEI K
Lodapolimab,Whole mAb,G1,Lambda,Phase-I,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARSPDYSPYYYYGMDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCQSYDSSLSGSVFGGGIKLTVL,na,na,None,None,None,2019,2020,PDL1,Dana-Farber Cancer Institute;Eli Lilly,na,na,Solid tumours,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSSYAISWVR QAPGQGL EWMGGIIPIF GTANYAQKFQG RVTITA DKSTS TAYMELS SLRSEDT AVYYCA RSPDYSP YYYYGMDV WGQG TTVTVS S,QSVLTQPPSASGTPGQ RVTISC SGSSSNIGSN TVNWYQQ LPGTAP KLLIY GNSNRPSGVPDRFSGSKSGT SASLAI SGLQSED EADY YCQ SYDSSLSGS VF GGG IKLTV L
Lodelcizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFSTMYMSWVRQAPGQGLEWMGRIDPANEHTNYAQKFQGRVTMTRDTSISTAYMELSRLTSDDTAVYYCARSYYYYNMDYWGQGTLVTVSS,QIVLTQSPATLSVSPGERATLSCRASQSVSYMHWYQQKPGQAPRLLIYGVFRRATGIPDRFSGSGSGTDFTLTIGRLEPEDFAVYYCLQWSSDPPTFGQGTKLEIK,na,na,None,None,None,2012,2013,PCSK9,Novartis,na,na,Hypercholesterolaemia,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFSTMYMSWVR QAPGQG LEWMGRI DPANEHTNY A Q KF QG RVTMT RDTS ISTAYMELS RLTSDDT AVYYCA RS YYYY NMDYWGQG TLVTV SS,Q IVLTQ SPA TLSV SPGE RATLSCR ASQS VSYMHWYQ QKPGQAP RLLIYGVFRR ATGIPDRFSGSGSGT DFTLTIGR LEPED FAVYYCLQW SSDPPTFGQG TKLEI K
Lokivetmab,Canine Whole mAb,G2,Kappa,Approved,NFD,EVQLVESGGDLVKPGGSLRLSCVASGFTFSNYGMSWVRQAPGKGLQWVATISYGGSYTYYPDNIKGRFTISRDNAKNTLYLQMNSLRAEDTAMYYCVRGYGYDTMDYWGQGTLVTVSS,EIVMTQSPASLSLSQEEKVTITCKASQSVSFAGTGLMHWYQQKPGQAPKLLIYRASNLEAGVPSRFSGSGSGTDFSFTISSLEPEDVAVYYCQQSREYPWTFGQGTKLEIK,na,na,None,None,None,2014,2015,IL31,Zoetis,Canine atopic dermatitis,na,na,na,,E VQLVE SGGD LV KPGG SLRLSCVA SGF TF SNYG MSWVRQ APGKG LQWVATIS YGGS YTY YPDNIK GRFTISR DNAKN TLYLQMN SLRAEDT AMYYCVR GYGYDTMDYWGQG TLVTVS S,E IVMT QSPA SLS LSQEE KVTITCK ASQ SVSF AGTG LMHWYQ QKPGQAP KLLIYRA SNLEAGVPSRFSGSGSGTD FSFTIS SLEPED VAVYYCQ QSREYPW T FGQGT KLEI K
Lomtegovimab,Whole mAb,G1,Kappa,Phase-II/III,Active,QVQLVESGGGVVQPGRSLRLSCAATGFTFRRYGMHWVRQAPGKGLEWVAGILFDGSNKYYVDSVKGRFTISRDSSRNTLYLQLNSLRREDTAVYYCAKGGDYEWELLESWGQGTLVTVSS,DIQMTQSPSTVSASVGDRVTITCRASQSIDNWLAWYQEKPGKAPKVLIYKASSLESGVPSRFSGRGSGTEFTLTISSLQPGDFATYYCQHYHSFPLTFGGGTKVDIK,na,na,None,None,None,2021,2022,SARS-CoV-2 Spike RBD,Boehringer Ingelheim,na,COVID-19,na,na,(June '22: Corrected VH sequence),Q VQLVES GGG VV QPGR SLRLSC AATG FTFRRY G MHWVRQ APGKGL EWVAGILF DGSNK YYVD SVKG RFTISR DSSRN TLYLQLN SLRREDT AVYYCA KGGDY EWELLES WGQG TLVTVS S,DIQ MT QSPS TVSAS VGD RVTITCR ASQS IDNWLAW Y QEKPGKAP KVLIYKA SSLESGVPS RF SGRGSGT EFTLTISS LQPGD FATYYCQ HYHSFP LTF GGGT KVDI K
Lomvastomig,Bispecific mAb with Domain Crossover,G1;G1,Kappa;Kappa,TBC,Active,EVQLLESGGGLVQPGGSLRLSCAASGFSFSSYTMSWVRQAPGKGLEWVATISGGGRDIYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVLLTGRVYFALDSWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKASESVDTSDNSFIHWYQQKPGQSPKLLIYRSSTLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNYDVPWTFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFNIKTTYMHWVRQAPGKGLEWVGRIDPADDNTKYAPKFQGKATISADTSKNTAYLQMNSLRAEDTAVYYCVRDFGYVAWFAYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRASQSVDNYVAWYLQKPGQSPQLLIYYASNRYIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQHYSSPYTFGQGTKVEIK,None;None,None;None,None;None,2022,na,PDCD1;HAVCR2,TBC,TBC,TBC,TBC,Humanised,,E VQLLES GGG LV QPGG SLRLSCA ASGF SF S SYTMSWVR QAPGKG LEWVATIS GGGRD IY YPDSVK GRFTISR DNSKN TLYLQMNS LRAEDT AVYYCVLL TGR VYFALD SWGQG TLVTVS S,D IVMT QSPDS LAVS LGER ATINCK ASESVDTSDNS FIHWYQ QKPGQSP KLLIYR SSTLESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQ QNYDVPW TF GQGT KVEI K
Loncastuximab,Whole mAb ADC,G1,Kappa,Approved,Active,QVQLVQPGAEVVKPGASVKLSCKTSGYTFTSNWMHWVKQAPGQGLEWIGEIDPSDSYTNYNQNFQGKAKLTVDKSTSTAYMEVSSLRSDDTAVYYCARGSNPYYYAMDYWGQGTSVTVSS,EIVLTQSPAIMSASPGERVTMTCSASSGVNYMHWYQQKPGTSPRRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEPEDAATYYCHQRGSYTFGGGTKLEIK,na,na,None,6ani:HL:IM,None,2017,2018,CD19,ADC Therapeutics,Diffuse large B cell lymphoma,Follicular lymphoma;Mantle-cell lymphoma;Non-Hodgkin's lymphoma,Precursor B-cell lymphoblastic leukaemia-lymphoma,na,,Q VQLV QPGA EVV KPGA SVKLSC KTSG YTFT SN WMHWVK QAPGQGL EWIGEI DPSDSYTNYNQNFQG KAKLTVD KSTS TAYMEVSSL RSDDT AVYYCA RGSNP YYYAMD YWGQGT SVTVS S,E IVLT QSP AIMS ASPGE RVTMTCS ASSGVN YMHWYQ QKPGTSPR RWIYD TSKLASGVP ARFS GSGSGT SYSLTISS MEPEDAA TYYCH QRGS YTF GGG TKLEI K
Lonigutamab,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYIHWVRQAPGQGLEWMGWIWPGDGSTKYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYFCASPMITPNYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISKYLNWYQQKPGKAPKLLIYYTSRLQSGVPSRFSGRGSGTDYSLTISSLQPEDFATYFCQQGSTLPYTFGGGTKVEIK,na,na,None,None,None,2020,2021,IGF1R,Pierre Fabre,na,Solid tumours,na,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYYIHWVR QAPGQG LEWMGWIW PGDGSTK YAQKF QG RVTMTR DTSTS TVYMELS SLRSEDT AVYFCA SPMITPNYA M DYWGQG TLVTV SS,DIQ MT QSPSS LSA SVGD RVTITCR ASQD ISKYLNWYQ QKPGKAP KLLIYYT SRLQSGVPS RF SGRGSGTD YSLTIS SLQ PEDFATY F C QQGSTLP YT FGGGT KVEI K
Lorigerlimab,Bispecific Mixed scFv (scFv-CH2-CH3-scFv),G4;G4,Kappa;Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYSFTSYWMNWVRQAPGQGLEWIGVIHPSDSETWLDQKFKDRVTITVDKSTSTAYMELSSLRSEDTAVYYCAREHYGTSPFAYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASESVDNYGMSFMNWFQQKPGQPPKLLIHAASNQGSGVPSRFSGSGSGTDFTLTISSLEPEDFAVYFCQQSKEVPYTFGGGTKVEIK,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGSNKHYADSVKGRFTVSRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,None;None,None;None,None;5xj3:AB/5tru:HL/6jc2:HL/6rp8:hl/7elx:HL:hl,2021,2022,PDCD1;CTLA4,MacroGenics,na,Solid tumours,na,Dual-Affinity Re-Targeting Technology,(June '22: Corrected VL sequences),Q VQLVQ SGA EVK KPGA SVKVSCK ASGYS FTSYWMNWVR QAPGQGL EWIGVI HPSDSET WL DQKFKD RVTITVD KSTS TAYMELS SLRSEDT AVYYCAR EHYGTSPF AYW GQG TLVTVS S,E IVLTQ SPA TLSL SPGE RATLSCRA SESVDNYGM SFMN W F QQKPGQPP KLLIHA ASNQGSGVPS R FSGSGSGTD FTLTIS SLEPED FAVYFC QQSKEVP YT FGGG TKVEI K
Lorukafusp,Whole mAb Fusion,G1,Kappa,Phase-II,Active,EVQLVQSGAEVEKPGASVKISCKASGSSFTGYNMNWVRQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKSTSTAYMHLKSLRSEDTAVYYCVSGMEYWGQGTSVTVSS,DVVMTQTPLSLPVTPGEPASISCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELK,na,na,None,None,4tuj:CD:AB/4tul:HL/4trp:HL/4tuo:CD:AB/4tuk:HL,2018,2019,Ganglioside GD2,Lexigen Pharmaceuticals;Apeiron Biologics;Merck KGaA;University of Wisconsin-Madison,na,Malignant melanoma;Neuroblastoma,na,na,,E VQLVQ SGA EVE KPGA SVKISCK ASGSSFTGYN MNW VR Q NIGKS LEWIGAI DPYYGGTSYNQKFKG RATLTVD KSTS TAYMHLKS LRSEDT AVYYCV SGM EY WGQG TSVTVS S,DV VMT QTPLSLPVTPGEPA SISC RSSQ SLVHR NGN TYLHWYLQ KPGQSP KLLIHKV SNRFSGVPDRFSGSGSGT DFTLKISRVE AEDL GVYFCS QSTHVPPL TF GAGT KLEL K
Lorvotuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSGSFTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARMRKGYAMDYWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQIIIHSDGNTYLEWFQQRPGQSPRRLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPHTFGQGTKVEIK,na,na,None,None,None,2010,2011,NCAM1,ImmunoGen,na,na,Multiple myeloma;Solid tumours;Small cell lung cancer;Haematological malignancies,na,,Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS F GMHWVRQ APGKG LEWVAYIS SGS FTIYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAR MRKG YAMD YWGQG TLVTVS S,DV VMT QSPLSLPV T LGQP ASISC RSS QIIIH SDGN TYLEWFQ QRPGQSPR RLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCF QGSHVPHTFGQG TKVEI K
Losatuxizumab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,EVQLQESGPGLVKPSQTLSLTCTVSGYSISRDFAWNWIRQPPGKGLEWMGYISYNGNTRYQPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTASRGFPYWGQGTLVTVSS,DIQMTQSPSSMSVSVGDRVTITCHSSQDINSNIGWLQQKPGKSFKGLIYHGTNLDDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCVQYAQFPWTFGGGTKLEIK,na,na,None,None,None,2016,2017,EGFR,AbbVie,na,Solid tumours,na,na,Losatuxizumab and Serclutamab have identical variable domains,E VQLQE SGPGLVKPSQ TLSLTCTV SG YSI SRD FAWNWIR QPPGKGL EWMGYISY NGNTRYQPSLK SRITISR DTSKN QFFLKLN S V TAADTA TYYCVTA SRGFPYWGQ GTLVTVS S,DIQ MT QSPSS MSVS VGD RVTITCH SSQDINSN IGWLQ QKPGKS FKGLIYH GTNLDDGVPS RF SGSGSGTD YTLTISS LQPEDF ATYYCVQYA QFPWTFGGGT KLEI K
Lucatumumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYEESNRYHADSVKGRFTISRDNSKITLYLQMNSLRTEDTAVYYCARDGGIAAPGPDYWGQGTLVTVSS,DIVMTQSPLSLTVTPGEPASISCRSSQSLLYSNGYNYLDWYLQKPGQSPQVLISLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQARQTPFTFGPGTKVDIR,na,na,None,None,None,2007,2008,CD40,Novartis;XOMA,na,na,Chronic lymphocytic leukaemia;Follicular lymphoma;Lymphoma;Multiple myeloma,na,,Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKG LEWVAVISY EESNR Y HADSV KGRFTIS RDNS KITLYLQM NSLRTEDT AVYYCA RDGG I AAPGPDYWGQG TLVTV SS,D IVMT QSPL SLTV TPGEP ASISCR SSQ SLLY SNGYN YLDWYL QKPGQSP QVLISL GSNRASGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCMQ ARQTPF TF GPGT KVD IR
Lulizumab,Single Domain Variable Fragment;L,na,Kappa,Phase-II,Active,na,DIQMTQSPSSLSASVGDRVTITCRASRPIWPFLEWYQQKPGKAPKLLIYFTSRLRHGVPSRFSGSGSGTCFTLTISSLQPEDFATYYCLQNVANPATFSQGTKVEIK,na,na,None,None,None,2014,2015,CD28,Bristol-Myers Squibb,na,Sjogren's syndrome;Systemic lupus erythematosus;Renal transplant rejection,na,na,,NA,DIQ M TQSPSS LSA SVGD RVTITCR ASRPI WPFLEWYQ QKPGKAP KLLIYFT SRLRHGVPSRFSGSGSGT CFTLTIS SLQPEDF ATYYCLQ NVANPATFSQGT KVEI K
Lumiliximab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLAKPGGSLRLSCAASGFRFTFNNYYMDWVRQAPGQGLEWVSRISSSGDPTWYADSVKGRFTISRENANNTLFLQMNSLRAEDTAVYYCASLTTGSDSWGQGVLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIRYYLNWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTEFTLTVSSLQPEDFATYYCLQVYSTPRTFGQGTKVEIK,na,na,None,3fzu:HL:CD,None,2004,2004,FCER2,Biogen Idec,na,na,Allergic asthma;Allergic rhinitis;Chronic lymphocytic leukaemia,na,Lumiliximab and Gomiliximab are the same mAb,E VQLVES GGGLAKPGG SLRLSC AASG FRFTF NNY YMDWVR QAPGQG LEWVSRI SSSGDPT WYA DSVKG RFTISR ENANN TLFLQMN SLRAEDT AVYYCASLT TGSDSWGQ GVLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQD IR YYLN W Y QQKPGKAP KLLIYVA SSLQSGVPS RF SGSGSGT EFTLTVSS LQPEDFA TYYCLQVYS TPRTFGQGT KVEI K
Lumretuzumab,Whole mAb,G1,Kappa,Phase-I/II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFRSSYISWVRQAPGQGLEWMGWIYAGTGSPSYNQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARHRDYYSNSLTYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQSDYSYPYTFGQGTKLEIK,na,na,4leo:AB,None,None,2014,2015,ERBB3,Roche,na,na,Breast cancer;Solid tumours;Non-small cell lung cancer,GlycoMAb Technology,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFRSSYISWVR QAPGQGL EWMGWIYA GTGSPSYNQK LQGRVTMTT DTSTS TAYMELRSL RSDDT AVYYCA RHRDYYSNS LTYW GQG TLVTVS S,D IVMT QSPDS LAVS LGER ATINC KSSQS VL NSGNQKN YLTWYQ QKPGQPP KLLIYWAS TRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC QSDYSYPY T FGQGT KLEI K
Lunaxafusp,Fusion Protein,na,Kappa,TBC,Active,QVQLQQSGPELKKPGETVKISCKASGYPFTNYGMNWVKQAPGQGLKWMGWINTSTGESTFADDFKGRFDFSLETSANTAYLQINNLKSEDSATYFCARWEVYHGYVPYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVYNAVAWYQQKPGQSPKLLIYSASSRYTGVPSRFTGSGSGPDFTFTISSVQAEDLAVYFCQQHFRTPFTFGSGTKLEIK,na,na,None,None,None,2022,na,ERBB2,TBC,TBC,TBC,TBC,TBC,Murine scFv against a human antigen,QV QLQQ SGPELKKPGE TVKISCK ASGYPFTNY GMNWVK QAPGQG LKWMGWIN TSTGES TF ADDFKG RFDFSLET SANT AYLQIN NLKSEDSA TYFCARWEVYH G Y VPYWGQG TTVTVS S,DIQ MT QSPSS LSA SVGD RVTITCK ASQD VYNA VAWYQ QKPGQSP KLLIYS ASSRYTGVPSRFTGSGSGPD FTFTISS VQ AEDLA VYF CQ QHFRTPF TF GSGT KLEI K
Lupartumab,Whole mAb ADC,G1,Lambda,Phase-I,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGLWAFDYWGQGTLVTVSS,ESVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYVVHWYQQLPGTAPKLLIYDNNKRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDRLNGPVFGGGTKLTVL,na,na,None,None,None,2016,2017,LYPD3,Bayer HealthCare,na,na,Solid tumours,na,,E VQLLES GGG LV QPGG SLRLSC AASGF TF SNA WMSWVR QAPGKGL EWVSYIS SSGS TIYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA REGL WAFDY WGQG TLVTVS S,ESVLTQPPSVSGAPGQ RVTISCT GSSSNIGAG YVVHW YQQ LPGTAP KLLIY DNNKRPSGVPDRFSGSKSGTS ASL A I SGLRSEDEAD YYCAAW DDRLNGP V FGGGT KLTV L
Lusvertikimab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVESGGGLVKPGGSLRLSCAVSGFTLSDYYMAWIRQAPGKGLEWVSTISASGLRTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARPLSAHYGFNYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSEDIYQGLAWYQQKPGKAPKLLLYSANTLHIGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQYYDYPLAFGGGTKVEIK,na,na,None,None,None,2020,2021,IL7R,OSE Immunotherapeutics,na,Autoimmune diseases,na,na,,Q VQLVES GGG LV KPGG SLRLSCAV SGF T LS DY YMAWIR QAPGKGL EWVSTIS ASGL RTY YPDSVKG RFTISR DNAKNS LYLQMNS LRAEDT AVYYCA RPLSAHYGFN YFD YWGQG TLVTV SS,DIQ MT QSPSS LSA SVGD RVTITCR TS EDIYQGLAWYQ QKPGKAP KLLLYS AN TLHIGV PSRFSGSGSGTD YTLTIS SLQ PEDFATYYCQQ YYDYPL AF GGG TKVEI K
Lutikizumab,Bispecific Dual Variable Domain IG,G1;G1,Kappa;Kappa,Phase-II,Discontinued,EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGAGTYYPDSVKGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKGYFDVWGQGTPVTVSS,DIQMTQSPSSLSASVGDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQIT,QVQLVESGGGVVQPGRSLRLSCTASGFTFSMFGVHWVRQAPGKGLEWVAAVSYDGSNKYYAESVKGRFTISRDNSKNILFLQMDSLRLEDTAVYYCARGRPKVVIPAPLAHWGQGTLVTFSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYEASNLETGVPSRFSGSGSGSDFTLTISSLQPEDFATYYCQQTSSFLLSFGGGTKVEHK,None;None,None;None,None;None,2016,2017,IL1A;IL1B,Abbott Laboratories;AbbVie,na,na,Osteoarthritis,Dual Variable Domain Immunoglobulin Technology,,E VQLVES GGG VV QPGR SLRLSC SASG FIFSR YDM SWVR QAPGKGL EWVAYIS HGGAGT Y YPDSVK GRFTISR DNSKN TLFLQM DSLRPEDT GVYFCA RGG VTKGYFDVW GQGT PVTVS S,DI QMT QSPSS LSA SVGD RVTITCR ASGNI HNYLTWYQ QTPGKAP KLLIYN AK T LADGVPS RF SGSGSGTD YTFTIS SLQ PEDIATY Y C QH FWS IPY T FGQGT KLQI T
Luveltamab,Whole mAb ADC,G1,Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGFNIRTQSIHWVRQAPGKGLEWIGDIFPIDGITDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARGSWSWPSGMDYYLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,na,na,None,None,None,2022,na,FOLR1,TBC,TBC,TBC,TBC,TBC,,E VQLVES GGG LV QPGG SLRLSC AASGF NIRTQSIHWVRQ APGKGL EWIGDIF PIDGITDYADSVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYCA RGS W SWPSGMD YYLDY WGQG TLVTV SS,DIQ MT QSPSS LSA SVGD RVTITCR ASQD VNTA VAWYQ QKPGKAP KLLIYSASFLY SGVPSRFSGSRSGTD FTLTIS SLQP EDFAT YYCQ QHYTTPPTFGQGT KVEI K
Maftivimab,Whole mAb,G1,Kappa,Preregistration,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTSSSYAMNWVRQAPGKGLEWVSTISGMGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKRGYPHSFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSFLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLTFGQGTRLEIK,na,na,None,None,None,2018,2019,Zaire Ebolavirus GP,Regeneron Pharmaceuticals,na,na,Ebola virus infections,na,,E VQLVES GGG LV QPGG SLRLSCA ASGFTSS SYAMNW VR QAPGKGL EWVSTI SGMGGS TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAE DTAVYYCAK RGYPH SFDIW GQG TMVTVS S,DIQ M TQSPSS LSA SVGD RVTITCR ASQS ISSFLNWYQ QKPGKAP KLLIYAA SSLQSGVPSRFSGSGSGTD FTLTIS SLQP EDFA TYYC QQSYS TLTF GQGT RLEI K
Magrolimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYNMHWVRQAPGQRLEWMGTIYPGNDDTSYNQKFKDRVTITADTSASTAYMELSSLRSEDTAVYYCARGGYRAMDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSIVYSNGNTYLGWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYTFGQGTKLEIK,na,na,None,5iwl:AA:BB,None,2018,2019,CD47,Forty Seven;Merck KGaA;Stanford University,na,Diffuse large B cell lymphoma;Follicular lymphoma;Non-Hodgkin's lymphoma;Colorectal cancer;Solid tumours;Acute myeloid leukaemia;Myelodysplastic syndromes;Ovarian cancer,Lymphoma,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTN Y NMHWVR QAPGQ RLEWMGTI YPGNDDTSYNQKFKD RVTITA DTSAS TAYMELS SLRSEDT AVYYC ARGG YRAMD YWGQG TLVTVS S,DI VMT QSPLSLPVTPGEPA SISC RSSQ SIVYS NGN TYLGWYLQ KPGQSP QLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCF QGSHVP YT FGQGT KLEI K
Manelimab,Whole mAb,G1,Lambda,Phase-I,Discontinued,EVQLVESGGGVVRPGGSLRLSCAASGFTFDDYAMSWVRQAPGKGLEWVSDISWSGSNTNYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYHCARAPLLLAMTFGVGSWGQGTLVTVSS,QTVVTQEPSLSVSPGGTVTLTCGLSSGTVTAINYPGWYQQTPGQAPRTLIYNTNTRHSGVPDRFSGSISGNKAALTITGAQAEDEADYYCALYMGNGGHMFGGGTKLTVL,na,na,None,None,None,2019,2020,PDL1,Biocad,na,Solid tumours;Cancer,na,na,,E VQLVES GG GVV RPGG SLRLSC AASGFT F DDY AMSWVR QAPGKGL EWVSDISW SGSNTNYADSVK GRFTISR DNAKN SLYLQMN SLRAEDT ALYHC ARAP LLLAMTF GVGSWGQG TLVTV SS,QT VVT QEP SLSV SPGG TVTLTC GLSSG TVTAIN YPGW Y QQTPGQAP RTLIYN TNTRHSGVPDRF S G SI SGNK AALTIT GAQAEDEAD YYCALYM GNGGHMFGGGT KLTV L
Manfidokimab,Whole mAb,G4,Kappa,Phase-I,Active,QVQLVQSGAEVVKPGASVKVSCKTSGYTFTEYTIHWVRQAPGQSLEWIGGINPNNGGTVYNQKFQGKVTLTVDKSTSTAYMELSSLRSEDTAVYYCARVRRGMDYWGQGTSVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVTTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSVQPEDLATYYCQQHYSAPWTFGGGTNLEIK,na,na,None,None,None,2021,2022,IL4R,Akeso Biopharma,na,Atopic dermatitis,na,na,,Q VQLVQ SGA EVV KPGA SVKVSC KTSGY TFTEYTIHWVR QAPGQ SLEWIGGI NPNNGG TVYN QK F QG KVTLTVD KSTS TAYMELSS LRSEDT AVYYCARVR RGMDYWGQG TSVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQDV TTAVAWYQ QKPGKAP KLLIYSASYRY TGVPSRFSGSGSGTD FTLTISS VQ PEDLATYYCQ QHYSAPW T FGGGT NLEI K
Margetuximab,Whole mAb,G1,Kappa,Approved,Active,QVQLQQSGPELVKPGASLKLSCTASGFNIKDTYIHWVKQRPEQGLEWIGRIYPTNGYTRYDPKFQDKATITADTSSNTAYLQVSRLTSEDTAVYYCSRWGGDGFYAMDYWGQGASVTVSS,DIVMTQSHKFMSTSVGDRVSITCKASQDVNTAVAWYQQKPGHSPKLLIYSASFRYTGVPDRFTGSRSGTDFTFTISSVQAEDLAVYYCQQHYTTPPTFGGGTKVEIK,na,na,None,None,None,2013,2014,ERBB2,Raven biotechnologies;GC Pharma;Green Cross;MacroGenics;Merck Sharp & Dohme,Breast cancer,Gastric cancer;Oesophageal cancer,Bladder cancer;Non-small cell lung cancer;Ovarian cancer;Haematological malignancies;Solid tumours,na,,QV QLQQ SGPE LV KPGA SLKLSCT ASGFNIKD TYIHWVK QRPEQGL EWIGRIY PTNGY TRY DPKFQDK ATITA DTSSN TAYLQVSR LTSEDT AVYYCSR WGGDG FYAMD YWGQGA SVTVS S,D IVMTQ SH KFMS TSVGD RVSITCK ASQDVN TAVAWYQ QKPGHSP KLLIYSASFRY TGVPDRFTGSRSGT DFTFTISSV QAED LAVYYCQ QHYTTPPTFGGG TKVEI K
Marstacimab,Whole mAb,G1,Lambda,Phase-III,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAILGATSLSAFDIWGQGTMVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSGVFGGGTKLTVL,na,na,None,None,None,2013,2014,ERBB2,Pfizer,na,Haemophilia,na,na,,E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKGL EWVSAIS GSGGS TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAI LGATSL SAFDI WGQG TMVTV SS,QSVLTQPPSVSGAPGQ RVTISCT GSSSNIGAG YDVHWYQ QLPGTAP KLLIYG NSNRPSGVPDRFSGSKSGTS A SLAIT GLQAEDEAD YYCQS YDSSLSGSGVFGGGT KLTV L
Masavibart,Whole mAb,G1,Lambda,Approved,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYAMYWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRTEDTAVYYCASGSDYGDYLLVYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQSEDEADYYCNSLTSISTWVFGGGTKLTVL,na,na,6xdg:CA,None,None,2020,2021,SARS-CoV-2 Spike RBD,Regeneron Pharmaceuticals,COVID-19,na,na,na,Imdevimab is former name for Masavibart,Q VQLVES GGG VV QPGR SLRLSC AASGF TF SN YAMYWVRQ APGKG LEWVAVISY DGSNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRTEDT AVYYC ASGSDYGD YLLVYW GQG TLVTVS S,QSALTQPA SV SGSPGQ SITISCT GTSSDVGG YNYVSWY Q QHPGKAP KLMIYD VSKRPSGVSNRFSGSKSGN TASLTIS GLQSED EADYYC NSLT SISTWVF GGGT KLTV L
Matuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSHWMHWVRQAPGQGLEWIGEFNPSNGRTNYNEKFKSKATMTVDTSTNTAYMELSSLRSEDTAVYYCASRDYDYDGRYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASSSVTYMYWYQQKPGKAPKLLIYDTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSHIFTFGQGTKVEIK,na,na,3c08:HL/5vr9:HL:AB,5vsi:HL/3c09:HL:CB,None,2003,2003,EGFR,ImClone Systems;Merck KGaA;Takeda,na,na,Cervical cancer;Colorectal cancer;Gastric cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSHWMHWVR QAPGQG LEWIGEF NPSNGRTNYNEKFKS KATMTVD TSTN TAYMELSS LRSEDT AVYYCAS RDYDYDGR YFDY WGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCS ASSS VTYMYWYQ QKPGKAP KLLIYD TSNLASGVPS R FSGSGSGT DYTFTIS SLQ PEDIATYYC QQWSS HIFTF GQGT KVEI K
Mavrilimumab,Whole mAb,G4,Lambda,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFDPEENEIVYAQRFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCAIVGSFSPLTLGLWGQGTMVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSGSNIGAPYDVSWYQQLPGTAPKLLIYHNNKRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCATVEAGLSGSVFGGGTKLTVL,na,na,None,None,None,2009,2010,CSF2RA,Zenyth Therapeutics Kiniksa Pharmaceuticals;MedImmune,na,Giant cell arteritis;COVID-19;Inflammation,Rheumatoid arthritis,CAT Phage Display,,Q VQLVQ SGA EVK KPGA SVKVSCKV SGY TLTELSIHWVR QAPGKG LEWM GGFDPEEN EIVYAQRF QG RVTMT EDTSTDT AYMELSS LRSEDT AVYYCAIVG SFSPL TLGLW GQG TMVTVS S,QSVLTQPPSVSGAPGQ RVTISCT GSGSNIGAPYDV SWYQ QLPGTAP KLLIYH NNKRPSGVPDRFSGSKSGTS ASLAIT GLQAEDEAD YYCATVE AGLSGS VF GGGT KLTV L
Mazorelvimab,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLILSCAASGFTFSGFAMSWVRQAPGKGLEWVATISSGGTYTYSPDSVMGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRLRRNYYSMDYWGQGTMVTVSS,DIVMTQSPLSLPVTPGEPASISCKSTKSLLNSDGFTYLDWYLQKPGQSPQLLIYLVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQSNYLPFTFGGGTKVEIK,na,na,None,None,None,2021,2022,Rabies Virus Spike Glycoprotein G,Synermore,na,Rabies post-exposure,na,na,,E VQLVES GGG LV QPGG SLILSC AASGF TFSGFAMSWVR QAPGKG LEWVATIS SGG TYTY SPDSV MGRFTISR DNAKN SLYLQMN SLRAEDT AVYYCA RR LRRNY YSM DYWGQG TMVTVS S,DI VMT QSPLSLPVTPGEPA SISCK STK SLL NSDGF TYLDWYL QKPGQSP QLLIYLVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCF QSNYLP FTF GGG TKVEI K
Mecbotamab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGATVKISCKVSGYSFWGATMNWIRQPPGKGLEWIGLIKPSNGGTSYNQKFKGRVTISADKSISTAYLQWSSLKASDTAMYYCAHGHYESYEAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVVSAVAWYQQKPGQAPRLLIYWQDTRHTGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQEHFSPPLTFGQGTKVEIK,na,na,None,None,None,2022,na,AXL,BioAtla,na,Non-small cell lung cancer;Ovarian cancer;Soft tissue sarcoma;Solid tumours,na,na,,E VQLVQ SGA EVK KPGA TVKISCKV SGY SFWGATMNWIR QPPGKGL EWIGLIK PSNGGTSYNQ KFKGRVTIS ADKS ISTAYLQWS SLKASDT AMYYC AHGH Y ES YEAM DYWGQG TLVTV SS,DI QMT QSPSS LSA SVGD RVTITCK ASQD VVSAVAWYQ QKPGQAP RLLIYWQ DTRHTGVPSRFSGSGSGT EFTLTISS LQPDDF ATYYC QEHFSPPL TF GQGT KVEI K
Melredableukin,Whole mAb Fusion,G1,Kappa,Phase-I,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGSGFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGQGTKVEIK,na,na,None,6ghg:HL:AB,5i1c:HL,2021,2022,Non-Binding,Roche,na,Ulcerative colitis,na,na,Fused to IL2. (June '22: Corrected FWL3 sequence),E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKGL EWVSAIS GSGGS TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA KGSGFDYWGQG TLVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQSVS SSY LAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEP EDF AVYYC QQ YGSSPL TF GQGT KVEI K
Melrilimab,Whole mAb,G2,Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSIYDMIWVRQAPGKGLEWVSSIRGEGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPWSTEGSFFVLDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVDDDLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYITAPLTFGQGTKVEIK,na,na,None,None,None,2020,2021,IL1RL1,GlaxoSmithKline,na,na,Asthma;Atopic dermatitis,na,,E VQLLES GGG LV QPGG SLRLSC AASGF TFSIYDMIWVRQ APGKG LEWVSSIR GEGGG TYYAD SVKG RFTISR DNSKN TLYLQMN SLRAED TAVYYCA RDPWSTEG SFFVLDY WGQG TLVTVS S,E IVLTQ SPA TLSL SPGE RATLSCRA SQSVDDD LA WYQ QKPGQAP RLLIYD ASNRATG I P ARF SGSGSGT DFTLTIS SLEPED FAVYYCQ Q YIT AP LT FGQGT KVEI K
Metelimumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKELEWVAVISYDGSIKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTGEYSGYDTDPQYSWGQGTTVTVSS,EIVLTQSPSSLSASVGDRVTITCRASQGIGDDLGWYQQKPGKAPILLIYGTSTLQSGVPSRFSGSGSGTDFTLTINSLQPEDFATYYCLQDSNYPLTFGGGTRLEIK,na,na,6amj:HL:BA/6amm:HL,6anp:HL:BA,None,2003,2003,TGFB1,Cambridge Antibody Technology,na,na,Cancer;Fibrosis;Scleroderma,na,,E VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKE LEWVAVIS YDGS IKYYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RTGEYSGYDTDPQYSWGQG TTVTVS S,E IVLT QSPSS LSA SVGD RVTITCR ASQGIGDDLG WYQ QKPGKAP ILLIY GTSTLQSGVPSRFSGSGSGTD FTLTIN SLQPED F ATYYCL QDSNYP LTF GGG TRLEI K
Mepolizumab,Whole mAb,G1,Kappa,Approved,Active,QVTLRESGPALVKPTQTLTLTCTVSGFSLTSYSVHWVRQPPGKGLEWLGVIWASGGTDYNSALMSRLSISKDTSRNQVVLTMTNMDPVDTATYYCARDPPSSLLRLDYWGRGTPVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLAWYQQKPGQPPKLLIYGASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNVHSFPFTFGGGTKLEIK,na,na,None,None,None,1999,2000,IL5,GlaxoSmithKline;McMaster University;National Institute of Allergy and Infectious Diseases,Asthma;Churg-Strauss syndrome;Hypereosinophilic syndrome,Chronic obstructive pulmonary disease;Hypereosinophilic syndrome;Nasal polyps;Eosinophilic oesophagitis,Atopic dermatitis,na,,Q VTLRE SGPA LV KPTQ TLTLTCTV SGF SLTSYSVHWVR QPPGKGL EWLGVIWA SGGTDYN SAL MSRLSIS KDTSRN QVVLTMT NMDPVDT ATYYCA RDPPSS LLRLDY WGRGT PVTVS S,D IVMT QSPDS LAVS LGER ATINC KSS QSLL NSGNQ KNYLAWYQ QKPGQPP KLLIYG ASTRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC QNVHSFP FTF GGGT KLEI K
Mevonlerbart,Whole mAb,G4,Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGRGYNADYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKLEYFDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTDFTLTISSLRPEDFATYYCQQYNSYPLTFGGGTKVEIK,na,na,5vyf:HL:BA,None,None,2022,na,Fel d 1,Regeneron,na,Cat allergies,na,Antigen: Felis silvestris catus (domestic cat) allergen 1,,E VQLVES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKGL EWVSAI SGRGYNADYADSVK GRFTISR DNSKN TLYLQMN SLRAEDT AVYYCAKLEYF DYWGQG TLVTVS S,DIQMTQSPS TLSAS VGD RVTITCR ASQS ISSWLAWYQ QKPGKAP KLLIYK ASSLESGVPSRFSGSGSGTD FTLTIS SLR PEDFATYYCQQ YNSYP LTF GGGT KVEI K
Mezagitamab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSDISWNGGKTHYVDSVKGQFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSLFHDSSGFYFGHWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGDNYVSWYQQLPGTAPKLLIYRDSQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCQSYDSSLSGSVFGGGTKLTVL,na,na,None,None,None,2019,2020,CD38,Takeda,na,Multiple myeloma;Systemic lupus erythematosus;Idiopathic thrombocytopenic purpura;Myasthenia gravis,Rheumatoid arthritis,na,,E VQLLES GGG LV QPGG SLRLSC AASGF TF DDYGM SWVRQ APGKGL EWVSDIS WNGGK THYVD SVKG QFTISR DNSKN TLYLQMN SLRAEDT AVYYC ARGS LFH DSSGF YF GHWGQG TLVTVS S,QSVLTQPPSASGTPGQ RVTISC SGSSSNIGD NYVSWYQQ LPGTAP KLLIYR DSQRPSGVPDRFSGSKSGTS ASLAI SGLRSEDE ADY YCQ SYDSSLSGS V FGGGT KLTV L
Mibavademab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVESGGSVVQPGRSLRLSCAASGFTFSTYAMYWVRQTPGKGLEWVAVLYSDGSNKYYIDSVKGRFTISRDTSTNTLYLQMSSLRADDSALYYCARLNWDYWYFDLWGRGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK,na,na,None,None,None,2020,2021,LEPR,Regeneron Pharmaceuticals,na,Lipodystrophy,na,na,,Q VQLVE SGG SVV QPGR SLRLSC AASGF TFSTYAMYWVRQ TPGKG LEWVAVLYS DGSN KYYID SVKG RFTISR DTSTN TLYLQMS SLRADDS ALYYCAR LNWD YWYFD LWGRG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQS ISSYLNWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQP EDFA TYYC QQSYSTPP ITF GQGT RLEI K
Milatuzumab,Whole mAb,G1,Kappa,Phase-I/II,Discontinued,QVQLQQSGSELKKPGASVKVSCKASGYTFTNYGVNWIKQAPGQGLQWMGWINPNTGEPTFDDDFKGRFAFSLDTSVSTAYLQISSLKADDTAVYFCSRSRGKNEAWFAYWGQGTLVTVSS,DIQLTQSPLSLPVTLGQPASISCRSSQSLVHRNGNTYLHWFQQRPGQSPRLLIYTVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSSHVPPTFGAGTRLEIK,na,na,None,None,None,2007,2008,CD74,Immunomedics,na,na,Graft-versus-host disease;Haematological malignancies;Chronic lymphocytic leukaemia;Multiple myeloma;Non-Hodgkin's lymphoma;Systemic lupus erythematosus,na,,QV QLQQ SGS E LKKPGA SVKVSCK ASGY TFTNYGVNWIK QAPGQG LQWMGWI NPNTGEPTFDDDFKG RFAFSL DTSVS TAYLQISSL KADDT AVYFCS RSRGKNE AWFAYW GQG TLVTVS S,DI QLT QSPLSLPV T LGQPA SISC RSSQ SLVHR NGN TYLHWFQ QRPGQSP RLLIYTVS NRFSGVPDRFSGSGSGT DFTLKISRVE AED VGVYFCS QSSHVPPTFGAG TRLEI K
Mipasetamab,Whole mAb,G1,Kappa,Phase-I,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVATISSGGSYTYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHPIYYTYDDTMDYWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCSASSSVSSGNFHWYQQKPGLAPRLLIYRTSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQWSGYPWTFGGGTKLEIK,na,na,None,None,None,2020,2021,AXL,ADC Therapeutics,na,Solid tumours;Advanced or metastatic solid tumours,na,na,,Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS YG MSWVRQ APGKG LEWVATIS SGGS YTY YPDSVK GRFTISR DNSKN TLYLQMN SLRAEDT AVYYC ARHP IYYT YDDTMDYWGQG TTVTVS S,E IVLTQ SPG TLSL SPGE RATLSCS ASSSVSSGN FHWYQ QKPGLAP RLLIYRT SNLASGIP ARFS GSGSGT DFTLTISS LEPED FAVYYCQ QWSGYPW TF GGG TKLEI K
Miptenalimab,Whole mAb,G4,Kappa,Phase-II,Active,QVTLVESGGGVVQPGRSLRLSCAFSGFSLSTSDMGVGWIRQAPGKGLEWVAHIWWDDVKRYNPALKSRFTISRDNSKNTLYLQMNSLRAEDTAVYFCARIEDYGVSYYFDYWGQGTTVTVSS,DIQMTQSPSFLSASVGDRVSITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPDRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSIPLTFGQGTKLEIK,na,na,None,None,None,2019,2020,LAG3,Boehringer Ingelheim,na,Solid tumours;Head and neck cancer;Non-small cell lung cancer,na,na,,Q VTLVES GGG VV QPGR SLRLSCAF SGF SLS TSDMG VGWIRQ APGKGL EWVAHIWW DDV K RYNPALK SRFTISR DNSKN TLYLQMNS LRAEDT AVYFCARI EDYG VSYYFD YWGQG TTVTVS S,DIQMTQSPS FLSA SVGD RVSITCK ASQD VSTA VAWY Q QKPGKAP KLLIYSASYRY TGVPDRFSGSGSGTD FTLTIS SLQ PEDFATYYC QQHYSIP LTF GQGT KLEI K
Mirikizumab,Whole mAb,G4,Kappa,Preregistration,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYKFTRYVMHWVRQAPGQGLEWMGYINPYNDGTNYNEKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNWDTGLWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASDHILKFLTWYQQKPGKAPKLLIYGATSLETGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQMYWSTPFTFGGGTKVEIK,na,na,None,None,None,2017,2018,IL23A,Eli Lilly,na,Plaque psoriasis;Ulcerative colitis;Crohn's disease,na,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGY KFTRYVMHWVR QAPGQG LEWMGYI NPYNDGTNYNEK F KG RVTITA DKSTS TAYMELS SLRSEDT AVYYCAR NWDTGLWGQG TTVTVS S,DIQ MT QSPSS LSA SVGD RVTITCK ASD HILKFLTWY QQKPGKAP KLLIYG ATSLETGVPSRFSGSGSGTD FTLTIS SLQ PEDFAT YYCQMY WSTPF T FGGGT KVEI K
Miromavimab,Whole mAb (Mouse),G1,Kappa,Approved,NFD,QVQLQQPGSVLVRPGASVKLSCKTSGYAFTSSWMHWAKQRPGQGLEWIGQTHPNSGYTNYNEKFKGKATLTVDTSSSTAYVDLSSLTSEDSAVYYCARESGDGPHWYFDVWGAGTAVTVSS,DIVMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSSPHTFGGGTKLETK,na,na,None,None,None,2019,2020,Rabies Virus Strain ERA GP Ectodomain Epitope G-II,Candila Healthcare,Rabies,na,na,na,,QV QL QQPG SVLV RPGA SVKLSC KTSGY AFT SS WMHWAK QRPGQGL EWIG QTHPNSGYTNYNEKFKG KATLTVD TSSS TAYVD LSSLTSEDS AVYYCAR ESGDGP HWYFDVW GAG TAVTVS S,D IVMTQ SH KFMS TSVGD RVSITCK ASQD VST AVAWYQ QKPGQSP KLLIYSASYRY TGVPDRFTGSGSGT DFTFTISS VQ A ED L AVYYCQ QHYSSPHTFGGGT KLE TK
Mirvetuximab,Whole mAb ADC,G1,Kappa,Preregistration,Active,QVQLVQSGAEVVKPGASVKISCKASGYTFTGYFMNWVKQSPGQSLEWIGRIHPYDGDTFYNQKFQGKATLTVDKSSNTAHMELLSLTSEDFAVYYCTRYDGSRAMDYWGQGTTVTVSS,DIVLTQSPLSLAVSLGQPAIISCKASQSVSFAGTSLMHWYHQKPGQQPRLLIYRASNLEAGVPDRFSGSGSKTDFTLTISPVEAEDAATYYCQQSREYPYTFGGGTKLEIK,na,na,None,None,None,2015,2016,FOLR1,ImmunoGen;National Comprehensive Cancer Network,na,Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Breast cancer;Endometrial cancer,Solid tumours,na,,Q VQLVQ SGA EVV KPGA SVKISCK ASGY TFTGYFMNWVK QSPGQS LEWIGRI HPYDGDT FY NQK F QG KATLTVD KSSNT AHMELLSL TSED FAVYYCTR YDGSRA M D Y WGQG TTVTVS S,D IVLT QSPL SLAVS LGQP AIISC KASQS VSF AGT SLMHWYH QKPGQQP RLLIYR ASNLEAGVPDRFSGSGSKTD FTLTIS PVE AEDAATYYCQ QSREYPY T FGGGT KLEI K
Mirzotamab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLQESGPGLVKPSETLSLTCAVTGYSITSGYSWHWIRQFPGNGLEWMGYIHSSGSTNYNPSLKSRISISRDTSKNQFFLKLSSVTAADTAVYYCAGYDDYFEYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVGFNVAWYQQKPGKSPKALIYSASYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFAEYFCQQYNWYPFTFGQGTKLEIK,na,na,None,None,None,2019,2020,CD276,AbbVie,na,na,Haematological malignancies;Solid tumours,na,,E VQLQE SGPGL V KPSE TLSLTCAVT G YSI TSGY SWHWIRQ FPGNGL EWMGYIH SSGSTNYNPSLK SRISISR DTSKN QFFLKLS SVTAADT AVYYC AGYDDY FEYW GQG TTVTVS S,DI QMT QSPSS LSA SVGD RVTITCK ASQNV GFNVAWYQ QKPGKSPK ALIYSASYRY SGVPSRFSGSGSGTD FTLTIS SLQ PEDFAEYFCQQ YNWYPF T FGQGT KLEI K
Mitazalimab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWLSYISGGSSYIFYADSVRGRFTISRDNSENALYLQMNSLRAEDTAVYYCARILRGGSGMDLWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCTGSSSNIGAGYNVYWYQQLPGTAPKLLIYGNINRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDKSISGLVFGGGTKLTVL,na,na,None,None,None,2017,2019,CD40,Alligator Bioscience;Janssen Biotech,na,Solid tumours,na,na,Mitazalimab is the new name for Vanalimab (PL119),E VQLLES GGG LV QPGG SLRLSC AASGF TFST YG MHWVRQ APGKGL EWLSYI SGGS SYIFYA DSVRG RFTISR DNSEN ALYLQMN SLRAEDT AVYYCARILR GGSGMDL W GQG TLVTVS S,QSVLTQPPSASGTPGQ RVTISCT GSSSNIGAG YNVYWYQQ LPGTAP KLLIYG NINRPSGVPDRFSGSKSGTS ASLAI SGLRS E D EADYYCAAW DKSIS GLVF GGGT KLTV L
Modakafusp,Whole mAb Fusion,G4,Kappa,Phase-I/II,Active,EVQLVQSGAEVKKPGATVKISCKVSGYTFTDSVMNWVQQAPGKGLEWMGWIDPEYGRTDVAEKFQGRVTITADTSTDTAYMELSSLRSEDTAVYYCARTKYNSGYGFPYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVDSDVDWYQQKPGKAPKLLIYKASNDYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCMQSNTHPRTFGGGTKVEIK,na,na,None,None,None,2019,2020,ADPRC,Takeda,na,Multiple myeloma,na,na,,E VQLVQ SGA EVK KPGA TVKISCKV SG YTF TDS VMNW VQ QAPGKGL EWMGWI DPEYGRTD VAE KFQG RVTITA DTSTDT AYMELS SLRSEDT AVYYCAR TKYNSGYGFPYWGQG TTVTVS S,DI QMT QSPSS LSA SVGD RVTITCK ASQNVDSDVD WYQ QKPGKAP KLLIYK ASNDYTGVPSRFSGSGSGT DFTFTIS SLQPEDI ATYYCM QSNTHPRTFGGG TKVEI K
Modotuximab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLQQPGAELVEPGGSVKLSCKASGYTFTSHWMHWVKQRPGQGLEWIGEINPSSGRNNYNEKFKSKATLTVDKSSSTAYMQFSSLTSEDSAVYYCVRYYGYDEAMDYWGQGTSVTVSS,DIVMTQAAFSNPVTLGTSASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELPYTFGGGTKLEIK,na,na,None,None,None,2012,2014,EGFR,Symphogen;Merck,na,Colorectal cancer;Glioma;Non-small cell lung cancer,Head and neck cancer;Oesophageal cancer,na,Modotuximab is the new name for Zatuximab (PL110),QV QLQ QPGA ELV EPGG SVKLSCK ASGY TFTSHWMHWVK QRPGQGL EWIGEI NPSSGRNNYNEKFKS KATLTVD KSSST AYMQFS SLTSEDS AVYYCVRYY GYDEAMDYWGQG TSVTVS S,D IVMTQ AAFSNPV T LGTS ASISC RSSK SLLH SNG ITYLYWYLQ KPGQSP QLLIYQM SNLASGVPDR F SSSGSGT DFTLRISRVE AEDV GVYYCA QNLELPY T FGGG TKLEI K
Mogamulizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGDLVQPGRSLRLSCAASGFIFSNYGMSWVRQAPGKGLEWVATISSASTYSYYPDSVKGRFTISRDNAKNSLYLQMNSLRVEDTALYYCGRHSDGNFAFGYWGQGTLVTVSS,DVLMTQSPLSLPVTPGEPASISCRSSRNIVHINGDTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSLLPWTFGQGTKVEIK,na,na,None,None,None,2010,2011,CCR4,Amgen;Bristol-Myers Squibb;Kagoshima University Dental School;Kyowa Hakko;Kyowa Hakko Kirin;Ono Pharmaceutical,Adult T-cell leukaemia-lymphoma;Cutaneous T-cell lymphoma;Peripheral T-cell lymphoma;Mycosis fungoides;Sezary syndrome;Mycosis fungoides,Spinal cord disorders,Non-small cell lung cancer;Asthma;Hypersensitivity;Solid tumours,POTELLIGENT Technology,,E VQLVE SGGD LV QPGR SLRLSC AASG FIFS NYG MSWVRQ APGKG LEWVATIS SAST YSY YPDSVK GRFTISR DNAKNS LYLQMNSLRV EDT ALYYCGR HSDGN FAFGYW GQG TLVTVS S,DV LMT QSPLSLPVTPGEPA SISCR SSRN IVHI NGD TYLEWYL QKPGQSP QLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCF QGS L LPW TF GQGT KVEI K
Monalizumab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGGYDFDVGTLYWFFDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASENIYSYLAWYQQKPGKAPKLLIYNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGTPRTFGGGTKVEIK,na,na,None,None,None,2015,2016,KLRC1,Innate Pharma;MedImmune;NCIC Clinical Trials Group;Novo Nordisk,na,Head and neck cancer;Non-small cell lung cancer;Cervical cancer;Chronic lymphocytic leukaemia;Endometrial cancer;Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Solid tumours;Haematological malignancies,Inflammation;Rheumatoid arthritis,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYWMNWVR QAPGQGL EWMGRI DPYDSETH YAQK LQG RVTMTT DTSTS TAYMELRSL RSDDT AVYYCA RGGY D FDVG TLYWFFDV WGQG TTVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASEN IYSY LAWY QQKPGKAP KLLIYN AKTLAEGVPSRFSGSGSGTD FTLTIS SLQP EDFAT YYCQ HHYGTPRTFGGG TKVEI K
Mosunetuzumab,Bispecific mAb,G1,Kappa;Kappa,Approved,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVRQAPGQGLEWIGWIYPGDGNTKYNEKFKGRATLTADTSTSTAYLELSSLRSEDTAVYYCARDSYSNYYFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRTRKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCTQSFILRTFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWVGAIYPGNGDTSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVYYSNSYWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASSSVSYMHWYQQKPGKAPKPLIYAPSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSFNPPTFGQGTKVEIK,None;None,None;None,None;4k7p:YX,2017,2018,CD3E;MS4A1,Genentech,na,Diffuse large B cell lymphoma;Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Follicular lymphoma,na,na,,E VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTNYYIHWVRQ APGQG LEWIGWIY PGDGNTKYNEKFKG RATLTA DTSTS TAYLELS SLRSEDT AVYYCA RDSYSN YYFDY WGQG TLVTVS S,D IVMT QSPDS LAVS LGER ATINC KSSQ SLL NSRTR KNYLAWYQ QKPGQPP KLLIYWA STRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC TQ SFILRT FGQGT KVEI K
Motavizumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,QVTLRESGPALVKPTQTLTLTCTFSGFSLSTAGMSVGWIRQPPGKALEWLADIWWDDKKHYNPSLKDRLTISKDTSKNQVVLKVTNMDPADTATYYCARDMIFNFYFDVWGQGTTVTVSS,DIQMTQSPSTLSASVGDRVTITCSASSRVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTKVEIK,na,na,3qwo:AB:HL/3ixt:HL:AB/4zyp:NO:JL:KM/6oe5:BC/6ywd:AB,5k8a:BA:FE:VM:HL/4jlr:AB:HL,None,2006,2007,RSV gpF,MedImmune,na,na,Respiratory syncytial virus infections,Affinity Matured from Palivizumab,,Q VTLRE SGPA LV KPTQ TLTLTCTF SGF SL STAG MSVGWIR QPPGKA LEWLADIWW DDKKHYNPSLKD RLTISK DTSKN QVVLKVTN MDPADT ATYYCA RDM IFNFYFDV WGQG TTVTVS S,DI QMT QSPS TLSAS VGD RVTITCS ASSR VGYMHWYQ QKPGKAP KLLIYD TSKLASGVPS RF SGSGSGT EFTLTISS LQPDDF ATYYCF QGSGYP FTF GGG TKVEI K
Moxetumomab,Fv Fusion,na,Kappa,Approved,NFD,EVQLVESGGGLVKPGGSLKLSCAASGFAFSIYDMSWVRQTPEKCLEWVAYISSGGGTTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARHSGYGTHWGVLFAYWGQGTLVTVSA,DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSILHSGVPSRFSGSGSGTDYSLTISNLEQEDFATYFCQQGNTLPWTFGCGTKLEI,na,na,None,None,None,2009,2010,CD22,National Cancer Institute (USA);AstraZeneca;M. D. Anderson Cancer Center;MedImmune;National Cancer Institute (USA),Hairy cell leukaemia,na,Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma;Precursor cell lymphoblastic leukaemia-lymphoma,CAT Phage Display,,E VQLVES GGG LV KPGG SLKLSC AASG FAFSIYD MS WV RQTPEKC LEWVAYIS SGGGT TY YPDTV KGRFTISR DNAKN TLYLQMS SLKSEDT AMYYCAR HSGYGTH WGVLFAYW GQG TLVTVS A,DIQ MTQ TTS SLSA SLGD RVTISCR ASQD ISNYLNWYQ QKPDGT VKLLIYYTSIL HSGVPSRFSGSGSGTD YSLTIS NLEQE DFATY FC QQGNTLPW TF GCGT KLE I
Murlentamab,Whole mAb,G1,Kappa,Phase-II,Active,QVRLVQSGAEVKKPGASVKVSCKASGYTFTSYHIHWVRQAPGQRLEWMGWIYPGDDSTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCTRGDRFAYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASSSVRYIAWYQQKPGKAPKLLTYPTSSLKSGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCLQWSSYPWTFGGGTKVEIK,na,na,None,None,None,2018,2019,AMHR2,LFB Biotechnologies;GamaMabs Pharma,na,Colorectal cancer;Gynaecological cancer,na,na,,Q VRLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYHIHWVR QAPGQ RLEWMGWIY PGDDSTKYS QKF QG RVTITR DTSAS TAYMELS SLRSEDT AVYYCT RGD RFAYW GQG TLVTVS S,DI QMT QSPS TLSAS VGD RVTITCR ASSS VRYIAWYQ QKPGKAPK LLT YPTSSLKSGVPS RF SGSGSGT EFTLTISS LQPDDF ATYYCLQW SSYPW TF GGG TKVEI K
Mupadolimab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVEKPGASVKVSCKASGYTFTSYWITWVRQAPGQGLEWMGDIYPGSGNTNYNEKFKTRVTITADKSTSTAYMELSSLRSEDTAVYYCAKEGGLTTEDYALDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASKNVSTSGYSYMHWYQQKPGQAPRLLIYLASNLESGIPPRFSGSGYGTDFTLTINNIESEDAAYYFCQHSRELPFTFGQGTKVEIK,na,na,None,None,None,2021,2022,NT5E,Corvus Pharmaceuticals,na,COVID-19 infections;Oropharyngeal cancer;Cancer,na,na,,Q VQLVQ SGA EVE KPGA SVKVSCK ASGY TFTSYWITWVR QAPGQG LEWMGDI YPGSGNTNYNEKF KTRVTITA DKSTS TAYMELS SLRSEDT AVYYCAK EGGLTTED YALDY WGQG TLVTV SS,E IVLTQ SPA TLSL SPGE RATLSCRA SKNVSTSGY SYMHWYQ QKPGQAP RLLIYLA SNLESGIPPRFSGSGYGTD FTLTIN NIESEDA AYYFC QHSRELPF T FGQGT KVEI K
Muromonab,Whole mAb,G2a,Kappa,Approved,Discontinued,QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSS,QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAEDAATYYCQQWSSNPFTFGSGTKLEIN,na,na,1sy6:HL,None,None,1988,1989,CD3E,Cancer Research UK;Ortho-McNeil;XOMA,na,na,Diabetes mellitus;Graft-versus-host disease;Renal transplant rejection;Rheumatoid arthritis,na,LC IMGT 127 is N not K as in Jain paper.,QV QLQ QSGA EL ARPGA SVKMSCK ASGY TFTRYTMHWVK QRPGQG LEWIGYI NPSRGYTNYNQKFKDK ATLTT DKSSST AYMQLS SLTSEDS AVYYCARY YDDH YCLDY WGQG TTLTVS S,Q IVLT QSP AIMS ASPGE KVTMTCS ASSS VSYMN W YQ QKSGTSPK RWIYD TSKLASGVPA HFR GSGSGT SYSLTIS GME AEDAAT YYCQ QWSSNPF T FGSGT KLEI N
Nadecnemab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSVISGSGGSTYYADAVKGRFTISRDNSKHTLYLQMNSLRAEDTAVYYCTKPSSYSSSNFYYGMDVWGQGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTNSFPFPFGPGTKVDIK,na,na,None,None,None,2020,2021,GFRA3,Regeneron Pharmaceuticals,na,Osteoarthritis;Pain chronic,na,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKGL EWVSVIS GSGGS TYYAD AVKG RFTISR DNSKH TLYLQMN SLRAED TAVYYCT KPSSYSSSN FYYGMDV WGQG TTVTVS S,DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISSWLAWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQ PEDFAT YYC QQTNSFPFPFGPGT KVDI K
Nadunolimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYAFTSSWMNWVRQAPGQGLEWMGRIYPGDGNTHYAQKFQGRVTLTADKSTSTAYMELSSLRSEDTAVYYCGEGYLDPMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQGINNYLNWYQQKPGKAPKLLIHYTSGLHAGVPSRFSGSGSGTDYTLTISSLEPEDVATYYCQQYSILPWTFGGGTKVEIK,na,na,None,None,None,2018,2019,IL1RAP,Lund University;Cantargia,na,Non-small cell lung cancer;Pancreatic cancer;Solid tumours,na,na,Nadunolimab is the new name for Nidanilimab (PL122),Q VQLVQ SGA EVK KPGS SVKVSCK ASGY AFT SSW MNWVR QAPGQG LEWMGRI YPGDGNT HYAQKF QG RVTLTA DKSTS TAYMELS SLRSEDT AVYYC GEGYLDPMDYWGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCQ ASQG INNYLNWYQ QKPGKAP KLLIHY TSGLHAGVPSRFSGSGSGTD YTLTIS SLE PEDVATYYCQQ YSILPW T FGGGT KVEI K
Namilumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKAFGYPFTDYLLHWVRQAPGQGLEWVGWLNPYSGDTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCTRTTLISVYFDYWGQGTMVTVSS,DIQMTQSPSSVSASVGDRVTIACRASQNIRNILNWYQQRPGKAPQLLIYAASNLQSGVPSRFSGSGSGTDFTLTINSLQPEDFATYYCQQSYSMPRTFGGGTKLEIK,na,na,None,None,None,2010,2011,CSF2,Micromet Inc;Izana Bioscience;Takeda Pharmaceuticals International GmbH,na,Ankylosing spondylitis;COVID-19,Plaque psoriasis;Rheumatoid arthritis,Human Phage Display,,Q VQLVQ SGA EVK KPGA SVKVSCKA FGYPFT DY LLHWVR QAPGQGL EWVGWL NPYSGDTNY AQ KF QG RVTMT RDTS ISTAYMELS RLRSDDT AVYYC TRT TLISVYFD YWGQG TMVTVS S,DIQMTQSPSS VSA SVGD RVTIACR AS QNIRNILNWYQQ RPGKAP QLLIYA ASNLQSGVPSRFSGSGSGTD FTLTIN SLQ PEDFAT YYC QQSYSMPRTFGGGT KLEI K
Naptumomab,Fab Fusion,G1,Kappa,Phase-III,Discontinued,EVQLQQSGPDLVKPGASVKISCKASGYSFTGYYMHWVKQSPGKGLEWIGRINPNNGVTLYNQKFKDKATLTVDKSSTTAYMELRSLTSEDSAVYYCARSTMITNYVMDYWGQGTSVTVSS,SIVMTQTPTSLLVSAGDRVTITCKASQSVSNDVAWYQQKPGQSPKLLISYTSSRYAGVPDRFSGSGYGTDFTLTISSVQAEDAAVYFCQQDYNSPPTFGGGTKLEIK,na,na,None,None,None,2006,2007,TPBG,Active Biotech,na,na,Non-small cell lung cancer;Pancreatic cancer;Renal cancer,na,,EV QLQQ SGPDLVKPGA SVKISCK ASGY SFTGYYMHWVK QSPGKG LEWIGRI NPNNG VTLYN QKFKDK ATLTVD KSST TAYMELRS LTSEDS AVYYCA RST MITNYVMD YWGQGT SVTVS S,S IVMT QTPT SLLVS AGD RVTITCK ASQSVSND VAWYQ QKPGQSP KLLISYT SSRYAGVPDRFSGSGYGTD FTLTISSV QAEDA AVYFCQQ DYNSPPTFGGG TKLEI K
Naratuximab,Whole mAb ADC,G1,Kappa,Phase-II,Active,QVQVQESGPGLVAPSQTLSITCTVSGFSLTTSGVSWVRQPPGKGLEWLGVIWGDGSTNYHPSLKSRLSIKKDHSKSQVFLKLNSLTAADTATYYCAKGGYSLAHWGQGTLVTVSS,DIQMTQSPSSLSVSVGERVTITCRASENIRSNLAWYQQKPGKSPKLLVNVATNLADGVPSRFSGSGSGTDYSLKINSLQPEDFGTYYCQHYWGTTWTFGQGTKLEIK,na,na,None,None,None,2015,2016,CD37,ImmunoGen;Chronic lymphocytic leukaemia,na,Diffuse large B cell lymphoma;Non-Hodgkin's lymphoma,Chronic lymphocytic leukaemia,na,,Q VQVQE SGPG LV APSQ TLSITCTV SG FSLTT SG VSWVR QPPGKGL EWLGVIW GDGSTNYHPSLKS RLSIK KDHSKS QVFLKL NSLT A AD T ATYYC AKGGY SLAH WGQG TLVTVS S,DI QMT QSPS SLSVS VGE RVTITCR ASENI R SN L AWYQ QKPGKSP KLLVNVAT NLADGVPS RF SGSGSGTD YSLKI NSLQPEDFGT YYCQHY WGT TWTF GQGT KLEI K
Narlumosbart,Whole mAb,G4,Kappa,TBC,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGITGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGTTVIMSWFDPWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVRGRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVFYCQQYGSSPRTFGQGTKVEIK,na,na,None,None,None,2022,na,TNFSF11,TBC,TBC,TBC,TBC,TBC,"6ghg is technically within 95% ID, but CDRH3 length 7 vs length 15",E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKG LEWVSGI TGSGGS TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAED TAVYYCA KDPGT TVIMSWF DPWGQ GTLVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQSVRG RYLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPED FAVFYCQ QYGSSPRTFGQGT KVEI K
Narnatumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYLMTWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLNLQMNSLRAEDTAVYYCTRDGYSSGRHYGMDVWGQGTTVIVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSRYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIK,na,na,None,None,None,2011,2012,MST1R,ImClone Systems;Eli Lilly;ImClone Systems,na,na,Solid tumours,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFSSYLMTWVR QAPGKG LEWVANIK QDGS EKYYVD SVKG RFTIS RDNAKNS LNLQM N SL RAEDT AVYYCT RDGYSSGR HYGMDV WGQG TTVIVS S,E IVLT QSPA TLSL SPGE RATLSCR ASQS VSRYLAWY QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPED FAVYYCQ QRSNWPRTFGQGT KVEI K
Narsoplimab,Whole mAb,G4,Lambda,Preregistration,Active,QVTLKESGPVLVKPTETLTLTCTVSGFSLSRGKMGVSWIRQPPGKALEWLAHIFSSDEKSYRTSLKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIRRGGIDYWGQGTLVTVSS,QPVLTQPPSLSVSPGQTASITCSGEKLGDKYAYWYQQKPGQSPVLVMYQDKQRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTAVFGGGTKLTVL,na,na,None,None,None,2019,2020,MASP2,Omeros,na,Haemolytic uraemic syndrome;IgA nephropathy;Immediate hypersensitivity;Thrombotic microangiopathies;Glomerulonephritis;Lupus nephritis;Membranous glomerulonephritis,Stroke;Wet age-related macular degeneration,na,,QV TLK ESGP VLV KPTE TLTLTCTVS G FS LSRG KMGVSWIR QPPGK ALEWLAHIF SSDEKS YRT SLK SRLTIS KDTSKN QVVLTMT NMDPVD TAT YYCARIR RGG I D Y WGQG TLVTV SS,QPVLTQPPS LSV SPGQ TASITC SGEKLGD KYAYWYQ QKPGQSP VLVMYQ DKQRPSGIPERFSGSNSGN TATLTIS GTQAMDEAD YYCQAW DSSTA VF GGGT KLTV L
Natalizumab,Whole mAb,G4,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQRLEWMGRIDPANGYTKYDPKFQGRVTITADTSASTAYMELSSLRSEDTAVYYCAREGYYGNYGVYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKTSQDINKYMAWYQQTPGKAPRLLIHYTSALQPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDNLWTFGQGTKVEIK,na,na,None,4irz:HL/6fg1:HL/6fg2:HL:IM,None,1998,1999,ITGA4,Biogen;Biogen Idec;Elan Corporation;Perrigo,Crohn's disease;Multiple sclerosis,Epilepsy;Graft-versus-host disease;Stroke,Multiple myeloma;Rheumatoid arthritis,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGFNIKD TYIHWVR QAPGQ RLEWMGRI DPANGY TKY DPKFQG RVTITA DTSAS TAYMELS SLRSEDT AVYYCA REGYYGN YGVYAMD YWGQG TLVTVS S,DIQMTQSPSS LSA SVGD RVTITCK TS QDINKYMAWYQ QTPGKAP RLLIHYT SALQPGIPSRFSGSGSGRD YTFTIS SLQ PEDIA TYYCLQ YDN LWTF GQGT KVEI K
Navivumab,Whole mAb,G1,Kappa,Preclinical,Discontinued,QVQLVQSGAEVKKPGASVKVSCKTSGYSFSTYGVSWVRQAPGQGPEWVGWISAYTGITDYAQKFQGRVTLTTDATTATAFLDLRSLRPDDTATYFCARDKVQGRVEVGSGGRHDYWGQGTLVIVSS,EVVLTQSPGTLALPPGERATLSCRASHRVGSTYIAWYQQKSGQAPRRLIYGASNRATDIPDRFSGSGSGTDFTLTIRRLEPEDSAVYYCQQFSVSPWTFGQGTRVEIK,na,na,4r8w:HL/4ubd:CD:KL:YX:ST:OP:GH,6fg1:HL/6fg2:HL,None,2015,2016,Influenza A HA,Celltrion,na,na,Influenza A virus H1N1 subtype;Influenza A virus H5N1 subtype;Influenza virus infections,na,,Q VQLVQ SGA EVK KPGA SVKVSC KTSGY SFSTYGVSWVR QAPGQGPE WVGWISAY TGITD YAQ KFQG RVTLTT DATTA TAFLD LRSLRPDDT ATYFCA RDKVQG RVEV GSGGRHDYWGQG TLVIVS S,E VVLTQ SPG TLA LPPGE RATLSCRAS HRVGS TYIAWYQ QKSGQAPR RLIYG ASNRATDIPDRFSGSGSGT DFTLTIRR LEPEDS AVYYCQQFSV SPWTFGQG TRVEI K
Navicixizumab,Bispecific mAb,G2;G2,Kappa;Kappa,Phase-I,Active,QVQLVQSGAEVKKPGASVKISCKASGYSFTAYYIHWVKQAPGQGLEWIGYISNYNRATNYNQKFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARDYDYDVGMDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATISCRASESVDNYGISFMKWFQQKPGQPPKLLIYAASNQGSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEVPWTFGGGTKVEIK,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPGQGLEWMGDINPSNGRTSYKEKFKRRVTLSVDKSSSTAYMELSSLRSEDTAVYFCTIHYDDKYYPLMDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATISCRASESVDNYGISFMKWFQQKPGQPPKLLIYAASNQGSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEVPWTFGGGTKVEIK,None;None,None;None,None;None,2015,2016,DLL4;VEGFA,OncoMed Pharmaceuticals,na,Fallopian tube cancer;Ovarian cancer;Peritoneal cancer,Colorectal cancer;Solid tumours,na,,Q VQLVQ SGA EVK KPGA SVKISCK ASGY SFTAYYIHWVK QAPGQG LEWIGYIS NYNRATNYNQK FKGRVTFTT DTSTS TAYMELRSL RSDDT AVYYCAR DYDYDVGMDYWGQG TLVTVS S,D IVMT QSPDS LAVS LGER ATISCR ASESVDNYG ISFMK W F QQKPGQPP KLLIYAA SNQGSGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC QQSKEVPW T FGGG TKVEI K
Naxitamab,Whole mAb,G1,Kappa,Approved,Active,QVQLVESGPGVVQPGRSLRISCAVSGFSVTNYGVHWVRQPPGKGLEWLGVIWAGGITNYNSAFMSRLTISKDNSKNTVYLQMNSLRAEDTAMYYCASRGGHYGYALDYWGQGTLVTVSS,EIVMTQTPATLSVSAGERVTITCKASQSVSNDVTWYQQKPGQAPRLLIYSASNRYSGVPARFSGSGYGTEFTFTISSVQSEDFAVYFCQQDYSSFGQGTKLEIK,na,na,None,None,None,2018,2019,Ganglioside GD2,Memorial Sloan-Kettering Cancer Center;Y-mAbs Therapeutics,Neuroblastoma,Osteosarcoma,Breast cancer;Sarcoma;Small cell lung cancer,na,,Q VQLVE SGPG VV QPGR SLRISCAV SGF SVTNYGVHWVR QPPGKGL EWLGVIWA GGITNYNSA FMSRLTIS KDNSKN TVYLQMNS LRAEDT AMYYCA SRGGHY GYALDY WGQG TLVTVS S,E IVMT QTPA TLSVS AGE RVTITCK ASQSVSND VTWYQ QKPGQAP RLLIYS ASNRYSGVP ARF SGSGYGT EFTFTISS VQSED FAVYFCQ QDYSSFGQG TKLEI K
Necitumumab,Whole mAb,G1,Kappa,Approved,Active,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVSS,EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAEIK,na,na,6b3s:JK:CD:HL:FG/3b2u:WX:QR:TU:JK:CD:NO:FG:HL/3b2v:HL,None,None,2008,2009,EGFR,ImClone Systems;Eli Lilly,Non-small cell lung cancer,Solid tumours,Colorectal cancer,na,,Q VQLQE SGPGLVKPSQ TLSLTCTV SGGSISSGD YYWSWIR QPPGKGL EWIGYIYYS GSTDYNPSLK SRVTMSVD TSKN QFSLKVNSVT AADT AVYYCARVSIF GVG TFD YWGQG TLVTVS S,E IVMT QSPA TLSL SPGE RATLSCR ASQS VSSYL A W Y QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPE D FAVYYCH QYGSTPL TF GGGT KAEI K
Nemolizumab,Whole mAb,G2,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYIMNWVRQAPGQGLEWMGLINPYNGGTDYNPQFQDRVTITADKSTSTAYMELSSLRSEDTAVYYCARDGYDDGPYTLETWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASEDIYSFVAWYQQKPGKAPKLLIYNAQTEAQGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYDSPLTFGGGTKVEIK,na,na,None,None,None,2014,2015,IL31RA,Chugai Pharmaceutical;Galderma;Maruho,Atopic dermatitis,Prurigo nodularis;Pruritus;Scleroderma,na,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTGYIMNWVR QAPGQGL EWMGLI NPYNGGTDYNPQFQD RVTITA DKSTS TAYMELS SLRSEDT AVYYCA RDGYDDGP YTLETW GQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITCQ ASED IYSFVAWYQ QKPGKAP KLLIYN AQTEAQGVPS R FSGSGSGTD FTLTISS LQP EDFA TYYCQ HHYDSPL TF GGG TKVEI K
Nepuvibart,Whole mAb,G1,Kappa,Approved,NFD,QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYITYSGSTIYYADSVKGRFTISRDNAKSSLYLQMNSLRAEDTAVYYCARDRGTTMVPFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYAASNLETGVPSRFSGSGSGTDFTFTISGLQPEDIATYYCQQYDNLPLTFGGGTKVEIK,na,na,6xdg:BD,None,None,2020,2021,SARS-CoV-2 Spike RBD,Regeneron Pharmaceuticals,COVID-19,na,na,na,Casirivimab is the former name for Nepuvibart,Q VQLVES GGG LV KPGG SLRLSC AASGF TF SD YYMSWIR QAPGKGL EWVSYITY SGS TIYYA DSVKG RFTIS RDNAKS SLYLQMN SLRAEDT AVYYCA RDRGT TMV PFDYWGQG TLVTV SS,DIQ M TQSPSS LSA SVGD RVTITCQ AS QDITNYLNWYQ QKPGKAP KLLIYAA SNLETGVPSRFSGSGSGTD FTFTIS GLQ PEDIATYYCQQ YDNLP LTF GGGT KVEI K
Nesvacumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDIHWVRQATGKGLEWVSAIGPAGDTYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARGLITFGGLIAPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYDNSQTFGQGTKVEIK,na,na,None,None,None,2012,2013,ANGPT2,Regeneron Pharmaceuticals;Sanofi,na,na,Solid tumours,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFSSYDIHWVRQ ATGKG LEWVSAI GPAGDT Y YPGS VKGRFTIS RENAKN SLYLQMNS LRAGD TAVYYC ARG LITF GG LI APFDYWGQG TLVTV SS,E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSS TYLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQH YDNSQTFGQG TKVEI K
Netakimab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGGGLVQAGGSLRLSCAASGGTFATSPMGWLRQAPGKGTEFVAAISPSGGDRIYADSVKGRFTISRDNAGYFIYLQMNSLKPEDTAVYYCAVRRRFDGTSYYTGDYDSWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYSYSPVTFGQGTKVEIK,na,na,None,None,None,2017,2018,IL17A,CJSC Biocad,Plaque psoriasis,Ankylosing spondylitis;Psoriatic Arthritis;Primary biliary cirrhosis,na,na,,Q VQLVQS GGG LVQ AGG SLRLSCA ASGGT FAT SPMG WLRQ APGKGT EFVAAI SPSGGD RIYAD SVKG RFTIS RDNAG YFIYLQM NSLKPEDT AVYYCAVRRR FDGT SYYTG DYDSWGQG TLVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSSS YLAWYQ QKPGQAP RLLIYD ASSRATGIPDRFSGSGSGT DFTLTISR LEP ED FAVYYCQ QYSYSPV T FGQGT KVEI K
Nimacimab,Whole mAb,G4,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYEFSYYWMNWVRQAPGQGLEWMGQIYPGDGETKYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARSHGNYLPYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSSYLHWYQQKPGQAPRLLIYSTSNLASGIPARFSGSGSGTDFTLTISRLEPEDFAVYYCHQYHRSPPTFGQGTKVEIK,na,na,None,None,None,2018,2019,CNR1,Bird Rock Bio,na,Diabetic nephropathies;Diabetic gastroparesis;Obesity,Non-alcoholic steatohepatitis;Non-alcoholic fatty liver disease,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGY EFSYYWMNWVR QAPGQG LEWMGQI YPGDGET KYAQKF QG RVTITA DKSTS TAYMELS SLRSEDT AVYYCAR SHGNYLPYWGQG TLVTVS S,E IVLTQ SPA TLSL SPGE RATLSCR ASQSVSSS YLHWYQ QKPGQAP RLLIYS TSNLASGIP ARFS GSGSGT DFTLTISR LEPED FAVYYCHQY HRSPPTFGQGT KVEI K
Nimotuzumab,Whole mAb,G1,Kappa,Approved,Active,QVQLQQSGAEVKKPGSSVKVSCKASGYTFTNYYIYWVRQAPGQGLEWIGGINPTSGGSNFNEKFKTRVTITADESSTTAYMELSSLRSEDTAFYFCTRQGLWFDSDGRGFDFWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQNIVHSNGNTYLDWYQQTPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCFQYSHVPWTFGQGTKLQIT,na,na,None,3gkw:HL,None,2005,2006,EGFR,Biocon Biopharmaceuticals;Biotech Pharmaceutical;Center of Molecular Immunology;CIMYM;Daiichi Sankyo Inc;Eurofarma;Gilead Sciences;Innogene Kalbiotech;InnoMab;Kuhnil Pharmaceutical Company;Laboratorios Pisa;Oncoscience,Anaplastic astrocytoma;Brain cancer;Glioblastoma;Glioma;Head and neck cancer;Nasopharyngeal cancer;Oesophageal cancer,Cervical cancer;Non-small cell lung cancer;Pancreatic cancer;Breast cancer;Colorectal cancer,Gastric cancer;Polycystic kidney disease;Prostrate cancer;Brain metastases;Squamous cell cancer,na,(Feb '22) Conflict between our sequence and IMGT-mAb/DB. We take the seminal paper as source of the sequence: https://cancerres.aacrjournals.org/content/69/14/5851.,Q VQLQQ SGA EVK KPGS SVKVSCK ASGY TFTNYYIYWVRQ APGQG LEWIGGI NPTSGGSNFNEKF KTRVTITA DESST TAYMELS SLRSEDT AFYFC TRQG LWF DSDGR GFDFW GQG TTVTVS S,DI QMT QSPSS LSA SVGD RVTITCR SSQN IVH SNGN TYLDWYQ QTPGKAP KLLIYKV SNRFSGVPS R FSGSGSGT DFTFTISS LQPEDI ATYYCFQY SHVPWTFGQGT KLQI T
Nipocalimab,Whole mAb,G1,Lambda,Phase-III,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSS,QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMIYGDSERPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYAGSGIYVFGTGTKVTVL,na,na,None,None,5whk:HL/5whj:HL,2019,2020,FCGRT,Momenta,na,Autoimmune haemolytic anaemia;Haemolytic disease of newborn;Myasthenia gravis,na,na,,E VQLLES GGG LV QPGG SLRLSC AASGF TFSTYAMGWVRQ APGKG LEWVSSI GASGSQ TRY ADSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCARLAI GDSYWGQG TMVTVS S,QSALTQPA SV SGSPGQ SITISC TGTGSDVG SY N LVSWYQ QHPGKAP KLMIY GDSERPSGVSNRFSGSKSGNT ASLTIS GLQAEDEAD YYCS SYAGS GIYVF GTGT KVTV L
Nirsevimab,Whole mAb,G1,Kappa,Preregistration,Active,QVQLVQSGAEVKKPGSSVMVSCQASGGLLEDYIINWVRQAPGQGPEWMGGIIPVLGTVHYGPKFQGRVTITADESTDTAYMELSSLRSEDTAMYYCATETALVVSETYLPHYFDNWGQGTLVTVSS,DIQMTQSPSSLSAAVGDRVTITCQASQDIVNYLNWYQQKPGKAPKLLIYVASNLETGVPSRFSGSGSGTDFSLTISSLQPEDVATYYCQQYDNLPLTFGGGTKVEIK,na,na,5udc:HL:BC:EG/5udd:JP:KQ:LR:MS:OU:NT,None,4jha:HL/4jhw:HL/6s3d:AB:CD:EF:HL,2018,2019,RSV,AIMM Therapeutics;MedImmune,na,Respiratory syncytial virus infections,na,na,,Q VQLVQ SGA EVK KPGS SVMVSCQ ASGGL LEDYI IN WVR QAPGQGPEWMGG IIPVLGTVHY GPKFQG RVTITA DESTD TAYMELS SLRSEDT AMYYCA TET ALVVSE TYLPHYFDNWGQG TLVTV SS,DIQMTQSPSS LSA AVGD RVTITCQ AS QDIVNYLNWYQ QKPGKAP KLLIYVA SNLETGVPSRFSGSGSGTD FSLTIS SLQ PEDVATYYCQQ YDNLP LTF GGGT KVEI K
Nisevokitug,Whole mAb,G2,Lambda,TBC,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGLWEVRALPSVYWGQGTLVTVSS,SYELTQPPSVSVAPGQTARITCGANDIGSKSVHWYQQKAGQAPVLVVSEDIIRPSGIPERISGSNSGNTATLTISRVEAGDEADYYCQVWDRDSDQYVFGTGTKVTVL,na,na,None,None,None,2022,na,TGFB1/TGFB2,TBC,TBC,TBC,TBC,TBC,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSSYAISWVR QAPGQGL EWMGGIIPIF GTANYAQKFQG RVTITA DESTS TAYMELS SLRSEDT AVYYC ARGL WEVRA LPS VYW GQG TLVTVS S,SYELTQPPS VSV APGQ TARITC GANDIGSK SVHWYQ QKAGQAP VLVVS ED II RPSGIPE RI SGSNSGN TATLTISRVE AGDE ADYYCQVWD RDSD QYVFG TGT KVTV L
Nivatrotamab,Bispecific Mixed mAb and scFv,G1;na,Kappa;Kappa,Phase-I/II,Active,QVQLVESGPGVVQPGRSLRISCAVSGFSVTNYGVHWVRQPPGKGLEWLGVIWAGGITNYNSAFMSRLTISKDNSKNTVYLQMNSLRAEDTAMYYCASRGGHYGYALDYWGQGTLVTVSS,EIVMTQTPATLSVSAGERVTITCKASQSVSNDVTWYQQKPGQAPRLLIYSASNRYSGVPARFSGSGYGTEFTFTISSVQSEDFAVYFCQQDYSSFGQGTKLEIK,QVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKCLEWIGYINPSRGYTNYNQKFKDRFTISRDNSKNTAFLQMDSLRPEDTGVYFCARYYDDHYSLDYWGQGTPVTVSS,DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGCGTKLQIT,None;None,None;None,None;None,2020,2021,GD2;CD3E,Memorial Sloan-Kettering Cancer Center,na,Neuroblastoma,na,na,,Q VQLVE SGPG VV QPGR SLRISCAV SGF SVTNYGVHWVR QPPGKGL EWLGVIWA GGITNYNSA FMSRLTIS KDNSKN TVYLQMNS LRAEDT AMYYCA SRGGHY GYALDY WGQG TLVTVS S,E IVMT QTPA TLSVS AGE RVTITCK ASQSVSND VTWYQ QKPGQAP RLLIYS ASNRYSGVP ARF SGSGYGT EFTFTISS VQSED FAVYFCQ QDYSSFGQG TKLEI K
Nivolumab,Whole mAb,G4,Kappa,Approved,Active,QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIK,na,na,5ggq:HL/5wt9:HL/5ggr:HL:AB,None,None,2012,2013,PDCD1,Aduro BioTech;AIO Studien gGmbH;Australian and New Zealand Urogenital and Prostate Cancer Group;Barbara Ann Karmanos Cancer Institute;Bavarian Nordic;Big Ten Cancer Research Consortium;Bristol-Myers Squibb;Canadian Cancer Trials Group;Celleron Therapeutics;Clatterbridge Cancer Centre NHS Foundation Trust;Clovis Oncology;Curie Institute;Daiichi Sankyo Company;Dana-Farber Cancer Institute;Duke University Medical Center;Eisai Inc;Eli Lilly;Emory University;European Thoracic Oncology Platform;Exelixis;Frontier Science foundation;Grupo Espanol Multidisciplinar de Melanoma;H. Lee Moffitt Cancer Center and Research Institute;Hellenic Genitourinary Cancer Group;Hoosier Cancer Research Network;HOVON Foundation;Incyte Corporation;Intergroupe Francophone de Cancerologie Thoracique;Janssen Biotech;Janssen Research & Development;Kansai Medical University;Kyoto Breast Cancer Research Network;M. D. Anderson Cancer Center;Massachusetts General Hospital;Medarex;Nantes University Hospital;National Cancer Center (Tokyo);National Cancer Centre (Singapore);National Cancer Institute (USA);Nektar Therapeutics;Neon Therapeutics;Netherlands Cancer Institute;Northwestern University;Ono Pharmaceutical;Pharmacyclics;PrECOG;Seattle Genetics;Sidney Kimmel Cancer Center;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Syneos Health;The University of Montreal Hospital Research Center;UNICANCER;University College London;University of Liverpool;University of Pittsburgh;University of Texas M. D. Anderson Cancer Center;Vanderbilt-Ingram Cancer Center;Zucero Therapeutics,Colorectal cancer;Gastric cancer;Head and neck cancer;Hodgkin's disease;Malignant melanoma;Non-small cell lung cancer;Renal cell carcinoma;Urogenital cancer;Liver cancer;Mesothelioma;Small cell lung cancer,Bladder cancer;Fallopian tube cancer;Glioblastoma;Multiple myeloma;Oesophageal cancer;Ovarian cancer;Peritoneal cancer;Non-Hodgkin's lymphoma;Acute myeloid leukaemia;Adrenocortical carcinoma;Biliary cancer;Brain metastases;Breast cancer;Bronchopulmonary dysplasia;Cancer;Cervical cancer;Cholangiocarcinoma;Chronic lymphocytic leukaemia;CNS cancer;Diffuse large B cell lymphoma;Follicular lymphoma;Genitourinary disorders;Leucoplakia;Liver metastases;Meningeal carcinomatosis;Myelodysplastic syndromes;Nasopharyngeal cancer;Oropharyngeal cancer;Pancreatic cancer;Penile cancer;Prostate cancer;Soft tissue sarcoma;Solid tumours;Testicular cancer;Thyroid cancer;Uterine cancer;Uveal melanoma;Haematological malignancies;Lymphoma;Rectal cancer;Glioma,Chronic myeloid leukaemia;Hepatitis C;Sepsis,Medarex UltiMAb Mouse,,Q VQLVES GGG VV QPGR SLRLDC KASG ITFS NSG MHWVRQ APGKGL EWVAVIWY DGSK RYYAD SVKG RFTISR DNSKN TLFLQMN SLRAEDT AVYYCA TNDDYWGQ GTLVTVS S,E IVLTQ SPA TLSL SPGE RATLSCR ASQS VSS YLAWY QQKPGQAP RLLIYD ASNRATG I P ARF SGSGSGT DFTLTIS SLEPED FAVYYCQ QSSNWPRTFGQGT KVEI K
Nofazinlimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGSSVKVSCKASGFTFTTYYISWVRQAPGQGLEYLGYINMGSGGTNYNEKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCAIIGYFDYWGQGTMVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSLLDSDGGTYLYWFQQRPGQSPRRLIYLVSTLGSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQLTHWPYTFGQGTKLEIK,na,na,None,None,None,2021,2022,PDCD1,Cstone Pharmaceuticals,na,Solid tumours;Hepatocellular carcinoma,na,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGF TFTTYYISWVR QAPGQGL EYLGYINM GSGGTNYNEKFKG RVTITA DKSTS TAYMELS SLRSEDT AVYYCAIIGYF DYWGQG TMVTVS S,DV VMT QSPLSLP VT LGQPA SISCR SSQ SLL DSDGG TYLYWFQ QRPGQSPR RLIYLVST LGSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCMQLT HWPYTFGQGT KLEI K
Nurulimab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,None,5xj3:AB:DE:GH:JK/5tru:HL:hl/6jc2:HL/6rp8:HL:hl/7elx:HL:hl,None,2019,2020,CTLA4,Biocad,na,na,Malignant melanoma,na,Likely to be an Ipilimumab Biosimilar,E VQLVES GGG VV QPGR SLRLSC AASGF TFSSYTMHWVRQ APGKGL EWVTFISY DGNNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AIYYCA RTGWLGPFDYWGQG TLVTV SS,E IVLTQ SPG TLSL SPGE RATLSCRA SQSVGS SYLAWYQ QKPGQAP RLLIYGAF SRATGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQ QYGSSPW TF GQGT KVEI K
Obexelimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSS,DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK,na,na,None,None,None,2018,2019,CD19,Xencor,na,Autoimmune disorders;Rheumatoid arthritis;Systemic lupus erythematosus,na,XmAb Antibody Engineering Technology,,E VQLVES GGG LV KPGG SLKLSC AASGY TFTSYVMHWVR QAPGKGL EWIGYI NPYNDGTKYNE KF Q GRVTIS SDKS ISTAYMELS SLRSEDT AMYYC ARGT YYY G TRVFD YWGQG TLVTVS S,D IVMT QSPA TLSL SPGE RATLSCR SSKSL Q NVNGN TYLYWFQ QKPGQSP QLLIYRM SNLNSGVPDRFSGSGSGT EFTLTIS SLEPED FAVYYCM QHLEYP ITF GAGT KLEI K
Obiltoxaximab,Whole mAb,G1,Kappa,Approved,NFD,QVQLQQSGPELKKPGASVKVSCKDSGYAFSSSWMNWVRQAPGQGLEWIGRIYPGDGDTNYNGKFQGRVTITADKSSSTAYMELSSLRSEDTAVYFCARSGLLRYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAVKLLIYYTSRLLPGVPSRFSGSGSGTDYSLTISSQEQEDIGTYFCQQGNTLPWTFGQGTKVEIR,na,na,None,None,None,2015,2016,Anthrax Protective Antigen,Elusys Therapeutics,Anthrax,na,na,na,,QV QLQ QSGPELKKPGA SVKVSC KDSGY AFS SS W MNWVR QAPGQG LEWIGRI YPGDGDTNYNG KFQGRVTITA DKSSS TAYMELS SLRSEDT AVYFCA RSGL LRYAMD YWGQG TLVTVS S,DIQMTQSPSS LSA SVGD RVTITCR AS QDIRNYLNWYQ QKPGK AVKLLIYYT SRLLPGVPSRFSGSGSGTD YSLTI SSQEQEDI GTYFC QQGNTLPW TF GQGT KVEI R
Obinutuzumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS,DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIK,na,na,3pp3:HL:IK/3pp4:HL,6y9a:HL,6y97:HL,2008,2011,MS4A1,GLYCART Biotechnology;Biogen Idec;Chugai Pharmaceutical;Dana-Farber Cancer Institute;Genentech;Lymphoma Academic Research Organisation;Nippon Shinyaku;OHSU Knight Cancer Institute;Pharmacyclics;Polish Myeloma Consortium;Roche;Thomas Jefferson University;University of Heidelberg;University of Leeds,Chronic lymphocytic leukaemia;Follicular lymphoma;Non-Hodgkin's lymphoma,Diffuse large B cell lymphoma;CNS cancer;Graft-versus-host disease;Lupus nephritis;Mantle-cell lymphoma;Waldenstrom's macroglobulinaemia,Primary biliary cirrhosis,GlycoMAb Technology,Obinutuzumab is the new name for Afutuzumab (PL101),Q VQLVQ SGA EVK KPGS SVKVSCK ASGY AFSYSWINWVR QAPGQG LEWMGRI FPGDGDTDYNGK FKGRVTITA DKSTS TAYMELSS LRSEDT AVYYCAR NVFDG YWLVYW GQG TLVTVS S,DI VMT QTPLSLPVTPGEPA SISCR SSK SLLH SNG ITYLYWYLQ KPGQSP QLLIYQM SNLVSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCA QNLELPY T FGGG TKVEI K
Obrindatamab,Bispecific scFv with Domain Crossover,na;na,Kappa;Lambda,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSDSSAIYYADTVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCGRGRENIYYGSRLDYWGQGTTVTVSS,DIQLTQSPSFLSASVGDRVTITCKASQNVDTNVAWYQQKPGKAPKALIYSASYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPFTFGQGTKLEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKDRFTISRDDSKNSLYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPWTPARFSGSLLGGKAALTITGAQAEDEADYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2020,2021,CD276;CD3E,MacroGenics,na,na,Advanced or Metastatic solid tumours,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFSS F GMHWVRQ APGKG LEWVAYIS SDSS AIYYAD TVKG RFTISR DNAKNS LYLQMN SLRDEDT AVYYC GRGREN IYY GS RLDY WGQG TTVTVS S,DI QLT QSPS FLSA SVGD RVTITCK ASQNVDTN VAWYQ QKPGKAPK ALIYSASYRY SGVPSRFSGSGSGTD FTLTISS LQP EDFAT YYCQ QYNNYPF T FGQGT KLEI K
Ocaratuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVQSGAEVKKPGESLKISCKGSGRTFTSYNMHWVRQMPGKGLEWMGAIYPLTGDTSYNQKSKLQVTISADKSISTAYLQWSSLKASDTAMYYCARSTYVGGDWQFDVWGKGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASSSVPYIHWYQQKPGQAPRLLIYATSALASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQWLSNPPTFGQGTKLEIK,na,na,None,None,None,2012,2013,MS4A1,Applied Molecular Evolution;MENTRIK Biotech,na,na,Follicular lymphoma;Non-Hodgkin's lymphoma;Rheumatoid arthritis,na,,E VQLVQ SGA EVK KPGE SLKISC KGSGR TFTSYNMHWVRQ MPGKGL EWMGAIYP LTGDTSYNQKS KLQVTIS ADKS ISTAYLQWSS LKASDT AMYYCARSTYV GGD WQFDVW GKG TTVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASSSVP YIHWYQ QKPGQAP RLLIYAT SALASGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYCQ QW LSNPPTFGQGT KLEI K
Ociperlimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMYWVRQAPGKGLEWVAYITKGGGSTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARQTNYDFTMDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCKASQDVGTSVAWYQQKPGQAPRLLIYWASARHTGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYSSYPLTFGGGTKVEIK,na,na,None,None,None,2020,2021,TIGIT,BeiGene,na,Non-small cell lung cancer; Cervical cancer; Small-cell lung cancer; Squamous cell cancer; Solid tumours,na,na,(June '22: Corrected CDRH1 sequence),E VQLVES GGG LV QPGG SLRLSCA ASGF TF SD YYMYWVRQ APGKG LEWVAYIT KGGGST Y YPDSVK GRFTISR DNAKN TLYLQMN SLRAEDT AVYYCAR QTNY DFTMDY WGQG TLVTVS S,E IVMT QSPA TLSV SPGE RATLSCKA SQDVGT SVAWYQ QKPGQAP RLLIYWAS ARHTGIP ARFS GSGSGT EFTLTISS LQSED FAVYYCQ QYSSYP LTF GGG TKVEI K
Ocrelizumab,Whole mAb,G1,Kappa,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWVGAIYPGNGDTSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVYYSNSYWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASSSVSYMHWYQQKPGKAPKPLIYAPSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSFNPPTFGQGTKVEIK,na,na,None,None,4k7p:YX,2005,2006,MS4A1,Biogen;Biogen Idec;Chugai Pharmaceutical;Genentech;Roche,Multiple sclerosis,na,Eye disorders;Haematological malignancies;Lupus nephritis;Rheumatoid arthritis;Systemic lupus erythematosus,na,,E VQLVES GGG LV QPGG SLRLSC AASGY TFTSYNMHWVRQ APGKG LEWVGAIY PGNGDTSYNQKFK GRFTISVD KSKN TLYLQMNSL RAEDT AVYYCARVVYY SNS YWYFDV WGQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITCR ASSS VSYMHWYQ QKPGKAPKP LIY APSNLASGVPS R FSGSGSGT DFTLTISS LQPEDF ATYYCQQW SFNPPTFGQGT KVEI K
Odesivimab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMHWVRQATGKGLEWVSAIGTAGDTYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARTWFGELYFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTEFTLTITSLQAEDVAVYYCQQYYSSPLTFGGGTKVEIK,na,na,None,None,None,2019,2020,Zaire Ebolavirus GP,Regeneron Pharmaceuticals,Ebola virus infections ,na,na,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFSS YD MHWVRQ ATGKGL EWVSAIG TAGDTYYPGS VKGRFTIS RENAKN SLYLQMNS LRAGD TAVYYCA RTWFG ELYFD YWGQG TLVTV SS,D IVMT QSPDS LAVS LGE RATINC KSSQ SVLYS SNNK NYLAWYQ QKPGQPP KLLIYWAS TRESGVPDRFSGSGSGT EFTLTITS LQAED VAVYYCQQ YYSSPL TF GGG TKVEI K
Odronextamab,Bispecific mAb,G4;G4,Kappa;Kappa,Phase-III,Active,EVQLVESGGGLVQPGRSLRLSCVASGFTFNDYAMHWVRQAPGKGLEWVSVISWNSDSIGYADSVKGRFTISRDNAKNSLYLQMHSLRAEDTALYYCAKDNHYGSGSYYYYQYGMDVWGQGTTVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQHYINWPLTFGGGTKVEIK,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYTMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDNSGYGHYYYGMDVWGQGTTVTVAS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQHYINWPLTFGGGTKVEIK,None;None,None;None,None;None,2019,2020,MS4A1;CD3E,Regeneron Pharmaceuticals,na,Follicular lymphoma;B-cell lymphoma;Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma,na,na,,E VQLVES GGG LV QPGR SLRLSCVA SGF TF NDY AMHWVRQ APGKGL EWVSVISW NSDSIGYADSVKG RFTISR DNAKNS LYLQMHSL RAEDT ALYYCA KDNHYGSGS YYYYQY GM DVW GQG TTVTVS S,E IVMT QSPA TLSV SPGE RATLSCR ASQSVSSN LAWYQ QKPGQAP RLLIYG ASTRATGIP ARFS GSGSGT EFTLTISS LQSED FAVYYCQHYI NWPL T FGGG TKVEI K
Ofatumumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIK,na,na,3giz:HL/6y92:HL:CD,None,None,2005,2006,MS4A1,Genmab;GlaxoSmithKline;Mundipharma International;National Cancer Centre (Singapore);Novartis;Roswell Park Cancer Institute;University Health Network,Chronic lymphocytic leukaemia,B-cell lymphoma;Diffuse large B cell lymphoma;Follicular lymphoma;Multiple sclerosis;Marginal zone B-cell lymphoma;Precursor cell lymphoblastic leukaemia-lymphoma,Neuromyelitis optica;Pemphigus vulgaris;Rheumatoid arthritis;Waldenstrom's macroglobulinaemia,Medarex HuMAb Mouse,,E VQLVES GGG LV QPGR SLRLSC AASGF TF NDY AMHWVRQ APGKGL EWVSTISW NSGSI GYA DSVKG RFTIS RDNAKK SLYLQM NSLRAEDT ALYYCA KDIQYGN YYYGMDV WGQG TTVTVS S,E IVLTQ SPA TLSL SPGE RATLSCR ASQS VSSY LAWY QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPE D FAVYYCQ QRSNWP ITF GQGT RLEI K
Ogalvibart,Whole mAb,G1,Kappa,Phase-II/III,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVIPFDGRNKYYADSVTGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASSSGYLFHSDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISNWLAWFQQKPGKAPKLLIYEASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYPWTFGQGTKVEIK,na,na,7k8r:HL/7k8z:HL:MN,None,None,2022,na,SARS-CoV-2 Spike RBD,National Institute of Allergy and Infectious Diseases;Rockefeller University;Xencor,na,COVID-19,na,na,,Q VQLVES GGG VV QPGR SLRLSC AASGF TFSSYAMHWVRQ APGKG LEWVAVIP FDGRNK YYA DSVT GRFTISR DNSKN TLYLQMN SLRAEDT AVYYCA SSSG YLFH SDYWGQG TLVTVS S,DIQMTQSPS TLSAS VGD RVTITCR ASQS ISNWLAWFQ QKPGKAP KLLIYE ASSLESGVPS R FSGSGSGT EFTLTIS SLQPDD FAT YYCQ QYNSYPW T FGQGT KVEI K
Olaratumab,Whole mAb,G1,Kappa,Approved,Active,QLQLQESGPGLVKPSETLSLTCTVSGGSINSSSYYWGWLRQSPGKGLEWIGSFFYTGSTYYNPSLRSRLTISVDTSKNQFSLMLSSVTAADTAVYYCARQSTYYYGSGNYYGWFDRWDQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPAFGQGTKVEIK,na,na,None,None,None,2010,2011,PDGFRA,ImClone Systems;Eli Lilly;Institute for Clinical Oncological Research,Soft tissue sarcoma,Pancreatic cancer;Solid tumours,Gastrointestinal stromal tumours;Glioblastoma;Non-small cell lung cancer;Ovarian cancer;Prostate cancer,Medarex UltiMAb Mouse,,QL QLQE SGPGL V KPSE TLSLTCTV SGGSINSSS YYWGWLR QSPGKGL EWIGSFFYT GST Y YNPSLR SRLTISVD TSKN QFSLMLSS VTAADT AVYYCA RQS TYYY GSGN YYGWFD RWDQG TLVTVS S,E IVLTQ SPA TLSL SPGE RATLSCR ASQS VSSY LAWY QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPED FAVYYCQ QRSNWPPAFGQGT KVEI K
Oleclumab,Whole mAb,G1,Lambda,Phase-III,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAYSWVRQAPGKGLEWVSAISGSGGRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLGYGRVDEWGRGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSLSNIGRNPVNWYQQLPGTAPKLLIYLDNLRLSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSHPGWTFGGGTKLTVL,na,na,None,None,None,2016,2017,NT5E,MedImmune;AstraZeneca;European Network of Gynaecological Oncological Trial Groups;Jules Bordet Institute,na,Non-small cell lung cancer;Ovarian cancer;Breast cancer;Pancreatic cancer;Bladder cancer;Solid tumours,Prostate cancer,na,,E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAYSWVR QAPGKGL EWVSAIS GSGGR TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAED T AVYYC AR LGYG RV DEWGRG TLVTVS S,QSVLTQPPSASGTPGQ RVTISC SGSLSNIGRNPVN WYQ QLPGTAP KLLIYL DNL RL SGVPDRFSGSKSGTS ASLAIS GLQSEDEAD YYCAT WDDSHPGW TF GGGT KLTV L
Olendalizumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSMDWVRQAPGQGLEWMGAIHLNTGYTNYNQKFKGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGFYDGYSPMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASESVDSYGNSFMHWYQQKPGKAPKLLIYRASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPYTFGGGTKVEIK,na,na,None,None,None,2015,2017,C5,Alexion Pharmaceuticals,na,na,Antiphospholipid syndrome;Graft-versus-host disease;Inflammation,na,Olendalizumab is the new name for Lendalizumab (PL116),Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTD YS MDWVR QAPGQGL EWMGAIHLN TGYTNYNQK FKGRVTMTR DTSTS TVYMELS SLRSEDT AVYYCAR GFYDGYSPMDYWGQG TTVTVS S,DIQ MT QSPSS LSA SVGD RVTITCRA SESVDSYGN SFMHWYQ QKPGKAP KLLIYRA SNLESGVPS R FSGSGSGTD FTLTIS SLQPED F ATYYCQ QSNEDPYTFGGG TKVEI K
Olinvacimab,Whole mAb,G1,Lambda,Phase-II,Active,QMQLVQSGAEVKKPGASVKLSCKASGYTFSSYWMHWVRQAPGQRLEWMGEINPGNGHTNYNEKFKSRVTITVDKSASTAYMELSSLRSEDTAVYYCAKIWGPSLTSPFDYWGQGTLVTVSS,NFMLTQPPSVSVSPGKTARITCRGDNLGDVNVHWYQQRPGQAPVLVMYYDADRPSGIPERFSGSNSGNTATLTISGVEAGDEADYYCQVWDRTSEYVFGTGTKVTVL,na,na,None,None,None,2018,2019,KDR,PharmAbcine;3SBio,na,Glioblastoma;Breast cancer,Cancer;Choroidal neovascularisation;Solid tumours,na,Olinvacimab is the new name for Tanibirumab,QM QLVQ SGA EVK KPGA SVKLSCK ASGY TFSSYWMHWVR QAPGQ RLEWMGEI NPGNGHTNYNEKFKS RVTITV DKSAS TAYMELS SLRSEDT AVYYCAKIW GPSLTSPFDYWGQG TLVTVS S,NFMLTQPPS VSV SPGK TARITCR GDNLGD VNVHWYQ QRPGQAP VLVMYY DADRPSGIPERFSGSNSGN TATLTISGV EAGDE ADYYCQVW DRTSE YVF GTGT KVTV L
Olokizumab,Whole mAb,G4,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFNFNDYFMNWVRQAPGKGLEWVAQMRNKNYQYGTYYAESLEGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARESYYGFTSYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDIGISLSWYQQKPGKAPKLLIYNANNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQHNSAPYTFGQGTKLEIK,na,na,4cni:HL:AB,None,7si0:CD:IJ:EF:KL,2010,2011,IL6,R-Pharm;UCB,Rheumatoid arthritis;SARS-CoV-2 acute respiratory disease,Inflammation,na,na,,E VQLVES GGG LV QPGG SLRLSC AASGFN FNDYFMNWVRQ APGKG L EWVAQM RNKNYQYG TYYAE SLEG RFTISR DDSKNS LYLQMN SLKTEDT AVYYCA RESYYG FTSY WGQG TLVTV SS,DI QMT QSPSS LSA SVGD RVTITCQ ASQD IGISLSWYQ QKPGKAP KLLIYN ANNLADGVPS RF SGSGSGTD FTLTISS LQPEDF ATYYCLQ HNSAPY T FGQGT KLEI K
Omalizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNYNPSVKGRITISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIK,na,na,4x7s:HL/2xa8:HL/4x7t:HL:AB/5hys:HL:AB:EF:CD/6tcm:HL/6tcn:HL/6tco:BA/6tcp:HL/7shy:EF:IJ:KL:CD,5g64:IM:HL/6tcq:HL/6tcr:HL/6tcs:AA/,7shu:CD:EF/7shz:CD:EF:IJ:KL,2000,2001,IGHE,Dana-Farber Cancer Institute;Genentech;John Hopkins University;Novartis,Allergic asthma;Urticaria,Seasonal allergic rhinitis;Nasal polyps;Mastocytosis;Asthma;Nephritis,Hypersensitivity;Peanut hypersensitivity,na,HC IMGT 71 is V not L as in Jain paper,E VQLVES GGG LV QPGG SLRLSCAV SGY SIT SGY SWNWIR QAPGKGL EWVASITY DGSTNYNPS VKGRITISR DDSKN TFYLQMN SLRAED TAVYYC ARGSHYFG HWHFAVW GQG TLVTVS S,DI QLT QSPSS LSA SVGD RVTITCR ASQS V DYDGD SYMNWYQ QKPGKAP KLLIYAASY LESGVPS RF SGSGSGTD FTLTIS SLQPED F ATYYCQ QSHEDPYTFGQGT KVEI K
Omburtamab,Whole mAb Radiolabelled,G1,Kappa,Preregistration,Active,QVQLQQSGAELVKPGASVKLSCKASGYTFTNYDINWVRQRPEQGLEWIGWIFPGDGSTQYNEKFKGKATLTTDTSSSTAYMQLSRLTSEDSAVYFCARQTTATWFAYWGQGTLVTVSA,DIVMTQSPATLSVTPGDRVSLSCRASQSISDYLHWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGSDFTLSINSVEPEDVGVYYCQNGHSFPLTFGAGTKLELK,na,na,5cma:BA,None,None,2018,2019,CD276,Memorial Sloan-Kettering Cancer Center;Y-mAbs Therapeutics,na,Neuroblastoma;Meningeal carcinomatosis;Soft tissue sarcoma;Peritoneal cancer,Solid tumours,na,,Q VQLQQ SGA ELV KPGA SVKLSCK ASGY TFTNYDINWVR QRPEQGL EWIGWIF PGDGSTQ Y NEKFKG KATLTT DTSSST AYMQLS RLTSEDS AVYFCA RQTT ATWFAYW GQG TLVTVS A,D IVMT QSPA TLSV TPGD RVSLSCR ASQS ISDYLHWYQQ KSHESP RLLIKYA SQSISGIPSRFSGSGSGSD FTLSIN SVEPED VGVYYC QNGH SFPLTF GAGT KLEL K
Omodenbamab,Whole mAb,G3,Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYGMSWVRQAPGKGLEWVSSITGSGRSTFYADSVKGRFTISRDNSTNTLSLQMNSLRAEDTAVYYCARSPADIVTGYYPWWFDLWGQGTLVTVSS,DIQMTQSPSSLSASIGDRVTITCRASQSINTYLNWYQQKPGKAPRLLIAGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPLTFGQGTRLEIK,na,na,None,None,None,2020,2021,SpA,XBiotech Inc.,na,Staphylococcal infections,na,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFST YG MSWVRQ APGKG LEWVSSI TGSGR STFYA DSVKG RFTISR DNSTN TLSLQMN SLRAEDT AVYYCA RSPAD IVT GYYPW WFD LWGQG TLVTVS S,DIQ M TQSPSS LSA SIGD RVTITCR ASQS INTYLNWYQ QKPGKAP RLLIA GASSLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYC QQANSFP LTF GQGT RLEI K
Onartuzumab,Fab + di-Fc,G1,Kappa,Phase-III,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTRFNPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIK,na,na,4k3j:HL,None,None,2010,2011,MET,Chugai Pharmaceutical;Genentech,na,na,Breast cancer;Colorectal cancer;Gastric cancer;Glioblastoma;Liver cancer;Non-small cell lung cancer;Solid tumours,na,,E VQLVES GGG LV QPGG SLRLSC AASGY TFTSYWLHWVR QAPGKGL EWVGMI DPSNSDTRFNPNFKD RFTISA DTSKN TAYLQMN SLRAEDT AVYYCATY RS Y VTPLDYWGQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITC KSSQ SLLYT SSQKN YLAWYQ QKPGKAP KLLIYWAS TRESGVPS RF SGSGSGTD FTLTISS LQP EDFA TYYCQQYY AYPW T FGQGT KVEI K
Onfekafusp,Whole mAb Fusion,na,Kappa,Phase-III,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK,na,na,None,None,None,2010,2011,FN extra domain B,Philogen,na,Malignant melanoma;Basal cell cancer;Squamous cell cancer;Solid tumours,na,na,Radretumab+Bifikafusp+Onfekafusp have identical V domains,E VQLLES GGG LV QPGG SLRLSC AASGF TFSSFSMSWVR QAPGKG LEWVSSIS GSSGT TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA KPFPYFDYWGQG TLVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQSVS SSFLAWY Q QKPGQAP RLLIYYA SSRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYCQ QTGRIPPTFGQGT KVEI K
Ongericimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLQESGPGLVKPSQTLSLTCTVSGFSISSYGIHWIRQSPGKGLEWIGVIWRGGITDYNAPFMSRVTISKDNSKNQVSFKLSSVTAADTAVYYCANHRDWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDINKYIDWYQHKPGKAPKLLIHYASTLQPGVPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDDLWTFGQGTKVEIK,na,na,None,None,None,2019,2020,PCSK9,Shanghai Junshi Biosciences,na,Hypercholesterolemia,na,na,,Q VQLQE SGPGLVKPSQ TLSLTCTV SG FSISSYGIHWIRQ SPGKGL EWIGVIWR GGITDYNAPF MSRVTIS KDNSKN QVSFKLSS VTAADT AVYYCA NHRDWGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCQ ASQD INKYIDWY QHKPGKAP KLLIHYA STLQPGVPS R FSGSGSGRD YTFTIS SLQPED I ATYYCLQ YDD LWTF GQGT KVEI K
Ontamalimab,Whole mAb,G2,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGINWVRQAPGQGLEWMGWISVYSGNTNYAQKVQGRVTMTADTSTSTAYMDLRSLRSDDTAVYYCAREGSSSSGDYYYGMDVWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCKSSQSLLHTDGTTYLYWYLQKPGQPPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGIYYCMQNIQLPWTFGQGTKVEIK,na,na,4hcr:MN:HL,None,None,2018,2019,MADCAM1,Pfizer;Takeda,na,na,Crohn's disease;Ulcerative colitis,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYGINWVRQ APGQGL EWMGWISVY SGNTNY AQKVQGRVTMTA DTSTS TAYMDLRS LRSDDT AVYYCA REGSSSSGD YYYGMDV WGQG TTVTVS S,DI VMT QTP LSLSV TPGQP ASISC KSSQ SLLH TDGT TYLYWYLQ KPGQPP QLLIYEVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GIYYCMQ NI Q LPW T FGQGT KVEI K
Ontuxizumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLQESGPGLVRPSQTLSLTCTASGYTFTDYVIHWVKQPPGRGLEWIGYINPYDDDTTYNQKFKGRVTMLVDTSSNTAYLRLSSVTAEDTAVYYCARRGNSYDGYFDYSMDYWGSGTPVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQNVGTAVAWLQQTPGKAPKLLIYSASNRYTGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQYTNYPMYTFGQGTKVQIK,na,na,None,None,None,2013,2014,CD248,Ludwig Institute for Cancer Research;Morphotek;National Cancer Institute (USA),na,Colorectal cancer;Malignant melanoma;Soft tissue sarcoma,Lymphoma;Solid tumours,na,,QV QLQE SGPGL V RPSQ TLSLTCT ASGY TFTDYVIHWVK QPPGRG LEWIGYI NPYDDDTTYNQK F KG RVTMLVD TSSN TAYLRLSS VTAEDT AVYYCAR RGNSYDG YFDYSM DYWGSGTP VTV SS,DIQ MT QSPSS LSA SVGD RVTITCR ASQN VGTAVAWLQ QTPGKAP KLLIYS ASNRYTGVPSRFSGSGSGTD YTFTIS SLQ PEDIATYYCQQ YTNYPM YTF GQGT KVQI K
Onvatilimab,Whole mAb,G1,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSSYGWSYEFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSIDTRLNWYQQKPGKAPKLLIYSASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSAYNPITFGQGTKVEIK,na,na,None,None,None,2017,2018,VSIR,Janssen Research & Development,na,Solid tumours,na,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSSYAISWVR QAPGQGL EWMGGIIPIF GTANYAQKFQG RVTITA DESTS TAYMELS SLRSEDT AVYYCAR SSYG WSYEFDY WGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQSIDTR LNWYQ QKPGKAP KLLIYS ASSLQSGVPS R FSGSGSGTD FTLTIS SLQPE DFA TYYCQ QSAYNPI T FGQGT KVEI K
Opicinumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSAYEMKWVRQAPGKGLEWVSVIGPSGGFTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATEGDNDAFDIWGQGTTVTVSS,DIQMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPMYTFGQGTKLEIK,na,na,4oqt:HL,None,None,2015,2016,LINGO1,Biogen Idec;Dyax;Biogen,na,na,Multiple sclerosis;Optic neuritis,Dyax Human Phage Display,,E VQLLES GGG LV QPGG SLRLSC AASGF TFSAYEMKWVRQ APGKG LEWVSVI GPSGG FTFYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA TEGDNDA FDIW GQG TTVTVS S,DIQ MT QSPA TLSL SPGE RATLSCR ASQS VSSY LAWY QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPED FAVYYCQ QRSNWP MYTF GQGT KLEI K
Oportuzumab,scFv,na,Kappa,Preregistration,Discontinued,EVQLVQSGPGLVQPGGSVRISCAASGYTFTNYGMNWVKQAPGKGLEWMGWINTYTGESTYADSFKGRFTFSLDTSASAAYLQINSLRAEDTAVYYCARFAIKGDYWGQGTLLTVSS,DIQMTQSPSSLSASVGDRVTITCRSTKSLLHSNGITYLYWYQQKPGKAPKLLIYQMSNLASGVPSRFSSSGSGTDFTLTISSLQPEDFATYYCAQNLEIPRTFGQGTKVELK,na,na,None,None,None,2008,2009,EPCAM,University of Zurich;National Cancer Institute (USA);Sesen Bio;Viventia Biotechnologies,na,na,Bladder cancer;Head and neck cancer;Liver cancer;Ovarian cancer,na,,E VQLVQ SGPG LV QPGG SVRISC AASGY TFTN YGM NWVK QAPGKGL EWMGWIN TYTGES TY ADSFKG RFTFSL DTSAS AAYLQINSL RAEDT AVYYCARFAIK GDYWGQ GTLLTVS S,DI QMT QSPSS LSA SVGD RVTITCR STK SLLH SNG ITYLYWYQ QKPGKAP KLLIYQM SNLASGVPS RF SSSGSGT DFTLTISS LQPE DF ATYYCA QNLEIPRTFGQGT KVEL K
Opucolimab,Whole mAb,G1,Lambda,Phase-I,Discontinued,EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYTMNWVRQAPGKGLEWVSSISSGSDYLYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARNELRWYPQAGAFDRWGQGTMVTVSS,QSVVTQPPSMSAAPGQRVTISCSGSSSYIESSYVGWYQQLPGTAPRLLIYDDDMRPSGIPDRFSGSKSGTSATLAITGLQTGDEADYYCEIWRSGLGGVFGGGTKLTVL,na,na,None,None,None,2019,2020,PDL1,Shanghai Henlius Biotech,na,na,Solid tumours,na,,E VQLVQS GGG LV KPGG SLRLSC AASGF TFSSYTMNWVR QAPGKG LEWVSS ISSGSD YLYYA DSVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCA RNE LRWY PQAGAFDRWGQG TMVTVS S,QSV V TQPPSMSAAPGQ RVTISC SGSSSY IE S SYV GWYQ QLPGTAP RLLIY DDDMRPSGIPDRFSGSKSGT SATLAITG LQTGDEA DYYCEIWR SGLGG V FGGGT KLTV L
Ordesekimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGESLKISCKVSGYFFTTYWIGWVRQMPGKGLEYMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGGNWNCFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASRRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQRYGSSHTFGQGTKLEIS,na,na,None,None,None,2020,2021,IL15,Genmab;Immunex Corporation;Amgen;Cellimmune,na,Psoriasis;Inflammatory arthritis diseases;Celiac disease,na,na,,E VQLVQ SGA EVK KPGE SLKISCKV SG YFFTTYWIGWVRQ MPGKGL EYMGII YPGDSDTRYSPSFQG QVTIS ADKS ISTAYLQWS SLKASDT AMYYCA RGGNW NCFD YWGQG TLVTV SS,E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSS S YLAWYQ QKPGQAP RLLIYG ASRRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYCQ RYGSSH T FGQGT KLEI S
Orilanolimab,Whole mAb,G4,Kappa,Phase-II,Discontinued,QVQLVQSGAELKKPGASVKLSCKASGYTFTSYGISWVKQATGQGLEWIGEIYPRSGNTYYNEKFKGRATLTADKSTSTAYMELRSLRSEDSAVYFCARSTTVRPPGIWGTGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASDHINNWLAWYQQKPGQAPRLLISGATSLETGVPSRFSGSGTGKDYTLTISSLQPEDFATYYCQQYWSTPYTFGGGTKVEIK,na,na,6nha:HL,None,None,2018,2019,FCGRT,Syntimmune,na,na,Autoimmune haemolytic anaemia;Autoimmune disorders;Pemphigus,na,,Q VQLVQ SGA EL KKPGA SVKLSCK ASGY TFTSYGISWVK QATGQG LEWIGEIY PRSGN TYY NEKFKG RATLTA DKSTS TAYMELRSL RSEDS AVYFCAR S TTV RPPGI W GTG TTVTVS S,DIQ MT QSPSS LSA SVGD RVTITCK ASD HINNWLAWYQ QKPGQAP RLLIS GATSLETGVPSRFSGSGTGKD YTLTIS SLQ PEDFATYYCQQ YWSTPY T FGGGT KVEI K
Ormutivimab,Whole mAb,G1,Lambda,Approved,NFD,QVQLVQSGAEVKKPGSSVKVSCKASGGTFNRYTVNWVRQAPGQGLEWMGGIIPIFGTANYAQRFQGRLTITADESTSTAYMELSSLRSDDTAVYFCARENLDNSGTYYYFSGWFDPWGQGTLVTVSS,QSALTQPRSVSGSPGQSVTISCTGTSSDIGGYNFVSWYQQHPGKAPKLMIYDATKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGDYTPGVVFGGGTKLTVL,na,na,None,None,None,2021,2022,Rabies Virus Surface Glycoprotein 4 (gp4) Epitope 1,North China Pharmaceutical Company,Rabies,na,na,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT F N RYTVNWVRQ APGQGL EWMGGIIPIF GTANYAQ R FQG RLTITA DESTS TAYMELSS LRSDDT AVYFCAR ENLDNSGT YYYFSGWF DPWGQ GTLVTVS S,QSALTQPR S VSGSPGQ SVTISCT GTSSDIGG YNFVSWYQ QHPGKAP KLMIYD ATKRPSGVPDRFSGSKSGN TASLTIS GLQAEDEAD YYCCS YAGDYTPG VVF GGGT KLTV L
Orticumab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVSSISVGGHRTYYADSVKGRSTISRDNSKNTLYLQMNSLRAEDTAVYYCARIRVGPSGGAFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSNTNIGKNYVSWYQQLPGTAPKLLIYANSNRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCASWDASLNGWVFGGGTKLTVL,na,na,None,None,None,2012,2013,OxLDL,Abcentra;BioInvent International;Genentech,na,Atherosclerosis;Psoriasis,na,Human Phage Display,,E VQLLES GGG LV QPGG SLRLSC AASGF TF SNA WMSWVR QAPGKGL EWVSSISV GGH RTYYA DSVKG RSTISR DNSKN TLYLQMNS LRAEDT AVYYCARIRV GPSGGA FDYW GQG TLVTVS S,QSVLTQPPSASGTPGQ RVTISC SGSNTN I G KNYVSWYQQ LPGTAP KLLIYA NSNRPSGVPDRFSGSKSGT SASLAIS GLRSEDEAD YYCASW DASLNG WVF GGGT KLTV L
Osemitamab,Whole mAb,G1,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYNMNWVRQAPGQGLEWMGNIDPYYGGTSYNQKFKGRVTMTIDKSTSTVYMELSSLRSEDTAVYYCARMYHGNAFDYWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNLKNYLTWYQQKPGQPPKLLIYWASTRKSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPLTFGGGTKVEIK,na,na,None,None,None,2022,na,CLDN18,TBC,TBC,TBC,TBC,TBC,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTGYNMNWVR QAPGQGL EWMG NIDPYYGGTSYNQKFKG RVTMTID KSTS TVYMELS SLRSEDT AVYYCARMY HGNAFDYWGQG TTVTVS S,D IVMT QSPDS LAVS LGER ATINC KSS QSLL NSGN LKNYLTWYQ QKPGQPP KLLIYWAS TRKSGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC QNDYSYP LTF GGG TKVEI K
Osocimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSQYGMDWVRQAPGKGLEWVSGIGPSGGSTVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGGPYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQADSFPVTFGGGTKVEIK,na,na,None,6hhc:HL,None,2018,2019,F11,Bayer HealthCare,na,Venous thromboembolism,Arterial thrombosis;Venous thrombosis,na,,E VQLLES GGG LV QPGG SLRLSC AASGF TFSQ YGM DWVR QAPGKG LEWVS GIGPSGGS TVYAD SVKG RFTISR DNSKN TLYLQMN SLRAED TAVYYC TRGGP YYYYGMDV WGQG TTVTVS S,DIQMTQSPSS LSA SVGD RVTITCQ ASQD ISNYLNWYQ QKPGKAP KLLIYD ASNLETGVPSRFSGSGSGTD FTFTIS SLQ PEDIATYYC QQADSFP VTF GGG TKVEI K
Otelixizumab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFPMAWVRQAPGKGLEWVSTISTSGGRTYYRDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKFRQYSGGFDYWGQGTLVTVSS,DIQLTQPNSVSTSLGSTVKLSCTLSSGNIENNYVHWYQLYEGRSPTTMIYDDDKRPDGVPDRFSGSIDRSSNSAFLTIHNVAIEDEAIYFCHSYVSSFNVFGGGTKLTVL,na,na,None,None,None,2007,2008,CD3E,BTG;GlaxoSmithKline;Tolerx,na,Type 1 diabetes mellitus,Graves ophthalmopathy;Multiple sclerosis;Myasthenia gravis;Psoriasis;Psoriatic arthritis;Rheumatoid arthritis,na,,E VQLLES GGG LV QPGG SLRLSC AASGF TF SSFP MAWVRQ APGKG LEWVSTIS TSGGR TYYRD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAKFR QYSGGFDYWGQG TLVTVS S,DI QLT QPN SVST SLGS TVKLSCTL SSGNIENN YVHWYQLY EGRSPT TMIY DDDKRPDGVPDR FSGSID RSSNS AFLTIHNVAI EDE AIYFCHSYVSSFNVF GGGT KLTV L
Otilimab,Whole mAb,G1,Lambda,Phase-III,Active,QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVSGIENKYAGGATYYAASVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGFGTDFWGQGTLVTVSS,DIELTQPPSVSVAPGQTARISCSGDSIGKKYAYWYQQKPGQAPVLVIYKKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSAWGDKGMVFGGGTKLTVL,na,na,None,5c7x:MN:HL/5d7s:HL,5d72:MN:HL/5d71:HL,2018,2019,CSF2,GlaxoSmithKline;MorphoSys,na,Rheumatoid arthritis,Inflammation;Multiple sclerosis;Osteoarthritis,MorphoSys HuCAL Phage Display,,Q VQLVES GGG LV QPGG SLRLSC AASGF TFSSYWMNWVR QAPGKGL EWVS GIENKYAGGA TYYAASV KG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RGFGTDFWGQG TLVTVS S,DIELTQPPS VSV APGQ TARISC SGDSIGK KYAYWYQ QKPGQAP VLVIYKK RPSGIPERFSGSNSGN TATLTIS GTQAEDEA DYYCSA WGDKG MVF GGGT KLTV L
Otlertuzumab,di-scFv+Fc,G1,Kappa,Phase-II,Discontinued,EVQLVQSGAEVKKPGESLKISCKGSGYSFTGYNMNWVRQMPGKGLEWMGNIDPYYGGTTYNRKFKGQVTISADKSISTAYLQWSSLKASDTAMYYCARSVGPFDSWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASENVYSYLAWYQQKPGQAPRLLIYFAKTLAEGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHHSDNPWTFGQGTKVEIK,na,na,None,None,None,2013,2014,CD37,Trubion Pharmaceuticals;Aptevo Therapeutics,na,na,Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Peripheral T-cell lymphoma,ADAPTIR Monospecific Platform,,E VQLVQ SGA EVK KPGE SLKISC KGSGY SFT G Y NMN WVR QMPGKGL EWM GNIDPYYGGTT Y NRK F KG QVTIS ADKS ISTAYLQWSS LKASDT AMYYCARS VGPFDSWGQ GTLVTVS S,E IVLT QSPA TLSL SPGE RATLSCR ASEN VY SYLA WY QQKPGQAP RLLIYFA KTLA EGIPA RFS GSGSGTD FTLTIS SLEPED FAVYYCQ HHSDNPWTFGQGT KVEI K
Oxelumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFNSYAMSWVRQAPGKGLEWVSIISGSGGFTYYADSVKGRFTISRDNSRTTLYLQMNSLRAEDTAVYYCAKDRLVAPGTFDYWGQGALVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPYTFGQGTKLEIK,na,na,None,None,None,2010,2011,TNFSF4,Genentech;Genmab;Roche,na,na,Allergic asthma;Allergic rhinitis,na,,E VQLLES GGG LV QPGG SLRLSC AASGF TFNSYAMSWVR QAPGKGL EWVSIIS GSGG FTYYA DSVKG RFTISR DNSR TTLYLQMN SLRAEDT AVYYC AKDR LV APGT FDY WGQG ALVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQG ISSWLAWYQ QKPEKAPK SLIYAA SSLQSGVPS RF SGSGSGTD FTLTIS SLQ PEDFATYYCQ QYNSYPY T FGQGT KLEI K
Ozanezumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWIGNINPSNGGTNYNEKFKSKATMTRDTSTSTAYMELSSLRSEDTAVYYCELMQGYWGQGTLVTVSS,DIVMTQSPLSNPVTLGQPVSISCRSSKSLLYKDGKTYLNWFLQRPGQSPQLLIYLMSTRASGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCQQLVEYPLTFGQGTKLEIK,na,na,None,None,None,2012,2013,RTN4,GlaxoSmithKline,na,na,Amyotrophic lateral sclerosis;Multiple sclerosis,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYWMHWVR QAPGQG LEWIGNI NPSNGGTNYNEKFKS KATMTR DTSTS TAYMELS SLRSEDT AVYYCELM QGYWGQG TLVTVS S,D IVMT QSPLSNPVTLGQP VSISC RSSK SLLYK DGK TYLNWFL QRPGQSPQ LLIYLMS TRASGVPDRFSGGGSGT DFTLKISRVE AEDV GVYYCQQLVE YPL T FGQGT KLEI K
Ozoralizumab,Bispecific Single Domains (VH-VH'-VH),na;na,na;na,Preregistration,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYWMYWVRQAPGKGLEWVSEINTNGLITKYPDSVKGRFTISRDNAKNTLYLQMNSLRPEDTAVYYCARSPSGFNRGQGTLVTVSS,na,EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS,na,None;None,None;None,5m2j:D;None,2011,2012,TNFA;ALB,Ablynx;Eddingpharm;Pfizer;Taisho Pharmaceutical,na,Rheumatoid arthritis,Ankylosing spondylitis;Crohn's disease;Psoriatic arthritis,Nanobody Technology,,E VQLVES GGG LV QPGG SLRLSCA ASGF TF SD YWMYWVRQ APGKGL EWVSEI NTNGL ITK YPDSVK GRFTISR DNAKN TLYLQMN SLRPEDT AVYYCAR SPSGFNRGQ GTLVTVS S,NA
Ozuriftamab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGESLRISCKGSGYTFTEYTMHWVRQAPGQGLEWMGGINTNNGGTGYNQKFKGRVTISADKSISTAYLQWSSLKASDTAMYYCAHGSLYSYGNSYFDYWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCSATSSVSYMHWYLQKPGQSPQLLIYGTSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQRSSYPFTFGQGTKVEIK,na,na,None,None,None,2022,na,ROR2,BioAtla,na,Malignant Melanoma;Non-small cell lung cancer;Ovarian cancer;Solid tumours,na,TBC,,E VQLVQ SGA EVK KPGE SLRISC KGSGY TFTEYTMHWVRQ APGQG LEWMGGIN TNNGGTGYNQK F K GRVTIS ADKS ISTAYLQWS SLKASDT AMYYC AHGS LYSY GNS YF DYWGQG TLVTV SS,AI QLT QSPSS LSAS VGD RVTITCS ATSS VSYMHWYL QKPGQSP QLLIYG TSNLASGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCQ QRSSYPF TF GQGT KVEI K
Pabinafusp,Whole mAb Fusion,G1,Kappa,Approved,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWLGWVRQMPGKGLEWMGDIYPGGDYPTYSEKFKVQVTISADKSISTAYLQWSSLKASDTAMYYCARSGNYDEVAYWGQGTLVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK,na,na,None,None,None,2018,2019,TFRC,JCR Pharmaceuticals,Mucopolysaccharidosis II,na,na,na,,E VQLVQ SGA EVK KPGE SLKISC KGSGYS F T NYWLGWVR QMPGKGL EWMGDI YPGGDYPTYSEK FKVQVTIS ADKS ISTAYLQWS SLKASDT AMYYCA RSGNYD EVAYW GQG TLVTVS S,DI VMT QTP LSLSV TPGQP ASISCR SSQ SLVH SNGN TYLHWYLQ KPGQSP QLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCS QSTHVPW T FGQGT KVEI K
Pacanalotamab,Bispecific scFv,na;na,Kappa;Lambda,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYPGYHAYNEKFQGRATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGSGSGTDFTFTISSLEPEDIATYYCQQGNTLPWTFGQGTKVEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2020,2021,TNFRSF17;CD3E,Amgen,na,Multiple myeloma,na,BiTE Technology,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFT N HIIHWVR QAPGQGL EWMGYI NPYPGYHAYNEKFQG RATMT SDTSTS TVYMELS SLRSEDT AVYYCA RDGY Y RDTD VLDY WGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCQ ASQD ISNYLNWYQ QKPGKAP KLLIYYT SRLHTGVPSRFSGSGSGTD FTFTIS SLE PEDIATY YC QQGNTLPW TF GQGT KVEI K
Pacmilimab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSSIWRNGIVTVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKWSAAFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQDNGYPSTFGGGTKVEIK,na,na,None,None,None,2019,2020,PDL1,CytomX Therapeutics,na,Solid tumours;Lymphoma,na,na,,E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKG LEWVSSIWR NG IVTVYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAK WSAA F DYWGQG TLVTV SS,DIQ MT QSPSS LSA SVGD RVTITCR ASQS ISSYLNWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQPE DF ATYYCQ QDNGYPSTFGGG TKVEI K
Palivizumab,Whole mAb,G1,Kappa,Approved,NFD,QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVGWIRQPPGKALEWLADIWWDDKKDYNPSLKSRLTISKDTSKNQVVLKVTNMDPADTATYYCARSMITNWYFDVWGAGTTVTVSS,DIQMTQSPSTLSASVGDRVTITCKCQLSVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTKLEIK,na,na,None,2hwz:HL,None,1998,1999,RSV gpF,MedImmune,Respiratory syncytial virus infections,na,na,GS Gene Expression System,,Q VTLRE SGPA LV KPTQ TLTLTCTF SG FSL STSG MSVGWIR QPPGKA LEWLADIWW DDKKDYNPSLK SRLTIS KDTSKN QVVLKVTN MDPADTA TYYCA RSMITN WYFDVW GAGT TVTVS S,DI QMT QSPS TLSAS VGD RVTITCKCQLSV G YMHWYQ QKPGKAP KLLIYD TSKLASGVPS RF SGSGSGT EFTLTISS LQPDDF ATYYCF QGSGYP FTF GGGT KLEI K
Pamrevlumab,Whole mAb,G1,Kappa,Phase-III,Active,EGQLVQSGGGLVHPGGSLRLSCAGSGFTFSSYGMHWVRQAPGKGLEWVSGIGTGGGTYSTDSVKGRFTISRDNAKNSLYLQMNSLRAEDMAVYYCARGDYYGSGSFFDCWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPPTFGQGTKLEIK,na,na,None,None,None,2015,2016,CTGF,FibroGen,na,Duchenne muscular dystrophy;Idiopathic pulmonary fibrosis;Pancreatic cancer,Diabetic cardiomyopathy;Diabetic nephropathies;Diabetic neuropathies;Glioblastoma;Glomerulonephritis;Hepatic fibrosis,na,,EG QLVQS GGG LV HPGG SLRLSC AGSG FTFS SYG MHWVRQ APGKG LEWVSGI GTGGG TYS TDSVK GRFTIS RDNAKN SLYLQMNS LRAEDM AVYYCA RGDYYGSGS FFD CWGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQG ISSWLAWYQ QKPEKAPK SLIYAA SSLQSGVPS RF SGSGSGTD FTLTIS SLQ PEDFATY Y CQQ YNSYPPTFGQGT KLEI K
Panitumumab,Whole mAb,G2,Kappa,Approved,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIK,na,na,5sx5:HL:JK/5sx4:HL:JI,None,None,2004,2005,EGFR,Amgen;Grupo Espanol Multidisciplinario del Cancer Digestivo;Netherlands Cancer Institute;Novartis;Takeda;University of Texas M. D. Anderson Cancer Center;Wissenschaftlicher Service Pharma,Colorectal cancer,Anal cancer;Bladder cancer;Breast cancer;Gastric cancer;Neuroendocrine tumours;Oesophageal cancer;Rectal cancer,Head and neck cancer;Malignant melanoma;Prostate cancer;Renal cell carcinoma;Solid tumours,Abgenix XenoMouse,,Q VQLQE SGPGL V KPSE TLSLTCTVS GGSVSSGD YYWTWIRQ SPGKGL EWIGHIYYS GNTNYNPSLK SRLTISID TSKT QFSLKLSS VTAADT AIYYCVR DRVTG AFDIW GQG TMVTVS S,DIQMTQSPSS LSA SVGD RVTITCQ AS QDISNYLNWYQ QKPGKAP KLLIYD ASNLETGVPSRFSGSGSGTD FTFTIS SLQ PEDIATYFCQH FDHLP LAF GGGT KVEI K
Panobacumab,Whole mAb,M,Kappa,Phase-II,Active,EEQVVESGGGFVQPGGSLRLSCAASGFTFSPYWMHWVRQAPGKGLVWVSRINSDGSTYYADSVKGRFTISRDNARNTLYLQMNSLRAEDTAVYYCARDRYYGPEMWGQGTMVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGGGTKVEIK,na,na,None,None,None,2008,2009,Serotype IATS O11,Berna Biotech;Aridis Pharmaceuticals,na,Nosocomial pneumonia,na,na,,EE QVVES GG GFV QPGG SLRLSCA ASGF TF SPY WMHWVR QAPGKG LVWVSRI NSDGS TYYAD SVKG RFTISR DNARN TLYLQMNS LRAEDT AVYYCA RDRYYGPEMWGQG TMVTVS S,DV VMT QSPLSLP VT LGQP ASISC RSSQ SLVY SDGN TYLNWFQ QRPGQSPR RLIYKVS NRDSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCM QGTHWP LTF GGG TKVEI K
Paridiprubart,Whole mAb,G1,Kappa,TBC,Active,QVQLQESGPGLVKPSDTLSLTCAVSGYSITGGYSWHWIRQPPGKGLEWMGYIHYSGYTDFNPSLKTRITISRDTSKNQFSLKLSSVTAVDTAVYYCARKDPSDAFPYWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCRASQSISDHLHWYQQKPDQSPKLLIKYASHAISGVPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQGHSFPLTFGGGTKVEIK,na,na,4r7d:AB:CD:EF:GH:IJ:MN:OP,None,4r7n:AB:CD:EF:GH:IJ:MN:OP:QR:ST,2022,na,TLR4,TBC,TBC,COVID-19,TBC,TBC,,QV QLQ ESGPGL V KPSD TLSLTCAV SGY SIT GG YSWHWIR QPPGKGL EWMGYIHY SGYTDFNPSL KTRITISR DTSKN QFSLKLSSVTA VD TAVYYCAR KDPSDAFPYWGQG TLVTV SS,E IVLTQ SPDFQSVTPKE KVTITCR ASQS ISDHLHWY QQKPDQSPK LLIKYA SH AI SGVPSRFSGSGSGTD FTLTIN SLE AEDAATY YC QQGHSFP LTF GGGT KVEI K
Parsatuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGYTFIDYYMNWVRQAPGKGLEWVGDINLDNSGTHYNQKFKGRFTISRDKSKNTAYLQMNSLRAEDTAVYYCAREGVYHDYDDYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSQSLVHINAITYLHWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCGQSTHVPLTFGQGTKVEIK,na,na,None,None,None,2012,2013,EGFL7,Chugai Pharmaceutical;Genentech,na,na,Colorectal cancer;Non-small cell lung cancer;Solid tumours,na,,E VQLVES GGG LV QPGG SLRLSC AASGY TFID YYMNW VR QAPGKGL EWVGDINL DNSGTHYNQK FKGRFTISR DKSKN TAYLQMN SLRAEDT AVYYCA REGV Y HDYDDYA M DYWGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR TSQS LVHINAITYLHWY QQKPGKAP KLLIYRVS NRFSGVPSRFSGSGSGT DFTLTISS LQPE D F ATYY CGQST HVPLT FGQGT KVEI K
Pasotuxizumab,Bispecific scFv,na;na,Kappa;Lambda,Phase-I,Discontinued,QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKGLEWVAIISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSASYRYSDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQYDSYPYTFGGGTKLEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2014,2015,FOLH1;CD3E,Amgen;Bayer HealthCare Pharmaceuticals;Micromet Inc,na,na,Prostate cancer,na,,Q VQLVES GGG LV KPGE SLRLSCA ASGF TF SD YYMYWVRQ APGKG LEWVAIIS DGG YYTYYS DI I KG RFTISR DNAKNS LYLQMN SLKAEDT AVYYC ARGFP LLR HGAMDYWGQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITCK ASQNVDTN VAWYQ QKPGQAPK SLIYSASYR YSDVPSRFSGSASGTD FTLTISS VQSEDF ATYYCQ QYDSYPY T FGGGT KLEI K
Pateclizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYVIHWVRQAPGKGLEWVGYNNPYNAGTNYNEKFKGRFTISSDKSKNTAYLQMNSLRAEDTAVYYCSRPTMLPWFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQAVSSAVAWYQQKPGKAPKLLIYSASHRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQESYSTPWTFGQGTKVEIK,na,na,4mxv:HL:YX:FE/4mxw:HL:WV,None,None,2011,2012,LTA,Genentech,na,na,Rheumatoid arthritis,na,,E VQLVES GGG LV QPGG SLRLSC AASGY TFTSYVIHWVR QAPGKG LEWVGY NNPYNAGTNYNEKFK GRFTISS DKSKN TAYLQMN SLRAEDT AVYYC SRPTMLP WFAYW GQG TLVTV SS,DIQ MT QSPSS LSA SVGD RVTITCR ASQA VSSA VAWYQ QKPGKAP KLLIYS ASHR Y TGVPSRFSGSGSGTD FTLTIS SLQPE DFA TYYC QESYSTPW T FGQGT KVEI K
Patritumab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVETSKNQFSLKLSSVTAADTAVYYCARDKWTWYFDLWGRGTLVTVSS,DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSNRNYLAWYQQNPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPRTFGQGTKVEIK,na,na,None,None,None,2011,2012,ERBB3,Amgen;U3 Pharma;Daiichi Sankyo Company,na,Non-small cell lung cancer;Head and neck cancer;Breast cancer,Solid tumours,na,,QV QLQQW GAGLLKPSE TLSLTCAVY GGSFS GYYWSWIR QPPGKGL EWIGEIN HSGSTNYNPSLKS RVTISVE TSKN QFSLKLSS VTAADT AVYYCA RDKW TWYFDL WGRG TLVTVS S,DIE M TQSPDS LAVS LGE RATINC RSSQ SVLYS SSNRN YLAWYQ QNPGQPP KLLIYWAS TRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQQ YYSTPRTFGQGT KVEI K
Pavurutamab,Bispecific scFv,na;na,Kappa;Lambda,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQCLEWMGYINPYPGYHAYNEKFQGRATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGSGSGTDFTFTISSLEPEDIATYYCQQGNTLPWTFGCGTKVEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2020,2021,TNFRSF17;CD3E,Amgen,na,Multiple myeloma,na,BiTE Technology,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFT N HIIHWVR QAPGQ CLEWMGYI NPYPGYHAYNEKFQG RATMT SDTSTS TVYMELS SLRSEDT AVYYCA RDGY Y RDTD VLDY WGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCQ ASQD ISNYLNWYQ QKPGKAP KLLIYYT SRLHTGVPSRFSGSGSGTD FTFTIS SLE PEDIATY YC QQGNTLP WTF GCGT KVEI K
Pelgifatamab,Whole mAb ADC,G1,Kappa,Phase-I,Active,QVQLVESGGGVVQPGRSLRLSCAASGFAFSRYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTQYLQMNSLRAEDTAVYYCARGGDFLYYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQKTGKVPKFLIYEASTLQSGVPSRFSGGGSGTDFTLTISSLQPEDVATYYCQNYNSAPFTFGPGTKVDIK,na,na,None,None,None,2020,2021,FOLH1,Bayer,na,Prostate cancer;Metastatic cancers,na,na,,Q VQLVES GGG VV QPGR SLRLSC AASGF AF SRY GMHWVRQ APGKGL EWVAVIWY DGSNK YYAD SVKG RFTISR DNSKNT QYLQMNSL RAEDT AVYYCA RGGD FLYYYYY G M DVWGQG TTVTVS S,DIQMTQSPSS LSA SVGD RVTITCR ASQG ISNYLAWYQQK TGKVP KFLIYE ASTLQSGVPSRFSGGGSGTD FTLTIS SLQ PEDVATYYCQ NYNSAPF T FGPGT KVDI K
Pembrolizumab,Whole mAb,G4,Kappa,Approved,Active,QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIK,na,na,5dk3:GF:BA/5ggs:CD:AB/5b8c:BA:HG:KJ:ED/5jxe:GF:DC,None,None,2013,2014,PDCD1,Aduro BioTech;AIO Studien gGmbH;Amgen;Augusta University;Bayer;BerGenBio;Big Ten Cancer Research Consortium;BioLineRx;Canadian Cancer Trials Group;Celgene Corporation;Columbia University;Dana-Farber Cancer Institute;DNAtrix;Duke University;Eisai Co Ltd;Eli Lilly;Emory University;Fox Chase Cancer Center;Genexine;Gilead Sciences;H. Lee Moffitt Cancer Center and Research Institute;Hoosier Cancer Research Network;Icahn School of Medicine at Mount Sinai;ImmunoGen;Incyte Corporation;Institut fuer Frauengesundheit;Institute of Cancer Research;M. D. Anderson Cancer Center;Massachusetts General Hospital;Mayo Clinic;Memorial Sloan-Kettering Cancer Center;Merck & Co;Merck Sharp & Dohme;National Cancer Center Hospital East;National Cancer Institute (France);National Cancer Institute (USA);Netherlands Cancer Institute;Northwestern University;NYU Langone Medical Center;Oslo University Hospital;Plexxikon;Providence Health & Services;Royal Marsden NHS Foundation Trust;Sarcoma Alliance for Research through Collaboration;Sellas Life Sciences Group;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Spanish Breast Cancer Research Group;Syndax Pharmaceuticals;TG Therapeutics Inc;University Health Network;University of Alabama;University of Birmingham;University of California at Los Angeles;University of California at San Francisco;University of California San Diego;University of Colorado at Denver;University of Miami;University of Pittsburgh;University of Utah;University of Washington;Verastem Oncology;Wakayama Medical University;Washington University School of Medicine;Yale University;The Leukemia & Lymphoma Society,Cervical cancer;Colorectal cancer;Diffuse large B cell lymphoma;Gastric cancer;Head and neck cancer;Hodgkin's disease;Liver cancer;Malignant melanoma;Non-small cell lung cancer;Pancreatic cancer;Solid tumours;Urogenital cancer;Cancer;Merkel cell carcinoma;Renal cell carcinoma,Small cell lung cancer;Bladder cancer;Breast cancer;Endometrial cancer;Fallopian tube cancer;Gastrointestinal cancer;Mesothelioma;Multiple myeloma;Nasopharyngeal cancer;Oesophageal cancer;Ovarian cancer;Peritoneal cancer;Prostate cancer;Squamous cell cancer;Acute myeloid leukaemia;Adenoid cystic carcinoma;Bone cancer;Brain metastases;Cholangiocarcinoma;Follicular lymphoma;Germ cell and embryonal neoplasms;Glioblastoma;Glioma;Inflammatory breast cancer;Liver metastases;Lymphoma;Meningioma;Myelodysplastic syndromes;Neuroendocrine tumours;Non-Hodgkin's lymphoma;Osteosarcoma;Penile cancer;Rectal cancer;Recurrent respiratory papillomatosis;Sarcoma;Soft tissue sarcoma;Thymoma;Thyroid cancer;Uveal melanoma;Chronic lymphocytic leukaemia;Haematological malignancies;Leiomyosarcoma;Mantle-cell lymphoma;Precursor cell lymphoblastic leukaemia-lymphoma;T-cell lymphoma;Gliosarcoma;Human papillomavirus infections,na,na,Pembrolizumab is the new name for Lambrolizumab (PL110),Q VQLVQ SG VEVK KPGA SVKVSCK ASGY TFTNYYMYWVRQ APGQG LEWMGGI NPSNGGTNFNEKFKN RVTLTT DSSTT TAYMELKSL QFDDT AVYYCAR RDY RF D MGFD YWGQG TTVTVS S,E IVLT QSPA TLSL SPGE RATLSCRA SKGVSTSGY SYLHWY QQKPGQAP RLLIYL ASY LESGVP ARFS GSGSGTD FTLTIS SLEPED FAVYYCQ HSRDLP LTF GGGT KVEI K
Penpulimab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFAFSSYDMSWVRQAPGKGLDWVATISGGGRYTYYPDSVKGRFTISRDNSKNNLYLQMNSLRAEDTALYYCANRYGEAWFAYWGQGTLVTVSS,DIQMTQSPSSMSASVGDRVTFTCRASQDINTYLSWFQQKPGKSPKTLIYRANRLVSGVPSRFSGSGSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELK,na,na,None,None,None,2020,2021,PDCD1,Akeso Biopharma;Chia Tai Tianqing Pharmaceutical,Hodgkin's disease,Non-small cell lung cancer;Cholangiocarcinoma;Colorectal cancer;Gastric cancer;Head and neck cancer;Liver cancer;Nasopharyngeal cancer;Neuroendocrine tumours;Urogenital cancer;Solid tumours,,na,,E VQLVES GGG LV QPGG SLRLSC AASGF AFSS YDM SWVR QAPGKGLD WVATI SGGG RYTY YPDSVK GRFTISR DNSKNN LYLQMN SLRAEDT ALYYCA NRYGE AWFAYW GQG TLVTV SS,DIQ MT QSPSSM SA SVGD RVTFTCR ASQD INTYLSWFQ QKPGKSPK TLIYRA N RLV SGVPS R FSGSGSGQD YTLTISS LQPEDM A TYYCLQ YDEFP LTF GAGT KLEL K
Pepinemab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYSFSDYYMHWVRQAPGQGLEWMGQINPTTGGASYNQKFKGKATITVDKSTSTAYMELSSLRSEDTAVYYCARYYYGRHFDVWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPYTFGQGTKLEIK,na,na,None,None,None,2018,2019,SEMA4D,Bristol-Myers Squibb;Children's Oncology Group;Emory University;Merck KGaA;National Cancer Institute (USA);Teva Pharmaceutical Industries;UCLAs Jonsson Comprehensive Cancer Center;Vaccinex,na,Huntington's disease;Non-small cell lung cancer;Osteosarcoma;Solid tumours;Colorectal cancer;Head and neck cancer;Malignant melanoma;Pancreatic cancer,Multiple sclerosis,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGYSFSD YYMHWVRQ APGQG LEWMGQI NPTTGGASYNQKFKG KATITVD KSTS TAYMELS SLRSEDT AVYYCARYY YGR HFDVW GQG TTVTVS S,D IVMT QSPDS LAVS LGER ATINCK ASQ SV DYDGD SYMNWYQ QKPGQPP KLLIYAA SNLESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQ QSNEDPY T FGQGT KLEI K
Perakizumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYTMLWVRQAPGKGLEWVAIIKSGGSYSYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDGDYGSSYGAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDINSYLSWFQQKPGKAPKSLIVRANRLVDGVPSRFSGSGSGQDYSLTISSLQPEDFATYYCLQYDAFPPYTFGQGTKLEIK,na,na,None,None,None,2012,2013,IL17A,Roche,na,na,Psoriatic arthritis,na,,E VQLVES GGG LV QPGG SLRLSCA ASGF TF SD YTMLWVRQ APGKG LEWVAIIK SGGS YSY YPDSVK GRFTISR DNAKNS LYLQMN SLRAEDT AVYYCA RDGDYGSSYG AM DYWGQG TLVTV SS,DIQ MT QSPSS LSA SVGD RVTITCR ASQD INSYLSWFQ QKPGKAPK SLIVRANRLV DGVPS R FSGSGSGQD YSLTIS SLQPEDF ATYYCLQ YDAFPPYTFGQGT KLEI K
Perenostobart,Whole mAb,G4,Kappa,TBC,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSEGISWVRQAPGQGLEWMGSILPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREAGYYRYRYFDLWGRGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQHALWPLTFGGGTKVEIK,na,na,None,None,None,2022,na,ENTPD1,TBC,TBC,TBC,TBC,TBC,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT FS SEG ISWVRQ APGQGL EWMGSILPIF GTANYA Q KFQG RVTITA DESTS TAYMELS SLRSEDT AVYYCAR EAGY YRYRYFDL WGRG TLVTVS S,E IVMT QSPA TLSV SPGE RATLSCR ASQSVSSN LAWYQ QKPGQAP RLLIYG ASTRATGIP ARFS GSGSGT EFTLTISS LQSED FAVYYC QQHALWP LT FGGGT KVEI K
Peresolimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKVSGYSLSKYDMSWVRQAPGKGLEWMGIIYTSGYTDYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGNPYYTNGFNSWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQSPNNLLAWYQQKPGKAPKLLIYGASDLPSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNNYYVGPVSYAFGGGTKVEIK,na,na,None,None,None,2022,na,PDCD1,Eli Lilly,na,Rheumatoid arthritis;Plaque Psoriasis,na,TBC,(June '22: Corrected CDRH3 sequence),Q VQLVQ SGA EVK KPGA SVKVSCKV SGY S LSKY DMSWVR QAPGKGL EWMGIIYT SGYTDY AQ KFQG RVTMT EDTSTD TAYMELSS LRSEDT AVYYC ATGNPYYTNGFNSWGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCQ ASQSPN NLLAWY Q QKPGKAP KLLIYG ASDLPSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATY YC QNN YYV GP VSYA FGGG TKVEI K
Pertuzumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIK,na,na,1l7i:HL/4llu:AB:CD/1s78:FE:DC/6oge:CB,None,4lly:AB:CD/4llw:CD:AB/5vsh:CD:AB:EF:HL,2003,2004,ERBB2,Chugai Pharmaceutical;Dana-Farber Cancer Institute;FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO;Genentech;International Breast Cancer Study Group;Japan Breast Cancer Research Group;Medica Scientia Innovation Research;Roche;West German Study Group,Breast cancer,Ovarian cancer;Brain metastases;Colorectal cancer,Gastric cancer;Non-small cell lung cancer;Prostate cancer,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFT DY TMDWVR QAPGKG LEWVADV NPNSGGS IY NQRFKG RFTLSVD RSKN TLYLQMNS LRAEDT AVYYCA RNLGPS FYFDY WGQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITCK ASQD VSIGVAWYQ QKPGKAP KLLIYSASYRY TGVPSRFSGSGSGTD FTLTISS LQPE DFA TYYCQQYYIYP Y T FGQGT KVEI K
Petosemtamab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-I,Discontinued,QVQLVQSGSELKKPGASVKISCKASGYDFTNYAMNWVRQAPGHGLEWMGWINANTGDPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAEDSAVYYCTRERFLEWLHFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,EVQLVQSGSKLKKPGASVKVSCKASGYTFTSYTMNWVRQAPGQGLEWMGWINTDTGDPTYAQGFTGRFVFSLDTSVSTAFLQINSLKAEDTAVYYCARGDCDSTSCYRYSYGYEDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,None;None,None;None,None;None,2019,2020,EGFR;LGR5,Merus,na,na,Colorectal cancer;Solid tumours,na,,Q VQLVQ SGS E LKKPGA SVKISCK ASGYDFT NY AMNWVR QAPGHGL EWMGWIN ANTGDPTYAQGF TGRFVFSL DTSVS TAYLQISS LKAEDS AVYYCT RE RFLE WLHFD YWGQG TLVTV SS,DIQ MT QSPSS LSA SVGD RVTITCR ASQS ISSYLNWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQPE DF ATYYCQ QSYSTPPTFGQGT KVEI K
Pexelizumab,scFv,na,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYIFSNYWIQWVRQAPGQGLEWMGEILPGSGSTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQRKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK,na,na,None,5i5k:HL:XY,None,2002,2002,C5,Stanford University,na,na,Myocardial infarction;Reperfusion injury,na,Same VH as eculizumab,Q VQLVQ SGA EVK KPGA SVKVSCK ASG YIF SN YWIQWVR QAPGQG LEWMGEI LPGSGST EYT ENFKD RVTMTR DTSTS TVYMELS SLRSEDT AVYYCARYF FGSSPN WYFDVW GQG TLVTVS S,DIQMTQSPSSL SA SVGD RVTITC GASEN IYGALNWY QRKPGKAP KLLIYG ATNLADGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQN VLNTPL T FGQGT KVEI K
Pidilizumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGSELKKPGASVKISCKASGYTFTNYGMNWVRQAPGQGLQWMGWINTDSGESTYAEEFKGRFVFSLDTSVNTAYLQITSLTAEDTGMYFCVRVGYDALDYWGQGTLVTVSS,EIVLTQSPSSLSASVGDRVTITCSARSSVSYMHWFQQKPGKAPKLWIYRTSNLASGVPSRFSGSGSGTSYCLTINSLQPEDFATYYCQQRSSFPLTFGGGTKLEIK,na,na,None,None,None,2012,2013,PDCD1,American Cancer Society;Beth Israel Deaconess Medical Center;CureTech;Georgia Regents University;Hadassah Medical Organization;Northwestern University;The Ohio State University Comprehensive Cancer Center;University of Texas M. D. Anderson Cancer Center,na,Acute myeloid leukaemia;Colorectal cancer;Diffuse large B cell lymphoma;Follicular lymphoma;Malignant melanoma;Multiple myeloma;Pancreatic cancer;Prostate cancer;Renal cell carcinoma;Glioma;Hepatitis C;Liver cancer,na,na,,Q VQLVQ SGS E LKKPGA SVKISCK ASGY TFTN YG MNWVRQ APGQG LQWMGWIN TDSGES TYAEEF KG RFVFSL DTSVN TAYLQITSL TAEDTG MYFCVRVG YDALDYWGQG TLVTVS S,E IVLT QSPSS LSA SVGD RVTITCS ARSS VSYMHWF QQKPGKAP KLWIYRT SNLASGVPSRFSGSGSGT SYCLTI NSLQ PEDFAT YYC QQRSSFP LTF GGGT KLEI K
Pimivalimab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFPSYYMHWVRQAPGQGLEWMGIINPEGGSTAYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGGTYYDYTYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYEASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSFPPTFGGGTKVEIK,na,na,None,None,None,2020,2021,PDCD1,Jounce Therapeutics,na,Solid tumours;Non-small cell lung cancer,na,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGYTFPS YYMHWVRQ APGQG LEWMGII NPEGGST AYAQKF QG RVTMTR DTSTS TVYMELS SLRSEDT AVYYC ARGG TYYDYTY WGQG TLVTVS S,DIQMTQSPS TLSAS VGD RVTITCR ASQS ISSWLAWYQ QKPGKAP KLLIYE ASSLESGVPS R FSGSGSGT EFTLTIS SLQPDD FAT YYCQ QYNSFPPTFGGGT KVEI K
Pimurutamab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFSLTNYGVHWVRQAPGKGLEWLGVIWSGGNTDYGNEFTSRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARALDYYDYEFAYWGQGTMVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSIGTNIHWYQQKPGQAPRLLIKYASESISGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQNNNWPTSFGGGTKVEIK,na,na,None,None,None,2019,2020,EGFR,Shanghai Henlius Biotech,na,Solid tumours,na,na,(June '22: Corrected FWH2 sequence),E VQLVES GGG LV QPGG SLRLSC AASGF SL TNY GVHWVRQ APGKGL EWLGVIWS GGNTDYGNE FTSRFTIS RDNAKN SLYLQMNS LRAEDT AVYYCA RALDYYD YEFAYW GQG TMVTVS S,E IVLTQ SPA TLSL SPGE RATLSCR ASQSIGT NIHWYQ QKPGQAP RLLIKYA SESISGIP ARFS GSGSGTD FTLTIS SLEPED FAVYYCQ QNNNWPTSFGGG TKVEI K
Pinatuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGYEFSRSWMNWVRQAPGKGLEWVGRIYPGDGDTNYSGKFKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDGSSWDWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQSIVHSVGNTFLEWYQQKPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFQGSQFPYTFGQGTKVEIK,na,na,None,6and:HL,None,2012,2013,CD22,Genentech,na,na,Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Non-Hodgkin's lymphoma,na,,E VQLVES GGG LV QPGG SLRLSC AASGY EFS RS WMNWVR QAPGKG LEWVGRI YPGDGDTNYSG KFKGRFTISA DTSKN TAYLQMN SLRAEDT AVYYCA RDGSSW DWYFDV WGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR SSQS IVHSV GNT FLE WYQ QKPGKAP KLLIYKV SNRFSGVPS R FSGSGSGT DFTLTISS LQPEDF ATYYCF QGSQFPY T FGQGT KVEI K
Pivekimab,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYIFTSSIMHWVRQAPGQGLEWIGYIKPYNDGTKYNEKFKGRATLTSDRSTSTAYMELSSLRSEDTAVYYCAREGGNDYYDTMDYWGQGTLVTVSS,EIQMTQSPSSLSASVGDRVTITCRASQDINSYLSWFQQKPGKAPKTLIYRVNRLVDGVPSRFSGSGSGNDYTLTISSLQPEDFATYYCLQYDAFPYTFGQGTKVEIK,na,na,None,None,None,2021,2022,IL3RA,ImmunoGen,na,Acute myeloid leukaemia;Blastic plasmacytoid dendritic cell neoplasm,na,na,,Q VQLVQ SGA EVK KPGA SVKVSC KASG YIFTS S IMHWVR QAPGQG LEWIGYIK PYNDGTKYNE KF KG RATLTS DRSTS TAYMELS SLRSEDT AVYYCAR EGGNDY Y DT M DYWGQG TLVTVS S,EI QMT QSPSS LSA SVGD RVTITCR ASQD INSYLSWFQ QKPGKAPK TLIYRVNRLV DGVPS RF SGSGSGND YTLTISS LQPEDF ATYYCLQY DAFPY T FGQGT KVEI K
Placulumab,Single Domain Variable Fragment (VL) + Fc,G1,Kappa,Phase-II,Discontinued,na,DIQMTQSPSSLSASVGDRVTITCRASQAIDSYLHWYQQKPGKAPKLLIYSASNLETGVPSRFSGSGSGTDFTLTISSLLPEDFATYYCQQVVWRPFTFGQGTKVEIK,na,na,None,None,None,2012,2013,TNFA,Domantis;Peptech;Arana Therapeutics;Teva Pharmaceutical Industries,na,na,Inflammation;Psoriasis;Rheumatoid arthritis;Sciatica,na,,NA,DIQ MT QSPSS LSA SVGD RVTITCR AS QAIDSYLHWYQ QKPGKAP KLLIYS ASNLETGVPSRFSGSGSGTD FTLTISS LLPE DFA TYYCQQVVWR PFTFGQGT KVEI K
Plamotamab,Bispecific Mixed mAb and scFv,G1;G1,Kappa;Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGAIYPGNGDTSYNQKFQGRVTITADKSISTAYMELSSLRSEDTAVYYCARSTYYGGDWYFNVWGAGTLVTVSS,QIVLTQSPSSLSASVGDRVTITCRASSSVSYIHWFQQKPGKSPKPLIYATSNLASGVPVRFSGSGSGTDYTLTISSLQPEDFATYYCQQWTSNPPTFGGGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGDSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQQKPGKSPRGLIGGTNKRAPGVPARFSGSLLGGKAALTISGAQPEDEADYYCALWYSNHWVFGGGTKLTVLEPK,None;None,None;None,None;None,2018,2019,MS4A1;CD3E,Xencor,na,B-cell lymphoma;Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma,na,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYNMHWVRQ APGQG LEWMGAI YPGNGDTSYNQ KF Q GRVTIT ADKS ISTAYMELS SLRSEDT AVYYCAR S T YYGGD WYFNVW GAG TLVTVS S,Q IVLT QSPSS LSA SVGD RVTITCR ASSS VSYIHWFQ QKPGKSPKP LIYAT SNLASGV PVRFS GSGSGTD YTLTISS LQPED F ATYYCQQW TSNPPTFGGG TKVEI K
Plonmarlimab,Whole mAb,G1,Kappa,Phase-II/III,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTSHYLHWVRQAPGQGLEWMGWIFPGDDKTKYNEKFKGRVTMTSDTSISTAYMELSRLRSDDTAVYYCARGTKYLNWNFDVWGQGTTVTVSS,DIQLTQSPSFLSASVGDRVTITCKANQNVGTTLAWYQQKPGKSPKALIYSASYRYSGVPDRFSGSGSGTDFTLTISSLQPEDFATYFCHQYTTYPLTFGGGTKVEIK,na,na,None,None,None,2020,2021,CSF2,I-Mab Biopharma,na,Rheumatoid arthritis;COVID-19;Osteoarthritis,na,na,(June '22: Corrected FWL4 sequence),E VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSHYLHWVR QAPGQGL EWMGWI FPGDDKTKYNEKFKG RVTMT SDTS ISTAYMELSR LRSDDT AVYYC ARGT KYLNWNFDV WGQG TTVTVS S,DI QLT QSPS FLSA SVGD RVTITCK ANQNVG TTLAWYQ QKPGKSPK ALIYSASYRY SGVPDRFSGSGSGTD FTLTISS LQP EDFA TYFCH QYTTYP LTF GGG TKVEI K
Plozalizumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSAYAMNWVRQAPGKGLEWVGRIRTKNNNYATYYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGNGVWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCKSSQSLLDSDGKTFLNWFQQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPYTFGQGTRLEIK,na,na,None,None,None,2015,2016,CCR2,Millennium;Millennium Pharmaceuticals;Takeda;Takeda Oncology,na,Atherosclerosis;Diabetic nephropathies;Malignant melanoma,Multiple sclerosis;Rheumatoid arthritis;Scleroderma;Solid tumours,Humanization by CDR Grafting,,E VQLVES GGG LV KPGG SLRLSC AASGF TFSAYAMNWVR QAPGKG LEWVGRIRT KNNNY ATYYA DSVKD RFTISR DDSKN TLYLQMN SLKTEDT AVYYCTTFY GNGV W G QGTLVTVS S,DV VMT QSPLSLPV T LGQPA SISC KSSQ SLL DSDGK TFLNWFQ QRPGQSPR RLIYLVSK LDSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCW QGTHFPY T FGQGT RLEI K
Polatuzumab,Whole mAb ADC,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKGLEWIGEILPGGGDTNYNEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTRRVPIRLDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCKASQSVDYEGDSFLNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPLTFGQGTKVEIK,na,na,None,None,None,2012,2013,CD79B,Chugai Pharmaceutical;Genentech;Roche,Diffuse large B cell lymphoma,Non-Hodgkin's lymphoma;Follicular lymphoma,Chronic lymphocytic leukaemia,na,,E VQLVES GGG LV QPGG SLRLSC AASGY TFSSYWIEWVR QAPGKGL EWIGEI LPGGGDTNYN EIF KG RATFSA DTSKN TAYLQMN SLRAEDT AVYYCT RRVP IRLDY WGQG TLVTVS S,DI QLT QSPSS LSA SVGD RVTITCK ASQS V DYEGD SFLN W Y QQKPGKAP KLLIYAA SNLESGVPS R FSGSGSGTD FTLTIS SLQPED F ATYYCQ QSNEDPL T FGQGT KVEI K
Polzastobart,Whole mAb,G4,Kappa,TBC,Active,QITLKESGPTLVKPTQTLTLTCTFSGFSLNTYAMGVSWIRQPPGKALEWLASIWWNGNKYNNPSLKSRLTVTKDTSKNQVVLTMTNMDPVDTATYYCAHSRIIRFTDYVMDAWGQGTLVTVSS,DIQMTQSPSSLSTSVGDRVTITCRASEDIYNDLAWYQQKPGKAPKLLIYNANSLHTGVASRFSGSGSGTDFTFTISSLQPEDVATYFCQQYYDYPLTFGQGTKLEIK,na,na,None,None,None,2022,na,LILRB2,TBC,TBC,TBC,TBC,TBC,,Q ITLK ESGP TLV KPTQ TLTLTCTF SGFSLN TYAMGVSWIR QPPGKA LE WLASIWW NGNKYNNPSLK SRLTVTK DTSKN QVVLTMT NMDPVDTA TYYC AHSR IIRFT D YVM DAWGQG TLVTVS S,DIQ MT QSPSSL S TSVGD RVTITCR AS EDIYNDLAWYQ QKPGKAP KLLIYN ANSLHT GVASR FSGSGSGT DFTFTIS SLQ PEDVATYFCQQY YDYPL T FGQGT KLEI K
Ponezumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYYTEAYYIHWVRQAPGQGLEWMGRIDPATGNTKYAPRLQDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCASLYSLPVYWGQGTTVTVSS,DVVMTQSPLSLPVTLGQPASISCKSSQSLLYSDAKTYLNWFQQRPGQSPRRLIYQISRLDPGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHYPVLFGQGTRLEIK,na,na,3u0t:BA:DC,None,None,2010,2011,APP,Rinat Neuroscience;Pfizer,na,na,Alzheimer's disease;Cerebral amyloid angiopathy,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY YTEAYYIHWVR QAPGQG LEWMGRI DPATGNTKYAPRLQD RVTMTR DTSTS TVYMELS SLRSEDT AVYYCASL YSLP VYW GQGT TVTVS S,DV VMT QSPLSLPVTLGQPA SISC KSSQS LLY SD AKTYLNWFQ QRPGQSPR RLIYQISR LDPGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCL QGTHYP VLF GQGT RLEI K
Ponsegromab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSYNIDWVRQAPGQGLEWMGGINPIFGTAFYNQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREAITTVGAMDHWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRTSQSVHNYLAWYQQKPGQAPRLLIYDASTRADGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQFWSWPWTFGQGTKVEIK,na,na,None,None,None,2020,na,GDF15,Pfizer,na,na,Cachexia,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TFSSYNIDWVR QAPGQGL EWM GGINPIFG TAFY NQKFQG RVTITA DESTS TAYMELS SLRSEDT AVYYCA RE AITTV GAMDHWGQG TLVTVS S,E IVLT QSPA TLSL SPGE RATLSCR TSQS VHNYL A W Y QQKPGQAP RLLIYD ASTRADGI PARFS GSGSGTD FTLTIS SLEPED FAVYYCQ QFWSWPWTFGQGT KVEI K
Porustobart,VH-CH2-CH3,G1,na,TBC,Active,EVQLVESGGGLIQPGGSLRLSCAVSGFTVSKNYMSWVRQAPGKGLEWVSVVYSGGSKTYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAVPHSPSSFDIWGQGTMVTVSS,na,na,na,7dv4:H:B:D:F,None,None,2022,na,CTLA4,TBC,TBC,TBC,TBC,TBC,,E VQLVES GGG LI QPGG SLRLSCAV SG FTV SKN YMSWVR QAPGKGL EWVSVVYS GGSKTYADSVK GRFTISR DNSKN TLYLQMNS LRAEDT AVYYCARA VPHSPSS FDIW GQG TMVTVS S,NA
Posdinemab,Whole mAb,G1,Kappa,TBC,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVASISKGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGWGDYGWFAYWGQVTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDINRYLNWFQQKPGKAPKSLIYRANRLLDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQYDEFPLTFGQGTKLEIK,na,na,None,None,None,2022,na,MAPT,TBC,TBC,TBC,TBC,TBC,,Q VQLVES GGG VV QPGR SLRLSC AASGF TFSSYAMSWVR QAPGKG LEWVASIS KGGN TYYA DSVKG RFTISR DNSKN TLYLQMNS LRAEDT AVYYCA RGWGDYG WFAYW G QVTLVTV SS,DIQ M TQSPSS LSA SVGD RVTITCK AS QDINRYLNWFQ QKPGKAP KSLIYRANRL LDGVPS R FSGSGSGTD FTLTIS SLQPEDF ATYYCLQ YDEFPL T FGQGT KLEI K
Pozelimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLQESGPGLVKPSETLSLTCTVSGDSVSSSYWTWIRQPPGKGLEWIGYIYYSGSSNYNPSLKSRATISVDTSKNQFSLKLSSVTAADTAVYYCAREGNVDTTMIFDYWGQGTLVTVSS,AIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYAASSLQSGVPSRFAGRGSGTDFTLTISSLQPEDFATYYCLQDFNYPWTFGQGTKVEIK,na,na,None,None,None,2018,2019,C5,Alnylam Pharmaceuticals;Regeneron Pharmaceuticals,na,Myasthenia gravis;Paroxysmal nocturnal haemoglobinuria;Gastrointestinal disorders,na,na,,QV QLQE SGPGL V KPSE TLSLTCTV SGDSVS SSYWTWIR QPPGKGL EWIGYIYYS GSSNYNPSLK SRATISVD TSKN QFSLKLSS VTAADT AVYYCA REGNVD TTMIFD YWGQG TLVTVS S,AI QMT QSPSS LSAS VGD RVTITCR ASQGIRNDLG WYQ QKPGKAP KLLIYAA SSLQSGVPS RF AGRGSGTD FTLTISS LQPEDF ATYYCL QDFNYPW T FGQGT KVEI K
Plutavimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSIIYPGGSTEYADSVKGRFTISRDNSRNTLYLQMNSLRAEDTAVYYCARELGYYGMDVWGQGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISTWLVWYQQKPGKAPNLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANAYPYTFGQGTKLEIK,na,na,None,None,None,2022,na,SARS-CoV-2 Spike RBD,Sorrento Therapeutics,na,COVID-19,na,na,,E VQLVES GGG LI QPGG SLRLSC AASGF TVS SN YMSWVR QAPGKG LEWVSII YPGGSTEYADSVK GRFTISR DNSRN TLYLQMNS LRAEDT AVYYC ARE LGYY GMDV WGQG TTVTVS S,DI QMT QSPSS VSAS VGD RVTITCR ASQG ISTWLVWYQ QKPGKAPN LLIYG ASSLQSGVPS R FSGSGSGTD FTLTIS SLQP EDFA TYYCQ QANAYPY T FGQGT KLEI K
Porgaviximab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLQESGGGLMQPGGSMKLSCVASGFTFSNYWMNWVRQSPEKGLEWVAEIRLKSNNYATHYAESVKGRFTISRDDSKRSVYLQMNTLRAEDTGIYYCTRGNGNYRAMDYWGQGTSVTVSS,DIQMTQSPASLSVSVGETVSITCRASENIYSSLAWYQQKQGKSPQLLVYSATILADGVPSRFSGSGSGTQYSLKINSLQSEDFGTYYCQHFWGTPYTFGGGTKLEIK,na,na,None,5kel:HL:PT:QU,None,2016,2017,Zaire Ebolavirus GP,Mapp Biopharmaceutical;Public Health Agency of Canada;National Institute of Allergy and Infectious Diseases,na,na,Ebola virus infections ,Zmapp Technology,,E VQLQE SGGG LM QPGGS MKLSCVA SGF TF SNY WMNWVR QSPEKGL EWVAEIRLK SNNYA THYAES VKG RFTISR DDSKR SVYLQMNTLR AEDT GIYYCT RGNGN YRAMD YWGQG TSVTVS S,DIQ M TQSPA SLSVS VGE TVSITCR ASEN IYSSLAWYQQ KQGKSPQ LLVYSATILA DGVPS RF SGSGSGT QYSLKIN SLQSEDFG TYYCQHF WGTPY T FGGGT KLEI K
Pradusinstobart,Whole mAb,G4,Kappa,TBC,Active,QVTLKESGPALVKPTQTLTLTCTFSGFSLSTSGTCVSWIRQPPGKALEWLATICWEDSKGYNPSLKSRLTISKDTSKNQAVLTMTNMDPVDTATYYCARREDSGYFWFPYWGQGTLVTVSS,NIQMTQSPSSLSASVGDRVTITCKAGQNVNNYLAWYQQKPGKAPKVLIFNANSLQTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSWTTFGGGTKVEIK,na,na,None,None,None,2022,na,PDCD1,TBC,TBC,TBC,TBC,TBC,,Q VTLK ESGPA LV KPTQ TLTLTCTF SG FSL STSG TCVSWIR QPPGKA LEWLATICWE DSKGYNPSLK SRLTIS KDTSKN QAVLTMT NMDPVDT ATYYCARR EDSG YFWF PYWGQG TLVTVS S,NIQ M TQSPSS LSA SVGD RVTITCK AGQN VNNYLAWYQ QKPGKAP KVLIFN ANSLQTGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ YNSW TT FGGGT KVEI K
Prafnosbart,Whole mAb,G1,Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGSTFSNYGMKWIRQAPGKGLEWVSSISRSSTYIYYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAAAISTPFYWYFDFWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCLASSSVSYMTWYQQKPGQSPRLWIYGTSNLASGVPDRFSGSGSGTDFLTLTIRLEPEDFAVYYCLHLTSYPPYTFGQGTKVEIK,na,na,None,None,None,2022,na,ACVR1,TBC,TBC,TBC,TBC,TBC,,E VQLVES GGG LV QPGG SLRLSCA ASGSTFSNY GMKWIRQ APGKG LEWVSSI SRSS TYIYYA DTVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAAAI STPF YWYFDF WGQG TLVTVS S,E IVLTQ SPG TLSL SPGER ATLSCL ASSS VSYMTWYQ QKPGQSP RLWIYG TSNLASGVPDRFSGSGSGTD FLTLTIRL EPEDF AVYYCLHLT SYPPYTFGQGT KVEI K
Praluzatamab,Whole mAb,G1,Kappa,Phase-II,Active,QITLKESGPTLVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWSEDKHYSPSLKSRLTITKDTSKNQVVLTITNVDPVDTATYYCVQIDYGNDYAFTYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGQGTKLEIK,na,na,None,None,None,2019,2020,CD166,CytomX Therapeutics;Immunogen,na,Solid tumours,na,na,,Q ITLK ESGP TLV KPTQ TLTLTCTF SGF SLSTYGMGVGWIR QPPGKA LE WLANIWW SEDKHYSPSLK SRLTITK DTSKN QVVLTITN VDPVDT ATYYCVQID YGND YAFTYW GQG TLVTVS S,DI VMT QSPLSLPVTPGEPA SISCR SSK SLLH SNG ITYLYWYLQ KPGQSP QLLIYQM SNLASGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCA QNLELPY T FGQGT KLEI K
Prasinezumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAPGKGLEWVASISSGGGSTYYPDNVKGRFTISRDDAKNSLYLQMNSLRAEDTAVYYCARGGAGIDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKSIQTLLYSSNQKNYLAWFQQKPGKAPKLLIYWASIRKSGVPSRFSGSGSGTDFTLTISSLQPEDLATYYCQQYYSYPLTFGGGTKLEIK,na,na,None,None,None,2017,2018,SNCA,Neotope Biosciences;Chugai Pharmaceutical;Prothena;Roche,na,Parkinson's disease,na,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFS NYG MSWVRQ APGKG LEWVASIS SGGGST Y YPDNVK GRFTISR DDAKNS LYLQMN SLRAEDT AVYYCA RGGAG IDY WGQG TLVTV SS,DIQ MT QSPSS LSA SVGD RVTITC KS IQTLLY SSNQK NYLAWFQ QKPGKAP KLLIYWASI RKSGVPS RF SGSGSGTD FTLTIS SLQ PEDLATYYCQQ YYSYP LTF GGGT KLEI K
Prezalumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAYIKQDGNEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGILWFGDLPTFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDSYPRTFGQGTKVEIK,na,na,6x4t:BE:DF,None,None,2015,2016,ICOSLG,Amgen;MedImmune,na,na,Cutaneous lupus erythematosus;Psoriasis;Sjogren's syndrome;Systemic lupus erythematosus,na,May have had a former name of Prezalizumab,E VQLVES GGG LV QPGG SLRLSC AASGF TFSSYWMSWVR QAPGKG LEWVAYIK QDGN EKYYVD SVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCA REG ILWF GDLPTFWGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQG ISNWLAWYQ QKPEKAPK SLIYAA SSLQSGVPS RF SGSGSGTD FTLTIS SLQP EDFAT YYCQ QYDSYPRTFGQGT KVEI K
Pritoxaximab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLQESGAELVRSGASVRMSCKASGYTFTSYNMHWVKQTPGQGLEWIGYIYPGNGGTNYIQKFKGKAILTADTSSSTAYMQISSLTSEDSAVYFCTRSPSHYSSDPYFDYWGQGTTLTVSS,DIVMSQSHKFMSTSVGDRVSITCKASQDVGTAVAWYQQNPGQSPKFLIYWASTRHTGVPDRFTGSGSGTDFTLTITNVQSEDLADYFCQQYSSYPLTFGAGTSLELK,na,na,None,None,None,2012,2013,Shiga Toxin Type 1,Sunol Molecular Corporation;Uniformed Services University of the Health Sciences;BELLUS Health;Taro Pharmaceuticals Inc,na,na,Haemolytic uraemic syndrome;Shiga-toxigenic Escherichia coli infections,na,,QV QLQ ESGA ELVR SGA SVRMSCK ASGY TFTSYNMHWVK QTPGQG LEWIGYIY PGNGGTN YIQKF KG KAILTA DTSSST AYMQISS LTSEDS AVYFCT RSPSHYSSDPYFDYWGQG TTLTVS S,DI VMS QSH KFMS TSVGD RVSITCK ASQDVG TAVAWYQ QNPGQSPK FLIYWA STRHTGVPDRFTGSGSGTD FTLTITN VQS EDLADYFCQQ YSSYP LTF GAGT SLEL K
Pritumumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLLESGGDLVQPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVSAITPSGGSTNYADSVKGRFTISRDNSQNTLYLQMNSLRVEDTAVYICGRVPYRSTWYPLYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLAWFQQKPGKAPKSLIYAASSLHSKVPTQFSGSGSGTDFTLTISSLQPEDFATYYCLQYSTYPITFGGGTKVEIK,na,na,None,None,None,2003,2004,Vimentin,UCSD;Nascent Biotech,na,Glioma;Breast cancer;COVID-19,Pancreatic cancer,na,,E VQLLE SGGD LV QPGG SLRLSC AASGF TFS NY AMSWVR QAPGKGL EWVSAI TPSGGSTNYADSVK GRFTISR DNSQN TLYLQMNSLRV EDT AVYIC GRVPYRST WYPLY WGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQD ISNYLAWFQ QKPGKAPK SLIYAA SSLHSKVPT QF SGSGSGTD FTLTISS LQPED F ATYYCLQ YSTYP ITF GGGT KVEI K
Prolgolimab,Whole mAb,G1,Lambda,Phase-III,Active,QVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYWMYWVRQVPGKGLEWVSAIDTGGGRTYYADSVKGRFAISRVNAKNTMYLQMNSLRAEDTAVYYCARDEGGGTGWGVLKDWPYGLDAWGQGTLVTVSS,QPVLTQPLSVSVALGQTARITCGGNNIGSKNVHWYQQKPGQAPVLVIYRDSNRPSGIPERFSGSNSGNTATLTISRAQAGDEADYYCQVWDSSTAVFGTGTKLTVL,na,na,None,None,None,2018,2019,PDCD1,Biocad,na,Malignant melanoma;Cervical cancer;Non-small cell lung cancer,Solid tumours,na,,Q VQLVQS GGG LV QPGG SLRLSCA ASGF TFSSYWMYWVRQ VPGKGL EWVSAID TGGGR TYYAD SVKG RFAISRV NAKNT MYLQMNSL RAEDT AVYYCAR DEGGGTG WGVLK DWPYGLDAWGQG TLVTVS S,QPVLTQP LSVSVA LGQ TARITC GGNNIGSK NVHWYQ QKPGQAP VLVIYR DSNRPSGIPERFSGSNSGN TATLTISR AQAGDE ADYYCQVWD SSTA VF GTGT KLTV L
Pucotenlimab,Whole mAb,G4,Kappa,Approved,Active,EVQLVQSGGGLVQPGGSLKLSCAASGFTFSSYGMSWVRQAPGKGLDWVATISGGGRDTYYPDSVKGRFTISRDNSKNNLYLQMNSLRAEDTALYYCARQKGEAWFAYWGQGTLVTVSS,DIVLTQSPASLAVSPGQRATITCRASESVDNYGISFMNWFQQKPGQPPKLLIYAASNKGTGVPARFSGSGSGTDFTLNINPMEENDTAMYFCQQSKEVPWTFGGGTKLEIK,na,na,None,None,None,2020,2021,PDCD1,Taizhou Hanzhong Pharmaceuticals,Solid tumours,Gastrointestinal cancer;Malignant Melanoma;Non-small cell lung cancer;Bladder cancer;Breast cancer;Liver cancer,na,na,,E VQLVQS GGG LV QPGG SLKLSC AASGF TFSS YG MSWVRQ APGKGL DWVATIS GGGRDTYYPDSVK GRFTISR DNSKNN LYLQMN SLRAEDT ALYYCAR QKGE AWFAYW GQG TLVTV SS,D IVLTQ SPA SLAV SPGQ RATITCRA SESVDNY GISFMNWF QQKPGQPP KLLIYAA SNKGTGVP ARF SGSGSGT DFTLNI NPMEENDT AMYFCQ QSKEVPW T FGGGT KLEI K
Pulocimab,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTDAFDIWGQGTMVTVSS,DIQMTQSPSSVSASIGDRVTITCRASQGLDNWLGWYQQKPGKAPKLLIYDASNLDTGVPSRFSGSGSGTYFTLTISSLQAEDFAVYFCQQAKAFPPTFGGGTKVDIK,na,na,None,3s34:HL/3s37:HL/3s36:HL,None,2021,2022,VEGFR2,Akeso Biopharma,na,Solid tumours,na,na,,E VQLVQS GGG LV KPGG SLRLSC AASGF TFSS Y SMNWVR QAPGKG LEWVSS ISSSSS YIYYA DSVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCARV TDAF DI WGQG TMVTVS S,DIQ MT QSPSS VSAS IGD RVTITCR ASQGLDN W LGWYQ QKPGKAP KLLIYD ASNLDTGVPSRFSGSGSGT YFTLTISS LQAED FAVYFCQ QAKAFPPTFGGGT KVDI K
Quavonlimab,Whole mAb,G1,Kappa,Phase-I,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDNWMNWVRQAPGKGLEWLAQIRNKPYNYETYYSASVKGRFTISRDDSKNSVYLQMNSLKTEDTGVYYCTAQFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSENIYGGLNWYQRKPGKSPKLLIYGATNLASGVSSRFSGSGSGTDYTLTISSLQPEDVATYYCQNVLRSPFTFGSGTKLEIK,na,na,None,None,None,2019,2020,CTLA4,Merck,na,Non-small cell lung cancer;Malignant melanoma;Renal cell carcinoma;Solid tumours,na,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TF SDN WMNWVRQ APGKG LEWLAQI RNKPYNYE TYYSASVKGRFTISR DDSKN SVYLQMNSL KTEDTG VYYCTAQFAY WGQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITCR TSENIYGG LNWYQ RKPGKSP KLLIYG ATNLASG VSSRF SGSGSGTD YTLTISS LQP EDVA TYYCQ NVLRSPF T FGSGT KLEI K
Quetmolimab,Whole mAb,G2,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVKQAPGQGLEWIGWIYPGDGSPKFNERFKGRTTLTADKSTNTAYMLLSSLRSEDTAVYFCATGPTDGDYFDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASGNIHNFLAWYQQKPGKAPKLLIYNEKTLADGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQQFWSTPYTFGGGTKVEIK,na,na,None,None,None,2018,2019,CX3CL1,KAN Research Institute;EA Pharma;Eisai Co Ltd,na,Crohn's disease;Rheumatoid arthritis,Primary biliary cirrhosis,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTNYYIHWVK QAPGQG LEWIGWIY PGDGSPKFNERFKG RTTLTA DKSTN TAYMLLSS LRSEDT AVYFCA TGPTDGD YFDY WGQG TTVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASGN IHNFLAWYQ QKPGKAP KLLIYN EKTLADGVPS R FSGSGSGTD YTLTIS SLQ PEDFATYFCQQF WSTPY T FGGGT KVEI K
Quilizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGIAWVRQAPGKGLEWVAFISDLAYTIYYADTVTGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDNWDAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQSLVHNNANTYLHWYQQKPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCSQNTLVPWTFGQGTKVEIK,na,na,3hr5:HL:JQ:BA:IP,None,None,2011,2012,IGHE,Genentech,na,na,Allergic asthma;Allergic rhinitis;Urticaria,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TF SDY GIAWVRQ APGKGL EWVAFI SDLA YTIYYA DTVT GRFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RDNWDAMDYWGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR SSQS LV HNNANT YLHWYQ QKPGKAP KLLIYKV SNRFSGVPS R FSGSGSGT DFTLTISS LQPEDF ATYYC SQNT LV PW T FGQGT KVEI K
Quisovalimab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYNWHWIRQPPGKGLEWIGEITHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCVREIAVAGTGYYGMDVWGQGTTVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGINSAFAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,na,na,None,None,None,2021,2022,TNFSF14,Avalo Therapeutics,na,Crohn's disease;COVID-19,na,na,,QV QLQQW GAGLLKPSE TLSLTCAVY GGSFSGY NWHWIR QPPGKGL EWIGEITH SGSTNYNPSLK SRVTISVD TSKN QFSLKLSS VTAADT AVYYCVREIAV AGTGY YGMDV WGQG TTVTVS S,AI QLT QSPSS LSAS VGD RVTITCR ASQGIN SAFAWYQ QKPGKAP KLLIYD ASSLESGVPS R FSGSGSGTD FTLTIS SLQ PEDFATYYCQQ FNSYP LTF GGGT KVEI K
Racotumomab,Whole mAb,G1,Kappa,Approved,Active,QVQLQQSGAELVKPGASVKLSCKASGYTFTSYDINWVRQRPEQGLEWIGWIFPGDGSTKYNEKFKGKATLTTDKSSSTAYMQLSRLTSEDSAVYFCAREDYYDNSYYFDYWGQGTTLTVSS,DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPWTFGGGTKLEIK,na,na,None,None,None,2008,2009,Idiotope of anti-NeuGc-ganliosides,Center of Molecular Immunology;Elea;Innogene Kalbiotech;Recombio,Non-small cell lung cancer,Neuroblastoma,Breast cancer;Colorectal cancer;Malignant melanoma;Small cell lung cancer;Solid tumours,na,,Q VQLQQ SGA ELV KPGA SVKLSCK ASGY TFTSYDINWVR QRPEQGL EWIGWIF PGDGSTKYNEKFKG KATLTT DKSSS TAYMQLSR LTSEDS AVYFCAR EDYYDNS YYFDY WGQG TTLTVS S,DIQ MTQ TTS SLSA SLGD RVTISCR ASQD ISNYLNWYQ QKPDGT VKLLIYYT SRLHSGVPSRFSGSGSGTD YSLTIS NLE QEDIATYFC QQGNTLP WT FGGGT KLEI K
Radretumab,di-scFv + CH4,E,Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK,na,na,None,None,None,2010,2011,FN extra domain B,Philogen,na,na,Brain cancer;Non-small cell lung cancer;Solid tumours;Haematological malignancies;Hodgkin's disease,na,Radretumab+Bifikafusp+Onfekafusp have identical V domains,E VQLLES GGG LV QPGG SLRLSC AASGF TFSSFSMSWVR QAPGKG LEWVSSIS GSSGT TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA KPFPYFDYWGQG TLVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQSVS SSFLAWY Q QKPGQAP RLLIYYA SSRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYCQ QTGRIPPTFGQGT KVEI K
Rafivirumab,Whole mAb,G1,Lambda,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGGTFNRYTVNWVRQAPGQGLEWMGGIIPIFGTANYAQRFQGRLTITADESTSTAYMELSSLRSDDTAVYFCARENLDNSGTYYYFSGWFDPWGQGTLVTVSS,QSALTQPRSVSGSPGQSVTISCTGTSSDIGGYNFVSWYQQHPGKAPKLMIYDATKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGDYTPGVVFGGGTKLTVL,na,na,None,None,None,2008,2009,RV Antigenic Site III,Crucell;Sanofi Pasteur,na,na,Rabies,Human Phage Display,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT F N RYTVNWVRQ APGQGL EWMGGIIPIF GTANYAQ R FQG RLTITA DESTS TAYMELSS LRSDDT AVYFCAR ENLDNSGT YYYFSGWF DPWGQ GTLVTVS S,QSALTQPR S VSGSPGQ SVTISCT GTSSDIGG YNFVSWYQ QHPGKAP KLMIYD ATKRPSGVPDRFSGSKSGN TASLTIS GLQAEDEAD YYCCS YAGDYTPG VVF GGGT KLTV L
Ragifilimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKGSGYTFTDYAMYWVRQAPGQGLEWIGVIRTYSGDVTYNQKFKDRATMTVDKSISTAYMELSRLRSDDTAVYYCAKSGTVRGFAYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYHCQNDYSYPYTFGQGTKLEIK,na,na,None,None,None,2019,2020,TNFRSF18,Incyte,na,Glioblastoma;Solid tumours,na,na,,Q VQLVQ SGA EVK KPGA SVKVSC KGSGY TF TD YAMYWVRQ APGQGL EWIGVIRTY SGD VTY NQKFKDR ATMTV DKSI STAYMELS RLRSDDT AVYYC AKSG TVRGFAYW GQG TLVTVS S,D IVMT QSPDS LAVS LGER ATINC KSSQ SL LNSGNQKN YLTWYQ QKPGQPP KLLIYWAS TRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYHC QNDYSYPY T FGQGT KLEI K
Ralpancizumab,Whole mAb,G2,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGEIHPSGGRTNYNEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARERPLYASDLWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVHTAVAWYQQKPGKAPKLLIYHASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQRYSLWRTFGQGTKLEIK,na,na,None,None,3sqo:HL,2013,2014,PCSK9,Pfizer,na,na,Hypercholesterolaemia,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYYMHWVR QAPGQG LEWMGEI HPSGGRTNYNEKF KSRVTMTR DTSTS TVYMELS SLRSEDT AVYYCA RERPL YA SDLWGQG TTVTVS S,DIQ MT QSPSS LSA SVGD RVTITCK ASQD VH TAVAWYQ QKPGKAP KLLIYHASYRY TGVPSRFSGSGSGT DFTFTIS SLQ PEDIATYYCQ QRY SLWRT FGQGT KLEI K
Raludotatug,Whole mAb,G1,Kappa,TBC,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTRNFMHWVRQAPGQGLEWMGWIYPGDGETEYAQKFQGRVTITADTSTSTAYMELSSLRSEDTAVYYCARGVYGGFAGGYFDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNIYKNLAWYQQKPGKAPKLLIYDANTLQTGVPSRFSGSGSGSDFTLTISSLQPEDFATYFCQQYYSGWAFGQGTKVEIK,na,na,None,None,None,2022,na,CDH6,TBC,TBC,TBC,TBC,TBC,,E VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTR N FMHWVR QAPGQGL EWMGWIY PGDGET EYAQ K FQG RVTITA DTSTS TAYMELS SLRSEDT AVYYCA RGVYGGFAGG YFDF WGQG TLVTV SS,DIQ MT QSPSS LSA SVGD RVTITCK ASQN IYKNLAWYQ QKPGKAP KLLIYD ANTL Q TGVPSRFSGSGSGSD FTLTIS SLQ PEDFATYFCQQY YSGW A FGQGT KVEI K
Ralzapastotug,Whole mAb,G1,Kappa,TBC,Active,QVQLQESGPGLVKPSGTLSLTCAVSGYSITSGYSWHWVRQPPGKGLEWIGYVHYSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARMDYGNYGGAMDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCKASQDVRTAVAWYQQKPGQAPRLLIYSASYRYTGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYYSTQWTFGGGTKVEIK,na,na,None,None,None,2022,na,TIGIT,TBC,TBC,TBC,TBC,TBC,,QV QLQE SGPG LV KPSG TLSLTCAV SGY SI TSG YSWHWVR QPPGKGL EWIGYVHY SGSTNYNPSLK SRVTISVD KSKN QFSLKLSSV TAADT AVYYCARM DYGNYGGAMDYWGQG TLVTVS S,E IVMT QSPA TLSV SPGE RATLSCK ASQD VR TAVAWYQ QKPGQAP RLLIYSASYRY TGIP ARF SGSGSGT EFTLTISS LQSED FAVYYCQQ YYST QWTF GGG TKVEI K
Ramucirumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTDAFDIWGQGTMVTVSS,DIQMTQSPSSVSASIGDRVTITCRASQGIDNWLGWYQQKPGKAPKLLIYDASNLDTGVPSRFSGSGSGTYFTLTISSLQAEDFAVYFCQQAKAFPPTFGGGTKVDIK,na,na,3s34:HL/3s37:HL/3s36:HL,None,None,2008,2009,KDR,Dyax;AstraZeneca;Dana-Farber Cancer Institute;Eli Lilly;Merck Sharp & Dohme;University of Texas M. D. Anderson Cancer Center;Washington University School of Medicine,Colorectal cancer;Gastric cancer;Non-small cell lung cancer;Liver cancer,Oesophageal cancer;Urogenital cancer;Biliary cancer;Carcinoid tumour;Solid tumours;Pancreatic cancer,Breast cancer;Malignant melanoma;Ovarian cancer;Prostate cancer;Renal cell carcinoma,Dyax Human Phage Display,,E VQLVQS GGG LV KPGG SLRLSC AASGF TFSS Y SMNWVR QAPGKG LEWVSS ISSSSS YIYYA DSVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCARV TDAF DI WGQG TMVTVS S,DIQ MT QSPSS VSAS IGD RVTITCR ASQGIDN W LGWYQ QKPGKAP KLLIYD ASNLDTGVPSRFSGSGSGT YFTLTIS SLQAED FAVYFCQ QAKAFPPTFGGGT KVD IK
Ranevetmab,Canine Whole mAb,G1,Kappa,Unknown,Active,EVQLVESGGGLVQPGGSLRLSCVASGFSLTNNNVNWVRQAPGKGLEWVGGVWAGGATDYNSALKSRFTISRDNAKNTVFLQMHSLRSEDTAVYYCARDGGYSSSTLYAMDAWGQGTSVTVSS,DIVMTQSPASLSLSQGETVTITCRASEDIYNALAWYQQKPGQAPKLLIYNTDTLHTGVPSRFSGSGSGTDFSLTISSLEPEDVAVYYCQHYFHYPRTFGQGTKVELK,na,na,None,None,None,2016,2017,NGFB,Nexvet,na,Osterarthritis,na,PETization Technology,,E VQLVES GGG LV QPGG SLRLSCVA SG FS LTNNN VNWVRQ APGKG LEWV GG VWA GGATDYNSALK SRFTIS RDNAKN TVFLQMHS LRSEDT AVYYCA RDGGYSSS TLYAMD AWGQG TSVTVS S,DI VMT QSPA SLSL SQGE TVTITCR AS EDIYNALAWYQ QKPGQAP KLLIYN TDTLHTGVPSRFSGSGSGTD FSLTIS SLEPE D VAVYYCQ HYFHYPRTFGQGT KVEL K
Ranibizumab,Fab,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,na,na,1cz8:HL:YX,None,1bj1:HL:KJ/6bft:HL:AB,2004,2004,VEGFA,Genentech;Manhattan Eye Ear & Throat Hospital;Novartis Ophthalmics;University of Bonn,Choroidal neovascularisation;Degenerative myopia;Diabetic macular oedema;Retinal oedema;Wet age-related macular degeneration;Diabetic retinopathy,Retinopathy of prematurity;Polypoidal choroidal vasculopathy,Retinal telangiectasis,na,,E VQLVES GGG LV QPGG SLRLSCA ASGYDF THYGMNWVR QAPGKGL EWVGWIN TYTGEPT YA ADFKR RFTFSL DTSKS TAYLQMN SLRAEDT AVYYCA KYPYYYGTS HWYFDV WGQG TLVTVS S,DI QLT QSPSS LSA SVGD RVTITCS ASQD ISNYLNWYQ QKPGKAP KVLIYFT SSLHSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ YSTVPW T FGQGT KVEI K
Ravagalimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYGMNWVRQAPGKGLEWIAYISSGRGNIYYADTVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARSWGYFDVWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNRGNQKNYLTWFQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYTYPLTFGQGTKLEIK,na,na,6pe7:HL/6pe8:HL:AB,None,6pe9:AB:CD:EF:HL:KM,2017,2018,CD40,AbbVie,na,Ulcerative colitis;Sjogren's syndrome,Crohn's disease,na,,E VQLVES GGG LV KPGG SLRLSC AASGF TFS DYGM NWVRQ APGKGL EWIAYIS SGRGN IYYAD TVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCA RSWG YFDV WGQG TTVTVS S,D IVMT QSPDS LAVS LGER ATINC KSSQ SLL NRGNQKN YLTWFQ QKPGQPP KLLIYWAS TRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC QNDYTYP LTF GQGT KLEI K
Ravulizumab,Whole mAb,G2,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGHIFSNYWIQWVRQAPGQGLEWMGEILPGSGHTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK,na,na,None,5i5k:HL:XY,None,2017,2018,C5,Alexion Pharmaceuticals,Paroxysmal nocturnal haemoglobinuria,Haemolytic uraemic syndrome;Myasthenia gravis;IgA nephropathy,na,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGH IF SN YWIQWVR QAPGQG LEWMGEI LPGSGHT EYT ENFKD RVTMTR DTSTS TVYMELS SLRSEDT AVYYCARYF FGSSPN WYFDVW GQG TLVTVS S,DIQMTQSPSSL SA SVGD RVTITC GASEN IYGALNWYQ QKPGKAP KLLIYG ATNLADGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQN VLNTPL T FGQGT KVEI K
Recaticimab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYWMHWVRQAPGQGLEWMGYINPSSGFTKYHQNFKDRVTMTRDTSISTAYMELSRLRSDDTAVYYCARQYDYDEDWYFDVWGQGTTVTVSS,DIVMSQSPSSLSASVGDRVTITCKSSQSLLNSRTRKNFLAWYQQKPGKSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQPEDFATYYCKQSFNLFTFGQGTKLEIK,na,na,None,None,None,2020,2021,PCSK9,Shanghai Hengrui Pharmaceuticals,na,Hypercholesterolemia,na,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTDYWMHWVR QAPGQGL EWMGYI NPSSGFT KY HQNFKDR VTM TRDTS ISTAYMELSR LRSDDT AVYYCARQ YDYDED WYFDVW GQG TTVTVS S,DI VMS QSPSS LSA SVGD RVTITC KSSQ SLL N SRTRKNFLAWYQ QKPGKSPK LLIYWA STRESGVPDRFSGSGSGTD FTLTIS SLQ PEDFAT YYC KQS FNLFTF GQGT KLEI K
Refanezumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGEPTYADDFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARNPINYYGINYEGYVMDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSHSVLYSSNQKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHQYLSSLTFGQGTKLEIK,na,na,None,None,None,2015,2016,MAG,GlaxoSmithKline,na,na,CNS trauma;Stroke,na,,Q VQLVQ SGS E LKKPGA SVKVSCK ASGY TFTN YG MNWVR QAPGQGL EWMGWIN TYTGEPT Y ADDFTG RFVFSL DTSVS TAYLQISS LKAEDT AVYYCA RNPIN Y YG IN YEG YVMDY WGQG TLVTVS S,D IVMT QSPDS LAVS LGE RATINC KSSH SVLYS SNQKN YLAWYQ QKPGQPP KLLIYWA STRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCHQYL SSL T FGQGT KLEI K
Regdanvimab,Whole mAb,G1,Lambda,Approved,Active,QITLKESGPTLVKPTQTLTLTCSFSGFSLSTSGVGVGWIRQPPGKALEWLALIDWDDNKYHTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGQGTTVTVSS,ELVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTELTVL,na,na,7cm4:HL,None,None,2020,2021,SARS-CoV-2 Spike RBD,Celltrion,na,COVID-19,na,na,,Q ITLK ESGP TLV KPTQ TLTLTCSF SG FSLS TSG VGVGWIR QPPGKA LEWLALID WDDNKY HTTSLKTRLTIS KDTSKN QVVLTMT NMDPVDT ATYYCAR IPG FLRY RNR YYYYGMD VWGQG TTVTVS S,EL VLT QPPS V SAAPGQ KVTISC SGSSSNIGNN YVSWYQ QLPGTAP KLLIY DNNKRPSGIPDRFSGSKSGTS ATLGITG LQTGDEAD YYC GTWDSSLSAG VF GGGT ELTV L
Relatlimab,Whole mAb,G4,Kappa,Phase-II/III,Active,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYYWNWIRQPPGKGLEWIGEINHRGSTNSNPSLKSRVTLSLDTSKNQFSLKLRSVTAADTAVYYCAFGYSDYEYNWFDPWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSISSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGTNLEIK,na,na,None,None,None,2018,2019,LAG3,Bristol-Myers Squibb;Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,na,Malignant melanoma;Colorectal cancer;Gastric cancer;Renal cell carcinoma;Solid tumours;Oesophageal cancer;Glioblastoma,Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Hodgkin's disease;Mantle-cell lymphoma;Non-Hodgkin's lymphoma,na,,QV QLQQW GAGLLKPSE TLSLTCAVY GGSFSDY YWNWIR QPPGKGL EWIGEINH RGSTNSNPSLK SRVTLSLD TSKN QFSLKLRSVT AADT AVYYCAF GYSDYEY NWF DPWGQG TLVTVS S,E IVLT QSPA TLSL SPGE RATLSCR ASQS ISSYLAWY QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPE D FAVYYCQ QRSNWPL T FGQGT NLEI K
Relfovetmab,Feline Whole mAb,G1,Kappa,Unknown,Active,DVQLVESGGDLVKPGGSLRLTCVASGFTYSNYWMHWVRQAPGKGLQWVARIDPYGGGTKHNEKFKRRFTISRDNAKNTLYLQMNSLKTEDTATYYCVRSGYDYYFDVWGQGTLVTVSS,EIQMTQSPSSLSASPGDRVTITCRASENIYSFLAWYQQKPGKVPKLLIYNANTLAEGVPSRFSGSGSGTDFTLTISSLEPEDAATYYCQHHFGTPFTFGSGTKLEIK,na,na,None,None,None,2018,2019,NGFB,na,na,na,na,na,,D VQLVE SGGD LV KPGG SLRLTCVA SGF TY SN YWMHWVRQ APGKG LQWVARI DPYGGGTKHNEK FKRRFTISR DNAKN TLYLQMN SLKTEDTA TYYCVR SGYD YYFDVW GQG TLVTVS S,EI QMT QSPSSLSASPGD RVTITCR ASEN IYSFLAWYQ QKPGKVP KLLIYN ANTLAEGVPSRFSGSGSGTD FTLTIS SLE PEDAATYYCQH HFGTPF T FGSGT KLEI K
Remtolumab,Bispecific Dual Variable Domain IG,G1;G1,Kappa;Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIK,EVQLVQSGAEVKKPGSSVKVSCKASGGSFGGYGIGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELSGLTSDDTAVYYCARDPNEFWNGYYSTHDFDSWGQGTTVTVSS,EIVLTQSPDFQSVTPKEKVTITCRASQDIGSELHWYQQKPDQPPKLLIKYASHSTSGVPSRFSGSGSGTDFTLTINGLEAEDAGTYYCHQTDSLPYTFGPGTKVDIK,4nyl:EF:AB:HL:CD/6cr1:HL;None,3wd5:HL;None,None;None,2016,2017,IL17A;TNFA,Abbott Laboratories;Abbvie,na,na,Psoriatic arthritis;Rheumatoid arthritis,Dual Variable Domain Immunoglobulin Technology,,E VQLVES GGG LV QPGR SLRLSC AASGFT F DDY AMHWVRQ APGKGL EWVSAITW NSGH ID YADSVE GRFTISR DNAKN SLYLQMNS LRAEDT AVYYCAKVSYL STASSLD Y WGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQG IRNYLAWYQ QKPGKAP KLLIYAA STLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDVATYYCQR YNRAPY T FGQGT KVEI K
Reozalimab,Bispecific mAb,G1;G1,Kappa;Lambda,TBC,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGLIIPSFDTAGYAQKFQGRVAITVDESTSTAYMELSSLRSEDTAVYYCARAEHSSTGTFDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLISAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANHLPFTFGGGTKVEIK,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARSPDYSPYYYYGMDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCQSYDSSLSGSVFGGGIKLTVL,None;None,None;None,None;None,2022,na,PDCD1;CD274,TBC,TBC,TBC,TBC,TBC,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSSYAISWVR QAPGQGL EWMGLII PSFDTAGY A Q K FQG RVAITV DESTS TAYMELS SLRSEDT AVYYCARAE HSSTG TFDY WGQG TLVTVS S,DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISSWLAWYQ QKPGKAP KLLISA ASSLQSGVPS R FSGSGSGTD FTLTIS SLQ PEDFATYYCQ QANHLP FTF GGGT KVEI K
Reslizumab,Whole mAb,G4,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAVSGLSLTSNSVNWIRQAPGKGLEWVGLIWSNGDTDYNSAIKSRFTISRDTSKSTVYLQMNSLRAEDTAVYYCAREYYGYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCLASEGISSYLAWYQQKPGKAPKLLIYGANSLQTGVPSRFSGSGSATDYTLTISSLQPEDFATYYCQQSYKFPNTFGQGTKVEVK,na,na,None,None,None,2001,2002,IL5,Celltech R&D;Schering-Plough;Allergy and Asthma Clinical Research;Celltech R&D;Teva Pharmaceutical Industries,Asthma,Sinusitis;Churg-Strauss syndrome,Oesophagitis,na,,E VQLVES GGG LV QPGG SLRLSCAV SGL SL TSNS VNWIR QAPGKGL EWVGLIWS NGDTDYNSA IKSRFTIS RDTSKS TVYLQM N S LRAEDT AVYYCARE YYG YFD YWGQG TLVTV SS,DIQMTQSPSS LSA SVGD RVTITCL ASEG ISSYLAWYQ QKPGKAP KLLIYG ANSLQTGVPSRFSGSGSATD YTLTIS SLQ PEDFAT YYCQ QSYKFPNTFGQGT KVEV K
Resugobart,Whole mAb,G4,Kappa,TBC,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNLDWLRQAPGEGLEWIGDIDPNDGDILYNQKFRDRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARRWAYYFDYWGQGTTVTVSS,DIVMTQSPSSLSASVGDRVTITCKASQSVSNDVAWYQQKPGKSPKLLIYYTSNRFTGVPDRFSGSGSGTDFTLTISSLQPEDFATYFCQQDYSSPVTFGGGTKVEIK,na,na,None,None,None,2022,na,SOST,TBC,TBC,TBC,TBC,TBC,,E VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTD YN LDWLR QAPGEGL EWIG DIDPNDGD ILY NQKFRD RVTMTT DTSTS TAYMELRS LRSDDT AVYYCA R RWAYYFD YWGQG TTVTVS S,D IVMT QSPSS LSA SVGD RVTITCK ASQSVSND VAWYQ QKPGKSP KLLIYYT SNRFTGVPDRFSGSGSGTD FTLTISS LQP EDFAT YFC QQDYSSP VTF GGG TKVEI K
Retifanlimab,Whole mAb,G4,Kappa,Preregistration,Active,QVQLVQSGAEVKKPGASVKVSCKASGYSFTSYWMNWVRQAPGQGLEWIGVIHPSDSETWLDQKFKDRVTITVDKSTSTAYMELSSLRSEDTAVYYCAREHYGTSPFAYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASESVDNYGMSFMNWFQQKPGQPPKLLIHAASNQGSGVPSRFSGSGSGTDFTLTISSLEPEDFAVYFCQQSKEVPYTFGGGTKVEIK,na,na,None,None,None,2019,2020,PDCD1,MacroGenics;Incyte Corporation;ZAI Lab,na,Gastic cancers;Oesophageal cancer;Anal cancer;Endometrial cancer;Merkel cell carcinoma;Solid tumours;Colorectal cancer;Acute myeloid leukaemia;Squamous cell cancer;Non-small cell lung cancer;Glioblastoma;Head and neck cancer;Liposarcoma;Pancreatic cancer;Penile cancer;Soft tissue sarcoma,Haematological malignancies,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGYS FTSYWMNWVR QAPGQGL EWIGVI HPSDSET WL DQKFKD RVTITVD KSTS TAYMELS SLRSEDT AVYYCAR EHYGTSPF AYW GQG TLVTVS S,E IVLTQ SPA TLSL SPGE RATLSCRA SESVDNYGM SFMN W F QQKPGQPP KLLIHA ASNQGSGVPS R FSGSGSGTD FTLTIS SLEPED FAVYFC QQSKEVP YT FGGG TKVEI K
Retlirafusp,Whole mAb Fusion,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWMGRIGPNSGFTSYNEKFKNRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGGSSYDYFDYWGQGTTVTVSS,DIVLTQSPASLAVSPGQRATITCRASESVSIHGTHLMHWYQQKPGQPPKLLIYAASNLESGVPARFSGSGSGTDFTLTINPVEAEDTANYYCQQSFEDPLTFGQGTKLEIK,na,na,None,None,None,2020,2021,CD274,Jiangsu Hengrui Medicine,na,Pancreatic cancer;Solid tumours;Head and neck squamous cell carcinoma,na,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYWMHWVR QAPGQG LEWMGRI GPNSGFTSYNEKFKN RVTMTR DTSTS TVYMELS SLRSEDT AVYYCA RGGSSYD YFD YWGQG TTVTVS S,D IVLTQ SPA SLAV SPGQ RATITCR ASE SVSIH G THLMHWYQ QKPGQPP KLLIYAA SNLESGVP ARFS GSGSGT DFTLTIN PVEAEDTA NYYCQQ SFEDPL T FGQGT KLEI K
Revdofilimab,Whole mAb,G1,Kappa,Phase-I,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYGMSWVRQAPGKGLELVATINSNGGRTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGITTAYAMDYWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKASQSVDYDGDSYMHWYQQKPGQPPKLLIYAASILESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPRTFGGGTKVEIK,na,na,None,None,None,2019,2020,TNFRSF4,AbbVie,na,Solid tumours,na,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFSR YG MSWVRQ APGKG LELVATIN SNGG RTY YPDSVKG RFTISR DNAKNS LYLQMN SLRAED TAVYYCA REGI TTAYAMD YWGQG TTVTVS S,D IVMT QSPDS LAVS LGER ATINCK ASQ SV DYDGD SYMHWYQ QKPGQPP KLLIYAASIL ESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQ QSNEDPRTFGGG TKVEI K
Rilotumumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,QVQLQESGPGLVKPSETLSLTCTVSGGSISIYYWSWIRQPPGKGLEWIGYVYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTAVYYCARGGYDFWSGYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVDSNLAWYRQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYINWPPITFGQGTRLEIK,na,na,None,None,None,2009,2010,HGF,Amgen;Astellas Pharma,na,na,Colorectal cancer;Gastric cancer;Glioma;Prostate cancer;Renal cancer;Small cell lung cancer;Solid tumours,Abgenix XenoMouse,,QV QLQE SGPGL V KPSE TLSLTCTV SGGS ISIYYWSWIR QPPGKGL EWIGYVYYS GSTNYNPSLK SRVTISVD TSKN QFSLKL N S VTAADT AVYYCA RGGYDF W SG YF DYWGQG TLVTVS S,E IVMT QSPA TLSV SPGE RATLSCRA SQSVDSN LAWYR QKPGQAP RLLIYG ASTRATGIP ARFS GSGSGT EFTLTISS LQSED FAVYYCQQYI NWPPI T FGQGT RLEI K
Riltovetbart,Whole mAb,G2,Kappa,TBC,Active,EVQLVESGGDLVKPGGSLRLSCVASGFTFSNYGMSWVRQAPGKGLQWVATISYGGSYTYYPDNIKGRFTISRDNAKNTLYLQMNSLRAEDTAMYYCVRGYGYDTMDYWGQGTLVTVSS,EIVMTQSPASLSLSQEEKVTITCKASQSVSFAGTGLMHWYQQKPGQAPKLLIYRASNLEAGVPSRFSGSGSGTDFSFTISSLEPEDVAVYYCQQSREYPWTFGQGTKLEIK,na,na,None,None,None,2022,na,IL31 (Canine),TBC,TBC,TBC,TBC,TBC,,E VQLVE SGGD LV KPGG SLRLSCVA SGF TF SNYG MSWVRQ APGKG LQWVATIS YGGS YTY YPDNIK GRFTISR DNAKN TLYLQMN SLRAEDT AMYYCVR GYGYDTMDYWGQG TLVTVS S,E IVMT QSPA SLS LSQEE KVTITCK ASQ SVSF AGTG LMHWYQ QKPGQAP KLLIYRA SNLEAGVPSRFSGSGSGTD FSFTIS SLEPED VAVYYCQ QSREYPW T FGQGT KLEI K
Rilvegostomig,Bispecific mAb,G1;G1,Kappa;Lambda,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGMHWVRQAPGKGLEWVAYISSGSYTIYSADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRAPNSFYEYYFDYWGQGTTVTVSS,QIVLTQSPATLSLSPGERATLSCSASSKHTNLYWSRHMYWYQQKPGQAPRLLIYLTSNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQWSSNPFTFGQGTKLEIK,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYAGEVKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPLPLHYYGMDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGRRPVNWYQQLPGTAPKLLIYSQNQRPSGVPDRFSGSQSGTSASLAISGLQSEDEADYFCAVWDDIGRVLQLGGGTQLTVL,None;None,None;None,None;None,2022,na,PDCD1;TIGIT,TBC,TBC,TBC,TBC,TBC,,E VQLVES GGG LV QPGG SLRLSC AASGF TF SDYG MHWVRQ APGKG LEWVAYIS SGS YTIYS ADSVKG RFTISR DNAKNS LYLQMNS LRAEDT AVYYCAR RAPNSF YEYYFD YWGQG TTVTVS S,Q IVLTQ SPA TLSL SPGE RATLSCS ASSKHTN LYWSRHMYWYQ QKPGQAP RLLIYLT SNRATGIP ARFS GSGSGT DFTLTISS LEPED FAVYYCQQ WSSNPF TF GQGT KLEI K
Rimteravimab,Mixed Nanobody (VHH-CH2-CH3 dimer),G1,na,Phase-I/II,Active,DVQLVESGGGLVQPGGSLRLSCAASGRTFSEYAMGWFRQAPGKEREFVATISWSGGATYYTDSVKGRFTISRDNAKNTVYLQMNSLRPEDTAVYYCAAAGLGTVVSEWDYDYDYWGQGTLVTVSS,na,na,na,None,None,None,2021,2022,SARS-CoV-2 Spike RBD,ExeVir,na,COVID-19,na,na,Also complementary vs. SARS-CoV Spike RBD and WIV-CoV Spike RBD,D VQLVES GGG LV QPGG SLRLSC AASGRT FSEYAMGWFR QAPGKER EFVATISW SGGA TYYT DSVKG RFTISR DNAKN TVYLQMN SLRPEDT AVYYCA AAGLG TVVSEWD YDYDYWGQG TLVTVS S,NA
Rinucumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,QLQLQESGPGLVKPSETLSLTCTVSGGSITSSSYYWGWIRQPPGKGLEWIGSIYYRGSTNYNPSLKSRVTISVDSSKNQFYLKVSSVTAVDTAVYYCARQNGAARPSWFDPWGQGTLVTVSS,EIVLTQSPDTISLSPGERATLSCRASQSISSIYLAWYQQKPGQAPRLLIYGASSRVTGIPDRFSVSGSGTDFTLTISRLEPEDFAVYYCQHYGISPFTFGPGTKVDIR,na,na,None,None,None,2015,2016,PDGFRB,Regeneron Pharmaceuticals,na,na,Wet age-related macular degeneration,na,,QL QLQE SGPGL V KPSE TLSLTCTV SGGS IT SSS YYWGWIR QPPGKGL EWIGSIYYR GSTNYNPSLK SRVTISVD SSKN QFYLKVSS V T AVDT AVYYCA RQNGAARPS WF DPWGQG TLVTV SS,E IVLTQ SPD TISL SPGE RATLSCR ASQSI S SIYLAWY QQKPGQAP RLLIYG ASSRVTGIPD RFSVS GSGT DFTLTISR LE PEDFAVYYCQHY GISPF T FGPGT KVD IR
Ripertamab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSA,QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIK,na,na,2osl:HL:AB/6y90:HL:CD/6vja:HL:IM,4kaq:HL,None,2019,2020,MS4A1,Sinocelltech,na,Non-Hodgkin's lymphoma,na,na,"Chimeric, Likely to be a Rituximab biosimilar",QV QLQ QPGA ELV KPGA SVKMSCK ASGY TFTSYNMHWVK QTPGRG LEWIGAI YPGNGDTSYNQK F KG KATLTA DKSSST AYMQLS SLTSEDS AVYYCAR S T YYGGD WYFNVW GAGT TVTVS A,Q IVLS QSP AILS ASPGE KVTMTCR ASSS VSYIHWFQ QKPGSSPKP WIYAT SNLASGV PVRFS GSGSGT SYSLTISRVE AEDA ATYYCQQW TSNPPTFGGGT KLEI K
Risankizumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDQTIHWMRQAPGQGLEWIGYIYPRDDSPKYNENFKGKVTITADKSTSTAYMELSSLRSEDTAVYYCAIPDRSGYAWFIYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASRDVAIAVAWYQQKPGKVPKLLIYWASTRHTGVPSRFSGSGSRTDFTLTISSLQPEDVADYFCHQYSSYPFTFGSGTKLEIK,na,na,None,None,None,2015,2016,IL23A,AbbVie;Boehringer Ingelheim,Erythrodermic psoriasis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis,Crohn's disease;Ulcerative colitis;Atopic dermatitis,Psoriasis;Ankylosing spondylitis;Asthma,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TF TDQ TIHWMR QAPGQGL EWIGYIY PRDDSPKYNENFKG KVTITA DKSTS TAYMELSS LRSEDT AVYYCAI PDRSGY AWFIYW GQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCK ASRD VAIAVAWY QQKPGKVP KLLIYWA STRHTGVPSRFSGSGSRTD FTLTIS SLQ PEDVADYFCHQ YSSYPF TF GSGT KLEI K
Rituximab,Whole mAb,G1,Kappa,Approved,Active,QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSA,QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIK,na,na,2osl:HL:AB/6y90:HL:CD/6vja:HL:IM,4kaq:HL,None,1997,1998,MS4A1,Biogen;Biogen Idec;Cedars-Sinai Medical Center;Chugai Pharmaceutical;Genentech;Hackensack University Medical Center;Hoosier Cancer Research Network;Janssen Research & Development;M. D. Anderson Cancer Center;Mayo Clinic;Nagoya University;Oregon Health & Science University;Roche;SCRI Development Innovations;Takeda Oncology;University of Gottingen;University of Texas M. D. Anderson Cancer Center;University of Tours;Zenyaku Kogyo,Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Follicular lymphoma;Idiopathic thrombocytopenic purpura;Lymphoproliferative disorders;Microscopic polyangiitis;Nephrotic syndrome;Non-Hodgkin's lymphoma;Pemphigus vulgaris;Rheumatoid arthritis;Wegener's granulomatosis,Mantle-cell lymphoma;Transplant rejection;Neuromyelitis optica;B-cell lymphoma;Chronic inflammatory demyelinating polyradiculoneuropathy;Glomerulonephritis;Precursor cell lymphoblastic leukaemia-lymphoma;Renal transplant rejection,Multiple sclerosis;Ocular inflammation;Primary biliary cirrhosis;Scleritis;Sjogren's syndrome;Ulcerative colitis;Dermatomyositis;Graft-versus-host disease;Lupus nephritis;Systemic lupus erythematosus,na,,QV QLQ QPGA ELV KPGA SVKMSCK ASGY TFTSYNMHWVK QTPGRG LEWIGAI YPGNGDTSYNQK F KG KATLTA DKSSST AYMQLS SLTSEDS AVYYCAR S T YYGGD WYFNVW GAGT TVTVS A,Q IVLS QSP AILS ASPGE KVTMTCR ASSS VSYIHWFQ QKPGSSPKP WIYAT SNLASGV PVRFS GSGSGT SYSLTISRVE AEDA ATYYCQQW TSNPPTFGGGT KLEI K
Rivabazumab,Fab,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGVVQPGRSLRLSCAASGFTFSNYPMHWVRQAPGKGLEWVAVISYDGSEKWYADSVKGRFTISRDNSKNTLYLEMNSLRPEDTAVYYCARNRGDIYYDFTYAMDIWGQGTTVTVSS,DIQLTQSPSTLSASVGDSVTITCRASEGVDRWLAWYQQKPGRAPKLLIYDASTLQSGVPSRFSGSGSGTEFSLTISSLQPDDVATYYCQHFWGTPYTFGQGTKLEIK,na,na,None,None,None,2015,2016,PcrV type III secretion system,KaloBios Pharmaceuticals Inc,na,na,Infectiology;Inflammation;Inherited diseases,Humaneering Technology,,E VQLVES GGG VV QPGR SLRLSC AASGF TF SNYP MHWVRQ APGKG LEWVAVISY DGSE KWYAD SVKG RFTISR DNSKN TLYLEMN SLRPEDT AVYYCA RNRGD IYYDFTYAMDI WGQG TTVTVS S,DI QLT QSPS TLSAS VGD SVTITCR ASEGVD R WLAWYQ QKPGRAP KLLIYD ASTLQSGVPS R FSGSGSGT EFSLTIS SLQPDDV ATYYCQH FWGTPY T FGQGT KLEI K
Robatumumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSFAMHWVRQAPGKGLEWISVIDTRGATYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLGNFYYGMDVWGQGTTVTVSS,EIVLTQSPGTLSVSPGERATLSCRASQSIGSSLHWYQQKPGQAPRLLIKYASQSLSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCHQSSRLPHTFGQGTKVEIK,na,na,None,None,None,2008,2009,IGF1R,Merck & Co;Schering-Plough,na,na,Colorectal cancer;Osteosarcoma;Sarcoma;Solid tumours,na,,E VQLVQS GGG LV KPGG SLRLSC AASGF TFSSFAMHWVR QAPGKGL EWISVID TRGA TYYAD SVKG RFTIS RDNAKN SLYLQMNS LRAEDT AVYYCAR LGN FYYGMDV WGQG TTVTVS S,E IVLTQ SPG TLSV SPGER ATLSCR ASQSIGS SLHWYQ QKPGQAP RLLIKYA SQSLSGIPDRFSGSGSGTD FTLTISR LEPED FAVYYCH QSSRLPHTFGQG TKVEI K
Rocatinlimab,Whole mAb,G1,Kappa,Phase-III,Active,QITLKESGPTLVKPKQTLTLTCTFSGFSLSTSGMGVGWIRQPPGKALEWLAVIYWDDHQLYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCAHRRGAFQHWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDSSLTFGGGTKVEIK,na,na,None,None,None,2021,2022,TNFRSF4,Kyowa Hakko Kirin,na,Ulcerative colitis;Atopic dermatitis,na,na,,Q ITLK ESGP TLV KPKQ TLTLTCTF SG FSLS TSGM GVGWIR QPPGKA LEWLAVIYW DDHQ L YSPSLK SRLTITK DTSKN QVVLTMT NMDPVDT ATYYCA HRRGA FQH WGQG TLVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSSS YLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQ QYDSS LTF GGG TKVEI K
Roledumab,Whole mAb,G1,Kappa,Phase-II/III,Active,QVQLVESGGGVVQPGRSLRLSCTASGFTFKNYAMHWVRQAPAKGLEWVATISYDGRNIQYADSVKGRFTFSRDNSQDTLYLQLNSLRPEDTAVYYCARPVRSRWLQLGLEDAFHIWGQGTMVTVSS,AIRMTQSPSSFSASTGDRVTITCRASQDIRNYVAWYQQKSGKAPKFLIYAASTLQSGVPSRFSGSGSGTDFTLTINSLQSEDFATYYCQQYYNSPPTFGQGTRVEIT,na,na,None,None,None,2010,2011,RHD,LFB Biotechnologies,na,Haemolytic disease of newborn,na,EMABling Platform,,Q VQLVES GGG VV QPGR SLRLSCT ASGF TFKNYAMHWVRQ APAKGL EWVATISY DGR NIQYA DSVKG RFTFS RDNSQD TLYLQLN SLRPEDT AVYYCA RPVRS RWLQL GLEDA FHIW GQG TMVTVS S,AI RMT QSPSS FS ASTGD RVTITCR AS QDIRNYVAWYQQK SGKAP KFLIYAA STLQSGVPSRFSGSGSGTD FTLTIN SLQSED FATY YC QQY YNSPPTFGQGT RVEI T
Rolinsatamab,Whole mAb ADC,G1,Kappa,Phase-I,Active,EVQLVQSGAEVKKPGSSVKVSCKASGYTFTTYWMHWVRQAPGQGLEWIGEIDPSDSYSNYNQKFKDRATLTVDKSTSTAYMELSSLRSEDTAVYYCARNGGLGPAWFSYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCKASQYVGTAVAWYQQKPGKSPKLLIYSASNRYTGVPSRFSDSGSGTDFTLTISSLQPEDFATYFCQQYSSYPWTFGGGTKVEIK,na,na,None,None,None,2018,2019,PRLR,AbbVie,na,Solid tumours,na,na,,E VQLVQ SGA EVK KPGS SVKVSCK ASGY TFTTYWMHWVR QAPGQG LEWIGEI DPSDSYSNYNQKFKD RATLTVD KSTS TAYMELS SLRSEDT AVYYCA RNGGLGP AWFSY WGQG TLVTVS S,DIQ MT QSPSS VSAS VGD RVTITCK ASQY VGTAVAWYQ QKPGKSP KLLIYS ASNRYTGVPSRFSDSGSGTD FTLTIS SLQ PEDFATYFCQQ YSSYPW T FGGG TKVEI K
Romilkimab,Bispecific Dual Variable Domain IG,G1;G1,Kappa;Kappa,Phase-II,Discontinued,EVQLKESGPGLVAPGGSLSITCTVSGFSLTDSSINWVRQPPGKGLEWLGMIWGDGRIDYADALKSRLSISKDSSKSQVFLEMTSLRTDDTATYYCARDGYFPYAMDFWGQGTSVTVSS,DIVLTQSPASLAVSLGQRATISCRASESVDSYGQSYMHWYQQKAGQPPKLLIYLASNLESGVPARFSGSGSRTDFTLTIDPVQAEDAATYYCQQNAEDSRTFGGGTKLEIK,QVQLQQSGPELVKPGASVKISCKASGYSFTSYWIHWIKQRPGQGLEWIGMIDPSDGETRLNQRFQGRATLTVDESTSTAYMQLRSPTSEDSAVYYCTRLKEYGNYDSFYFDVWGAGTLVTVSS,DIQMTQSPASLSVSVGDTITLTCHASQNIDVWLSWFQQKPGNIPKLLIYKASNLHTGVPSRFSGSGSGTGFTLTISSLQPEDIATYYCQQAHSYPFTFGGGTKLEIK,None;None,None;None,None;None,2017,2018,IL13;IL4,Sanofi,na,na,Idiopathic pulmonary fibrosis;Systemic scleroderma,na,,E VQLKE SGPG LV APGG SLSITCTV SG FS LTDS SINWVR QPPGKGL EWLGMIW GDGR I D YADALKSR LSI SKDSSKS QVFLEMTS LRTDDT ATYYCA RDGYFPY AMD FWGQGT SVTVS S,D IVLT QSPA SLAVS LGQ RATISCR ASESVDSYGQ SYMHWYQQK AGQPP KLLIYLA SNLESGVPA RF SGSGSRTD FTLTI DPVQ AEDAATYYCQQ NAEDSRTFGGGT KLEI K
Romlusevimab,Whole mAb,G1,Lambda,Phase-II/III,Active,QVQLVQSGSELKKPGASVKVSCKASGYTFTTYVMNWVRQAPGQGLEWMGWINTNTGNPTYAQGFTGRFVFSLDTSVSTASLQISSLKAEDTAVYYCSSEITTLGGMDVWGQGTTVTVSS,SYVLTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGNTATLTISGVEAGDEADYYCQVWDSISDHRVFGGGTKLTVL,na,na,None,None,None,2021,2022,SARS-CoV-2 Spike RBD,Brii Biosciences,na,COVID-19,na,na,,Q VQLVQ SGS E LKKPGA SVKVSCK ASGY TFTTYVMNWVR QAPGQGL EWMGWIN TNTGNPTYAQG FTGRFVFSL DTSVS TASLQISS LKAEDT AVYYCS SE ITT LGG MDV WGQG TTVTVS S,SY VL TQPPS VSV APGK TARITC GGNNIGSK SVHWYQ QKPGQAP VLVIYY DSDRPSGIPERFSGSNSGN TATLTISGV EAGDE ADYYCQVWD SISDH RVF GGGT KLTV L
Romosozumab,Whole mAb,G2,Kappa,Approved,NFD,EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMHWVRQAPGQGLEWMGEINPNSGGAGYNQKFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARLGYDDIYDDWYFDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLLSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDTLPYTFGGGTKVEIK,na,na,None,None,None,2011,2012,SOST,ChiroscienceGroup plc;Amgen;UCB,Male osteoporosis;Postmenopausal osteoporosis,na,Fracture,na,,E VQLVQ SGA EVK KPGA SVKVSCK ASGY TFT DYN MHWVRQ APGQG LEWMGEI NPNSGGAGYNQ KFKGRVTMTT DTSTS TAYMELRS LRSDDT AVYYCAR LGYDDIYDD WYFDV WGQG TTVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQD ISNYLNWYQ QKPGKAP KLLIYYT SRLLSGVPS R FSGSGSGTD FTLTIS SLQPE DF ATYYC QQGDTLP YTF GGGT KVEI K
Rontalizumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCATSGYTFTEYIIHWVRQAPGKGLEWVASINPDYDITNYNQRFKGRFTISLDKSKRTAYLQMNSLRAEDTAVYYCASWISDFFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSTSSYSYMHWYQQKPGKAPKVLISYASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSWGIPRTFGQGTKVEIK,na,na,4z5r:WV:BA:UT:SR:KJ:ML:QP:ZY,None,None,2009,2010,IFNA1,Chugai Pharmaceutical;Genentech,na,na,Systemic lupus erythematosus,na,,E VQLVES GGG LV QPGG SLRLSC ATSGY TFTEYIIHWVR QAPGKG LEWVASI NPDYDITNYNQRFK GRFTISL DKSKR TAYLQMN SLRAEDT AVYYCA SWISDFF DYWGQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITCR ASQSVSTSSY SYMHWYQ QKPGKAP KVLISYA SNLESGVPS R FSGSGSGTD FTLTISS LQPED F ATYYCQ HSWGIPRTFGQGT KVEI K
Rosmantuzumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSIHWVRQAPGQGLEWIGYIYPSNGDSGYNQKFKNRVTMTRDTSTSTAYMELSRLRSEDTAVYYCATYFANNFDYWGQGTTLTVSS,DIQMTQSPSSLSASVGDRVTITCKASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISPVQAEDFATYYCQQSNEDPLTFGAGTKLELK,na,na,None,None,None,2016,2017,RSPO3,OncoMed Pharmaceuticals,na,na,Colorectal cancer;Solid tumours,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TF T DYSIHWVRQ APGQG LEWIGYIY PSNGDSGYNQKFKN RVTMTR DTSTS TAYMELSR LRSEDT AVYYCATYF ANNFDYWGQG TTLTVS S,DI QMT QSPSS LSA SVGD RVTITCK ASQS V DYDGD SYMNWYQ QKPGKAP KLLIYAA SNLESGVPSRFSGSGSGTD FTLTIS PVQ AEDFA TYYCQ QSNEDPL TF GAGT KLEL K
Rosnilimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGSELKKPGASVKVSCKASNYTFTDYSMHWVRQAPGQGLEWMGWINIETYYPTYADQFKGRFAFSLDTSVSTAYLQISSLKAEDTAVYYCARDYYGRFYYAMDYWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCTASSSVSSSYFHWYQQKPGQAPRLLIYSTSNLASGIPARFSGSGSGTDFTLTISRLEPEDFAVYYCHQYHRSPLTFGGGTKVEIK,na,na,None,None,None,2022,na,PDCD1,AnaptysBio,na,Alopecia areata;Autoimmune disorders,na,na,,Q VQLVQ SGS E LKKPGA SVKVSCK ASNY TFT DY SMHWVRQ APGQGL EWMGWINIET YYPTYADQFKG RFAFSL DTSVS TAYLQISS LKAEDT AVYYCAR DYYGR FYYAMD YWGQG TTVTVS S,E IVLTQ SPA TLSL SPGE RATLSCTA SSSVSSS YFHWYQ QKPGQAP RLLIYS TSNLASGIP ARFS GSGSGT DFTLTISR LEPED FAVYYCH QYHRSPL TF GGG TKVEI K
Rosopatamab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVQSGPEVKKPGATVKISCKTSGYTFTEYTIHWVKQAPGKGLEWIGNINPNNGGTTYNQKFEDKATLTVDKSTDTAYMELSSLRSEDTAVYYCAAGWNFDYWGQGTLLTVSS,DIQMTQSPSSLSTSVGDRVTLTCKASQDVGTAVDWYQQKPGPSPKLLIYWASTRHTGIPSRFSGSGSGTDFTLTISSLQPEDFADYYCQQYNSYPLTFGPGTKVDIK,na,na,None,None,None,2019,2020,FOLH1,Weill Cornell Medical,na,Prostate cancer;Cancers,na,na,,E VQLVQ SGPEVKKPGA TVKISC KTSGY TFTEYTIHWVK QAPGKG LEWIGNI NPNNGGTT Y NQKFEDK ATLTVD KSTDT AYMELSS LRSEDT AVYYCA AGW NF DYWGQG TLLTVS S,DI QMT QSPSS LS TSVGD RVTLTCK ASQDVGT AVD WY QQKPGPSP KLLIYWA STRHTGIPSRFSGSGSGTD FTLTIS SLQ PEDFADYYCQQ YNSYPL TF GPGT KVDI K
Rovalpituzumab,Whole mAb ADC,G1,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGEPTYADDFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARIGDSSPSDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCKASQSVSNDVVWYQQKPGQAPRLLIYYASNRYTGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQDYTSPWTFGQGTKLEIK,na,na,None,None,None,2015,2016,DLL3,Bristol-Myers Squibb;Stemcentrx,na,na,Small cell lung cancer;Solid tumours,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTN YG MNWVR QAPGQGL EWMGWIN TYTGEPT Y ADDFKG RVTMTT DTSTS TAYMELRSL RSDDT AVYYCARI GDSSPSDYWGQ GTLVTVS S,E IVMT QSPA TLSV SPGE RATLSCK ASQSVSND VVWYQ QKPGQAP RLLIYYA SNRYTG I P ARFS GSGSGT EFTLTISS LQSED FAVYYCQ QDYTSPW T FGQGT KLEI K
Rovelizumab,Whole mAb,G4,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNNWMQWVRQAPGQGLEWMGAIFPGDDETRYTQKFRGKATITADTSTSTAYMELSSLRSEDTAVYYCGRGGKLRPFALDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASESVESYGNNFMYWYQQKPGKAPKLLIYLASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQDNEDPPTFGQGTKLEIK,na,na,None,None,None,1999,2000,CD11,ICOS Corporation,na,na,Adult respiratory distress syndrome;Cerebral vasospasm;CNS trauma;Multiple sclerosis;Myocardial infarction;Peripheral arterial occlusive disorders;Shock;Stroke;Vascular restenosis ,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TF TNN WMQWVR QAPGQGL EWMGAI FPGDDET RYTQKF RG KATITA DTSTS TAYMELS SLRSEDT AVYYC GRGGK L R PFALD YWGQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITCR ASESV ES YGNN FMYWYQ QKPGKAP KLLIYLA SNLESGVPS RF SGSGSGTD FTLTIS SLQPEDF ATYYCH QDNEDPPTFGQGT KLEI K
Rozanolixizumab,Whole mAb,G4,Kappa,Phase-III,Active,EVPLVESGGGLVQPGGSLRLSCAVSGFTFSNYGMVWVRQAPGKGLEWVAYIDSDGDNTYYRDSVKGRFTISRDNAKSSLYLQMNSLRAEDTAVYYCTTGIVRPFLYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKSSQSLVGASGKTYLYWLFQKPGKAPKRLIYLVSTLDSGIPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQGTHFPHTFGQGTKLEIK,na,na,6fgb:HL,None,None,2016,2017,FCGRT,UCB,na,Chronic inflammatory demyelinating polyradiculoneuropathy;Idiopathic thrombocytopenic purpura;Myasthenia gravis,Immunological disorders,na,,EVP LVE SGGG LV QPGG SLRLSCAV SGF TF SNY GMVWVRQ APGKG LEWVAYI DSDGDN TYYRD SVKG RFTIS RDNAKS SLYLQMN SLRAEDT AVYYC TTGI V R PFLYW GQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITC KSSQ SLV GASGK TYLYWLFQ KPGKAPK RLIYLVST LDSGIPS RF SGSGSGT EFTLTISS LQPEDF ATYYCL QGTHFPHTFGQGT KLEI K
Rozibafusp,Whole mAb Fusion,G2,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAYIKQDGNEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGILWFGDLPTFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDSYPRTFGQGTKVEIK,na,na,6x4t:BE:DF,None,None,2018,2019,ICOS,Amgen,na,Systemic lupus erythematosus,Rheumatoid arthritis,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFSSYWMSWVR QAPGKG LEWVAYIK QDGN EKYYVD SVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCA REG ILWF GDLPTFWGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQG ISNWLAWYQ QKPEKAPK SLIYAA SSLQSGVPS RF SGSGSGTD FTLTIS SLQP EDFAT YYCQ QYDSYPRTFGQGT KVEI K
Rulonilimab,Whole mAb,G1,Kappa,Phase-II/III,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYGMSWVRQTPEKRLEWVATISGGGRDTYYPDSVKGRFTISRDNAKNNLYLQMSSLRSEDTALYYCARQKDTSWFVHWGQGTLVTVSS,EIVLTQSPATLAVSPGERATISCRASESVDDYGISFMNWFQQKPGQPPKLLIYVASNQGSGVPARFSGSGSGTDFTLNIHPMEEDDTAMYFCQQSKEVPWTFGGGTKLEIK,na,na,None,None,None,2021,2022,PDCD1,Shandong New Time Pharmaceutical,na,Liver cancer,Lymphoma;Solid tumours,na,,E VQLVES GGG LV KPGG SLRLSC AASGF TFSS YG MSWVR QTPEKR LEWVATIS GGGRDTYYPDSVK GRFTISR DNAKNN LYLQMSS LRSEDT ALYYCAR QKDTS WFVHW GQG TLVTVS S,E IVLT QSPA TLAV SPGE RATISCRA SESVDDY GISFMNWF QQKPGQPP KLLIYVA SNQGSGVP ARFS GSGSGTD FTLNIH PMEEDDT AMYFCQ QSKEVPW T FGGGT KLEI K
Runimotamab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-I,Active,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,EVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVRQAPGQGLEWIGWIYPGDGNTKYNEKFKGRATLTADTSTSTAYLELSSLRSEDTAVYYCARDSYSNYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,1fvc:DC:BA/4hkz:BA/1n8z:BA/4ub0:HL/5xhf:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD/6oge:ED/7mn8:DC;None,1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC;None,5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL;None,2020,2021,ERBB2;CD3E,Genentech,na,Solid tumours,na,na,,E VQLVES GGG LV QPGG SLRLSCA ASGFNIKD TYIHWVRQ APGKG LEWVARIY PTNGY TRYA DSVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYCS RWGGDG FYAMD YWGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQD VNTA VAWYQ QKPGKAP KLLIYSASFLY SGVPSRFSGSRSGTD FTLTIS SLQP EDFAT YYCQ QHYTTPPTFGQGT KVEI K
Ruplizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVVKPGASVKLSCKASGYIFTSYYMYWVKQAPGQGLEWIGEINPSNGDTNFNEKFKSKATLTVDKSASTAYMELSSLRSEDTAVYYCTRSDGRNDMDSWGQGTLVTVSS,DIVLTQSPATLSVSPGERATISCRASQRVSSSTYSYMHWYQQKPGQPPKLLIKYASNLESGVPARFSGSGSGTDFTLTISSVEPEDFATYYCQHSWEIPPTFGGGTKLEIK,na,na,1i9r:HL:KM:XY/6w4w:HL,None,None,2000,2001,CD40LG,Biogen,na,na,Autoimmune disorders;Haemophilia A;Idiopathic thrombocytopenic purpura;Multiple sclerosis;Renal transplant rejection;Systemic lupus erythematosus,na,,Q VQLVQ SGA EVV KPGA SVKLSCK ASG YIFTSYYMYWVKQ APGQG LEWIGEI NPSNGDTNFNEKFKS KATLTV DKSAS TAYMELSS LRSEDT AVYYCTR SDGRNDMDSWGQ GTLVTVS S,D IVLTQ SPA TLSV SPGE RATISCRA SQRVSSST YSYMHWYQ QKPGQPP KLLIKYA SNLESGVP ARFS GSGSGTD FTLTISS VEPEDF ATYYCQ H SWE IPPTFGGG TKLEI K
Sabatolimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGDIYPGNGDTSYNQKFKGRVTITADKSTSTVYMELSSLRSEDTAVYYCARVGGAFPMDYWGQGTTVTVSS,AIQLTQSPSSLSASVGDRVTITCRASESVEYYGTSLMQWYQQKPGKAPKLLIYAASNVESGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQSRKDPSTFGGGTKVEIK,na,na,None,None,None,2019,2020,HAVCR2,Novartis,na,Chronic myelomonocytic leukaemia;Myelodysplastic syndromes;Acute myeloid leukaemia;Myelofibrosis;Solid tumours;Glioblastoma,na,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TFTSYNMHWVRQ APGQG LEWMGDI YPGNGDTSYNQK F K GRVTITA DKSTS TVYMELS SLRSEDT AVYYCARV GGAFPMDYWGQG TTVTVS S,AI QLT QSPSS LSA SVGD RVTITCR ASES VEYY G TSLMQWYQ QKPGKAP KLLIYAA SNVESGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYFCQ QSRKDPSTFGGGT KVEI K
Sacituzumab,Whole mAb ADC,G1,Kappa,Approved,Active,QVQLQQSGSELKKPGASVKVSCKASGYTFTNYGMNWVKQAPGQGLKWMGWINTYTGEPTYTDDFKGRFAFSLDTSVSTAYLQISSLKADDTAVYFCARGGFGSSYWYFDVWGQGSLVTVSS,DIQLTQSPSSLSASVGDRVSITCKASQDVSIAVAWYQQKPGKAPKLLIYSASYRYTGVPDRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHYITPLTFGAGTKVEIK,na,na,None,None,None,2016,2017,TACSTD2,IBC Pharmaceuticals;Immunomedics;University of Wisconsin Comprehensive Cancer Center;Yale University,Breast cancer,Prostate cancer;Solid tumours;Urogenital cancer;Endometrial cancer;Glioblastoma,na,na,,QV QLQQ SGS E LKKPGA SVKVSCK ASGY TFTN YG MNWVK QAPGQGL KWMGWIN TYTGEPT Y TDDFKG RFAFSL DTSVS TAYLQISS LKADDT AVYFCA RGGFGSS YWYFDV WGQG SLVTVS S,DI QLT QSPSS LSA SVGD RVSITCK ASQD VSIAVAWYQ QKPGKAP KLLIYSASYRY TGVPDRFSGSGSGTD FTLTIS SLQPED FAVYYC QQHYITP LTF GAGT KVEI K
Samalizumab,Whole mAb,G2,Kappa,Phase-I,Discontinued,QVQLQQSGSELKKPGASVKISCKASGYSFTDYIILWVRQNPGKGLEWIGHIDPYYGSSNYNLKFKGRVTITADQSTTTAYMELSSLRSEDTAVYYCGRSKRDYFDYWGQGTTLTVSS,DIQMTQSPSSLSASIGDRVTITCKASQDINSYLSWFQQKPGKAPKLLIYRANRLVDGVPSRFSGSGSGTDYTLTISSLQPEDFAVYYCLQYDEFPYTFGGGTKLEIK,na,na,None,None,None,2010,2011,CD200,Alexion Pharmaceuticals;The Leukemia & Lymphoma Society,na,na,Acute myeloid leukaemia;Chronic lymphocytic leukaemia;Multiple myeloma;Solid tumours,na,,QV QLQQ SGS E LKKPGA SVKISCK ASGYSFT DYIILWVR QNPGKG LEWIGHI DPYYGSSNY NLKFK G RVTITA DQSTT TAYMELS SLRSEDT AVYYC GRSKRDY F DYWGQG TTLTVS S,DIQ MT QSPSS LSA SIGD RVTITCK ASQD INSYLSWFQ QKPGKAP KLLIYRA N RLV DGVPS R FSGSGSGTD YTLTISS LQPED FAVYYCLQ YDEFPY T FGGG TKLEI K
Samrotamab,Whole mAb ADC,G1,Kappa,Phase-III,Active,EVQLVQSGAEVKKPGASVKVSCKASGYKFSSYWIEWVKQAPGQGLEWIGEILPGSDTTNYNEKFKDRATFTSDTSINTAYMELSRLRSDDTAVYYCARDRGNYRAWFGYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGGAVKFLIYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQQGEALPWTFGGGTKVEIK,na,na,None,None,None,2017,2018,LRRC15,AbbVie,na,na,Solid tumours,na,,E VQLVQ SGA EVK KPGA SVKVSCK ASGY KFSSYWIEWVK QAPGQG LEWIGEI LPGSDTTNYNEKFKDR ATF TSDTS INTAYMELSR LRSDDT AVYYCA RDRGN YRAWFGY WGQG TLVTV SS,DIQ MT QSPSS LSA SVGD RVTITCR ASQD ISNYLNWYQ QKPGGA VKFLIYYT SRLHSGVPS RF SGSGSGTD YTLTIS SLQ PEDFATY FC QQGEALPW T FGGG TKVEI K
Sarilumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGRSLRLSCAASRFTFDDYAMHWVRQAPGKGLEWVSGISWNSGRIGYADSVKGRFTISRDNAENSLFLQMNGLRAEDTALYYCAKGRDSFDIWGQGTMVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFASYYCQQANSFPYTFGQGTKLEIK,na,na,None,None,None,2011,2012,IL6R,Asahi Kasei Pharma Corp;Regeneron Pharmaceuticals;Sanofi,Rheumatoid arthritis,Juvenile rheumatoid arthritis,Ankylosing spondylitis;COVID-19;Giant cell arteritis;Polymyalgia rheumatica;Uveitis,VelocImmune Mouse,,E VQLVES GGG LV QPGR SLRLSC AASRFTFDDY AMHWVR QAPGKGL EWVSGIS WNSGR IGY ADSVKG RFTIS RDNAENS LFLQM NGLRAEDT ALYYC AKGRDS FDIW GQG TMVTV SS,DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISSWLAWYQ QKPGKAP KLLIYG ASSLESGVPSRFSGSGSGTD FTLTIS SLQ PEDFASYYCQ QANSFPY T FGQGT KLEI K
Sasanlimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWINWVRQAPGQGLEWMGNIYPGSSLTNYNEKFKNRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARLSTGTFAYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLWDSGNQKNFLTWYQQKPGQPPKLLIYWTSYRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYFYPHTFGGGTKVEIK,na,na,6xkr:HL,None,None,2019,2020,PDCD1,Pfizer,na,Bladder cancer;Non-small cell lung cancer;Solid tumours,na,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYWINWVR QAPGQG LEWMGNI YPGSSLTNYNEKFKN RVTMTR DTSTS TVYMELS SLRSEDT AVYYCAR LSTGT FAYW GQG TLVTVS S,D IVMT QSPDS LAVS LGER ATINC KSSQSLWDSGNQKN FLTWYQ QKPGQPP KLLIYWTS YRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC QNDY F YPHTFGGG TKVEI K
Satralizumab,Whole mAb,G2,Kappa,Approved,NFD,QVQLQESGPGLVKPSETLSLTCAVSGHSISHDHAWSWVRQPPGEGLEWIGFISYSGITNYNPSLQGRVTISRDNSKNTLYLQMNSLRAEDTAVYYCARSLARTTAMDYWGEGTLVTVSS,DIQMTQSPSSLSASVGDSVTITCQASTDISSHLNWYQQKPGKAPELLIYYGSHLLSGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCGQGNRLPYTFGQGTKVEIE,na,na,None,None,None,2015,2017,IL6R,Chugai Pharmaceutical;Roche,Neuromyelitis optica,na,Rheumatoid arthritis,na,Satralizumab is the new name for Sapelizumab (PL116),QV QLQE SGPGL V KPSE TLSLTCAV SGHS I SHDH AWSWVR QPPGEGL EWIGFISY SGITNYNPSLQ GRVTISR DNSKN TLYLQMN SLRAEDT AVYYCA RSLARTTAMDYWGEG TLVTVS S,DI QMT QSPSS LSAS VGD SVTITCQA STDISSHLN WYQ QKPGKAP ELLIYY GSHL L SGVPSRFSGSGSGTD FTFTISS LEAEDA ATYYC GQGNRLP YT FGQGT KVEI E
Satumomab,Whole mAb Radiolabelled,G1,Kappa,Approved,NFD,QVQLQQSDAELVKPGASVKISCKASGYTFTDHAIHWAKQKPEQGLEWIGYISPGNDDIKYNEKFKGKATLTADKSSSTAYMQLNSLTSEDSAVYFCKRSYYGHWGQGTTLTVSS,DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYAATNLADGVPSRFSGSGSGTQYSLKINSLQSEDFGSYYCQHFWGTPYTFGGGTRLEIK,na,na,None,1bbj:HL:BA,None,1999,2000,TAG72,Cytogen Corporation,Radionuclide imaging enhancers,na,na,na,,QV QLQ QSDA ELV KPGA SVKISCK ASGY TF T DHAIHWAK QKPEQGL EWIGYI SPGNDDIKYNEKFKG KATLTA DKSSST AYMQL NSLTSEDS AVYFCKR S Y YGHWGQG TTLTVS S,DIQ MT QSPA SLSVS VGE TVTITCR ASEN IYSNLAWYQQ KQGKSP QLLVYAAT NLADGVPS R FSGSGSGT QYSLKI NSLQSEDFGS YYCQHF WGTPY T FGGG TRLEI K
Secukinumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMNWVRQAPGKGLEWVAAINQDGSEKYYVGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCVRDYYDILTDYYIHYWYFDLWGRGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPCTFGQGTRLEIK,na,na,6wio:AB/6wir:AB,None,None,2009,2010,IL17A,Beth Israel Deaconess Medical Center;GWT-TUD GmbH;Icahn School of Medicine at Mount Sinai;Novartis;Alcon,Ankylosing spondylitis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis,Hidradenitis suppurativa;Juvenile rheumatoid arthritis;Non-radiographic axial spondyloarthritis;Rheumatoid arthritis;Alopecia areata;Atopic dermatitis;Giant cell arteritis;Necrobiosis lipoidica;Tendon injuries,Asthma;Crohn's disease;Dry eyes;Multiple sclerosis;Polymyalgia rheumatica;Type 1 diabetes mellitus;Uveitis,Abgenix XenoMouse,,E VQLVES GGG LV QPGG SLRLSC AASGF TFS N YWMNWVR QAPGKG LEWVAAI NQDGS EKYYVGSVKGRFTISR DNAKN SLYLQMNSLRV EDT AVYYCVR DYYDILTD YYIHYWYFD LWGRG TLVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSS S YLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEP EDF AVYYC Q QYGSSPCTFGQGT RLEI K
Selicrelumab,Whole mAb,G2,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPDSGGTNYAQKFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCARDQPLGYCTNGVCSYFDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGIYSWLAWYQQKPGKAPNLLIYTASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANIFPLTFGGGTKVEIK,na,na,None,None,None,2016,2017,CD40,Abramson Cancer Center of the University of Pennsylvania;Roche,na,na,Pancreatic cancer;Solid tumours;Non-Hodgkin's Lymphoma,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTGYYMHWVR QAPGQG LEWMGWI NPDSGGTNY AQKF QG RVTMT RDTS ISTAYMEL NRLRSDDT AVYYCA RDQPLG Y CTNGV CSYFD YWGQG TLVTV SS,DIQ MT QSPSS VSAS VGD RVTITCR ASQG IY SWLAWY QQKPGKAPN LLIYT ASTLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ ANIF PLTF GGG TKVEI K
Semorinemab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGLIFRSYGMSWVRQAPGKGLEWVATINSGGTYTYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCANSYSGAMDYWGQGTLVTVSS,DDVLTQTPLSLPVTPGQPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSLVPWTFGQGTKVEIK,na,na,None,None,None,2018,2019,MAPT,AC Immune;Genentech,na,Alzheimer's disease,na,na,,E VQLVES GGG LV QPGG SLRLSC AASG LIFRSY G MSWVRQ APGKG LEWVATI NSGG TYTY YPDSVK GRFTISR DNSKN TLYLQMN SLRAEDT AVYYCA NSYSGAMDYWGQG TLVTVS S,DDVLTQTPLSLPVTPGQPA SISC RSSQ SIVH SNGN TYLEWYL QKPGQSP QLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCF QGS LV PW T FGQGT KVEI K
Semzuvolimab,Whole mAb,G1,Kappa,TBC,Active,QVQLVQSGPELKKPGASVKVSCKASGYTFTDYVIHWVKQATGQGLEWIGEIYPGSGSAYSNAKFKDRVTMTADKSSNTAYMELSSLTSDDTAVYFCARRGNGTGFAYWGQGTLVTVSS,DIVLTQSPASLAVSLGQRATITCKAGQSVDYDGDSYMNWYQQKPGQPPKLLIYVASNLESGIPARFSGSGSGTDFTLNIHPVEENDAATYYCQQSYKDPLTFGQGTKLEIK,na,na,None,None,None,2022,na,CD4,TBC,TBC,TBC,TBC,TBC,,Q VQLVQ SGPELKKPGA SVKVSCK ASGY TFTDYVIHWVKQ ATGQGL EWIGEI YPGSGSAYSNAKFKD RVTMTA DKSSN TAYMELS SLTSDDT AVYFCAR RGNGT GFAYW GQG TLVTV SS,D IVLT QSPA SLAVS LGQ RATITC KAGQ SVD YDGDS YMNWYQ QKPGQPP KLLIYVA SNLESGIP ARFS GSGSGTD FTLNIHP VEENDA ATYYCQQ SYKDPLTFGQGT KLEI K
Serclutamab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,EVQLQESGPGLVKPSQTLSLTCTVSGYSISRDFAWNWIRQPPGKGLEWMGYISYNGNTRYQPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTASRGFPYWGQGTLVTVSS,DIQMTQSPSSMSVSVGDRVTITCHSSQDINSNIGWLQQKPGKSFKGLIYHGTNLDDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCVQYAQFPWTFGGGTKLEIK,na,na,None,None,None,2016,2017,EGFR,AbbVie,na,na,Solid tumours,na,Losatuxizumab and Serclutamab have identical variable domains,E VQLQE SGPGLVKPSQ TLSLTCTV SG YSI SRD FAWNWIR QPPGKGL EWMGYISY NGNTRYQPSLK SRITISR DTSKN QFFLKLN S V TAADTA TYYCVTA SRGFPYWGQ GTLVTVS S,DIQ MT QSPSS MSVS VGD RVTITCH SSQDINSN IGWLQ QKPGKS FKGLIYH GTNLDDGVPS RF SGSGSGTD YTLTISS LQPEDF ATYYCVQYA QFPWTFGGGT KLEI K
Seribantumab,Whole mAb,G2,Lambda,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYVMAWVRQAPGKGLEWVSSISSSGGWTLYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGLKMATIFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNVVSWYQQHPGKAPKLIIYEVSQRPSGVSNRFSGSKSGNTASLTISGLQTEDEADYYCCSYAGSSIFVIFGGGTKVTVL,na,na,None,None,None,2012,2013,ERBB3,Merrimack Pharmaceuticals;Sanofi,na,na,Breast cancer;Gynaecological cancer;Non-small cell lung cancer;Ovarian cancer;Solid tumours,Dyax Human Phage Display,,E VQLLES GGG LV QPGG SLRLSCA ASGF TFSHYVMAWVR QAPGKG LEWVSSIS SSGG WTLYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYC TRGL KMATIFD YWGQG TLVTVS S,QSALTQPA SV SGSPGQ SITISCT GTSSDVG SYNVVSWYQ QHPGKAP KLIIYEVS QRPSGVSNRFSGSKSGN TASLTIS GLQTEDEAD YYCCS YAGS SIFVIF GGGT KVTV L
Serplulimab,Whole mAb,G4,Kappa,Approved,Active,QVQLVESGGGLVKPGGSLRLSCAASGFTFSNYGMSWIRQAPGKGLEWVSTISGGGSNIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCVSYYYGIDFWGQGTSVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVTTAVAWYQQKPGKAPKLLIYWASTRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYTIPWTFGGGTKLEIK,na,na,7e9b:HL,None,None,2019,2020,PDCD1,Henlix Biotech;Shanghai Henlius Biotech,Solid tumours,Non-small cell lung cancer;Oesophageal cancer;Small cell lung cancer;Hepatitis B;Gastric cancer;Cervical cancer;Hepatitis B;Liver cancer,na,na,,Q VQLVES GGG LV KPGG SLRLSC AASGF TFS NYG MSWIR QAPGKGL EWVSTI SGGGSN IYYA DSVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCVSYYY G IDF WGQG TSVTVS S,DIQ MT QSPSS LSA SVGD RVTITCK ASQDV TTAVAWYQ QKPGKAP KLLIYWA STRHTGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYC QQHY T IP WT FGGGT KLEI K
Setoxaximab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLQQPGPELEKPGASVKLSCKASGYSFTDYNMNWVKQNNGESLEWIGKIDPYYGGPSYNQKFKDKATLTVDKSSSTAYMQLKSLTSEDSAVYYCTRGGNRDWYFDVWGAGTTLTVSA,DIVLSQSPSSLVVSVGEKVTMSCKSSQSLLYSRNQKNYLAWYQQKPGQSPKVLIYWASTRESGVPDRLTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPLTFGAGTKLELK,na,na,None,None,None,2012,2013,Shiga Toxin Type 2,Sunol Molecular Corporation;Uniformed Services University of the Health Sciences;BELLUS Health;Taro Pharmaceuticals Inc,na,na,Haemolytic uraemic syndrome;Shiga-toxigenic Escherichia coli infections,na,,EV QL QQPGPELEKPGA SVKLSCK ASGYS F TDYNM NWVK QNNGE SLEWIGKI DPYYGGPSYNQKFKDK ATLTVD KSSST AYMQLKS LTSEDS AVYYCT RGGNRD WYFDVW GAGT TLTVS A,D IVLS QSPS SLVVS VGE KVTMSC KSSQ SLLYS RNQKN YLAWYQ QKPGQSP KVLIYWAS TRESGVPD RL TGSGSGTD FTLTISS VK AEDL AVYYC QQYYSYP LTF GAGT KLEL K
Setrusumab,Whole mAb,G2,Lambda,Phase-II/III,Active,QVQLVESGGGLVQPGGSLRLSCAASGFTFRSHWLSWVRQAPGKGLEWVSNINYDGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDTYLHFDYWGQGTLVTVSS,DIALTQPASVSGSPGQSITISCTGTSSDVGDINDVSWYQQHPGKAPKLMIYDVNNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCQSYAGSYLSEVFGGGTKLTVL,na,na,None,None,None,2017,2018,SOST,MorphoSys;Novartis;Mereo BioPharma,na,Osteogenesis imperfecta,Hypophosphatasia;Postmenopausal osteoporosis,MorphoSys HuCAL Phage Display,,Q VQLVES GGG LV QPGG SLRLSC AASGF TFRSHWLSWVR QAPGKGL EWVSNIN YDGS STYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYC ARDT YLHFDY WGQG TLVTVS S,DI ALT QPA SV SGSPGQ SITISCT GTSSDVGDIND VSWYQ QHPGKAP KLMIYD VNNRPSGVSNRFSGSKSGN TASLTIS GLQAEDEA D YYC QSY AG SYLSEVF GGGT KLTV L
Sibeprenlimab,Whole mAb,G2,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYTIHWVRQATGQGLEWMGWIYPLRGSINYAQKFQGRVTMTADKSISTVYMELSSLRSEDTAVYFCARHGAYYSNAFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASESVDNDGIRFLHWYQQKPGQAPRLLIYRASTRATGIPARFSGSGSRTEFTLTISSLQSEDFAVYYCQQSNKDPYTFGGGTKVEIK,na,na,None,None,None,2020,2021,TNFSF13,Visterra,na,IgA Nephropathy,na,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TF TD YTIHWVRQ ATGQGL EWMGWIYP LRGS INYA Q KFQG RVTMT ADKS ISTVYMELS SLRSEDT AVYFCA RHGA YY SNAFDYWGQG TLVTV SS,E IVMT QSPA TLSV SPGER ATLSCRAS ESVDNDG IRFLHWYQ QKPGQAP RLLIYRA STRATGIP ARF SGSGSR TEFTLTISS LQSED FAVYYCQ QSNKDPY T FGGG TKVEI K
Sifalimumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYSISWVRQAPGQGLEWMGWISVYNGNTNYAQKFQGRVTMTTDTSTSTAYLELRSLRSDDTAVYYCARDPIAAGYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKVEIK,na,na,4ypg:HL:BA,None,None,2009,2010,IFNA1,Medarex;MedImmune,na,na,Myositis;Psoriasis;Systemic lupus erythematosus,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYSISWVR QAPGQGL EWMGWISVY NGNTNY AQKF QG RVTMTT DTSTS TAYLELRSL RSDDT AVYYCA RDPIAAG Y WGQG TLVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQSVS S TYLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEP ED FAVYYC Q QYGSSPRTFGQGT KVEI K
Siltuximab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGKLLKPGGSLKLSCAASGFTFSSFAMSWFRQSPEKRLEWVAEISSGGSYTYYPDTVTGRFTISRDNAKNTLYLEMSSLRSEDTAMYYCARGLWGYYALDYWGQGTSVTVSS,QIVLIQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPGSSPRLLIYDTSNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCQQWSGYPYTFGGGTKLEIK,na,na,None,None,None,2008,2009,IL6,Centocor Inc;Janssen Biotech;Memorial Sloan-Kettering Cancer Center,Giant lymph node hyperplasia,Multiple myeloma,Paraproteinaemia;Myelodysplastic syndromes;Non-Hodgkin's lymphoma;Prostate cancer;Renal cell carcinoma,na,,E VQLVE SGG KLL KPGG SLKLSC AASGF TFS SFAMSWF RQSPEKR LEWVAEI SSGGS YTY YPDTV TGRFTISR DNAKN TLYLEMS SLRSEDT AMYYC ARGL WGYYALDY WGQGT SVTVS S,Q IVLIQ SPA IMS ASPGE KVTMTCS ASSS VSYMYWYQ QKPGSSP RLLIYD TSNLASGV PVRFS GSGSGT SYSLTISR MEAEDA ATYYCQQ WSGYPY T FGGGT KLEI K
Simaravibart,Whole mAb,G1,Kappa,TBC,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYTISWVRQAPGQGLEWMGRIIPILDRVMYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARRAIDSDTYVEQSHFDYWGQGTLVTVSS,EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPSLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQPLTFGGGTKVEIK,na,na,7s6j:HL:CD:FG/7s6k:HL:CD:FG/7s6l:HL/7sbu:HL,None,None,2022,na,SARS-CoV-2 Spike RBD,TBC,TBC,COVID-19,TBC,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSSYTISWVR QAPGQGL EWMGRI IPILDRVMYAQ KFQG RVTITA DKSTS TAYMELS SLRSEDT AVYYCARRA IDSDT YVEQSHF D Y WGQG TLVTVS S,E IVMT QSPA TLSL SPGE RATLSCR ASQSV S SYLAWYQ QKPGQAP SLLIYD ASNRATG I P ARF SGSGSGT DFTLTIS SLEPED FAVYYC QQPL T FGGG TKVEI K
Simlukafusp,Whole mAb Fusion,G1,Kappa,Phase-I,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAIIGSGASTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGWFGGFNYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVTSSYLAWYQQKPGQAPRLLINVGSRRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQGIMLPPTFGQGTKVEIK,na,na,None,None,None,2019,2020,FAP,Roche,na,na,Malignant melanoma;Renal cell carcinoma;Solid tumours,na,,E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKGL EWVSAII GSGAS TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA KGWFGG FNY WGQG TLVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQSVTS SYLAWYQ QKPGQAP RLLINV GSRRATGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQ QG IM LPPTFGQGT KVEI K
Simridarlimab,Bispecific Mixed mAb/VH-VH-CH2-CH3,G1;G1,Kappa;na,Phase-I,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSIEHYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGKTGSAAWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTVSFPITFGGGTKVEIK,QVQLQESGGGLVQPGGSLRLSCAASAYTISRNSMGWFRQAPGKGLEGVAAIESDGSTSYSDSVKGRFTISLDNSKNTLYLEMNSLRAEDTAVYYCAAPKVGLGPRTALGHLAFMTLPALNYWGQGTLVTVSS,na,None;None,None;None,None;None,2021,2022,CD47;CD274,Innovent Biologics,na,Solid tumours,na,na,,Q VQLQE SGPGL V KPSE TLSLTCTV SGGS IEHYYWSWIR QPPGKGL EWIGYIYYS GSTNYNPSLK SRVTISVD TSKN QFSLKLSS VTAADT AVYYCA RGKTGSAAWGQG TLVTVS S,DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISRWLAWY QQKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQP EDFA TYYC QQ TVSFPITF GGG TKVEI K
Simtuzumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYAFTYYLIEWVRQAPGQGLEWIGVINPGSGGTNYNEKFKGRATITADKSTSTAYMELSSLRSEDTAVYFCARNWMNFDYWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSKSLLHSNGNTYLYWFLQKPGQSPQFLIYRMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQHLEYPYTFGGGTKVEIK,na,na,None,None,None,2012,2013,LOXL2,Arresto Biosciences;Gilead Sciences,na,na,Colorectal cancer;Hepatic fibrosis;Idiopathic pulmonary fibrosis;Liver cirrhosis;Myelofibrosis;Non-alcoholic steatohepatitis;Pancreatic cancer;Primary sclerosing cholangitis,na,,Q VQLVQ SGA EVK KPGA SVKVSC KASGY AFTYYLIEWVR QAPGQG LEWIGVI NPGSGGTNYNEKFKG RATITA DKSTS TAYMELS SLRSEDT AVYFCA RNWMN F DYWGQGT TVTV SS,D IVMT QTP LSLSV TPGQP ASISCR SSK SLLH SNGN TYLYWFLQ KPGQSP QFLIYRM SNLASGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCMQH LEYPY T FGGG TKVEI K
Sintilimab,Whole mAb,G4,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGLIIPMFDTAGYAQKFQGRVAITVDESTSTAYMELSSLRSEDTAVYYCARAEHSSTGTFDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLISAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANHLPFTFGGGTKVEIK,na,na,None,None,None,2018,2019,PDCD1,Adimab;Innovent Biologics;Jiangsu Provincial Peoples Hospital;Sun Yat-Sen University,Hodgkin's disease,Gastric cancer;Non-small cell lung cancer;Oesophageal cancer;Liver cancer;Extranodal NK-T-cell lymphoma;Small cell lung cancer;Solid tumours,na,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSSYAISWVR QAPGQGL EWMGLIIPMF DTAGY A Q K FQG RVAITV DESTS TAYMELS SLRSEDT AVYYCARAE HSSTG TFDY WGQG TLVTVS S,DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISSWLAWYQ QKPGKAP KLLISA ASSLQSGVPS R FSGSGSGTD FTLTIS SLQ PEDFATYYCQ QANHLP FTF GGGT KVEI K
Sirexatamab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYTMSWVRQAPGKGLEWVATISGGGFGTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARPGYNNYYFDIWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCHASDSISNSLHWYQQKPGQAPRLLIYYARQSIQGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSESWPLHFGGGTKVEIK,na,na,None,None,None,2021,2022,DKK1,Leap Therapeutics,na,DKK1,na,na,(June '22: Corrected VH/VL sequences),E VQLVES GGG LV QPGG SLRLSC AASGF TFSSYTMSWVR QAPGKG LEWVATIS GGGFG TY YPDSVK GRFTISR DNAKNS LYLQMNS LRAEDT AVYYCA RPGYNN YYFDIW GQG TTVTVS S,E IVLTQ SPA TLSL SPGE RATLSCH ASDSISNS LHWYQ QKPGQAP RLLIYYAR QSIQGIP ARFS GSGSGTD FTLTIS SLEPED FAVYYCQ QSESWP LHF GGG TKVEI K
Sirtratumab,Whole mAb ADC,G2,Kappa,Phase-I,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNQYYADSVKGRFTISRDNSKNTLFLQMHSLRAEDTAVYYCARGLTSGRYGMDVWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLLSHGFNYLDWYLQKPGQSPQLLIYLGSSRASGVPDRFSGSGSGTDFTLKISRVEAEDVGLYYCMQPLQIPWTFGQGTKVEIK,na,na,None,None,None,2017,2018,SLITRK6,Astellas/Agensys;Seattle Genetics,na,Bladder Cancer,na,na,,Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKGL EWVAVIWY DGSNQ YYAD SVKG RFTISR DNSKN TLFLQMHSL RAEDT AVYYCA RGLTSGR YGMDVW GQG TTVTVS S,DI VMT QSPLSLPVTPGEPA SISC RSSQ SLLLS HGFN YLDWYL QKPGQSP QLLIYL GSSRASGVPDRFSGSGSGT DFTLKISRVE AEDV GLYYCM QPL Q IPW T FGQGT KVEI K
Sirukumab,Whole mAb,G1,Kappa,Preregistration,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSPFAMSWVRQAPGKGLEWVAKISPGGSWTYYSDTVTGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQLWGYYALDIWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCSASISVSYMYWYQQKPGQAPRLLIYDMSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCMQWSGYPYTFGGGTKVEIK,na,na,None,None,None,2011,2012,IL6,Centocor Inc;GlaxoSmithKline;Janssen Biotech,na,COVID-19,Rheumatoid arthritis;Atherosclerosis;Giant cell arteritis;Asthma;Lupus nephritis;Major depressive disorder,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TF SPF AMSWVR QAPGKG LEWVAKI SPGGS WTYYS DTV TGRFTISR DNAKN SLYLQMN SLRAEDT AVYYC ARQL WG YYALDI WGQGT TVTVS S,E IVLTQ SPA TLSL SPGE RATLSCSASISVSYMYWYQ QKPGQAP RLLIYD MSNLASGIP ARFS GSGSGT DFTLTISS LEPED FAVYYCMQ WSGYPY TF GGG TKVEI K
Socazolimab,Whole mAb,G1,Lambda,Preregistration,Active,EVQLVESGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARAPYYYYYMDVWGQGTTVTVSS,QSALTQPASVSGSLGQSVTISCTGSSSDVGSYNLVSWYQQHPGKAPNLMIYDVSKRSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTGISTVVFGGGTKLTVL,na,na,None,None,None,2021,2022,CD274,Sorrento Therapeutics;China Oncology Focus Ltd;Lee's Pharmaceutical,na,Small cell lung cancer;Oesophageal cancer;Osteosarcoma;Urogenital cancer;Cervical cancer;Malignant melanoma,Cancer,na,,E VQLVE SGA EVK KPGS SVKVSCK ASGGT FSSYAISWVR QAPGQGL EWMGGIIPIF GTANYAQKFQG RVTITA DESTS TAYMELS SLRSEDT AVYYCA RAPY YYYYMDV WGQG TTVTVS S,QSALTQPA SVS GSLGQ SVTISCT GSSSDVGS YNLVSWY QQHPGKAPN LMIYD VSKRSGV S NRFSGSKSGN TASLTIS GLQAEDEAD YYCS SYTG ISTVVF GGGT KLTV L
Sofituzumab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGYSITNDYAWNWVRQAPGKGLEWVGYISYSGYTTYNPSLKSRFTISRDTSKNTLYLQMNSLRAEDTAVYYCARWTSGLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASDLIHNWLAWYQQKPGKAPKLLIYGATSLETGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYWTTPFTFGQGTKVEIK,na,na,None,None,None,2013,2014,MUC16,Genentech,na,na,Fallopian tube cancer;Ovarian cancer;Pancreatic cancer;Peritoneal cancer,na,,E VQLVES GGG LV QPGG SLRLSC AASGY SI TNDYA WNWVR QAPGKGL EWVGYISY SGY TTY NPSLK SRFTISR DTSKN TLYLQMN SLRAEDT AVYYCARW TSGLDYWGQG TLVTVS S,DIQ M TQSPSS LSA SVGD RVTITCK ASDLIHNWLAWYQ QKPGKAP KLLIYG ATSLETGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ YWTTPF T FGQGT KVEI K
Solanezumab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYSMSWVRQAPGKGLELVAQINSVGNSTYYPDTVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASGDYWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSLIYSDGNAYLHWFLQKPGQSPRLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK,na,na,None,4xxd:ED:BA,None,2008,2009,APP,Eli Lilly,na,Alzheimer's disease,na,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFSRYSMSWVR QAPGKG LELVAQIN SVGNST Y YPDTV KGRFTISR DNAKN TLYLQMNS LRAEDT AVYYC ASGDYWGQ GTLVTVS S,DV VMT QSPLSLP VT LGQP ASISC RSSQ SLIYS DGN AYLHWFL QKPGQSP RLLIYKV SNRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCS QSTHVPW T FGQGT KVEI K
Solitomab,Bispecific scFv,na;na,Kappa;Kappa,Phase-I,Discontinued,EVQLLEQSGAELVRPGTSVKISCKASGYAFTNYWLGWVKQRPGHGLEWIGDIFPGSGNIHYNEKFKGKATLTADKSSSTAYMQLSSLTFEDSAVYFCARLRNWDEPMDYWGQGTTVTVSS,ELVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPLTFGAGTKLEIK,DVQLVQSGAEVKKPGASVKVSCKASGYTFTRYTMHWVRQAPGQGLEWIGYINPSRGYTNYADSVKGRFTITTDKSTSTAYMELSSLRSEDTATYYCARYYDDHYCLDYWGQGTTVTVSS,DIVLTQSPATLSLSPGERATLSCRASQSVSYMNWYQQKPGKAPKRWIYDTSKVASGVPARFSGSGSGTDYSLTINSLEAEDAATYYCQQWSSNPLTFGGGTKVEIK,None;None,None;None,None;None,2011,2012,EPCAM;CD3E,Micromet Inc;Amgen,na,na,Solid tumours,na,,E VQLLEQ SGA ELV RPGT SVKISCK ASGY AFT N YWLGWVK QRPGHGL EWIG D I FPGSGN IHY NEKFKG KATLTA DKSSS TAYMQLSS L T FEDS AVYFCARL RNWDEPMDYWGQG TTVTVS S,EL VMT QSPS SLTVT AGE KVTMSC KSSQS L LNSGNQK NYLTWYQ QKPGQPP KLLIYWAS TRESGVPDR F TGSGSGTD FTLTISSV QAED LAVYYC QNDYSYP LTF GAGT KLEI K
Sotigalimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFSFSSTYVCWVRQAPGKGLEWIACIYTGDGTNYSASWAKGRFTISKDSSKNTVYLQMNSLRAEDTAVYFCARPDITYGFAINFWGPGTLVTVSS,DIQMTQSPSSLSASVGDRVTIKCQASQSISSRLAWYQQKPGKPPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQCTGYGISWPIGGGTKVEIK,na,na,None,None,None,2020,2021,CD40,Apexigen,na,Pancreatic cancer;Metastatic cancer;Non-small cell lung cancer;Renal cell carcinoma;Gastric adenocarcinoma;Soft-tissue sarcoma;Esophageal carcinoma;Rectal cancer;Malignant melanoma,Brain cancer;Glioma;Solid tumours,na,,Q VQLVES GGG VV QPGR SLRLSCA ASGFS F S STYVCWVRQ APGKG LEWIACIYT GDGTN YSASW AKG RFTISK DSSKN TVYLQMN SLRAED TAVYFCA RPDI TYGFAINFW GPG TLVTVS S,DI QMT QSPSS LSA SVGD RVTIKCQ ASQS I S SRLAWYQ QKPGKPP KLLIYRA STLASGVPS R FSGSGSGTD FTLTISS LQPEDV ATYYCQC TGYG IS WPIGGG TKVEI K
Sotevtamab,Whole mAb,G2,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGATVKISCKVSGFNIKDIYMHWVQQAPGKGLEWMGRIDPAYGNTKYDPKFQGRVTITADTSTDTAYMELSSLRSEDTAVYYCARRYDTAMDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRTRKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSYNLWTFGQGTKLEQL,na,na,None,None,None,2021,2022,CLU,Alethia Biotherapeutics,na,Solid tumours,na,na,,Q VQLVQ SGA EVK KPGA TVKISCKV SGFN I K DIYMHWVQ QAPGKG LEWMGRI DPAYGNTKYDPKFQG RVTITA DTSTDT AYMELS SLRSEDT AVYYCARR YDTAMDYWGQG TLVTVS S,D IVMT QSPDS LAVS LGER ATINC KSS QSLL NSRT RKNYLAWYQ QKPGQPP KLLIYWA STRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCK QSYN LWTF GQGTK LE QL
Sotrovimab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYPFTSYGISWVRQAPGQGLEWMGWISTYQGNTNYAQKFQGRVTMTTDTSTTTGYMELRRLRSDDTAVYYCARDYTRGAWFGESLIGGFDNWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQTVSSTSLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHDTSLTFGGGTKVEIK,na,na,None,7jx3:AB:CD:HL/6ws6:AB:CD:EF/6wps:CD:FG:HL/6wpt:DE:HL/7bep:HL:GI/7jwl:DC:GF:HL/7l0n:CD:AB/7nd8:HL/7r6x:AB/7r6w:AB/7tly:AB/7tm0:ED:GF:IH/7tn0:BA:CD,7sob:GI:HJ:NO/7soc:HL,2020,2021,SARS-CoV-2 Spike RBD,GlaxoSmithKline;Vir Biotechnology,COVID-19,na,na,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGYPFT SYGISWVRQ APGQGL EWMGWISTY QGNTNY AQKF QG RVTMTT DTSTTT GYMELRRL RSDDT AVYYCAR DYTRGA WF GE SLI GG F DNWGQG TLVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQ TV SST SLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQ QHDT SLTF GGG TKVEI K
Spartalizumab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYWMHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKNRVTITADKSTSTAYMELSSLRSEDTAVYYCTRWTTGTGAYWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCKSSQSLLDSGNQKNFLTWYQQKPGQAPRLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQNDYSYPYTFGQGTKVEIK,na,na,None,None,None,2017,2018,PDCD1,Asan Medical Center;Dana-Farber Cancer Institute;Novartis;Novartis Oncology;Palobiofarma;Seoul National University Hospital,na,Malignant melanoma;Breast cancer;Colorectal cancer;Diffuse large B cell lymphoma;Gastric cancer;Nasopharyngeal cancer;Non-small cell lung cancer;Solid tumours;Acute myeloid leukaemia;Cancer;Liver cancer;Lymphoma;Multiple myeloma;Myelodysplastic syndromes;Ovarian cancer;Pancreatic cancer;Renal cancer,Neuroendocrine tumours,na,,E VQLVQ SGA EVK KPGE SLRISC KGSGY TFTTYWMHWVRQ ATGQG LEWMGNI YPGTGGSNFDEKFKN RVTITA DKSTS TAYMELSS LRSEDT AVYYCTRWT TGTGA YW GQG TTVTVS S,E IVLT QSPA TLSL SPGE RATLSC KSSQS L LDSGNQKN FLTWYQ QKPGQAP RLLIYWAS TRESGVPS RF SGSGSGTD FTFTISS LEAEDA A TYYC QNDYSYPY T FGQGT KVEI K
Spesolimab,Whole mAb,G1,Kappa,Preregistration,Active,QVQLVQSGAEVKKPGASVKVSCKASGYSFTSSWIHWVKQAPGQGLEWMGEINPGNVRTNYNENFRNKVTMTVDTSISTAYMELSRLRSDDTAVYYCTVVFYGEPYFPYWGQGTLVTVSS,QIVLTQSPGTLSLSPGERATMTCTASSSVSSSYFHWYQQKPGQAPRLWIYRTSRLASGVPDRFSGSGSGTDFTLTISRLEPEDAATYYCHQFHRSPLTFGAGTKLEIK,na,na,6u6u:HL,None,None,2018,2019,IL36RN,Boehringer Ingelheim,na,Ulcerative colitis;Atopic dermatitis;Crohn's disease;Palmoplantar pustulosis;Pustular psoriasis,na,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY SFTSSWIHWVK QAPGQGL EWMGEI NPGNV RT NYNENFRN KVTMTV DTSI STAYMELSRL RSDDT AVYYCTVVFY GEPYFPYWGQ GTLVTVS S,Q IVLTQ SPG TLSL SPGER ATMTCTA SSSVSSS YFHWYQ QKPGQAP RLWIYRT SRLASGVPDRFSGSGSGT DFTLTISR LEPEDAA TYYCHQ FHRSPL TF GAGT KLEI K
Stamulumab,Whole mAb,G1,Lambda,Phase-I/II,Discontinued,EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDENWGFDPWGQGTLVTVSS,SYELTQPPSVSVSPGQTASITCSGHALGDKFVSWYQQKPGQSPVLVIYDDTQRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSFVFGGGTKVTVL,na,na,None,None,None,2006,2006,GDF8,Cambridge Antibody Technology;Wyeth,na,na,Muscular dystrophies;Sarcopenia,na,,E VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYYMHWVR QAPGQG LEWMGII NPSGGSTSY AQKF QG RVTMTR DTSTS TVYMELS SLRSEDT AVYYCA RDENWGFDPWGQG TLVTVS S,SYELTQPPS VSV SPGQ TASITC SGHALGD KFVSWYQ QKPGQSP VLVIY DDTQRPSGIPERFSGSNSGN TATLTIS GTQAMDEAD YYCQA WDSS FVF GGGT KVTV L
Suciraslimab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLQESGGGLVKPGGSLKLSCAASGFAFSIYDMSWVRQTPEKRLEWVAYISSGGGTTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARHSGYGSSYGVLFAYWGQGTLVTVSS,DIQLTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSILHSGVPSRFSGSGSGTDYSLTISNLEQEDFATYFCQQGNTLPWTFGGGTKLEIK,na,na,None,None,None,2021,2022,CD22,Lonn Ryonn Pharma; SinoMab Bioscience Ltd,na,Rheumatoid arthritis;Non-Hodgkin's lymphoma;Systemic lupus erythematosus;Sjogren's syndrome,na,na,,Q VQLQE SGGG LV KPGG SLKLSC AASGF AFSIYD M SWVR QTPEKR LEWVAYIS SGGGT TY YPDTV KGRFTISR DNAKN TLYLQMS SLKSEDT AMYYCAR HSGYGSSY GVLFAYW GQG TLVTVS S,DI QLTQ TTS SLS ASLGD RVTISCR ASQD ISNYLNWYQ QKPDGT VKLLIYYTSIL HSGVPSRFSGSGSGTD YSLTIS NLEQE DFATY FC QQGNTLP WT FGGGT KLEI K
Sudubrilimab,Whole mAb,G1,Kappa,Unknown,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSETWLHWVRQAPGKGLEWVAWVSPFGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFLYHPATFGQGTKVEIK,na,na,None,None,5x8l:GL:FK:SN:HM:JO/5xxy:HL,2020,2021,CD274,Zhejiang Hisun Pharmaceutical,na,TBC,TBC,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFS E TWLHWVR QAPGKG LEWVAWV SPFGGS TYYAD SVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYCAR RHWPGGFD Y WGQG TLVTV SS,DIQ MT QSPSS LSA SVGD RVTITCR ASQD VSTA VAWYQ QKPGKAP KLLIYSASFLY SGVPSRFSGSGSGTD FTLTIS SLQ PEDFATY YCQQFLY HPATFGQGT KVEI K
Sugemalimab,Whole mAb,G4,Lambda,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGISGSGGFTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPPRGYNYGPFDYWGQGTLVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL,na,na,None,None,None,2019,2020,PDL1,Cstone Pharmaceuticals,Non-small cell lung cancer,Cancers;T-cell Lymphoma;Solid tumours;Hodgkin Lymphoma;Gastric cancer,na,na,,E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKG LEWVS GISGSGG FTYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA KPPRGYNYGPFDYWGQG TLVTVS S,SY VL TQPPS VSV APGQ TARITC GGNNIGSK SVHWYQ QKPGQAP VLVVY DDSDRPSGIPE R FSGSNSGN TATLTISRVE AGDE ADYYCQVWD SSSD HVVFG GGT KLTV L
Suptavumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,EVQLVESGGDLVQPGRSLRLSCVASGFTFDDYAMHWVRQAPGKGLEWVSGVSWSGSTVGYADSVKGRFTVSRDNAQKSLYLQMNSLRAEDTALYYCVKDAYKFNYYYYGLDVWGQGTTVTVSS,EIVMTQSPATLSVSPGERATLSCRASQTILSNLAWYLQKPGQAPRLLIYGASTRATGLPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKVEIK,na,na,None,None,None,2016,2017,RSV gpF,Regeneron Pharmaceuticals,na,na,Respiratory syncytial virus infections,VelocImmune Mouse;VelociGene,,E VQLVE SGGD LV QPGR SLRLSCVA SGFTFDDY AMHWVR QAPGKG LEWVSGVS WSGS TVGY ADSVKG RFTVS RDNAQK SLYLQMN SLRAEDT ALYYCVK DAYKFN YYYYGLDV WGQG TTVTVS S,E IVMT QSPA TLSV SPGE RATLSCR AS QTILSNLAWYL QKPGQAP RLLIYG ASTRATGLP ARF SGSGSGT EFTLTISS LQSED FAVYYCQ QYNNWP LTF GGG TKVEI K
Surzebiclimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYAMSWVRQAPGKGLEWVAAISSGGSLYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARGREADGGYFDYWGQGTLVTVSS,EIVLTQSPATLSVSPGERATLSCRASESVEYYGTSLMQWYQQKPGQAPRLLIYAASNVESGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQSLKVPLTFGGGTKVEIK,na,na,None,None,None,2020,2021,HAVCR2,BeiGene,na,Solid tumours,na,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFSRYAMSWVR QAPGKGL EWVAAIS SGGS LY YPDSVK GRFTISR DNAKN TLYLQMNS LRAEDT AVYYCA RGREADGG YFDY WGQG TLVTVS S,E IVLT QSPA TLSV SPGE RATLSCR ASES VEYY GT S LMQWY QQKPGQAP RLLIYAA SNVESGIP ARFS GSGSGT EFTLTISS LQSED FAVYYCQ QSLKVP LTF GGG TKVEI K
Sutimlimab,Whole mAb,G4,Kappa,Approved,NFD,EVQLVESGGGLVKPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVATISSGGSHTYYLDSVKGRFTISRDNSKNTLYLQMNSLRAEDTALYYCARLFTGYAMDYWGQGTLVTVSS,QIVLTQSPATLSLSPGERATMSCTASSSVSSSYLHWYQQKPGKAPKLWIYSTSNLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCHQYYRLPPITFGQGTKLEIK,na,na,None,None,None,2017,2018,C1S,Bioverativ;True North Therapeutics,Autoimmune haemolytic anaemia,na,Idiopathic thrombocytopenic purpura;Bullous pemphigoid;Renal transplant rejection,na,,E VQLVES GGG LV KPGG SLRLSC AASGF TFS NY AMSWVR QAPGKG LEWVATIS SGGS HTYYLD SVKG RFTISR DNSKN TLYLQMN SLRAED TALYYCARLF TGY AM DYWGQG TLVTV SS,Q IVLTQ SPA TLSL SPGER ATMSCTA SSSVSSS YLHWYQ QKPGKAP KLWIYS TSNLASGVPS R FSGSGSGTD YTLTISS LQP EDFAT YYCHQYY RLPPI T FGQGT KLEI K
Suvizumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNSWIGWFRQAPGQGLEWIGDIYPGGGYTNYNEIFKGKATMTADTSTNTAYMELSSLRSEDTAVYYCSRGIPGYAMDYWGQGTLVTVSS,DIQMTQRPDSLSASVGDRVTMSCKSSQSLLNSGDQKNYLTWYQQKPGQPPKLLIYWASTGESGVPDRFSGSGSGTDFTFTISSLQPEDIATYYCQNDYSYPWTFGQGTKVEIK,na,na,3ntc:HL,None,None,2009,2010,HIV-1 gp120,Kaketsuken;Kumamoto University;University of Missouri-Columbia,na,na,HIV-1 infections,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFT NS WIGWFR QAPGQGL EWIGDI YPGGGYTNYN EIF KG KATMTA DTSTN TAYMELS SLRSEDT AVYYC SRGIPGY AMD YWGQG TLVTV SS,DIQ M TQRPDS LSAS VGD RVTMSC KSSQS L LNSGDQKN YLTWYQ QKPGQPP KLLIYWA STGESGVPDRFSGSGSGTD FTFTIS SLQ PEDIA TYYC QNDYSYPW T FGQGT KVEI K
Suvratoxumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSHDMHWVRQATGKGLEWVSGIGTAGDTYYPDSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARDRYSPTGHYYGMDVWGQGTTVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCKQYADYWTFGQGTKVEIK,na,na,4u6v:HL:KM,None,None,2016,2017,Toxin A,Biosynexus;GlaxoSmithKline;Regeneron Pharmaceuticals;MedImmune,na,Nosocomial pneumonia,na,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFS SHDM HWVRQ ATGKGL EWVS GIGTAGDT Y YPDSVK GRFTIS RENAKNS LYLQMNS LRAGD TAVYYCA RDRYSPTGH YYGMDV WGQG TTVTVS S,DIQ M TQSPS TLSAS VGD RVTITCR ASQS ISSWLAWYQ QKPGKAP KLLIYKA SSLESGVPS R FSGSGSGT EFTLTIS SLQPDD FA TYYC K QYAD YWTF GQGT KVEI K
Tabalumab,Whole mAb,G4,Kappa,Phase-III,Discontinued,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGYYDILTGYYYYFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSRYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDSTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIK,na,na,None,None,None,2011,2012,TNFSF13B,Eli Lilly,na,na,Multiple myeloma;Multiple sclerosis;Renal failure;Rheumatoid arthritis;Systemic lupus erythematosus,na,,QV QLQQW GAGLLKPSE TLSLTCAVY GGSFS GYYWSWIR QPPGKGL EWIGEIN HSGSTNYNPSLK SRVTISVD TSKN QFSLKLSS VTAADT AVYYCA RGY YD ILTG YYYYFDY WGQG TLVTVS S,E IVLT QSPA TLSL SPGE RATLSCR ASQS VSRYLAWYQ QKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTDS TLTIS SLEPED FAVYYCQ QRSNWPRTFGQGT KVEI K
Tabituximab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,EVQLQQSGAELVKPGASVKLSCTASGFNINDTYMHWVKQRPEQGLEWIGRIDPANGNTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCARGARGSRFAYWGQGTLVTVSA,DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYVATNLADGVPSRFSGSGSGTQYSLKINSLQSEDFGSYYCQHFWGTPYTFGGGTKLEIK,na,na,None,None,None,2018,2019,FZD10,OncoTherapy Science;Centre Leon Berard,na,na,Synovial sarcoma,na,,E VQLQQ SGA ELV KPGA SVKLSCT ASGFNINDT YMHWVK QRPEQGL EWIGRI DPANGNTKYDPKFQG KATITA DTSSN TAYLQLS SLTSEDT AVYYCA RGARGS RFAYW GQG TLVTVS A,DIQ MT QSPA SLSVS VGE TVTITCR ASEN IYSNLAWYQQ KQGKSPQ LLVYVAT NLADGVPS RF SGSGSGT QYSLKI NSLQSEDFGS YYCQHF WGTPY T FGGGT KLEI K
Tacatuzumab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,QVQLQQSGAEVKKPGSSVKVSCKASGYAFTSYVIHWVRQAPGQGLYWIGYIHPYNGGTKYNEKFKGKATITADESTNTAYMELSSLRSEDTAFYFCARSGGGDPFAYWGQGSLVTVSS,DIQLTQSPSSLSASVGDRVTITCKASQDINKYIGWYQQKPGKAPKLLMHYTSALLPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDDLWTFGGGTKLQIK,na,na,None,None,None,2005,2006,Alpha Ferroprotein,Immunomedics,na,na,Liver cancer,na,,Q VQLQQ SGA EVK KPGS SVKVSCK ASGY AFTSYVIHWVR QAPGQG LYWIGYIH PYNGGTKYNEKFKG KATITA DESTN TAYMELS SLRSEDT AFYFCAR SGGGDPF AYW GQG SLVTV SS,DI QLT QSPSS LSA SVGD RVTITCK ASQD INKY IGWYQ QKPGKAP KLLMHYT SALLPGIPSRFSGSGSGRD YTFTIS SLQPEDI ATYYCLQ YDD LWTF GGGT KLQI K
Tadocizumab,Fab,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGYAFTNYLIEWVRQAPGQGLEWIGVIYPGSGGTNYNEKFKGRVTLTVDESTNTAYMELSSLRSEDTAVYFCARRDGNYGWFAYWGQGTLVTVSS,DIQMTQTPSTLSASVGDRVTISCRASQDINNYLNWYQQKPGKAPKLLIYYTSTLHSGVPSRFSGSGSGTDYTLTISSLQPDDFATYFCQQGNTLPWTFGQGTKVEVK,na,na,None,None,None,2005,2006,ITGA2B_ITGB3,PDL BioPharma;Yamanouchi,na,na,Coronary artery restenosis;Stroke;Thrombosis,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGY AFTNY LIEW V R QAPGQGL EWIGVIY PGSGGTNYNEKFKG RVTLTVD ESTN TAYMELSS LRSEDT AVYFCAR RDGN YGWFAYW GQG TLVTVS S,DIQMTQTPS TLSAS VGD RVTISCR ASQD INNYLNWYQ QKPGKAP KLLIYYT STLHSGVPSRFSGSGSGTD YTLTIS SLQPDD FA TYFC QQGNTLPW T FGQGT KVEV K
Tafasitamab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSS,DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK,na,na,None,None,None,2018,2019,CD19,MorphoSys;The Ohio State University Comprehensive Cancer Center;Xencor,Diffuse large B cell lymphoma,Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma;Follicular lymphoma;Marginal zone B-cell lymphoma,na,MorphoSys HuCAL Phage Display;XmAb Engineering Technology,,E VQLVES GGG LV KPGG SLKLSC AASGY TFTSYVMHWVR QAPGKGL EWIGYI NPYNDGTKYNE KF Q GRVTIS SDKS ISTAYMELS SLRSEDT AMYYC ARGT YYY G TRVFD YWGQG TLVTVS S,D IVMT QSPA TLSL SPGE RATLSCR SSKSL Q NVNGN TYLYWFQ QKPGQSP QLLIYRM SNLNSGVPDRFSGSGSGT EFTLTIS SLEPED FAVYYCM QHLEYP ITF GAGT KLEI K
Tafolecimab,Whole mAb,G2,Kappa,Preregistration,Active,QLQLQESGPGLVKPSETLSLTCTVSGGSISSASYYWSWIRQPPGKGLEWIGSINYRGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARENSGVVPAAGPNWFGPWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRRNWFTFGGGTKVEIK,na,na,None,None,None,2019,2020,PCSK9,Innovent Biologics,na,Hypercholesterolaemia,na,na,,QL QLQE SGPGL V KPSE TLSLTCTV SGGSISSA SYYWSWIR QPPGKGL EWIGSINY RGS TYY NPSLKS RVTISVD TSKN QFSLKLSS VTAADT AVYYCAR ENSGVVPAAGPNWFGPWGQG TLVTVS S,E IVLTQ SPA TLSL SPGE RATLSCR ASQS VSSY LAWY QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPE D FAVYYCQ QRRN WFTF GGG TKVEI K
Tagitanlimab,Whole mAb,G1,Kappa,Preregistration,Active,QVQLQESGPGLVKPSETLSITCTVSGFSLSNYDISWIRQPPGKGLEWLGVIWTGGATNYNPALKSRLTISRDNSKNQVSLKMSSVTAADTAVYYCVRDSNYRYDEPFTYWGQGTLVTVSS,EIVLTQSPDTLSVTPKEKVTLTCRASQSIGTNIHWFQQKPGQSPKLLIKYASESISGVPSRFSGSGSGTDFTLTINSVEAEDAATYYCQQSNSWPYTFGQGTKLEIK,na,na,None,None,None,2021,2022,CD274,Sichuan Kelun-Biotech Biopharmaceutical,na,Hodgkin Lymphoma;Nasopharyngeal Carcinoma,na,na,(June '22: Corrected FWL4 sequence),Q VQLQE SGPGL V KPSE TLSITCTV SGF S LSN YDISWIR QPPGKGL EWLGVIWT GGATNYNPALK SRLTISR DNSKN QVSLKMSS VTAADT AVYYCVR DSNYRYDEPF TYW GQG TLVTVS S,E IVLTQ SPD TLSV TPKE KVTLTCR ASQSIGT NIHWFQ QKPGQSP KLLIKYA SESISGVPS R FSGSGSGT DFTLTINSV EAEDA ATYYCQ QSNSWP YT FGQGT KLEI K
Talacotuzumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFTDYYMKWARQMPGKGLEWMGDIIPSNGATFYNQKFKGQVTISADKSISTTYLQWSSLKASDTAMYYCARSHLLRASWFAYWGQGTMVTVSS,DIVMTQSPDSLAVSLGERATINCESSQSLLNSGNQKNYLTWYQQKPGQPPKPLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPYTFGQGTKLEIK,na,na,4jzj:HL:AB,None,None,2017,2018,IL3RA,CSL;Janssen Biotech,na,Myelodysplastic syndromes,Acute myeloid leukaemia;Systemic lupus erythematosus,na,,E VQLVQ SGA EVK KPGE SLKISC KGSGYS FTDYYMKWARQ MPGKGL EWM GD II PSNGA TFY NQKFKG QVTIS ADKS ISTTYLQWS SLKASDT AMYYC ARSHL LRASWFAYW GQG TMVTV SS,D IVMT QSPDS LAVS LGE RATINC ESSQ SL LNSGNQKN YLTWYQ QKPGQPPKP LIYWAS TRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC QNDYSYPY T FGQGT KLEI K
Talizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFSMYWLEWVRQAPGHGLEWVGEISPGTFTTNYNEKFKARATFTADTSTNTAYMELSSLRSEDTAVYYCARFSHFSGSNYDYFDYWGQGTLVTVSS,DILLTQSPGTLSLSPGERATLSCRASQSIGTNIHWYQQKPGQAPRLLIKYASESISGIPSRFSGSGSGTDFTLTISRLEPEDFAMYYCQQSDSWPTTFGQGTKVEIK,na,na,None,None,None,2002,2004,IgE,Tanox,na,na,Peanut hypersensitivity,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFSMYWLEWVR QAPGHG LEWVGEI SPGT FTT NYNEK FKARATFTA DTSTN TAYMELSS LRSEDT AVYYCARFS HFSGSNYD YFDY WGQG TLVTVS S,D ILLTQ SPG TLSL SPGE RATLSCR ASQSIGT NIHWYQ QKPGQAP RLLIKYA SESISGIPSRFSGSGSGTD FTLTISR LEPED FAMYYCQ QSDSWPTTFGQG TKVEI K
Talquetamab,Bispecific mAb,G4;G4,Kappa;Lambda,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYSFTGYTMNWVRQAPGQGLEWMGLINPYNSDTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARVALRVALDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVATHVGWYQQKPGKAPKRLIYSASYRYSGVPSRFSGSGSGTEFTLTISNLQPEDFATYYCQQYNRYPYTFGQGTKLEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYAASVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARHGNFGNSYVSWFAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2019,2020,GPRC5D;CD3E,Genmab;Janssen Research & Development,na,Multiple myeloma,na,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY SFTGYTMNWVR QAPGQG LEWMGLI NPYNSDTN YAQ K LQG RVTMTT DTSTS TAYMELRS LRSDDT AVYY CARVALRVALDY WGQG TLVTV SS,DI QMT QSPSS LSA SVGD RVTITCK ASQN VATHVGWYQ QKPGKAPK RLIYSASYRY SGVPSRFSGSGSGT EFTLTIS NLQ PEDFA TYYCQ QYNRYPY T FGQGT KLEI K
Tamgiblimab,Whole mAb,G4,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTEYYMHWVRQAPGQGLEWMGIISPSAGSTKYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDHDIRLAGRLADYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLISAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAVILPITFGGGTKVEIK,na,na,None,None,None,2021,2022,TIGIT,Innovent Biologics,na,Cancer,na,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTEYYMHWVR QAPGQG LEWMGII SPSAGSTK YAQ K FQG RVTMTR DTSTS TVYMELS SLRSEDT AVYYCA RDHD IRLAGRL AD YWGQG TLVTV SS,DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISSWLAWY QQKPGKAP KLLISA ASSLQSGVPS RF SGSGSGTD FTLTIS SLQP EDFA TYYC QQ AVILPITF GGG TKVEI K
Tamrintamab,Whole mAb ADC,G1,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYWIEWVRQAPGQGLEWMGEILPGSGNTYYNERFKDRVTITADESTSTAYMELSSLRSEDTAVYYCARRAAAYYSNPEWFAYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCTASSSVNSFYLHWYQQKPGLAPRLLIYSTSNLASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCHQYHRSPYTFGQGTKLEIK,na,na,6vgr:HL:CD,None,None,2018,2019,DPEP3,Stemcentrx,na,Ovarian cancer;Solid tumours,na,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSSYWIEWVR QAPGQG LEWMGEI LPGSGNT YY NERFKD RVTITA DESTS TAYMELS SLRSEDT AVYY CARRAAAYY SNP EW FAYW GQG TLVTVS S,E IVLTQ SPA TLSL SPGE RATLSCTA SSSVN SFYLHWYQ QKPGLAP RLLIYS TSNLASGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCH QYHRSPYTFGQGT KLEI K
Tamtuvetmab,Canine Whole mAb,G2,Kappa,Unknown,Active,EVKLLESGGGLVQPGGSMRLSCAGSGFTFTDFYMNWIRQPAGKAPEWLGFIRDKAKGYTTEYNPSVKGRFTISRDNTQNMLYLQMNTLRAEDTATYYCAREGHTAAPFDYWGQGTLVTVSS,DIKMTQSPSFLSASVGDRVTLNCKASQNIDKYLNWYQQKLGESPKLLIYNTNNLQTGIPSRFSGSGSGTDFTLTISSLQPEDVATYFCLQHISRPRTFGGGTHLTVL,na,na,None,None,1bfo:HG:FE:BA:DC,2015,2016,CD52,Aratana Pharmaceuticals,na,Canine T-cell lymphoma,na,na,,E VKLLES GGG LV QPGGS MRLSC AGSGF TFTDFYMNWIR QPAGKAPE W LGFIR DKAKGY TTE YNPSVK GRFTISR DNTQN MLYLQMNTL RAEDT ATYYCA REGHTAAPFDYWGQG TLVTVS S,DIKMTQSPS FLS ASVGD RVTLNC KAS Q N IDKYLNWYQQKL GESP KLLIYN TNNLQTGIPSRFSGSGSGTD FTLTIS SLQ PEDVATYFCLQH ISRPRTFGGGT HLTV L
Tanezumab,Whole mAb,G2,Kappa,Preregistration,Active,QVQLQESGPGLVKPSETLSLTCTVSGFSLIGYDLNWIRQPPGKGLEWIGIIWGDGTTDYNSAVKSRVTISKDTSKNQFSLKLSSVTAADTAVYYCARGGYWYATSYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISNNLNWYQQKPGKAPKLLIYYTSRFHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQEHTLPYTFGQGTKLEIK,na,na,4edw:HL,None,None,2008,2009,NGFB,Rinat Neuroscience;Pfizer,na,Back pain;Musculoskeletal pain,Diabetic neuropathies;Postherpetic neuralgia;Cancer pain,na,,QV QLQE SGPGL V KPSE TLSLTCTV SG FSLIGYDLNWIR QPPGKGL EWIGIIW GDGTTDYNSA VKSRVTIS KDTSKN QFSLKLSS VTAADT AVYYCA RGG YWYATSYYF DYWGQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITCR ASQSISNNLN WYQ QKPGKAP KLLIYYT SRFHSGVPSRFSGSGSGTD FTFTIS SLQ PEDIA TYYC QQEHTLP YT FGQGT KLEI K
Tarcocimab,Whole mAb,G1,Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,na,na,1cz8:HL:YX,None,1bj1:HL:KJ/6bft:HL:AB,2021,2022,VEGFA,TBC,TBC,TBC,TBC,TBC,Name corrected from tarcolimab in previous version,E VQLVES GGG LV QPGG SLRLSCA ASGYDF THYGMNWVR QAPGKGL EWVGWIN TYTGEPT YA ADFKR RFTFSL DTSKS TAYLQMN SLRAEDT AVYYCA KYPYYYGTS HWYFDV WGQG TLVTVS S,DI QLT QSPSS LSA SVGD RVTITCS ASQD ISNYLNWYQ QKPGKAP KVLIYFT SSLHSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ YSTVPW T FGQGT KVEI K
Tarextumab,Whole mAb,G2,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSSGMSWVRQAPGKGLEWVSVIASSGSNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSIFYTTWGQGTLVTVSS,DIVLTQSPATLSLSPGERATLSCRASQSVRSNYLAWYQQKPGQAPRLLIYGASSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYSNFPITFGQGTKVEIK,na,na,None,None,None,2013,2014,NOTCH2&3,OncoMed Pharmaceuticals,na,Pancreatic cancer;Small cell lung cancer,Solid tumours,MorphoSys HuCAL Phage Display;XmAb Engineering Technology,,E VQLVES GGG LV QPGG SLRLSC AASG FTFS SSGM SWVRQ APGKGL EWVSVIA SSGSNT YYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCARSIFYT TWGQG TLVTVS S,D IVLTQ SPA TLSL SPGE RATLSCR ASQSVR SN YLAWYQ QKPGQAP RLLIYG ASSRATGVP ARF SGSGSGT DFTLTIS SLEP ED FAVYYCQ QYSNFP ITF GQGT KVEI K
Tarlatamab,Bispecific scFv,na;na,Kappa;Lambda,Phase-II,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKCLEWIGYVYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCASIAVTGFYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERVTLSCRASQRVNNNYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGCGTKLEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2020,2021,DLL3;CD3E,Amgen,na,Small cell lung cancer,na,BiTE Technology,,QV QLQE SGPGL V KPSE TLSLTCTV SGGS ISSYYWSWIR QPPGKC LEWIGYVYYS GTTNYNPSLK SRVTISVD TSKN QFSLKLSS VTAADT AVYYCASIAVTGFYFD YWGQG TLVTV SS,E IVLTQ SPG TLSL SPGE RVTLSCRA SQRVNNN YLAWYQ QRPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQ QYDRSPL TF GCGT KLEI K
Tarperprumig,Bispecific Single Domains (VH-VH'),na;na,na;na,TBC,Active,QVQLVESGGGLVKPGGSLRLSCAASGRPVSNYAAAWFRQAPGKEREFVSAINWQKTATYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAAVFRVVAPKTQYDYDYWGQGTLVTVSS,na,EVQLLESGGGLVQPGGSLRLSCAASGRISSIIHMAWFRQAPGKERELVSEISRVGTTVYADSVKGRFTISRDNSKNTLYLQMNSLKPEDTAVYYCNALQYEKHGGADYWGQGTLVTVSS,na,None;None,None;None,None;None,2022,na,CFP;ALB,TBC,TBC,TBC,TBC,TBC,,Q VQLVES GGG LV KPGG SLRLSC AASGRPVS NYAAAWF R QAPGKER EFVSAIN WQKTA TY ADSVK GRFTISR DNAKN SLYLQMNS LRAEDT AVYYCAAVFRVV APKTQYDYD Y WGQG TLVTVS S,NA
Tavolimab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLQESGPGLVKPSQTLSLTCAVYGGSFSSGYWNWIRKHPGKGLEYIGYISYNGITYHNPSLKSRITINRDTSKNQYSLQLNSVTPEDTAVYYCARYKYDYDGGHAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSKLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGSALPWTFGQGTKVEIK,na,na,None,None,None,2016,2018,TNFSF4,European Network of Gynaecological Oncological Trial Groups;MedImmune,na,na,Ovarian cancer;Solid tumours,na,Tavolimab is the new name for Tavolixizumab (PL118),QV QLQ ESGPGLVKPSQ TLSLTCAVY GGSFSSG YWNWIR KHPGKGL EYIGYISY NG ITYH NPSLK SRITIN RDTSKN QYSLQL NSVTPEDT AVYYCARYKY DYDGGHA MDY WGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQD ISNYLNWYQ QKPGKAP KLLIYYT SKLHSGVPS R FSGSGSGTD YTLTIS SLQP EDFA TYYC QQGSALPW T FGQGT KVEI K
Tebentafusp,scFv Fusion,na,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSS,AIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIK,na,na,None,None,None,2017,2018,CD3E,Immunocore;MedImmune,Uveal melanoma,Malignant melanoma,na,na,T-Beta section specific for PMEL peptide 280-288 presented by MH1,E VQLVES GGG LV QPGG SLRLSC AASGY SFTGYTMNWVR QAPGKG LEWVALI NPYKGV STY NQKFKD RFTISVD KSKN TAYLQMN SLRAEDT AVYYCA RSGYYGDSD WYFDVW GQG TLVTVS S,AIQMTQSPSS LSA SVGD RVTITCR AS QDIRNYLNWYQ QKPGKAP KLLIYYTS RLESGVPS RF SGSGSGTD YTLTIS SLQP EDFA TYYC QQGNTLPW TF GQGT KVEI K
Tebotelimab,Bispecific scFv with Crossover,G4;G4,Kappa;Kappa,Phase-II/III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYSFTSYWMNWVRQAPGQGLEWIGVIHPSDSETWLDQKFKDRVTITVDKSTSTAYMELSSLRSEDTAVYYCAREHYGTSPFAYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASESVDNYGMSFMNWFQQKPGQPPKLLIHAASNQGSGVPSRFSGSGSGTDFTLTISSLEPEDFAVYFCQQSKEVPYTFGGGTKVEIK,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWMGDINPDNGVTIYNQKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAREADYFYFDYWGQGTTLTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVSSVVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSTPWTFGGGTKLEIK,None;None,None;None,None;None,2019,2020,PDCD1;LAG3,MacroGenics,na,Gastic cancer;Oesophageal cancer;Head and neck cancer;Cholangiocarcinoma;Liver cancer;Haematological malignancies;Malignant melanoma;Solid tumours,na,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGYS FTSYWMNWVR QAPGQGL EWIGVI HPSDSET WL DQKFKD RVTITVD KSTS TAYMELS SLRSEDT AVYYCAR EHYGTSPF AYW GQG TLVTVS S,E IVLTQ SPA TLSL SPGE RATLSCRA SESVDNYGM SFMN W F QQKPGQPP KLLIHA ASNQGSGVPS R FSGSGSGTD FTLTIS SLEPED FAVYFC QQSKEVP YT FGGG TKVEI K
Tecaginlimab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-I/II,Active,EVQLVQSGAEVKKPGASVKVSCKTSGYTFTEYIMHWVRQAPGQGLEWMGGIIPNNGGTSYNQKFQGRVTMTVDKSTSTGYMELSSLRSEDTAVYYCTRREVYGRNYYALDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQGINNYLNWYQQKPGKAVKLLIYYTSSLHSGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQYSNLPYTFGGGTKVEIK,EVQLVESGGGLVQPGRSLRLSCTASGFSLNDYWMSWVRQAPGKGLEWVGYIDVGGSLYYAASVKGRFTISRDDSKSIAYLQMNSLKTEDTAVYYCARGGLTYGFDLWGQGTLVTVSS,DIVMTQSPSSLSASVGDRVTITCQASEDISSYLAWYQQKPGKAPKRLIYGASDLASGVPSRFSASGSGTDYTFTISSLQPEDIATYYCHYYATISGLGVAFGGGTKVEIK,None;None,None;None,None;None,2021,2022,CD40;TNFRSF9,Genmab,na,Solid tumours,na,na,,E VQLVQ SGA EVK KPGA SVKVSC KTSGY TFTEYIMHWVR QAPGQG LEWMGGII PNNGGTSYNQK F QG RVTMTVD KSTST GYMELSS LRSEDT AVYYCTR R EV YGRN YYALDY WGQG TLVTVS S,DIQMTQSPSS LSA SVGD RVTITCS ASQG INNYLNWYQ QKPGK AVKLLIYYT SSLHSGVPSRFSGSGSGTD YTFTIS SLQ PEDIATYYCQQ YSNLPY T FGGGT KVEI K
Teclistamab,Bispecific mAb,G4;G4,Lambda;Lambda,Preregistration,Active,QLQLQESGPGLVKPSETLSLTCTVSGGSISSGSYFWGWIRQPPGKGLEWIGSIYYSGITYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHDGAVAGLFDYWGQGTLVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQPPGQAPVVVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEAVYYCQVWDSSSDHVVFGGGTKLTVL,EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYAASVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARHGNFGNSYVSWFAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2018,2019,TNFRSF17;CD3E,Genmab;Janssen Research & Development,na,Multiple myeloma,na,na,,QL QLQE SGPGL V KPSE TLSLTCTV SGGSISSGS YFWGWIR QPPGKGL EWIGSIYYS G ITYY NPSLKS RVTISVD TSKN QFSLKLSS VTAADT AVYYCA RHDGA VAGLFD YWGQG TLVTVS S,SY VLT QPPS VSV APGQ TARITC GGNNIGSK SVHWYQ QPPGQAP VVVVY DDSDRPSGIPE R FSGSNSGN TATLTISRVE AGDE AVYYCQVW DSSSD HVVFG GGT KLTV L
Telazorlimab,Whole mAb,G1,Kappa,Phase-II,Active,QVTLKESGPALVKPTQTLTLTCSFSGFSLSTSGMGVGWIRQPPGKALEWIAHIWWDDDKYYNTALKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIDWDGFAYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASSSVSYMHWYQQKPGQAPRPWIYATSNRATGIPARFSGSGSGTDYTLTISSLEPEDFAVYYCQQWSSNPWTFGQGTKVEIK,na,na,None,None,None,2019,2020,TNFRSF4,Glenmark Pharmaceuticals,na,Atopic dermatitis;Systemic lupus erythematosus;Ulcerative colitis;Rheumatoid arthritis,na,na,,Q VTLK ESGPA LV KPTQ TLTLTCSF SG FSLS TSGM GVGWIR QPPGKA LEWIAHIWW DDDKYYNTA LKTRLTIS KDTSKN QVVLTMT NMDPVDT ATYYCARI DWDGF AYW GQG TLVTVS S,E IVLTQ SPA TLSL SPGE RATLSCR ASSS VSYMHWYQ QKPGQAPRP WIYAT SNRATGIP ARFS GSGSGTD YTLTISS LEPED FAVYYCQQ WSSNPWT F GQGT KVEI K
Telisotuzumab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYIFTAYTMHWVRQAPGQGLEWMGWIKPNNGLANYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSEITTEFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSESVDSYANSFLHWYQQKPGQPPKLLIYRASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEDPLTFGGGTKVEIK,na,na,None,None,None,2016,2017,MET,Pierre Fabre;AbbVie,na,na,Solid tumours,na,,Q VQLVQ SGA EVK KPGA SVKVSC KASG YIFTAYTMHWVR QAPGQG LEWMGWI KPNNGLA NYAQK FQG RVTMT RDTS ISTAYMELSR LRSDDT AVYYCA RSEI TTEFDY WGQG TLVTV SS,D IVMT QSPDS LAVS LGE RATINC KSSES VDSYANSFLHWYQ QKPGQPP KLLIYRA STRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQ QSKEDPL T FGGG TKVEI K
Temelimab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYEMHWVRQAPGQGLEWIGAVAPETGGTAYNQKFKGRATITADKSTSTAYMELSSLRSEDTAVYYCTSTVVPFAYWGQGTLVTVSS,QIQLTQSPSSLSASVGDRVTITCSASSSVSYMYWYQQKPGKAPKAWIYRTSNLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQYQSLPLTFGGGTKVEIK,na,na,None,None,None,2018,2019,MRSV envelope protein,GeNeuro,na,Multiple sclerosis;Type 1 diabetes mellitus;Chronic inflammatory demyelinating polyradiculoneuropathy,na,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TF TDY EMHWVRQ APGQG LEWIGAV APETGGTAYNQKFKG RATITA DKSTS TAYMELSS LRSEDT AVYYCT ST VVPFAY WGQG TLVTVS S,QI QLT QSPSS LSA SVGD RVTITCS ASSS VSYMYWYQ QKPGKAPK AWIYRT SNLASGVPS RF SGSGSGTD YTLTISS LQ PEDFAT YYC Q QYQSLP LTF GGG TKVEI K
Tenatumomab,Whole mAb Radiolabelled,G2b,Kappa,Phase-I,Discontinued,EIQLQQSGPELVKPGASVKVSCKASGYAFTSYNMYWVKQSHGKSLEWIGYIDPYNGVTSYNQKFKGKATLTVDKSSSTAYMHLNSLTSEDSAVYYCARGGGSIYYAMDYWGQGTSVTVSS,DIVMTQAAPSVPVTPGESVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLASGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCMQHLEYPLTFGAGTKLELK,na,na,None,None,None,2007,2008,TNC,sigma-tau SpA,na,na,Cancer,na,,EI QLQ QSGPE LV KPGA SVKVSCK ASGY AFTSYNMYWVK QSHGK SLEWIGYI DPYNGV TSY NQKFKG KATLTVD KSSS TAYMHLN SLTSEDS AVYYCA RGGG SIYYAMD YWGQG TSVTVS S,DI VMT QAAPSVPVTPGE SVSISC RSSK SLLH SNGN TYLYWFLQ RPGQSP QLLIYRM SNLASGVPDRFSGSGSGT AFTLRISRVE AEDV GVYYCMQH LEYP LTF GAGT KLEL K
Teneliximab,Whole mAb,G1,Kappa,Phase-II,ND,QIQLVQSGPELKKPGETVRISCKASGYAFTTTGMQWVQEMPGKGLKWIGWINTHSGVPKYVEDFKGRFAFSLETSANTAYLQISNLKNEDTATYFCVRSGNGNYDLAYFAYWGQGTLVTVSA,DIVLTQSPATLSVTPGDRVSLSCRASQSISDYLHWYQQKSHESPRLLIKYASHSISGIPSRFSGSGSGSDFTLSINSVEPEDVGIYYCQHGHSFPWTFGGGTKLEIK,na,na,5dmi:HL,None,None,2002,2003,CD40,Bristol-Myers Squibb,na,Cancer,na,na,,Q IQLVQ SGPELKKPGE TVRISCK ASG YAFT TTGM QWVQE MPGKGL KWIGWIN THSGVP KYVE DFKG RFAFSLET SANT AYLQIS NLKNEDT ATYFCVR SGNGN YDLAYFAYW GQG TLVTVS A,D IVLT QSPA TLSV TPGD RVSLSCR ASQS ISDYLHWYQQ KSHESP RLLIKYA SHS I SGIPSRFSGSGSGSD FTLSIN SVEPED VGIYYC QHGHSFPW TF GGGT KLEI K
Teplizumab,Whole mAb,G1,Kappa,Preregistration,Active,QVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISRDNSKNTAFLQMDSLRPEDTGVYFCARYYDDHYCLDYWGQGTPVTVSS,DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGQGTKLQIT,na,na,None,None,None,2007,2008,CD3E,Immune Tolerance Network;MacroGenics;National Institute of Diabetes and Digestive and Kidney Diseases;National Institutes of Health (USA);Provention Bio;Tolerance Therapeutics,na,Type 1 diabetes mellitus,Multiple sclerosis;Psoriasis;Psoriatic arthritis,na,,Q VQLVQS GGG VV QPGR SLRLSCK ASGY TFTRYTMHWVRQ APGKG LEWIGYI NPSRGYTNYNQKVKD RFTISR DNSKN TAFLQM DSLRPEDT GVYFCARY YDDH YCLDY WGQGT PVTVS S,DI QMT QSPSS LSAS VGD RVTITCS ASSS VSYMNWY QQTPGKAPK RWIYD TSKLASGVPS RF SGSGSGT DYTFTISS LQ PEDIAT YYCQ QWSSNPF T FGQGT KLQI T
Tepoditamab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAKGTTGDWFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,QVQLVQSGGGVVQPGRSLRLSCVASGFTFSSYGMHWVRQAPGKGLEWVAAIWYNARKQDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGTGYNWFDPWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,None;None,None;None,None;None,2017,2018,CLEC12A;CD3E,Genmab;Janssen Research & Development,na,na,Acute myeloid leukaemia;Myelodysplastic syndromes,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYYMHWVR QAPGQG LEWMGII NPSGGSTSY AQKF QG RVTMTR DTSTS TVYMELS SLRSEDT AVYYCA KGTTGDW FDY WGQG TLVTV SS,DIQ MT QSPSS LSA SVGD RVTITCR ASQS ISSYLNWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQPE DF ATYYCQ QSYSTPPTFGQGT KVEI K
Teprotumumab,Whole mAb,G1,Kappa,Approved,Active,QVELVESGGGVVQPGRSQRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIIWFDGSSTYYADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCARELGRRYFDLWGRGTLVSVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASKRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSKWPPWTFGQGTKVESK,na,na,None,None,None,2009,2010,IGF1R,Genmab;Roche;Horizon Therapeutics plc,Graves ophthalmopathy,Diffuse scleroderma,Diabetic macular oedema;Advanced breast cancer;Hodgkin's disease;Non-Hodgkin's lymphoma;Non-small cell lung cancer;Sarcoma;Solid tumours,Medarex UltiMAb Mouse,,Q VELVE SGGG VV QPGRSQ RLSC AASGF TFSS Y GMHWVRQ APGKGL EWVAIIWF DGSST YYAD SVRG RFTISR DNSKN TLYLQMN SLRAEDT AVYFCA RE LGR R YFDL WGRG TLVSV SS,E IVLTQ SPA TLSL SPGE RATLSCR ASQS VSSYL A W Y QQKPGQAP RLLIYD ASKRATGIP ARF SGSGSGTD FTLTIS SLEPED FAVYYCQ QRSKWPPWTFGQGT KVE SK
Teropavimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLLQSGAAVTKPGASVRVSCEASGYNIRDYFIHWWRQAPGQGLQWVGWINPKTGQPNNPRQFQGRVSLTRHASWDFDTFSFYMDLKALRSDDTAVYFCARQRSDYWDFDVWGSGTQVTVSS,DIQMTQSPSSLSASVGDTVTITCQANGYLNWYQQRRGKAPKLLIYDGSKLERGVPSRFSGRRWGQEYNLTINNLQPEDIATYFCQVYEFVVPGTRLDLK,na,na,None,4lsv:HL/4jpv:HL/5v8l:HL:GK:IM:GN/5v8m:HL:RT:SU/7ly9:HL:AM:EI:BC/7mxd:CD:JK:SU/7n28:CD:JK:SU/7pc2:GH:IJ:KL,None,2021,2022,HIV-1 gp120 CD4bs,Gilead,na,HIV-1,na,na,,Q VQLLQ SGA AVT KPGA SVRVSCE ASGYNIR DYFIHWWR QAPGQG LQWVGWI NPKTGQPNNPRQ FQ G RVSLTR HAS W DFDT FSFYMDLKA LRSDDT AVYFCAR QRSDY WDFDVW GSG TQVTVS S,DIQ MT QSPSS LSA SVGD TVTITCQ ANGY LNWYQQ RRGKAP KLLIY DGSKLERGVPSRFSGRRWGQ EYNLTI NNLQ PEDIATYFCQVY EFV VPGT RLD LK
Tesidolumab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIGPFFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDTPYFDYWGQGTLVTVSS,SYELTQPLSVSVALGQTARITCSGDSIPNYYVYWYQQKPGQAPVLVIYDDSNRPSGIPERFSGSNSGNTATLTISRAQAGDEADYYCQSFDSSLNAEVFGGGTKLTVL,na,na,None,None,None,2014,2015,C5,MorphoSys;Novartis,na,Paroxysmal nocturnal haemoglobinuria,Choroiditis;Dry age-related macular degeneration;Panuveitis;Thrombotic microangiopathy;Wet age-related macular degeneration,MorphoSys HuCAL Phage Display;XmAb Engineering Technology,,E VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSSYAISWVR QAPGQGL EWM GGIGPFFGTANYAQKFQG RVTITA DESTS TAYMELS SLRSEDT AVYYCA RDTPYFDYWGQG TLVTV SS,SYELTQP LSVSVA LGQ TARITC SGDSIPN YYVYWYQ QKPGQAP VLVIY DDSNRPSGIPERFSGSNSGN TATLTISR AQAGDE ADYYCQSF DSSLN AEVF GGGT KLTV L
Tesnatilimab,Whole mAb,G4,Kappa,Phase-II,Active,QVHLQESGPGLVKPSETLSLTCTVSDDSISSYYWSWIRQPPGKGLEWIGHISYSGSANYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCANWDDAFNIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,None,None,None,2019,2020,KLRK1,Janssen Research & Development,na,Crohn's disease,na,na,,Q VHLQE SGPGL V KPSE TLSLTCTV SDDSI SSYYWSWIR QPPGKGL EWIGHISYS GSANYNPSLK SRVTISVD TSKN QFSLKLSS VTAADT AVYYCA NWDDAFN IW GQG TMVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSS S YLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYC Q QYGSSPWTFGQGT KVEI K
Tezepelumab,Whole mAb,G2,Lambda,Approved,Active,QMQLVESGGGVVQPGRSLRLSCAASGFTFRTYGMHWVRQAPGKGLEWVAVIWYDGSNKHYADSVKGRFTITRDNSKNTLNLQMNSLRAEDTAVYYCARAPQWELVHEAFDIWGQGTMVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNLGSKSVHWYQQKPGQAPVLVVYDDSDRPSWIPERFSGSNSGNTATLTISRGEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL,na,na,5j13:CB,None,None,2015,2016,TSLP,Amgen;AstraZeneca;Bispebjerg Hospital;Lund University;MedImmune;University of Copenhagen;University of Newcastle in Australia,Asthma,Atopic dermatitis;Rhinosinusitis;Chronic obstructive pulmonary disease,na,na,,QM QLVES GGG VV QPGR SLRLSC AASGF TFRTYGMHWVRQ APGKG LEWVAVIWY DGSNKH YA DS V K GRFTITR DNSKN TLNLQMNSL RAEDT AVYYCA RAPQW ELVHEAFDI WGQG TMVTV SS,SY VL TQPPS VSV APGQ TARITC GGNNLGSK SVHWYQ QKPGQAP VLVVY DDSDRPSWIPERFSGSNSGN TATLTISR GEAGDE ADYYCQVWD SSSD HVVFG GGT KLTV L
Tibulizumab,Bispecific Mixed mAb and scFv,G4;G4,Kappa;Kappa,Phase-I,Discontinued,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGYYDILTGYYYYFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSRYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDSTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIK,QVQLVQSGAEVKKPGSSVKVSCKASGYKFTDYHIHWVRQAPGQCLEWMGVINPTYGTTDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGETYLHWYLQKPGQSPQLLIYKVSNRFIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGCGTKLEIK,None;None,None;None,None;6nou:AA/6nov:AB,2017,2018,TNFSF13B;IL17A,Eli Lilly,na,na,Rheumatoid arthritis;Sjogren's syndrome,na,,QV QLQQW GAGLLKPSE TLSLTCAVY GGSFS GYYWSWIR QPPGKGL EWIGEIN HSGSTNYNPSLK SRVTISVD TSKN QFSLKLSS VTAADT AVYYCA RGY YD ILTG YYYYFDY WGQG TLVTVS S,E IVLT QSPA TLSL SPGE RATLSCR ASQS VSRYLAWYQ QKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTDS TLTIS SLEPED FAVYYCQ QRSNWPRTFGQGT KVEI K
Tidutamab,Bispecific Mixed mAb and scFv,G1;G1,Kappa;Lambda,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGMAWFRQAPGKGLEWVSFISNLGYSIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARAPYDYDSFDPMDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRNRKNYLAWYQQKPDQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSYYLWTFGGGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGDSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQQKPGKSPRGLIGGTNKRAPGVPARFSGSLLGGKAALTISGAQPEDEADYYCALWYSNHWVFGGGTKLTVL,None;None,None;None,None;None,2018,2019,SSTR2;CD3E,ICON;Xencor,na,na,Gastrointestinal stromal tumours;Neuroendocrine tumours,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TF SDYG MAWFR QAPGKGL EWVSFI SNLGY SIYYA DSVKG RFTISR DNAKNS LYLQMNS LRAEDT AVYYCA RAPYDYDSFDPMDYWGQG TLVTV SS,D IVMT QSPDS LAVS LGER ATINC KSS QSLL NSRNR KNYLAWYQ QKPDQSPK LLIYWAS TRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC KQS YYLWTF GGG TKVEI K
Tifcemalimab,Whole mAb,G4,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKLSCKASGYNFKHTYAHWVRQAPGQGLEWIGRIDPANGNTKYDPKFQGRATMTADTASNTAYLELSSLRSEDTAVYYCVADHYGSSLLDYWGQGTLVTVSS,DVVMTQTPLSLSVTPGQPASISCKSSQSLLDSDGKTYLNWFQQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTYFPYTFGQGTKLEIK,na,na,None,None,None,2019,2020,BTLA,Shanghai Junshi Biosciences,na,Solid tumours,na,na,Chimeric. Tifcemalimab is the new name for Icatolimab (PL124),Q VQLVQ SGA EVK KPGA SVKLSCK ASGYN FKHTYAHWVR QAPGQG LEWIGRI DPANGNTKYDPKFQG RATMTA DTASN TAYLELS SLRSEDT AVYYCVA DHYGSS LLDY WGQG TLVTVS S,DV VMT QTP LSLSV TPGQP ASISC KSSQ SLL DSDGK TYLNWFQ QRPGQSPR RLIYLVSK LDSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCW QGT Y FPY T FGQGT KLEI K
Tigatuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMSWVRQAPGKGLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARRGDSMITTDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSSYRTFGQGTKVEIK,na,na,None,None,None,2007,2008,TNFRSF10B,Daiichi Sankyo Company;University of Alabama at Birmingham,na,na,Breast cancer;Colorectal cancer;Liver cancer;Lymphoma;Non-small cell lung cancer;Ovarian cancer;Pancreatic cancer,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFSSYVMSWVR QAPGKG LEWVATIS SGGS YTY YPDSVK GRFTISR DNAKN TLYLQMN SLRAEDT AVYYCAR RGDS MITT DYWGQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITCK ASQDVG TAVAWYQ QKPGKAP KLLIYWA STRHTGVPSRFSGSGSGTD FTLTIS SLQP EDFAT YYC QQYSSY RTF GQGT KVEI K
Tilavonemab,Whole mAb,G4,Kappa,Phase-II,Active,EVKVVESGGGLVQPGGSMKLSCVVSGFTFSNYWVNWVRQAPGKGLEWVAQIRLKSDNYATHYEESVKGRFTISRDDSKSSVYLQMNNLRAEDSGIYYCTNWEDYWGQGTTVTVSS,DIVLTQSPDSLAVSLGERATISCRASQSVSTSRYSYIHWYQQKPGQPPKLLIKYASNLESGVPSRFSGSGSGTDFTLNIHPLEPEDFATYYCHHSWEIPLTFGQGTKLEIK,na,na,None,None,None,2018,2019,MAPT,AbbVie;C2N Diagnostics,na,Alzheimer's disease;Progressive supranuclear palsy,na,na,Fixed missing FWL3 residue from Jan '22 release onwards,E VKVVES GGG LV QPGGS MKLSCVV SGF TF SN YWVNWVR QAPGKGL EWVAQIRLK SDNYAT HYEESV K GRFTIS RDDSKS SVYLQM NNLRAEDSG IYYC TNWEDYWGQG TTVTVS S,D IVLT QSPDS LAVS LGER ATISCR ASQSVSTSR YSYIHWYQ QKPGQPP KLLIKYA SNLESGVPS R FSGSGSGTD FTLNIH PLEP ED F ATYYC HHS WEIPLT FGQGT KLEI K
Tildrakizumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYIFITYWMTWVRQAPGQGLEWMGQIFPASGSADYNEKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGGGGFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSENIYSYLAWYQQKPGKAPKLLIYNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGIPFTFGQGTKVEIK,na,na,None,None,None,2012,2013,IL23A,Almirall S.A.;Merck & Co;Schering-Plough;Sun Pharmaceutical Industries,Plaque psoriasis,Ankylosing spondylitis;Intervertebral disc degeneration;Non-radiographic axial spondyloarthritis;Psoriatic arthritis,Autoimmune disorders,na,,Q VQLVQ SGA EVK KPGA SVKVSC KASG YIFITYWMTWVR QAPGQG LEWMGQIF PASGSADYNEK F EG RVTMTT DTSTS TAYMELRSL RSDDT AVYYCA RGGGG FAYW GQG TLVTV SS,DIQ MT QSPSS LSA SVGD RVTITCR TSEN IYSYLAWY QQKPGKAP KLLIYN AK T LAEGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQ HHYGIP FTF GQGT KVEI K
Tilogotamab,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTHMHWVRQAPGQRLEWIGRIDPANGNTEYDQKFQGRVTITVDTSASTAYMELSSLRSEDTAVYYCARWGTNVYFAYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCSASSSVSYMYWYQQKPGKAPKPWIYRTSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYHSYPPTFGGGTKVEIK,na,na,None,6t3j:CD:HI,None,2019,2020,TNFRSF10B,Genmab,na,Solid tumours,na,na,(June '22) Corrected FWL4 sequence,Q VQLVQ SGA EVK KPGA SVKVSCK ASGF NI KDT HMHWVRQ APGQ RLEWIGRI DPANGNTEYDQ KF QG RVTITVD TSAST AYMELS SLRSEDT AVYYCAR WGTN VYFAYW GQG TLVTVS S,DI QLT QSPSS LSA SVGD RVTITCS ASSS VSYMYWYQ QKPGKAPKP WIYRT SNLASGVPS R FSGSGSGT DFTLTISS LQP EDFA TYYCQ QYHSYPPTFGGGT KVEI K
Tilvestamab,Whole mAb,G1,Kappa,Phase-I,Active,EVQLVESGGGLVQPGGSLRLSCAASGYSFTDFYINWVRQAPGKGLEWVARIFPGGDNTYYNEKFKGRFTLSADTSKSTAYLQMNSLRAEDTAVYYCARRGLYYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGIPYLHWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCSQGTHVPPTFGQGTKVEIK,na,na,None,None,None,2019,2020,AXL,BerGenBio,na,Cancer,na,na,(Feb '22) Removed erroneous W insertion from CDRH1.,E VQLVES GGG LV QPGG SLRLSC AASGYS F T DFYINWVR QAPGKG LEWVARI FPGGDNT YY NEKFKG RFTLSA DTSKS TAYLQM NSLRAEDT AVYYCA RRGL YYAMD YWGQG TLVTV SS,DI QMT QSPSS LSA SVGD RVTITCR SSQ SLVH SNGI PYLHWYQ QKPGKAP KLLIYRVS NRFSGVPS R FSGSGSGT DFTLTISS LQPEDF ATYYC SQGTHVPPTFGQGT KVEI K
Timigutuzumab,Whole mAb,G1,Kappa,Phase-I,NFD,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,na,na,1fvc:DC:BA/4hkz:BA/1n8z:BA/4ub0:HL/5xhf:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD/6oge:ED/7mn8:DC,1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC,5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,1997,1998,ERBB2,Roche,Breast cancer,na,na,na,Timigutuzumab is a biosimilar of Trastuzumab and Coprelotamab with an identical Variable region. Cinrebafusp and Anvatabart have identical V domains.,E VQLVES GGG LV QPGG SLRLSCA ASGFNIKD TYIHWVRQ APGKG LEWVARIY PTNGY TRYA DSVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYCS RWGGDG FYAMD YWGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQD VNTA VAWYQ QKPGKAP KLLIYSASFLY SGVPSRFSGSRSGTD FTLTIS SLQP EDFAT YYCQ QHYTTPPTFGQGT KVEI K
Timolumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFFSYAMHWVRQTPGKGLEWVAVIWFDGSNENYVDSVKGRFTISRDNSKNTLYLQMNTLRAEDTAVYYCARDAWSYFDYWGQGTLVTVSS,VIQLTQSPSSLSASVGDRVTITCRASQGISRALAWYQQKPGKGPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,na,na,None,None,None,2015,2016,AOC3,Acorda Therapeutics;Biotie Therapies Corp.;Seikagaku Corporation,na,na,Inflammation;Plaque psoriasis;Rheumatoid arthritis;Primary sclerosing cholangitis,na,,Q VQLVES GGG VV QPGR SLRLSC AASGF TFFSYAMHWVRQ TPGKGL EWVAVIWF DGSNEN YVD SVKG RFTISR DNSKN TLYLQMNTL RAEDT AVYYCA RDAWS YFD YWGQG TLVTVS S,V IQLT QSPSS LSA SVGD RVTITCR ASQG ISRALAWYQ QKPGKGP KLLIYD ASSLESGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ FNSYP LTF GGGT KVEI K
Tinurilimab,Whole mAb,G2,Kappa,Phase-I,Discontinued,QVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGIGVGWIRQPPGKALEWLAHIWWNDNKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARISLPYFDYWGQGTTLTVSS,DIQLTQSPSFLSASVGDRVTITCKASQNVGTAVAWYQQKPGKAPKLLIYSASNRYTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQYSSYPLTFGGGTKVEIK,na,na,None,None,None,2019,2020,CEACAM6,Bayer;German Cancer Research Center,na,na,Solid tumours,na,,Q VTLRE SGPA LV KPTQ TLTLTCTF SGF SL S TYGIGVGWIR QPPGKA LEWLAHIWW NDNKY Y STSL KTRLTIS KDTSKN QVVLTMT NMDPVDTA TYYCARIS LPYFDYWGQG TTLTVS S,DI QLT QSPS FLSA SVGD RVTITCK ASQNVG TAVAWYQ QKPGKAP KLLIYS ASNRYTGVPSRFSGSGSGT EFTLTIS SLQ PEDFATY YC QQYSSYP LTF GGG TKVEI K
Tiragolumab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGKTYYRFKWYSDYAVSVKGRITINPDTSKNQFSLQLNSVTPEDTAVFYCTRESTTYDLLAGPFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQTVLYSSNNKKYLAWYQQKPGQPPNLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPFTFGPGTKVEIK,na,na,None,None,None,2017,2018,TIGIT,Genentech,na,Non-small cell lung cancer;Solid tumours;Oesophageal cancer;Small cell lung cancer;Squamous cell cancer;Cervical cancer;Liver cancer;B-cell lymphoma;Breast cancer;Multiple myeloma,na,na,,EV QLQQ SGPGLVKPSQ TLSLTCAI SGDSVSSNS AAWNWIR QSPSRGL EW LGK TYYRFKWY SDY AVSVKGRITI NPDTSKN QFSLQL NSVTPEDT AVFYCT REST TYDL LAGPFDYWGQG TLVTVS S,D IVMT QSPDS LAVS LGE RATINC KSSQ TVLYS SNNK KYLAWYQ QKPGQPPN LLIYWAS TRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQQ YYSTPF TF GPGT KVEI K
Tirnovetmab,Whole mAb (Canine),G2,Kappa,Unknown,Active,EVQLVESGPSLVKPGGSLRLTCSVTGDSITSGYWNWIRKFPGNKLEYMGYISYSGITDYNPSLKSRITISRDTSKNQYYLQLNSVTTEDTATYYCARYGNYGYAMDYWGQGTSVTVSS,DIVMTQSPASLSVSLGQRATISCRASESVDTYGNSFMHWYQQKPGQSPKLLIYRASNLESGIPARFGGSGSGTDFTLTIDPVQADDVATYYCQQSYEDPWTFGGGTKLEIK,na,na,None,None,None,2020,2021,IL31 (Canine),Kindred Biosciences,na,Canine atopic dermatitis,na,na,,E VQLVE SGPS LV KPGG SLRLTCSV TGDS ITS G YWNWIR KFPGNK LEYMGYISY SGITDYNPSLK SRITISR DTSKN QYYLQLNS V T TEDT ATYYCAR YGNYG YAMD YWGQGT SVTVS S,D IVMT QSPA SLSVS LGQ RATISCRA SESVDTYGN SFMHWYQ QKPGQSP KLLIYRA SNLESGIPA RF GGSGSGTD FTLTI DPVQADD VATYYCQ QSYEDPWTFGGG TKLEI K
Tislelizumab,Whole mAb,G4,Kappa,Approved,Active,QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYGVHWIRQPPGKGLEWIGVIYADGSTNYNPSLKSRVTISKDTSKNQVSLKLSSVTAADTAVYYCARAYGNYWYIDVWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKSSESVSNDVAWYQQKPGQPPKLLINYAFHRFTGVPDRFSGSGYGTDFTLTISSLQAEDVAVYYCHQAYSSPYTFGQGTKLEIK,na,na,7bxa:BC:HL/7cgw:HL:AB,None,None,2017,2018,PDCD1,BeiGene;Celgene Corporation,Hodgkin's disease;Urogenital cancer,Gastric cancer;Liver cancer;Nasopharyngeal cancer;Non-small cell lung cancer;Oesophageal cancer;Lung cancer;Lymphoma;Solid tumours;Ovarian cancer;Renal cancer,na,na,,QV QLQE SGPGL V KPSE TLSLTCTV SG FSLTSYGVHWIR QPPGKGL EWIGVIYA DGSTNYNPSLK SRVTIS KDTSKN QVSLKLSS VTAADT AVYYCARA YGN YWYIDV WGQGT TVTVS S,D IVMT QSPDS LAVS LGE RATINC KSSESVSND VAWYQ QKPGQPP KLLINYAFHRF TGVPDRFSGSGYGTD FTLTISS LQAED VAVYYCH QAYSSPY T FGQGT KLEI K
Tisotumab,Whole mAb,G1,Kappa,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVSSISGSGDYTYYTDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSPWGYYLDSWGQGTLVTVSS,DIQMTQSPPSLSASAGDRVTITCRASQGISSRLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPYTFGQGTKLEIK,na,na,None,None,None,2015,2016,F3,Genmab;Seattle Genetics,Cervical cancer,Bladder cancer;Endometrial cancer;Fallopian tube cancer;Oesophageal cancer;Ovarian cancer;Peritoneal cancer;Prostate cancer;Solid tumours,na,na,,E VQLLES GGG LV QPGG SLRLSC AASGF TFS NY AMSWVR QAPGKG LEWVSSI SGSGD YTYYT DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RSPWG YYL DSWGQG TLVTVS S,DIQ MT QSPPS LS ASAGD RVTITCR ASQGIS SRLAWY QQKPEKAPK SLIYAA SSLQSGVPS RF SGSGSGTD FTLTIS SLQ PEDFATY YC Q QYNSYPY T FGQGT KLEI K
Tixagevimab,Whole mAb,G1,Kappa,Approved,NFD,QMQLVQSGPEVKKPGTSVKVSCKASGFTFMSSAVQWVRQARGQRLEWIGWIVIGSGNTNYAQKFQERVTITRDMSTSTAYMELSSLRSEDTAVYYCAAPYCSSISCNDGFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYGSSRGWTFGQGTKVEIK,na,na,7l7d:HL,7l7e:AB:HL:IJ:TU,7b0b:HL/7e3k:DE:HL:FG/7mm0:HL/7mlz:HL/7tbf:HL/7tb8:HL/7tcc:FG:JK:OP/7u0d:OP,2020,2021,SARS-CoV-2 Spike RBD,AstraZeneca,COVID-19,na,na,na,,QM QLVQ SGPEVKKPGT SVKVSC KASGF TFMS SAVQ WVR Q ARGQR LEWIGWIVIG SGNTN YAQK FQE RVTITR DMSTST AYMELS SLRSEDT AVYYCA APYCSS IS CNDGF DIW GQG TMVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSS S YLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYCQ HYGSSRG WTF GQGT KVEI K
Tobemstomig,Bispecific mAb with Domain Crossover,G1;G1,Kappa;Kappa,TBC,Active,EVQLLESGGGLVQPGGSLRLSCAASGFSFSSYTMSWVRQAPGKGLEWVATISGGGRDIYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVLLTGRVYFALDSWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKASESVDTSDNSFIHWYQQKPGQSPKLLIYRSSTLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNYDVPWTFGQGTKVEIK,EVQLLESGGGLVQPGGSLRLSCAASGFIFDDYTMNWVRQAPGKGLEWVAVISWDGGGTYYTDSVKGRFTISRDDFKNTLYLQMNSLRAEDTAVYYCAKGLTDTTLYGSDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTYSSPLTFGGGTKVEIK,None;None,None;None,None;None,2022,na,PDCD1;LAG3,TBC,TBC,TBC,TBC,TBC,,E VQLLES GGG LV QPGG SLRLSCA ASGF SF S SYTMSWVR QAPGKG LEWVATIS GGGRD IY YPDSVK GRFTISR DNSKN TLYLQMNS LRAEDT AVYYCVLL TGR VYFALD SWGQG TLVTVS S,D IVMT QSPDS LAVS LGER ATINCK ASESVDTSDNS FIHWYQ QKPGQSP KLLIYR SSTLESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQ QNYDVPW TF GQGT KVEI K
Tobevibart,Whole mAb,G1,Lambda,TBC,Active,ELQLVESGGGWVQPGGSQRLSCAASGRIFRSFYMSWVRQAPGKGLEWVATINQDGSEKLYVDSVKGRFTISRDNAKNSLFLQMNNLRVEDTAVYYCAAWSGNSGGMDVWGQGTTVSVSS,SYELTQPPSVSVSPGQTVSIPCSGDKLGNKNVAWFQHKPGQSPVLVIYEVKYRPSGIPERFSGSNSGNTATLTISGTQAMDEAAYFCQTFDSTTVVFGGGTRLTVL,na,na,None,None,None,2022,na,HPV Envelope Protein,TBC,TBC,TBC,TBC,TBC,,E LQLVES GGG WV QPGGSQ RLSC AASGR IFRSFYMSWVR QAPGKG LEWVATI NQDGS EKLYVD SVKG RFTISR DNAKNS LFLQM NNL RV EDT AVYYCAAW SGNSGGM DVW GQG TTVSVS S,SYELTQPPS VSV SPGQ TVSIP CSGDKLGN KNVAWFQ HKPGQSP VLVIYEVKY RPSGIPERFSGSNSGN TATLTIS GTQAMDE AAYFCQT FDST TVVF GGGT RLTV L
Tocilizumab,Whole mAb,G1,Kappa,Approved,Active,QVQLQESGPGLVRPSQTLSLTCTVSGYSITSDHAWSWVRQPPGRGLEWIGYISYSGITTYNPSLKSRVTMLRDTSKNQFSLRLSSVTAADTAVYYCARSLARTTAMDYWGQGSLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQGNTLPYTFGQGTKVEIK,na,na,None,None,None,2004,2004,IL6R,Assistance Publique Hopitaux de Paris;Charite - Universitatsmedizin Berlin;Chugai Pharmaceutical;Hospital for Special Surgery;JW Pharmaceutical;Roche;University Hospital Inselspital;University Hospital;Osaka University Tubingen;University of Bern;University of Pittsburgh,Drug hypersensitivity;Giant cell arteritis;Giant lymph node hyperplasia;Juvenile rheumatoid arthritis;Rheumatoid arthritis;Vasculitis,Adult-onset Still's disease;Osteoarthritis;Systemic scleroderma;Amyotrophic lateral sclerosis;Dermatomyositis;Familial Mediterranean fever;Polymyalgia rheumatica;Polymyositis;Pulmonary arterial hypertension;Schnitzler syndrome;Urogenital cancer,Chronic lymphocytic leukaemia;Ankylosing spondylitis;Crohn's disease;Multiple myeloma;Pancreatic cancer;Systemic lupus erythematosus,na,,Q VQLQE SGPGL V RPSQ TLSLTCTV SG YSI TSDH AWSWVR QPPGRGL EWIGYISY SG ITTY NPSLKS RVTMLR DTSKN QFSLRLSS VTAADT AVYYCA RSLARTTAMDYWGQG SLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQD ISSYLNWYQ QKPGKAP KLLIYYT SRLHSGVPSRFSGSGSGTD FTFTIS SLQ PEDIA TYYC QQGNTLP YT FGQGT KVEI K
Tomaralimab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVQSGSELKKPGASVKLSCKASGFTFTTYGINWVRQAPGQGLEWIGWIYPRDGSTNFNENFKDRATITVDTSASTAYMELSSLRSEDTAVYFCARLTGGTFLDYWGQGTTVTVSS,DIVLTQSPATLSLSPGERATLSCRASESVEYYGTSLMQWYQQKPGQPPKLLIFGASNVESGVPDRFSGSGSGTDFTLKISRVEAEDVGMYFCQQSRKLPWTFGGGTKVEIK,na,na,None,None,None,2018,2019,TLR2,Opsona Therapeutics,na,Delayed graft function;Myelodysplastic syndromes;Cancer,Autoimmune disorders;Inflammation,na,,E VQLVQ SGS E LKKPGA SVKLSCK ASGF TFTTYGINWVRQ APGQG LEWIGWIY PRDGSTNFNENFKDR ATITVD TSAST AYMELS SLRSEDT AVYFCARL TGGT FLDY WGQG TTVTVS S,D IVLTQ SPA TLSL SPGE RATLSCR ASES VEYY GT SLMQWYQ QKPGQPP KLLIFG ASNVESGVPDRFSGSGSGTD FTLKISRVE AEDVG MYFCQ QSRKLPWTFGGGT KVEI K
Tomuzotuximab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVST,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK,na,na,None,6au5:DC:BA/6axp:BA:DC/6ayn:BA:DC/6azk:DC:BA/6azl:BA:DC/5i76:DC:BA/1yy8:DC:BA/5th2:DC:BA/5f88:DC:BA/5hyq:DC:BA/5ir1:DC:BA/5ivz:DC:BA/5iv2:DC:BA/5t1k:DC:BA/5t1l:DC:BA/5id0:DC:BA/5id1:DC:BA/5euk:DC:BA/5ff6:DC:BA/5iop:DC:BA/5icy:DC:BA/5itf:DC:BA/5etu:DC:BA/5t1m:DC:BA/5esq:DC:BA/5icz:DC:BA/5i2i:DC:BA/5icx:DC:BA/5hpm:DC:BA/4gw5:DC:BA/4gw1:DC:BA/1yy9:DC/4krp:DC/4kro:DC,5gz0:BA:DC/6arp:BA:DC/6aru:CB,2016,2017,EGFR,Glycotope,na,Head and neck cancer;Colorectal cancer;Gastric cancer;Non-small cell lung cancer;Renal cancer;Solid tumours,na,GlycoExpress Technology,,QV QLKQ SGPGLVQPSQ SLSITCTV SGF SL T N Y GVHWVRQ SPGKGL EWLGVIWS GGNTDYNTPF TSRLSI NKDNSKS QVFFKM NSLQSNDT AIYYCA RAL TYY D YEFAYW GQG TLVTVS T,DI LLT QSP VILSV SPGE RVSFSCR ASQSIGT NIHWYQQ RTNGSP RLLIKYA SESISGIPSRFSGSGSGT DFTLSIN SVES EDIADYYCQ QNNNWPTTFGAGT KLEL K
Toripalimab,Whole mAb,G4,Kappa,Approved,Active,QGQLVQSGAEVKKPGASVKVSCKASGYTFTDYEMHWVRQAPIHGLEWIGVIESETGGTAYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREGITTVATTYYWYFDVWGQGTTVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPLTFGQGTKLEIK,na,na,6jbt:HL,None,None,2018,2019,PDCD1,Fudan University;Peking University;Shanghai Junshi Biosciences;Sun Yat-Sen University,Malignant melanoma,Nasopharyngeal cancer;Oesophageal cancer;Biliary cancer;Gastric cancer;Non-small cell lung cancer;Solid tumours;Urogenital cancer;Head and neck cancer;Alveolar soft part sarcoma;Breast cancer;Cancer;Liver cancer;Lymphoma;Neuroendocrine tumours;Renal cancer,na,na,,QGQ LVQ SGA EVK KPGA SVKVSCK ASGY TF TDY EMHWVRQ APIHG LEWIGVIES ETGGTAYNQK F K GRVTITA DKSTS TAYMELS SLRSEDT AVYYCA REGI TTVATTYYWYFDV WGQG TTVTVS S,DV VMT QSPLSLP VT LGQP ASISC RSSQ SIVH SNGN TYLEWYL QKPGQSP QLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCF QGSHVP LTF GQGT KLEI K
Torudokimab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVETGGGLIQPGGSLRLSCAASGFTFSFYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTIHGIRAAYDAFIIWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVGINLSWYQQKPGQAPRLLIYGASHRLTGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCHQYSQPPPFTFGGGTKVEIK,na,na,None,None,None,2020,2021,IL33,Eli Lilly,na,Atopic dermatitis,na,na,,E VQLVET GGG LI QPGG SLRLSCA ASGF TFSFYAMSWVR QAPGKG LEWVSAIS GSGGS TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA R T IHGIRAA YD AFIIW GQG TLVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQS VGINLSWY QQKPGQAP RLLIYG ASH RL TGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCHQ YSQPPPF TF GGG TKVEI K
Tosatoxumab,Whole mAb,G1,Lambda,Phase-III,Active,EVQMVQSGAEVKKPGEPLKISCKGSGYKFGTHWIGWVRQRPGKGLEWMGIIHPADSETKYSPSFQGQVSFSADKSSNTAYLHWSTLRASDTAMYYCARRSGSSSWYALDFWGQGTMVTVSS,QSVLTQSPSASGTPGQRVTISCSGGSSNIGSNTVNWYQQFPGAAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLNGLYVFGTGTKVTVL,na,na,None,None,None,2013,2014,Toxin A,Aridis Pharmaceuticals;Kenta Biotech,na,Nosocomial pneumonia,Sepsis,na,,E VQMVQ SGA EVK KPGEP LKISC KGSGYKFGT HWIGWVRQ RPGKGL EWMGII HPADSETKYSPSFQG QVSFSA DKSSN TAYLHWSTL RASDT AMYYCAR RSGSSS WYALDF WGQG TMVTVS S,QSV LT QSPSASGTPGQ RVTISC SGGSSNIG SNTVNWYQQ FPGAAP KLLIYT NNQRPSGVPDRFSGSKSGT SASLAIS GLQSEDEAD YYCATW DDSLNG LYVF GTGT KVTV L
Tovetumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMNWIRQAPGKGLEWVSYISSSGSIIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGRIAARGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVSITCRPSQSFSRYINWYQQKPGKAPKLLIHAASSLVGGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTYSNPPITFGQGTRLEMK,na,na,None,None,None,2013,2014,PDGFRA,Cambridge Antibody Technology;MedImmune,na,na,Glioblastoma;Non-small cell lung cancer;Solid tumours,na,,Q VQLVES GGG LV KPGG SLRLSC AASGF TF SDYYMNWI R QAPGKGL EWVSYI SSSGS IIYYA DSVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCA REG RIAARGMDV WGQG TTVTVS S,DIQMTQSPSS LSA SVGD RVSITC RPSQS FSRYINWYQ QKPGKAP KLLIHA ASSLVGGVPSRFSGSGSGTD FTLTIS SLQP EDFA TYYCQ QTYSNPPI TF GQGT RLE MK
Tozorakimab,Whole mAb,G1,Lambda,Phase-III,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGISAIDQSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQKFMQLWGGGLRYPFGYWGQGTMVTVSS,SYVLTQPPSVSVSPGQTASITCSGEGMGDKYAAWYQQKPGQSPVLVIYRDTKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCGVIQDNTGVFGGGTKLTVL,na,na,None,None,None,2020,2021,IL33,AstraZeneca,na,Chronic Obstructive Pulmonary Disease;Diabetic nephropathy,na,na,,E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKGL EWVS GI SAI DQST YY ADSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYC ARQKFMQL WGGGLRYPFGYWGQG TMVTVS S,SY VLT QPPS VSV SPGQ TASITC SGEGMGDK YAAWYQ QKPGQSP VLVIYR DTKRPSGIPERFSGSNSGN TATLTIS GTQAMDEAD YYCGVIQ DNTG VF GGGT KLTV L
Tralokinumab,Whole mAb,G4,Lambda,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGLSWVRQAPGQGLEWMGWISANNGDTNYGQEFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDSSSSWARWFFDLWGRGTLVTVSS,SYVLTQPPSVSVAPGKTARITCGGNIIGSKLVHWYQQKPGQAPVLVIYDDGDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDTGSDPVVFGGGTKLTVL,na,na,5l6y:HL,None,None,2009,2010,IL13,Cambridge Antibody Technology;Icahn School of Medicine at Mount Sinai;LEO Pharma;MedImmune,na,Atopic dermatitis;Alopecia areata,Asthma;Chronic obstructive pulmonary disease;Idiopathic pulmonary fibrosis;Ulcerative colitis,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTNYGLSWVRQ APGQGL EWMGWISA NNGDTNYGQ EFQGRVTMTT DTSTS TAYMELRSL RSDDT AVYYCA RDSSSS W ARWFFD LWGRG TLVTV SS,SY VL TQPPS VSV APGK TARITC GGN II G SK L VHWYQ QKPGQAP VLVIY DDGDRPSGIPERFSGSNSGN TATLTISRVE AGDE ADYYCQVWD TGSDP VVF GGGT KLTV L
Trastuzumab,Whole mAb,G1,Kappa,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,na,na,1fvc:DC:BA/4hkz:BA/4ub0:HL/5xhf:BA/1n8z:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD/6oge:ED/7mn8:DC,1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC,5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,1997,1998,ERBB2,Roche,Breast cancer,na,na,na,Timigutuzumab is a biosimilar of Trastuzumab and Coprelotamab with an identical Variable region. Cinrebafusp and Anvatabart have identical V domains.,E VQLVES GGG LV QPGG SLRLSCA ASGFNIKD TYIHWVRQ APGKG LEWVARIY PTNGY TRYA DSVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYCS RWGGDG FYAMD YWGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQD VNTA VAWYQ QKPGKAP KLLIYSASFLY SGVPSRFSGSRSGTD FTLTIS SLQP EDFAT YYCQ QHYTTPPTFGQGT KVEI K
Tregalizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EEQLVESGGGLVKPGGSLRLSCAASGFSFSDCRMYWLRQAPGKGLEWIGVISVKSENYGANYAESVRGRFTISRDDSKNTVYLQMNSLKTEDTAVYYCSASYYRYDVGAWFAYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCRASKSVSTSGYSYIYWYQQKPGQPPKLLIYLASILESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQHSRELPWTFGQGTKVEIK,na,na,None,None,None,2010,2011,CD4,Biotest AG,na,na,Multiple sclerosis;Plaque psoriasis;Rheumatoid arthritis,na,,EE QLVES GGG LV KPGG SLRLSCA ASGFSFSDC RMYWLRQ APGKGL EWIGVISVK SENYGANYAE SVRGRFTISR DDSKN TVYLQMN SLKTEDT AVYYCSASYYRY DVG AWFAYW GQG TLVTVS S,D IVMT QSPDS LAVS LGER ATINCR ASKSVSTSGY SYIYWYQ QKPGQPP KLLIYLASIL ESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC QHSRELPW T FGQGT KVEI K
Tremelimumab,Whole mAb,G2,Kappa,Preregistration,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPRGATLYYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSINSYLDWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYSTPFTFGPGTKVEIK,na,na,5ggu:HL:AB/5ggv:HL,None,None,2005,2008,CTLA4,AIO Studien gGmbH;Amgen;ARCAGY/GINECO Group;AstraZeneca;Azienda Ospedaliera Universitaria Senese;Canadian Cancer Trials Group;Charite - Universitatsmedizin Berlin;Dana-Farber Cancer Institute;Fondazione IRCCS Istituto Nazionale dei Tumori;Grupo Espanol de Tumores Neuroendocrinos;Hoosier Cancer Research Network;Immunocore;Institute Gustave-Roussy;Kyoto Breast Cancer Research Network;M. D. Anderson Cancer Center;MedImmune;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);Northwestern University;Pfizer;Seoul National University Hospital;UNICANCER;University College London;University of Maryland Greenbaum Cancer Center;Yonsei University College of Medicine,na,Head and neck cancer;Liver cancer;Mesothelioma;Non-small cell lung cancer;Renal cell carcinoma;Small cell lung cancer;Solid tumours;Urogenital cancer;Biliary cancer;Bladder cancer;Breast cancer;Cholangiocarcinoma;Colorectal cancer;Endometrial cancer;Fallopian tube cancer;Gallbladder cancer;Gastric cancer;Gastrointestinal cancer;Germ cell and embryonal neoplasms;Glioblastoma;Lung cancer;Neuroendocrine tumours;Oropharyngeal cancer;Ovarian cancer;Pancreatic cancer;Peritoneal cancer;Prostate cancer;Sarcoma;Soft tissue sarcoma;Thyroid cancer;Haematological malignancies;Malignant melanoma;Oesophageal cancer;Cervical cancer,Diffuse large B-cell lymphoma;Gynaecological cancer;Myelodysplastic syndromes,Abgenix XenoMouse,Tremelimumab is the new name for Ticilimumab (PL97),Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKGL EWVAVIWY DGSNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAED TAVYYCAR DPRGA TLYYYYY G M DVWGQG TTVTVS S,DIQ M TQSPSS LSA SVGD RVTITCR ASQS INSYLDWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQ PEDFATYYCQQ YYSTPF T FGPGT KVEI K
Trevogrumab,Whole mAb,G4,Kappa,Phase-II,Active,EVQVLESGGDLVQPGGSLRLSCAASGFTFSAYAMTWVRQAPGKGLEWVSAISGSGGSAYYADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAKDGAWKMSGLDVWGQGTTVIVSS,DIQMTQSPASLSASVGDRVTITCRASQDISDYLAWYQQKPGKIPRLLIYTTSTLQSGVPSRFRGSGSGTDFTLTISSLQPEDVATYYCQKYDSAPLTFGGGTKVEIK,na,na,None,None,None,2015,2016,MSTN,Regeneron Pharmaceuticals;Sanofi,na,Muscular atrophy;Osteoporosis,na,VelocImmune Mouse,,E VQVLE SGGD LV QPGG SLRLSC AASGF TFSAYAMTWVR QAPGKG LEWVSAIS GSGGS AYYA DSVKG RFTISR DNSKN TVYLQMN SLRAED TAVYYC AKDGA WKMSGLDVW GQG TTVIVS S,DIQMTQSPA SLSAS VGD RVTITCR ASQD ISDYLAWYQ QKPGKIP RLLIYT TSTLQSGVPSRFRGSGSGTD FTLTIS SLQ PEDVATYYCQK YDSAP LTF GGGT KVEI K
Trinbelimab,Whole mAb,G1,Lambda,TBC,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGIFRTYAISWVRQAPGQGLEWMGGIIPMFGTVNYAQKFQGRVTISADKSTSTAYMELSRLRSEDTAVYYCARPPSGGCGGDCSRRGYYYAMDVWGQGTTITVSS,QSALTQPASVSGSPGQSITISCSGSSSDVGGYKYVSWYQQHPGKAPQLMIYDVNNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGGGTKLTVL,na,na,None,None,None,2021,2022,RhD,Bharat Serums and Vaccines,TBC,TBC,TBC,na,(June '22: Corrected CDRH3 sequence),Q VQLVQ SGA EVK KPGS SVKVSCK ASGGI FRTYAISWVR QAPGQGL EWM GG IIPM FG TVNY AQKFQG RVTISA DKSTS TAYMELSR LRSEDT AVYYCA RPPSGGCGGDCSRRG YYYAMD VWGQG TTITVS S,QSALTQPA SV SGSPGQ SITISC SGSSSDVGG YKYVSWYQ QHPGKAP QLMIYD VNNRPSGV SN RFSGSKSGN TASLTIS GLQAEDEAD YYCSS YTSSST RVF GGGT KLTV L
Trontinemab,Bispecific Mixed Format with Domain Crossover,G1;G1,Kappa;Kappa,TBC,Active,QVELVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINASGTRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGKGNTHKPYGYVRYFDVWGQGTLVTVSS,DIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGVPARFSGSGSGTDFTLTISSLEPEDFATYYCLQIYNMPITFGQGTKVEIK,QSMQESGPGLVKPSQTLSLTCTVSGFSLSSYAMSWIRQHPGKGLEWIGYIWSGGSTDYASWAKSRVTISKTSTTVSLKLSSVTAADTAVYYCARRYGTSYPDYGDASGFDPWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQSISSYLAWYQQKPGKAPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQNYASSNVDNTFGGGTKVEIK,5csz:AB:HL;None,None;None,None;None,2022,na,APP Abeta 1-40/42;TFRC,TBC,TBC,TBC,TBC,TBC,Arm 1 has same Fv as Gantenerumab,Q VELVE SGGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKGL EWVSAI NASGT RTYYA DSVKG RFTISR DNSKN TLYLQMN SLRAED TAVYYCA RGKGNTHKPY GYVRYFDV WGQG TLVTVS S,D IVLTQ SPA TLSL SPGE RATLSCR ASQSVSS S YLAWYQ QKPGQAP RLLIYG ASSRATGVP ARFS GSGSGT DFTLTIS SLE PEDFAT YYCLQIY NMP ITF GQGT KVEI K
Tucotuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,EIQLVQSGAEVKKPGETVKISCKASGYTFTNYGMNWVKQTPGKGLKWMGWINTYTGEPTYADDFKGRFAFSLETSTSTAFLQINNLRSEDTATYFCVRFISKGDYWGQGTSVTVSS,EIVLTQSPATLSLSPGERVTLTCSASSSVSYMLWYQQKPGSSPKPWIFDTSNLASGFPARFSGSGSGTSYSLIISSMEAEDAATYYCHQRSGYPYTFGGGTKLEIK,na,na,None,None,None,2005,2006,EPCAM,EMD Lexigen;Merck KGaA,na,na,Ovarian cancer;Small cell lung cancer,na,,E IQLVQ SGA EVK KPGE TVKISCK ASGY TFTN YGM NWVK QTPGKGL KWMGWIN TYTGEPTYADDFKG RFAFSLE TSTST AFLQIN NLRSEDTA TYFCVRFIS KGDYWGQG TSVTVS S,E IVLTQ SPA TLSL SPGE RVTLTCS ASSS VSYMLWYQ QKPGSSPKP WIFD TSNLASGFP ARFS GSGSGT SYSLIISS MEAED AA TYYCH QRSGYPY TF GGGT KLEI K
Tulisokibart,Whole mAb,G1,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGFDIQDTYMHWVKQRPGQGLEWMGRIDPASGHTKYDPKFQVRVTITRDTSTSTVYLELSSLRSEDTAVYYCARSGGLPDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASSSVSYMYWYQQKPGQAPRPLIYATSNLASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQWEGNPRTFGGGTKLEIK,na,na,None,None,None,2022,na,TNFSF15,TBC,TBC,TBC,TBC,TBC,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGFDIQDT YMHWVK QRPGQG LEWMGRI DPASGHTKYDPKF QVRVTITR DTSTS TVYLELS SLRSEDT AVYYCA RSGGLPDVWGQG TTVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASSS VSYMYWYQ QKPGQAPRP LIYAT SNLASGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQQ WEGNPRTFGGG TKLEI K
Tuparstobart,Whole mAb,G1,Kappa,TBC,Active,QVQMVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQGLEWMGEIDPANDNTKYDPKFQGRVTITADTSTSTVYMELSSLRSEDTAVYYCATYYYKYDVGGFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCSVSSSISSSNLHWYQQKPGQAPRLLIYGTSNLASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQWSSYPFTFGQGTKVEIK,na,na,None,None,None,2022,na,LAG3,TBC,TBC,TBC,TBC,TBC,,Q VQMVQ SGA EVK KPGA SVKVSCK ASGFNIKD TYIHWVRQ APGQG LEWMGEI DPANDNTKYDPKFQG RVTITA DTSTS TVYMELS SLRSEDT AVYYCATYYYKY DVGGF DY WGQG TLVTVS S,E IVLTQ SPG TLSL SPGER ATLSCSVS SSISSSNL HWYQ QKPGQAP RLLIYG TSNLASGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQ QWSSYPF TF GQGT KVEI K
Tusamitamab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLQESGPGLVKPGGSLSLSCAASGFVFSSYDMSWVRQTPERGLEWVAYISSGGGITYAPSTVKGRFTVSRDNAKNTLYLQMNSLTSEDTAVYYCAAHYFGSSGPFAYWGQGTLVTVSS,DIQMTQSPASLSASVGDRVTITCRASENIFSYLAWYQQKPGKSPKLLVYNTRTLAEGVPSRFSGSGSGTDFSLTISSLQPEDFATYYCQHHYGTPFTFGSGTKLEIK,na,na,None,None,None,2020,2021,CEACAM5,Sanofi-Aventis,na,Non-small cell lung cancer;Breast cancer;Pancreatic cancer;Solid tumours,na,na,,EV QLQ ESGPG LV KPGG SLSLSC AASG FVFSS YDM SWVR QTPERGL EWVAYIS SGGG ITY APSTV KGRFTVSR DNAKN TLYLQMN SLTSEDT AVYYCAAHY FGSSGP FAYW GQG TLVTV SS,DIQ MT QSPA SLSAS VGD RVTITCR ASEN IF SYLAWY QQKPGKSP KLLVYN TRTLAEGVPSRFSGSGSGTD FSLTIS SLQ PEDFAT YYCQ HHYGTPF TF GSGT KLEI K
Tuvonralimab,Whole mAb,G1,Kappa,Phase-I,Active,QVQLVESGGGVVEPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYKPSEKDYADSAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGGLLGYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSINSYLAWYQQKPGQAPRPLIYGVSSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGRYPFTFGPGTKVDIK,na,na,None,None,None,2021,2022,CTLA4,Qilu Puget Sound Biotherapeutics,na,Neoplasms,na,na,,Q VQLVES GG GVV EPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKGL EWVAVIWYK PSEKDYADSAKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYC ARGG LLGYFD YWGQG TLVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQS INSYLAWYQ QKPGQAPRP LIYGVS SRATGIPDRFSGSGSGTD FTLTISR LE PEDF AVYYC QQ YGRYPF TF GPGT KVDI K
Ubamatamab,Bispecific mAb,G4;G4,Kappa,Phase-I/II,Active,QVQLVESGGGLVKPGGSLRLSCAASGFTFSNYYMSWVRQAPGKGLEWISYISGRGSTIFYADSVKGRITISRDNAKNSLFLQMNSLRAEDTAVYFCVKDRGGYSPYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISTYLNWYQQKPGKAPKLLIYTASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYSMHWVRQAPGKGLEWVSGISWNSGSKGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKYGSGYGKFYHYGLDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISTYLNWYQQKPGKAPKLLIYTASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK,None;None,None;None,None;None,2021,2022,MUC16;CD3E,Regeneron Pharmaceuticals,na,Fallopian tube cancer;Ovarian cancer;Peritoneal cancer,na,na,,Q VQLVES GGG LV KPGG SLRLSC AASGF TFS N YYMSWVR QAPGKGL EWISYI SGRGS TIFYAD SVKG RITISR DNAKNS LFLQMN SLRAEDT AVYFCVK DRGGYSPYWGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQS ISTYLNWYQ QKPGKAP KLLIYT ASSLQSGVPSRFSGSGSGTD FTLTIS SLQP EDFAT YYC QQSYSTPP ITF GQGT RLEI K
Ublituximab,Whole mAb,G1,Kappa,Preregistration,Active,QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGGIYPGNGDTSYNQKFKGKATLTVGKSSSTAYMQLSSLTSEDSAVYFCARYDYNYAMDYWGQGTSVTVSS,QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYATSNLASGVPARFSGSGSGTSYSFTISRVEAEDAATYYCQQWTFNPPTFGGGTRLEIK,na,na,None,None,None,2010,2011,MS4A1,LFB Biotechnologies;rEVO Biologics;Johns Hopkins University;TG Therapeutics Inc,na,Chronic lymphocytic leukaemia;Multiple sclerosis;Diffuse large B cell lymphoma;Follicular lymphoma;Mantle-cell lymphoma;Non-Hodgkin's lymphoma,Neuromyelitis optica,EMABling Platform,,QA YLQ QSGA ELV RPGA SVKMSCK ASGY TFTSYNMHWVK QTPRQGL EWIGGI YPGNGDTSYNQKFKG KATLTV GKSSST AYMQLS SLTSEDS AVYFCARY DYNYA M DYWGQG TSVTVS S,Q IVLS QSP AILS ASPGE KVTMTCR ASSS VSYMHWYQ QKPGSSPKP WIYAT SNLASGVP ARFS GSGSGT SYSFTISRVE AEDA ATYYCQQWTF NPPTFGGG TRLEI K
Ulenistamab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGFNIKDYYMHWVRQAPGQGLEWMGWIDPENGNTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARRAITTATAWFAYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRTRKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSYNLYTFGQGTKVEIK,na,na,None,None,None,2021,2022,PAUF,Prestige Biopharma,na,Pancreatic cancer;Ovarian cancer,na,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGFNIK D YYMHWVR QAPGQGL EWMGWI DPENGNTNY AQKF QG RVTMT RDTS ISTAYME LS RLRSDDT A VYY CARRAITTATAWFA Y WGQG TLVTVS S,D IVMT QSPDS LAVS LGER ATINC KSSQ SLL NSRTR KNYLAWYQ QKPGQPP KLLIYWA STRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC KQSY NLYTF GQGT KVEI K
Uliledlimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLQESGPGLVKPSETLSLTCAVSGYSITSGYYWNWIRQPPGKKLEWMGYINYGGSNGYNPSLKSRITISRDTSKNQFSLKLSSVTAADTAVYYCARDYDAYYEALDDWGQGTTVTVSS,EIVLSQSPATLSLSPGERATLSCRASSRVNYMHWYQQKPGQSPRPWISATSNLASGVPARFSGSGSGTSYTLTISSLEPEDFAVYYCQQWSSNPPTFGGGTKVEIK,na,na,None,None,None,2020,2021,NT5E,TRACON Pharmaceuticals;I-Mab Biopharma,na,Breast cancer;Gastrointestinal cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer;Solid tumours,na,na,,EV QLQ ESGPGL V KPSE TLSLTCAV SGY SIT SG YYWNWIR QPPGK KLEWMGYINY GGSNGYNPSLK SRITISR DTSKN QFSLKLSS VTAADT AVYYCA RDY DAYYEAL DDWGQGT TVTV SS,E IVLS QSPA TLSL SPGE RATLSCRA SSRV NYMHWYQ QKPGQSPRP WISA TSNLASGVP ARFS GSGSGT SYTLTISS LEPED FAVYYCQQ WSSNPPTFGGG TKVEI K
Ulocuplumab,Whole mAb,G4,Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLRLSCAAAGFTFSSYSMNWVRQAPGKGLEWVSYISSRSRTIYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARDYGGQPPYYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFVTYYCQQYNSYPRTFGQGTKVEIK,na,na,None,None,None,2013,2014,CXCR4,Bristol-Myers Squibb;Medarex;University of Bari,na,Acute myeloid leukaemia;Solid tumours;Waldenstrom's macroglobulinaemia;Neuroectodermal tumours,B-cell lymphoma;B-cell prolymphocytic leukaemia;Precursor cell lymphoblastic leukaemia-lymphoma;Multiple myeloma,na,,E VQLVES GGG LV QPGG SLRLSC AAAG FTFSS Y SMNWVR QAPGKGL EWVSYIS SRSR TIYYA DSVKG RFTISR DNAKNS LYLQMN SLRDEDT AVYYCAR DYGGQPP YYYYYGMDV WGQG TTVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQG ISSWLAWYQ QKPEKAPK SLIYAA SSLQSGVPS RF SGSGSGTD FTLTIS SLQPE D FVTYYCQ QYNSYPRTFGQGT KVEI K
Ulviprubart,Whole mAb,G1,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDHNMHWVKQATGQGLEWFGFINPNTGVTRYNQKFQGRVTLTINKAISTAYLELSSLRSEDTAVYYCARDYYGSAWFAYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQTLLYSSDQKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYNYPTFGGGTKVEIK,na,na,None,None,None,2022,na,KLRG1,TBC,TBC,TBC,TBC,TBC,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TF TDHN MHWVKQ ATGQGL EWFGFI NPNTG VTRY NQKFQG RVTLTI NKAI STAYLELS SLRSEDT AVYYCAR DYYGS AWFAYW GQG TLVTVS S,D IVMT QSPDS LAVS LGE RATINC KSSQ TLLYS SDQKN YLAWYQ QKPGQPP KLLIYWAS TRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQQ YYNYPTFGGG TKVEI K
Umesolerbart,Whole mAb,G4,Kappa,TBC,Active,EVQLVESGGDLVQPGGSLRLSCAASGFTFSSYEMNWVRQAPGKGLEWVSFISDSSSNIYYADSVKGRFTISRDNAKKSLYLQMTSLRAEDTAVYYCAREAIGSTSFDNWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSSLAWYQQKPGQAPRRLIYSASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAIYYCHQYNNWPLTFGGGTKVEIK,na,na,7mxl:HL,None,None,2022,na,Bet v 1,Regeneron,TBC,TBC,TBC,TBC,Antigen: Bet v 1 (Betula alleghaniensis (yellow birch) pollen allergen 1. Also known as REGN5714.,E VQLVE SGGD LV QPGG SLRLSC AASGF TFSSYEMNWVRQ APGKG LEWVSFIS DSSSN IYYAD SVKG RFTIS RDNAKK SLYLQMTSL RAEDT AVYYCARE AIGSTSFDNWGQG TLVTVS S,E IVMT QSPA TLSV SPGE RATLSCR ASQSVSSS LAWYQ QKPGQAPR RLIYS ASTRATGIP ARFS GSGSGT EFTLTISS LQSED FAIYYCH QYNNWP LTF GGG TKVEI K
Unasnemab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGRSLRLSCTASGFTFSDAWMDWVRQAPGKGLEWVAEIRSKANNHATYYAESVKGRFTISRDDSKSIVYLQMNSLRTEDTALYYCTRRDGAYWGKGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTLTISSLQPEDFASYFCQQLNTLPWTFGGGTKVEME,na,na,None,None,None,2020,2021,RGMA,Mitsubishi Tanabe Pharma Corporation,na,Acute spinal cord injury,na,na,,E VQLVES GGG LV QPGR SLRLSCT ASGF T FS DAWMDWVRQ APGKGL EWVAEIRS KANNH ATYYAES VKG RFTIS RDDSK SIVYLQM NSLRTEDT ALYYCTR RDGA YW GKG TTVTVS S,DIQ MT QSPSS VSAS VGD RVTITCR ASQD ISSYLNWYQ QKPGKAP KLLIYYT SRLHSGVPSRFSGSGSGTD FTLTIS SLQ PEDFASYFCQQL NTLPWTFGGGT KVEM E
Upanovimab,Whole mAb,G1,Kappa,Phase-II/III,Active,EVKLVESGGGLVKPGGSLRLSCAASGFTFSNYGMSWVRQAPGKRLEWVAEISSGGSYTYYPDTVTGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARFRYDGGGGTVDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASESVDNYGISFMNWFQQKPGQAPRLLIYAASNQGSGVPARFSGSGSGTDFSLTISSLEPEDFAVYFCQQSKEVPRTFGQGTKVEIK,na,na,None,None,7cyh:ED/7cyp:GF:IH:ED/7cwt:IJ:GF:ED/7e5s:RO,2021,2022,SARS-CoV-2 Spike RBD,Sinocelltech,na,COVID-19,na,na,,E VKLVES GGG LV KPGG SLRLSC AASGF TFS NYG MSWVR QAPGK RLEWVAEI SSGGS YTY YPDTV TGRFTISR DNAKN TLYLQMNSL RAEDT AVYYCARFRY DGGGG TVDYW GQG TLVTVS S,E IVLTQ SPA TLSL SPGE RATLSCRA SESVDNY GISFMNWF QQKPGQAP RLLIYAA SNQGSGVP ARFS GSGSGTD FSLTIS SLEPED FAVYFCQ QSKEVPRTFGQGT KVEI K
Upifitamab,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVVKPGASVKMSCKASGYTFTGYNIHWVKQAPGQGLEWIGAIYPGNGDTSYKQKFRGRATLTADTSTSTVYMELSSLRSEDSAVYYCARGETARATFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDIGNFLNWYQQKPGKTVKVLIYYTSSLYSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQYSKLPLTFGQGTKLELK,na,na,None,None,None,2019,2020,SLC34A2,Mersana Therapeutics,na,Non-small cell lung cancer;Ovarian cancer,na,na,,Q VQLVQ SGA EVV KPGA SVKMSCK ASGY TFTGYNIHWVK QAPGQG LEWIGAIY PGNGDTSY KQKF RG RATLTA DTSTS TVYMELS SLRSEDS AVYYCA RGET ARATFAYW GQG TLVTVS S,DIQMTQSPSS LSA SVGD RVTITCS ASQD IGNFLNWYQ QKPGK TVKVLIYYT SSLYSGVPSRFSGSGSGTD YTLTIS SLQ PEDFATYYCQQ YSKLPL T FGQGT KLEL K
Urabrelimab,Whole mAb,G4,Kappa,Phase-I,Discontinued,QVQLQESGPGLVKPSGTLSLTCAVSGVSIRSINWWNWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLNSVTAADTAVYYCARDGGIAVTDYYYYGLDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASESVSSNLAWYQQKPGQAPRLLIYGAFNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSDWFTFGGGTKVEIK,na,na,None,None,None,2019,2020,CD47,Surface Oncology,na,na,Haematological malignancies;Solid tumours,na,,QV QLQE SGPG LV KPSG TLSLTCAV SG VSIRSINWWNWVR QPPGKGL EWIGEIYH SGSTNYNPSLK SRVTISVD KSKN QFSLKLN S V TAAD TAVYYCA RDGG IAVTDYYYYGLDVW GQG TTVTVS S,E IVLTQ SPA TLSL SPGE RATLSCRA SESVSSN LAWYQ QKPGQAP RLLIYGAF NRATGIP ARFS GSGSGTD FTLTIS SLEPED FAVYYCQ QRSD WFTF GGG TKVEI K
Urelumab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQSPEKGLEWIGEINHGGYVTYNPSLESRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDYGPGNYDWYFDLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPALTFGGGTKVEIK,na,na,6mhr:AB:DE,None,None,2010,2011,TNFRSF9,Bristol-Myers Squibb;National Cancer Institute (USA);Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;University of Chicago;Medarex,na,Non-Hodgkin's lymphoma;Solid tumours;Glioblastoma;Multiple myeloma,Colorectal cancer;Head and neck cancer;Malignant melanoma;Non-small cell lung cancer,Medarex UltiMAb Mouse,"Jain paper: ""VL sequence modified at one position to match patent document (US7659384) and JK germline""",QV QLQQW GAGLLKPSE TLSLTCAVY GGSFSG YYWSWIR QSPEKGL EWIGEI NHGG YVTY NPSLES RVTISVD TSKN QFSLKLSS VTAADT AVYYCAR DYGPGNYD WYFDL WGRG TLVTVS S,E IVLTQ SPA TLSL SPGE RATLSCR ASQS VSSY LA W Y QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPED FAVYYCQ QRSNWPPA LTF GGG TKVEI K
Urtoxazumab,scFv,na,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVATISTGGSYTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARRGDAWGNLDYWGQGTLVTVSS,EIVLTQSPATLSVSPGERATLSCRASQTISNNLHWYQQKPGQAPRLLIKSASQSISGIPARFSGSGSGTDFTLTISSLESEDFAVYYCQQSYSWPLTFGQGTKVEIK,na,na,None,None,None,2004,2005,Shiga-like Toxin II,Teijin Pharma,na,na,Haemolytic uraemic syndrome,na,Anti-e coli mAb,E VQLVES GGG LV QPGG SLRLSC AASGF TFSS YG MSWVRQ APGKG LEWVATIS TGGS YTY YPDSVK GRFTISR DNAKN TLYLQMN SLRAEDT AVYYCAR RGDAWGN LDY WGQG TLVTVS S,E IVLTQ SPA TLSV SPGE RATLSCR ASQ TI SNN LHWYQ QKPGQAP RLLIKS ASQS I SGIP ARFS GSGSGTD FTLTISS LESED FAVYYCQ QSYSWP LTF GQGT KVEI K
Ustekinumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWLGWVRQMPGKGLDWIGIMSPVDSDIRYSPSFQGQVTMSVDKSITTAYLQWNSLKASDTAMYYCARRRPGQGYFDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPYTFGQGTKLEIK,na,na,3hmw:HL/3hmx:HL,None,None,2008,2009,IL12B,Centocor Inc;Janssen Biotech;Medarex,Crohn's disease;Plaque psoriasis;Psoriatic arthritis,Ulcerative colitis;Spondylarthritis;Systemic lupus erythematosus;Atopic dermatitis,Multiple sclerosis;Palmoplantar pustulosis;Primary biliary cirrhosis;Rheumatoid arthritis;Sarcoidosis,Medarex UltiMAb Mouse,,E VQLVQ SGA EVK KPGE SLKISC KGSGYS FTTYWLGWVR QMPGKGLD WIGIM SPVDSDI RY SPSFQG QVTMSV DKS ITTAYLQWN SLKASDT AMYYCAR RRPGQG YFDFW GQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQG ISSWLAWYQ QKPEKAPK SLIYAA SSLQSGVPS RF SGSGSGTD FTLTIS SLQ PEDFATYYCQQ YNIY P Y T FGQGT KLEI K
Utomilumab,Whole mAb,G2,Lambda,Phase-II,Active,EVQLVQSGAEVKKPGESLRISCKGSGYSFSTYWISWVRQMPGKGLEWMGKIYPGDSYTNYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGYGIFDYWGQGTLVTVSS,SYELTQPPSVSVSPGQTASITCSGDNIGDQYAHWYQQKPGQSPVLVIYQDKNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYTGFGSLAVFGGGTKLTVL,na,na,6a3w:GH:DE:AB:JK/6mi2:DE:AB,None,None,2016,2017,TNFRSF9,Dana-Farber Cancer Institute;Immatics US;Kite Pharma;Kyowa Hakko Kirin;M. D. Anderson Cancer Center;Pfizer,na,Breast cancer;Oropharyngeal cancer;Solid tumours;B-cell lymphoma;Diffuse large B cell lymphoma;Follicular lymphoma;Ovarian cancer,Non-Hodgkin's lymphoma;Colorectal cancer,MorphoSys HuCAL Phage Display,,E VQLVQ SGA EVK KPGE SLRISC KGSGYS FSTYWISWVR QMPGKGL EWMGKI YPGDSYTNYSPSFQG QVTIS ADKS ISTAYLQWS SLKASDT AMYYCA RGY GIFD YWGQG TLVTV SS,SYELTQPPS VSV SPGQ TASITC SGDNIGDQ YAHWYQ QKPGQSP VLVIYQ DKNRPSGIPERFSGSNSGN TATLTIS GTQAMDEAD YYCATY TGFG SLAVF GGGT KLTV L
Vadastuximab,Whole mAb ADC,G1,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYDINWVRQAPGQGLEWIGWIYPGDGSTKYNEKFKAKATLTADTSTSTAYMELRSLRSDDTAVYYCASGYEDAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTINCKASQDINSYLSWFQQKPGKAPKTLIYRANRLVDGVPSRFSGSGSGQDYTLTISSLQPEDFATYYCLQYDEFPLTFGGGTKVEIK,na,na,None,None,None,2015,2016,CD33,Seattle Genetics,na,na,Acute myeloid leukaemia;Myelodysplastic syndromes,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTNYDINWVR QAPGQG LEWIGWIY PGDGSTKYNEK FKAKATLTA DTSTS TAYMELRSL RSDDT AVYYCA SGYEDAMDYWGQG TTVTVS S,DIQ M TQSPSS LSA SVGD RVTINCK ASQD INSYLSWFQ QKPGKAPK TLIYRA N RLV DGVPS RF SGSGSGQD YTLTISS LQPEDF ATYYCLQ YDEFP LTF GGG TKVEI K
Valanafusp,Whole mAb Fusion,G1,Kappa,Phase-II,Active,QVQLQQSGPELVKPGALVKISCKASGYTFTNYDIHWVKQRPGQGLEWIGWIYPGDGSTKYNEKFKGKATLTADKSSSTAYMHLSSLTSEKSAVYFCAREWAYWGQGTLVTVSA,DIQMTQSPSSLSASLGERVSLTCRASQDIGGNLYWLQQGPDGTIKRLIYATSSLDSGVPKRFSGSRSGSDYSLTISSLESEDFVDYYCLQYSSSPWTFGGGTKMEIK,na,na,None,5kqv:PQ:CD/4zxb:CD,3loh:CD/2dtg:CD/3w14:CD:PQ,2017,2018,INSR,ArmaGen Technologies,na,Mucopolysaccharidosis I,na,na,,QV QLQ QSGPE LV KPGA LVKISCK ASGY TFTNYDIHWVKQ RPGQG LEWIGWIY PGDGSTKYNEKFKG KATLTA DKSSS TAYMHLS SLTSEKS AVYFCAREWAYW GQG TLVTVS A,DI QMT QSPSS LS ASLGE RVSLTCRA SQDIGGN LYWLQQ GPDGT IKRLIYAT SSLDSGVPK R FSGSRSGSD YSLTISS LESEDF VDYYCLQY SSSPW T FGGGT KMEI K
Vandortuzumab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAVSGYSITSDYAWNWVRQAPGKGLEWVGYISNSGSTSYNPSLKSRFTISRDTSKNTLYLQMNSLRAEDTAVYYCARERNYDYDDYYYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKSSQSLLYRSNQKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYNYPRTFGQGTKVEIK,na,na,None,None,None,2014,2015,STEAP1,Roche;Genentech,na,na,Cancers;Prostate Cancer,na,,E VQLVES GGG LV QPGG SLRLSCAV SGY SI TSD YAWNWVR QAPGKGL EWVGYIS NSGSTSYNPSLK SRFTISR DTSKN TLYLQMN SLRAEDT AVYYCAR ERNYDYDD YYYAMD YWGQG TLVTV SS,DI QMT QSPSS LSA SVGD RVTITC KSSQ SLLYR SNQKN YLAWYQ QKPGKAP KLLIYWAS TRESGVPS RF SGSGSGTD FTLTIS SLQP EDFAT YYCQ Q Y YNYPRTFGQGT KVEI K
Vantictumab,Whole mAb,G2,Lambda,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSHYTLSWVRQAPGKGLEWVSVISGDGSYTYYADSVKGRFTISSDNSKNTLYLQMNSLRAEDTAVYYCARNFIKYVFANWGQGTLVTVSS,DIELTQPPSVSVAPGQTARISCSGDNIGSFYVHWYQQKPGQAPVLVIYDKSNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYANTLSLVFGGGTKLTVL,na,na,None,None,None,2013,2014,FZD Family,Bayer HealthCare Pharmaceuticals;OncoMed Pharmaceuticals,na,na,Breast cancer;Non-small cell lung cancer;Pancreatic cancer,MorphoSys HuCAL Phage Display,,E VQLVES GGG LV QPGG SLRLSCA ASGF TFSHYTLSWVR QAPGKG LEWVSVIS GDGS YTYYA DSVKG RFTISS DNSKN TLYLQMN SLRAEDT AVYYC AR N FI KYVFA NWGQG TLVTV SS,DIELTQPPS VSV APGQ TARISC SGDNIG SFYVHWYQ QKPGQAP VLVIY DKSNRPSGIPERFSGSNSGN TATLTIS GTQAEDEAD YYCQ SYAN TLSLVF GGGT KLTV L
Vanucizumab,Bispecific mAb,G1;G1,Lambda;Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSPNPYYYDSSGYYYPGAFDIWGQGTMVTVSS,QPGLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHYVFGTGTKVTVL,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,4imk:AD:BC/4iml:HL:AB;1bj1:HL:KJ,None;None,None;6bft:AB:HL/1cz8:HL:YX,2014,2015,ANGPT2;VEGFA,Roche,na,na,Solid tumours;Colorectal cancer,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTGYYMHWVR QAPGQG LEWMGWI NPNSGGTNY AQKF QG RVTMT RDTS ISTAYMELSR LRSDDT AVYYCA RSPNPYY Y DSSGY Y YPGA FDIW GQG TMVTVS S,QPGLTQPP SVSV APGQ TARITC GGNNIGSK SVHWYQ QKPGQAP VLVVY DDSDRPSGIPE R FSGSNSGN TATLTISRVE AGDE ADYYCQVWD SSSD HYVFG TGT KVTV L
Varisacumab,Whole mAb,G1,Kappa,Phase-II/III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGRSMVRGVIIPFNGMDVWGQGTTVTVSS,DIRMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIK,na,na,None,None,None,2016,2017,VEGFA,Peregrine Pharmaceuticals;University of Texas Southwestern Medical Center;Affitech Research AS,na,na,Breast cancer;Colorectal cancer;Eye disorders;Glioblastoma;Non-small cell lung cancer,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGGT FSSYAISWVR QAPGQG LEWMG G F DPEDGE TIYAQKF QG RVTMT EDTSTDT AYMELS SLRSEDT AVYYC ATGR SMVRGVIIP FNGM DV WGQG TTVTVS S,DIR MT QSPSS LSA SVGD RVTITCR ASQS ISSYLNWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQP EDFA TYYCQ QSYSTP LTF GGG TKVEI K
Varlilumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYDMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSGNWGFFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISRWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNTYPRTFGQGTKVEIK,na,na,None,None,None,2014,2015,CD27,Celldex Therapeutics Inc;Oncothyreon;University of California at San Francisco;University of Virginia,na,Malignant melanoma;Solid tumours;Non-Hodgkin's lymphoma;Renal cell carcinoma;Glioblastoma,Haematological malignancies;Prostate cancer;Breast cancer;Ovarian cancer;Glioma,na,,Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y DMHWVRQ APGKGL EWVAVIWY DGSNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RGSGN WGFFD YWGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQG ISRWLAWYQ QKPEKAPK SLIYAA SSLQSGVPS RF SGSGSGTD FTLTIS SLQ PEDFATYYCQQ YNTYPRTFGQGT KVEI K
Varokibart,Whole mAb,G4,Lambda,TBC,Active,QVQLQESGPGLVKPSQTLSLTCTVSGGSISNGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCASLGNWFDYWGQGTLVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNIGSKNVYWYQQKPGQAPVLVVHDDSDRPSGIPERFSGSNSGNTATLTISRVEVGDEADYSCQVWDSSSDHVVFGGGTKLTVL,na,na,None,None,None,2022,na,IL5,TBC,TBC,TBC,TBC,TBC,,QV QLQE SGPGLVKPSQ TLSLTCTV SGGSISNGG YYWSWIR QHPGKGL EWIGYIYYS GST Y YNPSLK SRVTISVD TSKN QFSLKLSS VTAADT AVYYCA SLGNW FD YWGQG TLVTVS S,SY VL TQPPS VSV APGQ TARITC GGNNIGSK NVYWYQ QKPGQAP VLVVH DDSDRPSGIPE R FSGSNSGN TATLTISRVE VGDE ADYSCQVWD SSSD HVVFG GGT KLTV L
Vatelizumab,Whole mAb,G4,Kappa,Phase-II/III,Discontinued,QVQLQESGPGLVKPSETLSLTCTVSGFSLTNYGIHWIRQPPGKGLEWLGVIWARGFTNYNSALMSRLTISKDNSKNQVSLKLSSVTAADTAVYYCARANDGVYYAMDYWGQGTLVTVSS,DFVMTQSPAFLSVTPGEKVTITCSAQSSVNYIHWYQQKPDQAPKKLIYDTSKLASGVPSRFSGSGSGTDYTFTISSLEAEDAATYYCQQWTTNPLTFGQGTKVEIK,na,na,None,None,None,2011,2012,ITGA2,Chromos Molecular Systems;Glenmark Pharmaceuticals S.A.;Sanofi,na,na,Cancer;Chronic obstructive pulmonary disease;Multiple sclerosis;Retinal disorders;Rheumatoid arthritis;Ulcerative colitis,na,,QV QLQE SGPGL V KPSE TLSLTCTV SGF SL TN YGIHWIR QPPGKGL EWLGVIWAR GFTNYNSA LMSRLTIS KDNSKN QVSLKLSS VTAADT AVYYCAR ANDG VYYAMDY WGQG TLVTVS S,DF VMT QSP AFLSV TPGE KVTITCS AQSS VNYIHWYQ QKPDQAPK KLIYD TSKLASGVPS RF SGSGSGTD YTFTISS LEAEDA ATYYCQQW TTNPL T FGQGT KVEI K
Vedolizumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKGSGYTFTSYWMHWVRQAPGQRLEWIGEIDPSESNTNYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCARGGYDGWDYAIDYWGQGTLVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSLAKSYGNTYLSWYLQKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHQPYTFGQGTKVEIK,na,na,None,None,None,2008,2009,ITGA4_ITGB7,Medical College of Wisconsin;Millennium Pharmaceuticals;Takeda;Takeda Oncology,Crohn's disease;Ulcerative colitis,Graft-versus-host disease;Coeliac disease,Malignant melanoma,na,,Q VQLVQ SGA EVK KPGA SVKVSC KGSG YTFTSYWMHWVR QAPGQ RLEWIGEI DPSESNTNYNQKFKG RVTLTVDI SAST AYMELSS LRSEDT AVYYCA RGGYDGW DYAIDY WGQG TLVTVS S,DV VMT QSPLSLPVTPGEPA SISCR SSQ SLAK SYGN TYLSWYL QKPGQSP QLLIYGI SNRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCL QGTHQPY T FGQGT KVEI K
Veltuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLQQSGAEVKKPGSSVKVSCKASGYTFTSYNMHWVKQAPGQGLEWIGAIYPGMGDTSYNQKFKGKATLTADESTNTAYMELSSLRSEDTAFYYCARSTYYGGDWYFDVWGQGTTVTVSS,DIQLTQSPSSLSASVGDRVTMTCRASSSVSYIHWFQQKPGKAPKPWIYATSNLASGVPVRFSGSGSGTDYTFTISSLQPEDIATYYCQQWTSNPPTFGGGTKLEIK,na,na,None,None,None,2007,2008,MS4A1,Immunomedics;Weill Cornell Medical College,na,na,Chronic lymphocytic leukaemia;Rheumatoid arthritis;Idiopathic thrombocytopenic purpura;Non-Hodgkin's lymphoma;Follicular lymphoma,na,,Q VQLQQ SGA EVK KPGS SVKVSCK ASGY TFTSYNMHWVK QAPGQG LEWIGAI YPGMGDTSYNQK F KG KATLTA DESTN TAYMELS SLRSEDT AFYYCAR S T YYGGD WYFDVW GQG TTVTVS S,DI QLT QSPSS LSAS VGD RVTMTCR ASSS VSYIHWFQ QKPGKAPKP WIYAT SNLASGV PVRFS GSGSGT DYTFTISS LQ PEDIA TYYCQQ WTSNPPTFGGGT KLEI K
Vepsitamab,Bispecific scFv-scFv-scFc,na;na,Lambda;Lambda,Phase-I,Active,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKCLEWIGDIDASGSTKYNPSLKSRVTISLDTSKNQFSLKLNSVTAADTAVYFCARKKYSTVWSYFDNWGQGTLVTVSS,SYELTQPSSVSVPPGQTASITCSGDKLGDKYASWYQQKPGQSPVLVIYQDRKRPSGVPERFSGSNSGNTATLTISGTQAMDEADYYCQAWGSSTAVFGCGTKLTVL,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2021,2022,MUC17;CD3E,Amgen,na,GE Junction Cancer;Gastric Adenocarcinoma,na,BiTE Technology,,QV QLQQW GAGLLKPSE TLSLTCAVY GGSFS GYYWSWIR QPPGK CLEWIGDI DASGSTKYNPSLKS RVTISLD TSKN QFSLKL N S VTAADT AVYFCA RKKYS TVWSYF DNWGQG TLVTVS S,SYELTQPS SVS VPPGQ TASITC SGDKLGDK YA S WYQ QKPGQSP VLVIYQ DRKRPSGVPERFSGSNSGN TATLTIS GTQAMDEAD YYCQA WGSST AVF GCGT KLTV L
Vesencumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSQISPAGGYTNYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARGELPYYRMSKVMDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQYFSSYLAWYQQKPGKAPKLLIYGASSRASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLGSPPTFGQGTKVEIK,na,na,2qqn:HL,None,None,2010,2011,NRP1,Genentech;Roche,na,na,Solid tumours,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKGL EWVSQI SPAGGYTNYADSVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYC ARGELP YYRMSKVMDV WGQG TLVTVS S,DIQ M TQSPSS LSA SVGD RVTITCR AS QYFSSYLAWYQ QKPGKAP KLLIYG ASSRASGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQY LGSPPTFGQGT KVEI K
Vibecotamab,Bispecific Mixed mAb and scFv,G1;G1,Kappa;Kappa,Phase-I,Discontinued,QVQLQQSGAEVKKPGASVKVSCKASGYTFTDYYMKWVKQSHGKSLEWMGDIIPSNGATFYNQKFKGKATLTVDRSTSTAYMELSSLRSEDTAVYYCARSHLLRASWFAYWGQGTLVTVSS,DFVMTQSPDSLAVSLGERATINCKSSQSLLNTGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPYTFGGGTKLEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGDSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQQKPGKSPRGLIGGTNKRAPGVPARFSGSLLGGKAALTISGAQPEDEADYYCALWYSNHWVFGGGTKLTVLEPK,None;None,None;None,None;None,2018,2019,IL3RA;CD3E,Xencor,na,na,Haematological malignancies,na,,QV QLQQ SGA EVK KPGA SVKVSCK ASGY TF TDYYMKW VK QSHGKS LEWM GD II PSNGA TFY NQKFKG KATLTVD RSTS TAYMELS SLRSEDT AVYYC ARSHL LRASWFAYW GQG TLVTVS S,DF VMT QSPDS LAVS LGER ATINC KSSQS LL NTGNQKN YLTWYQ QKPGQPP KLLIYWAS TRESGVPDR F TGSGSGTD FTLTISS LQAED VAVYYC QNDYSYPY T FGGGT KLEI K
Vibostolimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVQSGAEVKKPGSSVKVSCKASGYTFSSYVMHWVRQAPGQGLEWIGYIDPYNDGAKYAQKFQGRVTLTSDKSTSTAYMELSSLRSEDTAVYYCARGGPYGWYFDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASEHIYSYLSWYQQKPGKVPKLLIYNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQHHFGSPLTFGQGTRLEIK,na,na,None,None,None,2019,2020,TIGIT,Merck,na,Solid tumours;Non-small cell lung cancer;Malignant melanoma,na,na,,E VQLVQ SGA EVK KPGS SVKVSCK ASGY TFSSYVMHWVR QAPGQG LEWIGYI DPYNDGA KYA QK FQG RVTLTS DKSTS TAYMELS SLRSEDT AVYYCA RGGPY GWYFDV WGQG TTVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASEH IYSYLSWY QQKPGKVP KLLIYN AK T LAEGVPSRFSGSGSGTD FTLTIS SLQ PEDVATY YC Q HHFGSPL T FGQGT RLEI K
Vilamakitug,Whole mAb,G4,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGRFTNYAILWVRQAPGQGLQWLGGIIPIFDETDHAQDFQDRLTITVDESMTTAYMELSSLRPEDTAIYYCATGSNSYYGLYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPSTFGQGTKVEIK,na,na,None,None,None,2022,na,IL1A,"XBiotech USA, Inc",na,Pancreatic cancer;Arthritis;Colorectal cancer,na,na,,Q VQLVQ SGA EVK KPGS SVKVSCK ASGGR FTNYAILWVRQ APGQG LQWLGGIIPIF DETDHAQDFQD RLTITV DESMT TAYMELS SLRPEDT AIYYCA TGSNS YYGLYW GQG TLVTVS S,D IVMT QSPDS LAVS LGE RATINC KSSQ SVLYS SNNK NYLAWYQ QKPGQPP KLLIYWAS TRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQQY YSTPSTFGQGT KVEI K
Vilobelimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLQQSGPQLVRPGTSVKISCKASGYSFTTFWMDWVKQRPGQGLEWIGRIDPSDSESRLDQRFKDRATLTVDKSSSTVYMQLSSPTSEDSAVYYCARGNDGYYGFAYWGQGTLVTVSS,DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMKWYQQKPGQPPKLLIYAASNLQSGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPYTFGGGTKLEIK,na,na,None,None,None,2019,2020,C5,InflaRX,na,Hidradenitis suppurativa;Inflammation;COVID-19;Microscopic polyangiitis;Pyoderma gangrenosum;Sepsis;Systemic inflammatory response syndrome;Squamous cell cancer,Inflammation,na,Chimeric,QV QLQ QSGP QLV RPGT SVKISCK ASGY SFTTFWMDWVK QRPGQG LEWIGRI DPSDSESRLDQRFKDR ATLTVD KSSS TVYMQL SSPTSEDS AVYYCAR GNDG YYGFAYW GQG TLVTVS S,D IVLT QSPA SLAVS LGQ RATISCK ASQ SV DYDGD SYMKWYQ QKPGQPP KLLIYAA SNLQSGIP ARFS GSGSGTD FTLNIHP VEEEDA A TYYCQ QSNEDPYTFGGGT KLEI K
Visilizumab,Whole mAb,G2,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFISYTMHWVRQAPGQGLEWMGYINPRSGYTHYNQKLKDKATLTADKSASTAYMELSSLRSEDTAVYYCARSAYYDYDGFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQKPGKAPKRLIYDTSKLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSSNPPTFGGGTKVEIK,na,na,None,None,None,2000,2001,CD3E,PDL BioPharma,na,na,Crohn's disease;Graft-versus-host disease;Psoriasis;Renal transplant rejection;Ulcerative colitis,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFISYTMHWVR QAPGQG LEWMGYI NPRSGY TH YNQKLKDK ATLTA DKSAS TAYMELS SLRSEDT AVYYCAR S AYY DYDGF AYW GQG TLVTV SS,DI QMT QSPSS LSAS VGD RVTITCS ASSS VSYMNWY QQKPGKAPK RLIYD TSKLASGVPS RF SGSGSGT DFTLTISS LQPE DF ATYYCQQ WSSNPPTFGGGT KVEI K
Visugromab,Whole mAb,G4,Kappa,Phase-I,Active,QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPTLKSRLTITKDPSKNQVVLTMTNMDPVDTATYYCARSSYGAMDYWGQGTLVTVSS,DIVLTQSPSFLSASVGDRVTITCKASQNVGTNVAWFQQKPGKSPKALIYSASYRYSGVPDRFTGSGSGTEFTLTISSLQPEDFAAYFCQQYNNFPYTFGGGTKLEIK,na,na,None,None,None,2022,na,GDF15,CatalYm,na,Solid tumours,na,na,,Q ITLK ESGP TLV KPTQ TLTLTCTF SG FSLS TSGM GVSWIR QPPGKGL EWLAHIYW DDDKRYNPTL KSRLTITK DPSKN QVVLTMT NMDPVDT ATYYCAR SSYGAMDYWGQG TLVTVS S,D IVLT QSPS FLSA SVGD RVTITCK ASQNVGT NVAWFQ QKPGKSPK ALIYSASYRY SGVPDR F TGSGSGT EFTLTIS SLQ PEDFAAYFCQQ YNNFPY T FGGGT KLEI K
Vixarelimab,Whole mAb,G4-G1,Lambda,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYEINWVRQATGQGLEWMGWMNPNSGYTGYAQKFQGRVTMTRDTSISTAYMEMSSLRSEDTAVYYCARDIVAANTDYYFYYGMDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSNSNIGSNTVNWYHQLPGTAPKLLIYNINKRPSGVPDRFSGSKSGSSASLAISGLQSEDEADYYCSTWDDSLDGVVFGGGTKLTVL,na,na,None,None,None,2020,2021,OSMR,Kiniksa Pharmaceuticals,na,Prurigo nodularis;Pruritus;Atopic dermatitis,na,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYEINWVRQ ATGQG LEWMGWM NPNSGYT GYAQKF QG RVTMT RDTS ISTAYMEMS SLRSEDT AVYYCA RD IVA ANTD YYFYYGMD VWGQG TTVTVS S,QSVLTQPPSASGTPGQ RVTISC SGSNSNIGSN TVNWYH QLPGTAP KLLIYN INKRPSGVPDRFSGSKSGSS ASLAI SGLQSEDEAD YYC STWDDSLDG VVF GGGT KLTV L
Vixtimotamab,"Bispecific Homodimer (VK-VH-VL'-VH', Tandem diabody)",na;na,Kappa;Lambda,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQAPGQGLEWMGWMNPNSGNTGFAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDRANTDYSLGMDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSTGAVTTSNYANWVQQKPGKAPKALIGGTNKRAPGVPSRFSGSLIGDKATLTISSLQPEDFATYYCALWYSNLWVFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKDRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARHGNFGNSYVSYFAYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSRSNIGSNTVNWYQQLPGTAPKLLIYGNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLIGWVFGGGTKVTVL,None;None,None;None,None;None,2020,2021,CD3E;CD33,Amphivena Therapeutics,na,Acute myeloid leukemia;Myelodysplastic syndromes,na,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYDINWVR QAPGQG LEWMGWM NPNSGNTGF AQKF QG RVTMTR DTSTS TVYMELS SLRSEDT AVYYCAR DRANTDY SLGMDV WGQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITCR SSTGA VTT SN YANWVQ QKPGKAPK ALI GGTNKRAPGVPSRFSG SL IGDK ATLTISS LQP EDFAT YYCALWY SN LWVF GQGT KVEI K
Vobarilizumab,Bispecific Single Domains (VH-VH'),na;na,na;na,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGSVFKINVMAWYRQAPGKGRELVAGIISGGSTSYADSVKGRFTISRDNAKNTLYLQMNSLRPEDTAVYYCAFITTESDYDLGRRYWGQGTLVTVSS,na,EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS,na,None;None,None;None,None;None,2015,2016,IL6R;ALB,Ablynx,na,na,Rheumatoid arthritis;Systemic lupus erythematosus,Nanobody Technology,,E VQLVES GGG LV QPGG SLRLSC AASGS VFKINVMAWYR QAPGKGR ELVAGIIS GGSTSYADSVK GRFTISR DNAKN TLYLQMN SLRPEDT AVYYCAFIT TESDYDLGRR YW GQG TLVTVS S,NA
Vobramitamab,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVATINSGGSNTYYPDSLKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARHDGGAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASESIYSYLAWYQQKPGKAPKLLVYNTKTLPEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGTPPWTFGQGTRLEIK,na,na,None,None,None,2022,na,CD276,TBC,TBC,TBC,TBC,TBC,,E VQLVES GGG LV KPGG SLRLSC AASGF TFSS YG MSWVRQ APGKG LEWVATIN SGGSNT Y YPDSLKG RFTISR DNAKNS LYLQMNS LRAEDT AVYYCAR HDGGAMDYWGQG TTVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASES IYSYLAWY QQKPGKAP KLLVYN TKTLPEGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYY C Q HHYGTPPWTFGQGT RLEI K
Vofatamab,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFTSTGISWVRQAPGKGLEWVGRIYPTSGSTNYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARTYGIYDLYVDYTEYVMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVDTSLAWYKQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSTGHPQTFGQGTKVEIK,na,na,None,None,4wv1:BA:ED/3grw:HL,2018,2019,FGFR3,BioClin Therapeutics;Rainier Therapeutics,na,Urogenital cancer,Multiple myeloma;Solid tumours;Achondroplasia,na,,E VQLVES GGG LV QPGG SLRLSC AASG FTFTS T GISWVRQ APGKG LEWVGRIY PTSGSTNYADSVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYCA RTYG IYDLYVD YT EYVMD YWGQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQDVDTS LAWYK QKPGKAP KLLIYSASFLY SGVPSRFSGSGSGTD FTLTIS SLQPED F ATYYCQ QSTGHPQTFGQGT KVEI K
Volagidemab,Whole mAb,G2,Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVMWYDGSNKDYVDSVKGRFTISRDNSKNTLYLQMNRLRAEDTAVYYCAREKDHYDILTGYNYYYGLDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSVQPEDFVTYYCLQHNSNPLTFGGGTKVEIK,na,na,None,4lf3:ED:BA/5xf1:HL:CD/5xez:CD:HL/4ers:HL,None,2018,2019,GCCR,Amgen;REMD Biotherapeutics,na,Type 1 diabetes mellitus;Type 2 diabetes mellitus;Metabolic disorders;Glucose intolerance,na,na,,Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKGL EWVAVMWY DGSNKD YVD S V KG RFTISR DNSKN TLYLQMNRL RAEDT AVYYCA REKDH YDIL TGYN YYYGLDVW GQG TTVTVS S,DI QMT QSPSS LSA SVGD RVTITCR ASQGIRNDLG WYQ QKPGKAPK RLIYAA SSLQSGVPS RF SGSGSGT EFTLTISS VQPED FVTYYCLQ HNSNPL TF GGG TKVEI K
Volociximab,Whole mAb,G4,Kappa,Phase-II,Discontinued,QVQLKESGPGLVAPSQSLSITCTISGFSLTDYGVHWVRQPPGKGLEWLVVIWSDGSSTYNSALKSRMTIRKDNSKSQVFLIMNSLQTDDSAMYYCARHGTYYGMTTTGDALDYWGQGTSVTVSS,QIVLTQSPAIMSASLGERVTMTCTASSSVSSNYLHWYQQKPGSAPNLWIYSTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQYLRSPPTFGGGTKLEIK,na,na,None,None,None,2005,2006,a5b1 Integrin,Abbott Biotherapeutics Corp;Biogen Idec;IVERIC bio;National Cancer Institute (USA);PDL BioPharma,na,na,Age-related macular degeneration;Intestinal cancer;Non-small cell lung cancer;Peritoneal cancer;Malignant melanoma;Pancreatic cancer;Renal cell carcinoma,na,,Q VQLKE SGPGL V APSQ SLSITCTI SGF SL TDY GVHWVR QPPGKGL EWLVVIW SDGSSTYNSAL KSRMTIR KDNSKS QVFLIMN SLQTDDS AMYYCA RHGT YYGMT TTGDA L DYWGQGT SVTV SS,Q IVLT QSPA IMSA SLGE RVTMTCTA SSSVSSN YLHWYQ QKPGSAPN LWIYS TSNLASGVP ARFS GSGSGT SYSLTISS MEAEDA ATYYCHQYL RSPPTFGGGT KLEI K
Volrustomig,Bispecific mAb,G1,Kappa;Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPRGATLYYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSINSYLDWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYSTPFTFGPGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGMHWVRQAPGKGLEWVAYISSGSYTIYSADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRAPNSFYEYYFDYWGQGTTVTVSS,QIVLTQSPATLSLSPGERATLSCSASSKHTNLYWSRHMYWYQQKPGQAPRLLIYLTSNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQWSSNPFTFGQGTKLEIK,5ggu:HL:AB/5ggv:HL;None,None;None,None;None,2022,na,CTLA4;PDCD1,AstraZeneca,na,Solid tumours;Renal cell carcinoma,na,na,,Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKGL EWVAVIWY DGSNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAED TAVYYCAR DPRGA TLYYYYY G M DVWGQG TTVTVS S,DIQ M TQSPSS LSA SVGD RVTITCR ASQS INSYLDWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQ PEDFATYYCQQ YYSTPF T FGPGT KVEI K
Vonlerolizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQGLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRSEDTAVYYCVLAPRWYFSVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGHTLPPTFGQGTKVEIK,na,na,6okn:AB:CD/6ogx:CD,None,None,2015,2017,TNFRSF4,Genentech,na,na,Solid tumours;Urogenital cancer,na,Vonlerolizumab is the new name for Pogalizumab (PL116),E VQLVQ SGA EVK KPGA SVKVSCK ASGY TFT DS YMSWVR QAPGQGL EWIGD MYPDNGDSSYNQKF RERVTITR DTSTS TAYLELSS LRSEDT AVYYCVL APR WYFSVW GQG TLVTVS S,DIQ MT QSPSS LSA SVGD RVTITCR ASQD ISNYLNWYQ QKPGKAP KLLIYYT SRLRSGVPS R FSGSGSGTD FTLTIS SLQ PEDFAT YYC QQGHTLPPTFGQGT KVEI K
Vopratelimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYWMDWVRQAPGKGLVWVSNIDEDGSITEYSPFVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCTRWGRFGFDSWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLSGSFNYLTWYQQKPGQPPKLLIFYASTRHTGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHHHYNAPPTFGPGTKVDIK,na,na,None,None,None,2017,2018,ICOS,Jounce Therapeutics,na,Solid tumours;Urogenital cancer;Non-small cell lung cancer,na,na,,E VQLVES GGG LV QPGG SLRLSC AASGFT F S DYWMDWVRQ APGKG LVWVSNI DEDGS ITEY SPFVKG RFTISR DNAKN TLYLQMN SLRAEDT AVYYCT RWGR F G F DSWGQG TLVTVS S,D IVMT QSPDS LAVS LGE RATINC KSSQSLLSGS FNYLTWYQ QKPGQPP KLLIFYA STRHTGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCH HHYNAPPTFGPGT KVDI K
Vorsetuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLKWMGWINTYTGEPTYADAFKGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDYGDYGMDYWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCRASKSVSTSGYSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQHSREVPWTFGQGTKVEIK,na,na,None,None,None,2012,2013,CD70,Seattle Genetics,na,na,Autoimmune disorders;Cancer;Inflammation;Plaque psoriasis,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTN YG MNWVRQ APGQG LKWMGWIN TYTGEPTY AD AFKG RVTMT RDTS ISTAYMELSR LRSDDT AVYYCA RDYGDYGMDYWGQG TTVTVS S,D IVMT QSPDS LAVS LGER ATINCR ASKSVSTSGY SFMHWYQ QKPGQPP KLLIYLA SNLESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC QHSREVPW T FGQGT KVEI K
Voxalatamab,Bispecific mAb,G4;G4,Kappa;Lambda,Phase-I,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFKSDAMHWVRQAPGKGLEWVSEISGSGGYTNYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDSYDSSLYVGDYFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYAASVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARHGNFGNSYVSWFAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2021,na,FOLH1;CD3E,Janssen Research & Development,na,Solid tumours,na,na,,E VQLLES GGG LV QPGG SLRLSC AASGF TFK SDA MHWVRQ APGKGL EWVSEI SGSGGYTNYADSVK GRFTISR DNSKN TLYLQMN SLRAEDT AVYYCAR DSYDSS LYV GDY F DYWGQG TLVTVS S,E IVLTQ SPA TLSL SPGE RATLSCR ASQS VSSY LAWY QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPED FAVYYCQ QRSNWPL TF GQGT KVEI K
Vudalimab,Bispecific Mixed mAb and scFv,G1;G1,Kappa;Kappa,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVSFISYDGNNKYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARTGWLGPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,EVQLVESGGGLVKPGGSLRLSCVASGFTFSNYWMNWVRQAPGKGLEWVAEIRLYSNNYATHYAESVKGRFTISRDDSKSTLYLQMNNLKTEDTGVYYCTRYYGNYGGYFDVWGRGTLVTVSS,EIVLTQSPATLSASPGERVTLTCRASQSVGNDVAWYQQKPGQAPRLLINYASHRYTGVPDRFTGSGYGTEFTLTISSVQSEDFGVYYCQQDFSSPRTFGGGTKVEIK,None;None,None;None,5tru:HL:hl/5xj3:AB:DE:GH:JK/6jc2:HL/6rp8:HL:hl/7elx:HL:hl;None,2020,2021,CTLA4;PDCD1,Xencor,na,Solid tumours,na,na,,E VQLVES GGG LV KPGG SLRLSC AASGF TFSSYTMHWVRQ APGKGL EWVSFISY DGNNK YYAD SVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYC ARTGWLGPFDYWGQG TLVTV SS,E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSS S YLAWYQ QKPGQAP RLLIYGAF SRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYCQ QYGSSPWTFGQGT KVEI K
Vulinacimab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVQSGGGLVQPGGSLRLSCAASGFSFSTYAMSWVRQAPGKGLEWVSGISGSGGTTHYADSVKGRFTISRDNSKNTVNLQMNSLRAEDTAVYYCAKGLWFGEGLWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSLYYRSGYTFLDWYVQKPGQSPQLLIYQSSKRDSGVPDRISGSGSGTDFTLRISRVEAEDVGVYYCFQGTHWPYTFGQGTKLEIK,na,na,None,None,None,2019,2020,VEGFR2,Henlix,na,na,Solid tumours,na,,Q VQLVQS GGG LV QPGG SLRLSCA ASGF SFSTYAMSWVR QAPGKG LEWVSGI SGSGGT THY ADSVKG RFTISR DNSKN TVNLQM N SL RAEDT AVYYC AKG LWF GEGLWGQG TLVTVS S,DV VMT QSPLSLP VT LGQPA SISC RSSQ SLYYR SGY TFLDWYV QKPGQSP QLLIYQS SKRDSGVPD RIS GSGSGT DFTLRISRVE AEDV GVYYCF QGTHWPY T FGQGT KLEI K
Vunakizumab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYEVHWVRQAPGQGLEWMGVIDPGTGGVAYNQKFEGRVTMTADTSTSTAYMELRSLRSDDTAVYYCTRYSLFYGSSPYAMDYWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCSASSSVNYMHWFQQKPDQSPKLWIYRTSNLASGVPSRFSGSGSGTDYTLTINSLEAEDAATYYCQQRSSYPWTFGQGTKLEIK,na,na,None,None,None,2016,2017,IL17A,Atridia;Jiangsu Hengrui Medicine Co.,na,Plaque psoriasis;Psoriasis;Spondylarthritis,Autoimmune disorders,na,,E VQLVQ SGA EVK KPGA SVKVSCK ASGY TF T DYEVHWVRQ APGQG LEWMGVI DPGTGG VAY NQ KF E GRVTMTA DTSTS TAYMELRSL RSDDT AVYYCTRYSLF YGSSPYA M DYWGQG TLVTVS S,E IVLTQ SPDFQSVTPKE KVTITCS ASSSVN YMHWF QQKPDQSP KLWIYRT SNLASGVPS R FSGSGSGTD YTLTINS LE A ED AAT YYCQ QRSSYPW T FGQGT KLEI K
Xaluritamig,Bispecific Mixed mAb and scFv,G1;na,Kappa;Lambda,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFSTYWIEWVRQAPGQRLEWMGEILPGSGQTDFNEKFQGRVTFTADTSSDTAYMELSSLRSEDTAVYYCTRWGYYGTRGYFNVWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASSSVSYMHWFQQKPGQAPRLLIYSTSNLASGIPARFSGSGSGTDYTLTISSLEPEDFAVYYCQQRRSFPYTFGQGTKLEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGDSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQQKPGKSPRGLIGGTNKRAPGVPARFSGSLLGGKAALTISGAQPEDEADYYCALWYSNHWVFGGGTKLTVL,None;None,None;None,None;None,2022,na,STEAP1;CD3,TBC,TBC,TBC,TBC,TBC,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFSTYWIEWVR QAPGQ RLEWMGEI LPGSGQTDFNEKFQG RVTFTA DTSSDT AYMELSS LRSEDT AVYYCT RWGYYGTRG YFNVW GQG TLVTVS S,E IVLTQ SPA TLSL SPGE RATLSCR ASSS VSYMHWFQ QKPGQAP RLLIYS TSNLASGIP ARFS GSGSGTD YTLTIS SLEPED FAVYYCQ QRRSFPY T FGQGT KLEI K
Xeligekimab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGMSMSDYWMNWVRQAPGKGLEWVAAINQDGDEKYYVGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCVRDYYDLISDYYIHYWYFDLWGRGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQNVHNRLTWYQQKPGKAPKLLIYGASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNGSPTTFGQGTKVEIK,na,na,None,None,None,2021,na,IL17A,Genrix Biopharmaceutical,na,Psoriasis,na,na,,E VQLVES GGG LV QPGG SLRLSC AASGMS MSDYWMNWVRQ APGKG LEWVAAIN QDGD EKYYVGSVKGRFTISR DNAKN SLYLQMNSLRV EDT AVYYCVR DYYDLISDY YIHYWYFD LWGRG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITCR ASQNVHN RLTWYQ QKPGKAP KLLIYG ASNLESGVPSRFSGSGSGTD FTLTIS SLQP EDFAT YYCQ Q YNGSPTTFGQGT KVEI K
Xentuzumab,Whole mAb,G1,Lambda,Phase-II,Active,QVELVESGGGLVQPGGSLRLSCAASGFTFTSYWMSWVRQAPGKGLELVSSITSYGSFTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARNMYTHFDSWGQGTLVTVSS,DIVLTQPPSVSGAPGQRVTISCSGSSSNIGSNSVSWYQQLPGTAPKLLIYDNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCQSRDTYGYYWVFGGGTKLTVL,na,na,None,None,None,2015,2016,IGF1&IGF2,Boehringer Ingelheim;Eli Lilly,na,Breast cancer;Prostate cancer,Non-small cell lung cancer;Solid tumours,MorphoSys HuCAL Phage Display,,Q VELVE SGGG LV QPGG SLRLSC AASGF TFTSYWMSWVR QAPGKG LELVSSIT SYGS FTYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RNM YTHF DSWGQG TLVTVS S,DI VLT QPPSVSGAPGQ RVTISC SGSSSNIGSNS VSWYQ QLPGTAP KLLIY DNSKRPSGVPDRFSGSKSGTS ASLAIT GLQSEDEA D YYCQ SRDTY GYYWVF GGGT KLTV L
Zagotenemab,Whole mAb,G4,Kappa,Phase-II,Discontinued,EVQLVQSGAEVKKPGESLKISCKGSGYTFSNYWIEWVRQMPGKGLEWMGEILPGSDSIKYEKNFKGQVTISADKSISTAYLQWSSLKASDTAMYYCARRGNYVDDWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRSSQSLVHSNQNTYLHWYQQKPGQAPRLLIYKVDNRFSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCSQSTLVPLTFGGGTKVEIK,na,na,None,None,None,2019,2020,MAPT,Eli Lilly,na,na,Alzheimer's disease,na,,E VQLVQ SGA EVK KPGE SLKISC KGSGY TF S N YWIEW VR QMPGKGL EWMGEI LPGSDS IKYEK NFKG QVTIS ADKS ISTAYLQWS SLKASDT AMYYCA RRGN YV DDWGQG TLVTV SS,E IVLTQ SPG TLSL SPGE RATLSCR SSQS LVH SNQNT YLHWYQ QKPGQAP RLLIYKV DNRFSGIPDRFSGSGSGT DFTLTISR LEPED FAVYYC SQST LVPLTF GGG TKVEI K
Zalifrelimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVGLMGPFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSRYLGWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTITRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,None,None,None,2018,2019,CTLA4,4-Antibody;Ludwig Institute for Cancer Research;Agenus;Recepta biopharma,na,Non-small cell lung cancer;Cervical cancer;Cancer;Haemangiosarcoma;Soft tissue sarcoma;Sold tumours,na,na,,E VQLVES GGG LV KPGG SLRLSC AASGF TFSS Y SMNWVR QAPGKG LEWVSS ISSSSS YIYYA DSVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCARV GLMGPF DI WGQG TMVTVS S,E IVLTQ SPG TLSL SPGE RATLSCR ASQS VSRY LGWY QQKPGQAP RLLIYG ASTRATGIPDRFSGSGSGTD FTLTITR LEP ED FAVYYCQ QYGSSPW T FGQGT KVEI K
Zalutumumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSESGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,na,na,None,None,None,2005,2006,EGFR,Danish Head and Neck Cancer Group;Genmab,na,na,Head and neck cancer;Colorectal cancer;Non-small cell lung cancer,na,,Q VQLVES GGG VV QPGR SLRLSC AASGF TFSTYGMHWVRQ APGKG LEWVAVIW DDGS YKYY GDS VKGRFTISR DNSKN TLYLQMN SLRAED TAVYYCA RDG ITMVRGVM KDYFDYWGQG TLVTVS S,AI QLT QSPSS LSAS VGD RVTITCR ASQDIS SALVWYQ QKPGKAP KLLIYD ASSLESGVPSRFSGSESGTD FTLTIS SLQ PEDFATYYCQQ FNSYP LTF GGG TKVEI K
Zamerovimab,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYSFTDYIMLWVRQAPGQRLEWIGDIYPYYGSTSYNLKFKGKATLTVDTSASTAYMELSSLRSEDTAVYYCARQGGDGNYVLFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVGTTVAWYQQKPGKAPKALIYSASYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPFTFGQGTKLEIK,na,na,None,None,None,2021,na,Rabies Virus Spike Glycoprotein G,TBC,TBC,TBC,TBC,TBC,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGYSFTD YIMLWVRQ APGQ RLEWIGDI YPYYGST SYNLKF KG KATLTVD TSAST AYMELS SLRSEDT AVYYCAR QGGDGN YVLFDY WGQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITCK ASQNVG TTVAWYQ QKPGKAPK ALIYSASYRY SGVPSRFSGSGSGTD FTLTISS LQP EDFA TYYCQ QYNSYPF TF GQGT KLEI K
Zampilimab,Whole mAb,G4,Kappa,Phase-I/II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTLSTHAMSWVRQAPGKGLEWVATISSGGRSTYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCARLISTYWGQGTLVTVSS,DITMTQSPSSLSASVGDRVTITCKASQDINSYLTWFQQKPGKAPKILIYLVNRLVDGVPSRFSGSGSGQDYALTISSLQPEDFATYYCLQYDDFPYTFGQGTKVEIK,na,na,None,None,None,2018,2019,TGM2,UCB,na,Autoimmune disorders,na,na,,E VQLLES GGG LV QPGG SLRLSC AASGF TLSTHAMSWVR QAPGKG LEWVATIS SGGRS TY YPDSVK GRFTISR DNSKN TLYLQMN SLRAED TA VYF CARL I STY WGQG TLVTV SS,DIT MT QSPSS LSA SVGD RVTITCK ASQD INSYLTWFQ QKPGKAP KILIYLVN R LVDGVPS R FSGSGSGQD YALTIS SLQPEDF ATYYCLQ YDDFPY T FGQGT KVEI K
Zanidatamab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFADYTMDWVRQAPGKGLEWVGDVNPNSGGSIYNQRFKGRFTFSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPATFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,None;6bi0:HL:IM/4hkz:BA/6mh2:BA:DC/5xhg:DC:BA/1n8z:BA/6bi2:HL:IM/1fvc:BA:DC/6bhz:HL:IM/6oge:ED/7mn8:DC/4ub0:HL/5xhf:BA:DC/,None;1fve:BA:DC/4x4x:AB:CD/5tdn:BA:DC/6bgt:BA/7kbp:CC,1s78:FE:DC/4llu:AB:CD/1l7i:HL/4llw:CD:AB/5vsh:CD:EF:AB:HL/4lly:AB:CD;5tdn:BA:DC/1fvd:BA:DC/5tdp:BA:DC/4x4y:CD:AB/5tdo:BA:DC/6dn0:CD:AB/3be1:HL/3bdy:HL/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,2019,2020,ERBB2;ERBB2,Zymeworks,na,Gastric cancer;Oesophageal cancer;Breast cancer;Solid tumours,Ovarian cancer,na,Biparatopic Bispecific,E VQLVES GGG LV QPGG SLRLSC AASGF TFA D YTM DWV R QAPGKGL EWVG DVNPNSGGS IY NQRFKG RFTFSVD RSKN TLYLQMNS LRAEDT AVYYCA RNLGPS FYFDY WGQG TLVTVS S,DI QMT QSPSS LSA SVGD RVTITCK ASQD VSIGVAWYQ QKPGKAP KLLIYSASYRY TGVPSRFSGSGSGT DFTLTISS LQPEDF ATYYCQQYYIY PATFGQGT KVEI K
Zanolimumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARVINWFDPWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQDISSWLAWYQHKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPYTFGQGTKLEIK,na,na,None,None,None,2004,2004,CD4,Emergent BioSolutions;Genmab,na,na,Cutaneous T-cell lymphoma;Peripheral T-cell lymphoma;Psoriasis;Rheumatoid arthritis,Medarex HuMAb Mouse,,QV QLQQW GAGLLKPSE TLSLTCAVY GGSFS GYYWSWIR QPPGKGL EWIGEIN HSGSTNYNPSLK SRVTISVD TSKN QFSLKLSS VTAADT AVYYCARVINWF DPWGQG TLVTVS S,DIQ MT QSPSS VSAS VGD RVTITCR ASQD ISSWLAW Y QHKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQP EDFAT YYC QQANSFPY T FGQGT KLEI K
Zansecimab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYSFTDYNMVWVRQAPGQGLEWMGYIDPYNGGTGYNQKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARTRDRYDVWYFDVWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCKASQDVYIAVAWYQQKPGKAPKLLIYWASTRDTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQYSSYPPTFGGGTKVEIK,na,na,None,None,None,2020,na,ANGPT2,Eli Lilly,na,COVID-19,Solid tumours,na,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGYSFTDY NMVWVRQ APGQG LEWMGYI DPYNGGTGYNQ KFEGRVTMTT DTSTS TAYMELRSL RSDDT AVYYCAR TRDRY DVWYFDV WGQG TLVTVS S,DI QMT QSPSS VSAS VGD RVTITCK ASQD VYIAVAWYQ QKPGKAP KLLIYWAS TRDTGVPS R FSGSGSGTD FTLTISS LQPEDF ATYYCHQ YSSYPPTFGGG TKVEI K
Zelminemab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVESGAEVVKPGASVKVSCKASGFTFSRFAMHWVRQAPGQGLEWMGVISYDGGNKYYAESVKGRVTMTRDTSTSTLYMELSSLRSEDTAVYYCARGYDVLTGYPDYWGQGTLVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQSIGRSLHWYQQKPGKAPKLLIKYASQSLSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCHQSSRLPFTFGPGTKVDIK,na,na,None,None,None,2019,2020,ADCYAP1R1,Amgen,na,Migraine,na,na,,Q VQLVE SGA EVV KPGA SVKVSCK ASGF TFSRFAMHWVRQ APGQGL EWMGVISY DGGNK YYAESV KG RVTMTR DTSTS TLYMELS SLRSEDT AVYYCA RGY DVL TGYPDYWGQG TLVTVS S,DI QLT QSPS FLSA SVGD RVTITCR ASQSIGR SLHWYQ QKPGKAP KLLIKYA SQSLSGVPS RF SGSGSGT EFTLTISS LQPEDF ATYYCH QSSRLP FTF GPGT KVDI K
Zeluvalimab,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSLISGGGSQTYYAESVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCASPSGHYFYAMDVWGQGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISNWLAWYQQKPGKAPKLLIFAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAESFPHTFGGGTKVEIK,na,na,None,None,None,2020,na,PDCD1,Amgen,na,Solid tumours,na,na,(June '22: Corrected CDRH1 sequence),E VQLLES GGG LV QPGG SLRLSC AASGF TFSS YDM SWVR QAPGKGL EWVSLIS GGGSQ TYYAES VKG RFTISR DNSKN TLYLQMN SLRAED TAVYFCA SPSGH YFYAMD VWGQG TTVTVS S,DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISNWLAWYQ QKPGKAP KLLIFAA SSLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQ QAESFPHTFGGGT KVEI K
Zenocutuzumab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDHGSRHFWSYWGFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,QVQLVQSGAEVKKPGASVKLSCKASGYTFTAYYINWVRQAPGQGLEWIGRIYPGSGYTSYAQKFQGRATLTADESTSTAYMELSSLRSEDTAVYFCARPPVYYDSAWFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,5o4o:BA/5o7p:BA;5o4g:BA,None;None,None;None,2017,2018,ERBB3;ERBB2,Merus,na,Breast cancer;Colorectal cancer;Gastric cancer;Non-small cell lung cancer,Endometrial cancer;Ovarian cancer,GlymaxX Technology,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTGYYMHWVR QAPGQG LEWMGWI NPNSGGTNY AQKF QG RVTMT RDTS ISTAYMELSR LRSDDT AVYYCAR DHGSRH FWSYWGFD YWGQG TLVTV SS,DIQ MT QSPSS LSA SVGD RVTITCR ASQS ISSYLNWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQPE DF ATYYCQ QSYSTPPTFGQGT KVEI K
Zeripatamig,Bispecific mAb,G1;G1,Kappa;Lambda,TBC,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSYGAFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQMHPRAPKTFGQKTKVEIK,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSYGAFDYWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTRSSGSIEDKYVQWYQQRPGSSPTIVIYYDNERPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQTYDQSLYGWVFGGGTKVTVL,None;None,None;None,None;None,2022,na,CD47;CD19,TBC,TBC,TBC,TBC,TBC,,E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKGL EWVSAIS GSGGS TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAK SYGA F DYWGQG TLVTV SS,DIQ MT QSPSS LSA SVGD RVTITCR ASQS ISSYLNWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQ PEDFATYYCQQ MHPRAPKTFGQK TKVEI K
Zifibancimig,Whole mAb,G1;G1,Kappa,TBC,Active,SEHLVESGGGLVKPGGSLRLSCATADFFEYDDMSWVRQAPGKGLEWVGSISPKGDHKYLNTKFIGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCARDVGFFDWWGQGTLVTVSS,AIYMHQEPSSLSASVGDRVTITCHGSYWLNSEVAWYQQKPGKAPKLLIFDGDFKVYEVPSRFSGSGSHEDYTLTISSLQPEDFATYYCQQYRYHPYTFGHGTKVEIK,na,na,None,None,None,2022,na,ANPT2,TBC,TBC,TBC,TBC,TBC,Biparatopic Bispecific with same V region,SEH LVES GGG LV KPGG SLRLSC ATADF FE YDDM SWVRQ APGKGL EWVGSI SPKGDHK YL NT KFIGRFTISR DDSKN TLYLQMNS LRAEDT AVYYCA RDVG FF DWWGQG TLVTVS S,A IYMH QEPSS LSAS VGD RVTITCH GS YWL NS EVAWYQ QKPGKAP KLLIF DGD FKVYEV PSRFSGSGSHED YTLTISS LQ PEDFATYYCQQ YRYHPYTFGHGT KVEI K
Zigakibart,Whole mAb,G4,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVMHWVRQAPGQGLEWMGYINPYNDAPKYNEKFKGKATMTSDTSASTAYMELSSLRSDDTAVYYCARGLGYALYYAMDYWGQGTTVTVSS,DIVMTQSPSTLSASVGDRVTITCKASQNVGNNVAWYQQKPGKAPKLLISSASNRDSGVPSRFSGSGSGTEFTLTISSLQPDDFATYFCQQYNIYPFTFGQGTKLEIK,na,na,None,None,None,2022,na,TNFSF13,TBC,TBC,TBC,TBC,TBC,,Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYVMHWVR QAPGQGL EWMGYI NPYNDAPKYNEKFKG KATMT SDTSAS TAYMELS SLRSDDT AVYYCA RGLG Y ALYYAM DYWGQGT TVTVS S,D IVMT QSPS TLSAS VGD RVTITCK ASQNVGNN VAWYQ QKPGKAP KLLISS ASNRDSGVPS RF SGSGSGT EFTLTIS SLQP DDFATYFCQQ YNIY PFTF GQGT KLEI K
Ziltivekimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTISSNYMIWVRQAPGKGLEWVSDLYYYAGDTYYADSVKGRFTMSRDISKNTVYLQMNSLRAEDTAVYYCARWADDHPPWIDLWGRGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKVLIYKASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQSWLGGSFGQGTKLEIK,na,na,None,None,None,2019,2020,IL6,AstraZeneca;Corvidia,na,Cardiovascular disorders,na,na,,E VQLVES GGG LV QPGG SLRLSC AASGF TIS SN YMIWVRQ APGKGL EWVSDLYYY AGD TYYA DSVKG RFTMSR DISKN TVYLQMN SLRAEDT AVYYCAR WADDHPPW IDL WGRG TLVTV SS,DIQ MT QSPS TLSAS VGD RVTITCR ASQGIS SW LAWY QQKPGKAP KVLIYK ASTLESGVPS R FSGSGSGT EFTLTISS LQPDDF ATYYCQQ SWLGGSFGQGT KLEI K
Zilovertamab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLQESGPGLVKPSQTLSLTCTVSGYAFTAYNIHWVRQAPGQGLEWMGSFDPYDGGSSYNQKFKDRLTISKDTSKNQVVLTMTNMDPVDTATYYCARGWYYFDYWGHGTLVTVSS,DIVMTQTPLSLPVTPGEPASISCRASKSISKYLAWYQQKPGQAPRLLIYSGSTLQSGIPPRFSGSGYGTDFTLTINNIESEDAAYYFCQQHDESPYTFGEGTKVEIK,na,na,None,None,None,2020,na,ROR1,University of California;Oncternal Therapeutics;Merck,na,Breast cancers;Chronia lymphocytic leukemia;Mantle cell leukemia;Lymphoma,na,na,(June '22: Corrected FWL2 sequence),Q VQLQE SGPGLVKPSQ TLSLTCTV SGY AFTAYNIHWVRQ APGQG LEWMGSF DPYDGGSSYNQKFKD RLTISK DTSKN QVVLTMT NMDPVDT ATYYC ARG WYYFD YWGHG TLVTVS S,DI VMT QTPLSLPVTPGEPA SISCR AS KSISKYLAWYQ QKPGQAP RLLIYS GSTLQSGIPPRFSGSGYGTD FTLTI NNIES EDAAYYFCQQ HDESPY T FGEGT KVEI K
Zimberelimab,Whole mAb,G4,Lambda,Approved,Active,QLQLQESGPGLVKPSETLTLTCTVSADSISSTTYYWVWIRQPPGKGLEWIGSISYSGSTYYNPSLKSRVTVSVDTSKNQFSLKLNSVAATDTALYYCARHLGYNGRYLPFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGFYNYVSWYQQHPGKAPELMIYDVSNRPSGVSDRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSISTWVFGGGTKLTVL,na,na,None,None,None,2020,na,PDCD1,Harbin Gloria Pharmaceuticals;WuXi Biologics;Arcus Biosciences;Beijing Cancer Hospital;Guangzhou Gloria Biosciences;Strata Oncology,Hodgkin's disease,Cervical cancer;Non-small cell lung cancer;Breast cancer;Cancer;Ovarian cancer;Pancreatic cancer;Solid tumours,na,na,,QL QLQE SGPGL V KPSE TLTLTCTVS ADSISST TYYWVWIR QPPGKGL EWIGSISY SGS TYY NPSLK SRVTVSVD TSKN QFSLKLNS VAATD TALYYCARH LGYNGR YL PFDYWGQG TLVTVS S,QSALTQPA SV SGSPGQ SITISCT GTSSDVG FYNYVSWY Q QHPGKAP ELMIYD VSNRPSGVSDRFSGSKSGN TASLTIS GLQAEDEAD YYC SSYT SISTWVF GGGT KLTV L
Zinlirvimab,Whole mAb,G1,Lambda,Phase-I,Active,QVQLQESGPGLVKPSETLSVTCSVSGDSMNNYYWTWIRQSPGKGLEWIGYISDRESATYNPSLNSRVVISRDTSKNQLSLKLNSVTPADTAVYYCATARRGQRIYGVVSFGEFFYYYSMDVWGKGTTVTVSS,SYVRPLSVALGETARISCGRQALGSRAVQWYQHRPGQAPILLIYNNQDRPSGIPERFSGTPDINFGTRATLTISGVEAGDEADYYCHMWDSRSGFSWSFGGATRLTVL,na,na,6orn:AB:FI:OP/6udk:AB:FI:OP/6udj:AR:KL:QB/6v8z:DE:PQ:JK/6ccb:DE:HL/6okp:KL,5t3x:HL/5t3z:HL,4fq2:HL,2022,na,HIV-1 gp120 V3,TBC,TBC,TBC,TBC,TBC,,Q VQLQE SGPGL V KPSE TLSVTCSV SGDSMNN YYWTWIRQ SPGKGL EWIGYIS DRESA TY NPSLNS RVVISR DTSKN QLSLKL NSVTPADT AVYYCATA RRGQ RIYGVVSF GE FFYYYSMDV WGKG TTVTVS S,SYVRP LSVA LGE TARISC GRQALGSR AVQWYQ HRPGQAP ILLIY NNQDRPSGIPERFSGTPDINFGT RATLTISGV EAGDEA DYYCHMWD SRSG FSWSF GGA TRLTV L
Zolbetuximab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLQQPGAELVRPGASVKLSCKASGYTFTSYWINWVKQRPGQGLEWIGNIYPSDSYTNYNQKFKDKATLTVDKSSSTAYMQLSSPTSEDSAVYYCTRSWRGNSFDYWGQGTTLTVSS,DIVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPFTFGSGTKLEIK,na,na,None,None,None,2017,2018,CLDN18,Ganymed Pharmaceuticals,na,Gastric cancer;Oesophageal cancer;Pancreatic cancer,Solid tumours,na,Zolbetuximab and Claudiximab are the same mAb,QV QLQ QPGA ELV RPGA SVKLSCK ASGY TFTSYWINWVK QRPGQG LEWIGNI YPSDSYTNYNQKFKDK ATLTVD KSSS TAYMQL SSPTSEDS AVYYCTR SWRGNS F D Y WGQG TTLTVS S,D IVMT QSPS SLTVT AGE KVTMSC KSSQS L LNSGNQK NYLTWYQ QKPGQPP KLLIYWAS TRESGVPDR F TGSGSGTD FTLTISSV QAED LAVYYC QNDYSYP FTF GSGT KLEI K
Zuberitamab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSS,DIELSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLEIK,na,na,None,None,3bky:HL,2019,2020,MS4A1,Zhejiang Hisun Pharmaceutical,na,na,Diffuse large B-cell lymphoma,na,Chimeric. (June '22: Corrected CDRH2 sequence),E VQLQQ SGA ELV RPGA SVKMSCK ASGY TFTSYNMHWVK QTPRQGL EWIGAI YPGNGDTSYNQKFKG KATLTVD KSSST AYMQLS SLTSEDS AVYFCARVVYY SNS YWYFDVW GTGT TVTVS S,DI EL SQSP AILS ASPGE KVTMTCR ASSS VSYMHWYQ QKPGSSPKP WIY APSNLASGVP ARFS GSGSGT SYSLTISRVE AEDA ATYYCQQWS FNPPTFGAGT KLEI K
